PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dyer, C				Dyer, C			Whistleblower inquiry clears British hospital	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					68	68		10.1136/bmj.321.7253.68	http://dx.doi.org/10.1136/bmj.321.7253.68			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884241	Green Published			2022-12-28	WOS:000088196600009
J	Beecham, L				Beecham, L			MPs say NHS consultants should not do private work	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					133	133		10.1136/bmj.321.7254.133	http://dx.doi.org/10.1136/bmj.321.7254.133			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894683	Green Published			2022-12-28	WOS:000088305700010
J	Dyer, C				Dyer, C			Surgeon vows to fight injunction	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					68	68		10.1136/bmj.321.7253.68	http://dx.doi.org/10.1136/bmj.321.7253.68			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884241	Green Published			2022-12-28	WOS:000088196600010
J	Beecham, L				Beecham, L			No evidence of racism in GMC complaints procedures	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					133	133		10.1136/bmj.321.7254.133	http://dx.doi.org/10.1136/bmj.321.7254.133			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894683	Green Published			2022-12-28	WOS:000088305700011
J	Sharma, A; Kumar, S				Sharma, A; Kumar, S			Induced damage in the developing brain	SCIENCE			English	Letter							ANTIEPILEPTIC DRUGS; TERATOGENESIS; RATS		Cent Inst Med & Aromat Plants, Lucknow 226015, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Institute of Medicinal & Aromatic Plants (CIMAP)	Sharma, A (corresponding author), Cent Inst Med & Aromat Plants, Picnic Spot Rd, Lucknow 226015, Uttar Pradesh, India.		; Kivisild, Toomas/P-5889-2017	Sharma, Abhay/0000-0003-1306-1497; Kivisild, Toomas/0000-0002-6297-7808				Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; DOW KE, 1989, NEW ENGL J MED, V321, P1480; FINNELL RH, 1987, TERATOLOGY, V35, P177, DOI 10.1002/tera.1420350203; MINCK DR, 1991, TERATOLOGY, V43, P279, DOI 10.1002/tera.1420430402; Samren EB, 1997, EPILEPSIA, V38, P981, DOI 10.1111/j.1528-1157.1997.tb01480.x; VORHEES CV, 1987, TERATOLOGY, V35, P195, DOI 10.1002/tera.1420350205; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114	7	42	42	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					977	977						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10841717				2022-12-28	WOS:000086988400018
J	Atwood, JE; Osterberg, L				Atwood, JE; Osterberg, L			Constrictive pericarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA		Atwood, JE (corresponding author), Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA.								0	0	0	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					106	106		10.1056/NEJM200007133430205	http://dx.doi.org/10.1056/NEJM200007133430205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891518				2022-12-28	WOS:000088116500005
J	Valleroy, LA; MacKellar, DA; Karon, JM; Rosen, DH; McFarland, W; Shehan, DA; Stoyanoff, SR; LaLota, M; Celentano, DD; Koblin, BA; Thiede, H; Katz, MH; Torian, LV; Janssen, RS				Valleroy, LA; MacKellar, DA; Karon, JM; Rosen, DH; McFarland, W; Shehan, DA; Stoyanoff, SR; LaLota, M; Celentano, DD; Koblin, BA; Thiede, H; Katz, MH; Torian, LV; Janssen, RS		Young Mens Survey Study Grp	HIV prevalence and associated risks in young men who have sex with men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; UNPROTECTED ANAL INTERCOURSE; SAN-FRANCISCO; BISEXUAL MEN; VACCINE TRIALS; UNITED-STATES; GAY MEN; BEHAVIORS; SEROCONVERSION; HEALTH	Context Studies conducted in the late 1980s on human immunodeficiency virus (HIV) infection among older men who have sex with men (MSM) suggested the epidemic had peaked; however, more recent studies in younger MSM have suggested continued high HIV incidence. Objective To investigate the current state of the HIV epidemic among adolescent and young adult MSM in the United States by assessing the prevalence of HIV infection and associated risks in this population in metropolitan areas. Design The Young Men's Survey, a cross-sectional, multisite, venue-based survey conducted from 1994 through 1998. Setting One hundred ninety-four public venues frequented by young MSM in Baltimore, Md; Dallas, Tex; Los Angeles, Calif; Miami, Fla; New York, NY; the San Francisco (Calif) Bay Area; and Seattle, Wash. Subjects A total of 3492 15- to 22-year-old MSM who consented to an interview and HIV testing. Main Outcome Measures Prevalence of HIV infection and associated characteristics and risk behaviors. Results Prevalence of HIV infection was high (overall, 7.2%; range for the 7 areas, 2.2%-12.1%) and increased with age, from 0% among 15-year-olds to 9.7% among 22-year-olds. Multivariate-adjusted HIV infection prevalence was higher among blacks (odds ratio [OR], 6.3; 95% confidence interval [CI], 4.1-9.8), young men of mixed or other race (OR, 4.8; 95% CI, 3.0-7.6), and Hispanics (OR, 2.3; 95% CI, 1.5-3.4), compared with whites (referent) and Asian Americans and Pacific Islanders (OR, 1.1; 95% CI, 0.5-2.8). Factors most strongly associated with HIV infection were being black, mixed, or other race; having ever had anal sex with a man (OR, 5.0; 95% CI, 1.8-13.8); or having had sex with 20 or more men (OR, 3.0; 95% CI, 2.0-4.7). Only 46 (18%) of the 249 HIV-positive men knew they were infected before this testing; 37 (15%) were receiving medical care for HIV, and 19 (8%) were receiving medical drug therapy for HIV. Prevalence of unprotected anal sex during the past 6 months was high (overall, 41%; range, 33%-49%). Conclusions Among these young MSM, HIV prevalence was high, underscoring the need to evaluate and intensify prevention efforts for young MSM, particularly blacks, men of mixed race or ethnicity, Hispanics, and adolescents.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; San Francisco Dept Publ Hlth, San Francisco, CA USA; Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Florida Dept Hlth, Tallahassee, FL USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD USA; New York Blood Ctr, New York, NY 10021 USA; New York City Dept Hlth, New York, NY 10013 USA; Publ Hlth Seattle & King Cty, Seattle, WA USA	Centers for Disease Control & Prevention - USA; San Francisco Department of Public Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Florida Department of Health; Johns Hopkins University; New York Blood Center; New York City Department of Health & Mental Hygiene	Valleroy, LA (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, NCHSTP, Mailstop E-46,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	lav0@cdc.gov						ASCHER DP, 1993, J ACQ IMMUN DEF SYND, V6, P241; Breslow NE, 1980, STAT METHODS CANC RE; Buchbinder SP, 1996, J INFECT DIS, V174, P954, DOI 10.1093/infdis/174.5.954; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P45; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P773; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; DEAN L, 1995, J ACQ IMMUN DEF SYND, V8, P208; DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; Katz MH, 1998, J ACQ IMMUN DEF SYND, V19, P178, DOI 10.1097/00042560-199810010-00012; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; Koblin BA, 1996, AIDS, V10, P1555, DOI 10.1097/00002030-199611000-00015; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MacKellar D, 1996, PUBLIC HEALTH REP, V111, P138; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCKUSICK L, 1990, AM J PUBLIC HEALTH, V80, P978, DOI 10.2105/AJPH.80.8.978; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; Ruiz J, 1998, SEX TRANSM DIS, V25, P100, DOI 10.1097/00007435-199802000-00007; Seage GR, 1997, PUBLIC HEALTH REP, V112, P158; STALL R, 1992, J ACQ IMMUN DEF SYND, V5, P682; Unger T F, 1995, J Perinatol, V15, P152; Valleroy LA, 1998, J ACQ IMMUN DEF SYND, V19, P67, DOI 10.1097/00042560-199809010-00011; Weinstock H, 1998, J ACQ IMMUN DEF SYND, V19, P506, DOI 10.1097/00042560-199812150-00010; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472	26	467	473	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					198	204		10.1001/jama.284.2.198	http://dx.doi.org/10.1001/jama.284.2.198			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	329XE	10889593				2022-12-28	WOS:000087933100024
J	Charatan, F				Charatan, F			US court refutes Nebraska's antiabortion law	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					70	70						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884248				2022-12-28	WOS:000088196600016
J	Kerpelman, LC; Connell, DB; Gunn, WJ				Kerpelman, LC; Connell, DB; Gunn, WJ			Effect of a monetary sanction on immunization rates of recipients of aid to families with dependent children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARYLAND	Context Immunization rates among low-income families have lagged behind those for the general community, with several possible barriers cited in the literature. Objective To evaluate the effect of an initiative aimed at improving immunization rates among low-income preschool children by imposing a sanction on families who failed to provide proof of up-to-date immunization status. Design and Setting Randomized, controlled before-after trial conducted from January 1, 1993, through December 31, 1996, in Muscogee County, Georgia. Participants A total of 2500 families with children aged 6 years or younger who received Aid to Families with Dependent Children assistance. Intervention Families in the intervention group (n = 1500) were informed that receipt of the welfare benefit for any preschool-aged children was contingent on provision of proof of up-to-date immunization status at the beginning of welfare eligibility and, subsequently, semiannually or annually, Case families in the control group (n = 1000) were encouraged to immunize their preschool children but were not informed of any aid sanctions nor did such sanctions apply to them. Main Outcome Measure Age-appropriate rates of 5 immunizations (measles-mumps-rubella; poliovirus; diphtheria and tetanus toxoids and pertussis; Haemophilus influenzae type b; and hepatitis B), based on examination (with family's written consent) of medical provider records, compared among intervention-group vs control-group families. Results There were no significant differences at baseline between intervention and control families in immunization rates of preschool children. Families in the intervention group were significantly more likely than families in the control group to have up-to-date immunization status in all 4 years of the study for all 5 immunizations (with 3 exceptions). At age 2 years, 72.4% of children in the intervention group vs 60.6% of those in the control group achieved vaccine series completion, which included 4 diphtheria and tetanus toxoids and pertussis, 3 poliovirus, and 1 measles-mumps-rubella (P < .001). Sanctions were implemented only 11 times. There was relatively little increased burden on the part of families to comply with requirements. Conclusion In our study, a monetary sanction in a population receiving welfare benefits stimulated a significant increase in childhood immunization rates, suggesting that when welfare recipients are given an incentive to keep their children's immunizations up-to-date, most are able to do so.	ABT Associates Inc, Cambridge, MA 02138 USA; Arlington Associates, Cambridge, MA USA	ABT Associates	Kerpelman, LC (corresponding author), ABT Associates Inc, 55 Wheeler St, Cambridge, MA 02138 USA.							ALUDERDALE DS, 1999, JAMA-J AM MED ASSOC, V282, P1725; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BESHAROV DJ, 1997, EVALUATING WELFARE R; Bolton P, 1998, PUBLIC HEALTH REP, V113, P521; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P956; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P176; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P613; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P619; FOSSETT JW, 1992, J HEALTH POLIT POLIC, V17, P273, DOI 10.1215/03616878-17-2-273; GEORGE E, 1993, NEEDLING SYSTEM WELF; GRABOWSKY M, 1996, PEDIATRICS, V97, P729; LANNON C, 1995, ARCH PEDIAT ADOL MED, V149, P1070, DOI 10.1001/archpedi.1995.02170230024003; Minkovitz C, 1999, ARCH PEDIAT ADOL MED, V153, P1242, DOI 10.1001/archpedi.153.12.1242; ROBINSON CA, 1993, PUBLIC HEALTH REP, V108, P419; *SCHAEF CTR PUBL P, 1997, MAR PRIM PREV IN FIN; WILLIAMS IT, 1994, ARCH PEDIAT ADOL MED, V148, P350, DOI 10.1001/archpedi.1994.02170040016003; WOOD D, 1995, PEDIATRICS, V96, P295	18	27	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					53	59		10.1001/jama.284.1.53	http://dx.doi.org/10.1001/jama.284.1.53			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	328GX	10872013				2022-12-28	WOS:000087843000025
J	Morrison, RS; Siu, AL				Morrison, RS; Siu, AL			Survival in end-stage dementia following acute illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; HIP FRACTURE; PREDICTORS; MORTALITY; CARE; EXPERIENCE; PNEUMONIA; ADULTS; TIME	Context Little is known about the prognosis of acutely ill patients with end-stage dementia or about the type of care that these patients receive. If their prognosis is poor, then emphasis should be placed on palliative care for these patients rather than on curative interventions. Objectives To examine survival for patients with end-stage dementia following hospitalization for hip fracture or pneumonia and to com pare their care with that of cognitively intact older adults. Design Prospective cohort study with 6 months of follow-up. Setting and Patients Patients aged 70 years or older who were hospitalized with hip fracture (cognitively intact, n = 59; with end-stage dementia, n = 38) or pneumonia (cognitively intact, n = 39; with end-stage dementia, n = 80) in a large hospital in New York, NY, between September 1, 1996, and March 1, 1998, Main Outcome Measures Mortality, treatments directed at symptoms, and application of distressing and painful procedures in cognitively intact patients vs those with end-stage dementia. Results Six-month mortality for patients with end-stage dementia and pneumonia was 53% (95% confidence interval [CI], 41%-64%) compared with 13% (95% CI, 4%-27%) for cognitively intact patients (adjusted hazard ratio, 4.6; 95% CI, 1.8-11.8), Six month mortality for patients with end-stage dementia and hip fracture was 55% (95% CI, 42%-75%) compared with 12% (95% CI, 5%-24%) for cognitively intact patients (adjusted hazard ratio, 5.8; 95% CI, 1.7-20.4). Patients with end-stage dementia received as many burdensome procedures as cognitively intact patients and only 8 (7%) of 118 patients with end-stage dementia had a documented decision made to forego a life-sustaining treatment other than cardiopulmonary resuscitation, Only 24% of patients with end-stage dementia and hip fracture received a standing order for analgesics. Conclusions In this study, patients with advanced dementia and hip fracture or pneumonia had a very poor prognosis. Given the limited life expectancy of patients with endstage dementia following these illnesses and the burdens associated with their treatment, increased attention should be focused on efforts to enhance comfort in this patient population.	CUNY Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Morrison, RS (corresponding author), CUNY Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl, New York, NY 10029 USA.				AHRQ HHS [U18HS09549-0] Funding Source: Medline; NIA NIH HHS [K08AG00833-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R13HS009549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000833] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACKERMANN RJ, 1995, J FAM PRACTICE, V40, P129; Aguero-Torres H, 1998, J AM GERIATR SOC, V46, P444, DOI 10.1111/j.1532-5415.1998.tb02464.x; Bowen JD, 1996, NEUROLOGY, V47, P433, DOI 10.1212/WNL.47.2.433; Claus JJ, 1998, DEMENT GERIATR COGN, V9, P284, DOI 10.1159/000017073; DAVIDSON TI, 1986, INJURY, V17, P12, DOI 10.1016/0020-1383(86)90005-7; FABISZEWSKI KJ, 1990, JAMA-J AM MED ASSOC, V263, P3168, DOI 10.1001/jama.263.23.3168; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Hanrahan P, 1995, Hosp J, V10, P47; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; INCALZI RA, 1994, J TRAUMA, V36, P79; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; LUYAO GL, 1994, AM J PUBLIC HEALTH, V84, P1287, DOI 10.2105/AJPH.84.8.1287; MAGAZINER J, 1990, J GERONTOL, V45, pM101, DOI 10.1093/geronj/45.3.M101; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; MCGEER A, 1991, AM J INFECT CONTROL, V19, P1, DOI 10.1016/0196-6553(91)90154-5; Morrison RS, 1998, J PAIN SYMPTOM MANAG, V15, P91, DOI 10.1016/S0885-3924(97)00261-3; Muder RR, 1996, ARCH INTERN MED, V156, P2365, DOI 10.1001/archinte.156.20.2365; *OFF TECHN ASS CON, 1990, BURD FAM FIND HELP P; Reisberg B, 1996, Int Psychogeriatr, V8, P291, DOI 10.1017/S1041610296002657; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; ROCCAFORTE WH, 1992, J AM GERIATR SOC, V40, P697, DOI 10.1111/j.1532-5415.1992.tb01962.x; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; Vigano A, 2000, ARCH INTERN MED, V160, P861, DOI 10.1001/archinte.160.6.861; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x	25	262	264	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					47	52		10.1001/jama.284.1.47	http://dx.doi.org/10.1001/jama.284.1.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	328GX	10872012	Bronze			2022-12-28	WOS:000087843000024
J	Macfarlane, GJ; Thomas, E; Cherry, N				Macfarlane, GJ; Thomas, E; Cherry, N			Mortality among UK Gulf War veterans	LANCET			English	Article							VIETNAM; HEALTH; COUNTERPOINT	Background Armed forces personnel who served in the Gulf War report more current ill-health than those who were not deployed. There has been concern expressed that they may also experience higher mortality rates. Methods A retrospective cohort study was done including all 53 462 UK Gulf War veterans (Gulf cohort) and a comparison group equivalent in size of personnel who were not deployed but matched for age, sex, rank, service, and level of fitness (Era cohort). Individuals were identified on central registers of the Office for National Statistics and information on death among cohort subjects, including cause of death, obtained. Follow-up extended from April 1, 1991 (the end of the Gulf War) until March 31, 1999. Findings There were 395 deaths among the Gulf cohort and 378 deaths amongst the Era cohort (mortality rate ratio [MRR] 1.05, 95% CI 0.91-1.21). Mortality from "external" causes was higher in the Gulf cohort (Gulf 254, Era 216; MRR 1.18 [0.98-1.42] while mortality from "disease-related" causes was lower (Gulf 122, Era 141; 0.87 [0.67-1.11]). The higher mortality rate from "external" causes in the Gulf cohort was principally due to higher mortality rates from accidents. There was, however, no excess of deaths recorded as suicide in the Gulf cohort. Interpretation This follow-up of Veterans of the Gulf war has shown, 8 years after the end of the conflict, that although they have experienced higher mortality rates than a comparison cohort, the excess mortality rate is very small and does not approach statistical significance. The excess is related mainly to accidents rather than disease, a pattern that is consistent both with US veterans of the Gulf war and veterans from other conflicts.	Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Unit Chron Dis Epidemiol, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Arthrit Res Campaign, Epidemiol Unit, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Epidemiol & Hlth Sci, Ctr Environm & Occupat Hlth, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester; University of Manchester	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Med, Sch Epidemiol & Hlth Sci, Unit Chron Dis Epidemiol, Oxford Rd, Manchester M13 9PT, Lancs, England.		Macfarlane, Gary J/I-9521-2014	Macfarlane, Gary J/0000-0003-2322-3314				BOYLE CA, 1989, EPIDEMIOL REV, V11, P1; BRESLIN P, 1988, J OCCUP ENVIRON MED, V30, P412, DOI 10.1097/00043764-198805000-00007; *CDC VIETN EXP STU, 1987, JAMA-J AM MED ASSOC, V257, P7890; Gray GC, 1998, AM J EPIDEMIOL, V148, P328; Haley RW, 1998, AM J EPIDEMIOL, V148, P315, DOI 10.1093/oxfordjournals.aje.a009645; Kang HK, 1998, AM J EPIDEMIOL, V148, P324; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; Rothman K, 1986, MODERN EPIDEMIOLOGY; THOMAS TL, 1991, AM J EPIDEMIOL, V134, P973, DOI 10.1093/oxfordjournals.aje.a116182; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; WHO (World Health Organization), 1977, MAN INT STAT CLASS D	11	63	63	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					17	21		10.1016/S0140-6736(00)02428-4	http://dx.doi.org/10.1016/S0140-6736(00)02428-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892759				2022-12-28	WOS:000087933400010
J	Glowatzki, E; Fuchs, PA				Glowatzki, E; Fuchs, PA			Cholinergic synaptic inhibition of inner hair cells in the neonatal mammalian cochlea	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR SUBUNIT; POTASSIUM CURRENT; WAITING PERIOD; RAT COCHLEA; RT-PCR; EXPRESSION; ALPHA-9; INNERVATION; RESPONSES; SYSTEM	Efferent feedback onto sensory organs provides a means to modulate input to the central nervous system. In the developing mammalian cochlea, inner hair cells are transiently innervated by efferent fibers, even before sensory function begins. Here, we show that neonatal inner hair cells are inhibited by cholinergic synaptic input before the onset of hearing. The synaptic currents, as well as the inner hair cell's response to acetylcholine, are mediated by a nicotinic (alpha 9-containing) receptor and result in the activation of small-conductance calcium-dependent potassium channels.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Ctr Hearing Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Glowatzki, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Ctr Hearing Sci, Baltimore, MD 21205 USA.			Glowatzki, Elisabeth/0000-0003-3135-658X	NIDCD NIH HHS [DC 00276] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ART JJ, 1984, J PHYSIOL-LONDON, V356, P525, DOI 10.1113/jphysiol.1984.sp015481; Blanchet C, 1996, J NEUROSCI, V16, P2574; BOULTER J, AF196344 GENB; Dulon D, 1996, EUR J NEUROSCI, V8, P1945, DOI 10.1111/j.1460-9568.1996.tb01338.x; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; EMMERLING MR, 1990, J ELECTRON MICR TECH, V15, P123, DOI 10.1002/jemt.1060150205; Evans MG, 1996, J PHYSIOL-LONDON, V491, P563, DOI 10.1113/jphysiol.1996.sp021240; FUCHS PA, 1992, P ROY SOC B-BIOL SCI, V248, P35, DOI 10.1098/rspb.1992.0039; GINZBERG RD, 1984, HEARING RES, V14, P109, DOI 10.1016/0378-5955(84)90011-X; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V262, P141, DOI 10.1098/rspb.1995.0188; GUMMER AW, 1994, NEUROREPORT, V5, P685, DOI 10.1097/00001756-199402000-00006; He DZZ, 1999, J NEUROPHYSIOL, V81, P1162, DOI 10.1152/jn.1999.81.3.1162; Hiel H, 2000, BRAIN RES, V858, P215, DOI 10.1016/S0006-8993(00)01947-8; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; LENOIR M, 1980, ANAT EMBRYOL, V160, P253, DOI 10.1007/BF00305106; LIPPE WR, 1994, J NEUROSCI, V14, P1486, DOI 10.1523/JNEUROSCI.14-03-01486.1994; Lustig LR, 1999, J VESTIBUL RES-EQUIL, V9, P359; LUSTIG LR, AF199235 GENB; Morley BJ, 1998, MOL BRAIN RES, V53, P78, DOI 10.1016/S0169-328X(97)00272-6; Park HJ, 1997, HEARING RES, V112, P95, DOI 10.1016/S0378-5955(97)00111-1; PUJOL R, 1996, J PHYSIOL-PARIS, V61, P411; SANES DH, 1998, DEV AUDITORY SYSTEM, P271; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; Simmons DD, 1998, J COMP NEUROL, V397, P281; Simmons DD, 1998, MOL BRAIN RES, V56, P287, DOI 10.1016/S0169-328X(98)00056-4; Simmons DD, 1996, J COMP NEUROL, V370, P551, DOI 10.1002/(SICI)1096-9861(19960708)370:4<551::AID-CNE10>3.0.CO;2-M; SOBKOWICZ HM, 1994, HEARING RES, V75, P81, DOI 10.1016/0378-5955(94)90059-0; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; UZIEL A, 1981, AUDIOLOGY, V20, P89; WALSH EJ, 1997, DIVERSITY AUDITORY M, P376	30	229	236	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2366	2368		10.1126/science.288.5475.2366	http://dx.doi.org/10.1126/science.288.5475.2366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875922				2022-12-28	WOS:000087913400040
J	Leinders-Zufall, T; Lane, AP; Puche, AC; Ma, WD; Novotny, MV; Shipley, MT; Zufall, F				Leinders-Zufall, T; Lane, AP; Puche, AC; Ma, WD; Novotny, MV; Shipley, MT; Zufall, F			Ultrasensitive pheromone detection by mammalian vomeronasal neurons	NATURE			English	Article							OLFACTORY RECEPTOR NEURONS; FEMALE MICE; RESPONSE PROPERTIES; SYNTHETIC ANALOGS; MULTIGENE FAMILY; HOUSE MOUSE; PUBERTY; SYSTEM; IDENTIFICATION; ORGANIZATION	The vomeronasal organ (VNO) is a chemoreceptive organ that is thought to transduce pheromones into electrical responses that regulate sexual, hormonal and reproductive function in mammals(1-5). The characteristics of pheromone signal detection by vomeronasal neurons remain unclear(3,5). Here we use a mouse VNO slice preparation to show that six putative pheromones evoke excitatory responses in single vomeronasal neurons, leading to action potential generation and elevated calcium entry. The detection threshold for some of these chemicals is remarkably low, near 10(-11) M, placing these neurons among the most sensitive chemodetectors in mammals. Using confocal calcium imaging, we map the epithelial representation of the pheromones to show that each of the ligands activates a unique, nonoverlapping subset of vomeronasal neurons located in apical zones of the epithelium. These neurons show highly selective tuning properties and their tuning curves do not broaden with increasing concentrations of ligand, unlike those of receptor neurons in the main olfactory epithelium. These findings provide a basis for understanding chemical signals that regulate mammalian communication and sexual behaviour.	Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Zufall, F (corresponding author), Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA.		Leinders-Zufall, Trese/S-3664-2019; Zufall, Frank/AAE-5290-2021; Leinders-Zufall, Trese/B-4103-2009	Leinders-Zufall, Trese/0000-0002-0678-362X; Zufall, Frank/0000-0002-4383-8618; Leinders-Zufall, Trese/0000-0002-0678-362X				Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; Belluscio L, 1999, CELL, V97, P209, DOI 10.1016/S0092-8674(00)80731-X; Berghard A, 1996, J NEUROSCI, V16, P909; Bozza TC, 1998, J NEUROSCI, V18, P4560; Duchamp-Viret P, 1999, SCIENCE, V284, P2171, DOI 10.1126/science.284.5423.2171; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; Inamura K, 1997, CHEM SENSES, V22, P93, DOI 10.1093/chemse/22.1.93; JEMIOLO B, 1989, PHYSIOL BEHAV, V46, P293, DOI 10.1016/0031-9384(89)90270-9; JEMIOLO B, 1986, P NATL ACAD SCI USA, V83, P4576, DOI 10.1073/pnas.83.12.4576; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Leinders-Zufall T, 1998, J NEUROSCI, V18, P5630; LeindersZufall T, 1997, J NEUROSCI, V17, P4136; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; NOVOTNY M, 1984, EXPERIENTIA, V40, P217, DOI 10.1007/BF01963608; NOVOTNY M, 1986, SCIENCE, V231, P722, DOI 10.1126/science.3945805; Novotny MV, 1999, CHEM BIOL, V6, P377, DOI 10.1016/S1074-5521(99)80049-0; Novotny MV, 1999, P ROY SOC B-BIOL SCI, V266, P2017, DOI 10.1098/rspb.1999.0880; RESTREPO D, 1993, J GEN PHYSIOL, V102, P907, DOI 10.1085/jgp.102.5.907; Rodriguez I, 1999, CELL, V97, P199, DOI 10.1016/S0092-8674(00)80730-8; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Wysocki C.J., 1987, P125; ZIDEK L, UNPUB CHEM SENSES	30	446	458	2	40	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					792	796		10.1038/35015572	http://dx.doi.org/10.1038/35015572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866200				2022-12-28	WOS:000087620600051
J	Morris, J; Lehmann, R; Navarro, C				Morris, J; Lehmann, R; Navarro, C			Development - PARallels in axis formation	SCIENCE			English	Editorial Material							CAENORHABDITIS-ELEGANS; POLARITY; LOCALIZATION; PAR-1		NYU, Sch Med, Dept Cell Biol,Dev Genet Program, Howard Hughes Med Inst,Skirball Inst, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University	Morris, J (corresponding author), NYU, Sch Med, Dept Cell Biol,Dev Genet Program, Howard Hughes Med Inst,Skirball Inst, 540 1st Ave, New York, NY 10016 USA.			Navarro, Caryn/0000-0002-9701-477X				Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ETERNADMOGHADAM B, 1995, CELL, V83, P743; Gruidl ME, 1996, P NATL ACAD SCI USA, V93, P13837, DOI 10.1073/pnas.93.24.13837; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Nelson WJ, 1997, CURR BIOL, V7, pR562, DOI 10.1016/S0960-9822(06)00282-X; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; TOMANCAK P, IN PRESS NATURE CELL; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128	16	3	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 9	2000	288	5472					1759	1760		10.1126/science.288.5472.1759	http://dx.doi.org/10.1126/science.288.5472.1759			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	322HH	10877696				2022-12-28	WOS:000087503800034
J	Super, M				Super, M			CFTR and disease: implications for drug development	LANCET			English	Editorial Material							CYSTIC-FIBROSIS GENE; REGULATOR; CLONING		Royal Manchester Childrens Hosp, Reg Cyst Fibrosis Ctr, Manchester M27 4HA, Lancs, England	Royal Manchester Children's Hospital	Super, M (corresponding author), Royal Manchester Childrens Hosp, Reg Cyst Fibrosis Ctr, Manchester M27 4HA, Lancs, England.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BAXTER PS, 1988, NATURE, V335, P211, DOI 10.1038/335211a0; Cai Z, 1999, BRIT J PHARMACOL, V128, P108, DOI 10.1038/sj.bjp.0702748; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; O'Sullivan DA, 1998, AM J KIDNEY DIS, V32, P976, DOI 10.1016/S0272-6386(98)70072-1; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz B. D., 1999, Physiological Reviews, V79, pS109; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SUPER M, 1999, PAEDIAT PULMONOL, V19, P208; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilschanski M, 2000, AM J RESP CRIT CARE, V161, P860, DOI 10.1164/ajrccm.161.3.9904116; 1999, PAEDIAT PULMONOL S, V19, P87	15	4	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1840	1842		10.1016/S0140-6736(00)02282-0	http://dx.doi.org/10.1016/S0140-6736(00)02282-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866434				2022-12-28	WOS:000087306500004
J	Munro, J; Nicholl, J; O'Cathain, A; Knowles, E				Munro, J; Nicholl, J; O'Cathain, A; Knowles, E			Impact of NHS Direct on demand for immediate care: observational study	BRITISH MEDICAL JOURNAL			English	Article							NURSE	Objectives To quantify the impact of NHS Direct on the use of accident and emergency, ambulance, and general practitioner cooperative services. Design Observational study of trends in use of NHS Direct and other immediate care services over 24 months spanning introduction of NHS Direct Setting Three areas in England in first wave of introduction of NHS Direct, and six nearby general practitioner cooperatives as controls. Subjects All contacts with these immediate care services. Main outcome measures Changes in trends in use after introduction of NHS Direct. Results NHS Direct received about 68 500 calls from a population of 1.3 million in its first year of operation, of which 72% were out of hours and 22% about a child aged under 5 years. Changes in trends in use of accident and emergency departments and ambulance services after introduction of NHS Direct were small and non-significant. Changes in trends in use of general practitioner cooperatives were also small but significant, from an increase of 2.0% a month before introduction of NHS Direct to -0.8% afterwards (relative change -2.9% (95% confidence interval -4.2% to -1.5%)). This reduction in trend was significant both for calls handled by telephone advice alone and for those resulting in direct contact with a doctor. In contrast, the six control cooperatives showed no evidence of change in trend; an increase of 0.8% a month before NHS Direct and 0.9% after (relative change 0.1% (-0.9% to 1.1%)). Conclusion In its first year NHS Direct did not reduce the pressure on NHS immediate care services, although it may have restrained increasing demand on one important part-general practitioners' out of hours services.	Univ Sheffield, Med Care Res Unit, Sheffield, S Yorkshire, England	University of Sheffield	Munro, J (corresponding author), Univ Sheffield, Med Care Res Unit, Regent Court, Sheffield, S Yorkshire, England.		Nicholl, Jon/B-8257-2008					Balas EA, 1997, JAMA-J AM MED ASSOC, V278, P152, DOI 10.1001/jama.278.2.152; CALMAN K, 1997, DEV EMERGENCY SERVIC; *DEP HLTH, 1998, DMD 3807; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Gallagher M, 1998, BRIT J GEN PRACT, V48, P1141; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054; MUNRO J, 1999, EVALUATION NHS DIREC; MUNRO J, 2000, EVALUATION NHS DIREC; WATT N, 2000, GUARDIAN        0320, P1	9	128	129	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					150	153		10.1136/bmj.321.7254.150	http://dx.doi.org/10.1136/bmj.321.7254.150			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894694	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000088305700023
J	Finkelstein, G; Glicofridis, PI; Ashoori, RC; Shayegan, M				Finkelstein, G; Glicofridis, PI; Ashoori, RC; Shayegan, M			Topographic mapping of the quantum hall liquid using a few-electron bubble	SCIENCE			English	Article							MAGNETIC-FIELD; STATES; REGIME; EDGE; CURRENTS; DENSITY; ANTIDOT; DOT	A scanning probe technique was used to obtain a high-resolution map of the random electrostatic potential inside the quantum Hall liquid. A sharp metal tip, scanned above a semiconductor surface, sensed charges in an embedded two-dimensional (2D) electron gas. Under quantum Hall effect conditions, applying a positive voltage to the tip locally enhanced the 2D electron density and created a "bubble" of electrons in an otherwise unoccupied Landau Level. As the rip scanned along the sample surface, the bubble followed underneath. The tip sensed the motions of single electrons entering or leaving the bubble in response to changes in the Local 2D electrostatic potential.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Princeton University	Finkelstein, G (corresponding author), MIT, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							ASHOORI RC, 1993, PHYS REV LETT, V71, P613, DOI 10.1103/PhysRevLett.71.613; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; ASHOORI RC, 1992, PHYS REV LETT, V68, P3088, DOI 10.1103/PhysRevLett.68.3088; BEENAKKER CWJ, 1990, PHYS REV LETT, V64, P216, DOI 10.1103/PhysRevLett.64.216; CHANG AM, 1990, SOLID STATE COMMUN, V74, P871, DOI 10.1016/0038-1098(90)90447-J; CHKLOVSKII DB, 1992, PHYS REV B, V46, P4026, DOI 10.1103/PhysRevB.46.4026; EFROS AL, 1988, SOLID STATE COMMUN, V65, P1281, DOI 10.1016/0038-1098(88)90077-4; EFROS AL, 1988, SOLID STATE COMMUN, V67, P1019, DOI 10.1016/0038-1098(88)91177-5; Eriksson MA, 1996, APPL PHYS LETT, V69, P671, DOI 10.1063/1.117801; Finkelstein G, 2000, PHYS REV B, V61, pR16323, DOI 10.1103/PhysRevB.61.R16323; Kataoka M, 1999, PHYS REV LETT, V83, P160, DOI 10.1103/PhysRevLett.83.160; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; Maasilta IJ, 1998, PHYS REV B, V57, pR4273, DOI 10.1103/PhysRevB.57.R4273; McCormick KL, 1999, PHYS REV B, V59, P4654, DOI 10.1103/PhysRevB.59.4654; Prange R. E., 1990, QUANTUM HALL EFFECT; SHOCKLEY W, 1963, PHYS REV LETT, V11, P489, DOI 10.1103/PhysRevLett.11.489; Tessmer SH, 1998, NATURE, V392, P51, DOI 10.1038/32112; VANDERVAART NC, 1994, PHYS REV LETT, V73, P320, DOI 10.1103/PhysRevLett.73.320; Yacoby A, 1999, SOLID STATE COMMUN, V111, P1, DOI 10.1016/S0038-1098(99)00139-8	19	104	105	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	2000	289	5476					90	94		10.1126/science.289.5476.90	http://dx.doi.org/10.1126/science.289.5476.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884231	Green Submitted			2022-12-28	WOS:000088090400037
J	Rensenbrink, K				Rensenbrink, K			Pretzels and fruitcake	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Ellsworth Internal Med, Ellsworth, ME 04605 USA		Rensenbrink, K (corresponding author), Ellsworth Internal Med, Ellsworth, ME 04605 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					71	71		10.7326/0003-4819-133-1-200007040-00013	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877743				2022-12-28	WOS:000087923100010
J	Frankel, S; Ebrahim, S; Smith, GD				Frankel, S; Ebrahim, S; Smith, GD			The limits to demand for health care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY ADMISSIONS; DEATH; EPIDEMIOLOGY; CATARACT; SERVICES; ENGLAND; SURGERY; PLACE		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	stephen.frankel@bris.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ALTMAN SH, 1979, MED TECHNOLOGY CULPR, P24; Bagust A, 1999, BRIT MED J, V319, P155, DOI 10.1136/bmj.319.7203.155; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Blatchford O, 1999, BRIT MED J, V319, P1201; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; Coulter A., 2000, GLOBAL CHALLENGE HLT; COURTNEY P, 1992, EYE, V6, P487, DOI 10.1038/eye.1992.103; Department of Health, 2000, SHAP FUT NHS LONG TE; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; Frankel S, 1999, LANCET, V353, P1304, DOI 10.1016/S0140-6736(98)06451-4; FRANKEL SJ, 1989, HLTH TRENDS, V21, P54; Grande GE, 1998, SOC SCI MED, V47, P565, DOI 10.1016/S0277-9536(98)00115-4; GRUNDY E, 1997, HLTH ADULT BRITAIN 1, P182; HAM C, 1999, BRIT MED J, V318, P1258; Hart J T, 1976, J R Coll Gen Pract, V26, P885; Higginson IJ, 1998, PALLIATIVE MED, V12, P353, DOI 10.1191/026921698672530176; Himsworth RL, 1999, BRIT MED J, V319, P1338, DOI 10.1136/bmj.319.7221.1338; HOPPER C, 1999, J EPIDEMIOL COMMUNIT, V53, P661; Khaw KT, 1999, BRIT MED J, V319, P1350, DOI 10.1136/bmj.319.7221.1350; Klein R, 1998, BMJ-BRIT MED J, V317, P959, DOI 10.1136/bmj.317.7164.959; LACRONIQUE J, 1985, INNOVATION HLTH POLI, P87; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; MCCORMICK A, 1995, MORBIDITY STAT GEN P; Morgan K, 1999, BRIT MED J, V319, P158, DOI 10.1136/bmj.319.7203.158; Murphy S, 1998, J Health Serv Res Policy, V3, P215; *OFF NAT STAT, 1997, LIV BRIT RES GEN HOU; PERDERSEN TR, 1996, CIRCULATION, V93, P1796; Smith GD, 1999, LANCET, V353, P1097, DOI 10.1016/S0140-6736(05)76452-7; SWERDLOW A, 1997, HLTH ADULT BRITAIN 1, P30; THOMAS HF, 1989, BRIT MED J, V299, P961, DOI 10.1136/bmj.299.6705.961; TOYNBEE P, 2000, GUARDIAN        0531, P1; VATES J, 1995, PRIVATE EYE HEART HI; Wood D, 1998, HEART, V80, pS1	37	34	35	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					40	44		10.1136/bmj.321.7252.40	http://dx.doi.org/10.1136/bmj.321.7252.40			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875836	Green Published			2022-12-28	WOS:000088030100028
J	Aitman, TJ; Cooper, LD; Norsworthy, PJ; Wahid, FN; Gray, JK; Curtis, BR; McKeigue, PM; Kwiatkowski, D; Greenwood, BM; Snow, RW; Hill, AV; Scott, J				Aitman, TJ; Cooper, LD; Norsworthy, PJ; Wahid, FN; Gray, JK; Curtis, BR; McKeigue, PM; Kwiatkowski, D; Greenwood, BM; Snow, RW; Hill, AV; Scott, J			Population genetics - Malaria susceptibility and CD36 mutation	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; GLYCOPROTEIN; ANTIGENS; ASIANS		MRC, Ctr Clin Sci, Mol Med Grp, London W12 0NN, England; Hammersmith Hosp, Imperial Coll Genet, London W12 0NN, England; Hammersmith Hosp, Genom Res Inst, London W12 0NN, England; Med Coll Wisconsin, Blood Ctr SE Wisconsin, Milwaukee, WI 53201 USA; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; MRC Labs, Fajara, Gambia; KEMRI, Coastal Res Unit, Kilifi, Kenya; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	Imperial College London; Imperial College London; Medical College of Wisconsin; Versiti Blood Center of Wisconsin; University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology; University of Oxford; Wellcome Centre for Human Genetics	Aitman, TJ (corresponding author), MRC, Ctr Clin Sci, Mol Med Grp, London W12 0NN, England.	t.aitman@csc.mrc.ac.uk	Curtis, Brian R/AAT-7861-2020; HILL, Adrian V>S>/C-1306-2008; Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Kwiatkowski, Dominic/0000-0002-5023-0176; Aitman, Timothy/0000-0002-7875-4502; Norsworthy, Penny/0000-0002-5572-8491				ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Baruch DI, 1999, BLOOD, V94, P2121, DOI 10.1182/blood.V94.6.2121.418k09_2121_2127; Curtis BR, 1996, TRANSFUSION, V36, P331, DOI 10.1046/j.1537-2995.1996.36496226147.x; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749; LIPSKY RH, 1994, HUM MOL GENET, V3, P217, DOI 10.1093/hmg/3.1.217; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; URWIJITAROON Y, 1995, TRANSFUSION, V35, P868, DOI 10.1046/j.1537-2995.1995.351096026370.x	11	168	174	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1015	1016		10.1038/35016636	http://dx.doi.org/10.1038/35016636			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890433				2022-12-28	WOS:000087871700033
J	Barton, RA; Harvey, PH				Barton, RA; Harvey, PH			Mosaic evolution of brain structure in mammals	NATURE			English	Article							PRIMATES; INSECTIVORES; AMYGDALA; VOLUMES; NUCLEI	The mammalian brain comprises a number of functionally distinct systems. It might therefore be expected that natural selection on particular behavioural capacities would have caused size changes selectively, in the systems mediating those capacities(1-3). It has been claimed, however, that developmental constraints limited such mosaic evolution, causing co-ordinated size change among individual brain components(3). Here we analyse comparative data to demonstrate that mosaic change has been an important factor in brain structure evolution. First, the neocortex shows about a fivefold difference in volume between primates and insectivores even after accounting for its scaling relationship with the rest of the brain. Second, brain structures with major anatomical and functional links evolved together independently of evolutionary change in other structures. This is true at the level of both basic brain subdivisions and more fine-grained functional systems. Hence, brain evolution in these groups involved complex relationships among individual brain components.	Univ Durham, Dept Anthropol, Evolutionary Anthropol Res Grp, Durham DH1 3HN, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	Durham University; University of Oxford	Barton, RA (corresponding author), Univ Durham, Dept Anthropol, Evolutionary Anthropol Res Grp, Durham DH1 3HN, England.							BARTON RA, 1995, PHILOS T ROY SOC B, V348, P381, DOI 10.1098/rstb.1995.0076; Butler A. B., 1996, COMP VERTEBRATE NEUR, DOI DOI 10.1002/0471733849.CH19; Cousens G, 1998, BEHAV NEUROSCI, V112, P1092, DOI 10.1037/0735-7044.112.5.1092; Dunbar RIM, 1998, EVOL ANTHROPOL, V6, P178, DOI 10.1002/(SICI)1520-6505(1998)6:5<178::AID-EVAN5>3.0.CO;2-8; Eisenberg J.F., 1981, MAMMALIAN RAD; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FINLAY BL, 1995, SCIENCE, V268, P1578, DOI 10.1126/science.7777856; FINLAY BL, IN PRESS BEHAV BRAIN; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HARVEY PH, 1990, SCIENCE, V249, P140, DOI 10.1126/science.2196673; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; INNOCENTI GM, 1995, TRENDS NEUROSCI, V18, P371, DOI 10.1016/0166-2236(95)93931-M; KAAS JH, 1995, BRAIN BEHAV EVOLUT, V46, P187, DOI 10.1159/000113273; KREBS JR, 1990, PHILOS T ROY SOC B, V329, P153, DOI 10.1098/rstb.1990.0160; MATANO S, 1986, FOLIA PRIMATOL, V47, P189, DOI 10.1159/000156277; MATANO S, 1985, FOLIA PRIMATOL, V44, P182, DOI 10.1159/000156212; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; RINGO JL, 1991, BRAIN BEHAV EVOLUT, V38, P1, DOI 10.1159/000114375; STEPHAN H, 1981, FOLIA PRIMATOL, V35, P1, DOI 10.1159/000155963; Stephan H, 1991, COMP BRAIN RES MAMMA, V1; Swanson LW, 1998, TRENDS NEUROSCI, V21, P323, DOI 10.1016/S0166-2236(98)01265-X	23	501	506	1	136	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1055	1058		10.1038/35016580	http://dx.doi.org/10.1038/35016580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890446				2022-12-28	WOS:000087871700046
J	Steinbach, G; Lynch, PM; Phillips, RKS; Wallace, MH; Hawk, E; Gordon, GB; Wakabayashi, N; Saunders, B; Shen, Y; Fujimura, T; Su, LK; Levin, B; Godio, L; Patterson, S; Rodriguez-Bigas, MA; Jester, SL; King, KL; Schumacher, M; Abbruzzese, J; DuBois, RN; Hittelman, WN; Zimmerman, S; Sherman, JW; Kelloff, G				Steinbach, G; Lynch, PM; Phillips, RKS; Wallace, MH; Hawk, E; Gordon, GB; Wakabayashi, N; Saunders, B; Shen, Y; Fujimura, T; Su, LK; Levin, B; Godio, L; Patterson, S; Rodriguez-Bigas, MA; Jester, SL; King, KL; Schumacher, M; Abbruzzese, J; DuBois, RN; Hittelman, WN; Zimmerman, S; Sherman, JW; Kelloff, G			The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INDUCED COLON CARCINOGENESIS; RHEUMATOID-ARTHRITIS; COLORECTAL-CANCER; SULINDAC THERAPY; RECTAL ADENOMAS; ASPIRIN USE; EXPRESSION; RISK; RATS	Background: Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal antiinflammatory drugs may be related to their inhibition of cyclooxygenase-2. Methods: We studied the effect of celecoxib, a selective cyclooxygenase-2 inhibitor, on colorectal polyps in patients with familial adenomatous polyposis. In a double-blind, placebo-controlled study, we randomly assigned 77 patients to treatment with celecoxib (100 or 400 mg twice daily) or placebo for six months. Patients underwent endoscopy at the beginning and end of the study. We determined the number and size of polyps from photographs and videotapes; the response to treatment was expressed as the mean percent change from base line. Results: At base line, the mean (+/-SD) number of polyps in focal areas where polyps were counted was 15.5+/-13.4 in the 15 patients assigned to placebo, 11.5+/-8.5 in the 32 patients assigned to 100 mg of celecoxib twice a day, and 12.3+/-8.2 in the 30 patients assigned to 400 mg of celecoxib twice a day (P=0.66 for the comparison among groups). After six months, the patients receiving 400 mg of celecoxib twice a day had a 28.0 percent reduction in the mean number of colorectal polyps (P = 0.003 for the comparison with placebo) and a 30.7 percent reduction in the polyp burden (the sum of polyp diameters) (P = 0.001), as compared with reductions of 4.5 and 4.9 percent, respectively, in the placebo group. The improvement in the extent of colorectal polyposis in the group receiving 400 mg twice a day was confirmed by a panel of endoscopists who reviewed the videotapes. The reductions in the group receiving 100 mg of celecoxib twice a day were 11.9 percent (P = 0.33 for the comparison with placebo) and 14.6 percent (P = 0.09), respectively. The incidence of adverse events was similar among the groups. Conclusions: In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps. (N Engl J Med 2000;342:1946-52.) (C)2000, Massachusetts Medical Society.	Univ Texas, MD Anderson Canc Ctr, Div Canc Prevent, Houston, TX 77030 USA; St Marks Hosp, Imperial Canc Res Fund, London EC1V 2PS, England; NCI, Bethesda, MD 20892 USA; GD Searle & Co, Skokie, IL 60077 USA	University of Texas System; UTMD Anderson Cancer Center; Cancer Research UK; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Steinbach, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Canc Prevent, Box 203,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsteinb@aol.com	DuBois, Raymond N./AAX-8869-2020; Saunders, Brian/AAP-4137-2020	Steinbach, Gideon/0000-0001-7597-0544; Shen, Yu/0000-0002-3899-7868	DIVISION OF CANCER PREVENTION AND CONTROL [N01CN065118] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman D.G., 1991, PRACTICAL STAT MED R; Boolbol SK, 1996, CANCER RES, V56, P2556; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Geis GS, 1999, J RHEUMATOL, V26, P31; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Lipsky PE, 1997, J RHEUMATOL, V24, P9; *MED EC, 2000, PHYS DESK REF; *NCI, 1998, CANC THER EV PROGR C; NIV Y, 1994, GASTROENTEROLOGY, V107, P854, DOI 10.1016/0016-5085(94)90136-8; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Piazza GA, 1997, CANCER RES, V57, P2909; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; Reddy BS, 1996, CANCER RES, V56, P4566; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vane JR, 1996, SCAND J RHEUMATOL, P9; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WINDE G, 1995, DIS COLON RECTUM, V38, P813, DOI 10.1007/BF02049838; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Wolfe MM, 1999, NEW ENGL J MED, V341, P548	39	1938	2031	2	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1946	1952		10.1056/NEJM200006293422603	http://dx.doi.org/10.1056/NEJM200006293422603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874062				2022-12-28	WOS:000087867400003
J	Woodward, J; Orr, M; Cordray, K; Greenbaum, E				Woodward, J; Orr, M; Cordray, K; Greenbaum, E			Biotechnology - Enzymatic production of biohydrogen	NATURE			English	Article							HYDROGEN-PRODUCTION		Oak Ridge Natl Lab, Div Chem Technol, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Woodward, J (corresponding author), Oak Ridge Natl Lab, Div Chem Technol, Oak Ridge, TN 37831 USA.	woodwardj@ornl.gov		Orr, Mark/0000-0003-2684-4722				Benemann J, 1996, NAT BIOTECHNOL, V14, P1101, DOI 10.1038/nbt0996-1101; CHENAULT HK, 1987, APPL BIOCHEM BIOTECH, V14, P147, DOI 10.1007/BF02798431; COURI D, 1959, ARCH BIOCHEM BIOPHYS, V83, P195, DOI 10.1016/0003-9861(59)90024-4; GREENBAUM E, 1984, PHOTOBIOCH PHOTOBIOP, V8, P323; HORECKER BL, 1950, ARCH BIOCHEM, V29, P232; Keasling JD, 1998, BIOHYDROGEN, P87; Lee JW, 1996, SCIENCE, V273, P364, DOI 10.1126/science.273.5273.364; Lehninger A.L, 1975, BIOCHEMISTRY-US; Lide D., 1994, CRC HDB CHEM PHYS, p[5, 15]; MA KS, 1994, FEMS MICROBIOL LETT, V122, P245, DOI 10.1016/0378-1097(94)00330-0; NAKAJIMA H, 1991, ACS S SER, V466, P111; STULL DR, 1969, CHEM THERMODYN, P680; Woodward J, 1996, NAT BIOTECHNOL, V14, P872, DOI 10.1038/nbt0796-872	13	218	246	4	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1014	1015		10.1038/35016633	http://dx.doi.org/10.1038/35016633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890432				2022-12-28	WOS:000087871700032
J	Ferrannini, E				Ferrannini, E			Insulin resistance, iron, and the liver	LANCET			English	Editorial Material							TRANSFERRIN RECEPTORS; GENETIC HEMOCHROMATOSIS; METABOLIC SYNDROME; 3T3-L1 ADIPOCYTES; FATTY LIVER; HYPERINSULINEMIA; OVERLOAD; REDISTRIBUTION; OBESITY		Univ Pisa, Sch Med, CNR, Inst Clin Physiol,Metab Unit, I-56026 Pisa, Italy; Univ Pisa, Sch Med, Dept Internal Med, I-56026 Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa; University of Pisa	Ferrannini, E (corresponding author), Univ Pisa, Sch Med, CNR, Inst Clin Physiol,Metab Unit, I-56026 Pisa, Italy.							BANERJI MA, 1995, INT J OBESITY, V19, P846; Conte D, 1998, ANN INTERN MED, V128, P370, DOI 10.7326/0003-4819-128-5-199803010-00005; DANDONA P, 1983, ANN CLIN BIOCHEM, V20, P77, DOI 10.1177/000456328302000203; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; Ferrannini E, 1997, J CLIN INVEST, V100, P1166, DOI 10.1172/JCI119628; FERRANNINI E, 1991, DIABETOLOGIA, V34, P416, DOI 10.1007/BF00403180; Ferrannini E, 1995, DIABETES CLIN SCI PR, P200; GOTO T, 1995, INT J OBESITY, V19, P841; GUYADER D, 1992, J HEPATOL, V15, P304, DOI 10.1016/0168-8278(92)90060-3; Knobler H, 1999, QJM-MON J ASSOC PHYS, V92, P73, DOI 10.1093/qjmed/92.2.73; Marceau P, 1999, J CLIN ENDOCR METAB, V84, P1513, DOI 10.1210/jc.84.5.1513; Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4; Moirand R, 1997, LANCET, V349, P95, DOI 10.1016/S0140-6736(96)06034-5; NIEDERAU C, 1984, DIABETOLOGIA, V26, P441; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; ROWE JW, 1977, MEDICINE, V56, P197, DOI 10.1097/00005792-197705000-00002; SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975	20	114	122	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2181	2182		10.1016/S0140-6736(00)02397-7	http://dx.doi.org/10.1016/S0140-6736(00)02397-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881887				2022-12-28	WOS:000087779000005
J	Josefsson, AM; Magnusson, PKE; Ylitalo, N; Sorensen, P; Qwarforth-Tubbin, P; Andersen, PK; Melbye, M; Adami, HO; Gyllensten, UB				Josefsson, AM; Magnusson, PKE; Ylitalo, N; Sorensen, P; Qwarforth-Tubbin, P; Andersen, PK; Melbye, M; Adami, HO; Gyllensten, UB			Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study	LANCET			English	Article							HIGH-GRADE LESIONS; INTRAEPITHELIAL NEOPLASIA; RISK-FACTORS; TYPE-16 DNA; PREDICTOR; WOMEN; PCR; SUSCEPTIBILITY; POLYMERASE; DYSPLASIA	Background Infection with certain types of human papillomavirus (HPV), which is common among young women, increases the risk of cervical cancer. However, less than 1% of young women positive for oncogenic types of HPV develop cervical cancer. We investigated whether the amount of HPV DNA is a useful predictor of progression to cervical carcinoma in situ. Methods We estimated the amount of HPV 16 DNA by a PCR that uses the 5'-exonuclease (Taqman) method, in 478 women with cervical carcinoma in situ and 608 individually matched controls. To adjust for differences in the amount bf genomic DNA between samples, we estimated the amount of a nuclear gene (beta-actin). We studied multiple smears (total 3835 archived samples) from each woman, taken over periods of up to 26 years, that covered normal cytology to development of cervical cancer. Findings The risk of cervical carcinoma in situ increased with the amount of HPV 16 DNA. Analysis of the first smear from each woman, collected a mean of 7.8 years before cancer diagnosis, showed that women with the 20% highest amount of HPV 16 DNA were at a 60-fold higher risk of developing cervical carcinoma in situ than women negative for HPV 16. The first smear samples were classified as normal by squamous-cell cytology. Interpretation Analysis of the amount of HPV DNA can predict cancer risk at a stage when current screening methods are uninformative. Testing for the amount of HPV 16 DNA during gynaecological health checks might strikingly improve our ability to distinguish between infections that have a high or low risk of progressing into cervical cancer.	Uppsala Univ, Rudbeck Lab, Unit Med Genet, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Harvard Ctr Canc Prevent, Boston, MA 02115 USA	Uppsala University; Karolinska Institutet; Aarhus University; Statens Serum Institut; University of Copenhagen; Harvard University; Harvard University	Gyllensten, UB (corresponding author), Uppsala Univ, Rudbeck Lab, Unit Med Genet, Dept Genet & Pathol, SE-75185 Uppsala, Sweden.	ulf.gyllensten@genpat.uu.se	Magnusson, Patrik KE/C-4458-2017	Magnusson, Patrik KE/0000-0002-7315-7899; melbye, mads/0000-0001-8264-6785; Sorensen, Per Soelberg/0000-0002-2818-3780	NATIONAL CANCER INSTITUTE [R01CA061197] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA61197-01A3] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen M, 1996, TISSUE ANTIGENS, V48, P32, DOI 10.1111/j.1399-0039.1996.tb02602.x; APPLE RJ, 1995, JNCI-J NATL CANCER I, V87, P427, DOI 10.1093/jnci/87.6.427; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRISSON J, 1994, AM J EPIDEMIOL, V140, P700, DOI 10.1093/oxfordjournals.aje.a117318; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hildesheim A, 1998, CANCER EPIDEM BIOMAR, V7, P1035; Ho GYF, 1998, INT J CANCER, V78, P594, DOI 10.1002/(SICI)1097-0215(19981123)78:5&lt;594::AID-IJC11&gt;3.0.CO;2-B; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Ho GYF, 1998, INT J CANCER, V78, P281, DOI 10.1002/(SICI)1097-0215(19981029)78:3&lt;281::AID-IJC3&gt;3.0.CO;2-R; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Josefsson A, 1999, J CLIN MICROBIOL, V37, P490, DOI 10.1128/JCM.37.3.490-496.1999; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; Londesborough P, 1996, INT J CANCER, V69, P364; Magnusson PKE, 1999, NATURE, V400, P29, DOI 10.1038/21801; Munoz N, 1992, IARC Sci Publ, P251; Odunsi K, 1996, INT J CANCER, V67, P595, DOI 10.1002/(SICI)1097-0215(19960904)67:5<595::AID-IJC1>3.0.CO;2-P; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; TERRY G, 1993, ARCH VIROL, V128, P123, DOI 10.1007/BF01309793; Ylitalo N, 2000, LANCET, V355, P2194, DOI 10.1016/S0140-6736(00)02402-8; YLITALO N, 1995, J CLIN MICROBIOL, V33, P1822, DOI 10.1128/JCM.33.7.1822-1828.1995; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.3.CO;2-T; Zehbe I, 1998, CANCER RES, V58, P829	26	290	317	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2189	2193		10.1016/S0140-6736(00)02401-6	http://dx.doi.org/10.1016/S0140-6736(00)02401-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881891				2022-12-28	WOS:000087779000009
J	Sefton, L; Timmer, JR; Zhang, Y; Beranger, F; Cline, TW				Sefton, L; Timmer, JR; Zhang, Y; Beranger, F; Cline, TW			An extracellular activator of the Drosophila JAK/STAT pathway is a sex-determination signal element	NATURE			English	Article							MELANOGASTER; TRANSCRIPTION; ENCODES; PROTEIN; KINASE; GENES; ACTS	Metazoans use diverse and rapidly evolving mechanisms to determine sex. In Drosophila melanogaster an X-chromosome-counting mechanism determines the sex of an individual by regulating the master switch gene, Sex-lethal (Sxl)(1). The X-chromosome dose is communicated to Sxl by a set of X-linked signal elements (XSEs), which activate transcription of Sxl through its 'establishment' promoter, Sxl(Pe). Here we describe a new XSE called sisterlessC (sisC) whose mode of action differs from that of previously characterized XSEs, all of which encode transcription factors that activate Sxl(Pe) directly. In contrast, sisC encodes a secreted ligand for the Drosophila Janus kinase (JAK) and 'signal transducer and activator of transcription' (STAT) signal transduction pathway and is allelic to outstretched (os, also called unpaired). We conclude that sisC works indirectly on Sxl through this signalling pathway because mutations in sisC or in the genes encoding Drosophila JAK or STAT reduce expression of Sxl(Pe) similarly. The involvement of os in sex determination confirms that secreted ligands can function in cell-autonomous processes. Unlike sex signals for other organisms, sisC has acquired its sex-specific function while maintaining non-sex-specific roles in development, a characteristic that it shares with all other Drosophila XSEs2.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cline, TW (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Beranger, Florence/R-7581-2019	Timmer, John/0000-0002-6021-5199				ANAND A, 1994, J GENET, V73, P81, DOI 10.1007/BF02927944; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; Chou TB, 1996, GENETICS, V144, P1673; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Erickson JW, 1998, DEVELOPMENT, V125, P3259; ESTES PA, 1995, MOL CELL BIOL, V15, P904; FERRUS A, 1990, GENETICS, V125, P383; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HOU XS, 1996, CELL, V85, pA290; John S, 1999, MOL CELL BIOL, V19, P1910; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; Kuo YM, 1996, DEVELOPMENT, V122, P1909; SANCHEZ L, 1994, DEV GENET, V15, P251; TIMMER JR, 1995, THESIS U CALIFORNIA; Walker JJ, 2000, GENETICS, V155, P191; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	18	63	63	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					970	973		10.1038/35016119	http://dx.doi.org/10.1038/35016119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879541				2022-12-28	WOS:000087732700056
J	Engels, WR				Engels, WR			Genetics - Reversal of fortune for Drosophila geneticists?	SCIENCE			English	Editorial Material							STRAND BREAK REPAIR; INVERSE PCR		Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Engels, WR (corresponding author), Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.							Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; Bellaiche Y, 1999, GENETICS, V152, P1037; DALBY B, 1995, GENETICS, V139, P757; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GLOOR GB, 1991, SCIENCE, V253, P1110, DOI 10.1126/science.1653452; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Preston CR, 1996, GENETICS, V144, P1623; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; SENTRY JW, 1994, NUCLEIC ACIDS RES, V22, P3429, DOI 10.1093/nar/22.16.3429; TOWER J, 1993, GENETICS, V133, P347	12	17	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	2000	288	5473					1973	+		10.1126/science.288.5473.1973	http://dx.doi.org/10.1126/science.288.5473.1973			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	325QC	10877715				2022-12-28	WOS:000087687000024
J	Saether, BE				Saether, BE			Ecology - Weather ruins winter vacations	SCIENCE			English	Editorial Material							RAINFALL		Norwegian Univ Sci & Technol, Inst Zool, N-7491 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Saether, BE (corresponding author), Norwegian Univ Sci & Technol, Inst Zool, N-7491 Trondheim, Norway.							DENHELD JJ, 1981, ARDEA, V69, P185; Hughes L, 2000, TRENDS ECOL EVOL, V15, P56, DOI 10.1016/S0169-5347(99)01764-4; *INT PAN CLIM CHAN, 1996, SCI CLIM CHANGE; Mann ME, 1999, GEOPHYS RES LETT, V26, P759, DOI 10.1029/1999GL900070; PEACH W, 1991, IBIS, V133, P300, DOI 10.1111/j.1474-919X.1991.tb04573.x; ROBBINS CS, 1989, P NATL ACAD SCI USA, V86, P7658, DOI 10.1073/pnas.86.19.7658; Saether BE, 2000, SCIENCE, V287, P854, DOI 10.1126/science.287.5454.854; Sherry Thomas W., 1995, P85; Sillett TS, 2000, SCIENCE, V288, P2040, DOI 10.1126/science.288.5473.2040; Stone RC, 1996, NATURE, V384, P252, DOI 10.1038/384252a0	10	9	9	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	2000	288	5473					1975	1976						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	325QC	10877716				2022-12-28	WOS:000087687000025
J	Gibson, RS				Gibson, RS			Zinc supplementation for infants	LANCET			English	Editorial Material							MALNUTRITION; CHILDREN; GROWTH; TRIAL		Univ Otago, Dept Human Nutr, Dunedin 9015, New Zealand	University of Otago	Gibson, RS (corresponding author), Univ Otago, Dept Human Nutr, POB 56, Dunedin 9015, New Zealand.							*ADM COMM COORD SU, 1908, 3 ADM COMM COORD SUB; BATES CJ, 1993, BRIT J NUTR, V69, P243, DOI 10.1079/BJN19930026; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Brown KH, 1998, BIBL NUTR DIET, P76; CAVAN KR, 1993, AM J CLIN NUTR, V57, P344, DOI 10.1093/ajcn/57.3.344; Doherty CP, 1998, AM J CLIN NUTR, V68, P742, DOI 10.1093/ajcn/68.3.742; Gibson Rosalind S., 1994, Nutrition Research Reviews, V7, P151, DOI 10.1079/NRR19940010; Gibson RS, 1998, EUR J CLIN NUTR, V52, P764, DOI 10.1038/sj.ejcn.1600645; GOLDEN BE, 1992, EUR J CLIN NUTR, V46, P697; HAMBIDGE KM, 1988, P NUTR SOC, V47, P37, DOI 10.1079/PNS19880008; KIKAFUNDA JK, EFFECT ZINC SUPPLEME; King JC, 1996, AM J CLIN NUTR, V64, P375, DOI 10.1093/ajcn/64.3.375; KREBS NF, 1986, AM J CLIN NUTR, V43, P288, DOI 10.1093/ajcn/43.2.288; SCHLESINGER L, 1993, ACTA PAEDIATR, V82, P734, DOI 10.1111/j.1651-2227.1993.tb12548.x	14	13	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2000	355	9220					2008	2009		10.1016/S0140-6736(00)02341-2	http://dx.doi.org/10.1016/S0140-6736(00)02341-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885346				2022-12-28	WOS:000087519400002
J	Aebi, S; Gelber, S; Castiglione-Gertsch, M; Gelber, RD; Collins, J; Thurlimann, B; Rudenstam, CM; Lindtner, J; Crivellari, D; Cortes-Funes, H; Simoncini, E; Werner, ID; Coates, AS; Goldhirsch, A				Aebi, S; Gelber, S; Castiglione-Gertsch, M; Gelber, RD; Collins, J; Thurlimann, B; Rudenstam, CM; Lindtner, J; Crivellari, D; Cortes-Funes, H; Simoncini, E; Werner, ID; Coates, AS; Goldhirsch, A		IBCSG	Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?	LANCET			English	Article							AGE; CARCINOMA; PROGNOSIS; SURVIVAL; TUMOR	Background The prognosis of breast cancer in very young women is generally considered to be unfavourable. Therefore, the outcome of adjuvant therapy was analysed in a population of young (<35 years) premenopausal patients treated in four randomised controlled trials. Methods Between 1978 and 1993 the International Breast Cancer Study Group (IBCSG) treated 3700 premenopausal and perimenopausal patients with various timing and duration of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF with or without low-dose prednisone and oophorectomy). 314 of these women were less than 35 years old at randomisation. Findings Relapse and death occurred earlier and more often in younger (<35 years) than in older (greater than or equal to 35) patients with a 10-year disease-free survival of 35% (SE 3) versus 47% (1) (hazard ratio 1.41 [95% CI 1.22-1.62], p<0.001) and overall survival of 49% (3) versus 62% (1) (1.50 [1.28-1.77], p<0.001). Younger patients with oestrogen-receptor positive tumours had a significantly worse disease-free survival than younger patients with oestrogen-receptor negative tumours. By contrast, among older patients the disease-free survival was similar irrespective of oestrogen-receptor status. Interpretation Young premenopausal breast cancer patients treated with adjuvant CMF chemotherapy had higher risk of relapse and death than older premenopausal patients, especially if their tumours expressed oestrogen receptors. The endocrine effects of chemotherapy alone are insufficient for the younger age group and these patients should strongly consider additional endocrine therapies (tamoxifen or ovarian ablation) if their tumours express oestrogen receptors.	Univ Hosp Inselspital, Bern, Switzerland; Frontier Sci & Technol Res Fdn Inc, Brookline, MA USA; IBCSG Coordinating Ctr, Bern, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Anticanc Council Victoria, Melbourne, Vic, Australia; Kantonsspital, CH-9007 St Gallen, Switzerland; SU Molndals Hosp, Dept Surg, Molndal, Sweden; Inst Oncol, Ljubljana, Slovenia; Ctr Riferimento Oncol, I-33081 Aviano, Italy; Hosp Seguridad Social 12 Octubre, Madrid, Spain; Spedali Civil Brescia, I-25125 Brescia, Italy; Fdn Beretta, Brescia, Italy; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Univ Sydney, Australian Canc Soc, Sydney, NSW 2006, Australia; European Inst Oncol, Milan, Italy	University of Bern; University Hospital of Bern; Frontier Science Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Sahlgrenska University Hospital; Institute of Oncology - Slovenia; IRCCS Aviano (CRO); Hospital Universitario 12 de Octubre; Hospital Spedali Civili Brescia; University of Cape Town; University of Sydney; IRCCS European Institute of Oncology (IEO)	Aebi, S (corresponding author), Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland.	aebi@insel.ch	Aebi, Stefan/F-2004-2010	Aebi, Stefan/0000-0002-3383-9449	NCI NIH HHS [CA75362] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ALBAIN KS, 1994, MONOGR NATL CANC I, V16, P35; ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; CastiglioneGertsch M, 1996, J CLIN ONCOL, V14, P1885; Chung M, 1996, CANCER, V77, P97, DOI 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.3.CO;2-T; Clarke M, 1998, LANCET, V351, P1451; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; COX DR, 1972, J R STAT SOC B, V34, P187; Donegan WL, 1997, CA-CANCER J CLIN, V47, P28, DOI 10.3322/canjclin.47.1.28; GARNIER HS, 1995, EUR J CANCER, V31, P1851; GERTSCH MC, 1994, ANN ONCOL, V5, P717; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; GOLDHIRSCH A, 1985, J CLIN ONCOL, V3, P1059; GOLDHIRSCH A, 1988, NEW ENGL J MED, V319, P677; Greenwood M., 1926, NATURAL DURATION CAN; Holli K, 1997, EUR J CANCER, V33, P425; JORDAN VC, 1983, EUR J CANCER CLIN ON, V19, P357, DOI 10.1016/0277-5379(83)90133-5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kollias J, 1997, BRIT J CANCER, V75, P1318, DOI 10.1038/bjc.1997.223; Ludwig Breast Cancer Study Group, 1985, Cancer Res, V45, P4454; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; NOYES RD, 1982, CANCER, V49, P1302, DOI 10.1002/1097-0142(19820315)49:6<1302::AID-CNCR2820490638>3.0.CO;2-0; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; QUIET CA, 1995, J CLIN ONCOL, V13, P1144, DOI 10.1200/JCO.1995.13.5.1144; RIBEIRO GG, 1981, CLIN RADIOL, V32, P231, DOI 10.1016/S0009-9260(81)80168-7; Swanson G M, 1994, J Natl Cancer Inst Monogr, P69; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; Winchester DP, 1996, CANCER-AM CANCER SOC, V78, P1838, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1838::AID-CNCR27>3.0.CO;2-Y; 1992, P229 SAS I INC	32	203	210	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1869	1874		10.1016/S0140-6736(00)02292-3	http://dx.doi.org/10.1016/S0140-6736(00)02292-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866443				2022-12-28	WOS:000087306500014
J	Haydel, MJ; Preston, CA; Mills, TJ; Luber, S; Blaudeau, E; DeBlieux, PMC				Haydel, MJ; Preston, CA; Mills, TJ; Luber, S; Blaudeau, E; DeBlieux, PMC			Indications for computed tomography in patients with minor head injury.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACRANIAL INJURY; SELECTION CRITERIA; BRAIN INJURY; CT SCANS; TRAUMA; MILD; PREDICTORS; RADIOGRAPHY; ADMISSION; UTILITY	Background: Computed tomography (CT) is widely used as a screening test in patients with minor head injury, although the results are often normal. We performed a study to develop and validate a set of clinical criteria that could be used to identify patients with minor head injury who do not need to undergo CT. Methods: In the first phase of the study, we recorded clinical findings in 520 consecutive patients with minor head injury who had a normal score on the Glasgow Coma Scale and normal findings on a brief neurologic examination; the patients then underwent CT. Using recursive partitioning, we derived a set of criteria to identify all patients who had abnormalities on CT scanning. In the second phase, the sensitivity and specificity of the criteria for predicting a positive scan were evaluated in a group of 909 patients. Results: Of the 520 patients in the first phase, 36 (6.9 percent) had positive scans. All patients with positive CT scans had one or more of seven findings: headache, vomiting, an age over 60 years, drug or alcohol intoxication, deficits in short-term memory, physical evidence of trauma above the clavicles, and seizure. Among the 909 patients in the second phase, 57 (6.3 percent) had positive scans. In this group of patients, the sensitivity of the seven findings combined was 100 percent (95 percent confidence interval, 95 to 100 percent). All patients with positive CT scans had at least one of the findings. Conclusions: For the evaluation of patients with minor head injury, the use of CT can be safely limited to those who have certain clinical findings. (N Engl J Med 2000;343:100-5.) (C) 2000, Massachusetts Medical Society.	Louisiana State Univ, Hlth Sci Ctr, Sect Emergency Med, New Orleans, LA USA; Louisiana State Univ, Hlth Sci Ctr, Sect Emergency Radiol, New Orleans, LA USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Haydel, MJ (corresponding author), Charity Hosp, 13th Floor,1532 Tulane Ave, New Orleans, LA 70112 USA.							BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; Cook L S, 1994, Acad Emerg Med, V1, P227; DIROCCO A, 1991, NEURORADIOLOGY, V33, P253, DOI 10.1007/BF00588229; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; DUUS BR, 1993, BRIT J SURG, V80, P988, DOI 10.1002/bjs.1800800817; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MADDEN C, 1995, ACAD EMERG MED, V2, P248, DOI 10.1111/j.1553-2712.1995.tb03217.x; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MORAN SG, 1994, AM SURGEON, V60, P533; Nagurney JT, 1998, ACAD EMERG MED, V5, P678, DOI 10.1111/j.1553-2712.1998.tb02485.x; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; *SPSS, 1997, SPSS WIND VERS 8 0 S; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437	33	685	703	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					100	105		10.1056/NEJM200007133430204	http://dx.doi.org/10.1056/NEJM200007133430204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891517				2022-12-28	WOS:000088116500004
J	D'Souza, MP; Cairns, JS; Plaeger, SF				D'Souza, MP; Cairns, JS; Plaeger, SF			Current evidence and future directions for targeting HIV entry - Therapeutic and prophylactic strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4; SMALL-MOLECULE INHIBITOR; SYNCYTIUM-INDUCING PHENOTYPE; CANDIDATE AIDS VACCINES; INFECTION IN-VIVO; DISEASE PROGRESSION; ENVELOPE GLYCOPROTEIN; COILED-COIL; NEUTRALIZING ANTIBODIES	Great strides have been made in developing potent antiretroviral regimens that block human immunodeficiency virus (HIV) transcription and assembly. Despite these therapeutic advances, problems of drug resistance, latent viral reservoirs, and drug-induced toxic effects that compromise effective viral central point to the need for new classes of anti-HIV drugs with different modes of action. One promising approach involves blocking HIV entry into human cells, a complex process that involves multiple protein interactions. The process of HIV entry begins with binding of the viral envelope glycoprotein to both the CD4 receptor and one of several chemokine receptors and ends with fusion of viral and cell membranes. Conceptually, there are 3 steps in the HIV entry process that could serve as therapeutic targets: binding of the viral envelope glycoprotein with the CD4 receptor, binding of the envelope-CD4 complex to chemokine receptors, and fusion of the viral and cell membranes. Preclinical and clinical assessment of these entry inhibitors is ongoing and will determine if they possess properties required for drug licensure. Moreover, the worldwide epidemic is largely occurring in developing countries that cannot afford these drugs: a prophylactic vaccine is necessary and urgent. New knowledge of the HIV-envelope glycoprotein has also provided insight into possibilities for the design of novel HIV vaccines.	NIAID, Vaccine Clin Res Branch, Div AIDS, NIH, Bethesda, MD 20892 USA; NIAID, Branch Targeted Intervent, Div AIDS, NIH, Bethesda, MD 20892 USA; NIAID, Branch Pathogenesis & Basic Sci, Div AIDS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	D'Souza, MP (corresponding author), NIAID, Vaccine Clin Res Branch, Div AIDS, NIH, Room 4152,6700-B Rockledge Dr, Bethesda, MD 20892 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; ALLAWAY GP, 1995, AIDS RES HUM RETROV, V11, P533, DOI 10.1089/aid.1995.11.533; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BAROUDY BM, 2000, 7 C RETR OPP INF JAN; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berger EA, 1997, AIDS, V11, pS3; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Burton DR, 2000, VIROLOGY, V270, P1, DOI 10.1006/viro.2000.0239; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Connor RI, 1998, J VIROL, V72, P1552, DOI 10.1128/JVI.72.2.1552-1576.1998; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DARBYSHIRE JH, 1999, NAT HIV PREV C AUG 2; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DeVreese K, 1996, J VIROL, V70, P689, DOI 10.1128/JVI.70.2.689-696.1996; Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000; DOMS RW, 1998, HUMAN RETROVIRUSES A; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Edinger AL, 1999, J VIROL, V73, P4062, DOI 10.1128/JVI.73.5.4062-4073.1999; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ERON JJ, 2000, 7 C RETR OPP INF JAN; Este JA, 1999, J VIROL, V73, P5577; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; Gauduin MC, 1998, J VIROL, V72, P3475, DOI 10.1128/JVI.72.4.3475-3478.1998; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Graham BS, 1998, J INFECT DIS, V177, P310, DOI 10.1086/514209; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; Howard OMZ, 1998, J LEUKOCYTE BIOL, V64, P6, DOI 10.1002/jlb.64.1.6; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JACOBSON J, 1999, 39 INT C ANT AG CHEM; *JOINT UN PROGR, 2000, JOINT UN PROGR HIV A; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; LALEZARI J, 1999, 39 INT C ANT AG CHEM; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu S, 1998, AIDS RES HUM RETROV, V14, P151, DOI 10.1089/aid.1998.14.151; Luo ZW, 1999, BIOCHEM BIOPH RES CO, V263, P691, DOI 10.1006/bbrc.1999.1441; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; MOORE JP, 1994, J VIROL, V68, P469, DOI 10.1128/JVI.68.1.469-484.1994; Mosier DE, 1999, J VIROL, V73, P3544, DOI 10.1128/JVI.73.5.3544-3550.1999; Mummidi S, 1997, J BIOL CHEM, V272, P30662, DOI 10.1074/jbc.272.49.30662; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; POLO S, 1999, J HUMAN VIROL, V2, P105; PROFY A, 2000, PRO 2000 GEL CANDIDA; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234, DOI 10.1128/AAC.40.1.234; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Sanders RW, 2000, J VIROL, V74, P5091, DOI 10.1128/JVI.74.11.5091-5100.2000; Schols D, 1997, ANTIVIR RES, V35, P147, DOI 10.1016/S0166-3542(97)00025-9; SHEARER W, 2000, 7 C RETR OPP INF JAN; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SINGER I, 2000, 7 C RETR OPP INF JAN; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TREMBLAY C, 2000, 7 C RETR OPP INF JAN; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Unutmaz D, 1998, SEMIN IMMUNOL, V10, P225, DOI 10.1006/smim.1998.0134; VANCOTT TC, 1995, J IMMUNOL, V155, P4100; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Willett BJ, 1997, J VIROL, V71, P6407, DOI 10.1128/JVI.71.9.6407-6415.1997; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; ZIMMERMAN PA, 1997, MOL MED, V3, P22; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	99	81	85	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					215	222		10.1001/jama.284.2.215	http://dx.doi.org/10.1001/jama.284.2.215			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889596				2022-12-28	WOS:000087933100027
J	Banatvala, N; Zwi, AB				Banatvala, N; Zwi, AB			Conflict and health - Public health and humanitarian interventions: developing the evidence base - part 1	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVENT CHOLERA DEATHS; DEVELOPING-COUNTRIES; TREATMENT CENTERS; POPULATION; REFUGEE; RWANDA; GOMA; WAR		Med Emergency Relief Int, London W1M 1HW, England; Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Banatvala, N (corresponding author), Suffolk Hlth, Dept Publ Hlth, POB 55, Ipswich IP3 8NN, Suffolk, England.	banatvala@hq.suffolk-ha.anglox.nhs.uk; Zwi@lshtm.ac.uk	Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602; Banatvala, Nick/0000-0001-8130-154X				*AM PUBL HLTH ASS, 1993, AM J PUBLIC HEALTH, V83, P463; ARMENIAN HK, 1989, SOC SCI MED, V28, P643, DOI 10.1016/0277-9536(89)90211-6; BOK S, 1999, HUMANITARIAN CRISES, P179; Burkle F M Jr, 1995, Prehosp Disaster Med, V10, P48; *CDCP, 1992, MMWR MORB MORTAL WKL, V41; Dean K, 1996, SOC SCI MED, V42, P745, DOI 10.1016/0277-9536(95)00394-0; *DIV EM HUM ACT, 1998, CONS APPL HLTH RES C; GARFIELD R, 1999, 31 OV DEV I; HAM C, 1995, BRIT MED J, V310, P71, DOI 10.1136/bmj.310.6972.71; *INT COMM RED CROS, 1992, MIN PERV US TECHN; *INT FED RED CROSS, 1999, WORLD DIS REP 1998; *INT PROGR ADV DEV, 1998, OMB HUM ASS REP P; *JOINT EV EM ASS R, 1996, INT RESP CONF GEN LE; LAMONTGREGORY E, 1994, LANCET, V344, P546, DOI 10.1016/S0140-6736(94)91937-2; Levy Barry S, 1997, WAR PUBLIC HLTH; MEARS C, 1994, HLTH CARE REFUGEES D; *MED FRONT, 1997, WORLD CRIS POL SURV; *OMB PROJ WORK GRO, 1998, OMB HUM ASS; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PROTHERO RM, 1994, INT J EPIDEMIOL, V23, P657, DOI 10.1093/ije/23.4.657; PROTHERO RM, 1977, INT J EPIDEMIOL, V6, P259, DOI 10.1093/ije/6.3.259; REED H, 1998, DEM FORC MIGR SUMM W; RESSLER EM, 1993, CHILDREN WAR GUIDE P; SHORT C, 1998, PRINCIPLES NEW HUMAN; SIDDIQUE AK, 1995, LANCET, V346, P379, DOI 10.1016/S0140-6736(95)92259-8; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; SLIM H, 1995, DISASTERS, V19, P110, DOI 10.1111/j.1467-7717.1995.tb00362.x; SMITH R, 1995, BRIT MED J, V311, P961; *STEER COMM HUM RE, 1998, SPHER PROJ HUM CHART; TALBOT D, 1998, SUMM REP HLTH SAF FI; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; *UN HIGH COMM REF, 1995, SEX VIOL REF; United Nations High Commissioner for Refugees, 1994, REF CHILDR GUID PROT; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; VIS HL, 1994, LANCET, V344, P957, DOI 10.1016/S0140-6736(94)92312-4; ZWI A, 1989, SOC SCI MED, V28, P633, DOI 10.1016/0277-9536(89)90210-4; 1995, LANCET, V345, P529	38	80	80	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2000	321	7253					101	105		10.1136/bmj.321.7253.101	http://dx.doi.org/10.1136/bmj.321.7253.101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	334QF	10884265	Green Published			2022-12-28	WOS:000088196600030
J	Koranda, M; Schleiffer, A; Endler, L; Ammerer, G				Koranda, M; Schleiffer, A; Endler, L; Ammerer, G			Forkhead-like transcription factors recruit Ndd1 to the chromatin of G2/M-specific promoters	NATURE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; GENES; MCM1; IDENTIFICATION; EXPRESSION; REPRESSOR; COMPLEX; DOMAIN; ROX1	Many cell-cycle-specific events are supported by stage-specific gene expression. In budding yeast, at least three different nuclear factors seem to cooperate in the periodic activation of G2/M-specific genes(1-3). Here we show, by using chromatin immunoprecipitation polymerase chain reaction assays, that a positive regulator, Ndd1, becomes associated with G2/M promoter regions in manner that depends on the stage in cell cycle. Its recruitment depends on a permanent protein-DNA complex consisting of the MADS box protein, Mcm1, and a recently identified partner Fkh2, a forkhead/winged helix related transcription factor(4,5). The lethality of Ndd1 depletion is suppressed by fkh2 null mutations, which indicates that Fkh2 may also have a negative regulatory role in the transcription of G2/M-induced RNAs. We conclude that Ndd1-Fkh2 interactions may be the transcriptionally important process targeted by Cdk activity.	Univ Vienna, Ludwig Boltzmann Forsch Stelle, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	Ludwig Boltzmann Institute; University of Vienna	Ammerer, G (corresponding author), Univ Vienna, Ludwig Boltzmann Forsch Stelle, Dept Biochem & Mol Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.		Lukas, Endler/ABD-2002-2021	Lukas, Endler/0000-0002-9115-8756; Schleiffer, Alexander/0000-0001-6251-2747				ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; DiFlumeri C, 1996, NUCLEIC ACIDS RES, V24, P808, DOI 10.1093/nar/24.5.808; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hollenhorst PC, 2000, GENETICS, V154, P1533; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Loy CJ, 1999, MOL CELL BIOL, V19, P3312; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	21	172	175	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					94	98		10.1038/35017589	http://dx.doi.org/10.1038/35017589			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894549				2022-12-28	WOS:000087991200052
J	May, C; Rivella, S; Callegari, J; Heller, G; Gaensler, KML; Luzzatto, L; Sadelain, M				May, C; Rivella, S; Callegari, J; Heller, G; Gaensler, KML; Luzzatto, L; Sadelain, M			Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin	NATURE			English	Article							LOCUS ACTIVATION REGION; GENETIC TREATMENT; TRANSGENIC MICE; MOUSE MODEL; VECTORS; CELLS; DERIVATIVES; MEDIATE	The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia(1) and sickle-cell disease(2). Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells(3) might circumvent the limitations and risks of allogeneic cell transplants(4). However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences(5). Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human beta(A)-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; University of California System; University of California San Francisco	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Rivella, Stefano/A-1597-2010	Rivella, Stefano/0000-0002-0938-6558; Callegari Jr., A. John/0000-0003-3959-1947				Amado RG, 1999, SCIENCE, V285, P674, DOI 10.1126/science.285.5428.674; Boulad F, 1998, ANN NY ACAD SCI, V850, P498, DOI 10.1111/j.1749-6632.1998.tb10532.x; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; ESAN GJF, 1971, NATURE-NEW BIOL, V229, P143, DOI 10.1038/newbio229143a0; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Grosveld F, 1998, SEMIN HEMATOL, V35, P105; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; LEBOULCH P, 1994, EMBO J, V13, P3065, DOI 10.1002/j.1460-2075.1994.tb06605.x; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nathan DG, 1998, HEMATOLOGY INFANCY C; NOVAK U, 1990, P NATL ACAD SCI USA, V87, P3386, DOI 10.1073/pnas.87.9.3386; Porcu S, 1997, BLOOD, V90, P4602, DOI 10.1182/blood.V90.11.4602.4602_4602_4609; Raftopoulos H, 1997, BLOOD, V90, P3414, DOI 10.1182/blood.V90.9.3414; Rivella S, 1998, SEMIN HEMATOL, V35, P112; Rivella S, 2000, J VIROL, V74, P4679, DOI 10.1128/JVI.74.10.4679-4687.2000; Sadelain M, 1997, BRIT J HAEMATOL, V98, P247, DOI 10.1046/j.1365-2141.1997.2313048.x; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Weatherall DJ, 1981, THALASSEMIA SYNDROME; YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	30	457	495	1	40	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					82	86		10.1038/35017565	http://dx.doi.org/10.1038/35017565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894546				2022-12-28	WOS:000087991200049
J	Sharp, D				Sharp, D			Jehovah's Witnesses' blood policy	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), The Lancet, London WC1X 8RR, England.							GILLIES P, 2000, TIMES           0621; GLEDHILL R, 2000, TIMES           0614	2	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					8	8		10.1016/S0140-6736(00)02424-7	http://dx.doi.org/10.1016/S0140-6736(00)02424-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892756				2022-12-28	WOS:000087933400006
J	Kao, H; Chen, WP				Kao, H; Chen, WP			The Chi-Chi earthquake sequence: Active, out-of-sequence thrust faulting in Taiwan	SCIENCE			English	Article							COLLISION	We combined precise focal depths and fault plane solutions of more than 40 events from the 20 September 1999 Chi-Chi earthquake sequence with a synthesis of subsurface geology to show that the dominant structure for generating earthquakes in central Taiwan is a moderately dipping (20 degrees to 30 degrees) thrust fault away from the deformation front. A second, subparallel seismic zone Lies about 15 kilometers below the main thrust. These seismic zones differ from previous models, indicating that both the basal decollement and relic normal faults are aseismic.	Acad Sinica, Inst Earth Sci, Taipei 115, Taiwan; Univ Illinois, Dept Geol, Urbana, IL 61801 USA; Univ Illinois, MAE Ctr, Urbana, IL 61801 USA	Academia Sinica - Taiwan; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kao, H (corresponding author), Acad Sinica, Inst Earth Sci, Taipei 115, Taiwan.							[Anonymous], 1988, ACTA GEOL TAIWAN; BOYER SE, 1992, STRUCTURAL GEOLOGY F, P161; Chang S.S.L., 1971, PETROL GEOL TAIWAN, V8, P21; Chang YF, 1996, CATAL TODAY, V30, P163, DOI 10.1016/0920-5861(95)00007-0; CHEN CH, 1999, EOS S, V80, P12; Chen J.S., 1978, PET GEOL TAIWAN, V15, P199; CHEN WP, 1983, J GEOPHYS RES, V88, P4183, DOI 10.1029/JB088iB05p04183; CHEN WP, 2000, SG6B MID EARTHQ CTR; Chen Y, UNPUB; Chiu H.T., 1971, PETROL GEOL TAIWAN, V8, P7; DAVIS D, 1983, J GEOPHYS RES, V88, P1153, DOI 10.1029/JB088iB02p01153; Fuh S-C, 1997, PET GEOL TAIWAN, V31, P43; Hsiao P.T., 1968, PETROL GEOL TAIWAN, V6, P209; Huang B. S., 1996, J GEOL SOC CHINA, V39, P235; Kao H, 1998, GEOPHYS RES LETT, V25, P3619, DOI 10.1029/98GL02803; LEE CT, 1999, EOS S, V80, P14; Lee J.C., 1996, TERR ATMOS OCEAN SCI, V7, P431, DOI [10.3319/TAO.1996.7.4.431(ACCT), DOI 10.3319/TAO.1996.7.4.431(ACCT)]; Lee T-Y, 1992, J GEOL SOC CHINA, V35, P353; Ma K.F., 1999, EOS T AM GEOPHYS UN, V80, P605, DOI [DOI 10.1029/99EO00405, 10.1029/99EO00405]; Ma Kai, UNPUB; Molnar P., 1982, MOUNTAIN BUILDING PR, P41; MORELY CK, 1988, TECTONICS, V7, P539; Nabelek J.L., 1984, THESIS MIT CAMBRIDGE; RAU RJ, 1995, EARTH PLANET SC LETT, V133, P517, DOI 10.1016/0012-821X(95)00076-O; SENO T, 1993, J GEOPHYS RES-SOL EA, V98, P17941, DOI 10.1029/93JB00782; Shin T.C., 2000, SEISMOL RES LETT, V71, P23; SUN SC, 1965, PET GEOL TAIWAN, V4, P161; Suppe J., 1984, PET GEOL TAIWAN, V20, P85; SUPPE J, 1981, GEOL SOC CHINA MEM, V4, P67; Suppe J., 1979, PETROL GEOL TAIWAN, V16, P1; Wu FT, 1997, TECTONOPHYSICS, V274, P191, DOI 10.1016/S0040-1951(96)00304-6; Yu SB, 1997, TECTONOPHYSICS, V274, P41, DOI 10.1016/S0040-1951(96)00297-1	32	237	245	4	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2346	2349		10.1126/science.288.5475.2346	http://dx.doi.org/10.1126/science.288.5475.2346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875915				2022-12-28	WOS:000087913400033
J	Metcalf, D; Greenhalgh, CJ; Viney, E; Willson, TA; Starr, R; Nicola, NA; Hilton, DJ; Alexander, WS				Metcalf, D; Greenhalgh, CJ; Viney, E; Willson, TA; Starr, R; Nicola, NA; Hilton, DJ; Alexander, WS			Gigantism in mice lacking suppressor of cytokine signalling-2	NATURE			English	Article							GROWTH-FACTOR-I; RECEPTOR GENE-EXPRESSION; TRANSGENIC MICE; C-MPL; HORMONE; INSULIN; LIVER; SOCS-3; DEFICIENCIES; TRANSDUCTION	Suppressor of cytokine signalling-2 (SOCS-2) is a member of the suppressor of cytokine signalling family, a group of related proteins implicated in the negative regulation of cytokine action through inhibition of the Janus kinase (JAK) signal transducers and activators of transcription (STAT) signal-transduction pathway(1). Here we use mice unable to express SOCS-2 to examine its function in vivo. SOCS-2(-/-) mice grew significantly larger than their wild-type littermates. Increased body weight became evident after weaning and was associated with significantly increased long bone lengths and the proportionate enlargement of most organs. Characteristics of deregulated growth hormone and insulin-like growth factor-I (IGF-I) signalling, including decreased production of major urinary protein, increased local IGF-I production, and collagen accumulation in the dermis, were observed in SOCS-2-deficient mice, indicating that SOCS-2 may have an essential negative regulatory role in the growth hormone/IGF-I pathway.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Alexander, WS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Post Off, Melbourne, Vic 3050, Australia.		Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Favre H, 1999, FEBS LETT, V453, P63, DOI 10.1016/S0014-5793(99)00681-X; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kopchick JJ, 1999, ANNU REV NUTR, V19, P437, DOI 10.1146/annurev.nutr.19.1.437; Lopaczynski W, 1999, ACTA BIOCHIM POL, V46, P51, DOI 10.18388/abp.1999_4183; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Shoba L, 1999, MOL CELL ENDOCRINOL, V152, P125, DOI 10.1016/S0303-7207(99)00045-3; Sjogren K, 1999, P NATL ACAD SCI USA, V96, P7088, DOI 10.1073/pnas.96.12.7088; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Wanke R, 1999, J INVEST DERMATOL, V113, P967, DOI 10.1046/j.1523-1747.1999.00807.x; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; [No title captured]	25	381	401	1	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1069	1073		10.1038/35016611	http://dx.doi.org/10.1038/35016611			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890450				2022-12-28	WOS:000087871700050
J	He, XW; Asthana, S; Sorger, PK				He, XW; Asthana, S; Sorger, PK			Transient sister chromatid separation and elastic deformation of chromosomes during mitosis in budding yeast	CELL			English	Article							NEWT LUNG-CELLS; SACCHAROMYCES-CEREVISIAE; MITOTIC SPINDLE; DIRECTIONAL INSTABILITY; KINETOCHORE MOTILITY; MICROTUBULE CAPTURE; ANAPHASE ONSET; TENSION; PROTEIN; ATTACHMENT	The accurate segregation of chromosomes at mitosis requires that all pairs of chromatids bind correctly to microtubules prior to the dissolution of sister cohesion and the initiation of anaphase. By analyzing the motion of GFP-tagged S. cerevisiae chromosomes, we show that kinetochore-microtubule attachments impose sufficient tension on sisters during prometaphase to transiently separate centromeric chromatin toward opposite sides of the spindle. Transient separations of 2-10 min duration occur in the absence of cohesin proteolysis, are characterized by independent motion of the sisters along the spindle, and are followed by the apparent reestablishment of sister linkages. The existence of transient sister separation in yeast explains the unusual bilobed localization of kinetochore proteins and supports an alternative model for spindle structure. By analogy with animal cells, we propose that yeast centromeric chromatin acts as a tensiometer.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sorger, PK (corresponding author), MIT, Dept Biol, Room 68-371,77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sorger, Peter/0000-0002-3364-1838	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051464] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19483, GM51464] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Choo KHA., 1997, CENTROMERE; CIOSK R, 1998, THESIS U VIENNA VIEN; Cohen-Fix O, 1999, GENE DEV, V13, P1950, DOI 10.1101/gad.13.15.1950; Copenhaver GP, 1999, SCIENCE, V286, P2468, DOI 10.1126/science.286.5449.2468; Donaldson AD, 1996, J CELL BIOL, V132, P887, DOI 10.1083/jcb.132.5.887; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; Hunt AJ, 1998, MOL BIOL CELL, V9, P2857, DOI 10.1091/mbc.9.10.2857; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; O'Toole ET, 1999, MOL BIOL CELL, V10, P2017, DOI 10.1091/mbc.10.6.2017; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Waters JC, 1996, J CELL SCI, V109, P2823; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	48	229	232	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					763	775		10.1016/S0092-8674(00)80888-0	http://dx.doi.org/10.1016/S0092-8674(00)80888-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892747	Bronze			2022-12-28	WOS:000087821400010
J	Clark, CM; Fradkin, JE; Hiss, RG; Lorenz, RA; Vinicor, F; Warren-Boulton, E				Clark, CM; Fradkin, JE; Hiss, RG; Lorenz, RA; Vinicor, F; Warren-Boulton, E			Promoting early diagnosis and treatment of type 2 diabetes - The National Diabetes Education Program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NON-HISPANIC WHITES; GLYCEMIC CONTROL; CARE; MANAGEMENT; NIDDM; MELLITUS; ADULTS; POPULATION; BENEFITS; QUALITY		NIDDKD, NIH, Bethesda, MD 20892 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Univ Michigan Hlth Syst, Michigan Diabet Res & Training Ctr, Demonstrat & Educ Div, Ann Arbor, MI USA; Univ Illinois, Coll Med, Dept Pediat, Peoria, IL 61656 USA; Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA; Hager Sharp, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Peoria; Centers for Disease Control & Prevention - USA	Clark, CM (corresponding author), Natl Diabet Educ Program, Box JAMA Reprint,1 Diabet Way, Bethesda, MD 20892 USA.							Amer Diabet Assoc, 2000, DIABETES CARE, V23, pS32; Aubert RE, 1998, ANN INTERN MED, V129, P605, DOI 10.7326/0003-4819-129-8-199810150-00004; Beckles GLA, 1998, DIABETES CARE, V21, P1432, DOI 10.2337/diacare.21.9.1432; Buse JB, 1999, DIABETES CARE, V22, pC65; Cowie CC, 1995, NIH PUBLICATION, V95-1468, P117; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Etzwiler DD, 1997, DIABETES EDUCATOR, V23, P569, DOI 10.1177/014572179702300509; Gavin JR, 2000, DIABETES CARE, V23, pS4; Gilmer TP, 1997, DIABETES CARE, V20, P1847, DOI 10.2337/diacare.20.12.1847; HAFFNER SM, 1989, DIABETES CARE, V12, P530, DOI 10.2337/diacare.12.8.530; Haffner SM, 1998, DIABETES CARE, V21, P160, DOI 10.2337/diacare.21.1.160; HAMMAN RF, 1989, DIABETES, V38, P1231, DOI 10.2337/diabetes.38.10.1231; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403; Marshall CL, 2000, AM J MED QUAL, V15, P65, DOI 10.1177/106286060001500205; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; *NAT DIAB ED PROGR, 1998, NIH PUBL; *NAT I DIAB DIAGN, 1990, SURV PHYS PRACT BEH; Peterson K A, 1998, J Fam Pract, V47, pS55; Ray NF, 1998, DIABETES CARE, V21, P296; Roman SH, 1997, ENDOCRIN METAB CLIN, V26, P443, DOI 10.1016/S0889-8529(05)70260-7; RUBIN RJ, 1994, J CLIN ENDOCR METAB, V78, pA809, DOI 10.1210/jcem.78.4.8157701; Selby JV, 1997, DIABETES CARE, V20, P1396, DOI 10.2337/diacare.20.9.1396; SHAFFER J, 1995, ARCH INTERN MED, V155, P2330, DOI 10.1001/archinte.155.21.2330; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stearne MR, 1998, BRIT MED J, V317, P713; Testa MA, 1998, JAMA-J AM MED ASSOC, V280, P1490, DOI 10.1001/jama.280.17.1490; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008; Wagner E H, 1996, Manag Care Q, V4, P12; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; Zimmet P, 1999, DIABETES CARE, V22, pB59	32	52	55	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					363	365		10.1001/jama.284.3.363	http://dx.doi.org/10.1001/jama.284.3.363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891969				2022-12-28	WOS:000088123000030
J	Hu, FZ; Preston, RA; Post, JC; White, GJ; Kikuchi, LW; Wang, X; Leal, SM; Levenstien, MA; Ott, J; Self, TW; Allen, G; Stiffler, RS; McGraw, C; Pulsifer-Anderson, EA; Ehrlich, GD				Hu, FZ; Preston, RA; Post, JC; White, GJ; Kikuchi, LW; Wang, X; Leal, SM; Levenstien, MA; Ott, J; Self, TW; Allen, G; Stiffler, RS; McGraw, C; Pulsifer-Anderson, EA; Ehrlich, GD			Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BARRETTS-ESOPHAGUS; SUBGLOTTIC STENOSIS; RESPIRATORY-DISEASE; CHILDREN; INFANTS; MAPS; ADENOCARCINOMA; ADULT	Context Gastroesophageal reflux (CER) has not previously been widely regarded as a hereditary disease, A few reports have suggested, however, that a genetic component may contribute to the incidence of GER, especially in its severe or chronic forms. Objective To identify a genetic locus that cosegregates with a severe pediatric GER phenotype in families with multiple affected members. Design A genome-wide scan of families affected by severe pediatric GER using polymorphic microsatellite markers spaced at an average of 8 centimorgans (cM), followed by haplotyping and by pairwise and multipoint linkage analyses. Setting General US community, with research performed in a university tertiary care hospital. Subjects Affected and unaffected family members from 5 families having multiple individuals affected by severe pediatric GER, identified through a patient support group. Main Outcome Measures Determination of inheritance patterns and linkage of a genetic locus with the severe pediatric GER phenotype by logarithm-of-odds (lod) score analysis, considering a lod score of 3 or greater as evidence of linkage. Results In these families, severe pediatric GER followed an autosomal dominant hereditary pattern with high penetrance. A gene for severe pediatric GER was mapped to a 13-cM region on chromosome 13q between microsatellite markers D13S171 and D13S263. A maximum multifamily 2-point lod score of 5.58 and a maximum multifamily multipoint lod score of 7.15 were obtained for marker D13S1253 at map position 35 cM when presumptively affected persons were modeled as unknown (a maximum multipoint score of 4.88 was obtained when presumptively affected persons were modeled as unaffected). Conclusion These data suggest that a gene for severe pediatric GER maps to chromosome 13q14.	Allegheny Gen Hosp, Ctr Genome Sci, Pittsburgh, PA 15212 USA; Allegheny Gen Hosp, Dept Human Genet, Pittsburgh, PA 15212 USA; MCP Hahnemann Univ, Pittsburgh, PA USA; Rockefeller Univ, Lab Stat Gen, New York, NY 10021 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Univ Colorado, Hlth Sci Ctr, Dept Otolaryngol, Denver, CO USA; Pediat Adolescent Gastroesophageal Reflux Assoc, Germantown, MD USA	Allegheny General Hospital; Allegheny General Hospital; Drexel University; Rockefeller University; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ehrlich, GD (corresponding author), Allegheny Gen Hosp, Ctr Genome Sci, Room 1030,320 E North Ave, Pittsburgh, PA 15212 USA.	gehrlich@wpahs.org		Ehrlich, Garth/0000-0003-1140-6594	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002398, R01DC003594, R01DC002148, R29DC002398, R01DC004591] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG000008] Funding Source: Medline; NIDCD NIH HHS [DC02148, R01 DC003594, R01 DC002148, DC02398, R01 DC002398, R29 DC002398, DC04591, R01 DC004591] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altman KW, 1999, ARCH OTOLARYNGOL, V125, P525, DOI 10.1001/archotol.125.5.525; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Callahan CW, 1998, ACTA PAEDIATR, V87, P1219, DOI 10.1080/080352598750030861; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; CRABB DW, 1985, ANN INTERN MED, V103, P52, DOI 10.7326/0003-4819-103-1-52; del Rosario J F, 1998, Gastroenterologist, V6, P104; Euler AR, 1998, DIGEST DIS, V16, P111, DOI 10.1159/000016854; FAHMY N, 1993, AM J GASTROENTEROL, V88, P1262; Faubion WA, 1998, MAYO CLIN PROC, V73, P166; Fonkalsrud EW, 1996, CURR PROB SURG, V33, P6; Giannoni C, 1998, INT J PEDIATR OTORHI, V43, P11, DOI 10.1016/S0165-5876(97)00151-1; Halstead LA, 1999, OTOLARYNG HEAD NECK, V120, P683, DOI 10.1053/hn.1999.v120.a91766; Halstead LA, 1999, OTOLARYNG HEAD NECK, V120, P208, DOI 10.1016/S0194-5998(99)70408-0; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Little JP, 1997, ANN OTO RHINOL LARYN, V106, P1; MALFROOT A, 1987, PEDIATR PULM, V3, P208, DOI 10.1002/ppul.1950030403; Marcon Margaret A., 1997, Current Opinion in Pediatrics, V9, P490, DOI 10.1097/00008480-199710000-00008; McMurray JS, 1997, OTOLARYNG HEAD NECK, V116, P575, DOI 10.1016/S0194-5998(97)70230-4; Orenstein SR, 1997, AM J MED, V103, p114S, DOI 10.1016/S0002-9343(97)00335-5; ORENSTEIN SR, 1988, J PEDIATR-US, V112, P847, DOI 10.1016/S0022-3476(88)80204-X; ORENSTEIN SR, 1993, PEDIAT GASTROINTESTI, P337; Ott J., 1999, ANAL HUMAN GENETIC L; PRESTON RA, 1994, NAT GENET, V7, P149, DOI 10.1038/ng0694-149; Romero Y, 1999, AM J GASTROENTEROL, V94, P1127, DOI 10.1111/j.1572-0241.1999.01127.x; Romero Y, 1997, GASTROENTEROLOGY, V113, P1449, DOI 10.1053/gast.1997.v113.pm9352846; Seri M, 1999, AM J HUM GENET, V64, P586, DOI 10.1086/302241; Stephen T C, 1994, J Ky Med Assoc, V92, P188; STEPHEN TC, 1998, W V MED J, V94, P22; Terwilliger J., 1994, HDB HUMAN GENETIC LI; Trudgill NJ, 1999, AM J GASTROENTEROL, V94, P1172, DOI 10.1016/S0002-9270(99)00116-1; Walner DL, 1998, ARCH OTOLARYNGOL, V124, P551, DOI 10.1001/archotol.124.5.551; Whitcomb DC, 1996, GASTROENTEROLOGY, V110, P1975, DOI 10.1053/gast.1996.v110.pm8964426	32	64	66	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					325	334		10.1001/jama.284.3.325	http://dx.doi.org/10.1001/jama.284.3.325			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891964	Green Accepted, Bronze			2022-12-28	WOS:000088123000025
J	Tsai, RJ; Li, LM; Chen, JK				Tsai, RJ; Li, LM; Chen, JK			Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)	MAY 10-15, 1998	FT LAUDERDALE, FL	Assoc Res Vis & Ophthalmol			OCULAR-SURFACE DISORDERS; AMNIOTIC MEMBRANE TRANSPLANTATION; STEM-CELLS; AUTOGRAFT; DEFICIENCY	Background: The Stevens-Johnson syndrome, ocular pemphigoid, and thermal or chemical burns can cause scarring and opacification of the cornea and loss of vision. Transplantation of epithelial cells from the limbus of the contralateral cornea can restore useful vision. However, this procedure requires a large limbal graft from the healthy eye and is not possible in patients who have bilateral lesions. Methods: We took specimens of limbal epithelial cells from the healthy contralateral eyes of six patients with severe unilateral corneal disease. The epithelial cells were cultured and expanded on amniotic membrane. The amniotic membrane, together with the sheet of limbal epithelial cells, was transplanted to the denuded corneal surface of the damaged eye after superficial keratectomy to remove fibrovascular ingrowth. The mean (+/-SD) follow-up period was 15+/-2 months. Results: Complete reepithelialization of the corneal surface occurred within two to four days of transplantation in all six eyes receiving transplants. By one month, the ocular surface was covered with corneal epithelium, and the clarity of the cornea was improved. In five of the six eyes receiving transplants (83 percent), the mean visual acuity improved from 20/112 to 20/45. In one patient with a chemical burn who had total opacification of the cornea, the acuity improved from the ability to count fingers at 40 cm to 20/200. No patient had recurrent neovascularization or inflammation in the transplanted area during the follow-up period. Conclusions: Transplantation of autologous limbal epithelial cells cultured on amniotic membrane is a simple and effective method of reconstructing the corneal surface and restoring useful vision in patients with unilateral deficiency of limbal epithelial cells. (N Engl J Med 2000;343:86-93.) (C) 2000, Massachusetts Medical Society.	Chang Gung Mem Hosp, Dept Ophthalmol, Tao Yuan, Taiwan; Chang Gung Univ, Dept Physiol, Tao Yuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Tsai, RJ (corresponding author), 2F 350 Sect 4 Cheng Kung Rd, Taipei, Taiwan.	raytsai@ms4.hinet.net						CHEN JJY, 1990, INVEST OPHTH VIS SCI, V31, P1301; CHEN JJY, 1991, INVEST OPHTH VIS SCI, V32, P2219; COPELAND RA, 1990, AM J OPHTHALMOL, V110, P412, DOI 10.1016/S0002-9394(14)77023-0; Holland E J, 1996, Trans Am Ophthalmol Soc, V94, P677; Kenyon K R, 1989, Dev Ophthalmol, V18, P53; Kenyon KR, 1995, OPHTHALMOLOGY, V102, P101; KIM JC, 1995, CORNEA, V14, P473; KIM JC, 1997, ADV CORNEAL RES SELE, V4, P117; KIM JS, 1998, INVEST OPHTHALMO S90, V39; KRUSE FE, 1989, INVEST OPHTHALM S520, V30; KWITKO S, 1995, OPHTHALMOLOGY, V102, P1020; Lee SH, 1997, AM J OPHTHALMOL, V123, P303, DOI 10.1016/S0002-9394(14)70125-4; Mashima Y, 1993, JPN J CLIN OPHTHALMO, V47, P607; Meller D, 1999, INVEST OPHTH VIS SCI, V40, pS329; Morgan S, 1996, EYE, V10, P349, DOI 10.1038/eye.1996.72; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; Shimazaki J, 1998, BRIT J OPHTHALMOL, V82, P235, DOI 10.1136/bjo.82.3.235; Tan DTH, 1996, OPHTHALMOLOGY, V103, P29, DOI 10.1016/S0161-6420(96)30737-9; Thang JTS, 1997, OPHTHALMIC SURG LAS, V28, P765; TSAI RJF, 1990, OPHTHALMOLOGY, V97, P446, DOI 10.1016/S0161-6420(90)32575-7; TSAI RJF, 1995, CORNEA, V14, P439; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; TSAI RJF, 1988, INVEST OPHTH VIS SCI, V29, P1565; TSAI RJF, 1994, INVEST OPHTH VIS SCI, V35, P2865; Tseng SCG, 1998, ARCH OPHTHALMOL-CHIC, V116, P431, DOI 10.1001/archopht.116.4.431; Tseng SCG, 1996, MOL BIOL REP, V23, P47, DOI 10.1007/BF00357072; TSENG SCG, 1989, EYE, V3, P141, DOI 10.1038/eye.1989.22; Tseng SCG, 1990, OPHTHALMOL CLIN N AM, V3, P595; Tsubota K, 1996, AM J OPHTHALMOL, V122, P38, DOI 10.1016/S0002-9394(14)71962-2; TSUBOTA K, 1995, OPHTHALMOLOGY, V102, P1486; Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201	31	734	813	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					86	93		10.1056/NEJM200007133430202	http://dx.doi.org/10.1056/NEJM200007133430202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	333EP	10891515	Bronze			2022-12-28	WOS:000088116500002
J	Charatan, F				Charatan, F			New York votes to post doctors' details on net	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					69	69						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884246				2022-12-28	WOS:000088196600013
J	Krosnar, K				Krosnar, K			Slovak president's fight for life raises health care fears	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					71	71						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884252				2022-12-28	WOS:000088196600019
J	Lamar, J				Lamar, J			Japan plans to monitor medical mishaps	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					69	69						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884245				2022-12-28	WOS:000088196600012
J	Backman, V; Wallace, MB; Perelman, LT; Arendt, JT; Gurjar, R; Muller, MG; Zhang, Q; Zonios, G; Kline, E; McGillican, T; Shapshay, S; Valdez, T; Badizadegan, K; Crawford, JM; Fitzmaurice, M; Kabani, S; Levin, HS; Seiler, M; Dasari, RR; Itzkan, I; Van Dam, J; Feld, MS				Backman, V; Wallace, MB; Perelman, LT; Arendt, JT; Gurjar, R; Muller, MG; Zhang, Q; Zonios, G; Kline, E; McGillican, T; Shapshay, S; Valdez, T; Badizadegan, K; Crawford, JM; Fitzmaurice, M; Kabani, S; Levin, HS; Seiler, M; Dasari, RR; Itzkan, I; Van Dam, J; Feld, MS			Detection of preinvasive cancer cells	NATURE			English	Article									MIT, George R Harrison Spect Lab, Laser Biomed Res Ctr, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Cleveland Clin Fdn, Dept Urol, Cleveland, OH 44106 USA; New England Med Ctr, Boston, MA 02132 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44106 USA; US Vet Adm Hosp, W Roxbury, MA 02132 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Cleveland Clinic Foundation; Tufts Medical Center; Harvard University; Boston Children's Hospital; Yale University; University Hospitals of Cleveland; Case Western Reserve University; Cleveland Clinic Foundation	Backman, V (corresponding author), MIT, George R Harrison Spect Lab, Laser Biomed Res Ctr, Cambridge, MA 02139 USA.		Backman, Vadim/B-6689-2009					Backman V, 1999, IEEE J SEL TOP QUANT, V5, P1019, DOI 10.1109/2944.796325; Crawford J.M., 1994, ROBBINS PATHOLOGIC B, V5th, P910; Perelman LT, 1998, PHYS REV LETT, V80, P627, DOI 10.1103/PhysRevLett.80.627; van de Hulst H.C., 1981, LIGHT SCATTERING SMA	4	492	515	1	52	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					35	36		10.1038/35017638	http://dx.doi.org/10.1038/35017638			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894529				2022-12-28	WOS:000087991200032
J	Irving, RJ; Oram, SH; Boyd, J; Rutledge, P; McRae, F; Bloomfield, P				Irving, RJ; Oram, SH; Boyd, J; Rutledge, P; McRae, F; Bloomfield, P			Ten year audit of secondary prevention in coronary bypass patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHOLESTEROL LEVELS; EVENTS		Royal Infirm Edinburgh NHS Trust, Dept Cardiol, Edinburgh EH3 9YW, Midlothian, Scotland; Western Gen Hosp, Dept Med Sci, Edinburgh EH4 2XU, Midlothian, Scotland; Royal Infirm Edinburgh NHS Trust, Dept Clin Audit, Edinburgh EH3 9YW, Midlothian, Scotland; Lothian Hlth, Edinburgh BH8 9RS, Midlothian, Scotland; Broxburn Med Ctr, Broxburn EH52 5JZ, W Lothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Bloomfield, P (corresponding author), Royal Infirm Edinburgh NHS Trust, Dept Cardiol, Edinburgh EH3 9YW, Midlothian, Scotland.	PSBloomfield@compuserve.com		Irving, John/0000-0002-5687-8133				Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campeau L, 1997, NEW ENGL J MED, V336, P153; CAVENDER JB, 1992, J AM COLL CARDIOL, V20, P287, DOI 10.1016/0735-1097(92)90092-2; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					22	+		10.1136/bmj.321.7252.22	http://dx.doi.org/10.1136/bmj.321.7252.22			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875829	Bronze, Green Published			2022-12-28	WOS:000088030100022
J	Aeschbach-Hertig, W; Peeters, F; Beyerle, U; Kipfer, R				Aeschbach-Hertig, W; Peeters, F; Beyerle, U; Kipfer, R			Palaeotemperature reconstruction from noble gases in ground water taking into account equilibration with entrapped air	NATURE			English	Article							SEA-SURFACE TEMPERATURE; LAST GLACIAL MAXIMUM; AQUIFER; HELIUM; H-3/HE-3; RECHARGE; RECORDS; ORIGIN; VALLEY	Noble-gas concentrations in ground water have been used as a proxy for past air temperatures(1-7), but the accuracy of this approach has been limited by the existence of a temperature-independent component of the noble gases in ground water, termed 'excess air', whose origin and composition is poorly understood(7-9). In particular, the evidence from noble gases in a Brazilian aquifer for a cooling of more than 5 degrees C in tropical America during the Last Glacial Maximum(4) has been called into question(9). Here we propose a model for dissolved gases in ground water, which describes the formation of excess air by equilibration of ground water with entrapped air in quasi-saturated soils(10-12). Our model predicts previously unexplained noble-gas data sets, including the concentration of atmospheric helium, and yields consistent results for the non-atmospheric helium isotopes that are used for dating ground water. Using this model of excess air, we re-evaluate the use of noble gases from ground water for reconstructing past temperatures. Our results corroborate the inferred cooling in Brazil during the Last Glacial Maximum(4), and indicate that even larger cooling took place at mid-latitudes.	Swiss Fed Inst Environm Sci & Technol, Dept Water Resources & Drinking Water, CH-8600 Dubendorf, Switzerland; Swiss Fed Inst Technol, CH-8902 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Swiss Federal Institutes of Technology Domain; ETH Zurich	Aeschbach-Hertig, W (corresponding author), Swiss Fed Inst Environm Sci & Technol, Dept Water Resources & Drinking Water, CH-8600 Dubendorf, Switzerland.	aeschbach@eawag.ch	Aeschbach, Werner/C-1026-2008; Beyerle, Urs/M-9490-2017	Aeschbach, Werner/0000-0003-0917-1239; Beyerle, Urs/0000-0002-6464-0838				Aeschbach-Hertig W, 1998, GROUND WATER, V36, P661, DOI 10.1111/j.1745-6584.1998.tb02841.x; Aeschbach-Hertig W, 1999, WATER RESOUR RES, V35, P2779, DOI 10.1029/1999WR900130; AESCHBACHHERTIG W, 1996, EOS S, V77, pS157; ANDREWS JN, 1979, J HYDROL, V41, P233, DOI 10.1016/0022-1694(79)90064-7; [Anonymous], 1998, IAEA VIENN S 1997; Ballentine CJ, 1999, GEOCHIM COSMOCHIM AC, V63, P2315, DOI 10.1016/S0016-7037(99)00131-3; BENSON BB, 1980, J SOLUTION CHEM, V9, P895, DOI 10.1007/BF00646402; Beyerle U, 1998, SCIENCE, V282, P731, DOI 10.1126/science.282.5389.731; Beyerle U, 1999, J HYDROL, V220, P169, DOI 10.1016/S0022-1694(99)00069-4; Christiansen JE, 1944, SOIL SCI, V58, P355, DOI 10.1097/00010694-194411000-00002; FAYBISHENKO BA, 1995, WATER RESOUR RES, V31, P2421, DOI 10.1029/95WR01654; FAYER MJ, 1986, SOIL SCI SOC AM J, V50, P568, DOI 10.2136/sssaj1986.03615995005000030005x; HEATON THE, 1981, J HYDROL, V50, P201, DOI 10.1016/0022-1694(81)90070-6; HEATON THE, 1983, J HYDROL, V62, P243, DOI 10.1016/0022-1694(83)90105-1; Lehmann BE, 1997, APPL GEOCHEM, V12, P727, DOI 10.1016/S0883-2927(97)00039-5; Mamyrin B.A., 1984, HELIUM ISOTOPES NATU; MAZOR E, 1972, GEOCHIM COSMOCHIM AC, V36, P1321, DOI 10.1016/0016-7037(72)90065-8; McIntyre A., 1976, Science, V191, P1131, DOI 10.1126/science.191.4232.1131; Osenbruck K, 1998, GEOCHIM COSMOCHIM AC, V62, P3041, DOI 10.1016/S0016-7037(98)00198-7; RIND D, 1985, QUATERNARY RES, V24, P1, DOI 10.1016/0033-5894(85)90080-8; ROSTEK F, 1993, NATURE, V364, P319, DOI 10.1038/364319a0; SCHLOSSER P, 1989, EARTH PLANET SC LETT, V94, P245, DOI 10.1016/0012-821X(89)90144-1; Shapiro SD, 1998, WATER RESOUR RES, V34, P1165, DOI 10.1029/97WR03322; Solomon DK, 1996, WATER RESOUR RES, V32, P1805, DOI 10.1029/96WR00600; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; Stute M., 2000, ENV TRACERS SUBSURFA, P349, DOI DOI 10.1007/978-1-4615-4557-6_11; Stute M., 1993, CLIMATE CHANGE CONTI, P89, DOI [10.1029/GM078p0089, DOI 10.1029/GM078P0089]; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Weyhenmeyer CE, 2000, SCIENCE, V287, P842, DOI 10.1126/science.287.5454.842; Wilson GB, 1997, APPL GEOCHEM, V12, P747, DOI 10.1016/S0883-2927(97)00035-8	30	254	269	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1040	1044		10.1038/35016542	http://dx.doi.org/10.1038/35016542			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890441	Green Published			2022-12-28	WOS:000087871700041
J	Hartman, EE; Parker, RA				Hartman, EE; Parker, RA			A 40-year-old woman with a strong family history of breast cancer, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Garber J, 1999, JAMA-J AM MED ASSOC, V282, P1953, DOI 10.1001/jama.282.20.1953	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3243	3243		10.1001/jama.283.24.3243	http://dx.doi.org/10.1001/jama.283.24.3243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866873				2022-12-28	WOS:000087753900038
J	Mofenson, LM; McIntyre, JA				Mofenson, LM; McIntyre, JA			Advances and research directions in the prevention of mother-to-child HIV-1 transmission	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED TRIAL; COTE-DIVOIRE; VERTICAL TRANSMISSION; SOUTH-AFRICA; PERINATAL TRANSMISSION; HIV-1-INFECTED WOMEN; PREGNANCY OUTCOMES; CESAREAN-SECTION; ORAL ZIDOVUDINE	Although substantial progress has been made in preventing mother-to-child HIV-1 transmission in the past decade, critical research questions remain. Two perinatal epidemics now exist. In more-developed countries, integration of prenatal HIV-1 counselling and testing programmes into an existing antenatal infrastructure, availability of effective antiretroviral prophylaxis, and access to infant formula have resulted in new perinatal infections becoming rare. However, identification of missed prevention opportunities, the causes of prophylaxis failure, and the potential effects of in-utero antiretroviral exposure have become a priority. In less-developed countries, antenatal care is limited, testing programmes are almost non-existent, effective interventions remain unimplemented, and prevention of postnatal transmission through breastmilk while maintaining adequate infant nutrition is a major dilemma. The challenge for the next decade is to simultaneously address questions relevant to both epidemics while bridging the gap in prevention of perinatal transmission between more-developed and less-developed countries.	NICHHD, Pediat Adolescent & Mat AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA; Chris Hani Baragwanath Hosp, Johannesburg, South Africa	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Mat AIDS Branch, Ctr Res Mothers & Children, NIH, 6100 Execut Blvd,Room 4B11, Rockville, MD 20852 USA.	LM65D@nih.gov	Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; BATH GJ, 1998, 12 WORLD AIDS C GEN; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; Bulterys M, 1996, AIDS, V10, P923, DOI 10.1097/00002030-199607000-00019; BULTERYS M, 2000, IN PRESS ANN NY ACAD; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; Cherry M, 1999, NATURE, V402, P225, DOI 10.1038/46140; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Control CfD Prevention, 1998, MMWR-MORBID MORTAL W, V47, pi, DOI DOI 10.1001/jamahealthforum.2021.0325; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Coutsoudis A, 1999, AIDS, V13, P1517, DOI 10.1097/00002030-199908200-00012; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; DITRAME ANRS 049 Study Grp, 1999, LANCET, V354, P2050, DOI 10.1016/S0140-6736(99)04388-3; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Graham WJ, 1999, LANCET, V353, P836, DOI 10.1016/S0140-6736(98)12374-7; Grubert TA, 1999, LANCET, V354, P1612, DOI 10.1016/S0140-6736(99)03141-4; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hanson IC, 1999, J ACQ IMMUN DEF SYND, V20, P463, DOI 10.1097/00042560-199904150-00008; JACKSON JB, 2000, IN PRESS AIDS; Katzenstein DA, 1999, J INFECT DIS, V179, P1382, DOI 10.1086/314767; LALLEMONT M, 1999, 2 C GLOB STRAT PREV; LANGE J, 1999, 2 C GLOB STRAT PREV; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Lorenzi P, 1998, AIDS, V12, pF241, DOI 10.1097/00002030-199818000-00002; Maiques-Montesinos V, 1999, ACTA OBSTET GYN SCAN, V78, P789, DOI 10.1034/j.1600-0412.1999.780909.x; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Msellati P, 1999, SEX TRANSM INFECT, V75, P420, DOI 10.1136/sti.75.6.420; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Ramon R, 1998, J ACQ IMMUN DEF SYND, V17, P470, DOI 10.1097/00042560-199804150-00013; SABA J, 1999, 6 C RETR OPP INF CHI; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, NEW ENGL J MED, V340, P1042; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SHAPIRO D, 2000, 7 C RETR OPP INF SAN; SMITH M, 1999, 2 C GLOB STRAT PREV; Soderlund N, 1999, BRIT MED J, V318, P1650, DOI 10.1136/bmj.318.7199.1650; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; THAINEAU V, 1999, 2 C GLOB STRAT PREV; The European Collaborative Study Group, 1998, AIDS, V13, P119; *UNAIDS, 1999, AIDS EP UPD; Van Rompay KKA, 1998, AIDS RES HUM RETROV, V14, P761, DOI 10.1089/aid.1998.14.761; Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; *WOM INF TRANSM ST, 1999, 2 C GLOB STRAT PREV	52	142	151	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2237	2244		10.1016/S0140-6736(00)02415-6	http://dx.doi.org/10.1016/S0140-6736(00)02415-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881908				2022-12-28	WOS:000087779000041
J	Weaver, WD; Reisman, MA; Griffin, JJ; Buller, CE; Leimgruber, PP; Henry, T; D'Haem, C; Clark, VL; Martin, JS; Cohen, DJ; Neil, N; Every, NR				Weaver, WD; Reisman, MA; Griffin, JJ; Buller, CE; Leimgruber, PP; Henry, T; D'Haem, C; Clark, VL; Martin, JS; Cohen, DJ; Neil, N; Every, NR		OPUS-1 Investigators	Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial	LANCET			English	Article							ANGIOGRAPHIC FOLLOW-UP; BALLOON ANGIOPLASTY; ARTERY DISEASE; THREATENED CLOSURE; IMPLANTATION; RESTENOSIS; DISSECTION; OUTCOMES	Background Whether routine implantation of coronary stents is the best strategy to treat flow-limiting coronary stenoses is unclear. An alternative approach is to do balloon angioplasty and provisionally use stents only to treat suboptimum results. We did a multicentre trial to compare the outcomes of patients treated with these strategies. Methods We randomly assigned 479 patients undergoing single-vessel coronary angioplasty routine stent implantation or initial balloon angioplasty and provisional stenting. We followed up patients for 6 months to determine the composite rate of death, myocardial infarction, cardiac surgery, and target-vessel revascularisation. Results Stents were implanted in 227 (98.7%) of the patients assigned routine stenting. 93 (37%) patients assigned balloon angioplasty had at least one stent placed because of suboptimum angioplasty results. At 6 months the composite endpoint was significantly lower in the routine stent strategy (14 events, 6.1%) than with the strategy of balloon angioplasty with provisional stenting (37 events, 14.9%, p=0.003). The cost of the initial revascularisation procedure was higher than when a routine stent strategy was used (US$389 vs $339, p<0.001) but at 6 months, average per-patient hospital costs did not differ ($10 206 vs $10 490). Bootstrap replication of 6-month cost data showed continued economic benefit of the routine stent strategy. Interpretation Routine stent implantation leads to better acute and long-term clinical outcomes at a cost similar to that of initial balloon angioplasty with provisional stenting.	Henry Ford Hlth Syst, Inst Heart & Vasc, Div Cardiovasc Med, Detroit, MI 48202 USA; Swedish Med Ctr, Seattle, WA USA; Virginia Beach Med Ctr, Virginia Beach, VA USA; Vancouver Hosp & Med Ctr, Vancouver, BC, Canada; Heart Inst Spokane, Spokane, WA USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; Michigan Capital Med Ctr, Lansing, MI USA; Beth Israel Hosp, Boston, MA 02215 USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; Virginia Mason Med Ctr, Seattle, WA 98101 USA; VA Puget Sound Healthcare Syst, Seattle, WA USA	Henry Ford Health System; Henry Ford Hospital; Swedish Medical Center; University of British Columbia; Hennepin County Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Weaver, WD (corresponding author), Henry Ford Hlth Syst, Inst Heart & Vasc, Div Cardiovasc Med, 2799 W Grand Blvd, Detroit, MI 48202 USA.	wweaver1@hfhs.org	Neil, Nancy/I-4913-2012	Neil, Nancy/0000-0002-1442-028X				Baim DS, 1998, CIRCULATION, V97, P322; BAIM DS, 1993, AM J CARDIOL, V71, P364, DOI 10.1016/0002-9149(93)90813-R; BAIM DS, 1997, CIRCULATION, V96, P593; Di Mario C, 1998, CIRCULATION, V98, P228; Efron B., 1994, MONOGRAPHS STAT APPL; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; *FROST STUD GROUP, 1998, CIRCULATION, V98, P1184; GEORGE BS, 1993, J AM COLL CARDIOL, V22, P135, DOI 10.1016/0735-1097(93)90827-N; George C. J., 1997, Journal of the American College of Cardiology, V29, p495A; GORDON PC, 1993, J AM COLL CARDIOL, V21, P1166, DOI 10.1016/0735-1097(93)90241-R; HEARN JA, 1993, CIRCULATION, V88, P2086, DOI 10.1161/01.CIR.88.5.2086; HERMANN HC, 1997, CIRCULATION, V96, P91; HERMILLER J, 1995, J AM COLL CARDIOL, V25, pA375; KIMURA I, 1995, J AM COLL CARDIOL, V25, pA375; KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B; LINCOFF AM, 1993, J AM COLL CARDIOL, V21, P866, DOI 10.1016/0735-1097(93)90341-W; MACANDER PJ, 1994, CATHETER CARDIO DIAG, V32, P125, DOI 10.1002/ccd.1810320206; MAIELLO L, 1993, AM HEART J, V125, P1570, DOI 10.1016/0002-8703(93)90742-R; Narins CR, 1998, CIRCULATION, V97, P1298, DOI 10.1161/01.CIR.97.13.1298; Rodriguez A, 1998, J AM COLL CARDIOL, V32, P1351, DOI 10.1016/S0735-1097(98)00388-X; Sawada Yoshihiro, 1996, Journal of the American College of Cardiology, V27, p252A; SCHOMIG A, 1994, J AM COLL CARDIOL, V23, P1053, DOI 10.1016/0735-1097(94)90589-4; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SPERTUS JA, 1995, J AM COLL CARDIOL, V25, P333, DOI 10.1016/0735-1097(94)00397-9; TOPOL EJ, 1994, NEW ENGL J MED, V331, P539, DOI 10.1056/NEJM199408253310811; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; WOHL V, 1998, MERRILL LYNCH CO HLT; Yokoi Hiroyoshi, 1996, Journal of the American College of Cardiology, V27, p224A	29	76	77	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2199	2203		10.1016/S0140-6736(00)02403-X	http://dx.doi.org/10.1016/S0140-6736(00)02403-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881893				2022-12-28	WOS:000087779000011
J	Buschmann, T; Fuchs, SY; Lee, CG; Pan, ZQ; Ronai, Z				Buschmann, T; Fuchs, SY; Lee, CG; Pan, ZQ; Ronai, Z			SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53	CELL			English	Article							TUMOR-SUPPRESSOR P53; CONJUGATING ENZYME; PROTEIN LIGASE; COMPLEX; FAMILY; NEDD8; YEAST; E3; PHOSPHORYLATION; IDENTIFICATION	Mdm2 is an E3 ubiquitin ligase for the p53 tumor suppressor protein. We demonstrate that Mdm2 is conjugated with SUMO-1 (sumoylated) at Lys-446, which is located within the RING finger domain and plays a critical role in Mdm2 self-ubiquitination. Whereas mutant Mdm2(K446R) is stabilized, it elicits increased degradation of p53 and concomitant inhibition of p53-mediated apoptosis. In vitro sumoylation of Mdm2 abrogates its self-ubiquitination and increases its ubiquitin ligase activity toward p53. Radiation caused a dose- and time-dependent decrease in the degree of Mdm2 SUMO-1 modification, which is inversely correlated with the levels of p53. Our results suggest that the maintenance of the intrinsic activity of a RING finger E3 ubiquitin ligase is sumoylation dependent and that reduced Mdma sumoylation in response to DNA damage contributes to p53 stability.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA.	ronaiz01@doc.mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA80058, CA55908] Funding Source: Medline; NIGMS NIH HHS [GM55059] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	49	216	227	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					753	762		10.1016/S0092-8674(00)80887-9	http://dx.doi.org/10.1016/S0092-8674(00)80887-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892746	Bronze			2022-12-28	WOS:000087821400009
J	Dalton, R; Abbott, A				Dalton, R; Abbott, A			Hawaii reaches for the stars with astronomy master plan	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					872	872		10.1038/35016216	http://dx.doi.org/10.1038/35016216			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879498	Bronze			2022-12-28	WOS:000087732700005
J	de Forges, BR; Koslow, JA; Poore, GCB				de Forges, BR; Koslow, JA; Poore, GCB			Diversity and endemism of the benthic seamount fauna in the southwest Pacific	NATURE			English	Article							BIOGEOGRAPHY; COMMUNITY; SLOPE	Seamounts comprise a unique deep-sea environment, characterized by substantially enhanced currents and a fauna that is dominated by suspension feeders, such as corals(1-4). The potential importance of these steep-sided undersea mountains, which are generally of volcanic origin, to ocean biogeography and diversity was recognized over 40 years ago(5), but this environment has remained very poorly explored. A review(3) of seamount biota and biogeography reported a total of 597 invertebrate species recorded from seamounts worldwide since the Challenger expedition of 1872. Most reports, based on a single taxonomic group, were extremely limited: 5 seamounts of the estimated more than 30,000 seamounts in the world's oceans(4,6) accounted for 72% of the species recorded. Only 15% of the species occurring on seamounts were considered potential seamount endemics. Here we report the discovery of more than 850 macro- and megafaunal species from seamounts in the Tasman Sea and southeast Coral Sea, of which 29-34% are new to science and potential seamount endemics. Low species overlap between seamounts in different portions of the region indicates that the seamounts in clusters or along ridge systems function as 'island groups' or 'chains,' leading to highly localized species distributions and apparent speciation between groups or ridge systems that is exceptional for the deep sea. These results have substantial implications for the conservation of this fauna, which is threatened by fishing activity(7).	CSIRO, Hobart, Tas 7001, Australia; Ctr IRD Noumea, Noumea 98848, New Caledonia; Museum Victoria, Abbotsford, Vic 3067, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Institut de Recherche pour le Developpement (IRD); Museum Victoria	Koslow, JA (corresponding author), CSIRO, GPO Box 1538, Hobart, Tas 7001, Australia.	tony.koslow@marine.csiro.au						AMEZIANECOMINARDI N, 1987, CR ACAD SCI III-VIE, V304, P15; [Anonymous], 1943, GEOLOGICAL SOC AM SP, V44, P1, DOI DOI 10.1130/SPE44-P1; BOUCHET P, 1982, NEW ZEAL J ZOOL, V9, P309, DOI 10.1080/03014223.1982.10423862; DEFORGES BR, 1990, MEMOIRES MUSEUM NATL, V145, P9; DEFORGES BR, 1993, MEM MUS NATL HIST NA, V156, P475; GENIN A, 1986, NATURE, V322, P59, DOI 10.1038/322059a0; GRIGG RW, 1984, PSZNI MAR ECOL, V5, P57, DOI 10.1111/j.1439-0485.1984.tb00307.x; HUBBS CARL L., 1959, PACIFIC SCI, V13, P311; JOHANNESSON K, 1988, MAR BIOL, V99, P507, DOI 10.1007/BF00392558; KOSLOW JA, 1994, DEEP-SEA RES PT I, V41, P113; KOSLOW JA, 1993, PROG OCEANOGR, V31, P321; KOSLOW JA, UNPUB MAR ECOL PROG; LAURIN B, 1992, CR ACAD SCI III-VIE, V314, P343; LUTJEHARMS JRE, 1981, DEEP-SEA RES, V28, P631, DOI 10.1016/0198-0149(81)90123-0; Mullineaux LS, 1997, DEEP-SEA RES PT I, V44, P745, DOI 10.1016/S0967-0637(96)00130-6; PARKER T, 1994, BIOL BULL-US, V187, P336, DOI 10.2307/1542290; PIELOU EC, 1974, POPULATION COMMUNITY, P311; POORE GCB, 1994, DEEP-SEA RES PT I, V41, P677, DOI 10.1016/0967-0637(94)90049-3; Richer de Forges B, 1998, THESIS MUSEUM NATL H; Roden G.I., 1986, NOAA TECHNICAL REPOR, V43, P3; ROGERS AD, 1994, ADV MAR BIOL, V30, P305, DOI 10.1016/S0065-2881(08)60065-6; Sibuet M, 1998, DEEP-SEA RES PT II, V45, P517, DOI 10.1016/S0967-0645(97)00074-X; SMITH DK, 1988, J GEOPHYS RES-SOLID, V93, P2899, DOI 10.1029/JB093iB04p02899; Tunnicliffe V, 1998, ADV MAR BIOL, V34, P353, DOI 10.1016/S0065-2881(08)60213-8; VACELET J, 1992, CR ACAD SCI III-VIE, V314, P379; Wilson RR, 1987, GEOPHYS MONOGR SER, P355, DOI DOI 10.1029/GM043P0355	26	259	268	3	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					944	947		10.1038/35016066	http://dx.doi.org/10.1038/35016066			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879534				2022-12-28	WOS:000087732700049
J	Wu, WJ; Erickson, JW; Lin, R; Cerione, RA				Wu, WJ; Erickson, JW; Lin, R; Cerione, RA			The gamma-subunit of the coatomer complex binds Cdc42 to mediate transformation	NATURE			English	Article							GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; CELL POLARITY; PROTEIN; TRANSPORT; ACTIN; MEMBRANE; GTPASE; RHO; IDENTIFICATION	The Ras-related GTP-binding protein Cdc42 is implicated in a variety of biological activities including the establishment of cell polarity in yeast, the regulation of cell morphology, motility and cell-cycle progression in mammalian cells and the induction of malignant transformation(1,2). We identified a Cdc42 mutant (Cdc42F28L) which binds GTP in the absence of a guanine nucleotide exchange factor, but still hydrolyses GTP with a turnover number identical to that for wild-type Cdc42 (ref. 3). Expression of this mutant in NIH 3T3 fibroblasts causes cellular transformation, mimicking many of the characteristics of cells transformed by the Dbl oncoprotein, a known guanine nucleotide exchange factor for Cdc42 (ref. 4). Here we searched for new Cdc42 targets in an effort to understand how Cdc42 mediates cellular transformation. We identified the gamma-subunit of the coatomer complex (gamma COP) as a specific binding partner for activated Cdc42. The binding of Cdc42 to gamma COP is essential for a transforming signal distinct from those elicited by Ras.	Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, VMC, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, VMC, Dept Mol Med, Ithaca, NY 14853 USA.							BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655	30	179	180	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					800	804		10.1038/35015585	http://dx.doi.org/10.1038/35015585			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866202				2022-12-28	WOS:000087620600053
J	Singleton, MR; Sawaya, MR; Ellenberger, T; Wigley, DB				Singleton, MR; Sawaya, MR; Ellenberger, T; Wigley, DB			Crystal structure of T7 gene 4 ring helicase indicates a mechanism for sequential hydrolysis of nucleotides	CELL			English	Article							TERMINATION FACTOR-RHO; SINGLE-STRANDED-DNA; BINDING CHANGE MECHANISM; CONFORMATIONAL-CHANGES; OLIGOMERIC STRUCTURE; HEXAMER FORMATION; PRIMASE ACTIVITY; PCRA HELICASE; PROTEIN-RHO; BACTERIOPHAGE-T7	We have determined the crystal structure of arl active, hexameric fragment of the gene 4 helicase from bacteriophage T7. The structure reveals how subunit contacts stabilize the hexamer. Deviation from expected six-fold symmetry of the hexamer indicates that the structure is of an intermediate on the catalytic pathway. The structural consequences of the asymmetry suggest a "binding change" mechanism to explain how cooperative binding and hydrolysis of nucleotides are coupled to conformational changes in the ring that most likely accompany duplex unwinding. The structure of a complex with a nonhydrolyzable ATP analog provides additional evidence for this hypothesis, with only four of the six possible nucleotide binding sites being occupied in this conformation of the hexamer. This model suggests a mechanism for DNA translocation.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of Oxford; Harvard University; Harvard Medical School	Wigley, DB (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	wigley@eric.path.ox.ac.uk		Singleton, Martin/0000-0001-5716-7715; Sawaya, Michael/0000-0003-0874-9043				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fass D, 1999, STRUCTURE, V7, P691, DOI 10.1016/S0969-2126(99)80090-2; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Kaplan DL, 1999, J BIOL CHEM, V274, P6889, DOI 10.1074/jbc.274.11.6889; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; ODA T, 1972, J MOL BIOL, V71, P799; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Picha KM, 1998, J BIOL CHEM, V273, P27315, DOI 10.1074/jbc.273.42.27315; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; San Martin C, 1998, STRUCTURE, V6, P501; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; STITT BL, 1988, J BIOL CHEM, V263, P11130; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Wittinghofer A, 1998, BIOL CHEM, V379, P933; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	54	411	413	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2000	101	6					589	600		10.1016/S0092-8674(00)80871-5	http://dx.doi.org/10.1016/S0092-8674(00)80871-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892646	Bronze			2022-12-28	WOS:000087504500006
J	Mocarelli, P; Gerthoux, PM; Ferrari, E; Patterson, DG; Kieszak, SM; Brambilla, P; Vincoli, N; Signorini, S; Tramacere, P; Carreri, V; Sampson, EJ; Turner, WE; Needham, LL				Mocarelli, P; Gerthoux, PM; Ferrari, E; Patterson, DG; Kieszak, SM; Brambilla, P; Vincoli, N; Signorini, S; Tramacere, P; Carreri, V; Sampson, EJ; Turner, WE; Needham, LL			Paternal concentrations of dioxin and sex ratio of offspring	LANCET			English	Article							WOOD PRESERVATIVES; AIR-POLLUTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; SEVESO; EXPOSURE; BIRTHS; SERUM; TCDD; SPERMATOZOA; CHEMICALS	Background 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD or dioxin), is commonly considered the most toxic man-made substance. We have previously shown that high serum concentrations of TCDD in parents from Seveso, Italy, were linked to their having a relative increase in the number of female births after the parents exposure to a release of dioxin in 1976. We have continued the study to determine whether the parents' sex and/or age at exposure affected the sex ratio of their children. Methods We measured the TCDD concentrations in serum samples from potentially exposed parents collected in 1976 and 1977, and investigated the sex ratio of their offspring. Findings Serum samples were collected from 239 men and 296 women. 346 girls and 328 boys were born to potentially exposed parents between 1977 and 1996, showing an increased probability of female births (lower sex ratio) with increasing TCDD concentrations in the serum samples from the fathers (p=0008). This effect starts at concentrations less than 20 ng per kg bodyweight. Fathers exposed when they were younger than 19 years of age sired significantly more girls than boys (sex ratio 0.38 [95% CI 0.30-0.47]). Interpretation Exposure of men to TCDD is linked to a lowered male/female sex ratio in their offspring, which may persist for years after exposure. The median concentration of dioxin in fathers in this study is similar to doses that induce epididymal impairments in rats and is about 20 times the estimated average concentration of TCDD currently found in human beings in industrialised countries. These observations could have important public-health implications.	Univ Milano Bicocca, Hosp Desio, Dept Lab Med, I-20033 Desio, Italy; Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA; Minist Hlth Reg Lobardia, Dept Prevent Med, Milan, Italy	University of Milano-Bicocca; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Mocarelli, P (corresponding author), Univ Milano Bicocca, Hosp Desio, Dept Lab Med, Via Benefattori 2, I-20033 Desio, Italy.	mocarelli@uds.unimib.it	Needham, Larry/E-4930-2011		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007171] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07171] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allan BB, 1997, CAN MED ASSOC J, V156, P37; Astolfi P, 1999, HUM REPROD, V14, P3116, DOI 10.1093/humrep/14.12.3116; BARTELS I, 1990, AM J MED GENET, V35, P297, DOI 10.1002/ajmg.1320350235; Bertazzi PA, 1998, ENVIRON HEALTH PERSP, V106, P625, DOI 10.2307/3433813; Bonduelle M, 1998, HUM REPROD, V13, P196, DOI 10.1093/humrep/13.suppl_1.196; Davis DL, 1998, JAMA-J AM MED ASSOC, V279, P1018, DOI 10.1001/jama.279.13.1018; DEVITO MJ, 1995, ENVIRON HEALTH PERSP, V103, P820, DOI 10.2307/3432395; DIDOMENICO A, 1990, CHEMOSPHERE, V20, P1559, DOI 10.1016/0045-6535(90)90313-I; DimichWard H, 1996, SCAND J WORK ENV HEA, V22, P267, DOI 10.5271/sjweh.141; Durkee TJ, 1998, AM J OBSTET GYNECOL, V178, P1288, DOI 10.1016/S0002-9378(98)70335-7; Faqi AS, 1998, TOXICOL APPL PHARM, V150, P383, DOI 10.1006/taap.1998.8433; Grassman JA, 1998, ENVIRON HEALTH PERSP, V106, P761, DOI 10.2307/3433831; Gray LE, 1997, TOXICOL APPL PHARM, V146, P11, DOI 10.1006/taap.1997.8223; IDAOMAR M, 1989, ARCH ANDROLOGY, V22, P197, DOI 10.3109/01485018908986772; IDAOMAR M, 1987, Advances in Contraceptive Delivery Systems, V3, P337; James WH, 1996, J THEOR BIOL, V180, P271, DOI 10.1006/jtbi.1996.0102; James WH, 1997, SCAND J WORK ENV HEA, V23, P69, DOI 10.5271/sjweh.182; Kreuzer PE, 1997, ARCH TOXICOL, V71, P383, DOI 10.1007/s002040050402; Landi MT, 1998, ENVIRON HEALTH PERSP, V106, P273, DOI 10.2307/3434015; LOBEL SM, 1993, FERTIL STERIL, V59, P387; Marcus M, 1998, FERTIL STERIL, V70, P270, DOI 10.1016/S0015-0282(98)00149-6; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; MOCARELLI P, 1986, JAMA-J AM MED ASSOC, V256, P2687, DOI 10.1001/jama.256.19.2687; MOCARELLI P, 1991, J TOXICOL ENV HEALTH, V32, P357, DOI 10.1080/15287399109531490; MOCARELLI P, 1991, BANB REPORT, V35, P95; MOCARELLI P, 1992, TOXIC SUBST J, V12, P151; Moller H, 1996, LANCET, V348, P828, DOI 10.1016/S0140-6736(05)65253-1; Needham LL, 1997, TERATOGEN CARCIN MUT, V17, P225, DOI 10.1002/(SICI)1520-6866(1997)17:4/5<225::AID-TCM5>3.3.CO;2-P; Needham LL, 1999, ENVIRON RES, V80, pS200, DOI 10.1006/enrs.1998.3928; PATTERSON DG, 1987, ANAL CHEM, V59, P2000, DOI 10.1021/ac00142a023; Rogan WJ, 1999, LANCET, V353, P206, DOI 10.1016/S0140-6736(05)77215-9; ROMAN E, 1998, REPROD DEV TOXICOLOG, P593; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; vanderPaldeBruin KM, 1997, LANCET, V349, P62, DOI 10.1016/S0140-6736(05)62204-0; WILLIAMS FLR, 1992, INT J EPIDEMIOL, V21, P311, DOI 10.1093/ije/21.2.311; WILLIAMS FLR, 1995, OCCUP ENVIRON MED, V52, P164, DOI 10.1136/oem.52.3.164; ZURLO N, 1979, DIASTRO ICMESA SCI P, P209	37	302	319	0	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1858	1863		10.1016/S0140-6736(00)02290-X	http://dx.doi.org/10.1016/S0140-6736(00)02290-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866441				2022-12-28	WOS:000087306500012
J	Lichtenstein, P; Holm, NV; Verkasalo, PK; Iliadou, A; Kaprio, J; Koskenvuo, M; Pukkala, E; Skytthe, A; Hemminki, K				Lichtenstein, P; Holm, NV; Verkasalo, PK; Iliadou, A; Kaprio, J; Koskenvuo, M; Pukkala, E; Skytthe, A; Hemminki, K			Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-DEGREE RELATIVES; PROSTATE-CANCER; OVARIAN-CANCER; COMPLEX TRAITS; FAMILIAL RISK; BREAST-CANCER; POPULATION; EPIDEMIOLOGY; WOMEN; CONCORDANCE	Background: The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases. Methods: We combined data on 44,788 pairs of twins listed in the Swedish, Danish, and Finnish twin registries in order to assess the risks of cancer at 28 anatomical sites for the twins of persons with cancer. Statistical modeling was used to estimate the relative importance of heritable and environmental factors in causing cancer at 11 of those sites. Results: At least one cancer occurred in 10,803 persons among 9512 pairs of twins. An increased risk was found among the twins of affected persons for stomach, colorectal, lung, breast, and prostate cancer. Statistically significant effects of heritable factors were observed for prostate cancer (42 percent of the risk may be explained by heritable factors; 95 percent confidence interval, 29 to 50 percent), colorectal cancer (35 percent; 95 percent confidence interval, 10 to 48 percent), and breast cancer (27 percent; 95 percent confidence interval, 4 to 41 percent). Conclusions: Inherited genetic factors make a minor contribution to susceptibility to most types of neoplasms. This finding indicates that the environment has the principal role in causing sporadic cancer. The relatively large effect of heritability in cancer at a few sites (such as prostate and colorectal cancer) suggests major gaps in our knowledge of the genetics of cancer. (N Engl J Med 2000;343:78-85.) (C) 2000, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Univ So Denmark, Danish Twin Registry, Odense, Denmark; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Univ Oulu, Dept Publ Hlth & Gen Practice, Oulu, Finland; Univ Turku, Dept Publ Hlth, Turku, Finland; Finnish Canc Registry, FIN-00170 Helsinki, Finland; Karolinska Inst, Novum, Dept Biosci, SE-17177 Stockholm, Sweden	Karolinska Institutet; University of Southern Denmark; University of Southern Denmark; University of Helsinki; University of Oulu; University of Turku; Finnish Cancer Registry; Karolinska Institutet	Lichtenstein, P (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, SE-17177 Stockholm, Sweden.		Skytthe, Axel E/G-4820-2019; Kaprio, Jaakko/A-1820-2008; Ogunwobi, Olorunseun/F-3172-2010; Pillay, Nischalan/F-9536-2012	Skytthe, Axel E/0000-0002-8629-4913; Kaprio, Jaakko/0000-0002-3716-2455; lichtenstein, paul/0000-0003-3037-5287	NATIONAL CANCER INSTITUTE [R35CA042581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 42581] Funding Source: Medline; NIA NIH HHS [P01-AG08761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARINO M, 1999, INT J CANCER, V81, P214; Ahlbom A, 1997, J NATL CANCER I, V89, P287, DOI 10.1093/jnci/89.4.287; Auranen A, 1996, BRIT J CANCER, V74, P280, DOI 10.1038/bjc.1996.352; Auranen A, 1996, AM J EPIDEMIOL, V144, P548, DOI 10.1093/oxfordjournals.aje.a008964; BRAUN MM, 1995, CANCER EPIDEM BIOMAR, V4, P469; BRAUN MM, 1994, LANCET, V344, P440, DOI 10.1016/S0140-6736(94)91770-1; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; Cederlof R, 1978, Prog Clin Biol Res, V24 Pt B, P189; Clemmesen J., 1965, STAT STUDIES AETIOLO, VI; Easton DF, 1996, INT J CANCER, V65, P284, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;284::AID-IJC2&gt;3.0.CO;2-W; EASTON DF, 1994, BRIT MED BULL, V50, P527, DOI 10.1093/oxfordjournals.bmb.a072908; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; GRONBERG H, 1994, J UROLOGY, V152, P1484, DOI 10.1016/S0022-5347(17)32452-7; Gronberg H, 1999, AM J HUM GENET, V65, P134, DOI 10.1086/302447; Gruber SB, 1996, CANCER EPIDEM BIOMAR, V5, P411; HAUGE M, 1968, ACTA GENET MED GEMEL, V17, P315, DOI 10.1017/S1120962300012749; Hauge M, 1981, PROSPECTIVE LONGITUD, P217; HEATH AC, 1989, BEHAV GENET, V19, P9, DOI 10.1007/BF01065881; Hemminki K, 1999, EUR J CANCER, V35, P1109, DOI 10.1016/S0959-8049(99)00066-0; Hemminki K, 1998, INT J CANCER, V78, P172, DOI 10.1002/(SICI)1097-0215(19981005)78:2<172::AID-IJC9>3.0.CO;2-W; HOLM NV, 1980, J NATL CANCER I, V65, P285; HOLM NV, 1982, CANCER SURV, V1, P17; HOLM NV, 1983, THESIS ODENSE U ODEN; *INT AG RES CANC, 1990, IARC SCI PUBL, V100; Kaprio J, 1978, Prog Clin Biol Res, V24 Pt B, P179; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Kyvik KO, 1996, DAN MED BULL, V43, P467; LANDER ES, 1994, SCIENCE, V266, P353; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lesko SM, 1996, AM J EPIDEMIOL, V144, P1041, DOI 10.1093/oxfordjournals.aje.a008876; LI FP, 1995, CANCER EPIDEM BIOMAR, V4, P579; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.3.CO;2-Q; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; Martin N, 1997, NAT GENET, V17, P387, DOI 10.1038/ng1297-387; MCGUE M, 1992, SCHIZOPHRENIA BULL, V18, P171, DOI 10.1093/schbul/18.2.171; NEALE MC, 1994, BEHAV GENET, V24, P239, DOI 10.1007/BF01067191; Neale MC, 1992, METHODOLOGY GENETIC; NEALE MC, 1999, MX STAT MODELING; Page WF, 1997, PROSTATE, V33, P240; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; SHAM PC, 1997, STAT HUMAN GENETICS; Storm HH, 1997, DAN MED BULL, V44, P535; STORM HH, 1996, CANC INCIDENCE DENMA; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; THOMPSON WD, 1994, CANCER, V74, P279; Verkasalo PK, 1999, INT J CANCER, V83, P743, DOI 10.1002/(SICI)1097-0215(19991210)83:6<743::AID-IJC8>3.0.CO;2-Q	50	2881	2990	7	237	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					78	85		10.1056/NEJM200007133430201	http://dx.doi.org/10.1056/NEJM200007133430201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891514	Bronze			2022-12-28	WOS:000088116500001
J	Lahat, E; Goldman, M; Barr, J; Bistritzer, T; Berkovitch, M				Lahat, E; Goldman, M; Barr, J; Bistritzer, T; Berkovitch, M			Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study	BRITISH MEDICAL JOURNAL			English	Article							ADULT EPILEPTIC PATIENTS; ACUTE CHILDHOOD SEIZURES; INTRAMUSCULAR MIDAZOLAM; RECTAL BENZODIAZEPINES; NASAL RATHER; MANAGEMENT; SEDATION	Objective To compare the safety and efficacy of midazolam given intranasally with diazepam given intravenously in the treatment of children with prolong ed febrile seizures. Design Prospective randomised study Setting Paediatric emergency department in a general hospital. Subjects 47 children aged six months to live years with prolonged febrile seizure (at least 10 minutes) during a 12 month period. Interventions Intranasal midazolam (0.2 mg/kg) and intravenous diazepam (0.3 mg/kg). Main outcome measures Time from arrival at hospital to starting treatment and cessation of seizures. Results Intranasal midazolam and intravenous diazepam were equally effective. Overall, 23 of 26 seizures were controlled with midazolam and 24 out of 26 with diazepam. The mean time from arrival at hospital to starting treatment was significantly shorter in die midazolam group (3.5 (SD 1.8) minutes, 95% confidence interval 3.3 to 3.7) than the diazepam group (5.5 (2.0), 5.3 to 5.7). The mean time to control of seizures was significantly sooner (0.1 (3.6), 6.3 to 6.7) in the midazolam group than the diazepam group (8.0 (0.5), 7.9 to 8.3). No significant side effects were observed in either group. Conclusion Seizures were controlled more quickly with intravenous diazepam than with intranasal midazolam, although midazolam was as safe and effective as diazepam. The overall time to cessation of seizures after arrival at hospital was faster with intranasal midazolam than with intravenous diazepam. The intranasal route can possibly be used not only in medical centres but in general practice and, with appropriate instructions, by families of children with recurrent febrile seizures at home.	Assaf Harofeh Med Ctr, Pediat Neurol Unit, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Dept Pediat, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Pediat Intens Care Unit, IL-70300 Zerifin, Israel; Assaf Harofeh Med Ctr, Pediat Clin Pharmacol Unit, IL-70300 Zerifin, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University	Lahat, E (corresponding author), Assaf Harofeh Med Ctr, Pediat Neurol Unit, IL-70300 Zerifin, Israel.							ALLDREDGE BK, 1995, PEDIATR NEUROL, V12, P213, DOI 10.1016/0887-8994(95)00044-G; ARENDT RM, 1983, J PHARMACOL EXP THER, V227, P98; Chamberlain JM, 1997, PEDIATR EMERG CARE, V13, P92, DOI 10.1097/00006565-199704000-00002; CONNER JT, 1978, ANESTH ANALG, V57, P1; CRISP CB, 1988, CLIN PHARM, V7, P332; DEJONG RH, 1981, ANESTH ANALG, V60, P385; DHILLON S, 1982, BRIT J CLIN PHARMACO, V13, P427, DOI 10.1111/j.1365-2125.1982.tb01397.x; DODSON WE, 1993, JAMA-J AM MED ASSOC, V270, P854; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; DUNDEE JW, 1984, DRUGS, V28, P519, DOI 10.2165/00003495-198428060-00002; GALVIN GM, 1987, ARCH EMERG MED, V4, P169; Ghialin S, 1988, J NEUROL NEUROSUR PS, V51, P732; GREENBLATT DJ, 1983, BRIT J ANAESTH, V55, P985, DOI 10.1093/bja/55.10.985; HIRTZ DG, 1989, PEDIATR CLIN N AM, V36, P375; JAWAD S, 1986, J NEUROL NEUROSUR PS, V49, P1050, DOI 10.1136/jnnp.49.9.1050; Koul RL, 1997, ARCH DIS CHILD, V76, P445, DOI 10.1136/adc.76.5.445; Lacon A, 1994, ACTA ANAESTH SCAND, V38, P259; Lahat E, 1998, LANCET, V352, P620, DOI 10.1016/S0140-6736(05)79574-X; LAHAT E, 1992, PEDIATR NEUROL, V8, P215, DOI 10.1016/0887-8994(92)90071-6; LATSON LA, 1991, AM HEART J, V121, P209, DOI 10.1016/0002-8703(91)90981-M; LOMBROSO CT, 1989, EPILEPSIA, V30, pS11, DOI 10.1111/j.1528-1157.1989.tb05819.x; MAGNUSSEN I, 1979, ACTA PHARMACOL TOX, V45, P87; MILLIGAN NM, 1984, J NEUROL NEUROSUR PS, V47, P235, DOI 10.1136/jnnp.47.3.235; OREBAUGH SL, 1994, AM J EMERG MED, V12, P284, DOI 10.1016/0735-6757(94)90139-2; ORegan ME, 1996, DEV MED CHILD NEUROL, V38, P1037; REMY C, 1992, EPILEPSIA, V33, P353, DOI 10.1111/j.1528-1157.1992.tb02327.x; REY E, 1991, EUR J CLIN PHARMACOL, V41, P355, DOI 10.1007/BF00314967; SAINTMAURICE C, 1990, ACTA ANESTHESIOL S92, V94, P39; Scott RC, 1997, DEV MED CHILD NEUROL, V39, P137; SIEGLER RS, 1990, J EMERGENCY MED, V8, P155; WILTON NCT, 1988, ANESTHESIOLOGY, V69, P972, DOI 10.1097/00000542-198812000-00032; YAGER JY, 1988, AM J DIS CHILD, V142, P931, DOI 10.1001/archpedi.1988.02150090029016	32	195	202	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					83	86		10.1136/bmj.321.7253.83	http://dx.doi.org/10.1136/bmj.321.7253.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884257	Bronze, Green Published			2022-12-28	WOS:000088196600025
J	Gulbis, JM; Zhou, M; Mann, S; MacKinnon, R				Gulbis, JM; Zhou, M; Mann, S; MacKinnon, R			Structure of the cytoplasmic beta subunit - T1 assembly of voltage-dependent K+ channels	SCIENCE			English	Article							SHAKER POTASSIUM CHANNEL; TETRAMERIZATION DOMAIN; ALPHA-SUBUNITS; INACTIVATION; PORE	The structure of the cytoplasmic assembly of voltage-dependent K+ channels was solved by x-ray crystallography at 2.1 angstrom resolution. The assembly includes the cytoplasmic (T1) domain of the integral membrane or subunit together with the oxidoreductase beta subunit in a fourfold symmetric T1(4)beta(4) complex. An electrophysiological assay showed that this complex is oriented with four T1 domains facing the transmembrane pore and four beta subunits facing the cytoplasm. The transmembrane pore communicates with the cytoplasm through lateral, negatively charged openings above the T1(4)beta(4) complex. The inactivation peptides of voltage-dependent K+ channels reach their site of action by entering these openings.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; *AX INSTR, CLAMP VERS 8; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GOMEZLAGUNAS F, 1995, BIOPHYS J, V68, P89, DOI 10.1016/S0006-3495(95)80162-1; GULBIS JM, UNPUB; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Lee TE, 1996, J MEMBRANE BIOL, V151, P225, DOI 10.1007/s002329900073; LU Z, 1994, J GEN PHYSIOL, V104, P477, DOI 10.1085/jgp.104.3.477; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; *WARN INSTR, OC725B WARN INSTR; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	33	261	270	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					123	127		10.1126/science.289.5476.123	http://dx.doi.org/10.1126/science.289.5476.123			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884227				2022-12-28	WOS:000088090400047
J	Stampfer, MJ; Hu, FB; Manson, JE; Rimm, EB; Willett, WC				Stampfer, MJ; Hu, FB; Manson, JE; Rimm, EB; Willett, WC			Primary prevention of coronary heart disease in women through diet and lifestyle.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MODERATE ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY QUESTIONNAIRE; MIDDLE-AGED WOMEN; PROSPECTIVE COHORT; CIGARETTE-SMOKING; VITAMIN-E; RISK; MORTALITY; STROKE; REPRODUCIBILITY	Background: Many lifestyle-related risk factors for coronary heart disease have been identified, but little is known about their effect on the risk of disease when they are considered together. Methods: We followed 84,129 women participating in the Nurses' Health Study who were free of diagnosed cardiovascular disease, cancer, and diabetes at base line in 1980. Information on diet and lifestyle was updated periodically. During 14 years of follow-up, we documented 1128 major coronary events (296 deaths from coronary heart disease and 832 nonfatal infarctions). We defined subjects at low risk as those who were not currently smoking, had a body-mass index (the weight in kilograms divided by the square of the height in meters) under 25, consumed an average of at least half a drink of an alcoholic beverage per day, engaged in moderate-to-vigorous physical activity (which could include brisk walking) for at least half an hour per day, on average, and scored in the highest 40 percent of the cohort for consumption of a diet high in cereal fiber, marine n-3 fatty acids, and folate, with a high ratio of polyunsaturated to saturated fat, and low in trans fat and glycemic load, which reflects the extent to which diet raises blood glucose levels. Results: Many of the factors were correlated, but each independently and significantly predicted risk, even after further adjustment for age, family history, presence or absence of diagnosed hypertension or diagnosed high cholesterol level, and menopausal status. Women in the low-risk category (who made up 3 percent of the population) had a relative risk of coronary events of 0.17 (95 percent confidence interval, 0.07 to 0.41) as compared with all the other women. Eighty-two percent of coronary events in the study cohort (95 percent confidence interval, 58 to 93 percent) could be attributed to lack of adherence to this low-risk pattern. Conclusions: Among women, adherence to lifestyle guidelines involving diet, exercise, and abstinence from smoking is associated with a very low risk of coronary heart disease. (N Engl J Med 2000;343:16-22.) (C) 2000, Massachusetts Medical Society.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Stampfer, MJ (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.				NHLBI NIH HHS [HL24074, HL34594, HL60712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594, R01HL060712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CM, 1998, JAMA-J AM MED ASSOC, V279, P23, DOI 10.1001/jama.279.1.23; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hu F B, 1999, Curr Atheroscler Rep, V1, P204, DOI 10.1007/s11883-999-0033-7; Hu FB, 1999, AM J CLIN NUTR, V69, P890; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; KAWACHI I, 1993, ANN INTERN MED, V119, P992, DOI 10.7326/0003-4819-119-10-199311150-00005; KAWACHI I, 1994, ARCH INTERN MED, V154, P169, DOI 10.1001/archinte.154.2.169; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; National Center for Chronic Disease Prevention and Health Promotion, 1996, PHYS ACT HLTH REP SU; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; Rothman K., 1998, MODERN EPIDEMIOLOGY; Sacco RL, 1999, JAMA-J AM MED ASSOC, V281, P53, DOI 10.1001/jama.281.1.53; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STONE PH, 1996, PREVENTION MYOCARDIA, P463; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VANGIJN J, 1993, HLTH ISSUES RELATED, P43; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P668; Walker AE, 1981, STROKE S1, V12, P13; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; Willett WC, 1998, OXFORD SCHOLARSHIP O; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; Wolk A, 1999, JAMA-J AM MED ASSOC, V281, P1998, DOI 10.1001/jama.281.21.1998	39	1146	1179	0	156	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					16	22		10.1056/NEJM200007063430103	http://dx.doi.org/10.1056/NEJM200007063430103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882764	Bronze			2022-12-28	WOS:000087987600003
J	McGinn, TG; Guyatt, GH; Wyer, PC; Naylor, CD; Stiell, IG; Richardson, WS				McGinn, TG; Guyatt, GH; Wyer, PC; Naylor, CD; Stiell, IG; Richardson, WS		Evidence-Based Med Working Grp	Users' guides to the medical literature - XXII: How to use articles about clinical decision rules	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OTTAWA ANKLE RULES; VENTRICULAR EJECTION FRACTION; PREDICTION RULE; MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES; VALIDATION; RADIOGRAPHY; INJURIES; IMPLEMENTATION; EDUCATION	Clinical experience provides clinicians with an intuitive sense of which findings on history, physical examination, and investigation are critical in making an accurate diagnosis, or an accurate assessment of a patient's fate. A clinical decision rule (CDR) is a clinical tool that quantifies the individual contributions that various components of the history, physical examination, and basic laboratory results make toward the diagnosis, prognosis, or likely response to treatment in a patient, Clinical decision rules attempt to formally test, simplify, and increase the accuracy of clinicians' diagnostic and prognostic assessments. Existing CDRs guide clinicians, establish pretest probability, provide screening tests for com mon problems, and estimate risk, Three steps are involved in the development and testing of a CDR: creation of the rule, testing or validating the rule, and assessing the impact of the rule on clinical behavior. Clinicians evaluating CDRs for possible clinical use should assess the following components: the method of derivation; the validation of the CDR to ensure that its repeated use leads to the same results; and its predictive power, We consider CDRs that have been validated in a new clinical setting to be level 1 CDRs and most appropriate for implementation, Level 1 Cops have the potential to inform clinical judgment, to change clinical behavior, and to reduce unnecessary costs, while maintaining quality of care and patient satisfaction.	McMaster Univ, Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Stiell, Ian/0000-0002-2583-6408				Auleley GR, 1997, JAMA-J AM MED ASSOC, V277, P1935; Auleley GR, 1998, ANN EMERG MED, V32, P14, DOI 10.1016/S0196-0644(98)70093-9; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cameron C, 1999, CAN MED ASSOC J, V160, P1165; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; GUYATT G, 1995, CAN MED ASSOC J, V152, P497; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KERR L, 1994, NEW ZEAL MED J, V107, P294; Krumholz HM, 1997, AM J CARDIOL, V80, P11, DOI 10.1016/S0002-9149(97)00299-3; LANDEFELD CS, 1989, AM J MED, V87, P144; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LUCCHESI GM, 1995, ANN EMERG MED, V26, P1, DOI 10.1016/S0196-0644(95)70229-6; Martin TP, 1997, ANN EMERG MED, V29, P459, DOI 10.1016/S0196-0644(97)70217-8; RUDY TE, 1992, J CRIT CARE, V7, P30, DOI 10.1016/0883-9441(92)90006-S; SILVER MT, 1994, ANN INTERN MED, V121, P750, DOI 10.7326/0003-4819-121-10-199411150-00004; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; Tobin K, 1999, ARCH INTERN MED, V159, P353, DOI 10.1001/archinte.159.4.353; WALSH BT, 1975, ARCH INTERN MED, V135, P1493, DOI 10.1001/archinte.135.11.1493; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x	29	730	742	1	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					79	84		10.1001/jama.284.1.79	http://dx.doi.org/10.1001/jama.284.1.79			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872017				2022-12-28	WOS:000087843000029
J	O'Connor, PG; Fiellin, DA				O'Connor, PG; Fiellin, DA			Pharmacologic treatment of heroin-dependent patients	ANNALS OF INTERNAL MEDICINE			English	Review							METHADONE-MAINTENANCE PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; RAPID OPIATE DETOXIFICATION; RANDOMIZED CONTROLLED TRIAL; SUBSTANCE-ABUSE TREATMENT; INJECTION-DRUG USERS; OPIOID DEPENDENCE; PRIMARY-CARE; NALTREXONE TREATMENT; CLINICAL-TRIAL	Patients with heroin dependence frequently present to internists and other physicians for heroin-related medical, psychiatric, and behavioral health problems and often seek help with reducing their heroin use. Thus, physicians should be familiar with the identification and diagnosis of heroin dependence in their patients and be able to initiate treatment of heroin dependence both directly and by referral. Recent research has provided much information concerning effective pharmacologically based treatment approaches for managing opioid withdrawal and helping patients to remain abstinent. Methadone maintenance and newer approaches using L-alpha acetylmethadol and buprenorphine seem to be particularly effective in promoting relapse prevention. Although these treatments are currently provided in special drug treatment settings, recent and ongoing research indicates that the physician's office may be an effective alternative site for these treatments.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale New Haven Hosp Primary Care Ctr, New Haven, CT USA	Yale University; Yale University	O'Connor, PG (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Box 208025, New Haven, CT 06520 USA.			Fiellin, David/0000-0002-4006-010X	NIDA NIH HHS [K12 DA00167] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K12DA000167] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Altice FL, 1999, AIDS, V13, P957, DOI 10.1097/00002030-199905280-00012; AMASS L, 1994, LIFE SCI, V54, P1215, DOI 10.1016/0024-3205(94)00848-5; AMASS L, 1994, J ADDICT DIS, V13, P33; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1978, ARCH GEN PSYCHIAT, V35, P335; Ball J.C., 2012, EFFECTIVENESS METHAD; BALL JC, 1988, J HEALTH SOC BEHAV, V29, P214, DOI 10.2307/2137033; Bearn J, 1998, DRUG ALCOHOL DEPEN, V50, P227, DOI 10.1016/S0376-8716(98)00030-1; Bearn J, 1996, DRUG ALCOHOL DEPEN, V43, P87, DOI 10.1016/S0376-8716(96)01289-6; BICKEL WK, 1988, CLIN PHARMACOL THER, V43, P72, DOI 10.1038/clpt.1988.13; Blaine J D, 1978, NIDA Res Monogr, P249; Brewer D D, 1998, Violence Vict, V13, P107; Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71; CAPLEHORN JRM, 1993, ADDICTION, V88, P119, DOI 10.1111/j.1360-0443.1993.tb02769.x; CAPLEHORN JRM, 1991, MED J AUSTRALIA, V154, P195, DOI 10.5694/j.1326-5377.1991.tb121030.x; Carroll KM, 1997, MED CLIN N AM, V81, P927, DOI 10.1016/S0025-7125(05)70556-3; CHARNEY DS, 1981, ARCH GEN PSYCHIAT, V38, P1273; CHARNEY DS, 1986, AM J PSYCHIAT, V143, P831; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; CHESKIN LJ, 1994, DRUG ALCOHOL DEPEN, V36, P115, DOI 10.1016/0376-8716(94)90093-0; Chutuape MA, 1997, J NERV MENT DIS, V185, P289, DOI 10.1097/00005053-199705000-00002; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; COOPER JR, 1992, JAMA-J AM MED ASSOC, V267, P281; Cucchia AT, 1998, DRUG ALCOHOL DEPEN, V52, P243, DOI 10.1016/S0376-8716(98)00100-8; Darke S, 1997, DRUG ALCOHOL DEPEN, V48, P135, DOI 10.1016/S0376-8716(97)00117-8; Dashe JS, 1998, OBSTET GYNECOL, V92, P854, DOI 10.1016/S0029-7844(98)00312-3; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; Davis AM, 1999, J PHARMACOL EXP THER, V289, P1048; *DEP HHS SUBST AB, 1997, YEAR END PREL EST 19; DOLE VP, 1966, ARCH INTERN MED, V118, P304, DOI 10.1001/archinte.118.4.304; DOLE VP, 1988, JAMA-J AM MED ASSOC, V260, P3025, DOI 10.1001/jama.260.20.3025; DOLE VP, 1965, J AMER MED ASSOC, V193, P646, DOI 10.1001/jama.1965.03090080008002; Ebert B, 1998, BIOCHEM PHARMACOL, V56, P553, DOI 10.1016/S0006-2952(98)00088-4; Eissenberg T, 1997, JAMA-J AM MED ASSOC, V277, P1945, DOI 10.1001/jama.277.24.1945; FARREN CK, 1997, NEW TREATMENTS OPIAT, P104; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FRAM DH, 1989, J SUBST ABUSE TREAT, V6, P119, DOI 10.1016/0740-5472(89)90039-1; FRASER HF, 1952, J PHARMACOL EXP THER, V105, P458; FREEDMAN RR, 1981, DRUG ALCOHOL DEPEN, V8, P215, DOI 10.1016/0376-8716(81)90064-8; Friedmann PD, 1998, JAMA-J AM MED ASSOC, V279, P1227, DOI 10.1001/jama.279.15.1227; FUDALA PJ, 1990, CLIN PHARMACOL THER, V47, P525, DOI 10.1038/clpt.1990.67; FULTZ JM, 1975, ANN INTERN MED, V82, P815, DOI 10.7326/0003-4819-82-6-815; Gagnon B, 1999, J PAIN SYMPTOM MANAG, V18, P120, DOI 10.1016/S0885-3924(99)00049-4; Gilman AG, 1985, GOODMAN GILMANS PHAR, V7th; Glanz M, 1997, AM J ADDICTION, V6, P339; GOSSOP M, 1988, DRUG ALCOHOL DEPEN, V21, P253, DOI 10.1016/0376-8716(88)90078-6; GOSSOP M, 1990, ADDICT BEHAV, V15, P487, DOI 10.1016/0306-4603(90)90036-W; GREENSTEIN RA, 1984, J CLIN PSYCHIAT, V45, P25; GUNNE LM, 1981, DRUG ALCOHOL DEPEN, V7, P249, DOI 10.1016/0376-8716(81)90096-X; Hamid A, 1997, J PSYCHOACTIVE DRUGS, V29, P375, DOI 10.1080/02791072.1997.10400565; Harwood H.J., 1998, EC COSTS ALCOHOL DRU; Hubbard RL, 1997, PSYCHOL ADDICT BEHAV, V11, P261, DOI 10.1037/0893-164X.11.4.261; Iribarne C, 1998, FUNDAM CLIN PHARM, V12, P194, DOI 10.1111/j.1472-8206.1998.tb00941.x; Iribarne C, 1998, DRUG METAB DISPOS, V26, P257; JAFFE JH, 1970, J AMER MED ASSOC, V211, P1834; JAFFE JH, 1972, J AMER MED ASSOC, V222, P437, DOI 10.1001/jama.222.4.437; JASINSKI DR, 1978, ARCH GEN PSYCHIAT, V35, P501; JASINSKI DR, 1989, CLIN PHARMACOL THER, V45, P513, DOI 10.1038/clpt.1989.66; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; JOHNSON RE, 1995, DRUG ALCOHOL DEPEN, V40, P17, DOI 10.1016/0376-8716(95)01186-2; Kahn A, 1997, DRUG ALCOHOL DEPEN, V44, P57, DOI 10.1016/S0376-8716(96)01316-6; KLEBER H D, 1985, Journal of Substance Abuse Treatment, V2, P117, DOI 10.1016/0740-5472(85)90036-4; KLEBER HD, 1985, ARCH GEN PSYCHIAT, V42, P391; KLEBER HD, 1987, AM J DRUG ALCOHOL AB, V13, P1, DOI 10.3109/00952998709001497; KOSTEN TR, 1990, PSYCHOPHARMACOL BULL, V26, P69; Kosten TR, 1996, AM J ADDICTION, V5, P58; KOSTEN TR, 1993, J NERV MENT DIS, V181, P358, DOI 10.1097/00005053-199306000-00004; Kraft MK, 1997, AM J PSYCHIAT, V154, P1214; Kreek M J, 1986, NIDA Res Monogr, V68, P193; Kreek M J, 1988, NIDA Res Monogr, V81, P428; Landabaso MA, 1998, ADDICTION, V93, P739, DOI 10.1046/j.1360-0443.1998.9357399.x; Liebschutz JM, 1997, ARCH INTERN MED, V157, P1093, DOI 10.1001/archinte.157.10.1093; Lin SK, 1997, DRUG ALCOHOL DEPEN, V48, P127, DOI 10.1016/S0376-8716(97)00116-6; Ling W, 1996, ARCH GEN PSYCHIAT, V53, P401; Ling W, 1998, ADDICTION, V93, P475, DOI 10.1046/j.1360-0443.1998.9344753.x; LING W, 1984, J CLIN PSYCHIAT, V45, P46; LING W, 1978, ARCH GEN PSYCHIAT, V35, P345; LING W, 1976, ARCH GEN PSYCHIAT, V33, P709; LING W, 1997, NEW TREATMENTS OPIAT, P286; LOIMER N, 1988, BRIT J PSYCHIAT, V153, P851, DOI 10.1192/bjp.153.6.851b; Malaty LI, 1999, DRUG SAFETY, V20, P147, DOI 10.2165/00002018-199920020-00005; McCann MJ, 1997, AM J ADDICTION, V6, P218; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; MELLO NK, 1982, J PHARMACOL EXP THER, V223, P30; METZGER DS, 1993, J ACQ IMMUN DEF SYND, V6, P1049; Metzger DS, 1999, PUBLIC HEALTH, V113, P97; *NAT HOUSEH SURV D, 1999, MAIN FIND 1997; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1997, NEW TREATMENTS OPIAT, P286; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; NEWMAN RG, 1979, LANCET, V2, P485; NIGAM AK, 1993, J SUBST ABUSE TREAT, V10, P391, DOI 10.1016/0740-5472(93)90024-V; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; NOVICK DM, 1994, J GEN INTERN MED, V9, P127, DOI 10.1007/BF02600025; NOVICK DM, 1990, ARCH INTERN MED, V150, P97, DOI 10.1001/archinte.150.1.97; O'Connor PG, 1998, AM J MED, V105, P100, DOI 10.1016/S0002-9343(98)00194-6; O'Connor PG, 1998, JAMA-J AM MED ASSOC, V279, P229, DOI 10.1001/jama.279.3.229; OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707; OConnor PG, 1997, ANN INTERN MED, V127, P526, DOI 10.7326/0003-4819-127-7-199710010-00004; Oliveto AH, 1998, AM J ADDICTION, V7, P272; PARRINO MW, 1998, J MAINTENANCE ADDICT, V1, P71; PAYTE JT, 1993, 931991 US DEP HHS; Pfab R, 1999, J TOXICOL-CLIN TOXIC, V37, P43, DOI 10.1081/CLT-100102407; PROCHASKA JO, 1992, BRIT J ADDICT, V87, P825; Rabinowitz J, 1997, DRUG ALCOHOL DEPEN, V47, P77, DOI 10.1016/S0376-8716(97)00073-2; Rawson RA, 1998, ADDICTION, V93, P533, DOI 10.1046/j.1360-0443.1998.9345338.x; Regidor E, 1996, DRUG ALCOHOL DEPEN, V40, P249, DOI 10.1016/0376-8716(96)01217-3; RESNICK RB, 1977, CLIN PHARMACOL THER, V21, P409; Rosen MI, 1996, J PHARMACOL EXP THER, V276, P1128; Rounsaville B J, 1995, NIDA Res Monogr, V150, P37; Samet JH, 1998, AM J MED, V105, P302, DOI 10.1016/S0002-9343(98)00258-7; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; SAN L, 1991, BRIT J ADDICT, V86, P983; SAN L, 1995, AM J PSYCHIAT, V152, P956; Scherbaum N, 1998, PHARMACOPSYCHIATRY, V31, P205, DOI 10.1055/s-2007-979329; Schorling JB, 1997, MED CLIN N AM, V81, P845, DOI 10.1016/S0025-7125(05)70552-6; SCHOTTENFELD RS, 1993, J SUBST ABUSE TREAT, V10, P5, DOI 10.1016/0740-5472(93)90092-G; SENAY EC, 1977, JAMA-J AM MED ASSOC, V237, P138, DOI 10.1001/jama.237.2.138; Senay Edward C., 1993, Journal of Addictive Diseases, V12, P59, DOI 10.1300/J069v12n04_05; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; STRAIN EC, 1993, ANN INTERN MED, V119, P23, DOI 10.7326/0003-4819-119-1-199307010-00004; Strain EC, 1999, JAMA-J AM MED ASSOC, V281, P1000, DOI 10.1001/jama.281.11.1000; STRAIN EC, 1994, PSYCHOPHARMACOLOGY, V116, P401, DOI 10.1007/BF02247469; Strang J, 1997, BRIT MED J, V315, P1249, DOI 10.1136/bmj.315.7118.1249; TENNANT FS, 1975, JAMA-J AM MED ASSOC, V232, P1019, DOI 10.1001/jama.232.10.1019; Tracqui A, 1998, J ANAL TOXICOL, V22, P430, DOI 10.1093/jat/22.6.430; *US DEP HHS, 1993, STAT METH TREATM GUI, V1; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WALSH SL, 1994, CLIN PHARMACOL THER, V55, P569, DOI 10.1038/clpt.1994.71; WARD J, 1998, METHADONE MAINTENANC, P571; Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1; Wyshak G, 1996, ARCH FAM MED, V5, P441, DOI 10.1001/archfami.5.8.441; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; Ziedonis D, 1997, MED CLIN N AM, V81, P1017, DOI 10.1016/S0025-7125(05)70561-7; ZIELBAUER P, 1999, NY TIMES        1031, P41; ZWEBEN JE, 1990, WESTERN J MED, V152, P588; 1998, JAMA, V280, P1936, DOI DOI 10.1001/JAMA.280.22.1936	138	130	134	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					40	54		10.7326/0003-4819-133-1-200007040-00008	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00008			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	329TB	10877739				2022-12-28	WOS:000087923100006
J	Berek, JS				Berek, JS			Interferon plus chemotherapy for primary treatment of ovarian cancer	LANCET			English	Editorial Material							RECOMBINANT GAMMA-INTERFERON; GYNECOLOGIC-ONCOLOGY-GROUP; TUMOR-NECROSIS-FACTOR; ALPHA-INTERFERON; CARCINOMA CELLS; EXPRESSION; CISPLATIN; TRIAL		Univ Calif Los Angeles, Sch Med, Div Gynecol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berek, JS (corresponding author), Univ Calif Los Angeles, Sch Med, Div Gynecol Oncol, Los Angeles, CA 90095 USA.							ALLAVENA P, 1990, CANCER RES, V50, P7318; BEREK JS, 1990, J CLIN ONCOL, V8, P1610, DOI 10.1200/JCO.1990.8.10.1610; Berek JS, 1999, GYNECOL ONCOL, V74, P48, DOI 10.1006/gyno.1999.5455; BEREK JS, 1992, EUR J CANCER, V28A, P719, DOI 10.1016/0959-8049(92)90100-G; BEREK JS, 1991, GYNECOL ONCOL, V40, P237; Berek JS, 1999, GYNECOL ONCOL, V75, P10, DOI 10.1006/gyno.1999.5532; BEREK JS, 2000, PRACTICAL GYNECOLOGI, P457; COLOMBO N, 1992, INT J CANCER, V51, P42, DOI 10.1002/ijc.2910510109; DACQUISTO R, 1988, J CLIN ONCOL, V6, P689, DOI 10.1200/JCO.1988.6.4.689; Duda DG, 2000, CANCER RES, V60, P1111; MARKMAN M, 1992, INT J GYNECOL CANCER, V2, P30; MARTH C, 1990, CANCER RES, V50, P7037; Marth C, 1997, BRIT J CANCER, V76, P1328, DOI 10.1038/bjc.1997.556; Marth C, 1996, INT J CANCER, V67, P826, DOI 10.1002/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#; NARDI M, 1990, J CLIN ONCOL, V8, P1036, DOI 10.1200/JCO.1990.8.6.1036; NEHME A, 1994, EUR J CANCER, V30A, P520, DOI 10.1016/0959-8049(94)90430-8; PujadeLauraine E, 1996, J CLIN ONCOL, V14, P343, DOI 10.1200/JCO.1996.14.2.343; SAITO T, 1986, CANCER RES, V46, P1142; WILLEMSE PHB, 1990, EUR J CANCER, V26, P353, DOI 10.1016/0277-5379(90)90233-J; Windbichler GH, 2000, BRIT J CANCER, V82, P1138	20	16	18	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					6	7		10.1016/S0140-6736(00)02422-3	http://dx.doi.org/10.1016/S0140-6736(00)02422-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892754				2022-12-28	WOS:000087933400004
J	Schiermeier, Q				Schiermeier, Q			Call for more accelerator research	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					988	988		10.1038/35016720	http://dx.doi.org/10.1038/35016720			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890415	Bronze			2022-12-28	WOS:000087871700011
J	Li, X; Kind, R; Priestley, K; Sobolev, SV; Tilmann, F; Yuan, X; Weber, M				Li, X; Kind, R; Priestley, K; Sobolev, SV; Tilmann, F; Yuan, X; Weber, M			Mapping the Hawaiian plume conduit with converted seismic waves	NATURE			English	Article							UPPER-MANTLE; VOLCANISM; VELOCITY; ORIGIN; MELT; LITHOSPHERE; TOMOGRAPHY; HOTSPOT; WATER; TIBET	The volcanic edifice of the Hawaiian islands and seamounts, as well as the surrounding area of shallow sea floor known as the Hawaiian swell, are believed to result from the passage of the oceanic lithosphere over a mantle hotspot(1-3). Although geochemical and gravity observations indicate the existence of a mantle thermal plume beneath Hawaii(4-6), no direct seismic evidence for such a plume in the upper mantle has yet been found. Here we present an analysis of compressional-to-shear (P-to-S) converted seismic phases, recorded on seismograph stations on the Hawaiian islands, that indicate a zone of very low shear-wave velocity (< 4 km s(-1)) starting at 130-140 km depth beneath the central part of the island of Hawaii and extending deeper into the upper mantle. We also find that the upper-mantle transition zone (410-660 km depth) appears to be thinned by up to 40-50 km to the south-southwest of the island of Hawaii. We interpret these observations as localized effects of the Hawaiian plume conduit in the asthenosphere and mantle transition zone with excess temperature of similar to 300 degrees C. Large variations in the transition-zone thickness suggest a lower-mantle origin of the Hawaiian plume similar to the Iceland plume(7), but our results indicate a 100 degrees C higher temperature for the Hawaiian plume.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Free Univ Berlin, FR Geophys, D-12249 Berlin, Germany; Univ Cambridge, Bullard Labs, Dept Earth Sci, Cambridge CB3 0EZ, England; Univ Potsdam, Inst Geowissensch, D-14415 Potsdam, Germany	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Free University of Berlin; University of Cambridge; University of Potsdam	Kind, R (corresponding author), Geoforschungszentrum Potsdam, Telegrafenberg, D-14473 Potsdam, Germany.		Tilmann, Frederik J/E-4293-2012; Yuan, Xiaohui/G-5149-2010; Weber, Michael/D-8330-2013; Sobolev, Stephan V/G-3813-2011	Tilmann, Frederik J/0000-0002-7439-8782; Yuan, Xiaohui/0000-0002-2891-1354; Sobolev, Stephan V/0000-0002-3382-4028				BINA CR, 1994, J GEOPHYS RES-SOL EA, V99, P15853, DOI 10.1029/94JB00462; BOCK G, 1991, GEOPHYS RES LETT, V18, P869, DOI 10.1029/91GL01055; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Gaherty JB, 1996, J GEOPHYS RES-SOL EA, V101, P22291, DOI 10.1029/96JB01882; Hauri EH, 1996, J GEOPHYS RES-SOL EA, V101, P11793, DOI 10.1029/95JB03346; Hilton DR, 1998, NATURE, V396, P359, DOI 10.1038/24603; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; Ito G, 1999, EARTH PLANET SC LETT, V165, P81, DOI 10.1016/S0012-821X(98)00216-7; Ji Y, 1998, EARTH PLANET SC LETT, V159, P99, DOI 10.1016/S0012-821X(98)00060-0; Karato S, 1998, EARTH PLANET SC LETT, V157, P193, DOI 10.1016/S0012-821X(98)00034-X; Kennet BLN., 1991, TERRA NOVA, V3, P122, DOI [10.1111/j.1365-3121.1991.tb00863.x, DOI 10.1111/J.1365-3121.1991.TB00863.X]; Kosarev G, 1999, SCIENCE, V283, P1306, DOI 10.1126/science.283.5406.1306; MCKENZIE D, 1988, J PETROL, V29, P625, DOI 10.1093/petrology/29.3.625; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P8045, DOI 10.1029/94JB02887; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; NATAF HC, 1993, NATURE, V364, P115, DOI 10.1038/364115a0; NISHIMURA CE, 1988, GEOPHYS J INT, V94, P479, DOI 10.1111/j.1365-246X.1988.tb02270.x; Priestley K, 1999, GEOPHYS RES LETT, V26, P1493, DOI 10.1029/1999GL900299; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; RIBE NM, 1994, J GEOPHYS RES-SOL EA, V99, P669, DOI 10.1029/93JB02386; Russell SA, 1998, NATURE, V396, P255, DOI 10.1038/24364; Shen Y, 1998, NATURE, V395, P62, DOI 10.1038/25714; Sobolev AV., 1994, PETROLOGY+, V2, P111; Sobolev SV, 1996, EARTH PLANET SC LETT, V139, P147, DOI 10.1016/0012-821X(95)00238-8; VINNIK L, 1997, GEOPHYS RES LETT, V33, P149; WATSON S, 1991, J PETROL, V32, P501, DOI 10.1093/petrology/32.3.501; WILSON JT, 1963, CAN J PHYS, V41, P863, DOI 10.1139/p63-094; WOODS MT, 1991, GEOPHYS RES LETT, V18, P105, DOI 10.1029/90GL02718; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379	30	138	146	1	38	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					938	941		10.1038/35016054	http://dx.doi.org/10.1038/35016054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879532				2022-12-28	WOS:000087732700047
J	Ortiz, JL; Sada, PV; Rubio, LRB; Aceituno, FJ; Aceituno, J; Gutierrez, PJ; Thiele, U				Ortiz, JL; Sada, PV; Rubio, LRB; Aceituno, FJ; Aceituno, J; Gutierrez, PJ; Thiele, U			Optical detection of meteoroidal impacts on the Moon	NATURE			English	Article							ATMOSPHERE	Impacts of meteoroids on the Moon should cause detectable optical flashes(1), but the population of objects that are big enough is very low, and hitherto no unambiguous impact flashes have been recorded. The flux of meteoroids associated with the Leonid meteor shower of 18 November 1999 was predicted to produce observable flashes on the night side of the Moon(2). Here we report the unambiguous detection of five such impact flashes, three of which were seen simultaneously by other observers(3). We also observed a possible impact flash on 16 July 1999. All of the flashes were of very brief duration (<0.02 s), as expected for high-speed impacts.	CSIC, Inst Astrofis Andalucia, Granada 18080, Spain; Univ Monterrey, Dept Fis & Matemat, Nuevo Leon 66238, Mexico; Inst Astrofis Canarias, E-38200 Tenerife, Spain; Ctr Astron Hispano Aleman, Almeria 04080, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Astrofisica de Andalucia (IAA); Universidad de Monterrey; Instituto de Astrofisica de Canarias	Ortiz, JL (corresponding author), CSIC, Inst Astrofis Andalucia, Aptdo 3004, Granada 18080, Spain.		Ortiz, Jose L./L-3192-2014; Gutiérrez, Pedro J/AAJ-6177-2020	Ortiz, Jose L./0000-0002-8690-2413; Gutiérrez, Pedro J/0000-0002-7332-6269; Bellot Rubio, Luis Ramon/0000-0001-8669-8857; Aceituno, Jesus/0000-0003-0487-1105				Ant R., 1999, J IMO, V27, P286; Asher DJ, 1999, MON NOT R ASTRON SOC, V307, P919, DOI 10.1046/j.1365-8711.1999.02698.x; Brown P, 1999, ICARUS, V138, P287, DOI 10.1006/icar.1998.6074; Brown P, 1997, ASTRON ASTROPHYS, V322, P687; Brown P. G, 1999, THESIS U W ONTARIO; CEPLECHA Z, 1994, ASTRON ASTROPHYS, V286, P967; DUNHAM DW, 1999, 7320 IAU; Frank LA, 1997, GEOPHYS RES LETT, V24, P2435, DOI 10.1029/97GL02413; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HUNTEN DM, 1998, B AM ASTRON SOC, V30, P1115; MCNAUGHT RH, 1999, J INT METEOR ORG, V27, P85; Melosh H.J., 1993, LPSC, VXXIV, P975; Ortiz JL, 1999, ASTRON ASTROPHYS, V343, pL57; Verani S, 1998, PLANET SPACE SCI, V46, P1003, DOI 10.1016/S0032-0633(98)00024-5	14	61	62	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					921	923		10.1038/35016015	http://dx.doi.org/10.1038/35016015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879526				2022-12-28	WOS:000087732700041
J	Grobner, G; Burnett, IJ; Glaubitz, C; Choi, G; Mason, AJ; Watts, A				Grobner, G; Burnett, IJ; Glaubitz, C; Choi, G; Mason, AJ; Watts, A			Observations of light-induced structural changes of retinal within rhodopsin	NATURE			English	Article							PROTEIN-COUPLED RECEPTORS; SOLID-STATE NMR; TRANSMEMBRANE HELICES; BOVINE RHODOPSIN; ABSOLUTE SENSE; C-12-C-13 BOND; CHROMOPHORE; BACTERIORHODOPSIN; ORIENTATION; MEMBRANES	Photo-isomerization of the 11-cis retinal chromophore activates the mammalian light-receptor rhodopsin(1), a representative member of a major superfamily of transmembrane G-protein-coupled receptor proteins (GPCRs) responsible for many cell signal communication pathways. Although low-resolution (5 Angstrom) electron microscopy studies(2,3) confirm a seven transmembrane helix bundle as a principal structural component of rhodopsin, the structure of the retinal within this helical bundle is not known in detail. Such information is essential for any theoretical or functional understanding of one of the fastest occurring photoactivation processes in nature, as well as the general mechanism behind GPCR activation(4-6). Here we determine the three-dimensional structure of 11-cis retinal bound to bovine rhodopsin in the ground state at atomic level using a new high-resolution solid-state NMR method(7). Significant structural changes are observed in the retinal following activation by light to the photo-activated M-I state of rhodopsin giving the all-trans isomer of the chromophore. These changes are linked directly to the activation of the receptor, providing an insight into the activation mechanism of this class of receptors at a molecular level.	Univ Oxford, Dept Biochem, Biomembrane Struct Unit, Oxford OX1 3QU, England	University of Oxford	Watts, A (corresponding author), Umea Univ, Dept Chem, SE-90187 Umea, Sweden.	awatts@bioch.ox.ac.uk	Glaubitz, Clemens/D-5714-2011; Mason, James/J-2273-2012	Glaubitz, Clemens/0000-0002-3554-6586; Mason, James/0000-0003-0411-602X				Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; Buss V, 1998, ANGEW CHEM INT EDIT, V37, P1893, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1893::AID-ANIE1893>3.0.CO;2-M; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; Eilers M, 1999, P NATL ACAD SCI USA, V96, P487, DOI 10.1073/pnas.96.2.487; Feng X, 2000, J BIOMOL NMR, V16, P1, DOI 10.1023/A:1008377231625; Feng X, 1997, J AM CHEM SOC, V119, P6853, DOI 10.1021/ja970710d; Glaubitz C, 1999, J AM CHEM SOC, V121, P5787, DOI 10.1021/ja990350p; Grobner G, 1998, FEBS LETT, V422, P201, DOI 10.1016/S0014-5793(97)01591-3; Grobner G, 1997, ANAL BIOCHEM, V254, P132, DOI 10.1006/abio.1997.2415; Herzyk P, 1998, J MOL BIOL, V281, P741, DOI 10.1006/jmbi.1998.1981; Hudson BS, 1999, J PHYS CHEM A, V103, P2274, DOI 10.1021/jp9836271; Jager S, 1997, P NATL ACAD SCI USA, V94, P8557, DOI 10.1073/pnas.94.16.8557; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; ROTHSCHILD KJ, 1980, BIOPHYS J, V31, P53, DOI 10.1016/S0006-3495(80)85040-5; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; SMITH SO, 1987, BIOCHEMISTRY-US, V26, P1606, DOI 10.1021/bi00380a018; Tan Q, 1997, ANGEW CHEM INT EDIT, V36, P2089, DOI 10.1002/anie.199720891; Verdegem PJE, 1999, BIOCHEMISTRY-US, V38, P11316, DOI 10.1021/bi983014e	22	113	115	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					810	813		10.1038/35015604	http://dx.doi.org/10.1038/35015604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866205				2022-12-28	WOS:000087620600056
J	Loff, B; Anderson, I				Loff, B; Anderson, I			Aboriginal reconciliation still a long way to go	LANCET			English	Editorial Material									Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; Univ Melbourne, Ctr Study Hlth & Soc, Melbourne, Vic 3004, Australia	Monash University; University of Melbourne	Loff, B (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.		Anderson, Ian PS/C-1498-2008; Loff, Bebe/G-9241-2014	Loff, Bebe/0000-0003-1963-6503					0	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2070	2070		10.1016/S0140-6736(00)02367-9	http://dx.doi.org/10.1016/S0140-6736(00)02367-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885372				2022-12-28	WOS:000087519400044
J	Scheiffele, P; Fan, JH; Choih, J; Fetter, R; Serafini, T				Scheiffele, P; Fan, JH; Choih, J; Fetter, R; Serafini, T			Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons	CELL			English	Article							STOP SIGNAL; SYNAPTIC CONNECTIONS; HIPPOCAMPAL-NEURONS; PROTEIN COMPLEX; SYNAPSIN-I; ADHESION; NEUREXINS; SYNAPTOTAGMIN; RECEPTOR; SURFACE	Most neurons form synapses exclusively with other neurons, but little is known about the molecular mechanisms mediating synaptogenesis in the central nervous system. Using an in vitro system, we demonstrate that neuroligin-1 and -2, postsynaptically localized proteins, can trigger the de novo formation of presynaptic structure. Nonneuronal cells engineered to express neuroligins induce morphological and functional presynaptic differentiation in contacting axons. This activity can be inhibited by addition of a soluble version of beta-neurexin, a receptor for neuroligin. Furthermore, addition of soluble beta-neurexin to a coculture of defined pre- and postsynaptic CNS neurons inhibits synaptic vesicle clustering in axons contacting target neurons. Our results suggest that neuroligins are part of the machinery employed during the formation and remodeling of CNS synapses.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Serafini, T (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	scheiffe@uclink4.berkeley.edu; tito@socrates.berkeley.edu						BAIRD DH, 1992, J NEUROSCI, V12, P619; Barth AL, 1997, NEURON, V19, P359, DOI 10.1016/S0896-6273(00)80945-9; Bellen HJ, 1998, TRENDS NEUROSCI, V21, P444, DOI 10.1016/S0166-2236(98)01267-3; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Botti SA, 1998, PROTEIN ENG, V11, P415, DOI 10.1093/protein/11.6.415; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURRY RW, 1982, BRAIN RES, V247, P1, DOI 10.1016/0006-8993(82)91022-8; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Campagna JA, 1995, NEURON, V15, P1365, DOI 10.1016/0896-6273(95)90014-4; DAI ZS, 1995, J NEUROSCI, V15, P5466; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Grifman M, 1998, P NATL ACAD SCI USA, V95, P13935, DOI 10.1073/pnas.95.23.13935; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; Hata Y, 1996, J NEUROSCI, V16, P2488; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; LI Y, 1991, J BIOL CHEM, V266, P23083; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MASON CA, 1986, NEUROSCIENCE, V19, P1319, DOI 10.1016/0306-4522(86)90146-6; Missler M, 1998, J NEUROCHEM, V71, P1339; MIYATANI S, 1989, SCIENCE, V245, P631, DOI 10.1126/science.2762814; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; Powell SK, 1997, J NEUROBIOL, V32, P223, DOI 10.1002/(SICI)1097-4695(199702)32:2<223::AID-NEU7>3.0.CO;2-A; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sanes JR, 1999, CURR OPIN NEUROBIOL, V9, P79, DOI 10.1016/S0959-4388(99)80010-5; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sato T, 1968, J Electron Microsc (Tokyo), V17, P158; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serpinskaya AS, 1999, DEV BIOL, V205, P65, DOI 10.1006/dbio.1998.9112; Sherrington C, 1906, INTEGRATIVE ACTION N; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	44	887	910	2	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2000	101	6					657	669		10.1016/S0092-8674(00)80877-6	http://dx.doi.org/10.1016/S0092-8674(00)80877-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892652	Bronze			2022-12-28	WOS:000087504500012
J	Howard, AD; Wang, RP; Pong, SS; Mellin, TN; Strack, A; Guan, XM; Zeng, ZZ; Williams, DL; Feighner, SD; Nunes, CN; Murphy, B; Stair, JN; Yu, H; Jiang, QP; Clements, MK; Tan, CP; McKee, KK; Hreniuk, DL; McDonald, TP; Lynch, KR; Evans, JF; Austin, CP; Caskey, CT; Van der Ploeg, LHT; Liu, QY				Howard, AD; Wang, RP; Pong, SS; Mellin, TN; Strack, A; Guan, XM; Zeng, ZZ; Williams, DL; Feighner, SD; Nunes, CN; Murphy, B; Stair, JN; Yu, H; Jiang, QP; Clements, MK; Tan, CP; McKee, KK; Hreniuk, DL; McDonald, TP; Lynch, KR; Evans, JF; Austin, CP; Caskey, CT; Van der Ploeg, LHT; Liu, QY			Identification of receptors for neuromedin U and its role in feeding	NATURE			English	Article							PORCINE SPINAL-CORD; RAT; PURIFICATION; EXPRESSION; U-25; GENE	Neuromedin U (NMU) is a neuropeptide with potent activity on smooth muscle which was isolated first from porcine spinal cord and later from other species(1-8). It is widely distributed in the gut and central nervous system(9,10). Peripheral activities of NMU include stimulation of smooth muscle(1), increase of blood pressure(1), alteration of ion transport in the gut(11), control of local blood flow(12,13) and regulation of adrenocortical function(14). An NMU receptor has not been molecularly identified. Here we show that the previously described orphan G-protein-coupled receptor FM-3 (ref. 15) and a newly discovered one (FM-4) are cognate receptors for NMU. FM-3, designated NMU1R, is abundantly expressed in peripheral tissues whereas FM-4, designated NMU2R, is expressed in specific regions of the brain. NMU is expressed in the ventromedial hypothalamus in the rat brain, and its level is significantly reduced following fasting. Intracerebroventricular administration of NMU markedly suppresses food intake in rats. These findings provide a molecular basis for the biochemical activities of NMU and may indicate that NMU is involved in the central control of feeding.	Merck Sharp & Dohme Ltd, Dept Pharmacol, W Point, PA 19486 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Anim Pharmacol, Rahway, NJ 07065 USA; Merck Res Labs, W Point, PA 19486 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; University of Virginia	Liu, QY (corresponding author), Merck Sharp & Dohme Ltd, Dept Pharmacol, Wp26-265, W Point, PA 19486 USA.							BALLESTA J, 1988, NEUROSCIENCE, V25, P797, DOI 10.1016/0306-4522(88)90037-1; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BROWN DR, 1988, EUR J PHARMACOL, V155, P159, DOI 10.1016/0014-2999(88)90415-3; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; CHAVEZ M, 1995, BEHAV NEUROSCI, V109, P547, DOI 10.1037/0735-7044.109.3.547; CONLON JM, 1988, J NEUROCHEM, V51, P988, DOI 10.1111/j.1471-4159.1988.tb01837.x; DOMIN J, 1992, REGUL PEPTIDES, V41, P1, DOI 10.1016/0167-0115(92)90508-R; DOMIN J, 1989, J BIOL CHEM, V264, P20881; DOMIN J, 1986, BIOCHEM BIOPH RES CO, V140, P1127, DOI 10.1016/0006-291X(86)90752-7; GARDINER SM, 1990, AM J PHYSIOL, V258, pR32, DOI 10.1152/ajpregu.1990.258.1.R32; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; HONZAWA M, 1987, NEUROSCIENCE, V23, P1103, DOI 10.1016/0306-4522(87)90185-0; KAGE R, 1991, REGUL PEPTIDES, V33, P191, DOI 10.1016/0167-0115(91)90213-Z; KISSILEFF HR, 1969, J COMP PHYSIOL PSYCH, V67, P284, DOI 10.1037/h0026773; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Liu QY, 1999, BIOCHEM BIOPH RES CO, V266, P174, DOI 10.1006/bbrc.1999.1796; MALENDOWICZ LK, 1994, NEUROPEPTIDES, V26, P47, DOI 10.1016/0143-4179(94)90092-2; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V156, P355, DOI 10.1016/S0006-291X(88)80848-9; MINAMINO N, 1985, BIOCHEM BIOPH RES CO, V130, P1078, DOI 10.1016/0006-291X(85)91726-7; Murphy B, 1998, NEUROPEPTIDES, V32, P491, DOI 10.1016/S0143-4179(98)90077-4; OHARTE F, 1991, PEPTIDES, V12, P809, DOI 10.1016/0196-9781(91)90138-F; Retief JD, 1999, GENOME RES, V9, P373; STRICKER EM, 1990, HDB BEHAVIORAL NEURO, V10, P45; SUMI S, 1987, LIFE SCI, V41, P1585, DOI 10.1016/0024-3205(87)90725-9; Tan CP, 1998, GENOMICS, V52, P223, DOI 10.1006/geno.1998.5441; Ungrin MD, 1999, ANAL BIOCHEM, V272, P34, DOI 10.1006/abio.1999.4145; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	337	366	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					70	74		10.1038/35017610	http://dx.doi.org/10.1038/35017610			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894543				2022-12-28	WOS:000087991200046
J	Lewis, FD; Liu, XY; Liu, JQ; Miller, SE; Hayes, RT; Wasielewski, MR				Lewis, FD; Liu, XY; Liu, JQ; Miller, SE; Hayes, RT; Wasielewski, MR			Direct measurement of hole transport dynamics in DNA	NATURE			English	Article							ELECTRON-TRANSFER; DISTANCE; MECHANISM; HAIRPINS; SEQUENCE; DAMAGE	Our understanding of oxidative damage to double helical DNA and the design of DNA-based devices for molecular electronics is crucially dependent upon elucidation of the mechanism and dynamics of electron and hole transport in DNA(1-4). Electrons and holes can migrate from the locus of formation to trap sites(1,5), and such migration can occur through either a single-step "superexchange'' mechanism or a multistep charge transport "hopping'' mechanism(6-17). The rates of single-step charge separation and charge recombination processes are found to decrease rapidly with increasing transfer distances(6-9), whereas multistep hole transport processes are only weakly distance dependent(10-13). However, the dynamics of hole transport has not yet been directly determined. Here we report spectroscopic measurements of photoinduced electron transfer in synthetic DNA that yield rate constants of similar to 5 x 10(7) s(-1) and 5 x 10(6) s(-1), respectively, for the forward and return hole transport from a single guanine base to a double guanine base step across a single adenine. These rates are faster than processes leading to strand cleavage, such as the reaction of guanine cation radical with water(2), thus permitting holes to migrate over long distances in DNA. However, they are too slow to compete with charge recombination in contact ion pairs(6,7), a process which protects DNA from photochemical damage.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Lewis, FD (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	lewis@chem.nwu.edu		Miller, Scott/0000-0003-4254-0788				Anderson RF, 1999, PHYS CHEM CHEM PHYS, V1, P4827, DOI 10.1039/a905550i; Armitage B, 1998, CHEM REV, V98, P1171, DOI 10.1021/cr960428+; BECKER D, 1993, ADV RADIAT BIOL, V17, P121; Berlin YA, 2000, J PHYS CHEM A, V104, P443, DOI 10.1021/jp9933323; Bixon M, 1999, P NATL ACAD SCI USA, V96, P11713, DOI 10.1073/pnas.96.21.11713; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Fukui K, 1999, J PHOTOCH PHOTOBIO B, V50, P18, DOI 10.1016/S1011-1344(99)00063-9; Giese B, 1999, ANGEW CHEM INT EDIT, V38, P996, DOI 10.1002/(SICI)1521-3773(19990401)38:7<996::AID-ANIE996>3.0.CO;2-4; Harriman A, 1999, ANGEW CHEM INT EDIT, V38, P945, DOI 10.1002/(SICI)1521-3773(19990401)38:7<945::AID-ANIE945>3.0.CO;2-S; Henderson PT, 1999, P NATL ACAD SCI USA, V96, P8353, DOI 10.1073/pnas.96.15.8353; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; Langenbacher T, 1997, J AM CHEM SOC, V119, P10532, DOI 10.1021/ja9721024; LETSINGER RL, 1995, J AM CHEM SOC, V117, P7323, DOI 10.1021/ja00133a005; Lewis FD, 1999, J AM CHEM SOC, V121, P9746, DOI 10.1021/ja9924997; Lewis FD, 2000, J AM CHEM SOC, V122, P2889, DOI 10.1021/ja993689k; Lewis FD, 1999, J AM CHEM SOC, V121, P9905, DOI 10.1021/ja991934u; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; Meggers E, 1998, J AM CHEM SOC, V120, P12950, DOI 10.1021/ja983092p; Nunez ME, 1999, CHEM BIOL, V6, P85, DOI 10.1016/S1074-5521(99)80005-2; Priyadarshy S, 1996, J PHYS CHEM-US, V100, P17678, DOI 10.1021/jp961731h; Ratner MA, 1997, MOLECULAR ELECTRONICS, P5; Steenken S, 1997, BIOL CHEM, V378, P1293	22	300	304	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					51	53		10.1038/35017524	http://dx.doi.org/10.1038/35017524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894536				2022-12-28	WOS:000087991200039
J	Sawyer, RJ				Sawyer, RJ			The abdication of Pope Mary III ... or, Galileo's revenge ...	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					23	23		10.1038/35017698	http://dx.doi.org/10.1038/35017698			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894522	Bronze			2022-12-28	WOS:000087991200024
J	Streit, A; Berliner, AJ; Papanayotou, C; Sirulnik, A; Stern, CD				Streit, A; Berliner, AJ; Papanayotou, C; Sirulnik, A; Stern, CD			Initiation of neural induction by FGF signalling before gastrulation	NATURE			English	Article							FIBROBLAST GROWTH-FACTOR; CHICK-EMBRYO; AVIAN EMBRYOS; ORGANIZER; RECEPTOR; CHORDIN; NOGGIN; INHIBITORS; EPIBLAST; INDUCERS	During neural induction, the 'organizer' of the vertebrate embryo instructs neighbouring ectodermal cells to become nervous system rather than epidermis. This process is generally thought to occur around the mid-gastrula stage of embryogenesis(1). Here we report the isolation of ERNI, an early response gene to signals from the organizer (Hensen's node). Using ERNI as a marker, we present evidence that neural induction begins before gastrulation - much earlier in development than previously thought. We show that the organizer and some of its precursor cells produce a fibroblast growth factor signal, which can initiate, and is required for, neural induction.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Stern, CD (corresponding author), Columbia Univ, Dept Genet & Dev, 701 W 168th St 1602, New York, NY 10032 USA.		Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008; Streit, Andrea/F-2683-2010	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X; Streit, Andrea/0000-0001-7664-7917				Alvarez IS, 1998, DEV BIOL, V199, P42, DOI 10.1006/dbio.1998.8903; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; EYALGILADI H, 1976, DEV BIOL, V49, P321, DOI 10.1016/0012-1606(76)90178-0; GARCIAMARTINEZ V, 1993, J EXP ZOOL, V267, P431, DOI 10.1002/jez.1402670409; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATADA Y, 1994, DEVELOPMENT, V120, P2879; Hongo I, 1999, DEV BIOL, V216, P561, DOI 10.1006/dbio.1999.9515; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Klingensmith J, 1999, DEV BIOL, V216, P535, DOI 10.1006/dbio.1999.9525; LAMB TM, 1995, DEVELOPMENT, V121, P3627; Launay C, 1996, DEVELOPMENT, V122, P869; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Stern CD, 1998, CURR TOP DEV BIOL, V36, P223; STERN CD, 1981, ANAT EMBRYOL, V163, P245, DOI 10.1007/BF00315703; Storey KG, 1998, DEVELOPMENT, V125, P473; Streit A, 1999, TRENDS GENET, V15, P20, DOI 10.1016/S0168-9525(98)01620-5; Streit A, 1999, MECH DEVELOP, V85, P85, DOI 10.1016/S0925-4773(99)00085-4; Streit A, 1998, DEVELOPMENT, V125, P507; Streit A, 1999, MECH DEVELOP, V82, P51, DOI 10.1016/S0925-4773(99)00013-1; STREIT A, 1997, DEVELOPMENT, V124, P119; Wilson PA, 1997, NEURON, V18, P699, DOI 10.1016/S0896-6273(00)80311-6; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	30	386	396	2	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					74	78		10.1038/35017617	http://dx.doi.org/10.1038/35017617			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894544				2022-12-28	WOS:000087991200047
J	Jager, EWH; Inganas, O; Lundstrom, I				Jager, EWH; Inganas, O; Lundstrom, I			Microrobots for micrometer-size objects in aqueous media: Potential tools for single-cell manipulation	SCIENCE			English	Article							MUSCLES; MICROACTUATORS; POLYPYRROLE; DEVICES	Conducting polymers are excellent materials for actuators that are operated in aqueous media. Microactuators based on polypyrrole-gold bilayers enable Large movement of structures attached to these actuators and are of particular interest for the manipulation of biological objects, such as single cells. A fabrication method for creating individually addressable and controllable polypyrrole-gold microactuators was developed. With these individually controlled microactuators, a micrometer-size manipulator, or microrobotic arm, was fabricated. This microrobotic arm can pick up, Lift, move, and place micrometer-size objects within an area of about 250 micrometers by 100 micrometers, making the microrobot an excellent tool for single-cell manipulation.	Linkoping Univ, Dept Phys & Measurement Technol, Div Appl Phys, S-58183 Linkoping, Sweden	Linkoping University	Jager, EWH (corresponding author), Linkoping Univ, Dept Phys & Measurement Technol, Div Appl Phys, S-58183 Linkoping, Sweden.		Jager, Edwin/F-1481-2013	Jager, Edwin/0000-0002-2071-7768; Inganas, Olle/0000-0002-6243-1450				Baughman RH, 1991, MOL ELECT, P267; Breen TL, 1999, SCIENCE, V284, P948, DOI 10.1126/science.284.5416.948; DellaSanta A, 1997, SMART MATER STRUCT, V6, P23, DOI 10.1088/0964-1726/6/1/003; Ebefors T., 1999, 10 INT C SOL STAT SE, P1202; FUHR G, 1995, J MICROMECH MICROENG, V5, P77, DOI 10.1088/0960-1317/5/2/006; GANDHI MR, 1995, SYNTHETIC MET, V73, P247, DOI 10.1016/0379-6779(95)80022-0; Jager EWH, 1999, SENSOR ACTUAT B-CHEM, V56, P73, DOI 10.1016/S0925-4005(99)00159-8; Jager EWH, 1999, P SOC PHOTO-OPT INS, V3669, P377, DOI 10.1117/12.349696; Kim C.-J., 1992, Journal of Microelectromechanical Systems, V1, P31, DOI 10.1109/84.128053; MITA Y, 1999, 10 INT C SOL STAT SE, P1196; Nakazawa H, 1999, 10 INT C SOL STAT SE, P1192; Otero TF, 1996, PROC SPIE, V2779, P365, DOI 10.1117/12.237143; PEI QB, 1992, ADV MATER, V4, P277, DOI 10.1002/adma.19920040406; Smela E, 1999, J MICROMECH MICROENG, V9, P1, DOI 10.1088/0960-1317/9/1/001; SMELA E, 1993, ADV MATER, V5, P630, DOI 10.1002/adma.19930050905; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; SMELA E, 1995, 8 INT C SOL STAT SEN, V9, P218; SUZUKI K, 1994, J MICROELECTROMECH S, V3, P4, DOI 10.1109/84.285718; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yeh R, 1996, J MICROELECTROMECH S, V5, P10, DOI 10.1109/84.485210	20	459	475	9	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2335	2338		10.1126/science.288.5475.2335	http://dx.doi.org/10.1126/science.288.5475.2335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875911				2022-12-28	WOS:000087913400029
J	Donaldson, JG; Lippincott-Schwartz, J				Donaldson, JG; Lippincott-Schwartz, J			Sorting and signaling at the Golgi complex	CELL			English	Review							BINDING-PROTEIN; GTP HYDROLYSIS; TRANSPORT; MEMBRANE; COATOMER; VESICLES; CDC42; CELLS; COPI		NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lippincott-Schwartz, J (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 18T,Room 101,18 Lib Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000517, Z01HL000517] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Gaynor EC, 1998, BBA-MOL CELL RES, V1404, P33, DOI 10.1016/S0167-4889(98)00045-7; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Goldberg J, 2000, CELL, V100, P671, DOI 10.1016/S0092-8674(00)80703-5; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Nickel W, 1998, HISTOCHEM CELL BIOL, V109, P477, DOI 10.1007/s004180050249; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; SZAFER E, 2000, IN PRESS J BIOL CHEM; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	20	75	79	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					693	696		10.1016/S0092-8674(00)80881-8	http://dx.doi.org/10.1016/S0092-8674(00)80881-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892740	Bronze			2022-12-28	WOS:000087821400003
J	Bayer, M; Stern, O; Hawrylak, P; Fafard, S; Forchel, A				Bayer, M; Stern, O; Hawrylak, P; Fafard, S; Forchel, A			Hidden symmetries in the energy levels of excitonic 'artificial atoms'	NATURE			English	Article							SINGLE QUANTUM DOTS; MAGNETIC-FIELD; GAAS; PHOTOLUMINESCENCE; NANOCRYSTALS; SPECTROSCOPY; STATES; GROWTH	Quantum dots(1-7) or 'artificial atoms' are of fundamental and technological interest-for example, quantum dots(8,9) may form the basis of new generations of lasers. The emission in quantum-dot lasers originates from the recombination of excitonic complexes, so it is important to understand the dot's internal electronic structure (and of fundamental interest to compare this to real atomic structure). Here we investigate artificial electronic structure by injecting optically a controlled number of electrons and holes into an isolated single quantum dot. The charge carriers form complexes that are artificial analogues of hydrogen, helium, lithium, beryllium, boron and carbon excitonic atoms. We observe that electrons and holes occupy the confined electronic shells in characteristic numbers according to the Pauli exclusion principle. In each degenerate shell, collective condensation of the electrons and holes into coherent many-exciton ground states takes place; this phenomenon results from hidden symmetries (the analogue of Hund's rules for real atoms) in the energy function that describes the multi-particle system. Breaking of the hidden symmetries leads to unusual quantum interferences in emission involving excited states.	Univ Wurzburg, D-97074 Wurzburg, Germany; Natl Res Council Canada, Inst Microstruct Sci, Ottawa, ON K1A 0R6, Canada	University of Wurzburg; National Research Council Canada	Bayer, M (corresponding author), Univ Wurzburg, Hubland, D-97074 Wurzburg, Germany.		Bayer, Manfred/I-7947-2013	Bayer, Manfred/0000-0002-0893-5949; Forchel, Alfred/0000-0002-9377-9935				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; [Anonymous], 1998, QUANTUM DOTS; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Banin U, 1999, NATURE, V400, P542, DOI 10.1038/22979; Bayer M, 1998, PHYS REV B, V58, P4740, DOI 10.1103/PhysRevB.58.4740; Bayer M, 1999, PHYS REV LETT, V82, P1748, DOI 10.1103/PhysRevLett.82.1748; Bonadeo NH, 1998, SCIENCE, V282, P1473, DOI 10.1126/science.282.5393.1473; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991; EAGLESHAM DJ, 1990, PHYS REV LETT, V64, P1943, DOI 10.1103/PhysRevLett.64.1943; Fafard S, 1996, SCIENCE, V274, P1350, DOI 10.1126/science.274.5291.1350; Gammon D, 1997, SCIENCE, V277, P85, DOI 10.1126/science.277.5322.85; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; GRUNDMANN M, 1998, QUANTUM DOT HETEROST; Hawrylak P, 1999, PHYS REV B, V60, P5597, DOI 10.1103/PhysRevB.60.5597; HAWRYLAK P, 1999, CONDENS MATTER NEWS, V7, P16; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; Landin L, 1998, SCIENCE, V280, P262, DOI 10.1126/science.280.5361.262; LEONARD D, 1994, PHYS REV B, V50, P11687, DOI 10.1103/PhysRevB.50.11687; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Raymond S, 1997, SOLID STATE COMMUN, V101, P883, DOI 10.1016/S0038-1098(96)00750-8; Toda Y, 1999, PHYS REV LETT, V82, P4114, DOI 10.1103/PhysRevLett.82.4114; Wojs A, 1996, SOLID STATE COMMUN, V100, P487, DOI 10.1016/0038-1098(96)00403-6; ZRENNER A, 1994, PHYS REV LETT, V72, P3382, DOI 10.1103/PhysRevLett.72.3382	26	382	386	0	62	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					923	926		10.1038/35016020	http://dx.doi.org/10.1038/35016020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879527				2022-12-28	WOS:000087732700042
J	Drenth, JPH; Pieters, GFFM; Hermus, ARMM				Drenth, JPH; Pieters, GFFM; Hermus, ARMM			Epilepsy, broken bones, and fatty stools	LANCET			English	Article							VITAMIN-D; METABOLISM		Univ Nijmegen, Med Ctr St Radboud, Dept Endocrinol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Drenth, JPH (corresponding author), Univ Nijmegen, Med Ctr St Radboud, Dept Endocrinol, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Drenth, Joost/V-7436-2019; Hermus, A.R.M.M./H-8043-2014; Drenth, J.P.H./H-8025-2014	Hermus, A.R.M.M./0000-0003-1075-2655; 				HAHN TJ, 1972, J CLIN INVEST, V51, P741, DOI 10.1172/JCI106868; HAHN TJ, 1980, CLIN ENDOCRINOL META, V9, P107, DOI 10.1016/S0300-595X(80)80023-5; SHAFER RB, 1975, J CLIN ENDOCR METAB, V41, P1125, DOI 10.1210/jcem-41-6-1125	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1882	1882		10.1016/S0140-6736(00)02294-7	http://dx.doi.org/10.1016/S0140-6736(00)02294-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866445				2022-12-28	WOS:000087306500016
J	Frary, A; Nesbitt, TC; Frary, A; Grandillo, S; van der Knaap, E; Cong, B; Liu, JP; Meller, J; Elber, R; Alpert, KB; Tanksley, SD				Frary, A; Nesbitt, TC; Frary, A; Grandillo, S; van der Knaap, E; Cong, B; Liu, JP; Meller, J; Elber, R; Alpert, KB; Tanksley, SD			fw2.2: A quantitative trait locus key to the evolution of tomato fruit size	SCIENCE			English	Article							WEIGHT; MAIZE	Domestication of many plants has correlated with dramatic increases in fruit size. In tomato, one quantitative trait Locus (QTL), fw2.2, was responsible for a Large step in this process. When transformed into large-fruited cultivars, a cosmid derived from the fw2.2 region of a small-fruited wild species reduced fruit size by the predicted amount and had the gene action expected for fw2.2. The cause of the QTL effect is a single gene, ORFX, that is expressed early in floral development, controls carpel cell number, and has a sequence suggesting structural similarity to the human oncogene c-H-ras p21. Alterations in fruit size, imparted by fw2.2 alleles, are most Likely due to changes in regulation rather than in the sequence and structure of the encoded protein.	Cornell Univ, Dept Plant Breeding, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Cornell Univ, Dept Comp Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Tanksley, SD (corresponding author), Cornell Univ, Dept Plant Breeding, 252 Emerson Hall, Ithaca, NY 14853 USA.		van der Knaap, Esther/D-6307-2012; Frary, Anne/A-5417-2015; Meller, Jaroslaw/A-1971-2011	Frary, Anne/0000-0002-8973-0100; Meller, Jaroslaw/0000-0002-1162-8253; LIU, JIPING/0000-0002-7558-0025; van der Knaap, Esther/0000-0003-4963-7427				ALPERT KB, 1995, THEOR APPL GENET, V91, P994, DOI 10.1007/BF00223911; Alpert KB, 1996, P NATL ACAD SCI USA, V93, P15503, DOI 10.1073/pnas.93.26.15503; DOEBLEY J, 1990, P NATL ACAD SCI USA, V87, P9888, DOI 10.1073/pnas.87.24.9888; Frary A, 1996, PLANT CELL REP, V16, P235, DOI 10.1007/BF01890875; Grandillo S, 1999, THEOR APPL GENET, V99, P978, DOI 10.1007/s001220051405; MELLER J, UNPUB; PATERSON AH, 1991, GENETICS, V127, P181; Phillips PC, 1999, TRENDS GENET, V15, P6, DOI 10.1016/S0168-9525(98)01622-9; RICK CM, 1974, P NATL ACAD SCI USA, V71, P835, DOI 10.1073/pnas.71.3.835; Smartt J., 1995, EVOLUTION CROP PLANT, V2nd; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; TANKSLEY SD, 1993, ANNU REV GENET, V27, P205, DOI 10.1146/annurev.ge.27.120193.001225; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435	13	973	1114	14	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					85	88		10.1126/science.289.5476.85	http://dx.doi.org/10.1126/science.289.5476.85			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884229	Green Submitted			2022-12-28	WOS:000088090400035
J	van den Akker, F; Zhang, XL; Miyagi, M; Huo, XW; Misono, KS; Yee, VC				van den Akker, F; Zhang, XL; Miyagi, M; Huo, XW; Misono, KS; Yee, VC			Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor	NATURE			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; DIRECTED MUTATIONAL ANALYSIS; SITE; PROTEIN; IDENTIFICATION; LOCATION; INSIGHTS	The atrial natriuretic peptide (ANP) hormone is secreted by the heart in response to an increase in blood pressure. ANP exhibits several potent anti-hypertensive actions in the kidney, adrenal gland and vascular system. These actions are induced by hormone binding extracellularly to the ANPreceptor(1), thereby activating its intracellular guanylyl cyclase domain for the production of cyclic GMP(2). Here we present the crystal structure of the glycosylated dimerized hormone-binding domain of the ANP receptor at 2.0-Angstrom resolution. The monomer comprises two interconnected subdomains, each encompassing a central beta-sheet flanked by alpha-helices, and exhibits the type I periplasmic binding protein fold. Dimerization is mediated by the juxtaposition of four parallel helices, arranged two by two, which brings the two protruding carboxy termini into close relative proximity. From affinity labelling and mutagenesis studies, the ANP-binding site maps to the side of the dimer crevice and extends to near the dimer interface. A conserved chloride-binding site is located in the membrane distal domain, and we found that hormone binding is chloride dependent. These studies suggest mechanisms for hormone activation and the allostery of the ANP receptor.	Cleveland Clin Fdn, Lerner Res Inst, Struct Biol Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Yee, VC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Struct Biol Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	misonok@ccf.org; yeev@ccf.org						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DUDA T, 1991, P NATL ACAD SCI USA, V88, P7882, DOI 10.1073/pnas.88.17.7882; ENGEL AM, 1995, FEBS LETT, V360, P169, DOI 10.1016/0014-5793(95)00096-R; Foster D C, 1999, Rev Physiol Biochem Pharmacol, V135, P1, DOI 10.1007/BFb0033668; HE XL, 1995, BIOCONJUGATE CHEM, V6, P541, DOI 10.1021/bc00035a007; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; Itakura M, 1997, BIOCHEM J, V322, P585, DOI 10.1042/bj3220585; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labrecque J, 1999, J BIOL CHEM, V274, P9752, DOI 10.1074/jbc.274.14.9752; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; McNicoll N, 1996, BIOCHEMISTRY-US, V35, P12950, DOI 10.1021/bi960818q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misono KS, 2000, CIRC RES, V86, P1135; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; MIYAGI M, UNPUB EUR J BIOCH; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Hara BP, 1999, EMBO J, V18, P5175, DOI 10.1093/emboj/18.19.5175; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SAPER MA, 1983, J BIOL CHEM, V258, P1057; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Veress AT, 1997, AM J PHYSIOL-RENAL, V272, pF545, DOI 10.1152/ajprenal.1997.272.4.F545; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	31	127	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					101	104		10.1038/35017602	http://dx.doi.org/10.1038/35017602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894551				2022-12-28	WOS:000087991200054
J	Gillum, LA; Mamidipudi, SK; Johnston, SC				Gillum, LA; Mamidipudi, SK; Johnston, SC			Ischemic stroke risk with oral contraceptives - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; CEREBRAL-VEIN-THROMBOSIS; YOUNG-WOMEN; VENOUS THROMBOEMBOLISM; USERS; HEALTH; AGE; EPIDEMIOLOGY; METAANALYSIS; PREGNANCY	Context The relationship between ischemic stroke and oral contraceptive (OC) use has been studied for 40 years, but disagreement about an association persists. Objective To review available literature to determine whether OC use is associated with increased stroke risk. Data Sources Studies published from January 1960 through November 1999 were identified from electronic databases (MEDLINE, BIOSIS, and Dissertation Abstracts Online), Index Medicus, bibliographies of pertinent review articles and pertinent original articles, textbooks, and expert consultation, Study selection From 804 potentially relevant references retrieved, 73 were studies investigating risk of ischemic stroke with OC use. Two reviewers independently applied the following inclusion criteria: more than 10 stroke cases sampled, clear stroke subtype differentiation, concurrent controls included, adequate data included to determine relative risks (RRs) and confidence intervals (Cls), analysis controlled Cor age, and no later publication of identical data. A third investigator adjudicated disagreements. Sixteen studies met all inclusion criteria and were included in the meta-analysis. Data Extraction Two investigators independently extracted data, with disagreements resolved through discussion. Data Synthesis The 16 studies were analyzed using random effects modeling. Current OC use was associated with increased risk of ischemic stroke (RR, 2.75; 95% CI, 2.24-3.38). Smaller estrogen dosages were associated with lower risk (P = .01 for trend), but risk was significantly elevated for all dosages, Studies that did not control for smoking (P = .01) and those using hospital-based controls (P < .001) found higher RRs, but no other patient characteristics or elements of study design were important. The summary RR was 1.93 (95% CI, 1.35-2.74) for low-estrogen preparations in population-based studies that controlled for smoking and hypertension. This translates to an additional 4.1 ischemic strokes per 100000 nonsmoking, normotensive women using low-estrogen OCs, or 1 additional ischemic stroke per year per 24000 such women. The RR of stroke due to OC use was not different in women who smoked, had migraines, or had hypertension. Conclusions Summary results indicate that risk of ischemic stroke is increased in current OC users. even with newer low-estrogen preparations. However, the absolute increase in stroke risk is expected to be small since incidence is very low in this population.	Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Johnston, SC (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurovasc Serv, Box 0114,505 Parnassus Ave, San Francisco, CA 94143 USA.	clayj@itsa.ucsf.edu			NINDS NIH HHS [NS 02042] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*A GUTTM I, 1998, SUPP FAM PLANN IMPR; *A GUTTM I, 1998, CONTR US; [Anonymous], 1973, NEW ENGL J MED, V288, P871; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; BEGG CB, 1994, PUBLICATIONS BIAS HD; Bloemenkamp KWM, 1999, ARCH INTERN MED, V159, P65, DOI 10.1001/archinte.159.1.65; Carolei A, 1996, LANCET, V347, P1503, DOI 10.1016/S0140-6736(96)90669-8; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Chasan-Taber L, 1998, ANN INTERN MED, V128, P467, DOI 10.7326/0003-4819-128-6-199803150-00008; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; de Bruijn SFTM, 1998, BRIT MED J, V316, P589, DOI 10.1136/bmj.316.7131.589; de Bruijn SFTM, 1998, LANCET, V351, P1404, DOI 10.1016/S0140-6736(05)79442-3; FARLEY TMM, 1995, LANCET, V346, P1582; Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Haapaniemi H, 1997, STROKE, V28, P26, DOI 10.1161/01.STR.28.1.26; HANNAFORD PC, 1994, STROKE, V25, P935, DOI 10.1161/01.STR.25.5.935; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; JICK H, 1978, JAMA-J AM MED ASSOC, V240, P2548, DOI 10.1001/jama.240.23.2548; Johnston SC, 1998, NEUROLOGY, V51, P411, DOI 10.1212/WNL.51.2.411; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P37; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P17; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Lewis MA, 1998, AM J OBSTET GYNECOL, V179, P1086, DOI 10.1016/S0002-9378(98)70220-0; Lidegaard O, 1998, CONTRACEPTION, V57, P291, DOI 10.1016/S0010-7824(98)00033-X; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; Lidegaard O, 1999, ACTA OBSTET GYN SCAN, V78, P142, DOI 10.1034/j.1600-0412.1999.780213.x; Lidegaard O, 1999, AM J OBSTET GYNECOL, V180, pS357, DOI 10.1016/S0002-9378(99)70696-4; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; Mant J, 1998, BRIT J OBSTET GYNAEC, V105, P890, DOI 10.1111/j.1471-0528.1998.tb10235.x; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Martinelli I, 1998, LANCET, V352, P326, DOI 10.1016/S0140-6736(05)60307-8; METTINGER KL, 1984, ACTA NEUROL SCAND, V70, P415; Miller K, 1996, ANNU REV PUBL HEALTH, V17, P359; PETITTI D, 1994, META ANAL DECISION A; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Petitti DB, 1997, STROKE, V28, P280, DOI 10.1161/01.STR.28.2.280; PETITTI DB, 1994, AM J EPIDEMIOL, V140, P779, DOI 10.1093/oxfordjournals.aje.a117325; Poole C, 1999, AM J EPIDEMIOL, V150, P469, DOI 10.1093/oxfordjournals.aje.a010035; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1999, LANCET, V354, P301, DOI 10.1016/S0140-6736(99)01013-2; POULTER NR, 1995, LANCET, V346, P1575; Poulter NR, 1996, LANCET, V348, P498; RAMCHARAN S, 1981, CTR POPULATION RES M; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; ROTHMAN KJ, 1986, MODER EPIDEMIOLOGY; *ROYAL COLL GEN PR, 1983, J R COLL GEN PRACT, V33, P75; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277; Schwartz SM, 1997, ANN INTERN MED, V127, P596, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00003; Spitzer WO, 1996, BRIT MED J, V312, P83; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; *UN, 1999, WORLD CONTR US 1998; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; VESSEY MP, 1977, LANCET, V2, P731; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; Villringer A, 1997, New Horiz, V5, P332; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	69	241	248	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					72	78		10.1001/jama.284.1.72	http://dx.doi.org/10.1001/jama.284.1.72			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872016				2022-12-28	WOS:000087843000028
J	Druss, BG				Druss, BG			Cardiovascular procedures in patients with mental disorders - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Yale Univ, Sch Med, New Haven, CT 06510 USA	Yale University	Druss, BG (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA.							FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819	1	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3198	3199						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866856				2022-12-28	WOS:000087753900021
J	Catteruccia, F; Nolan, T; Loukeris, TG; Blass, C; Savakis, C; Kafatos, FC; Crisanti, A				Catteruccia, F; Nolan, T; Loukeris, TG; Blass, C; Savakis, C; Kafatos, FC; Crisanti, A			Stable germline transformation of the malaria mosquito Anopheles stephensi	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; YELLOW-FEVER MOSQUITO; TRANSPOSABLE ELEMENT; AEDES-AEGYPTI; GENE; EXPRESSION; GAMBIAE; MARKER	Anopheline mosquito species are obligatory vectors for human malaria, an infectious disease that affects hundreds of millions of people living in tropical and subtropical countries. The lack of a suitable gene transfer technology for these mosquitoes has hampered the molecular genetic analysis of their physiology, including the molecular interactions between the vector and the malaria parasite. Here we show that a transposon, based on the Minos element(1) and bearing exogenous DNA, can integrate efficiently and stably into the germ line of the human malaria vector Anopheles stephensi, through a transposase-mediated process.	Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; European Mol Biol Lab, D-69117 Heidelberg, Germany; Fdn Res & Technol Hellas, Res Ctr Crete, Inst Mol Biol & Biotechnol, Heraklion, Crete, Greece	Imperial College London; European Molecular Biology Laboratory (EMBL); Foundation for Research & Technology - Hellas (FORTH)	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Coll Rd, London SW7 2AZ, England.		Savakis, Babis/D-3633-2009; Nolan, Tony/I-4925-2012	Nolan, Tony/0000-0002-2982-8333; Catteruccia, Flaminia/0000-0003-3295-6683; Crisanti, Andrea/0000-0002-2406-4426				Berghammer AJ, 1999, NATURE, V402, P370, DOI 10.1038/46463; Catteruccia F, 2000, P NATL ACAD SCI USA, V97, P2157, DOI 10.1073/pnas.040568397; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; FRANCE A, 1991, HLTH PROM J AUST, V1, P19; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; KLINAKIS AG, IN PRESS INSECT MOL; Kumar V., 1994, Insect Molecular Biology, V3, P41, DOI 10.1111/j.1365-2583.1994.tb00149.x; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; Pinkerton AC, 2000, INSECT MOL BIOL, V9, P1, DOI 10.1046/j.1365-2583.2000.00133.x; Tamura T, 2000, NAT BIOTECHNOL, V18, P81, DOI 10.1038/71978	14	299	324	0	22	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					959	962		10.1038/35016096	http://dx.doi.org/10.1038/35016096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879538				2022-12-28	WOS:000087732700053
J	Ford, JM				Ford, JM			In the days of the comet - Dispatch 135 from the Oort Cloud Survey.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					889	889		10.1038/35016169	http://dx.doi.org/10.1038/35016169			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879513	Bronze			2022-12-28	WOS:000087732700025
J	Page, NM; Woods, RJ; Gardiner, SM; Lomthaisong, K; Gladwell, RT; Butlin, DJ; Manyonda, IT; Lowry, PJ				Page, NM; Woods, RJ; Gardiner, SM; Lomthaisong, K; Gladwell, RT; Butlin, DJ; Manyonda, IT; Lowry, PJ			Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia	NATURE			English	Article							PORCINE SPINAL-CORD; SUBSTANCE-P; RECEPTOR ANTAGONISTS; RAT; PREECLAMPSIA; RESPONSES; SEQUENCE; VESSELS; PLASMA; POTENT	Pre-eclampsia is a principal cause of maternal morbidity and mortality, affecting 5-10% of first pregnancies worldwide. Manifestations include increased blood pressure, proteinuria, coagulopathy and peripheral and cerebral oedema. Although the aetiology and pathogenesis remain to be elucidated, the placenta is undoubtedly involved, as termination of pregnancy eradicates the disease. Here we have cloned a complementary DNA from human placental messenger RNA encoding a precursor protein of 121 amino acids which gives rise to a mature peptide identical to the neuropeptide neurokinin B (NKB)(1) of other mammalian species. In female rats, concentrations of NKB several-fold above that of an animal 20 days into pregnancy caused substantial pressor activity. In human pregnancy, the expression of NKB was confined to the outer syncytiotrophoblast of the placenta, significant concentrations of NKB could be detected in plasma as early as week 9, and plasma concentrations of NKB were grossly elevated in pregnancy-induced hypertension and pre-eclampsia. We conclude that elevated levels of NKB in early pregnancy may be an indicator of hypertension and pre-eclampsia, and that treatment with certain neurokinin receptor antagonists may be useful in alleviating the symptoms.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ London St Georges Hosp, Dept Obstet & Gynaecol, London SW17 0QT, England	University of Reading; University of Nottingham; St Georges University London	Lowry, PJ (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.			Lomthaisong, Khomsorn/0000-0002-0645-5757; Page, Nigel/0000-0002-7147-1550				ADAMS MD, 1995, NATURE, V377, P3; Baigent SM, 2000, J MOL ENDOCRINOL, V24, P53, DOI 10.1677/jme.0.0240053; BAUMANN H, 1991, AM J OBSTET GYNECOL, V165, P237, DOI 10.1016/0002-9378(91)90265-S; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; CAMPBELL EA, 1987, J CLIN ENDOCR METAB, V64, P1054, DOI 10.1210/jcem-64-5-1054; Cellier E, 1997, BRIT J PHARMACOL, V122, P643, DOI 10.1038/sj.bjp.0701435; CLEMENTJONES V, 1980, NATURE, V283, P295, DOI 10.1038/283295a0; Conrad KP, 1999, AM J PHYSIOL-RENAL, V277, pF48, DOI 10.1152/ajprenal.1999.277.1.F48; COUTURE R, 1989, N-S ARCH PHARMACOL, V340, P547; DORLEANSJUSTE P, 1991, EUR J PHARMACOL, V204, P329, DOI 10.1016/0014-2999(91)90860-S; Gecse A, 1996, IMMUNOPHARMACOLOGY, V33, P167, DOI 10.1016/0162-3109(96)00035-5; Hayman R, 1999, J SOC GYNECOL INVEST, V6, P3, DOI 10.1016/S1071-5576(98)00044-6; JANSEN I, 1991, J CEREBR BLOOD F MET, V11, P567, DOI 10.1038/jcbfm.1991.105; KANGAWA K, 1983, BIOCHEM BIOPH RES CO, V114, P533, DOI 10.1016/0006-291X(83)90813-6; KIMURA S, 1983, P JPN ACAD B-PHYS, V59, P101, DOI 10.2183/pjab.59.101; Kobari M, 1996, EUR J PHARMACOL, V317, P269, DOI 10.1016/S0014-2999(96)00725-X; Lim KH, 1997, AM J PATHOL, V151, P1809; Longmore J, 1997, CAN J PHYSIOL PHARM, V75, P612, DOI 10.1139/cjpp-75-6-612; Lyall F, 1996, Rev Reprod, V1, P107, DOI 10.1530/ror.0.0010107; MASTRANGELO D, 1987, EUR J PHARMACOL, V134, P321, DOI 10.1016/0014-2999(87)90363-3; MOUSSAOUI SM, 1992, NEUROSCIENCE, V48, P969, DOI 10.1016/0306-4522(92)90285-A; Page N. M., 1998, Journal of Endocrinology, V156, pP257; PERIANIN A, 1989, BIOCHEM BIOPH RES CO, V161, P520, DOI 10.1016/0006-291X(89)92630-2; PERRETTI M, 1993, IMMUNOLOGY, V80, P73; Roccon A, 1996, BRIT J PHARMACOL, V118, P1095, DOI 10.1111/j.1476-5381.1996.tb15511.x; Shimizu T, 1999, BRAIN RES, V830, P372, DOI 10.1016/S0006-8993(99)01386-4; STABLES JM, 1994, NEUROPEPTIDES, V27, P333, DOI 10.1016/0143-4179(94)90059-0; Thompson GW, 1998, AM J PHYSIOL-REG I, V44, P1683; von Euler US, 1931, J PHYSIOL-LONDON, V72, P74, DOI 10.1113/jphysiol.1931.sp002763	29	212	228	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					797	800		10.1038/35015579	http://dx.doi.org/10.1038/35015579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866201				2022-12-28	WOS:000087620600052
J	Pizzari, T; Birkhead, TR				Pizzari, T; Birkhead, TR			Female feral fowl eject sperm of subdominant males	NATURE			English	Article							MATING-BEHAVIOR; COMPETITION; CHOICE; POLYANDRY	Paternity is often determined by competition between the ejaculates of different males(1). Males can also use particular behaviours or structures to manipulate how females use sperm(2-5). However, the ability of females to bias sperm utilization in favour of preferred males independently of male manipulation has not been demonstrated(6). Females are predicted to respond differentially to the sperm of different males when the reproductive interests of the sexes differ and when females are coerced into copulating(4,6). Here we show that in female feral fowl most copulations are coerced, and that females consistently bias sperm retention in favour of the preferred male phenotype. Females prefer to copulate with dominant males, but when sexually coerced by subordinate males, they manipulate the behaviour of dominant males to reduce the likelihood of insemination. If this fails, females differentially eject ejaculates according to male status in the absence of any male manipulation and preferentially retain the sperm of dominant males.	Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Pizzari, T (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.							ALLEN T. E., 1957, AUSTRALIAN JOUR AGRIC RES, V8, P788, DOI 10.1071/AR9570788; Bakst M.R., 1997, TECHNIQUES SEMEN EVA; Birkhead TR, 1998, EVOLUTION, V52, P1212, DOI [10.1111/j.1558-5646.1998.tb01848.x, 10.2307/2411251]; Birkhead TR, 1999, P ROY SOC B-BIOL SCI, V266, P1759, DOI 10.1098/rspb.1999.0843; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHENG KM, 1988, CONDOR, V90, P697, DOI 10.2307/1368360; Clark AG, 1999, SCIENCE, V283, P217, DOI 10.1126/science.283.5399.217; CLUTTONBROCK TH, 1979, ANIM BEHAV, V27, P211, DOI 10.1016/0003-3472(79)90141-6; CLUTTONBROCK TH, 1995, ANIM BEHAV, V49, P1345, DOI 10.1006/anbe.1995.0166; CRAIG JV, 1965, ANIM BEHAV, V13, P114, DOI 10.1016/0003-3472(65)90081-3; Cunningham EJA, 1999, P ROY SOC B-BIOL SCI, V266, P905, DOI 10.1098/rspb.1999.0722; Darwin C., 1871, P475; DAVIES NB, 1983, NATURE, V302, P334, DOI 10.1038/302334a0; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Edvardsson M, 2000, P ROY SOC B-BIOL SCI, V267, P559, DOI 10.1098/rspb.2000.1037; Etches R. J., 1996, REPROD POULTRY; Harrison B., 1987, SVEN RASF TIDSKRIFT, V1, P12; ISHIKAWA H, 1930, P WORLD POULT J C, P90; JONES MEJ, 1991, POULTRY SCI, V70, P1493, DOI 10.3382/ps.0701493; MARTIN PA, 1974, J REPROD FERTIL, V39, P251, DOI 10.1530/jrf.0.0390251; OTRONEN M, 1990, BEHAV ECOL SOCIOBIOL, V26, P349, DOI 10.1007/BF00171101; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Parker J. E., 1942, MISSOURI AGR EXPT ST, V347, P1; PIZZARI T, 1999, THESIS U SHEFFIELD; SHELDON BC, 1993, P R SOC LOND B, V39, P491; SIMMONS LW, 1987, BEHAV ECOL SOCIOBIOL, V21, P197, DOI 10.1007/BF00303211; Sokal R. R, 1981, BIOMETRY; THORNHILL R, 1992, SPERM COMPETITION BI, P82; Wiley RH, 1996, EVOLUTION, V50, P1371, DOI [10.2307/2410875, 10.1111/j.1558-5646.1996.tb03911.x]; Zeh JA, 1997, P ROY SOC B-BIOL SCI, V264, P69, DOI 10.1098/rspb.1997.0010	30	272	273	1	84	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					787	789		10.1038/35015558	http://dx.doi.org/10.1038/35015558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866198				2022-12-28	WOS:000087620600049
J	Peel, M; Mahtani, A; Hinshelwood, G; Forrest, D				Peel, M; Mahtani, A; Hinshelwood, G; Forrest, D			The sexual abuse of men in detention in Sri Lanka	LANCET			English	Editorial Material							MALE RAPE; VICTIMS		Med Fdn Care Victims Torture, London NW5 3EJ, England		Peel, M (corresponding author), Med Fdn Care Victims Torture, London NW5 3EJ, England.							GROTH AN, 1980, AM J PSYCHIAT, V137, P806; HOWITT J, 1996, CLIN FORENSIC MED, P193; KAUFMAN A, 1980, AM J PSYCHIAT, V137, P221; SAGARIN E, 1976, PSYCHIATRY, V39, P245, DOI 10.1080/00332747.1976.11023894	4	27	27	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2069	2070		10.1016/S0140-6736(00)02368-0	http://dx.doi.org/10.1016/S0140-6736(00)02368-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885371				2022-12-28	WOS:000087519400042
J	Raymond, NA				Raymond, NA			The damage done to Chechnya's medical establishment	LANCET			English	Editorial Material									Physicians Human Rights, Boston, MA 02116 USA		Raymond, NA (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2068	2068		10.1016/S0140-6736(00)02365-5	http://dx.doi.org/10.1016/S0140-6736(00)02365-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885370				2022-12-28	WOS:000087519400041
J	Traber, MG; Jialal, I				Traber, MG; Jialal, I			Measurement of lipid-soluble vitamins - further adjustment needed?	LANCET			English	Editorial Material							CORONARY-DISEASE; HEART-DISEASE; E CONSUMPTION; TOCOPHEROL; RISK		Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol & Internal Med, Dallas, TX 75235 USA	Oregon State University; University of Texas System; University of Texas Dallas	Traber, MG (corresponding author), Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.		Traber, Maret G./ABI-2511-2020; Jialal, Ishwarlal/AAG-6218-2019	Traber, Maret G./0000-0002-2892-4024; 				Booth SL, 1998, J NUTR, V128, P785, DOI 10.1093/jn/128.5.785; Cavalier L, 1998, AM J HUM GENET, V62, P301, DOI 10.1086/301699; Cham BE, 1999, CLIN CHIM ACTA, V287, P45, DOI 10.1016/S0009-8981(99)00117-5; Devaraj S, 1998, CURR OPIN LIPIDOL, V9, P11, DOI 10.1097/00041433-199802000-00004; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; THURNHAM DI, 1986, ANN CLIN BIOCHEM, V23, P514, DOI 10.1177/000456328602300505; TRABER MG, 1999, MODERN NUTR HLTH DIS, P347; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; 2000, DIETARY REFERENCE IN	14	90	94	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2013	2014		10.1016/S0140-6736(00)02345-X	http://dx.doi.org/10.1016/S0140-6736(00)02345-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885350				2022-12-28	WOS:000087519400006
J	Donovan, B; Ross, MW				Donovan, B; Ross, MW			Preventing HIV: determinants of sexual behaviour	LANCET			English	Article							RISK BEHAVIOR; GAY MEN; AIDS; WORKERS; HEALTH; PROSTITUTION; INFECTION; PROMOTION; PARTNERS; SEEKING	AIDS has invigorated and distorted the study of sexual behaviour. Because that study began so recently, there remain many unanswered questions about why we have sex at all, why we do sex one way rather than another, or even how we define sex. Yet in every instance in which well-designed and adequately resourced behavioural interventions have been implemented, these have netted success in the form of falling HIV incidences or prevalences. But, despite these successes, such interventions remain patchy and poorly supported. Perhaps humankind's traditional aversion for the public discussion of sexual matters underlies this reticence. Or maybe a new era of "creeping absolutism"-in which biomedical advances are given premature credit for what they can achieve in HIV control-has arrived.	Sydney Hosp, Sydney Sexual Hlth Ctr, Sydney, NSW 2001, Australia; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Texas, Houston Hlth Sci Ctr, Sch Publ Hlth, WHO Ctr Hlth Promot & Prevent Res, Houston, TX USA; Univ Texas, Houston Hlth Sci Ctr, Sch Med, Dept Infect Dis, Houston, TX USA	University of Sydney; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston	Donovan, B (corresponding author), Sydney Hosp, Sydney Sexual Hlth Ctr, POB 1614, Sydney, NSW 2001, Australia.	donovanb@sesahs.nsw.gov.au	Donovan, Basil J/K-1246-2012	Donovan, Basil J/0000-0001-8851-4126; Ross, Michael/0000-0002-5718-9989				Anderson JE, 1999, FAM PLANN PERSPECT, V31, P24, DOI 10.2307/2991553; [Anonymous], 1992, AIDS WORLD; Baseman J, 1999, SEX TRANSM DIS, V26, P444, DOI 10.1097/00007435-199909000-00005; BOGAERT AF, 1995, J SEX RES, V32, P119, DOI 10.1080/00224499509551782; BROWNE J, 1995, BRIT J SOCIOL, V46, P598, DOI 10.2307/591574; Caldwell J. C., 1999, Resistances to behavioural change to reduce HIV/AIDS infection in predominantly heterosexual epidemics in Third World countries., P241; CALDWELL JC, 1992, SOC SCI MED, V34, P1169, DOI 10.1016/0277-9536(92)90310-M; Campbell C, 2000, SOC SCI MED, V50, P479, DOI 10.1016/S0277-9536(99)00317-2; CAMPBELL CA, 1991, SOC SCI MED, V32, P1367, DOI 10.1016/0277-9536(91)90197-K; Carrier Joseph, 1995, OTROS INTIMACY HOMOS; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; DAVIES P, 1994, SOC AS AIDS, V264, P57; Donovan B, 2000, LANCET, V355, P1908, DOI 10.1016/S0140-6736(05)73352-3; Donovan B, 2000, SEX TRANSM INFECT, V76, P7, DOI 10.1136/sti.76.1.7; DONOVAN B, 2000, IN PRESS SEX TRANSM, V76; Evans C, 1997, SOC SCI MED, V44, P1791, DOI 10.1016/S0277-9536(96)00288-2; Eysenck HJ, 1978, SEX PERSONALITY; Fishbein M, 1998, INT J GYNECOL OBSTET, V63, pS175, DOI 10.1016/S0020-7292(98)00202-1; FISHER WA, 1984, J APPL SOC PSYCHOL, V14, P104, DOI 10.1111/j.1559-1816.1984.tb02224.x; Ford K, 1996, AIDS, V10, P213, DOI 10.1097/00002030-199602000-00013; FRIEDMAN SR, 1999, AIDS BEHAV, V3, P85, DOI DOI 10.1023/A:1025427721485; JACKSON L, 1992, SOC SCI MED, V35, P281, DOI 10.1016/0277-9536(92)90024-K; KALICHMAN SC, 1994, J PERS ASSESS, V62, P385, DOI 10.1207/s15327752jpa6203_1; KELAHER M, 1994, AIDS, V8, P101, DOI 10.1097/00002030-199401000-00015; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Maddox J, 1999, SCI AM, V281, P62; Manderson L, 1999, Annu Rev Sex Res, V10, P184; MURRAY A, 1996, GENDER PLACE CULT, V3, P43; NAG M, 1994, INDIAN J SOC WORK, V55, P503; NILSSONSCHONNES.L, 1995, J PSYCHOL HUMAN SEXU, V7, P41; PAGESHAFER KA, 1999, MMWR-MORBID MORTAL W, V48, P45; Potterat JJ, 1998, J SEX RES, V35, P333, DOI 10.1080/00224499809551951; RAJANI R, 1996, LEARNING SEXUALITY P, P301; ROSS MW, 2000, CAD SAUDE PUBLICA, V16, P109; ROSS MW, 2000, IN PRESS SOC SCI MED; ROSS MW, 2000, AIDS PREVENT MENT H, P201; Sanders SA, 1999, JAMA-J AM MED ASSOC, V281, P275, DOI 10.1001/jama.281.3.275; Tolerton Jane, 1992, ETTIE LIFE E ROUT; Van de Ven P, 1998, AUST NZ J PUBL HEAL, V22, P814; van der Straten A, 2000, AIDS, V14, pF47, DOI 10.1097/00002030-200003100-00003; WEINSTEIN ND, 1989, PRIM PREV P, V13, P142; Winn M, 1996, VENEREOLOGY, V9, P68	42	34	35	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1897	1901		10.1016/S0140-6736(00)02302-3	http://dx.doi.org/10.1016/S0140-6736(00)02302-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	318VZ	10866459				2022-12-28	WOS:000087306500042
J	Stamler, J; Daviglus, ML; Garside, DB; Dyer, AR; Greenland, P; Neaton, JD				Stamler, J; Daviglus, ML; Garside, DB; Dyer, AR; Greenland, P; Neaton, JD			Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; FOLLOW-UP; ADULTS; DISEASE; LIFE	Context Based on observational and interventional data for middle-aged cohorts (aged 40-64 years), serum cholesterol level is known to be an established major risk factor for coronary heart disease (CHD). However, findings for younger people are limited, and the value of detecting and treating hypercholesterolemia in younger adults is debated. Objective To evaluate the long-term impact of unfavorable serum cholesterol levels on risk of death from CHD, cardiovascular disease (CVD), and all causes, Design, Setting, and Participants Three prospective studies, from which were selected 3 cohorts of younger men with baseline serum cholesterol level measurements and no history of diabetes mellitus or myocardial infarction. A total of 11 017 men aged 18 through 39 years screened in 1967-1973 for the Chicago Heart Association Detection Project in Industry (CHA); 1266 men aged 25 through 39 years examined in 1959-1963 in the Peoples Cas Company Study (PCI); and 69 205 men aged 35 through 39 years screened in 1973-1975 for the Multiple Risk Factor Intervention Trial (MRFIT). Main Outcome Measures Cause-specific mortality during 25 (CHA), 34 (PCI), and 16 (MRFIT) years of follow-up; mortality risks; and estimated life expectancy in relation to baseline serum cholesterol levels. Results Death due to CHD accounted for 26%, 34%, and 28% of all deaths in the CHA, PC, and MRFIT cohorts, respectively; and CVD death for 34%, 42%, and 39% of deaths in the same cohorts, respectively. Men in all 3 cohorts with unfavorable serum cholesterol levels (200-239 mg/dL [5.17-6.18 mmol/L] and greater than or equal to 240 mg/dl [greater than or equal to 6.21 mmol/L]) had strong gradients of relative mortality risk. For men with serum cholesterol levels of 240 mg/dL or greater (greater than or equal to 6.21 mmol/L) vs favorable levels (<200 mg/dL [<5.17 mmol/L]), CHD mortality risk was 2.15 to 3.63 times greater; CVD disease mortality risk was 2.10 to 2.87 times greater; and all-cause mortality was 1.31 to 1.49 times greater, Hypercholesterolemic men had age-adjusted absolute risk of CHD death of 59 per 1000 men in 25 years (CHA cohort), 90 per 1000 men in 34 years (PCI cohort), and 15 per 1000 men in 16 years (MRFIT cohort). Absolute excess risk was 43.6 per 1000 men (CHA), 81.4 per 1000 men (PCI), and 12.1 per 1000 men (MRFIT). Men with favorable baseline serum cholesterol levels had an estimated greater life expectancy of 3.8 to 8.7 years. Conclusions These results demonstrate a continuous, graded relationship of serum cholesterol level to long-term risk of CHD, CVD, and all-cause mortality, substantial absolute risk and absolute excess risk of CHD and CVD death for younger men with elevated serum cholesterol levels, and longer estimated life expectancy for younger men with favorable serum cholesterol levels.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Stamler, J (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	hwe216@nwu.edu	Greenland, Philip/ABD-5528-2021		NHLBI NIH HHS [HL 21010, HL 21785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021010] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Cleeman JI, 1997, CIRCULATION, V95, P1646; Davidoff F, 1996, ANN INTERN MED, V124, P513, DOI 10.7326/0003-4819-124-5-199603010-00011; Deckelbaum R. J., 1999, Circulation, V100, P450; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LaRosa JC, 1996, ANN INTERN MED, V124, P505, DOI 10.7326/0003-4819-124-5-199603010-00008; LEVINE JB, 1964, CLIN CHIM ACTA, V10, P381, DOI 10.1016/0009-8981(64)90073-7; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Mahoney LT, 1996, J AM COLL CARDIOL, V27, P277, DOI 10.1016/0735-1097(95)00461-0; NAT'L ACAD. ON AN AGING SOC'Y, 1999, HLTH EFF EXP POW LIN, P1; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; PRINEAS RJ, 1983, HYPERTENSION, V5, P160; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; STAMLER J, 1994, CIRCULATION, V90, P2573; Stamler J., 1967, LECT PREVENTIVE CARD; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; [No title captured]	24	395	415	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					311	318		10.1001/jama.284.3.311	http://dx.doi.org/10.1001/jama.284.3.311			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891962	Bronze			2022-12-28	WOS:000088123000023
J	Sharma, R				Sharma, R			India introduces regulations for making traditional medicines	BRITISH MEDICAL JOURNAL			English	News Item																			0	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					134	134		10.1136/bmj.321.7254.134	http://dx.doi.org/10.1136/bmj.321.7254.134			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894684	Green Published			2022-12-28	WOS:000088305700012
J	Tuffs, A				Tuffs, A			Germany reorganises its transplant services	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					134	134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894686				2022-12-28	WOS:000088305700014
J	Beecham, L				Beecham, L			BMA's annual meeting expresses "no confidence" in GMC	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					69	69		10.1136/bmj.321.7253.69	http://dx.doi.org/10.1136/bmj.321.7253.69			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884244	Green Published			2022-12-28	WOS:000088196600011
J	Luepker, RV; Raczynski, JM; Osganian, S; Goldberg, RJ; Finnegan, JR; Hedges, JR; Goff, DC; Eisenberg, MS; Zapka, JG; Feldman, HA; Labarthe, DR; McGovern, PG; Cornell, CE; Proschan, MA; Simons-Morton, DG				Luepker, RV; Raczynski, JM; Osganian, S; Goldberg, RJ; Finnegan, JR; Hedges, JR; Goff, DC; Eisenberg, MS; Zapka, JG; Feldman, HA; Labarthe, DR; McGovern, PG; Cornell, CE; Proschan, MA; Simons-Morton, DG		REACT Study Grp	Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease - The Rapid Early Action for Coronary Treatment (REACT) trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PREHOSPITAL DELAY; PUBLIC-EDUCATION; ATTACK SYMPTOMS; UNITED-STATES; RISK-FACTORS; TIME DELAYS; CHEST PAIN; CAMPAIGN; PROGRAM	Context Delayed access to medical care in patients with acute myocardial infarction (AMI) is common and increases myocardial damage and mortality. Objective To evaluate a community intervention to reduce patient delay from symptom onset to hospital presentation and increase emergency medical service (EMS) use. Design and Setting The Rapid Early Action for Coronary Treatment Trial, a randomized trial conducted from 1995 to 1997 in 20 US cities (10 matched pairs; population range, 55777-238912) in 10 states. Participants A total of 59944 adults aged 30 years or older presenting to hospital emergency departments (EDs) with chest pain, of whom 20364 met the primary population criteria of suspected acute coronary heart disease on admission and were discharged with a coronary heart disease-related diagnosis. Intervention One city in each pair was randomly assigned to an 18-month intervention that targeted mass media, community organizations, and professional, public, and patient education to increase appropriate patient actions for AMI symptoms (primary population, n = 10563). The other city in each pair was randomly assigned to reference status (primary population, n = 9801). Main Outcome Measures Time from symptom onset to ED arrival and EMS use, compared between intervention and reference city pairs. Results General population surveys provided evidence of increased public awareness and knowledge of program messages. Patient delay from symptom onset to hospital arrival at baseline (median, 140 minutes) was identical in the intervention and reference communities. Delay time decreased in intervention communities by -4.7% per year (95% confidence interval [CI], -8.6% to -0.6%), but the change did not differ significantly from that observed in reference communities (-6.8% per year; 95% CI, -14.5% to 1.6%; P = .54). EMS use by the primary study population increased significantly in intervention communities compared with reference communities, with a net effect of 20% (95% CI, 7%-34%; P < .005), Total numbers of ED presentations for chest pain and patients with chest pain discharged from the ED, as well as EMS use among patients with chest pain released from the ED, did not change significantly. Conclusions in this study, despite an Is-month intervention, time from symptom onset to hospital arrival for patients with chest pain did not change differentially between groups, although increased appropriate EMS use occurred in intervention communities. New strategies are needed if delay time from symptom onset to hospital presentation is to be decreased further in patients with suspected AMI.	Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55454 USA	University of Minnesota System; University of Minnesota Twin Cities	Luepker, RV (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.	luepker@epi.umn.edu	Feldman, Henry/M-2302-2013; Hedges, Jerris/AAC-1847-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL053135, U01HL053141] Funding Source: NIH RePORTER; NHLBI NIH HHS [UO1-HL53135, UO1-HL53141] Funding Source: Medline; PHS HHS [UO1-53142] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Bandura A., 1986, SOCIAL FDN THOUGHT A; BETT N, 1993, AUST NZ J MED, V23, P157, DOI 10.1111/j.1445-5994.1993.tb01810.x; BOLTE HD, 1987, HEARTBEAT, V4, P4; BRACHT N, 1994, HEALTH EDUC RES, V9, P243, DOI 10.1093/her/9.2.243; Bracht N, 1990, HLTH PROMOTION COMMU; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; CUMMINS R, 1997, ADV CARDIAC LIFE SUP; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; Feldman HA, 1998, CONTROL CLIN TRIALS, V19, P391, DOI 10.1016/S0197-2456(98)00014-2; Gail MH, 1996, STAT MED, V15, P1069, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.3.CO;2-H; Gaspoz JM, 1996, HEART, V76, P150, DOI 10.1136/hrt.76.2.150; Goff David C. Jr., 1995, Annals of Epidemiology, V5, P171, DOI 10.1016/1047-2797(94)00103-Z; Goff DC, 1999, AM HEART J, V138, P1046, DOI 10.1016/S0002-8703(99)70069-4; Goff DC, 1998, ARCH INTERN MED, V158, P2329, DOI 10.1001/archinte.158.21.2329; Goldberg RJ, 1998, AM HEART J, V135, P293, DOI 10.1016/S0002-8703(98)70096-1; Hand M, 1998, J THROMB THROMBOLYS, V6, P9, DOI 10.1023/A:1008868020782; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; Julian DG, 1996, EUR HEART J, V17, P43; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; Leventhal H, 1990, STRESS MED PROCEDURE, P25; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MEISCHKE H, 1993, ANN EMERG MED, V22, P1597, DOI 10.1016/S0196-0644(05)81267-3; MITIC WR, 1984, CAN J PUBLIC HEALTH, V75, P414; MOSES HW, 1991, AM J CARDIOL, V68, P249, DOI 10.1016/0002-9149(91)90753-8; MURRAY DM, 1998, DESIGN ANAL GROUP RA, P426; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; Novelli W. D., 1984, MARKETING HLTH BEHAV, P59; Perry C.L., 1990, INDIVIDUALS ENV HLTH; PUSKA P, 1995, N KARELIA PROJECT 20; Raczynski JM, 1999, AM J PREV MED, V16, P325, DOI 10.1016/S0749-3797(99)00023-9; RIDKER PM, 1992, AM J CARDIOL, V70, P10, DOI 10.1016/0002-9149(92)91381-D; Rimer BK., 1997, HLTH BEHAV HLTH ED T, P384; Rogers EM., 1983, DIFFUSION INNOVATION; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; SIMONSMORTON DB, 1998, ACAD EMERG MED, V5, P656; WEAVER WD, 1995, J AM COLL CARDIOL, V25, pS3; WENNERBLOM B, 1982, ACTA MED SCAND, P1; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4	43	379	386	3	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					60	67		10.1001/jama.284.1.60	http://dx.doi.org/10.1001/jama.284.1.60			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	328GX	10872014				2022-12-28	WOS:000087843000026
J	Huelsenbeck, JP; Rannala, B; Masly, JP				Huelsenbeck, JP; Rannala, B; Masly, JP			Accommodating phylogenetic uncertainty in evolutionary studies	SCIENCE			English	Article							INFERENCE	Many evolutionary studies use comparisons across species to detect evidence of natural selection and to examine the rate of character evolution, Statistical analyses in these studies are usually performed by means of a species phylogeny to accommodate the effects of shared evolutionary history. The phylogeny is usually treated as known without error; this assumption is problematic because inferred phylogenies are subject to both stochastic and systematic errors. We describe methods for accommodating phylogenetic uncertainty in evolutionary studies by means of Bayesian inference. The methods are computationally intensive but general enough to be applied in most comparative evolutionary studies.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Rochester; University of Alberta	Huelsenbeck, JP (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	johnh@brahms.biology.rochester.edu	Rannala, Bruce/M-3188-2014; Huelsenbeck, John P/C-6398-2013	Rannala, Bruce/0000-0002-8355-9955; 	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001988] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01-HG01988] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Donoghue MJ, 1996, PHILOS T R SOC B, V351, P1241, DOI 10.1098/rstb.1996.0107; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; HASTINGS WK, 1970, BIOMETRIKA, V57, P97, DOI 10.1093/biomet/57.1.97; HUELSENBECK JP, 1995, SYST BIOL, V44, P17, DOI 10.2307/2413481; Martins EP, 1996, EVOLUTION, V50, P12, DOI 10.1111/j.1558-5646.1996.tb04468.x; Mau B, 1999, BIOMETRICS, V55, P1, DOI 10.1111/j.0006-341X.1999.00001.x; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Rannala B, 1996, J MOL EVOL, V43, P304, DOI 10.1007/PL00006090; Simon D, 1999, BAYESIAN ANAL MOL BI; Stern DL, 1998, EVOLUTION, V52, P155, DOI 10.2307/2410930	13	238	245	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2349	2350		10.1126/science.288.5475.2349	http://dx.doi.org/10.1126/science.288.5475.2349			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875916				2022-12-28	WOS:000087913400034
J	Hu, DH; Yu, J; Wong, K; Bagchi, B; Rossky, PJ; Barbara, PF				Hu, DH; Yu, J; Wong, K; Bagchi, B; Rossky, PJ; Barbara, PF			Collapse of stiff conjugated polymers with chemical defects into ordered, cylindrical conformations	NATURE			English	Article							SPECTROSCOPY; MOLECULES; HOMOPOLYMER; EXCITATIONS; TRANSITION; ANISOTROPY; OLIGOMERS; DYNAMICS; GLOBULE; LENGTH	The optical, electronic and mechanical properties of synthetic and biological materials consisting of polymer chains depend sensitively on the conformation adopted by these chains. The range of conformations available to such systems has accordingly been of intense fundamental(1,2) as well as practical(3-6) interest, and distinct conformational classes have been predicted, depending on the stiffness of the polymer chains and the strength of attractive interactions between segments within a chain(7-10). For example, flexible polymers should adopt highly disordered conformations resembling either a random coil or, in the presence of strong intrachain attractions, a so-called 'molten globule'(2,10). Stiff polymers with strong intrachain interactions, in contrast, are expected to collapse into conformations with long-range order, in the shape of toroids or rod-like structures(8,9,11). Here we use computer simulations to show that the anisotropy distribution obtained from polarization spectroscopy measurements on individual poly[2-methoxy-5-(2'-ethylhexyl)oxy-1,4-phenylenevinylene] polymer molecules is consistent with this prototypical stiff conjugated polymer adopting a highly ordered, collapsed conformation that cannot be correlated with ideal toroid or rod structures. We rnd that the presence of so-called 'tetrahedral chemical defects', where conjugated carbon-carbon links are replaced by tetrahedral links, divides the polymer chain into structurally identifiable quasi-straight segments that allow the molecule to adopt cylindrical conformations. Indeed, highly ordered, cylindrical conformations may be a critical factor in dictating the extraordinary photophysical properties of conjugated polymers, including highly efficient intramolecular energy transfer and significant local optical anisotropy in thin films.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Indian Inst Sci, Solid State & Struct Chem Unit, Bangalore 560012, Karnataka, India	University of Texas System; University of Texas Austin; Indian Institute of Science (IISC) - Bangalore	Barbara, PF (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.		Hu, Dehong/B-4650-2010	Hu, Dehong/0000-0002-3974-2963				Basche T., 1996, SINGLE MOL OPTICAL D; Bassler H, 1999, ACCOUNTS CHEM RES, V32, P173, DOI 10.1021/ar960228k; Blatchford JW, 1996, PHYS REV B, V54, pR3683, DOI 10.1103/PhysRevB.54.R3683; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; CARMESIN I, 1988, MACROMOLECULES, V21, P2819, DOI 10.1021/ma00187a030; De Gennes P.-G., 1979, SCALING CONCEPTS POL; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; GETTINGER CL, 1994, J CHEM PHYS, V101, P1673, DOI 10.1063/1.468438; Grosberg A. Yu., 1979, Biophysics, V24, P30; GROSBERG AY, 1992, MACROMOLECULES, V25, P1970, DOI 10.1021/ma00033a022; Ha T, 1999, J PHYS CHEM B, V103, P6839, DOI 10.1021/jp990948j; HAGLER TW, 1994, PHYS REV B, V49, P10968, DOI 10.1103/PhysRevB.49.10968; HELFAND E, 1971, J CHEM PHYS, V54, P4651, DOI 10.1063/1.1674737; Hide F, 1997, ACCOUNTS CHEM RES, V30, P430, DOI 10.1021/ar950191o; Hu DH, 1999, J AM CHEM SOC, V121, P6936, DOI 10.1021/ja990139d; Ivanov VA, 1998, J CHEM PHYS, V109, P5659, DOI 10.1063/1.477184; Kuznetsov YA, 1999, J CHEM PHYS, V111, P3744, DOI 10.1063/1.479655; LODGE TP, 1992, MACROMOLECULES, V25, P5643, DOI 10.1021/ma00047a013; Mukamel S, 1997, SCIENCE, V277, P781, DOI 10.1126/science.277.5327.781; Nguyen TQ, 1999, J CHEM PHYS, V110, P4068, DOI 10.1063/1.478288; Noguchi H, 1998, J CHEM PHYS, V109, P5070, DOI 10.1063/1.477121; Orion I, 1998, PHYS REV B, V57, P7050, DOI 10.1103/PhysRevB.57.7050; Padmanaban G, 2000, J AM CHEM SOC, V122, P2244, DOI 10.1021/ja9932481; Thulstrup E.W., 1989, ELEMENTARY POLARIZAT; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; WOO HS, 1993, SYNTHETIC MET, V59, P13, DOI 10.1016/0379-6779(93)91153-S; Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441; Yaliraki SN, 1996, J CHEM PHYS, V104, P1245, DOI 10.1063/1.470782; Yang CY, 1998, POLYMER, V39, P2299, DOI 10.1016/S0032-3861(97)00509-0; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	30	416	419	2	139	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1030	1033		10.1038/35016520	http://dx.doi.org/10.1038/35016520			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890438				2022-12-28	WOS:000087871700038
J	Loder, N				Loder, N			UK studies ways of paying to join Chile observatory	NATURE			English	News Item																		2000, NATURE, V405, P382	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					990	990		10.1038/35016727	http://dx.doi.org/10.1038/35016727			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890417	Bronze			2022-12-28	WOS:000087871700014
J	Muir, G; Fleming, CC; Schlotterer, C				Muir, G; Fleming, CC; Schlotterer, C			Taxonomy - Species status of hybridizing oaks	NATURE			English	Article							QUERCUS-PETRAEA		Queens Univ Belfast, Dept Appl Plant Sci, Belfast BT9 5PX, Antrim, North Ireland; Vet Med Univ Wien, Inst Tierzucht & Genet, A-1210 Vienna, Austria	Queens University Belfast; University of Veterinary Medicine Vienna	Muir, G (corresponding author), Queens Univ Belfast, Dept Appl Plant Sci, Newforge Lane, Belfast BT9 5PX, Antrim, North Ireland.		Schlötterer, Christian/G-6326-2010; Schlötterer, Christian/Q-5264-2019	Schlötterer, Christian/0000-0003-4710-6526; Schlötterer, Christian/0000-0003-4710-6526				Bacilieri R, 1996, EVOLUTION, V50, P900, DOI 10.1111/j.1558-5646.1996.tb03898.x; Bodenes C, 1997, HEREDITY, V78, P433, DOI 10.1038/hdy.1997.67; Burger W. C., 1975, Taxon, V24, P45, DOI 10.2307/1218998; Cornuet JM, 1999, GENETICS, V153, P1989; Dumolin-Lapegue S, 1999, EVOLUTION, V53, P1406, DOI 10.1111/j.1558-5646.1999.tb05405.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERRIS C, 1993, MOL ECOL, V2, P337, DOI 10.1111/j.1365-294X.1993.tb00026.x; Harr B, 1998, CURR BIOL, V8, P1183, DOI 10.1016/S0960-9822(07)00490-3; Rushton B. S., 1983, Irish Forestry, V40, P52; Samuel R, 1999, PLANT SYST EVOL, V217, P137, DOI 10.1007/BF00984926; Zanetto A., 1994, Forest Genetics, V1, P111	11	116	119	0	27	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1016	1016		10.1038/35016640	http://dx.doi.org/10.1038/35016640			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890434	Bronze			2022-12-28	WOS:000087871700034
J	Naylor, RL; Goldburg, RJ; Primavera, JH; Kautsky, N; Beveridge, MCM; Clay, J; Folke, C; Lubchenco, J; Mooney, H; Troell, M				Naylor, RL; Goldburg, RJ; Primavera, JH; Kautsky, N; Beveridge, MCM; Clay, J; Folke, C; Lubchenco, J; Mooney, H; Troell, M			Effect of aquaculture on world fish supplies	NATURE			English	Review							ENVIRONMENTAL-IMPACT; NORTH-SEA; SALMON; MANGROVE; SHRIMP; POPULATIONS; HABITATS; WATERS; ECOSYSTEMS; CHILENSIS	Global production of farmed fish and shellfish has more than doubled in the past 15 years. Many people believe that such growth relieves pressure on ocean fisheries, but the opposite is true for some types of aquaculture. Farming carnivorous species requires large inputs of wild fish for feed. Some aquaculture systems also reduce wild fish supplies through habitat modification, wild seedstock collection and other ecological impacts. On balance, global aquaculture production still adds to world fish supplies; however, if the growing aquaculture industry is to sustain its contribution to world fish supplies, it must reduce wild fish inputs in feed and adopt more ecologically sound management practices.	Stanford Univ, Inst Int Studies, Stanford, CA 94305 USA; Environm Def, New York, NY 10010 USA; SE Asian Fisheries Dev Ctr, Dept Aquaculture, Iloilo 5021, Philippines; Univ Stockholm, Dept Syst Ecol, S-10691 Stockholm, Sweden; Beijer Inst, Stockholm, Sweden; Univ Stirling, Inst Aquaculture, Stirling FK9 4LA, Scotland; World Wildlife Fund, Washington, DC 20037 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA	Stanford University; Southeast Asian Fisheries Development Center; Stockholm University; Royal Swedish Academy of Sciences; Beijer Institute of Ecological Economics; University of Stirling; World Wildlife Fund; Oregon State University	Naylor, RL (corresponding author), Stanford Univ, Inst Int Studies, Encina Hall 400E, Stanford, CA 94305 USA.	roz@leland.stanford.edu	Folke, Carl/Z-1545-2019; Troell, Max/I-1724-2019	Troell, Max/0000-0002-7509-8140; Folke, Carl/0000-0002-4050-3281				Bagarinao T, 1998, TROPICAL MARICULTURE, P381, DOI 10.1016/B978-012210845-7/50012-X; Bagarinao T., 1986, P728; Baily C., 1997, WORLD AQUACUL, V27, P28; BANERJEE BK, 1993, SHRIMP BYCATCH W BEN; Bardach J. E., 1972, AQUACULTURE FARMING; Barlow S., 1989, FISH FARMER      OCT, V43, P40; Black K.D., 1998, BIOL FARMED FISH, P114; Braaten B, 1983, ICES COASTAL MANAGEM, V26, P11; Brown EG, 1998, MAR ECOL PROG SER, V167, P275, DOI 10.3354/meps167275; CAMACHO AS, 1987, RAS79002 UNDPUNESCO; Cremer M.C., 1999, INT AQUAFEED DIRECTO, P19; Crook F. W., 1999, Agricultural Outlook, P13; DALZELL P, 1987, REV FISHERIES SMALL; De Silva SS., 1994, FISH NUTR AQUACULTUR, P320; El-Sayed AFM, 1999, AQUACULTURE, V179, P149, DOI 10.1016/S0044-8486(99)00159-3; Ervik A, 1997, AQUACULTURE, V158, P85, DOI 10.1016/S0044-8486(97)00186-5; *FAO, 1998, 815 FAO; *FAO, 1999, AQ PROD STAT 1988 19; FISCHER J, 1997, INTERECOSYSTEM IMPAC; FOLKE C, 1989, AMBIO, V18, P234; FORSTER J, 1999, WORLD AQUACULTURE MA, V30, P69; FORSTER J, 1999, WORLD AQUACULTURE MA, V30, P35; FORSTER J, 1999, WORLD AQUACULTURE MA, V30, P40; Forster J, 1999, WORLD AQUACULTURE MA, V30, P35; GOWEN RJ, 1987, OCEANOGR MAR BIOL, V25, P563; Gross MR, 1998, CAN J FISH AQUAT SCI, V55, P131, DOI 10.1139/cjfas-55-S1-131; H. M. Johnson and Associates, 1998, ANN REPORT US SEAFOO; HAMER KC, 1993, IBIS, V135, P255, DOI 10.1111/j.1474-919X.1993.tb02842.x; Hansen L. P., 1993, Aquaculture and Fisheries Management, V24, P777, DOI 10.1111/j.1365-2109.1993.tb00657.x; Hargreaves JA, 1998, AQUACULTURE, V166, P181, DOI 10.1016/S0044-8486(98)00298-1; Hislop JRG, 1996, ICES J MAR SCI, V53, P1146, DOI 10.1006/jmsc.1996.0140; HUTTENBAUER S, 1999, ENTREPRENEURSHIP FOO; Islam M.M., 1997, Journal of the Marine Biological Association of India, V38, P1; IWAMA GK, 1991, CRIT REV ENV CONTR, V21, P177, DOI 10.1080/10643389109388413; JONES TO, 1991, AQUACULTURE, V92, P313, DOI 10.1016/0044-8486(91)90037-8; Lightner DV, 1997, REV SCI TECH OIE, V16, P146, DOI 10.20506/rst.16.1.1010; LIGHTNER DV, 1996, HDB SHRIMP PATHOLOGI; Lim C., 1991, P AQ FEED PROC NUTR, P163; Mark Freeberg J.G.Pope, 1994, GLOBAL ASSESSMENT FI; Martosubroto P., 1977, MAR RES INDONES, V18, P81; McGinnity P, 1997, ICES J MAR SCI, V54, P998, DOI 10.1016/S1054-3139(97)80004-5; McKinnell S, 1997, ICES J MAR SCI, V54, P1221, DOI 10.1016/S1054-3139(97)80029-X; McVicar AH, 1997, ICES J MAR SCI, V54, P1093, DOI 10.1016/S1054-3139(97)80014-8; Menasveta Piamsak, 1997, World Aquaculture, V28, P36; Milazzo, 1998, WORLD BANK TECHNICAL; MONAGHAN P, 1992, BIODIVERS CONSERV, V1, P98, DOI 10.1007/BF00731037; Mooney JW, 1998, J SCI FOOD AGR, V78, P134, DOI 10.1002/(SICI)1097-0010(199809)78:1&lt;134::AID-JSFA96&gt;3.0.CO;2-0; Morris CA, 1995, J FOOD SCI, V60, P1225, DOI 10.1111/j.1365-2621.1995.tb04561.x; Muir JF, 1998, J NW ATL FISH SCI, V23, P157; MUNRO JJ, 1994, REEF FISHERIES, P1; Nadala ECB, 1998, DIS AQUAT ORGAN, V33, P231, DOI 10.3354/dao033231; National Research Council, 1999, SUST MAR FISH; Naylor RL, 1998, SCIENCE, V282, P883, DOI 10.1126/science.282.5390.883; Neori A, 1996, AQUACULTURE, V141, P183, DOI 10.1016/0044-8486(95)01223-0; Nunan LM, 1998, AQUACULTURE, V160, P19, DOI 10.1016/S0044-8486(97)00222-6; Odum Eugene, 1979, FUNDAMENTALS ECOLOGY; OGDEN JC, 1988, 6TH P INT COR REEF S, V1, P123; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; PAULY D, 1987, PERUVIAN ANCHOVETA I, P325; Phang SM, 1996, HYDROBIOLOGIA, V327, P347, DOI 10.1007/BF00047829; Phillips RA, 1996, IBIS, V138, P410, DOI 10.1111/j.1474-919X.1996.tb08059.x; PIKE I, 1998, INT AQUAFEEDS, V1, P5; PIKE IH, 1998, INT AQUAFEED DIRECTO, P39; PILARCZYK A, 1995, AQUACULTURE, V129, P425, DOI 10.1016/0044-8486(94)00281-R; Pond C.M., 1998, FATS LIFE; Primavera JH, 1997, J EXP MAR BIOL ECOL, V215, P205, DOI 10.1016/S0022-0981(97)00046-4; Primavera JH, 1998, ESTUAR COAST SHELF S, V46, P457, DOI 10.1006/ecss.1997.0275; ROBERTSON AI, 1987, MAR BIOL, V96, P193, DOI 10.1007/BF00427019; ROBINSON E, 1998, INT AQUAFEED, V1, P15; Ronnback P, 1999, ESTUAR COAST SHELF S, V48, P223, DOI 10.1006/ecss.1998.0415; Ronnback P, 1999, ECOL ECON, V29, P235, DOI 10.1016/S0921-8009(99)00016-6; ROSENBERRRY B, 1998, WORLD SHRIMP FARMING; Sasekumar A., 1987, P 10 ANN SEM MAL SOC, P10; SASEKUMAR A, 1994, P 3 ASEAN AUSTR S LI, V1, P139; SINGH HR, 1994, P 3 ASEAN AUSTR S LI, P105; Slaney TL, 1996, FISHERIES, V21, P20, DOI 10.1577/1548-8446(1996)021<0020:SOASAT>2.0.CO;2; Soto D, 1999, AQUACULTURE, V171, P65, DOI 10.1016/S0044-8486(98)00420-7; Steffens W, 1997, AQUACULTURE, V151, P97, DOI 10.1016/S0044-8486(96)01493-7; TACON A, 1999, INT AQUAFEED, V2, P5; Tacon A., 1998, INT AQUAFEEDS, V2, P13; Tacon A. G. J., 1998, INT AQUAFEED DIRECTO, P5; Tacon A.G.J., 1996, WORLD AQUACULT, V27, P20; Tacon A.J., 1997, FAO FISHERIES CIRCUL, V886, P17; Tacon AGJ, 1997, AQUACULTURE, V151, P379, DOI 10.1016/S0044-8486(96)01494-9; TACON AGJ, 1994, FEED INGREDIENTS CAR; TRINIDAD AC, 1993, BIOECONOMICS PHILIPP; Troell M, 1999, J APPL PHYCOL, V11, P89, DOI 10.1023/A:1008070400208; Troell M, 1997, AQUACULTURE, V156, P45, DOI 10.1016/S0044-8486(97)00080-X; Webster CD, 1999, J WORLD AQUACULT SOC, V30, P443, DOI 10.1111/j.1749-7345.1999.tb00992.x; Williams M. J., 1997, Sustainable aquaculture., P15; World Forum of Fish Harvesters and Fish Workers (WFF), 1999, COORD COMM M REP SAN; Wright PJ, 1997, ICES J MAR SCI, V54, P578, DOI 10.1006/jmsc.1997.0245; YANEZARANCIBIA A, 1993, HYDROBIOLOGIA, V264, P1, DOI 10.1007/BF00014659	94	1908	2038	41	1136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1017	1024		10.1038/35016500	http://dx.doi.org/10.1038/35016500			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890435				2022-12-28	WOS:000087871700035
J	Wenk, HR; Matthies, S; Hemley, RJ; Mao, HK; Shu, J				Wenk, HR; Matthies, S; Hemley, RJ; Mao, HK; Shu, J			The plastic deformation of iron at pressures of the Earth's inner core	NATURE			English	Article							X-RAY-DIFFRACTION; TRAVEL-TIMES; IN-SITU; ANISOTROPY; TEMPERATURE; CONVECTION; ELASTICITY; ZIRCONIUM; SYSTEM; SLIP	Soon after the discovery of seismic anisotropy in the Earth's inner core(1), it was suggested that crystal alignment attained during deformation might be responsible(2). Since then, several other mechanisms have been proposed to account for the observed anisotropy(3,4), but the lack of deformation experiments performed at the extreme pressure conditions corresponding to the solid inner core has limited our ability to determine which deformation mechanism applies to this region of the Earth(5). Here we determine directly the elastic and plastic deformation mechanism of iron at pressures of the Earth's core, from synchrotron X-ray diffraction measurements of iron, under imposed axial stress, in diamond-anvil cells. The epsilon-iron (hexagonally close packed) crystals display strong preferred orientation, with c-axes parallel to the axis of the diamond-anvil cell. Polycrystal plasticity theory predicts an alignment of c-axes parallel to the compression direction as a result of basal slip, if basal slip is either the primary or a secondary slip system. The experiments provide direct observations of deformation mechanisms that occur in the Earth's inner core, and introduce a method for investigating, within the laboratory, the rheology of materials at extreme pressures.	Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Washington, Ctr High Pressure Res, Washington, DC 20015 USA	University of California System; University of California Berkeley; Carnegie Institution for Science; Carnegie Institution for Science	Wenk, HR (corresponding author), Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA.							AKHTAR A, 1973, ACTA METALL MATER, V21, P1, DOI 10.1016/0001-6160(73)90213-7; Andrault D, 1997, SCIENCE, V278, P831, DOI 10.1126/science.278.5339.831; BITTORF C, 1998, INTERMETALLICS, V7, P1; Greenspan J, 1965, BERYLLIUM ITS METALL, P240; HAUK V, 1979, Z METALLKD, V70, P500; Hemley RJ, 1997, SCIENCE, V276, P1242, DOI 10.1126/science.276.5316.1242; JEANLOZ R, 1988, GEOPHYS RES LETT, V15, P72, DOI 10.1029/GL015i001p00072; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; Karato S, 1999, NATURE, V402, P871, DOI 10.1038/47235; Kocks U.F., 1998, PREFERRED ORIENTATIO; LEBENSOHN RA, 1993, ACTA METALL MATER, V41, P2611, DOI 10.1016/0956-7151(93)90130-K; Mao HK, 1998, NATURE, V396, P741, DOI 10.1038/25506; MAO HK, 1990, J GEOPHYS RES-SOLID, V95, P21737, DOI 10.1029/JB095iB13p21737; MORELLI A, 1986, GEOPHYS RES LETT, V13, P1545, DOI 10.1029/GL013i013p01545; Poirier JP, 1999, PHYS EARTH PLANET IN, V110, P147, DOI 10.1016/S0031-9201(98)00131-9; PRANTIL VC, 1995, J MECH PHYS SOLIDS, V43, P1283, DOI 10.1016/0022-5096(95)00019-F; Romanowicz B, 1996, SCIENCE, V274, P963, DOI 10.1126/science.274.5289.963; SAXENA SK, 1995, SCIENCE, V269, P1703, DOI 10.1126/science.269.5231.1703; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P19647, DOI 10.1029/94JB01470; Shen GY, 1998, REV MINERAL, V37, P369; Singh AK, 1998, PHYS REV LETT, V80, P2157, DOI 10.1103/PhysRevLett.80.2157; Soderlind P, 1996, PHYS REV B, V53, P14063, DOI 10.1103/PhysRevB.53.14063; Song XD, 1997, REV GEOPHYS, V35, P297, DOI 10.1029/97RG01285; Stixrude L, 1998, REV MINERAL, V37, P261; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; SU WJ, 1995, J GEOPHYS RES-SOL EA, V100, P9831, DOI 10.1029/95JB00746; TENCKHOFF E, 1978, METALL TRANS A, V9, P1401, DOI 10.1007/BF02661811; Wenk HR, 2000, J GEOPHYS RES-SOL EA, V105, P5663, DOI 10.1029/1999JB900346; Wenk HR, 1998, J APPL CRYSTALLOGR, V31, P262, DOI 10.1107/S002188989700811X; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473	30	137	141	2	45	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1044	1047		10.1038/35016558	http://dx.doi.org/10.1038/35016558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890442				2022-12-28	WOS:000087871700042
J	Hopfner, KP; Karcher, A; Shin, DS; Craig, L; Arthur, LM; Carney, JP; Tainer, JA				Hopfner, KP; Karcher, A; Shin, DS; Craig, L; Arthur, LM; Carney, JP; Tainer, JA			Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily	CELL			English	Article							GTPASE-ACTIVATING PROTEINS; NUCLEOTIDE-BINDING FOLD; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; HISTIDINE PERMEASE; IONIZING-RADIATION; CRYSTAL-STRUCTURE; CHROMOSOMES SMC; MULTIDRUG-RESISTANCE; TRANSITION-STATE	To clarify the key role of Rad50 in DNA double-strand break repair (DSBR), we biochemically and structurally characterized ATP-bound and ATP-free Rad50 catalytic domain (Rad50cd) from Pyrococcus furiosus. Rad50cd displays ATPase activity plus ATP-controlled dimerization and DNA binding activities. Rad50cd crystal structures identify probable protein and DNA interfaces and reveal an ABC-ATPase fold, linking Rad50 molecular mechanisms to ABC transporters, including P glycoprotein and cystic fibrosis transmembrane conductance regulator. Binding of ATP gamma-phosphates to conserved signature motifs in two opposing Rad50cd molecules promotes dimerization that likely couples ATP hydrolysis to dimer dissociation and DNA release. These results, validated by mutations, suggest unified molecular mechanisms for ATP-driven cooperativity and allosteric control of ABC-ATPases in DSBR, membrane transport, and chromosome condensation by SMC proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Radiat Oncol,Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Mol & Cell Biol Grad Program, Baltimore, MD 21201 USA	Scripps Research Institute; Scripps Research Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tainer, JA (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022; Hopfner, Karl-Peter/B-6864-2014	Tainer, John/0000-0003-1659-2429; Hopfner, Karl-Peter/0000-0002-4528-8357; Craig, Lisa/0000-0001-8515-9915	PHS HHS [H1076950] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; ARMSTRONG S, 1998, PEDIAT PULMONOL, V17, P91; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; KADYK LC, 1992, GENETICS, V132, P387; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; LEACH DRF, 1996, GENETIC RECOMBINATIO; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; McKee AHZ, 1997, GENETICS, V146, P797; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Roth D., 1988, GENETIC RECOMBINATIO, P621; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; Sprang SR, 1997, CURR OPIN STRUC BIOL, V7, P849, DOI 10.1016/S0959-440X(97)80157-1; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; TURK D, 1992, THESIS TU MUNCHEN; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; van den Ent F, 1999, STRUCTURE, V7, P1181, DOI 10.1016/S0969-2126(00)80052-0; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Zdzienicka MZ, 1996, CANCER SURV, V28, P281; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	73	797	810	1	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					789	800		10.1016/S0092-8674(00)80890-9	http://dx.doi.org/10.1016/S0092-8674(00)80890-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892749	Bronze			2022-12-28	WOS:000087821400012
J	Olson, EN; Williams, RS				Olson, EN; Williams, RS			Calcineurin signaling and muscle remodeling	CELL			English	Review							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; FIBER-TYPE; SKELETAL; GENE; CA2+		Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	eolsen@hamon.swmed.edu						Calvo S, 1999, MOL CELL BIOL, V19, P515; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tsao LN, 2000, NAT MED, V6, P2, DOI 10.1038/71478; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	20	225	239	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					689	692		10.1016/S0092-8674(00)80880-6	http://dx.doi.org/10.1016/S0092-8674(00)80880-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892739	Bronze			2022-12-28	WOS:000087821400002
J	Magavi, SS; Leavitt, BR; Macklis, JD				Magavi, SS; Leavitt, BR; Macklis, JD			Induction of neurogenesis in the neocortex of adult mice	NATURE			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; NEURAL STEM-CELLS; SUBVENTRICULAR ZONE; MAMMALIAN FOREBRAIN; EMBRYONIC NEURONS; GENERATED NEURONS; GROWTH-FACTOR; MOUSE BRAIN; RAT; MIGRATION	Neurogenesis normally only occurs in limited areas of the adult mammalian brain-the hippocampus(1), olfactory bulb(2-4) and epithelium(5), and at low levels in some regions of macaque cortex(6). Here we show that endogenous neural precursors can be induced in situ to differentiate into mature neurons, in regions of adult mammalian neocortex that do not normally undergo any neurogenesis. This differentiation occurs in a layer- and region-specific manner, and the neurons can re-form appropriate corticothalamic connections. We induced synchronous apoptotic degeneration(7,8) of corticothalamic neurons in layer VI of anterior cortex of adult mice and examined the fates of dividing cells within cortex, using markers for DNA replication (5-bromodeoxyuridine; BrdU) and progressive neuronal differentiation. Newly made, BrdU-positive cells expressed NeuN, a mature neuronal marker, in regions of cortex undergoing targeted neuronal death and survived for at least 28 weeks. Subsets of BrdU+ precursors expressed Doublecortin, a protein found exclusively in migrating neurons(9,10), and Hu, an early neuronal marker(11,12). Retrograde labelling from thalamus demonstrated that BrdU+ neurons can form long-distance corticothalamic connections. Our results indicate that neuronal replacement therapies for neurodegenerative disease and CNS injury may be possible through manipulation of endogenous neural precursors in situ.	Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Macklis, JD (corresponding author), Childrens Hosp, Div Neurosci, Enders 350,320 Longwood Ave, Boston, MA 02115 USA.		Magavi, Sanjay/N-1551-2019; Leavitt, Blair R/G-1934-2012					ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; Craig CG, 1996, J NEUROSCI, V16, P2649; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gould E, 1996, DEV NEUROSCI-BASEL, V18, P22, DOI 10.1159/000111392; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; HernitGrant CS, 1996, EXP NEUROL, V139, P131, DOI 10.1006/exnr.1996.0088; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KIRN JR, 1993, J NEUROSCI, V13, P1654; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; MACKLIS JD, 1993, J NEUROSCI, V13, P3848; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Palmer TD, 1999, J NEUROSCI, V19, P8487; Parent JM, 1997, J NEUROSCI, V17, P3727; REH TA, 1987, J NEUROSCI, V7, P3317; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Scharff C, 2000, NEURON, V25, P481, DOI 10.1016/S0896-6273(00)80910-1; Sheen VL, 1995, J NEUROSCI, V15, P8378; SHIN JS, IN PRESS J NEUROSCI; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Wang YZ, 1998, EXP NEUROL, V154, P389, DOI 10.1006/exnr.1998.6965; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	31	1006	1082	0	80	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					951	955		10.1038/35016083	http://dx.doi.org/10.1038/35016083			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879536				2022-12-28	WOS:000087732700051
J	Wolpert, L				Wolpert, L			The well-spring - About 3,000 years ago, the Greeks invented science.	NATURE			English	Editorial Material									UCL, Dept Anat & Dev Biol, London WC1E 6BT, England	University of London; University College London	Wolpert, L (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.								0	2	2	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					887	887		10.1038/35016166	http://dx.doi.org/10.1038/35016166			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879512				2022-12-28	WOS:000087732700024
J	Lewis, AC; Carslaw, N; Marriott, PJ; Kinghorn, RM; Morrison, P; Lee, AL; Bartle, KD; Pilling, MJ				Lewis, AC; Carslaw, N; Marriott, PJ; Kinghorn, RM; Morrison, P; Lee, AL; Bartle, KD; Pilling, MJ			A larger pool of ozone-forming carbon compounds in urban atmospheres	NATURE			English	Article							2-DIMENSIONAL GAS-CHROMATOGRAPHY; ORGANIC-COMPOUNDS; MECHANISM	Volatile organic compounds play a central role in the processes that generate both urban photochemical smog and tropospheric ozone(1,2). For successful and accurate prediction of these pollution episodes, identification of the dominant reactive species within the volatile organic carbon pool is needed(3). At present, lack of resolution inherent in single-column chromatographic analysis(4) limits such a detailed chemical characterization of the complex urban atmosphere. Here we present an improved method of peak deconvolution from double-column (orthogonal) gas chromatography(5,6). This has enabled us to isolate and classify more than 500 chemical species of volatile organic compounds in urban air, including over 100 multi-substituted monoaromatic and volatile oxygenated hydrocarbons. We suggest that previous assessments of reactive carbon species may therefore have underestimated the contribution made by volatile organic compounds to urban pollution, particularly for compounds with more than six carbon atoms. Incorporating these species in predictive models should greatly improve our understanding of photochemical ozone yields and the formation of harmful secondary organic aerosols(7,8).	Univ Leeds, Sch Chem, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Environm, Leeds LS2 9JT, W Yorkshire, England; RMIT Univ, Dept Appl Chem, Melbourne, Vic 3001, Australia	University of Leeds; University of Leeds; Royal Melbourne Institute of Technology (RMIT)	Lewis, AC (corresponding author), Univ Leeds, Sch Chem, Woodhouse Lane, Leeds LS2 9JT, W Yorkshire, England.	alyl@chem.leeds.ac.uk	Carslaw, Nicola/A-7228-2008; Marriott, Philip J/E-7462-2010; Marriott, Philip J/H-6426-2013; Lewis, Alastair C/A-6721-2008	Carslaw, Nicola/0000-0002-5290-4779; Marriott, Philip J/0000-0001-5180-1041; Lewis, Alastair C/0000-0002-4075-3651				*AUSTR ENV PROT AU, 1998, AIR EM INV PORT PHIL, P4; BUSHEY MM, 1990, ANAL CHEM, V62, P978, DOI 10.1021/ac00209a002; Carslaw N, 1999, J GEOPHYS RES-ATMOS, V104, P30241, DOI 10.1029/1999JD900783; CARTER WPL, 1990, ATMOS ENVIRON A-GEN, V24, P481, DOI 10.1016/0960-1686(90)90005-8; CARTER WPL, 1994, J AIR WASTE MANAGE, V44, P881; Derwent RG, 1998, ATMOS ENVIRON, V32, P2429, DOI 10.1016/S1352-2310(98)00053-3; Duffy BL, 1998, ATMOS ENVIRON, V32, P2693, DOI 10.1016/S1352-2310(97)00367-1; Forstner HJL, 1997, ENVIRON SCI TECHNOL, V31, P1345, DOI 10.1021/es9605376; FOWLER D, 1997, 4 PHOT OX REV GROUP, P75; Gaines RB, 1999, ENVIRON SCI TECHNOL, V33, P2106, DOI 10.1021/es9810484; GIDDINGS JC, 1990, MULTIDIMENSIONAL CHR, P1; Houweling S, 1998, J GEOPHYS RES-ATMOS, V103, P10673, DOI 10.1029/97JD03582; Kinghorn RM, 1998, HRC-J HIGH RES CHROM, V21, P620; Lewis AC, 1996, HRC-J HIGH RES CHROM, V19, P686; LIU ZY, 1991, J CHROMATOGR SCI, V29, P227, DOI 10.1093/chromsci/29.6.227; MADRONICH S, 1990, J GEOPHYS RES-ATMOS, V95, P5697, DOI 10.1029/JD095iD05p05697; Marriott PJ, 1998, ANAL SCI, V14, P651, DOI 10.2116/analsci.14.651; McKeen SA, 1997, J GEOPHYS RES-ATMOS, V102, P6467, DOI 10.1029/96JD03322; MCMINN DG, 1992, DETECTORS CAPILLARY, P15; Stockwell WR, 1997, J GEOPHYS RES-ATMOS, V102, P25847, DOI 10.1029/97JD00849; VENKATRAMANI CJ, 1993, J MICROCOLUMN SEP, V5, P511, DOI 10.1002/mcs.1220050604	21	273	281	6	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					778	781		10.1038/35015540	http://dx.doi.org/10.1038/35015540			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866195				2022-12-28	WOS:000087620600046
J	Vukmirovic, OG; Tilghman, SM				Vukmirovic, OG; Tilghman, SM			Exploring genome space	NATURE			English	Article							ANGSTROM-RESOLUTION; CRYSTAL-STRUCTURE; PROTEIN; GENES	The completion of entire genome sequences of many experimental organisms, and the promise that the human genome will be completed in the next year, find biology suddenly awash in genome-based data. Scientists are scrambling to develop new technologies that exploit genome data to ask entirely new kinds of questions about the complex nature of living cells.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Vukmirovic, OG (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							ADAMS MD, SCIENCE, V287, P2185; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	12	66	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					820	822		10.1038/35015690	http://dx.doi.org/10.1038/35015690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866207				2022-12-28	WOS:000087620600059
J	Ugalde, A; Selva-Sutter, E; Castillo, C; Paz, C; Canas, S				Ugalde, A; Selva-Sutter, E; Castillo, C; Paz, C; Canas, S			Conflict and health - The health costs of war: can they be measured? Lessons from El Salvador	BRITISH MEDICAL JOURNAL			English	Article							VIOLENCE		Univ Texas, Dept Sociol, Austin, TX 78712 USA; Univ Ctr Amer Jose Simeon Canas, Dept Publ Hlth, San Salvador, El Salvador	University of Texas System; University of Texas Austin	Ugalde, A (corresponding author), Univ Texas, Dept Sociol, Austin, TX 78712 USA.							ARGUELLO R, 1994, MEDIO AMBIENTE SALUD; AYALDE J, 1994, PERFIL EPIDEMIOLOGIC; BARRY T, 1991, EL SALVADOR COUNTRY; Betancur Belisario, 1993, MADNESS HOPE 12 YEAR; CAGAN B, 1991, PROMISED LAND EL SAL; CERVANTES RC, 1989, HOSP COMMUNITY PSYCH, V40, P615; *FESAL 93, 1994, NAT HLTH SURV; GARFIELD RM, 1989, SOC SCI MED, V28, P669, DOI 10.1016/0277-9536(89)90214-1; Garst R., 1990, FEEDING CRISIS US FO; GODFREY N, 1989, SOC SCI MED, V28, P707, DOI 10.1016/0277-9536(89)90218-9; ITYAVYAR DA, 1989, SOC SCI MED, V28, P649, DOI 10.1016/0277-9536(89)90212-8; LARA T, 1994, RESCATE AUTOGESTION; Levy Barry S, 1997, WAR PUBLIC HLTH; LUNDGREN RI, 1989, SOC SCI MED, V28, P697, DOI 10.1016/0277-9536(89)90217-7; Macrae J, 1996, SOC SCI MED, V42, P1095, DOI 10.1016/0277-9536(95)00338-X; MONTGOMERY TS, 1995, REVOLUTION EL SALVAD; MOREL A, 1991, REFUGIADOS SALVADORE; MOZO SM, 1988, SALVADORAN MIGRATION; *PRISMA, 1995, EL SALV DIN DEGR AMB; *PROGR NAC UN DES, 1994, HOR PAZ DES HUM SAL; SANCHEZ SI, 1995, REALIDAD, V47, P747; SCHRADING R, 1991, EXODO AM LATINA MOVI; SISTI E, 1995, SALUD MENTAL BASE; *UNICEF, 1995, CLEAR MIN STEP PEAC; ZWI A, 1991, HEALTH POLICY PLANN, V6, P203, DOI 10.1093/heapol/6.3.203	25	21	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					169	172		10.1136/bmj.321.7254.169	http://dx.doi.org/10.1136/bmj.321.7254.169			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336MG	10894700	Green Published			2022-12-28	WOS:000088305700028
J	Davey, RT; Murphy, RL; Graziano, FM; Boswell, SL; Pavia, AT; Cancio, M; Nadler, JP; Chaitt, DG; Dewar, RL; Sahner, DK; Duliege, AM; Capra, WB; Leong, WP; Giedlin, MA; Lane, HC; Kahn, JO				Davey, RT; Murphy, RL; Graziano, FM; Boswell, SL; Pavia, AT; Cancio, M; Nadler, JP; Chaitt, DG; Dewar, RL; Sahner, DK; Duliege, AM; Capra, WB; Leong, WP; Giedlin, MA; Lane, HC; Kahn, JO			Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS INTERLEUKIN-2; INFECTION; TYPE-1; ZIDOVUDINE; PLASMA; HAART	Context While interleukin 2 (IL-2) is capable of inducing a marked expansion of the CD4 T-lymphocyte pool, limited data exist on whether IL-2 treatment can add significantly to the immunologic and virologic effects of potent antiretroviral therapy (ART). Objective To determine the rate and magnitude of CD4 cell recovery and viral suppression when using a combination therapy of IL-2 and ART com pared with ART alone. Design and Setting Randomized, controlled multicenter trial conducted from April 1996 through April 1998 at 8 clinical sites in the United States. Patients Eighty-two adult outpatients who were infected with human immunodeficiency virus (HIV) and had baseline CD4 cell counts of 200 x 10(6)/L to 500 x 10(6)/L and baseline RNA levels of fewer than 10 000 copies/mL were randomized; 78 completed the study. Interventions Thirty-nine patients were randomly assigned to receive a combination therapy of subcutaneous IL-2 (administered in 5-day courses every 8 weeks at a starting dosage of 7.5 mIU twice per day) and ART; 43 were to receive ART therapy alone. Main Outcome Measures Interleukin 2 safety and differential effects on CD4 cell counts, CD4 cell percentages, and plasma HIV RNA levels. Results The mean (SD) percentage increase in CD4 cell counts at 1 year for patients who received IL-2 was 112% (113%) compared with 18% (35%) in recipients of ART alone (P<.001). Both groups had, mean (SD) increases in CD4 cell percentage: from 20.4% (6.3%) to 32.3% (12.4%) for the combination therapy group compared with 20.4% (5.1%) to 23.0% (7.2%) for recipients of ART alone (P<.001). Using a sensitive viral RNA assay, mean viral load changes were -0.28 and 0.09 log(10) copies for IL-2 recipients and control patients, respectively (P=.03). Twenty (67%) of 30 evaluable patients receiving IL-2 achieved final viral loads of fewer than 50 copies/mL compared with 13 (36%) of 36 control patients (P=.02). Toxic effects were common among patients who received IL-2 and were managed with antipyretics, hydration, rest, and dosage reduction as needed. Conclusions Intermittent therapy with IL-2 and ART produced a substantially greater increase in CD4 cells and was associated with a larger decrease in viral load than ART alone. Clinical end-point trials will be necessary to determine whether the enhanced viral suppression and CD4 cell increases associated with IL-2 therapy will translate into improved clinical outcomes.	NIAID, NIH, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Bethesda, MD 20892 USA; Northwestern Univ, Div Infect Dis, Chicago, IL 60611 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Fenway Community Hlth Ctr, Boston, MA USA; Univ Utah, Div Pediat Infect Dis, Salt Lake City, UT USA; St Josephs Hosp, Tampa, FL USA; Univ S Florida, Div Infect Dis, Tampa, FL USA; Sci Applicat Int Corp, Frederick, MD USA; Chiron Corp, Emeryville, CA 94608 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ctr AIDS Res, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; Northwestern University; University of Wisconsin System; University of Wisconsin Madison; Utah System of Higher Education; University of Utah; State University System of Florida; University of South Florida; Science Applications International Corporation (SAIC); Novartis; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Davey, RT (corresponding author), NIAID, NIH, Bldg 10,Room 11C-103, Bethesda, MD 20892 USA.		Leong, Wai Yie/J-8181-2017	Murphy, Robert/0000-0003-3936-2052	PHPPO CDC HHS [PH30 MH59037] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000390, ZIAAI000390] Funding Source: NIH RePORTER	PHPPO CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arno A, 1999, J INFECT DIS, V180, P56, DOI 10.1086/314831; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, J INFECT DIS, V178, P992, DOI 10.1086/515653; CLARK AGB, 1992, J ACQ IMMUN DEF SYND, V5, P52; Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971; Davey RT, 1999, J INFECT DIS, V179, P849, DOI 10.1086/314678; De Paoli P, 1997, J CLIN INVEST, V100, P2737, DOI 10.1172/JCI119819; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EMERY S, 1998, 5 C RETR OPP INF FEB; Hengge UR, 1998, AIDS, V12, pF225, DOI 10.1097/00002030-199817000-00003; IZOPET J, 1998, 5 C RETR OPP INF FEB; Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KOVACS JA, 1995, NEW ENGL J MED, V332, P567, DOI 10.1056/NEJM199503023320904; Levy Y, 1999, LANCET, V353, P1923, DOI 10.1016/S0140-6736(98)07345-0; MCMAHON DK, 1994, AIDS, V8, P59, DOI 10.1097/00002030-199401000-00009; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PAVUR R, 1986, J STAT COMPUT SIM, V23, P231, DOI 10.1080/00949658608810873; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; Simonelli C, 1999, J ACQ IMMUN DEF SYND, V20, P20, DOI 10.1097/00042560-199901010-00003; URDEA M, 1993, AIDS S2, V7, P11; VANLUNZEN J, 1998, INT CONF AIDS, V12, P787; Zanussi S, 1999, CLIN EXP IMMUNOL, V116, P486; 1992, MMWR MORB MORTAL WKL, V41, P4; 1994, MMWR MORB MORTAL WKL, V42, P1	26	146	149	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					183	189		10.1001/jama.284.2.183	http://dx.doi.org/10.1001/jama.284.2.183			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889591	Bronze			2022-12-28	WOS:000087933100022
J	de Martino, M; Tovo, PA; Balducci, M; Galli, L; Gabiano, C; Rezza, G; Pezzotti, P				de Martino, M; Tovo, PA; Balducci, M; Galli, L; Gabiano, C; Rezza, G; Pezzotti, P		Italian Register HIV Infect Childr	Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; AIDS; TRANSMISSION; SURVIVAL; INFANTS; RISK; MORBIDITY; DURATION; IMPACT	Context Since the introduction of combined antiretroviral therapy, mortality rates in adults with human immunodeficiency virus type 1 (HIV-1) infection have decreased. However, little information is available outside the setting of controlled trials on survival of perinatally HIV-infected children treated with antiretroviral therapy. Objective To assess effect of availability of antiretroviral therapy on decreasing mortality in perinatally HIV-infected children, Design Population-based, multicenter longitudinal study involving data collected by the Italian Register for HIV Infection in Children. Setting A network of 106 pediatric clinical centers. Subjects A total of 1142 children born between November 1980 and December 1997 with perinatally acquired HIV infection with a median follow-up of 5.9 years. Main Outcome Measure Time to HIV-related death calculated for birth cohort and calendar period and grouped by distribution of predominant type of antiretroviral therapy administered over time. Results Survival was longer in the 1996-1997 birth cohort (crude relative hazard [RH] of death, 0.39; 95% confidence interval [CI], 0.15-0.96) and 1996-1998 calendar period (crude RH of death, 0.65; 95% CI, 0.45-0.95) than in birth cohort and calendar period 1980-1995, but not when adjusted for maternal antiretroviral treatment during pregnancy and clinical condition at time of delivery, gestational age, and birth weight (adjusted RH of death, 0.55; 95% CI, 0.20-1.50, for birth cohort; and adjusted RH of death, 0.71, 95% CI, 0.43-1.16, for calendar period). in a multivariate model with 1980-1995 as comparison, the 1996-1997 birth cohort had an RH of 0.57 (95% CI, 0.22-1.47; P=.27) but RH for calendar period 1996-1998 was 0.63 (95% CI, 0.47-0.85; P<.01). When the effects of birth cohort, calendar period, and type of antiretroviral therapy were evaluated simultaneously in the same model, the RH of death was not significantly different from 1.0 for the 1996-1997 birth cohort (P=.19) and calendar period 1996-1998 (P=.83) suggesting a causal relationship between decreased risk of death and use of combination therapy. The RH of death in children receiving monotherapy or double or triple combination therapy was 0.77 (95% CI, 0.55-1.08), 0.70 (95% CI, 0.42-1.17), and 0.29 (95% CI, 0.13-0.67), respectively, vs no antiretroviral therapy. Conclusion Survival of perinatally HIV-infected children improved in 1996-1998 as a result of the introduction of combined antiretroviral therapies.	Univ Florence, Dept Pediat, I-50132 Florence, Italy; Univ Turin, Dept Pediat, I-10124 Turin, Italy; Ist Super Sanita, Ctr Operat AIDS, I-00161 Rome, Italy	University of Florence; University of Turin; Istituto Superiore di Sanita (ISS)	de Martino, M (corresponding author), Univ Florence, Dept Pediat, Via Luca Giordano 13, I-50132 Florence, Italy.	mdm@ao-meyer.toscana.it	Marchisio, Paola G/J-7342-2016; Dodi, Icilio/ABD-9197-2020; Colafati, Giovanna Stefania/J-8937-2018; Canani, Roberto Berni/AAC-4810-2022; PEZZOTTI, PATRIZIO/C-6480-2016; rezza, giovanni/D-4393-2016; Zuccotti, Gianvincenzo/H-8572-2017	Marchisio, Paola G/0000-0002-5691-3920; Dodi, Icilio/0000-0002-6772-4180; Colafati, Giovanna Stefania/0000-0002-1142-4904; Canani, Roberto Berni/0000-0002-5169-9574; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; rezza, giovanni/0000-0003-0268-6790; Zuccotti, Gianvincenzo/0000-0002-2795-9874; Castelli-Gattinara, Guido/0000-0002-3282-7462; Tovo, Pier Angelo/0000-0002-0192-3240; GENOVESE, Orazio/0000-0002-1989-1363; Guarino, Alfredo/0000-0003-0199-0336; Pontali, Emanuele/0000-0002-1085-0442; Bernardi, Stefania/0000-0001-5672-0881				Aboulker JP, 1998, AIDS, V12, pF151; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; [Anonymous], 1996, Lancet, V348, P283; Beck EJ, 1999, AIDS, V13, P2157, DOI 10.1097/00002030-199910220-00020; BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; Burns DN, 1999, LANCET, V354, pS1, DOI 10.1016/S0140-6736(99)90249-0; CLAYTON C, 1993, STAT MODELS EPIDEMIO; de Martino M, 1999, AIDS, V13, P927, DOI 10.1097/00002030-199905280-00008; de Martino M, 1999, ACTA PAEDIATR, V88, P228, DOI 10.1080/08035259950170457; DEMARTINO M, 1992, AIDS, V6, P991, DOI 10.1097/00002030-199209000-00013; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; DEMARTINO M, 1994, LANCET, V343, P191; DEMARTINO M, 1993, AIDS, V7, P134, DOI 10.1097/00002030-199301000-00027; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; GABIANO C, 1992, PEDIATRICS, V90, P369; GALLI L, 1995, AIDS, V9, P455, DOI 10.1097/00002030-199509050-00007; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Haynes BF, 1999, CLIN IMMUNOL, V92, P3, DOI 10.1006/clim.1999.4738; *IT REG HIV INF CH, 1994, ACTA PAEDIATR, V400, P15; Kline MW, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e47; Krogstad P, 1999, CLIN IMMUNOL, V92, P25, DOI 10.1006/clim.1999.4728; Kuhn L, 1999, J INFECT DIS, V179, P52, DOI 10.1086/314551; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017; MUNOZ A, 1995, AIDS CLIN TRIALS, P423; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013; Porta D, 1999, AIDS, V13, P2125, DOI 10.1097/00002030-199910220-00016; Sabin CA, 1999, AIDS, V13, P2165, DOI 10.1097/00002030-199910220-00021; Sharland M, 1998, LANCET, V352, P577, DOI 10.1016/S0140-6736(05)79289-8; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Stuart JWTC, 1998, AIDS, V12, P2155, DOI 10.1097/00002030-199816000-00010; TOVO PA, 1988, LANCET, V2, P1043; Tovo PA, 1996, J ACQ IMMUN DEF SYND, V11, P88, DOI 10.1097/00042560-199601010-00012; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V	39	257	268	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					190	197		10.1001/jama.284.2.190	http://dx.doi.org/10.1001/jama.284.2.190			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889592	Bronze			2022-12-28	WOS:000087933100023
J	Elmore-Meegan, MK				Elmore-Meegan, MK			I held him in my arms and wept	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					152	152		10.1001/jama.284.2.152	http://dx.doi.org/10.1001/jama.284.2.152			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889571				2022-12-28	WOS:000087933100001
J	Nieuwkerk, PT; Reijers, MHE; Weigel, HM; Lange, JMA; Sprangers, MAG				Nieuwkerk, PT; Reijers, MHE; Weigel, HM; Lange, JMA; Sprangers, MAG			Quality of life in maintenance vs prolonged induction therapy for HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Onze Lieve Vrouw Hosp, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Onze Lieve Vrouwe Gasthuis Hospital	Nieuwkerk, PT (corresponding author), Univ Amsterdam, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Reijers, M.H.E./L-4594-2015; Nieuwkerk, Pythia/S-4084-2017	Nieuwkerk, Pythia/0000-0002-2616-1414				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	6	11	11	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					178	179		10.1001/jama.284.2.178	http://dx.doi.org/10.1001/jama.284.2.178			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889587				2022-12-28	WOS:000087933100018
J	Brooks, R				Brooks, R			Negative genetic correlation between male sexual attractiveness and survival	NATURE			English	Article							POECILIA-RETICULATA; SELECTION; CHROMOSOME; EVOLUTION; GUPPIES; POPULATION; VIABILITY; GROWTH	Indirect selection of female mating preferences may result from a genetic association between male attractiveness and offspring fitness(1,2). The offspring of attractive males may have enhanced growth(3-5), fecundity(3,4), viability(5-8) or attractiveness(4,9-11). However, the extent to which attractive males bear genes that reduce other fitness components has remained unexplored. Here I show that sexual attractiveness in male guppies (Poecilia reticulata) is heritable and genetically correlated with ornamentation. Like ornamentation(12-14), attractiveness may be substantially Y-linked. The benefit of mating with attractive males, and thus having attractive sons, is opposed by strong negative genetic correlation between attractiveness and both offspring survival and the number of sons maturing. Such correlations suggest either antagonistic pleiotropy between attractiveness and survival or linkage disequilibrium between attractive and deleterious alleles. The presence of many colour pattern genes on or near the nonrecombining section of the Y chromosome may facilitate the accumulation of deleterious mutations by genetic hitchhiking(15,16). These findings show that genes enhancing sexual attractiveness may be associated with pleiotropic costs or heavy mutational loads.	James Cook Univ N Queensland, Sch Trop Biol, Townsville, Qld 4811, Australia	James Cook University	Brooks, R (corresponding author), James Cook Univ N Queensland, Sch Trop Biol, Townsville, Qld 4811, Australia.	rob.brooks@jcu.edu.au	Langerhans, R. Brian/A-7205-2009; Brooks, Robert/A-1251-2008	Brooks, Robert/0000-0001-6926-0781				Andersson Malte, 1994; Angus R.A., 1989, P51; Blows MW, 1998, AM NAT, V152, P826, DOI 10.1086/286211; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Etges WJ, 1996, EVOLUTION, V50, P2095, DOI 10.1111/j.1558-5646.1996.tb03596.x; FARR JA, 1981, HEREDITY, V47, P237, DOI 10.1038/hdy.1981.79; Fisher R.A., 1930, GENETICAL THEORY NAT; GILMOUR AR, 1999, ASREML SOFTWARE; HASKINS CP, 1970, HEREDITY, V25, P575, DOI 10.1038/hdy.1970.64; Houde A.E., 1997, SEX COLOR MATE CHOIC; HOUDE AE, 1992, HEREDITY, V69, P229, DOI 10.1038/hdy.1992.120; Jones TM, 1998, P ROY SOC B-BIOL SCI, V265, P1651, DOI 10.1098/rspb.1998.0484; Lynch M., 1998, GENETICS ANAL QUANTI; Moller AP, 1999, P ROY SOC B-BIOL SCI, V266, P85, DOI 10.1098/rspb.1999.0607; MOORE AJ, 1994, BEHAV ECOL SOCIOBIOL, V35, P235, DOI 10.1007/s002650050093; NAYUDU PL, 1979, COPEIA, P225, DOI 10.2307/1443407; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; REYNOLDS JD, 1992, P ROY SOC B-BIOL SCI, V250, P57, DOI 10.1098/rspb.1992.0130; Reznick DN, 1996, EVOLUTION, V50, P1651, DOI 10.1111/j.1558-5646.1996.tb03937.x; RICE WR, 1994, SCIENCE, V263, P230, DOI 10.1126/science.8284674; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1987, GENETICS, V116, P161; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; RODLAN ERS, 1999, TRENDS ECOL EVOL, V14, P58; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; VONSCHANTZ T, 1995, HEREDITY, V75, P518, DOI 10.1038/hdy.1995.168; Wedell N, 1999, EVOLUTION, V53, P620, DOI 10.1111/j.1558-5646.1999.tb03797.x; YAMAMOTO T, 1975, HDB GENETICS	29	206	208	1	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					67	70		10.1038/35017552	http://dx.doi.org/10.1038/35017552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894542				2022-12-28	WOS:000087991200045
J	Lopinski, GP; Wayner, DDM; Wolkow, RA				Lopinski, GP; Wayner, DDM; Wolkow, RA			Self-directed growth of molecular nanostructures on silicon	NATURE			English	Article							SCANNING TUNNELING MICROSCOPE; SURFACE; CONDUCTANCE; HYDROGEN; SI(001); ADSORPTION; MONOLAYERS; ETHYLENE; SI(100); WIRES	Advances in techniques for the nanoscale manipulation of matter are important for the realization of molecule-based miniature devices(1-8) with new or advanced functions. A particularly promising approach involves the construction of hybrid organic-molecule/silicon devices(9-14). But challenges remain-both in the formation of nanostructures that will constitute the active parts of future devices, and in the construction of commensurately small connecting wires. Atom-by-atom crafting of structures with scanning tunnelling microscopes(15-17), although essential to fundamental advances, is too slow for any practical fabrication process; self-assembly approaches may permit rapid fabrication(18), but lack the ability to control growth location and shape. Furthermore, molecular diffusion on silicon is greatly inhibited(19), thereby presenting a problem for self-assembly techniques. Here we report an approach for fabricating nanoscale organic structures on silicon surfaces, employing minimal intervention by the tip of a scanning tunnelling microscope and a spontaneous self-directed chemical growth process. We demonstrate growth of straight molecular styrene lines-each composed of many organic molecules-and the crystalline silicon substrate determines both the orientation of the lines and the molecular spacing within these lines. This process should, in principle, allow parallel fabrication of identical complex functional structures.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Wolkow, RA (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	bob.wolkow@nrc.ca	Wayner, Danial D M/AAT-2059-2020	Wayner, Danial D M/0000-0002-1757-0793; Lopinski, Gregory/0000-0001-7621-4898				AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Avouris P, 1996, SURF SCI, V363, P368, DOI 10.1016/0039-6028(96)00163-X; BOLAND JJ, 1992, SURF SCI, V261, P17, DOI 10.1016/0039-6028(92)90214-Q; BOZACK MJ, 1986, SURF SCI, V177, P933; CICERO RL, IN PRESS LANGMUIR; Cohen R, 1997, CHEM PHYS LETT, V279, P270, DOI 10.1016/S0009-2614(97)01070-1; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Fisher AJ, 1997, SURF SCI, V374, P298, DOI 10.1016/S0039-6028(96)01190-9; Hamers RJ, 1997, J PHYS CHEM B, V101, P1489, DOI 10.1021/jp9626778; HATA K, IN PRESS J VAC SCI T; Hitosugi T, 1999, PHYS REV LETT, V82, P4034, DOI 10.1103/PhysRevLett.82.4034; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; LINFORD MR, 1995, J AM CHEM SOC, V117, P3145, DOI 10.1021/ja00116a019; Lopinski GP, 1998, NATURE, V392, P909, DOI 10.1038/31913; MAYNE AJ, 1993, SURF SCI, V284, P247, DOI 10.1016/0039-6028(93)90495-6; MO WY, 1991, PHYS REV LETT, V66, P1998; Ness H, 1999, PHYS REV LETT, V83, P452, DOI 10.1103/PhysRevLett.83.452; Nogami J, 1997, NATO ADV SCI I E-APP, V341, P11; ODRISCOLL KF, 1976, J POLYM SCI POL CHEM, V14, P869, DOI 10.1002/pol.1976.170140408; Pan W, 1997, J CHEM PHYS, V107, P3981, DOI 10.1063/1.474753; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Shen TC, 1997, PHYS REV LETT, V78, P1271, DOI 10.1103/PhysRevLett.78.1271; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tian WD, 1998, J CHEM PHYS, V109, P2874, DOI 10.1063/1.476841; Wolkow RA, 1999, ANNU REV PHYS CHEM, V50, P413, DOI 10.1146/annurev.physchem.50.1.413; Wolkow RA, 1995, J CHEM PHYS, V103, P10696, DOI 10.1063/1.469856; Wolkow RA, 1998, SURF SCI, V416, pL1107, DOI 10.1016/S0039-6028(98)00629-3; YOSHINOBU J, 1987, J CHEM PHYS, V87, P7332, DOI 10.1063/1.453327	30	546	549	1	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					48	51		10.1038/35017519	http://dx.doi.org/10.1038/35017519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894535				2022-12-28	WOS:000087991200038
J	Wu, H; Wang, ZH; Yan, A; Lyle, S; Fakharzadeh, S; Wahl, JK; Wheelock, MJ; Ishikawa, H; Uitto, J; Amagai, M; Stanley, JR				Wu, H; Wang, ZH; Yan, A; Lyle, S; Fakharzadeh, S; Wahl, JK; Wheelock, MJ; Ishikawa, H; Uitto, J; Amagai, M; Stanley, JR			Protection against pemphigus foliaceus by desmoglein 3 in neonates.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VULGARIS ANTIGEN; EXPRESSION; MICE; AUTOANTIBODIES; LOCALIZATION; EPIDERMIS; FOLLICLE; DISEASE; DSG3; HAIR		Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Toledo, Toledo, OH 43606 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan	University of Pennsylvania; University System of Ohio; University of Toledo; Jefferson University; Keio University	Stanley, JR (corresponding author), Univ Penn, Sch Med, Dept Dermatol, 211B Clin Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.		Amagai, Masayuki/K-5325-2013; Ishikawa, Hiroshi/ABC-6293-2020	Amagai, Masayuki/0000-0003-3314-7052; Ishikawa, Hiroshi/0000-0001-6310-5748				AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; BYSTRYN JC, 1978, J CLIN INVEST, V61, P339, DOI 10.1172/JCI108944; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; Chowdhury MMU, 1998, BRIT J DERMATOL, V139, P500; EYRE RW, 1988, ARCH DERMATOL, V124, P25, DOI 10.1001/archderm.124.1.25; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; ISHIKAWA H, 1994, MAMM GENOME, V5, P803, DOI 10.1007/BF00292018; Koch PJ, 1998, J CELL SCI, V111, P2529; Lyle S, 1998, J CELL SCI, V111, P3179; Mahoney MG, 1999, J INVEST DERMATOL, V113, P22, DOI 10.1046/j.1523-1747.1999.00632.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Montone KT, 1997, MODERN PATHOL, V10, P939; Proby CM, 2000, BRIT J DERMATOL, V142, P321, DOI 10.1046/j.1365-2133.2000.03328.x; ROCHAALVAREZ R, 1992, J INVEST DERMATOL, V99, P78, DOI 10.1111/1523-1747.ep12611868; ROSCOE JT, 1985, J INVEST DERMATOL, V85, P538, DOI 10.1111/1523-1747.ep12277362; Shirakata Y, 1998, J INVEST DERMATOL, V110, P76, DOI 10.1046/j.1523-1747.1998.00085.x; STANLEY JR, 1999, FITZPATRICKS DERMATO, V1, P654; Wu H, 1998, J HISTOCHEM CYTOCHEM, V46, P1189, DOI 10.1177/002215549804601011	20	89	89	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					31	35		10.1056/NEJM200007063430105	http://dx.doi.org/10.1056/NEJM200007063430105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882766				2022-12-28	WOS:000087987600005
J	Seto, TB; Kwiat, D; Taira, DA; Douglas, PS; Manning, WJ				Seto, TB; Kwiat, D; Taira, DA; Douglas, PS; Manning, WJ			Physicians' recommendations to patients for use of antibiotic prophylaxis to prevent endocarditis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MITRAL-VALVE PROLAPSE; AMERICAN-HEART-ASSOCIATION; BACTERIAL-ENDOCARDITIS; INFECTIVE ENDOCARDITIS; GUIDELINES; ECHOCARDIOGRAPHY; EPIDEMIOLOGY; NETHERLANDS; MANAGEMENT; AWARENESS	Context The American Heart Association recommendations for infectious endocarditis (IE) prophylaxis, published in June 1997, sought to improve patient and physician compliance by simplifying the dosing regimen and clarifying endocarditis risk. Adherence to these updated recommendations in patients with echocardiographic verification of their endocarditis risk profile is unknown. Objective To determine the recommended and actual use of IE prophylaxis as reported by patients undergoing echocardiography. Design, Setting, and Participants All patients who underwent outpatient transthoracic echocardiography at a university-based tertiary hospital in Boston, Mass, during December 1997 were contacted 6 to 9 months rater to respond to a survey, completed by 218 (80%) eligible subjects. Main Outcome Measure Patients' report of their physicians' instructions on actual use of IE prophylaxis in accordance with patient risk category, determined by echocardiographic data. Results One hundred eight patients (49.5%) had clinical or echocardiographic findings for which prophylaxis was indicated. Of these 108 patients, 71 (65.7%) reported that they were instructed to take IE prophylaxis. Sixteen high-risk patients (88.9%) but only 55 moderate-risk patients (61.1%) reported that they were instructed to take prophylaxis. Among the 110 negligible-risk patients, 29 (26.4%) reported that they had been instructed to take IE prophylaxis. Overall, 100 patients (45.9%) reported that they received physician instructions to take IE prophylaxis. Of those who subsequently underwent a procedure for which IE prophylaxis was indicated (n = 68), 9 (13.2%) elected not to follow their physician's advice to take prophylaxis. Conclusions We found that although most patients reported receiving instructions for IE prophylaxis use consistent with American Heart Association guidelines, IE prophylaxis overuse among negligible-risk patients and underuse among moderate-risk patients was common. Continued physician and patient education may lead to improved adherence to the current American Heart Association recommendations.	Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Harvard Thorndike Lab,Charles A Dana Res Lab, Boston, MA 02215 USA; Queens Med Ctr, Ctr Best Healthcare Practices, Honolulu, HI USA; Univ Hawaii, Dept Med, Div Cardiol, Honolulu, HI 96822 USA; Univ Hawaii, Div Clin Epidemiol, John A Burns Sch Med, Honolulu, HI 96822 USA; Hawaii Med Serv Assoc, Honolulu, HI USA	Harvard University; Beth Israel Deaconess Medical Center; The Queen's Medical Center; University of Hawaii System; University of Hawaii System	Manning, WJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Harvard Thorndike Lab,Charles A Dana Res Lab, 330 Brookline Ave, Boston, MA 02215 USA.			Douglas, Pamela/0000-0001-9876-4049				BAYLISS R, 1983, BRIT HEART J, V50, P506, DOI 10.1136/hrt.50.6.506; BOR DH, 1984, AM J MED, V76, P711, DOI 10.1016/0002-9343(84)90300-0; BROOKS SL, 1980, J AM DENT ASSOC, V101, P41, DOI 10.14219/jada.archive.1980.0361; CLEMENS JD, 1984, J CHRON DIS, V37, P531, DOI 10.1016/0021-9681(84)90004-3; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Delahaye F, 1999, J AM COLL CARDIOL, V33, P788, DOI 10.1016/S0735-1097(98)00624-X; DURACK DT, 1995, NEW ENGL J MED, V332, P38, DOI 10.1056/NEJM199501053320107; ELKODT AG, 1995, ANN INTERN MED, V122, P277; HASHWAY T, 1982, CIRCULATION, V66, P1110, DOI 10.1161/01.CIR.66.5.1110; Heidenreich PA, 1997, AM J MED, V102, P337, DOI 10.1016/S0002-9343(97)00084-3; IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223; LAVIE CJ, 1989, JAMA-J AM MED ASSOC, V262, P3308, DOI 10.1001/jama.262.23.3308; Meyers DG, 1997, AM J PREV MED, V13, P45, DOI 10.1016/S0749-3797(18)30224-1; Muhlestein JB, 1999, J AM COLL CARDIOL, V33, P794; NELSON CL, 1989, J AM DENT ASSOC, V118, P169, DOI 10.14219/jada.archive.1989.0215; OLIVE KE, 1990, J GEN INTERN MED, V5, P470, DOI 10.1007/BF02600871; ORMISTON JA, 1981, AUST NZ J MED, V11, P620, DOI 10.1111/j.1445-5994.1981.tb03536.x; RETCHIN SM, 1985, MED CARE, V23, P1156, DOI 10.1097/00005650-198510000-00004; SADOWSKY D, 1989, J AM DENT ASSOC, V118, P175, DOI 10.14219/jada.archive.1989.0242; Tomos MP, 1992, ANN INTERN MED, V117, P567; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1869, DOI 10.1001/archinte.152.9.1869; VANDERMEER JTM, 1992, J ANTIMICROB CHEMOTH, V29, P187, DOI 10.1093/jac/29.2.187; VANDERMEER JTM, 1992, ARCH INTERN MED, V152, P1863, DOI 10.1001/archinte.152.9.1863	25	25	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					68	71		10.1001/jama.284.1.68	http://dx.doi.org/10.1001/jama.284.1.68			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872015	Bronze			2022-12-28	WOS:000087843000027
J	Poses, RM; McClish, DK; Smith, WR; Huber, EC; Clemo, FLW; Schmitt, BP; Alexander, D; Racht, EM; Colenda, CC				Poses, RM; McClish, DK; Smith, WR; Huber, EC; Clemo, FLW; Schmitt, BP; Alexander, D; Racht, EM; Colenda, CC			Results of report cards for patients with congestive heart failure depend on the method used to adjust for severity	ANNALS OF INTERNAL MEDICINE			English	Article							III PROGNOSTIC SYSTEM; BYPASS GRAFT-SURGERY; HOSPITAL MORTALITY; RISK ADJUSTMENT; APACHE-II; CASE-MIX; QUALITY; ADMISSION; OUTCOMES; PREDICTION	Background: The validity of outcome report cards may depend on the ways in which they are adjusted for risk. Objectives: To compare the predictive ability of generic and disease-specific survival prediction models appropriate for use in patients with heart failure, to simulate outcome report cards by comparing survival across hospitals and adjusting for severity of illness using these models, and to assess the ways in which the results of these comparisons depend on the adjustment method. Design: Analysis of data from a prospective cohort, study. Setting: A university hospital, a Veterans Affairs (VA) medical center, and a community hospital. Patients: Sequential patients presenting in the emergency department with acute congestive heart failure. Measurements: Unadjusted 30-day and 1-year mortality across hospitals and 30-day and 1-year mortality adjusted by using disease-specific survival prediction models (two sickness-at-admission models, the Cleveland Health Quality Choice model, the Congestive Heart Failure Mortality Time-independent Predictive Instrument) and generic models (Acute Physiology and Chronic Health Evaluation [APACHE] II, APACHE III, the mortality prediction model, and the Charlson comorbidity index). Results: The community hospital's unadjusted 30-day survival rate (85.0%) and the VA medical center's unadjusted 1-year survival rate (60.9%) were significantly lower than corresponding rates at the university hospital (92.7% and 67.5%, respectively). No severity model had excellent ability to discriminate patients by survival rates tall areas under the receiver-operating characteristic curve < 0.73). Whether the VA medical center, the community hospital, both, or neither had worse survival rates on simulated report cards than the university hospital depended on the prediction model used for adjustment. Conclusions: Results of simulated outcome report cards for survival in patients with congestive heart failure depend on the method used to adjust for severity.	Brown Univ, Pawtucket, RI USA; Memorial Hosp Rhode Isl, Pawtucket, RI USA; Virginia Commonwealth Univ, Richmond, VA USA; Northwestern Univ, Sch Med, Chicago, IL USA; No Virginia Community Coll, Manassas, VA USA; Emergency Med Serv, Austin, TX USA; Michigan State Univ, E Lansing, MI 48824 USA	Brown University; Virginia Commonwealth University; Northwestern University; Michigan State University	Poses, RM (corresponding author), Brown Univ, Mem Hosp Rhode Isl, Ctr Primary Care & Prevent, 111 Brewster St, Pawtucket, RI 02860 USA.	royposes@brownvm.brown.edu			AHRQ HHS [HS-06274] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006274] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HLTH LIN, 1996, CONN HOSP REP CARD C; [Anonymous], 1994, CMAJ, V150, P1575; [Anonymous], 1994, CMAJ, V150, P1249; BOYD O, 1994, CRIT CARE MED, V22, P1706; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; Covinsky KE, 1997, J GEN INTERN MED, V12, P203, DOI 10.1007/s11606-006-5041-5; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; FIELDS J, 1999, RECORD          0306, pA1; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Hughes JS, 1996, J GEN INTERN MED, V11, P303, DOI 10.1007/BF02598273; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; Iezzoni LI, 1996, MED DECIS MAKING, V16, P348, DOI 10.1177/0272989X9601600405; IEZZONI LI, 1995, J INVEST MED, V43, P136; Iezzoni LI, 1998, MED CARE, V36, P28, DOI 10.1097/00005650-199801000-00005; Iezzoni LI, 1996, MED CARE, V34, P11, DOI 10.1097/00005650-199601000-00002; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; *JOINT COMM ACCR H, 1997, OR OUTC NEXT EV ACC; Jollis JG, 1998, NEW ENGL J MED, V338, P983, DOI 10.1056/NEJM199804023381410; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS W, 1989, CRIT CARE MED, V17, pS181, DOI 10.1097/00003246-198912001-00006; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KrouselWood MA, 1996, J GEN INTERN MED, V11, P32, DOI 10.1007/BF02603483; LANDRY S, 1996, STPETERSBURG TI 0226, pB1; MAZZOLINI J, 1998, CLEVELAND PLAIN 1203, pB4; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; MRQUIS J, 1997, LA TIMES        1215, pB1; *NHS, 1999, QUAL PERF NHS CLIN I; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ORR RK, 1995, ARCH SURG-CHICAGO, V130, P301; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1417; PALLARITO K, 1995, MOD HEALTHCARE, V25, P35; PAPP L, 1999, TORONTO STAR    0224, pA8; Pappachan JV, 1999, CHEST, V115, P802, DOI 10.1378/chest.115.3.802; Poses RM, 1996, J CLIN EPIDEMIOL, V49, P743, DOI 10.1016/0895-4356(96)00021-2; PRAGER LO, 1999, AM MED NEWS, V42, P1; PRAGER LO, 1999, AM MED NEWS, V42, P31; PRAGER LO, 1999, AM MED NEWS, V42, P32; Rosenthal GE, 2000, HEALTH SERV RES, V34, P1449; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; Sirio CA, 1999, CHEST, V115, P793, DOI 10.1378/chest.115.3.793; Taylor DH, 1999, NEW ENGL J MED, V340, P293, DOI 10.1056/NEJM199901283400408; TRILLO RA, 1997, AM MED NEWS, V40, P17; WONG DT, 1995, CRIT CARE MED, V23, P1177, DOI 10.1097/00003246-199507000-00005; 1994, CMAJ, V150, P1793; 1999, INTELLIGENCER J 0629, pB1; 1993, LANCET, V341, P1183	54	27	27	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					10	20		10.7326/0003-4819-133-1-200007040-00003	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00003			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877735				2022-12-28	WOS:000087923100002
J	Seckl, MJ; Fisher, RA; Salerno, G; Rees, H; Paradinas, FJ; Foskett, M; Newlands, ES				Seckl, MJ; Fisher, RA; Salerno, G; Rees, H; Paradinas, FJ; Foskett, M; Newlands, ES			Choriocarcinoma and partial hydatidiform moles	LANCET			English	Article							GESTATIONAL TROPHOBLASTIC TUMORS	Background Partial hydatidiform moles (PMs) rarely require chemotherapy and have never previously been proven to transform into choriocarcinoma, the most malignant form of gestational trophoblastic disease (GTD). Consequently, some have questioned whether women with PMs need human chorionic gonadotropin (hCG) follow-up. Here, we investigate whether PMs can transform into choriocarcinomas. Methods Patients with a PM who developed a subsequent choriocarcinoma were identified from our GTD database. The histology of both PM and ensuing choriocarcinoma was reviewed and flow cytometry used to verify the triploid status of the PMs. To determine whether the choriocarcinoma arose from the PM, DNA from the PM and choriocarcinoma in each patient was compared using microsatellite polymorphisms. Findings Of the 3000 patients with PM, 15 required chemotherapy for persisting GTD. This was identified as choriocarcinoma in three cases. In one patient, the local pathologist could not differentiate between a PM or a hydropic abortion and neither central histological review nor hCG follow-up were obtained. This patient nearly died before the diagnosis of choriocarcinoma was made. Fortunately, the local pathologists correctly diagnosed PM in the two other patients who were then registered for hCG follow-up. Some months later, the hCG was rising and repeat uterine evacuation revealed choriocarcinoma. The PM was confirmed to be triploid in all three cases and genetic analysis showed that the subsequent choriocarcinomas contained identical single maternal and two paternal alleles at several independent loci. Interpretation Our results show that PMs can transform into choriocarcinoma, All patients with suspected PM should be reviewed centrally and, if confirmed, need hCG follow-up.	Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Med Oncol, London W6 8RF, England; Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Histopathol, London W6 8RF, England; Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Canc Cell Biol, London W6 8RF, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Med Oncol, London W6 8RF, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Histopathol, London W6 8RF, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Canc Cell Biol, London W6 8RF, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London	Seckl, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Med Oncol, Charing Cross & Hammersmith Campuses, London W6 8RF, England.			Fisher, Rosemary/0000-0002-2721-8726				BAGSHAWE KD, 1990, LANCET, V335, P1074, DOI 10.1016/0140-6736(90)92641-T; Bower M, 1997, J CLIN ONCOL, V15, P2636, DOI 10.1200/JCO.1997.15.7.2636; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; JACOBS PA, 1982, BRIT J OBSTET GYNAEC, V89, P258, DOI 10.1111/j.1471-0528.1982.tb04693.x; Paradinas FJ, 1995, CURR OBSTET GYNECOL, V5, P6; World Health Organization Scientific Group, 1983, WHO TECH REP SER, V692, P7; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	7	230	234	1	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					36	39		10.1016/S0140-6736(00)02432-6	http://dx.doi.org/10.1016/S0140-6736(00)02432-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892763				2022-12-28	WOS:000087933400014
J	Siegel, RM; Frederiksen, JK; Zacharias, DA; Chan, FKM; Johnson, M; Lynch, D; Tsien, RY; Lenardo, MJ				Siegel, RM; Frederiksen, JK; Zacharias, DA; Chan, FKM; Johnson, M; Lynch, D; Tsien, RY; Lenardo, MJ			Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations	SCIENCE			English	Article							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; FAS GENE-MUTATIONS; LYMPHOCYTE APOPTOSIS; TNF-RECEPTOR; DEATH DOMAIN; MECHANISM; DISORDER; CASPASES; PROTEIN; BINDING	Heterozygous mutations encoding abnormal forms of the death receptor Fas dominantly interfere with Fas-induced Lymphocyte apoptosis in human autoimmune Lymphoproliferative syndrome. This effect, rather than depending on ligand-induced receptor oligomerization, was found to stem from ligand-independent interaction of wild-type and mutant Fas receptors through a specific region in the extracellular domain. Preassociated Fas complexes were found in living cells by means of fluorescence resonance energy transfer between variants of green fluorescent protein. These results show that formation of preassociated receptor complexes is necessary for Fas signaling and dominant interference in human disease.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	lenardo@nih.gov	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021; Siegel, Richard/C-7592-2009; Frederiksen, John Karl/C-4946-2012	Chan, Francis Ka-Ming/0000-0002-4803-8353; Siegel, Richard/0000-0001-5953-9893; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000769, Z01AI000718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Jackson CE, 1999, AM J HUM GENET, V64, P1002, DOI 10.1086/302333; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; Mahajan NP, 1999, CHEM BIOL, V6, P401, DOI 10.1016/S1074-5521(99)80051-9; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MIYAWAKI A, 1978, IN PRESS METHODS ENZ, V47, P819; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orlinick JR, 1997, J BIOL CHEM, V272, P28889, DOI 10.1074/jbc.272.46.28889; Papoff G, 1996, J IMMUNOL, V156, P4622; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Siegel R. M., 2000, SCI STKE, V2000, ppl1; SIEGEL RM, UNPUB; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331	30	505	530	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2354	2357		10.1126/science.288.5475.2354	http://dx.doi.org/10.1126/science.288.5475.2354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875918				2022-12-28	WOS:000087913400036
J	Bell, CE; Frescura, P; Hochschild, A; Lewis, M				Bell, CE; Frescura, P; Hochschild, A; Lewis, M			Crystal structure of the lambda repressor C-terminal domain provides a model for cooperative operator binding	CELL			English	Article							RECA-MEDIATED CLEAVAGE; TRANSCRIPTIONAL ACTIVATION FUNCTION; SINGLE-SITE MUTATIONS; BACTERIOPHAGE-LAMBDA; PHAGE REPRESSOR; GENE-REGULATION; UMUD' PROTEIN; MOLECULAR REPLACEMENT; POSITIVE CONTROL; P22 REPRESSORS	Interactions between transcription factors bound to separate operator sites commonly play an important role in gene regulation by mediating cooperative binding to the DNA. However, few detailed structural models for understanding the molecular basis of such cooperativity are available. The cl repressor of bacteriophage lambda is a classic example of a protein that binds to its operator sites cooperatively. The C-terminal domain of the repressor mediates dimerization as well as a dimer-dimer interaction that results in the cooperative binding of two repressor dimers to adjacent operator sites. Here, we present the x-ray crystal structure of the lambda repressor C-terminal domain determined by multiwavelength anomalous diffraction. Remarkably, the interactions that mediate cooperativity are captured in the crystal, where two dimers associate about a 2-fold axis of symmetry. Based on the structure and previous genetic and biochemical data, we present a model for the cooperative binding of two lambda repressor dimers at adjacent operator sites.	Johnson Fdn, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Brookhaven Natl Lab, NSLS Beamline X25, Upton, NY 11973 USA; Brookhaven Natl Lab, NSLS Beamline X12B, Upton, NY 11973 USA	University of Pennsylvania; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Brookhaven National Laboratory	Lewis, M (corresponding author), Johnson Fdn, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BECKETT D, 1993, BIOCHEMISTRY-US, V32, P9073, DOI 10.1021/bi00086a012; BENSON N, 1994, MOL MICROBIOL, V11, P567, DOI 10.1111/j.1365-2958.1994.tb00337.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURZ DS, 1994, BIOCHEMISTRY-US, V33, P8399, DOI 10.1021/bi00194a003; BURZ DS, 1994, BIOCHEMISTRY-US, V33, P8406, DOI 10.1021/bi00194a004; BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; Chang G, 1997, ACTA CRYSTALLOGR D, V53, P279, DOI 10.1107/S0907444996014990; CHANG G, 1994, ACTA CRYSTALLOGR D, V50, P667, DOI 10.1107/S0907444994000727; COHEN S, 1981, NATURE, V294, P182, DOI 10.1038/294182a0; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Ferentz AE, 1997, NAT STRUCT BIOL, V4, P979, DOI 10.1038/nsb1297-979; GIMBLE FS, 1985, J BACTERIOL, V162, P147, DOI 10.1128/JB.162.1.147-154.1985; GIMBLE FS, 1986, J MOL BIOL, V192, P39, DOI 10.1016/0022-2836(86)90462-6; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULDELL N, 1994, J BACTERIOL, V176, P2991, DOI 10.1128/JB.176.10.2991-2998.1994; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; MANIATIS T, 1975, CELL, V5, P109, DOI 10.1016/0092-8674(75)90018-5; MANIATIS T, 1973, P NATL ACAD SCI USA, V70, P1531, DOI 10.1073/pnas.70.5.1531; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; Peat TS, 1996, STRUCTURE, V4, P1401, DOI 10.1016/S0969-2126(96)00148-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Ptashne M., 1992, A GENETIC SWITCH; Revet B, 1999, CURR BIOL, V9, P151, DOI 10.1016/S0960-9822(99)80069-4; SAUER RT, 1982, J BIOL CHEM, V257, P4458; SAUER RT, 1979, THESIS HARVARD U CAM; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WEISS MA, 1983, J BIOMOL STRUCT DYN, V1, P151, DOI 10.1080/07391102.1983.10507431; Whipple FW, 1998, GENE DEV, V12, P2791, DOI 10.1101/gad.12.17.2791; WHIPPLE FW, 1994, GENE DEV, V8, P1212, DOI 10.1101/gad.8.10.1212	54	106	107	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					801	811		10.1016/S0092-8674(00)80891-0	http://dx.doi.org/10.1016/S0092-8674(00)80891-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892750	Bronze			2022-12-28	WOS:000087821400013
J	Tuljapurkar, S; Li, N; Boe, C				Tuljapurkar, S; Li, N; Boe, C			A universal pattern of mortality decline in the G7 countries	NATURE			English	Article							UNITED-STATES	Human lifespan has increased enormously this century(1-3). But we remain uncertain about the forces that reduce mortality, and about the cost implications of ageing populations(4,5) and their associated social burden. The poor understanding of the factors driving mortality decline(2,6,7), and the difficulty of forecasting mortality(8-11) are due in part to the pronounced irregularity of annual to decadal mortality change(7,12). Here we examine mortality over five decades in the G7 countries (Canada, France, Germany, Italy, Japan, UK, US). In every country over this period, mortality at each age has declined exponentially at a roughly constant rate. This trend places a constraint on any theory of society-driven mortality decline, and provides a basis for stochastic mortality forecasting. We rnd that median forecasts of life expectancy are substantially larger than in existing official forecasts. In terms of the costs of ageing, we forecast values of the dependency ratio (that is, the ratio of people over 65 to working people) in 2050 that are between 6% (UK) and 40% (Japan) higher than official forecasts.	Mt View Res, Los Altos, CA 94204 USA		Tuljapurkar, S (corresponding author), Mt View Res, 2251 Grant Rd, Los Altos, CA 94204 USA.			Tuljapurkar, Shripad/0000-0001-5549-4245				Bell W.R., 1997, J OFF STAT, V13, P279; Boe C., 1998, N AM ACTUAR J, V2, P13, DOI DOI 10.1080/10920277.1998.10595752; BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; De Beer J, 1996, Maandstat Bevolking, V44, P7; DELEON J, 1990, 50 CENTR BUR STAT; GOSS SC, 1998, N AM ACTUARIAL J, V2, P108; HIMES CL, 1994, POP STUD-J DEMOG, V48, P269, DOI 10.1080/0032472031000147796; Horiuchi S, 1997, J GERONTOL A-BIOL, V52, pB67, DOI 10.1093/gerona/52A.1.B67; Lee R, 1994, DEMOGRAPHY AGING, P8; LEE RD, 1994, J AM STAT ASSOC, V89, P1175, DOI 10.2307/2290980; LEE RD, 1992, J AM STAT ASSOC, V87, P659, DOI 10.2307/2290201; LEE RD, 1996, ASSESSING KNOWLEDGE, P195; MANTON KG, 1991, POPUL DEV REV, V17, P603, DOI 10.2307/1973599; McKeown Thomas, 1976, MODERN RISE POPULATI; Mesle F, 1999, POP STUD-J DEMOG, V53, P97, DOI 10.1080/00324720308071; *NAT I POP SOC SEC, 1997, POP PROJ JAP 1996 20; *OFF CHIEF ACT, 1998, 17 FIN I OFF CHIEF A; Preston, 1974, WHO STAT REPORT, V27, P719; PRESTON SH, 1991, FORECASTING HLTH ELD, P51; Preston SH, 1976, MORTALITY PATTERNS N; SMITH D, 1993, HUMAN LONGEVITY; VONSTORCH H, 1994, STAT SCI, V9, P215, DOI 10.1214/ss/1177010487; Wilmoth J R, 1995, Math Popul Stud, V5, P293; Wilmoth J. R., 1996, HLTH MORTALITY ELDER, P266; Wilmoth JR, 1998, SCIENCE, V280, P395, DOI 10.1126/science.280.5362.395; *WORLD BANK POL RE, 1994, AV OLD AG CRIS POL P	26	295	298	0	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					789	792		10.1038/35015561	http://dx.doi.org/10.1038/35015561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	324KJ	10866199				2022-12-28	WOS:000087620600050
J	Pinching, A				Pinching, A			A fresh look at HIV infection	LANCET			English	Editorial Material									St Bartholomews & Royal London Sch Med & Dent, Dept Immunol, London EC1A 7BE, England	University of London; Queen Mary University London	Pinching, A (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Immunol, London EC1A 7BE, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1844	1844		10.1016/S0140-6736(00)02286-8	http://dx.doi.org/10.1016/S0140-6736(00)02286-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866438				2022-12-28	WOS:000087306500008
J	Kodaira, S; Takahashi, N; Nakanishi, A; Miura, S; Kaneda, Y				Kodaira, S; Takahashi, N; Nakanishi, A; Miura, S; Kaneda, Y			Subducted seamount imaged in the rupture zone of the 1946 Nankaido earthquake	SCIENCE			English	Article							PHILIPPINE SEA PLATE; JAPAN; DEFORMATION; TROUGH; MODEL	The Nankai Trough is a vigorous subduction zone where large earthquakes have been recorded since the seventh century, with a recurrence time of 100 to 200 years. The 1946 Nankaido earthquake was unusual, with a rupture zone estimated from long-period geodetic data that was more than twice as Large as that derived from shorter period seismic data. In the center of this earthquake rupture zone, we used densely deployed ocean bottom seismographs to detect a subducted seamount 13 kilometers thick by 50 kilometers wide at a depth of 10 kilometers. We propose that this seamount might work as a barrier inhibiting brittle seismogenic rupture.	Japan Marine Sci & Technol Ctr, Kanagawa 2370061, Japan	Japan Agency for Marine-Earth Science & Technology (JAMSTEC)	Kodaira, S (corresponding author), Japan Marine Sci & Technol Ctr, Natsushima 2-15, Kanagawa 2370061, Japan.		Kodaira, Shuichi/G-8746-2016	Kodaira, Shuichi/0000-0002-5774-2561				ANDO M, 1975, TECTONOPHYSICS, V27, P63; ASADA A, 1998, P JPN SOC MARINE SUR, V10, P15; Cloos M, 1996, GEOLOGY, V24, P107, DOI 10.1130/0091-7613(1996)024<0107:SZTATS>2.3.CO;2; CUMMINS PR, 1999, EOS S, V80, P738; Dominguez S, 1998, TECTONOPHYSICS, V293, P207, DOI 10.1016/S0040-1951(98)00086-9; FITCH TJ, 1971, J GEOPHYS RES, V76, P7260, DOI 10.1029/JB076i029p07260; Kanamori H., 1972, Physics of the Earth and Planetary Interiors, V5, P129, DOI 10.1016/0031-9201(72)90082-9; KANAORI Y, 1993, ENG GEOL, V33, P289, DOI 10.1016/0013-7952(93)90031-7; Kato T, 1997, GEOPHYS RES LETT, V24, P2055, DOI 10.1029/97GL01978; KELLEHER J, 1976, J GEOPHYS RES, V81, P4885, DOI 10.1029/JB081i026p04885; KINOSHITA H, 1989, J GEOMAGN GEOELECTR, V41, P161, DOI 10.5636/jgg.41.161; Kobayashi K., 1995, BACKARC BASINS; Kodaira S, 2000, J GEOPHYS RES-SOL EA, V105, P5887, DOI 10.1029/1999JB900394; Mogi K., 1968, B EARTHQ RES I TOKYO, V46, P175; NAKANISHI A, 1999, EOS S, V80, P570; Scholz CH, 1997, GEOLOGY, V25, P487, DOI 10.1130/0091-7613(1997)025<0487:TEOSSO>2.3.CO;2; SENO T, 1993, J GEOPHYS RES-SOL EA, V98, P17941, DOI 10.1029/93JB00782; YAMAZAKI T, 1989, TECTONOPHYSICS, V160, P207, DOI 10.1016/0040-1951(89)90392-2; Zelt CA, 1998, J GEOPHYS RES-SOL EA, V103, P7187, DOI 10.1029/97JB03536	19	209	212	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					104	106		10.1126/science.289.5476.104	http://dx.doi.org/10.1126/science.289.5476.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884221				2022-12-28	WOS:000088090400041
J	Schuster, R; Kirchner, V; Allongue, P; Ertl, G				Schuster, R; Kirchner, V; Allongue, P; Ertl, G			Electrochemical micromachining	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; NANOFABRICATION; DEPOSITION; NANOSCALE; KINETICS; SURFACE; SILVER; TIP	The application of ultrashort voltage pulses between a tool electrode and a workpiece in an electrochemical environment allows the three-dimensional machining of conducting materials with submicrometer precision. The principle is based on the finite time constant for double-layer charging, which varies linearly with the local separation between the electrodes. During nanosecond pulses, the electrochemical reactions are confined to electrode regions in close proximity. This technique was used for local etching of copper and silicon as well as for local copper deposition.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; CNRS, UPR 15, F-75005 Paris, France	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Centre National de la Recherche Scientifique (CNRS)	Schuster, R (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.		Allongue, Philippe/AAW-8048-2020	Allongue, Philippe/0000-0001-9457-5312				Amato I, 1998, SCIENCE, V282, P402, DOI 10.1126/science.282.5388.402; Avouris P, 1997, APPL PHYS LETT, V71, P285, DOI 10.1063/1.119521; BARD AJ, 1990, ACCOUNTS CHEM RES, V23, P357, DOI 10.1021/ar00179a002; Bockris J. O. M., 1970, MODERN ELECTROCHEMIS, V2; Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; FRIEDRICH CR, 1997, HDB MICROLITHOGRAPHY, V2, P299; GERISCHER H, 1990, ELECTROCHIM ACTA, V35, P1677, DOI 10.1016/0013-4686(90)87067-C; HOFFMANN D, 1998, PHYS REV LETT, V73, P3279; Jensen K, 1998, NATURE, V393, P735, DOI 10.1038/31590; JERMAN H, 1997, HDB MICROLITHOGRAPHY, V2, P379; Kolb DM, 1997, SCIENCE, V275, P1097, DOI 10.1126/science.275.5303.1097; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; Lebreton C, 1996, J VAC SCI TECHNOL B, V14, P1356, DOI 10.1116/1.589097; Li W, 1996, J PHYS CHEM-US, V100, P20103, DOI 10.1021/jp962328d; LI WJ, 1992, APPL PHYS LETT, V60, P1181, DOI 10.1063/1.107398; MILAZZO G, 1963, ELECTROCHEMISTRY; Nyffenegger RM, 1997, CHEM REV, V97, P1195, DOI 10.1021/cr960069i; POTZSCHKE RT, 1995, ELECTROCHIM ACTA, V40, P1469, DOI 10.1016/0013-4686(95)00049-K; RAICOUDHURY P, 1997, HDB MICROLITHOGRAPHY; Santini JT, 1999, NATURE, V397, P335, DOI 10.1038/16898; Schneeweiss MA, 1999, PHYS STATUS SOLIDI A, V173, P51, DOI 10.1002/(SICI)1521-396X(199905)173:1<51::AID-PSSA51>3.0.CO;2-O; Schuster R, 1998, PHYS REV LETT, V80, P5599, DOI 10.1103/PhysRevLett.80.5599	22	475	528	11	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					98	101		10.1126/science.289.5476.98	http://dx.doi.org/10.1126/science.289.5476.98			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884233				2022-12-28	WOS:000088090400039
J	Hilmers, DC				Hilmers, DC			A view from there	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					98	98		10.1001/jama.284.1.98	http://dx.doi.org/10.1001/jama.284.1.98			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872023				2022-12-28	WOS:000087843000035
J	McDonald, CJ; Weiner, M; Hui, SL				McDonald, CJ; Weiner, M; Hui, SL			Deaths due to medical errors are exaggerated in institute of medicine report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; NEGLIGENCE; REMINDERS		Indiana Univ, Sch Med, Ctr Aging Res, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	McDonald, CJ (corresponding author), Indiana Univ, Sch Med, Ctr Aging Res, Regenstrief Inst Hlth Care, 1050 Wishard Blvd,5th Floor, Indianapolis, IN 46202 USA.		Weiner, Michael/M-5185-2013; Weiner, Michael/H-5342-2019	Weiner, Michael/0000-0002-0877-4583; Weiner, Michael/0000-0002-0877-4583				BATES DW, 1995, MED CARE, V33, P452, DOI 10.1097/00005650-199505000-00002; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 2000, NEW ENGL J MED, V342, P1123, DOI 10.1056/NEJM200004133421510; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; Rooney C, 1998, LANCET, V351, P1656, DOI 10.1016/S0140-6736(05)77710-2; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; *US GEN ACC OFF, 1988, MED ASS HCFAS 1988 H	14	196	198	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					93	95		10.1001/jama.284.1.93	http://dx.doi.org/10.1001/jama.284.1.93			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872021				2022-12-28	WOS:000087843000033
J	Swan, SK; Rudy, DW; Lasseter, KC; Ryan, CF; Buechel, KL; Lambrecht, LJ; Pinto, MB; Dilzer, SC; Obrda, O; Sundblad, KJ; Gumbs, CP; Ebel, DL; Quan, H; Larson, PJ; Schwartz, JI; Musliner, TA; Gertz, BJ; Brater, DC; Yao, SL				Swan, SK; Rudy, DW; Lasseter, KC; Ryan, CF; Buechel, KL; Lambrecht, LJ; Pinto, MB; Dilzer, SC; Obrda, O; Sundblad, KJ; Gumbs, CP; Ebel, DL; Quan, H; Larson, PJ; Schwartz, JI; Musliner, TA; Gertz, BJ; Brater, DC; Yao, SL			Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLOMERULAR-FILTRATION RATE; SODIUM-BALANCE; H SYNTHASE; INSUFFICIENCY; INDOMETHACIN; PROSTAGLANDINS; HOMEOSTASIS; ISOFORM; ASPIRIN	Background: Most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1), whose inhibition is associated with gastrointestinal ulceration, and COX-2, whose inhibition is associated with therapeutic benefits. Although agents that do not produce COX-1 activity may have fewer adverse effects, targeted disruption of the COX-2 allele in mice has resulted in severe renal problems, suggesting that COX-2 inhibition may also produce adverse effects. Objective: To determine the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients. Design: A randomized, three-period, single-dose crossover study and a randomized, parallel-group, multiple-dose study. Setting: Clinical research units. Patients: 75 patients 60 to 80 years of age. Intervention: In the first study, single doses of rofecoxib, 250 mg (about Ei-fold to 20-fold the recommended dose); indomethacin, 75 mg; and placebo were administered to 15 patients. In the second study, multiple doses of rofecoxib, 12.5 or 25 mg/d; indomethacin, 50 mg three times daily; or placebo were administered to 60 patients. Patients in both studies received a low-sodium diet Measurements: Glomerular filtration rate, creatinine clearance, and urinary and serum sodium and potassium values. Results: Compared with placebo, single doses of rofecoxib and indomethacin decreased the glomerular filtration rate by 0.23 mL/s (P < 0.001) and 0.18 mL/s (P = 0.003), respectively. In contrast, respective decreases of 0.14, 0.13, and 0.10 mL/s were observed after multiple doses of rofecoxib, 12.5 mg/d (P = 0.019); rofecoxib, 25 mg (P = 0.029), and indomethacin (P = 0.086) were administered. Changes in creatinine clearance and serum and urinary sodium and potassium were less pronounced. Conclusions: The effects of COX-2 inhibition on renal function are similar to those observed with nonselective NSAIDs. Thus, COX-2 seems to play an important role in human renal function.	Hennepin Cty Med Ctr, Div Nephrol, Minneapolis, MN 55415 USA; Total Renal Res Inc, Minneapolis, MN USA; Indiana Univ, Indianapolis, IN 46204 USA; Clin Pharmacol Associates, Miami, FL USA; PPD, Austin, TX USA; Merck Res Labs, Rahway, NJ USA	Hennepin County Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company	Yao, SL (corresponding author), Hennepin Cty Med Ctr, Div Nephrol, 701 Pk Ave, Minneapolis, MN 55415 USA.	siulong_yao@merck.com						BRATER DC, 1985, CLIN PHARMACOL THER, V38, P674, DOI 10.1038/clpt.1985.244; BRATER DC, 1979, CLIN PHARMACOL THER, V25, P322; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002-9343(98)00091-6; DONKER AJM, 1976, NEPHRON, V17, P288, DOI 10.1159/000180733; DUSING R, 1982, KLIN WOCHENSCHR, V60, P1229, DOI 10.1007/BF01716728; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; FJELDBO W, 1968, J LAB CLIN MED, V72, P353; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Komhoff M, 1997, AM J PHYSIOL-RENAL, V272, pF460, DOI 10.1152/ajprenal.1997.272.4.F460; KRAMER HJ, 1985, CLIN SCI, V68, P387, DOI 10.1042/cs0680387; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Murray MD, 1997, AM J MED SCI, V314, P80, DOI 10.1097/00000441-199708000-00009; MURRAY MD, 1992, BRIT J CLIN PHARMACO, V33, P385, DOI 10.1111/j.1365-2125.1992.tb04056.x; MURRAY MD, 1995, AM J MED SCI, V310, P188, DOI 10.1097/00000441-199511000-00003; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; MUTHER RS, 1981, ANN INTERN MED, V94, P317, DOI 10.7326/0003-4819-94-3-317; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; SIGMAN EM, 1966, J NUCL MED, V7, P60; SIGMAN EUGENE M., 1965, INVEST UROL, V2, P432; SIROIS J, 1992, J BIOL CHEM, V267, P11586; TOTO RD, 1986, KIDNEY INT, V30, P760, DOI 10.1038/ki.1986.253	25	274	287	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					1	9		10.7326/0003-4819-133-1-200007040-00002	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877734				2022-12-28	WOS:000087923100001
J	Meairs, S; Timpe, L; Beyer, J; Hennerici, M				Meairs, S; Timpe, L; Beyer, J; Hennerici, M			Acute aphasia and hemiplegia during karate training	LANCET			English	Article							ARTERY		Heidelberg Univ, Klinikum Mannheim, Dept Neurol, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Meairs, S (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept Neurol, Theodor Kutzer Ufer, D-68135 Mannheim, Germany.	meairs@neuro.ma.uni-heidelbeig.de						Granholdt MLM, 1998, CIRCULATION, V97, P34; Koennecke HC, 1998, CEREBROVASC DIS, V8, P107, DOI 10.1159/000015827; LEVY C, 1994, RADIOLOGY, V190, P97, DOI 10.1148/radiology.190.1.8259436; Meairs S, 1999, STROKE, V30, P1807, DOI 10.1161/01.STR.30.9.1807; Meairs S, 2000, ULTRASOUND MED BIOL, V26, P263, DOI 10.1016/S0301-5629(99)00130-1	5	18	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					40	40		10.1016/S0140-6736(00)02433-8	http://dx.doi.org/10.1016/S0140-6736(00)02433-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892764				2022-12-28	WOS:000087933400015
J	Chan, FKM; Chun, HJ; Zheng, LX; Siegel, RM; Bui, KL; Lenardo, MJ				Chan, FKM; Chun, HJ; Zheng, LX; Siegel, RM; Bui, KL; Lenardo, MJ			A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; RESONANCE ENERGY-TRANSFER; CRYSTALLOGRAPHIC EVIDENCE; ERYTHROPOIETIN RECEPTOR; DEATH DOMAIN; KAPPA-B; ACTIVATION; BINDING; APOPTOSIS; COMPLEX	A conserved domain in the extracellular region of the 60- and 80-kilodalton tumor necrosis factor receptors (TNFRs) was identified that mediates specific Ligand-independent assembly of receptor trimers. This pre-ligand-binding assembly domain (PLAD) is physically distinct from the domain that forms the major contacts with ligand, but is necessary and sufficient for the assembly of TNFR complexes that bind TNF-alpha and mediate signaling. Other members of the TNFR superfamily, including TRAIL receptor 1 and CD40, show similar homotypic association. Thus, TNFRs and related receptors appear to function as preformed complexes rather than as individual receptor subunits that oligomerize after ligand binding.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021; Siegel, Richard/C-7592-2009; Chun, Hyung/K-1859-2013; chun, hyung/AAE-1463-2020	Chan, Francis Ka-Ming/0000-0002-4803-8353; Siegel, Richard/0000-0001-5953-9893; Chun, Hyung/0000-0003-3508-2678	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000718, Z01AI000718, Z01AI000769, ZIAAI000769] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1996, CELL, V85, P805; CHAN F, UNPUB; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; CHEN PCH, 1995, J BIOL CHEM, V270, P2874, DOI 10.1074/jbc.270.6.2874; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; DAMJANOVICH S, 1996, P NATL ACAD SCI USA, V93, P13973; Declercq W, 1998, J IMMUNOL, V161, P390; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; Haridas V, 1998, J IMMUNOL, V160, P3152; HELLER RA, 1992, CELL, V70, P47; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HSU KC, 1993, J BIOL CHEM, V268, P16430; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones SJ, 1999, J IMMUNOL, V162, P1042; Klaus G G, 1997, Int Rev Immunol, V15, P5, DOI 10.3109/08830189709068169; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NAISMITH JH, 1995, J MOL RECOGNIT, V9, P113; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; REID T, 1994, CIRC SHOCK, V44, P84; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wajant H, 1998, CYTOKINE GROWTH F R, V9, P297; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weiss T, 1997, J IMMUNOL, V158, P2398; ZHENG L, UNPUB	47	633	679	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2351	2354		10.1126/science.288.5475.2351	http://dx.doi.org/10.1126/science.288.5475.2351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875917				2022-12-28	WOS:000087913400035
J	Falciatore, A; d'Alcala, MR; Croot, P; Bowler, C				Falciatore, A; d'Alcala, MR; Croot, P; Bowler, C			Perception of environmental signal by a marine diatom	SCIENCE			English	Article							EQUATORIAL PACIFIC-OCEAN; IRON LIMITATION; PHYTOPLANKTON; TRANSFORMATION; TRANSPORT; OSMOREGULATION; FLAVODOXIN; KINETICS; STRESS	Diatoms are a key component of marine ecosystems and are extremely important for the biogeochemical cycling of silica and as contributors to global fixed carbon. However, the answers to fundamental questions such as what diatoms can sense in their environment, how they respond to external signals, and what factors control their Life strategies are largely unknown. We generated transgenic diatom cells containing the calcium-sensitive photoprotein aequorin to determine whether changes in calcium homeostasis are used to respond to relevant environmental stimuli. Our results reveal sensing systems for detecting and responding to fluid motion (shear stress), osmotic stress, and iron, a key nutrient that controls diatom abundance in the ocean.	Staz Zool Anton Dohrn, Plant Mol Biol Lab, I-80121 Naples, Italy; Staz Zool Anton Dohrn, Lab Biol Oceanog, I-80121 Naples, Italy; Netherlands Inst Sea Res, Dept Marine Chem & Geol, NL-1790 AB Den Burg, Netherlands	Stazione Zoologica Anton Dohrn di Napoli; Stazione Zoologica Anton Dohrn di Napoli; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Bowler, C (corresponding author), Staz Zool Anton Dohrn, Plant Mol Biol Lab, Villa Comunale, I-80121 Naples, Italy.	chris@alpha.szn.it	Croot, Peter/U-5296-2019; d'Alcala', Maurizio Ribera/B-7114-2012; Bowler, Chris/AAC-6256-2019; Falciatore, Angela/Q-6161-2018; Croot, Peter L/C-8460-2009	d'Alcala', Maurizio Ribera/0000-0002-5492-9961; Croot, Peter L/0000-0003-1396-0601; Falciatore, Angela/0000-0003-3318-9578; Bowler, Chris/0000-0003-3835-6187				Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; Behrenfeld MJ, 1999, SCIENCE, V283, P840, DOI 10.1126/science.283.5403.840; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; Dunahay TG, 1995, J PHYCOL, V31, P1004, DOI 10.1111/j.0022-3646.1995.01004.x; EILERTSEN HC, 1995, MAR ECOL PROG SER, V116, P303, DOI 10.3354/meps116303; Falciatore A, 1999, MAR BIOTECHNOL, V1, P239, DOI 10.1007/PL00011773; FARIAS PAM, 1992, ANAL LETT, V25, P1929, DOI 10.1080/00032719208018263; HUDSON RJM, 1993, DEEP-SEA RES PT I, V40, P129, DOI 10.1016/0967-0637(93)90057-A; HUDSON RJM, 1990, LIMNOL OCEANOGR, V35, P1002, DOI 10.4319/lo.1990.35.5.1002; JENKINSON IR, 1986, NATURE, V323, P435, DOI 10.1038/323435a0; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KOSHLAND DE, 1981, ANNU REV BIOCHEM, V50, P765, DOI 10.1146/annurev.bi.50.070181.004001; LAROCHE J, 1995, J PHYCOL, V31, P520; LaRoche J, 1996, NATURE, V382, P802; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; MARTIN JH, 1994, NATURE, V371, P123, DOI 10.1038/371123a0; MARTIN JH, 1988, DEEP-SEA RES, V35, P177, DOI 10.1016/0198-0149(88)90035-0; MARTIN JH, 1990, NATURE, V345, P156, DOI 10.1038/345156a0; McKay RML, 1997, PLANT PHYSIOL, V114, P615, DOI 10.1104/pp.114.2.615; Plieth C, 1999, PLANT J, V18, P491, DOI 10.1046/j.1365-313X.1999.00471.x; SHIMOMUR.O, 1973, BIOCHEM BIOPH RES CO, V53, P490, DOI 10.1016/0006-291X(73)90688-8; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; SVERDRUP HU, 1942, OCEANS, P281; Villareal TA, 1999, NATURE, V397, P423, DOI 10.1038/17103	27	136	140	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2363	2366		10.1126/science.288.5475.2363	http://dx.doi.org/10.1126/science.288.5475.2363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875921				2022-12-28	WOS:000087913400039
J	Yu, L; Frey, EA; Pfuetzner, RA; Creagh, AL; Knoechel, DG; Haynes, CA; Finlay, BB; Strynadka, NCJ				Yu, L; Frey, EA; Pfuetzner, RA; Creagh, AL; Knoechel, DG; Haynes, CA; Finlay, BB; Strynadka, NCJ			Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex	NATURE			English	Article							BINDING PROTEIN; MODELS; CELLS; TIR; REPLACEMENT; DIFFRACTION; INFECTION; ADHESION	Intimin and its translocated intimin receptor (Tir) are bacterial proteins that mediate adhesion between mammalian cells and attaching and effacing (A/E) pathogens. Enteropathogenic Escherichia coli (EPEC) causes significant paediatric morbidity and mortality world-wide(1). A related A/E pathogen, enterohaemorrhagic E. coli (EHEC; O157:H7) is one of the most important food-borne pathogens in North America, Europe and Japan. A unique and essential feature of A/E bacterial pathogens is the formation of actin-rich pedestals beneath the intimately adherent bacteria and localized destruction of the intestinal brush border(2). The bacterial outer membrane adhesin, intimin(3), is necessary for the production of the A/E lesion and diarrhoea(4). The A/E bacteria translocate their own receptor for intimin, Tir(5), into the membrane of mammalian cells using the type III secretion system. The translocated Tir triggers additional host signalling events and actin nucleation, which are essential for lesion formation. Here we describe the the crystal structures of an EPEC intimin carboxyterminal fragment alone and in complex with the EPEC Tir intimin-binding domain, giving insight into the molecular mechanisms of adhesion of A/E pathogens.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; Betz SF, 1997, BIOCHEMISTRY-US, V36, P2450, DOI 10.1021/bi961704h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeVinney R, 1999, INFECT IMMUN, V67, P2389, DOI 10.1128/IAI.67.5.2389-2398.1999; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; GOOSNEY DL, IN PRESS CURR BIOL; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Knutton S, 1997, INFECT IMMUN, V65, P1644, DOI 10.1128/IAI.65.5.1644-1652.1997; Knutton S, 1995, BIOSCIENCE REP, V15, P469, DOI 10.1007/BF01204350; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Liu H, 1999, MOL MICROBIOL, V34, P67, DOI 10.1046/j.1365-2958.1999.01574.x; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; Todd Ewen C. D., 1997, World Health Statistics Quarterly, V50, P30; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	30	238	245	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1073	1077		10.1038/35016618	http://dx.doi.org/10.1038/35016618			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890451				2022-12-28	WOS:000087871700051
J	Huppert, SS; Le, A; Schroeter, EH; Mumm, JS; Saxena, MT; Milner, LA; Kopan, R				Huppert, SS; Le, A; Schroeter, EH; Mumm, JS; Saxena, MT; Milner, LA; Kopan, R			Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1	NATURE			English	Article							INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PRESENILIN; EXPRESSION; REDUNDANT; LACKING; PATHWAY; RELEASE; SEL-12; DELTA	The Notch genes encode single-pass transmembrane receptors that transduce the extracellular signals responsible for cell fate determination during several steps of metazoan development. The mechanism by which extracellular signals affect gene transcription and ultimately cell fate decisions is beginning to emerge for the Notch signalling pathway. One paradigm is that ligand binding to Notch triggers a Presenilin1-dependent proteolytic release of the Notch intracellular domain from the membrane(1), resulting in low amounts of Notch intracellular domain which form a nuclear complex with CBF1/Su(H)/Lag1 to activate transcription of downstream targets(2). Not all observations clearly support this processing model, and the most rigorous test of it is to block processing in vivo and then determine the ability of unprocessed Notch to signal. Here we report that the phenotypes associated with a single point mutation at the intramembranous processing site of Notch1, Val1,744-->Gly, resemble the null Notch1 phenotype(3,4). Our results show that efficient intramembranous processing of Notch1 is indispensable for embryonic viability and proper early embryonic development in vivo.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Med, Seattle, WA 98109 USA	Washington University (WUSTL); Washington University (WUSTL); Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Kopan, R (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	kopan@molecool.wustl.edu	Huppert, Stacey S/A-4103-2010; Kopan, Raphael/AAF-1357-2022; Kopan, Raphael/AFG-3275-2022; Mumm, Jeff S/F-3125-2013	Huppert, Stacey S/0000-0003-3977-8728; Kopan, Raphael/0000-0002-0350-2730; Mumm, Jeff/0000-0002-2575-287X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berechid BE, 1999, CURR BIOL, V9, P1493, DOI 10.1016/S0960-9822(00)80121-9; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; CONLON RA, 1995, DEVELOPMENT, V121, P1533; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krebs LT, 2000, GENE DEV, V14, P1343; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lewandoski M, 1997, NAT GENET, V17, P223, DOI 10.1038/ng1097-223; Li XJ, 1997, P NATL ACAD SCI USA, V94, P12204, DOI 10.1073/pnas.94.22.12204; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Neidhardt LM, 1997, DEV GENES EVOL, V207, P330, DOI 10.1007/s004270050120; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Westlund B, 1999, P NATL ACAD SCI USA, V96, P2497, DOI 10.1073/pnas.96.5.2497; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371	28	276	286	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					966	970		10.1038/35016111	http://dx.doi.org/10.1038/35016111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879540				2022-12-28	WOS:000087732700055
J	Kishida, H; Matsuzaki, H; Okamoto, H; Manabe, T; Yamashita, M; Taguchi, Y; Tokura, Y				Kishida, H; Matsuzaki, H; Okamoto, H; Manabe, T; Yamashita, M; Taguchi, Y; Tokura, Y			Gigantic optical nonlinearity in one-dimensional Mott-Hubbard insulators	NATURE			English	Article							CONJUGATED POLYMERS; COMPLEXES; SUSCEPTIBILITY; POLYACETYLENE; SPECTROSCOPY; CRYSTALS; SPECTRA; FILMS	The realization of all-optical switching, modulating and computing devices is an important goal in modern optical technology. Nonlinear optical materials with large third-order nonlinear susceptibilities (chi((3))) are indispensable for such devices, because the magnitude of this quantity dominates the device performance. A key strategy in the development of new materials with large nonlinear susceptibilities is the exploration of quasi-one-dimensional systems(1,2), or 'quantum wires'-the quantum confinement of electron-hole motion in one-dimensional space can enhance chi((3)). Two types of chemically synthesized quantum wires have been extensively studied: the band insulators of silicon polymers, and Peierls insulators of pi-conjugated polymers and platinum halides. In these systems, chi((3)) values of 10(-12) to 10(-7) e.s.u. (electrostatic system of units) have been reported(3-7). Here we demonstrate an anomalous enhancement of the third-order nonlinear susceptibility in a different category of quantum wires: one-dimensional Mott insulators of 3d transition-metal oxides and halides. By analysing the electroreflectance spectra of these compounds, we measure chi((3)) values in the range 10(-8) to 10(-5) e.s.u. The anomalous enhancement results from a large dipole moment between the lowest two excited states of these systems.	Univ Tokyo, Grad Sch Frontier Sci, Dept Adv Mat Sci, Tokyo 1138656, Japan; PRESTO, Struct & Transformat Grp, Tokyo 1138656, Japan; Nagoya Univ, Grad Sch Human Informat, Nagoya, Aichi 4648601, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920397, Japan; PRESTO, Struct & Transformat Grp, Hachioji, Tokyo 1920397, Japan; Univ Tokyo, Dept Appl Phys, Tokyo 1138656, Japan; Joint Res Ctr Atom Technol JRCAT, Tsukuba, Ibaraki 3058562, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Nagoya University; Tokyo Metropolitan University; Japan Science & Technology Agency (JST); University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Okamoto, H (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Adv Mat Sci, Tokyo 1138656, Japan.	okamotoh@ap.t.u-tokyo.ac.jp	Matsuzaki, Hiroyuki/C-6978-2012; Okamoto, Hiroshi/D-5663-2015; Tokura, Yoshinori/C-7352-2009; Taguchi, Yasujiro/A-3048-2010	Matsuzaki, Hiroyuki/0000-0002-3259-0266; Okamoto, Hiroshi/0000-0003-2807-5277; Tokura, Yoshinori/0000-0002-2732-4983; 				ASPNES DE, 1972, PHYS REV B, V5, P4022, DOI 10.1103/PhysRevB.5.4022; BUBECK C, 1991, CHEM PHYS, V154, P343, DOI 10.1016/0301-0104(91)80084-U; Butcher P. N., 1990, ELEMENTS NONLINEAR O; Cardona M., 1969, MODULATION SPECTROSC; DAGENAIS M, 1987, APPL OPTICS, V26, P211, DOI 10.1364/AO.26.000211; FANN WS, 1989, PHYS REV LETT, V62, P1492, DOI 10.1103/PhysRevLett.62.1492; GELSEN OM, 1992, J APPL PHYS, V71, P1064, DOI 10.1063/1.350401; HALVORSON C, 1992, CHEM PHYS LETT, V200, P364, DOI 10.1016/0009-2614(92)87004-9; HASEGAWA T, 1992, PHYS REV LETT, V69, P668, DOI 10.1103/PhysRevLett.69.668; HASEGAWA T, 1991, SYNTHETIC MET, V43, P3151, DOI 10.1016/0379-6779(91)91253-7; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; IWASA Y, 1991, APPL PHYS LETT, V59, P2219, DOI 10.1063/1.106075; Motoyama N, 1996, PHYS REV LETT, V76, P3212, DOI 10.1103/PhysRevLett.76.3212; OKAMOTO H, 1990, PHYS REV B, V42, P10381, DOI 10.1103/PhysRevB.42.10381; Okamoto H, 1996, PHYS REV B, V54, P8438, DOI 10.1103/PhysRevB.54.8438; PHILLIPS SD, 1989, PHYS REV B, V40, P9751, DOI 10.1103/PhysRevB.40.9751; ROESSLER DM, 1965, BRIT J APPL PHYS, V16, P1119, DOI 10.1088/0508-3443/16/8/310; SAUTERET C, 1976, PHYS REV LETT, V36, P956, DOI 10.1103/PhysRevLett.36.956; SERAPHIN BO, 1965, PHYS REV, V140, P1716, DOI 10.1103/PhysRev.140.A1716; STEGEMAN GI, 1990, OPT QUANT ELECTRON, V22, P95, DOI 10.1007/BF02189947; Stegeman GI, 1996, PHILOS T R SOC A, V354, P745, DOI 10.1098/rsta.1996.0028; Suzuura H, 1996, PHYS REV LETT, V76, P2579, DOI 10.1103/PhysRevLett.76.2579; TOKURA Y, 1986, J CHEM PHYS, V85, P99, DOI 10.1063/1.451602; TORIUMI K, 1989, J AM CHEM SOC, V111, P2341, DOI 10.1021/ja00188a080; WADA Y, 1990, PHYS REV B, V42, P7398, DOI 10.1103/PhysRevB.42.7398	25	317	321	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					929	932		10.1038/35016036	http://dx.doi.org/10.1038/35016036			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879529				2022-12-28	WOS:000087732700044
J	Strong, DR; Pemberton, RW				Strong, DR; Pemberton, RW			Ecology - Biological control of invading species - Risk and reform	SCIENCE			English	Editorial Material							NORTH-AMERICA; FLORIDA		Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; ARS, Invas Plant Res Lab, USDA, Ft Lauderdale, FL 33314 USA	University of California System; University of California Davis; United States Department of Agriculture (USDA)	Strong, DR (corresponding author), Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA.	drstrong@ucdavis.edu; bobpem@ars.usda.gov						ANDRES LA, 1980, P 5 INT S BIOL CONTR, P11; BAX N, IN PRESS CONSERV BIO; Bellotti AC, 1999, ANNU REV ENTOMOL, V44, P343, DOI 10.1146/annurev.ento.44.1.343; BOETTNER GH, IN PRESS CONSERV BIO; Bright C., 1998, LIFE OUT BOUNDS BIOI; Center Ted D., 1997, P245; Civeyrel L, 1996, BIODIVERS CONSERV, V5, P1231, DOI 10.1007/BF00051574; DELFOSSE ES, 1996, P BIOL CONTR WEEDS S; GOODMAN B, 1993, SCIENCE, V260, P887, DOI 10.1126/science.260.5110.887; Hager HA, 1998, BIODIVERS CONSERV, V7, P1069, DOI 10.1023/A:1008861115557; Hawkins BA, 1997, OECOLOGIA, V112, P566, DOI 10.1007/s004420050346; HODEK I, 1973, BIOL COCCINELIDAE; HOWARTH FG, 1991, ANNU REV ENTOMOL, V36, P485, DOI 10.1146/annurev.en.36.010191.002413; Johnson DM, 1996, ENVIRON ENTOMOL, V25, P743, DOI 10.1093/ee/25.4.743; Julien M. H., 1998, BIOL CONTROL WEEDS W; Lockwood JA, 2000, NONTARGET EFFECTS OF BIOLOGICAL CONTROL, P15; Louda SM, 1997, SCIENCE, V277, P1088, DOI 10.1126/science.277.5329.1088; Mabberley DJ, 1997, PLANT BOOK; McEvoy PB, 2000, NONTARGET EFFECTS OF BIOLOGICAL CONTROL, P167; MEDIEROS AC, 1997, BISHOP MUS OCCAS PAP, V48, P23; Miller M., 1993, Rutgers Law Review, V45, P285; MURRAY E, 1993, ENDEAVOUR, V17, P78, DOI 10.1016/0160-9327(93)90200-M; NICO LG, 1996, RISK ASSESSMENT BLAC, P1; OBRYCKI J, 2000, NONTARGET EFFECTS BI, P31; Pemberton Robert W., 1995, American Entomologist, V41, P230; Pemberton RW, 1998, AM FERN J, V88, P176, DOI 10.2307/1547770; PEMBERTON RW, IN PRESS OECOLOGIA; PEMBERTON RW, 1985, P 6 INT S BIOL CONTR, P55; QULSENBERRY SS, 1998, RESPONSE MODEL INTRO; QULSENBERRY SS, 1993, UNPUB; Stiling P, 2000, NONTARGET EFFECTS OF BIOLOGICAL CONTROL, P31; Strong DR, 1997, SCIENCE, V277, P1058, DOI 10.1126/science.277.5329.1058; STRONG DR, IN PRESS EVALUATING; Turner C. E., 1985, Proceedings of the VI International Symposium on Biological Control of Weeds., P203; TURNER CE, 1998, WETLANDS ECOL MANAGE, V4, P165; *US OFF TECHN ASS, 1995, BIOL BASED TECHN PES; Wagner WL, 1999, MANUAL FLOWERING PLA, V1	37	104	121	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	2000	288	5473					1969	1970		10.1126/science.288.5473.1969	http://dx.doi.org/10.1126/science.288.5473.1969			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	325QC	10877714				2022-12-28	WOS:000087687000021
J	Roses, AD				Roses, AD			Pharmacogenetics and the practice of medicine	NATURE			English	Review							FAMILIAL ALZHEIMERS-DISEASE; SINGLE-NUCLEOTIDE POLYMORPHISMS; IRRITABLE-BOWEL-SYNDROME; APOLIPOPROTEIN-E; GENE-EXPRESSION; OLIGONUCLEOTIDE ARRAYS; DIABETES-MELLITUS; DRUG-METABOLISM; TRANSGENIC MICE; HUMAN APOE	"If it were not for the great variability among individuals medicine might as well be a science and not an art." The thoughts of Sir William Osler in 1892 reflect the view of medicine over the past 100 years. The role of physicians in making the necessary judgements about the medicines that they prescribe is often referred to as an art, reflecting the lack of objective data available to make decisions that are tailored to individual patients. Just over a hundred years later we are on the verge of being able to identify inherited differences between individuals which can predict each patient's response to a medicine. This ability will have far-reaching benefits in the discovery, development and delivery of medicines. Sir William Osler, if he were alive today, would be re-considering his view of medicine as an art not a science.	Glaxo Wellcome plc, Genet Directorate, Greenford UB6 0HE, Middx, England; Duke Univ, Med Ctr, Durham, NC 27710 USA	GlaxoSmithKline; Duke University	Roses, AD (corresponding author), Glaxo Wellcome plc, Genet Directorate, Greenford UB6 0HE, Middx, England.							AITMAN TJ, 1995, BAILLIERE CLIN ENDOC, V9, P631, DOI 10.1016/S0950-351X(95)80655-5; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; BONNIE A, 2000, CONTROLLED CLIN TRIA, V21, P7; Boschert U, 1999, NEUROBIOL DIS, V6, P508, DOI 10.1006/nbdi.1999.0251; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Chen JW, 2000, GENOME RES, V10, P549, DOI 10.1101/gr.10.4.549; Cohen LJ, 1996, ANN PHARMACOTHER, V30, P1471, DOI 10.1177/106002809603001216; Collins A, 1999, P NATL ACAD SCI USA, V96, P15173, DOI 10.1073/pnas.96.26.15173; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Curran ME, 1998, CURR OPIN BIOTECH, V9, P565, DOI 10.1016/S0958-1669(98)80133-X; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Hacia JG, 1999, NAT GENET, V22, P164, DOI 10.1038/9674; Hamm LR, 1999, AM J GASTROENTEROL, V94, P1279, DOI 10.1016/S0002-9270(99)00133-1; Howard TD, 1999, CLIN EXP ALLERGY, V29, P86; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Koenig BA, 1998, J WOMENS HEALTH, V7, P531, DOI 10.1089/jwh.1998.7.531; Kozian DH, 1999, TRENDS BIOTECHNOL, V17, P73, DOI 10.1016/S0167-7799(98)01292-X; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lai E, 1998, GENOMICS, V54, P31, DOI 10.1006/geno.1998.5581; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Marez D, 1997, PHARMACOGENETICS, V7, P193, DOI 10.1097/00008571-199706000-00004; Martin ER, 2000, GENOMICS, V63, P7, DOI 10.1006/geno.1999.6057; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mather DB, 1999, AM J MANAG CARE, V5, P277; Mayeux R, 1998, NEW ENGL J MED, V338, P1325; McConnell LM, 1999, GENET TEST, V3, P3, DOI 10.1089/gte.1999.3.3; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V1, pR15; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; MUELLER RF, 1997, EMERYS ELEMENTS MED, P169; Ott J, 2000, P NATL ACAD SCI USA, V97, P2, DOI 10.1073/pnas.97.1.2; Paterson WG, 1999, CAN MED ASSOC J, V161, P154; Rockett JC, 1999, XENOBIOTICA, V29, P655, DOI 10.1080/004982599238317; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; Roses AD, 1997, ARCH NEUROL-CHICAGO, V54, P1226, DOI 10.1001/archneur.1997.00550220036011; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; ROSES AD, 1994, NEUROBIOL AGING, V15, pS165; ROSES AD, IN PRESS J COMM BIOT; RUDORFER MV, 1984, BRIT J CLIN PHARMACO, V17, P433, DOI 10.1111/j.1365-2125.1984.tb02368.x; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SAUNDERS AM, IN PRESS J NEUROPATH; Schork NJ, 1997, AM J RESP CRIT CARE, V156, pS103, DOI 10.1164/ajrccm.156.4.12-tac-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Talley NJ, 1998, EUR J SURG, V164, P24, DOI 10.1080/11024159850191193; Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8; VANNOSTRAND WE, 1992, ANN NEUROL, V32, P215, DOI 10.1002/ana.410320214; White J, 1999, J HEALTH POLIT POLIC, V24, P653; Wiley SR, 1998, CURR PHARM DESIGN, V4, P417; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512; Xu PT, 1998, NEUROSCI LETT, V246, P65, DOI 10.1016/S0304-3940(98)00247-X; Xu PT, 1999, AM J PATHOL, V154, P601, DOI 10.1016/S0002-9440(10)65305-9; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Zhao LP, 1998, AM J HUM GENET, V63, P225, DOI 10.1086/301909	59	551	611	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					857	865		10.1038/35015728	http://dx.doi.org/10.1038/35015728			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866212				2022-12-28	WOS:000087620600064
J	Wang, J; Hannon, GJ; Beach, DH				Wang, J; Hannon, GJ; Beach, DH			Cell biology - Risky immortalization by telomerase	NATURE			English	Article							HUMAN FIBROBLASTS; EPITHELIAL-CELLS; MYC; ACTIVATION; CANCER		Genet Inc, Cambridge, MA 02139 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11743 USA; UCL, Wolfson Inst Biomed Res, London WC1B 6BT, England	Cold Spring Harbor Laboratory; University of London; University College London	Wang, J (corresponding author), Genet Inc, 1 Kendall Sq,Bldg 600, Cambridge, MA 02139 USA.	d.beach@ucl.ac.uk	Hannon, Gregory/AAB-3568-2019					ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Foster SA, 1996, ONCOGENE, V12, P1773; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	12	110	129	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					755	756		10.1038/35015674	http://dx.doi.org/10.1038/35015674			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866187				2022-12-28	WOS:000087620600037
J	McLaren, A				McLaren, A			Cloning: Pathways to a pluripotent future	SCIENCE			English	Article							PRIMORDIAL GERM-CELLS; EMBRYONIC STEM-CELLS; NUCLEAR TRANSPLANTATION; MOUSE EMBRYOS; SHEEP EMBRYOS; CULTURE; PRECURSORS; DERIVATION; LINE		Wellcome CRC Inst, Cambridge, England		McLaren, A (corresponding author), Wellcome CRC Inst, Cambridge, England.							BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; BROMHALL JD, 1975, NATURE, V258, P719, DOI 10.1038/258719a0; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI; Driesch H, 1893, ANAT ANZEIGER, V8, P348; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GURDON JB, 1958, NATURE, V182, P64, DOI 10.1038/182064a0; GURDON JB, 1977, PROC R SOC SER B-BIO, V198, P211, DOI 10.1098/rspb.1977.0095; Hines PJ, 2000, SCIENCE, V287, P1417, DOI 10.1126/science.287.5457.1417; ILLMENSEE K, 1981, CELL, V23, P9, DOI 10.1016/0092-8674(81)90265-8; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; Morgan T. H., 1934, EMBRYOLOGY GENETICS; Needham J., 1934, HIST GENETICS; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Spemann H., 1938, EMBRYONIC DEV INDUCT; Tada T, 1998, DEV GENES EVOL, V207, P551, DOI 10.1007/s004270050146; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Weismann A., 1892, GERM PLASM THEORY HE; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; WILLADSEN SM, 1979, NATURE, V277, P298, DOI 10.1038/277298a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WILMUT I, 2000, 2 CREATION AGE BIOL; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029	27	48	51	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 9	2000	288	5472					1775	1780		10.1126/science.288.5472.1775	http://dx.doi.org/10.1126/science.288.5472.1775			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	322HH	10877698				2022-12-28	WOS:000087503800040
J	Nicholson, KG; Aoki, FY; Osterhaus, ADME; Trottier, S; Carewicz, O; Mercier, CH; Rode, A; Kinnersley, N; Ward, P				Nicholson, KG; Aoki, FY; Osterhaus, ADME; Trottier, S; Carewicz, O; Mercier, CH; Rode, A; Kinnersley, N; Ward, P		Neuraminidase Inhibitor Flu Treatm	Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial	LANCET			English	Article							VIRUS NEURAMINIDASE INHIBITOR; INFECTION; IMPACT; ACID; MICE	Background Use of some antiviral drugs for influenza infection is limited by potential rapid emergence of resistance, We studied the efficacy and safety of oseltamivir, the oral prodrug of the neuraminidase inhibitor GS4071, in adults with naturally acquired laboratory-confirmed influenza. Methods We did a randomised controlled trial of 726 previously healthy non-immunised adults with febrile influenza-like illness of vp to 36 h duration. Patients were assigned oral oseltamivir 75 mg (n=243), oseltamivir 150 mg (n=245), or placebo (n=238) twice daily for 5 days. We assessed recovery by questionnaire and temperature recordings. The primary endpoint was time to resolution of illness in influenza-infected patients. Findings 475 (66%) patients had confirmed infection. Duration of illness was significantly shorter by 29 h (25% reduction, median duration 87.4 h [95% CI 73.3-104.7], p=0.02) with oseltamivir 75 mg and by 35 h (30%, 81.8 h [68.2-100.0], p=0.01) with oseltamivir 150 mg than with placebo (116.5 h [101.5-137.8]). The effect of oseltamivir was apparent within 24 h of the start of treatment. In patients treated within 24 h of symptom onset, symptoms were alleviated 43 h (37% reduction) and 47 h (40%) earlier with oseltamivir 75 mg and 150 mg, respectively, compared with placebo (75 mg 74.5 h [68.2-98.0], p=0.02; 150 mg 70.7 h [54.0-89.4], p=0.01; placebo 117.5 h [103.0-143.8]). Oseltamivir was associated with higher symptom scores, less viral shedding, and improved health, activity, and sleep quality, and was well tolerated. Interpretation Oseltamivir was effective and well tolerated in the treatment of natural influenza infection in adults. The efficacy, tolerability, and ease of administration warrant further investigation in children, elderly patients, and at-risk patients.	Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England; Univ Manitoba, Winnipeg, MB, Canada; Erasmus Univ, Rotterdam, Netherlands; CHU Laval, Ste Foy, PQ, Canada; Humana Sandvika AS, Sandvika, Norway; Roche Gloval Dev, Welwyn Garden City, Herts, England	University of Leicester; University of Manitoba; Erasmus University Rotterdam; Laval University; Roche Holding	Nicholson, KG (corresponding author), Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England.			Ward, Penelope/0000-0002-7585-4313				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], [No title captured]; GLEZEN WP, 1987, J INFECT DIS, V155, P1119, DOI 10.1093/infdis/155.6.1119; He G, 1999, CLIN PHARMACOKINET, V37, P471, DOI 10.2165/00003088-199937060-00003; Keech M, 1998, OCCUP MED-OXFORD, V48, P85, DOI 10.1093/occmed/48.2.85; Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t; Mendel DB, 1998, ANTIMICROB AGENTS CH, V42, P640, DOI 10.1128/AAC.42.3.640; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Ogilvie MM, 1998, J INFECTION, V36, P31, DOI 10.1016/S0163-4453(98)80153-9; SCHOENBAUM SC, 1987, AM J MED, V82, P26, DOI 10.1016/0002-9343(87)90557-2; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; SMITH AP, 1993, BRIT MED J, V306, P760, DOI 10.1136/bmj.306.6880.760; Sullivan KM, 1996, PHARMACOECONOMICS, V9, P26, DOI 10.2165/00019053-199600093-00008; WOODS JM, 1993, ANTIMICROB AGENTS CH, V37, P1473, DOI 10.1128/AAC.37.7.1473	14	562	606	0	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1845	1850		10.1016/S0140-6736(00)02288-1	http://dx.doi.org/10.1016/S0140-6736(00)02288-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866439				2022-12-28	WOS:000087306500010
J	De Benedetti, E; Didier, D				De Benedetti, E; Didier, D			Constrictive pericarditis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hop Cantonal Univ, CH-1211 Geneva 14, Switzerland	University of Geneva	De Benedetti, E (corresponding author), Hop Cantonal Univ, CH-1211 Geneva 14, Switzerland.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					107	107		10.1056/NEJM200007133430206	http://dx.doi.org/10.1056/NEJM200007133430206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891519				2022-12-28	WOS:000088116500006
J	Channer, K				Channer, K			Helping the General Medical Council	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					123	123		10.1136/bmj.321.7253.123	http://dx.doi.org/10.1136/bmj.321.7253.123			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884273	Green Published			2022-12-28	WOS:000088196600057
J	Tuffs, A				Tuffs, A			Fraud study concludes that self regulation has failed	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					71	71						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884251				2022-12-28	WOS:000088196600018
J	Oberhummer, H; Csoto, A; Schlattl, H				Oberhummer, H; Csoto, A; Schlattl, H			Stellar production rates of carbon and its abundance in the universe	SCIENCE			English	Article							EVOLUTION; C-12	The bulk of the carbon in our universe is produced in the triple-alpha process in helium-burning red giant stars. We calculated the change of the triple-alpha reaction rate in a microscopic 12-nucleon model of the C-12 nucleus and Looked for the effects of minimal variations of the strengths of the underlying interactions. Stellar model calculations were performed with the alternative reaction rates. Here, we show that outside a narrow window of 0.5 and 4% of the values of the strong and Coulomb forces, respectively, the stellar production of carbon or oxygen is reduced by factors of 30 to 1000.	Vienna Univ Technol, Inst Nucl Phys, A-1040 Vienna, Austria; Eotvos Lorand Univ, Dept Atom Phys, H-1117 Budapest, Hungary; Max Planck Inst Astrophys, D-85741 Garching, Germany	Technische Universitat Wien; Eotvos Lorand University; Max Planck Society	Oberhummer, H (corresponding author), Vienna Univ Technol, Inst Nucl Phys, Wiedner Hauptstr 8-10, A-1040 Vienna, Austria.	ohu@kph.tuwien.ac.at	Schlattl, Helmut/M-9846-2014	Schlattl, Helmut/0000-0002-3365-7821				Barrow J., 1998, ANTHROPIC COSMOLOGIC; COOK CW, 1957, PHYS REV, V107, P508, DOI 10.1103/PhysRev.107.508; DUNBAR DNF, 1953, PHYS REV, V92, P649, DOI 10.1103/PhysRev.92.649; Furutani H., 1980, PROG THEOR PHYS SUPP, V68, P193; HENRY RBC, IN PRESS ASTROPHYS J; HOGAN CJ, ASTROPH9909295; HOYLE F, 1953, PHYS REV, V92, P1095; IBEN I, 1983, ANNU REV ASTRON ASTR, V21, P271, DOI 10.1146/annurev.aa.21.090183.001415; Jeltema TE, 2000, PHYS REV D, V61, DOI 10.1103/PhysRevD.61.017301; Kippenhahn R., 1990, STELLAR STRUCTURE EV; LIVIO M, 1989, NATURE, V340, P281, DOI 10.1038/340281a0; MAEDER A, 1992, ASTRON ASTROPHYS, V264, P105; Nomoto K, 1997, NUCL PHYS A, V616, pC79, DOI 10.1016/S0375-9474(97)00076-6; OBERHUMMER H, ASTROPH908247; Pichler R, 1997, NUCL PHYS A, V618, P55, DOI 10.1016/S0375-9474(97)00057-2; REICHSTEIN I, 1970, NUCL PHYS A, VA158, P529, DOI 10.1016/0375-9474(70)90201-0; Rolfs C. E., 1988, CAULDRONS COSMOS; Schlattl H, 1999, ASTRON ASTROPHYS, V347, P272; SCHWARZS.M, 1965, ASTROPHYS J, V142, P855, DOI 10.1086/148358; SHIRLEY VS, 1996, TABLE ISOTOPES, V1; THOMPSON DR, 1977, NUCL PHYS A, V286, P53, DOI 10.1016/0375-9474(77)90007-0; TIMMES FX, 1995, ASTROPHYS J SUPPL S, V98, P617, DOI 10.1086/192172; VOLKOV AB, 1965, NUCL PHYS, V74, P33, DOI 10.1016/0029-5582(65)90244-0; WAGENHUBER J, 1994, ASTRON ASTROPHYS, V286, P121; Weiss A, 2000, ASTRON ASTROPHYS SUP, V144, P487, DOI 10.1051/aas:2000223; Weiss A, 2000, ASTRON ASTROPHYS, V356, P181; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237	27	59	60	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	2000	289	5476					88	90		10.1126/science.289.5476.88	http://dx.doi.org/10.1126/science.289.5476.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884230	Green Submitted			2022-12-28	WOS:000088090400036
J	Schneider, D; Shahabuddin, M				Schneider, D; Shahabuddin, M			Malaria parasite development in a Drosophila model	SCIENCE			English	Article							PLASMODIUM-FALCIPARUM; MOSQUITO MIDGUT; SPOROZOITES; TRANSMISSION; HOST	Malaria is a devastating public health menace, killing over one million people every year and infecting about half a billion. Here it is shown that the protozoan Plasmodium gallinaceum, a close relative of the human malaria parasite Plasmodium falciparum, can develop in the fruit fly Drosophila melanogaster. Plasmodium gallinaceum ookinetes injected into the fly developed into sporozoites infectious to the vertebrate host with similar kinetics as seen in the mosquito host Aedes aegypti. In the fly, a component of the insect's innate immune system, the macrophage, can destroy Plasmodia. These experiments suggest that Drosophila can be used as a surrogate mosquito for defining the genetic pathways involved in both vector competence and part of the parasite sexual cycle.	Whitehead Inst, Cambridge, MA 02142 USA; NIAID, NIH, Bethesda, MD 20892 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schneider, D (corresponding author), Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000811] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; ELRODERICKSON M, IN PRESS CURR BIOL; GARNHAM PCC, 1966, MALARIA PARASITES OT, P609; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; KRETTLI AU, 1988, PARASITE IMMUNOL, V10, P523, DOI 10.1111/j.1365-3024.1988.tb00240.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; OZAKI LS, 1984, J PARASITOL, V70, P831, DOI 10.2307/3281779; Richman AM, 1998, NAT MED, V4, P552, DOI 10.1038/nm0598-552; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; SHAHABUDDIN M, 1994, B I PASTEUR, V92, P119; Shahabuddin M, 1998, PARASITOL TODAY, V14, P493, DOI 10.1016/S0169-4758(98)01348-9; TOURAY MG, 1992, J EXP MED, V175, P1607, DOI 10.1084/jem.175.6.1607; VAUGHAN JA, 1994, AM J TROP MED HYG, V51, P233, DOI 10.4269/ajtmh.1994.51.233; Vernick KD, 1996, AM J TROP MED HYG, V54, P430, DOI 10.4269/ajtmh.1996.54.430; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140	16	83	84	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2376	2379		10.1126/science.288.5475.2376	http://dx.doi.org/10.1126/science.288.5475.2376			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875925				2022-12-28	WOS:000087913400043
J	Liu, YJ; Gao, JH; Liu, HL; Fox, PT				Liu, YJ; Gao, JH; Liu, HL; Fox, PT			The temporal response of the brain after eating revealed by functional MRI	NATURE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; TASTE PERCEPTION; HYPOTHALAMUS; SATIATION; CORTEX; HUMANS; FOOD	After eating, the human brain senses a biochemical change and then signals satiation, but precisely when this occurs is unknown. Even for well-established physiological systems like glucose-insulin regulation, the timing of interaction between hormonal processes and neural events is inferred mostly from blood sampling(1-6). Recently, neuroimaging studies have provided in vivo information about the neuroanatomical correlates of the regulation of energy intake(7-10). Temporal orchestration of such systems, however, is crucial to the integration of neuronal and hormonal signals that control eating behaviour(11). The challenge of this functional magnetic resonance imaging study is to map not only where but also when the brain will respond after food ingestion. Here we use a temporal clustering analysis technique to demonstrate that eating-related neural activity peaks at two different times with distinct localization. Importantly, the differentiated responses are interacting with an internal signal, the plasma insulin. These results support the concept of temporal parcellation of brain activity(12), which reflects the different natures of stimuli and responses. Moreover, this study provides a neuroimaging basis for detecting dynamic processes without prior knowledge of their timing, such as the acute effects of medication and nutrition in the brain.	Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Inst Brain, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, YJ (corresponding author), Univ Florida, Dept Psychiat, 100 Newell Dr, Gainesville, FL 32610 USA.	yijunliu@ufl.edu; gao@uthscsa.edu	Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028				[Anonymous], 1987, HDB PHYSL 1 NERVOUS; BENDETTINI PA, 1993, MAGNET RESON MED, V30, P161; BENZO CA, 1983, LIFE SCI, V32, P2509, DOI 10.1016/0024-3205(83)90231-X; Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; Denton D, 1999, P NATL ACAD SCI USA, V96, P2532, DOI 10.1073/pnas.96.5.2532; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; Gautier JF, 1999, AM J CLIN NUTR, V70, P806; GROSSMAN SP, 1975, PSYCHOL REV, V82, P200, DOI 10.1037/0033-295X.82.3.200; KINOMURA S, 1994, BRAIN RES, V659, P263, DOI 10.1016/0006-8993(94)90890-7; LIU HL, 1999, P INT SOC MAGN RESON, V7, P271; LIU Y, 1999, NEUROIMAGE, V9, pS120; Liu YY, 1999, NATURE, V400, P364, DOI 10.1038/22547; Matsuda M, 1999, DIABETES, V48, P1801, DOI 10.2337/diabetes.48.9.1801; Ngan SC, 1999, MAGNET RESON MED, V41, P939, DOI 10.1002/(SICI)1522-2594(199905)41:5<939::AID-MRM13>3.0.CO;2-Q; OOMURA Y, 1981, HDB HYPOTHALAMUS PHY, P557; Reiman EM, 1997, J CLIN PSYCHIAT, V58, P4; Rohner-Jeanrenaud F, 1983, Adv Metab Disord, V10, P193; ROLLS ET, 1998, NEURAL NETWORK BRAIN, P17; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; Saper C.B., 1990, HUMAN NERVOUS SYSTEM, P389, DOI DOI 10.1016/B978-0-12-547625-6.50020-9; Scott T. R., 1995, Neurobiology (Budapest), V3, P281; Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; WORSLEY KJ, 1994, ADV APPL PROBAB, V26, P13, DOI 10.2307/1427576; Xiong JH, 1996, HUM BRAIN MAPP, V4, P153, DOI 10.1002/(SICI)1097-0193(1996)4:3<153::AID-HBM1>3.0.CO;2-2; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0	30	220	233	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1058	1062		10.1038/35016590	http://dx.doi.org/10.1038/35016590			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890447				2022-12-28	WOS:000087871700047
J	Atkinson, RL				Atkinson, RL			A 33-year-old woman with morbid obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INDUCED WEIGHT-LOSS; UNITED-STATES; DIETARY-FAT; ADENOVIRUS INFECTION; OVERWEIGHT; PREVALENCE; SURGERY; WOMEN; HYPERTENSION; INTERVENTION		Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA; Univ Wisconsin, Beers Murphy Clin Nutr Ctr, Madison, WI USA	Harvard University; Beth Israel Deaconess Medical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Atkinson, RL (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.		Atkinson, Richard/AAK-4953-2021	Atkinson, Richard L./0000-0003-1745-5645				Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Atkinson R. L., 1998, International Journal of Obesity, V22, pS57; ATKINSON RL, 1982, INT J OBESITY, V6, P351; ATKINSON RL, IN PRESS INT J OBES; BOOZER CN, 1995, AM J PHYSIOL-ENDOC M, V268, pE546; Bouchard C., 1998, HDB OBESITY, P157; BOWEN RL, 2000, OBES RES, V8, P118; BRAY GA, 1984, PEDIATR ANN, V13, P525; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; BRAY GA, 1997, HDB OBESITY; CARTER JK, 1983, INFECT IMMUN, V39, P410, DOI 10.1128/IAI.39.1.410-422.1983; Chagnon YC, 2000, OBES RES, V8, P89, DOI 10.1038/oby.2000.12; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; Dhurandhar NV, 1997, OBES RES, V5, P464, DOI 10.1002/j.1550-8528.1997.tb00672.x; DHURANDHAR NV, 1992, VET MICROBIOL, V31, P101, DOI 10.1016/0378-1135(92)90068-5; DHURANDHAR NV, IN PRESS INT J OBESI; DHURANDHAR NV, 1996, OBES RES, V4, pS24; Ernst Nancy D., 1997, American Journal of Clinical Nutrition, V66, p965S, DOI 10.1093/ajcn/66.4.965S; FLATT JP, 1985, J CLIN INVEST, V76, P1019, DOI 10.1172/JCI112054; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Foster GD, 1997, J CONSULT CLIN PSYCH, V65, P79, DOI 10.1037/0022-006X.65.1.79; GEORGE V, 1990, INT J OBESITY, V14, P1085; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; GORTMAKER SL, 1990, J AM DIET ASSOC, V90, P1247; GOSZTONYI G, 1995, CURR TOP MICROBIOL, V190, P39; JAKICIC JM, 1995, INT J OBESITY, V19, P893; KRAL JG, 1997, HDB OBESITY, P977; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; Lang K, 1986, Orv Hetil, V127, P2303; Lean MEJ, 1997, INT J OBESITY, V21, pS30; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LYONS MJ, 1982, SCIENCE, V216, P82, DOI 10.1126/science.7038878; MacDonald K G Jr, 1997, J Gastrointest Surg, V1, P213, DOI 10.1016/S1091-255X(97)80112-6; MAGNUSSON A, 1993, ARCH GEN PSYCHIAT, V50, P941; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Martin LF, 1998, WORLD J SURG, V22, P1008, DOI 10.1007/s002689900508; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MUNRO JF, 1968, BRIT MED J, V1, P352, DOI 10.1136/bmj.1.5588.352; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Pronk N P, 1994, Obes Res, V2, P587; RAND CSW, 1991, INT J OBESITY, V15, P577; Rolls BJ, 1997, J AM COLL NUTR, V16, P535; Sjostrom CD, 1999, OBES RES, V7, P477; Stunkard AJ., 1976, PAIN OBESITY; SUGERMAN HJ, 1988, ANN SURG, V207, P604, DOI 10.1097/00000658-198805000-00015; Sugerman HJ, 1999, ANN SURG, V229, P634, DOI 10.1097/00000658-199905000-00005; SUGERMAN HJ, 1995, NEUROLOGY, V45, P1655, DOI 10.1212/WNL.45.9.1655; SUGERMAN HJ, 1989, AM J SURG, V157, P93, DOI 10.1016/0002-9610(89)90427-3; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; *WHO, 1998, PREV MAN GLOB EP OB; WIGAND R, 1980, ARCH VIROL, V64, P225, DOI 10.1007/BF01322702; ZURLO F, 1992, AM J PHYSIOL, V263, pE296, DOI 10.1152/ajpendo.1992.263.2.E296	55	9	10	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3236	3243		10.1001/jama.283.24.3236	http://dx.doi.org/10.1001/jama.283.24.3236			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866872				2022-12-28	WOS:000087753900037
J	Chan, KA; Andrade, SE; Boles, M; Buist, DSM; Chase, GA; Donahue, JG; Goodman, MJ; Gurwitz, JH; LaCroix, AZ; Platt, R				Chan, KA; Andrade, SE; Boles, M; Buist, DSM; Chase, GA; Donahue, JG; Goodman, MJ; Gurwitz, JH; LaCroix, AZ; Platt, R			Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women	LANCET			English	Article							HIP FRACTURE; PEOPLE; DISEASE; FALLS	Background Inhibitors of hydroxymethylglutaryl-coenzyme A reductase (statins) increase new bone formation in rodents and in human cells in vitro. Statin use is associated with increased bone mineral density of the femoral neck. We undertook a population-based case-control study at six health-maintenance organisations in the USA to investigate further the relation between statin use and fracture risk among older women. Methods We investigated women aged 60 years or older. Exposure, outcome, and confounder information was obtained from automated claims and pharmacy data from October, 1994, to September, 1997. Cases had an incident diagnosis of non-pathological fracture of the hip, humerus, distal tibia, wrist, or vertebrae between October, 1996, and September, 1997. Controls had no fracture during this period. We excluded women with records of dispensing of drugs to treat osteoporosis. Findings There were 928 cases and 2747 controls. Compared with women who had no record of statin dispensing during the previous 2 years, women with 13 or more statin dispensings during this period had a decreased risk of non-pathological fracture (odds ratio 0.48 [95% CI 0.27-0.83]) after adjustment for age, number of hospital admissions during the previous year, chronic disease score, and use of non-statin lipid-lowering drugs. No association was found between fracture risk and fewer than 13 dispensings of statins or between fracture risk and use of non-statin lipid-lowering drugs. Interpretation Statins seem to be protective against nonpathological fracture among older women. These findings are compatible with the hypothesis that statins increase bone mineral density in human beings and thereby decrease the risk of osteoporotic fractures.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Fallon Healthcare Syst, Meyers Primary Care Inst, Worcester, MA USA; Kaiser Permanente NW, Portland, OR USA; Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA; Henry Ford Hlth Syst, Detroit, MI USA; HealthPartners Res Fdn, Minneapolis, MN USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard Pilgrim Health Care; Kaiser Permanente; Group Health Cooperative; Henry Ford Health System; Henry Ford Hospital; HealthPartners Institute for Education & Research	Chan, KA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			Chan, Kinwei/0000-0001-8161-1986				Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; Bauer DC, 1999, J BONE MINER RES, V14, pS179; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; Ernst ND, 1997, J AM DIET ASSOC, V97, pS47, DOI 10.1016/S0002-8223(97)00729-3; FISHMAN P, 1999, 2 INT HLTH EC C ROTT; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; Lennernas H, 1997, CLIN PHARMACOKINET, V32, P403, DOI 10.2165/00003088-199732050-00005; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140-6736(97)09528-7; LIU BA, 1995, J AM GERIATR SOC, V43, P1141, DOI 10.1111/j.1532-5415.1995.tb07016.x; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; RAY WA, 1992, J CLIN EPIDEMIOL, V45, P703, DOI 10.1016/0895-4356(92)90047-Q; RAY WA, 1989, LANCET, V1, P687; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837	20	345	377	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2185	2188		10.1016/S0140-6736(00)02400-4	http://dx.doi.org/10.1016/S0140-6736(00)02400-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881890				2022-12-28	WOS:000087779000008
J	Eberhardt, MV; Lee, CY; Liu, RH				Eberhardt, MV; Lee, CY; Liu, RH			Nutrition - Antioxidant activity of fresh apples	NATURE			English	Article							ASSAY		Cornell Univ, Dept Food Sci, Ithaca, NY 14853 USA	Cornell University	Eberhardt, MV (corresponding author), Cornell Univ, Dept Food Sci, 108 Stocking Hall, Ithaca, NY 14853 USA.	RL23@cornell.edu	Liu, Rui Hai/C-2865-2008; Liu, Rui Hai/AAE-4865-2019	Liu, Rui Hai/0000-0002-7018-7929				BURDA S, 1990, J AGR FOOD CHEM, V38, P945, DOI 10.1021/jf00094a006; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Herbert V, 1996, J NUTR, V126, pS1213, DOI 10.1093/jn/126.suppl_4.1213S; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; LUNEC J, 1992, J INT FED CLIN CHEM, V4, P58; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; *USDA, 1998, USDA NUTR DAT STAND; Wang H, 1996, J AGR FOOD CHEM, V44, P701, DOI 10.1021/jf950579y; Winston GW, 1998, FREE RADICAL BIO MED, V24, P480, DOI 10.1016/S0891-5849(97)00277-3	10	854	912	4	299	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					903	904		10.1038/35016151	http://dx.doi.org/10.1038/35016151			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879522				2022-12-28	WOS:000087732700036
J	Koronakis, V; Sharff, A; Koronakis, E; Luisi, B; Hughes, C				Koronakis, V; Sharff, A; Koronakis, E; Luisi, B; Hughes, C			Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export	NATURE			English	Article							ESCHERICHIA-COLI; SECRETION; CHANNEL; SYSTEM; TRANSLOCATION; RECEPTOR; FHUA	Diverse molecules, from small antibacterial drugs to large protein toxins, are exported directly across both cell membranes of Gram-negative bacteria. This export is brought about by the reversible interaction of substrate-specific inner-membrane proteins with an outer-membrane protein of the TolC family, thus bypassing the intervening periplasm. Here we report the 2.1-Angstrom crystal structure of TolC from Escherichia coli, revealing a distinctive and previously unknown fold. Three TolC protomers assemble to form a continuous, solvent-accessible conduit-a 'channel-tunnel' over 140 Angstrom long that spans both the outer membrane and periplasmic space. The periplasmic or proximal end of the tunnel is sealed by sets of coiled helices. We suggest these could be untwisted by an allosteric mechanism, mediated by protein-protein interactions, to open the tunnel. The structure provides an explanation of how the cell cytosol is connected to the external environment during export, and suggests a general mechanism for the action of bacterial efflux pumps.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Cambridge, Dept Biochem, Crystallog & Biocomp Unit, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge	Koronakis, V (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	vk103@mole.bio.cam.ac.uk		Koronakis, Vassilis/0000-0002-1353-1092				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENZ R, 1993, ZBL BAKT-INT J MED M, V278, P187, DOI 10.1016/S0934-8840(11)80836-4; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KREUSCH A, 1994, PROTEIN SCI, V3, P58; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schulz GE, 1996, CURR OPIN STRUC BIOL, V6, P485, DOI 10.1016/S0959-440X(96)80113-8; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; Sharff AJ, 2000, ACTA CRYSTALLOGR D, V56, P785, DOI 10.1107/S090744490000370X; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; STONE BJ, 1995, MOL MICROBIOL, V17, P701, DOI 10.1111/j.1365-2958.1995.mmi_17040701.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	40	838	873	1	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					914	919		10.1038/35016007	http://dx.doi.org/10.1038/35016007			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879525				2022-12-28	WOS:000087732700040
J	Miller, PJO; Biassoni, N; Samuels, A; Tyack, PL				Miller, PJO; Biassoni, N; Samuels, A; Tyack, PL			Whale songs lengthen in response to sonar	NATURE			English	Article							HUMPBACK WHALES		Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA; Chicago Zool Soc, Daniel F & Ada L Rice Conservat Biol & Res Ctr, Brookfield, IL 60513 USA	Woods Hole Oceanographic Institution	Miller, PJO (corresponding author), Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA.		Tyack, Peter L/D-6209-2013; Tyack, Peter/AAC-4513-2019	Tyack, Peter L/0000-0002-8409-4790; Tyack, Peter/0000-0002-8409-4790				ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534; Katona S., 1979, Behavior of Marine Animals, V3, P33; LEHMANN EL, 1958, ANN MATH STAT, V29, P1167, DOI 10.1214/aoms/1177706448; Miller PJ, 1998, DEEP-SEA RES PT II, V45, P1389, DOI 10.1016/S0967-0645(98)00028-9; PAYNE RS, 1971, SCIENCE, V173, P585, DOI 10.1126/science.173.3997.585; RICHARDSON WJ, 1995, MARINEMAMMALS NOISE; TYACK P, 1981, BEHAV ECOL SOCIOBIOL, V8, P105, DOI 10.1007/BF00300822; WATERS MA, 1996, US FED REG, V61, P37452; Zar JH., 1999, BIOSTAT ANAL	9	167	169	0	79	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					903	903		10.1038/35016148	http://dx.doi.org/10.1038/35016148			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879521	Bronze			2022-12-28	WOS:000087732700035
J	Esparza, J; Bhamarapravati, N				Esparza, J; Bhamarapravati, N			Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; AIDS VACCINE; EFFICACY; NEUTRALIZATION; PROTECTION; VOLUNTEERS; INFECTION; THAILAND; ISSUES; TRIALS	An HIV-1 vaccine offers the best long-term hope to control the AIDS pandemic, especially in less-developed countries. To ensure its future availability we need to increase our research efforts today, including clinical trials. Although small-scale clinical trials of HIV-1 vaccines have been underway since 1987, the first phase III efficacy trials started only recently in the USA and Thailand. Initial results from these trials will be available within the next 2-3 years, and we must start planning now how vaccines should be used if found to be effective. In the meantime, the continuing promotion of the parallel development and assessment of other candidate vaccines is important. Financial mechanisms should also be developed as an incentive to industry and to ensure equitable distribution of future vaccines in less-developed countries. Moreover, a concerted effort is needed to ensure the development and future availability of appropriate vaccines for Africa.	WHO, Hlth Technol & Pharmaceut, WHO UNAIDS HIV Vaccine Initiat, CH-1211 Geneva 27, Switzerland; Mahidol Univ, Ctr Vaccine Dev, Bangkok 10700, Thailand	UNAIDS; World Health Organization; Mahidol University	Esparza, J (corresponding author), WHO, Hlth Technol & Pharmaceut, WHO UNAIDS HIV Vaccine Initiat, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.							Anderson RM, 1996, LANCET, V348, P1010, DOI 10.1016/S0140-6736(96)07100-0; Berman PW, 1999, VIROLOGY, V265, P1, DOI 10.1006/viro.1999.0031; Berman PW, 1996, J INFECT DIS, V173, P52, DOI 10.1093/infdis/173.1.52; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Boily MC, 1999, VACCINE, V17, P989, DOI 10.1016/S0264-410X(98)00316-8; Bolognesi DP, 1998, NATURE, V391, P638, DOI 10.1038/35504; Boyer JD, 1999, VACCINE, V17, pS53, DOI 10.1016/S0264-410X(99)00235-2; Boyer JD, 2000, J INFECT DIS, V181, P476, DOI 10.1086/315229; Brown Arthur E., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P377; Clements-Mann ML, 1998, AIDS RES HUM RETROV, V14, pS197; Datta S, 1998, STAT MED, V17, P185, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;185::AID-SIM732&gt;3.0.CO;2-4; Davis NL, 2000, J VIROL, V74, P371, DOI 10.1128/JVI.74.1.371-378.2000; Esparza J, 1991, AIDS, V5 Suppl 2, pS159, DOI 10.1097/00002030-199101001-00022; Esparza J, 1996, AIDS, V10 Suppl A, pS123, DOI 10.1097/00002030-199601001-00017; ESPARZA J, IN PRESS HIV AIDS CO; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; Ferrari G, 1997, P NATL ACAD SCI USA, V94, P1396, DOI 10.1073/pnas.94.4.1396; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; Girard M, 1999, CR ACAD SCI III-VIE, V322, P959, DOI 10.1016/S0764-4469(00)87193-0; Goldenthal KL, 1998, AIDS RES HUM RETROV, V14, pS333; Guenter D, 2000, J MED ETHICS, V26, P37, DOI 10.1136/jme.26.1.37; Hanke T, 1999, IMMUNOL LETT, V66, P177, DOI 10.1016/S0165-2478(98)00164-3; Heeney JL, 1999, IMMUNOL TODAY, V20, P247, DOI 10.1016/S0167-5699(98)01437-6; Hilleman MR, 1999, VACCINE, V17, P1211, DOI 10.1016/S0264-410X(98)00345-4; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; MacQueen KM, 1999, J ACQ IMMUN DEF SYND, V21, P243, DOI 10.1097/00126334-199907010-00010; Mahoney RT, 1999, VACCINE, V17, P646, DOI 10.1016/S0264-410X(98)00246-1; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Nathanson N, 1999, J MED PRIMATOL, V28, P146, DOI 10.1111/j.1600-0684.1999.tb00263.x; Nitayaphan S, 2000, VACCINE, V18, P1448, DOI 10.1016/S0264-410X(99)00421-1; Nitayaphan S, 1998, AIDS, V12 Suppl B, pS155; OSMANOV S, 1998, HUMAN IMMUNODEFICIEN, P501; Rida W, 1997, J ACQ IMMUN DEF SYND, V16, P195, DOI 10.1097/00042560-199711010-00009; Rowland-Jones S, 1998, DEV BIOL STAND, V92, P209; Tartaglia J, 1998, AIDS RES HUM RETROV, V14, pS291; *UNAIDS, 2000, UNAIDS0007E; *UNAIDS WHO, 1999, UNAIDS99K3E; *UNAIDS WHO NIID, 1999, AIDS, V13; Van der Groen G, 1998, AIDS RES HUM RETROV, V14, pS211; Vermund SH, 1998, AIDS RES HUM RETROV, V14, pS321; Zolla-Pazner S, 1998, J INFECT DIS, V178, P1502, DOI 10.1086/314452	41	130	138	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2061	2066		10.1016/S0140-6736(00)02360-6	http://dx.doi.org/10.1016/S0140-6736(00)02360-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885368				2022-12-28	WOS:000087519400039
J	McKenna, RM; Takemoto, SK				McKenna, RM; Takemoto, SK			Improving HLA matching for kidney transplantation by use of CREGs	LANCET			English	Editorial Material							ALLOCATION; PRIVATE		Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada; Calgary Lab Serv, Calgary, AB, Canada; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	University of Calgary; University of Calgary; University of California System; University of California Los Angeles	Takemoto, SK (corresponding author), Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.							FULLER AA, 1990, HUM IMMUNOL, V28, P306, DOI 10.1016/0198-8859(90)90059-X; Fuller TC, 1999, TRANSPLANTATION, V68, P173, DOI 10.1097/00007890-199907270-00002; Hata Y, 1998, TRANSPLANTATION, V65, P208; KONOEDA Y, 1986, TRANSPLANTATION, V41, P253, DOI 10.1097/00007890-198602000-00023; McKenna RM, 1998, TRANSPLANTATION, V66, P38, DOI 10.1097/00007890-199807150-00006; McKenna RM, 2000, TRANSPLANTATION, V69, P319, DOI 10.1097/00007890-200002150-00001; Morris PJ, 1999, LANCET, V354, P1147, DOI 10.1016/S0140-6736(99)01104-6; SANFILIPPO F, 1984, TRANSPLANTATION, V38, P483, DOI 10.1097/00007890-198411000-00008; Sijpkens YWJ, 1999, KIDNEY INT, V56, P1920, DOI 10.1046/j.1523-1755.1999.00753.x; Starzl TE, 1997, TRANSPLANTATION, V64, P983, DOI 10.1097/00007890-199710150-00009; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; Wujciak T, 1999, TRANSPLANTATION, V68, P1097, DOI 10.1097/00007890-199910270-00006	12	18	21	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1842	1843		10.1016/S0140-6736(00)02283-2	http://dx.doi.org/10.1016/S0140-6736(00)02283-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866435				2022-12-28	WOS:000087306500005
J	Adrain, JM; Westrop, SR				Adrain, JM; Westrop, SR			An empirical assessment of taxic paleobiology	SCIENCE			English	Article							MARINE FOSSIL RECORD; BACKGROUND EXTINCTION; MASS EXTINCTIONS; PATTERNS; PERIODICITY; EVOLUTIONARY	The analysis of major changes in faunal diversity through time is a central theme of analytical paleobiology. The most important sources of data are literature-based compilations of stratigraphic ranges of fossil taxa. The levels of error in these compilations and the possible effects of such error have often been discussed but never directly assessed. We compared our comprehensive database of trilobites to the equivalent portion of J. J. Sepkoski Jr.'s widely used global genus database. More than 70% of entries in the global database are inaccurate; however, as predicted, the error is randomly distributed and does not introduce bias.	Univ Iowa, Dept Geosci, Iowa City, IA 52242 USA; Univ Oklahoma, Oklahoma Museum Nat Hist, Norman, OK 73019 USA; Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA	University of Iowa; University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma - Norman	Adrain, JM (corresponding author), Univ Iowa, Dept Geosci, Iowa City, IA 52242 USA.	jonathan-adrain@uiowa.edu						Adrain JM, 1998, SCIENCE, V280, P1922, DOI 10.1126/science.280.5371.1922; AGER DV, 1988, EXTINCTION SURVIVAL, V34, P89; Benton Michael J., 1999, P249; BOYAJIAN GF, 1986, GEOLOGY, V14, P955, DOI 10.1130/0091-7613(1986)14<955:PTIBEC>2.0.CO;2; CULVER SJ, 1987, PALEOBIOLOGY, V13, P169; FLESSA KW, 1985, NATURE, V313, P216, DOI 10.1038/313216a0; FOOTE M, 1988, PALEOBIOLOGY, V14, P258, DOI 10.1017/S0094837300011994; GILINSKY NL, 1994, PALEOBIOLOGY, V20, P445, DOI 10.1017/S0094837300012926; GILINSKY NL, 1987, PALEOBIOLOGY, V13, P427; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; MAXWELL WD, 1990, PALEOBIOLOGY, V16, P322, DOI 10.1017/S0094837300010022; MCKINNEY ML, 1985, PALEOBIOLOGY, V11, P227, DOI 10.1017/S0094837300011532; MCKINNEY ML, 1987, NATURE, V325, P143, DOI 10.1038/325143a0; Mishler BD, 1999, SPECIES, P307; PATTERSON C, 1987, NATURE, V330, P248, DOI 10.1038/330248a0; Raup D.M., 1991, Short Courses in Paleontology, P207; RAUP DM, 1986, SCIENCE, V231, P833, DOI 10.1126/science.11542060; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Sepkoski J. J., 1982, MILWAUKEE PUBLIC MUS, V51, P1; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; SEPKOSKI JJ, 1989, J GEOL SOC LONDON, V146, P7, DOI 10.1144/gsjgs.146.1.0007; SEPKOSKI JJ, 1981, PALEOBIOLOGY, V7, P36, DOI 10.1017/S0094837300003778; Sepkoski JJ, 1996, GLOBAL EVENTEVENT, P21; Sepkoski Jr J.J., 1992, MILWAUKEE PUBLIC MUS, V83, P1; Sepkoski Jr J. J., 1986, GLOBAL BIOEVENTS, P47; SMITH AB, 1988, EVOL BIOL, V23, P127; STEARN CW, 1999, PALAEONTOL ELECT, V2; Webby BD, 1998, NEWSL STRATIGR, V36, P1	30	76	79	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	2000	289	5476					110	112		10.1126/science.289.5476.110	http://dx.doi.org/10.1126/science.289.5476.110			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884223				2022-12-28	WOS:000088090400043
J	Schiermeier, Q				Schiermeier, Q			Austrian physics meeting passes without boycott	NATURE			English	News Item																		2000, NATURE, V403, P691	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					7	7		10.1038/35017728	http://dx.doi.org/10.1038/35017728			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894512	Bronze			2022-12-28	WOS:000087991200010
J	Jeffcoate, W				Jeffcoate, W			Names to remember	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Jeffcoate, W (corresponding author), The Lancet, London WC1X 8RR, England.							[Anonymous], 1962, ANATOMICAL EPONYMS; BEIGHTON P, 1986, MAN BEHIND SYNDROME; Bishop W.J., 1959, NOTABLE NAMES MED SU; MAGALINI S, 1990, DICT MED SYNDROMES	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					8	8		10.1016/S0140-6736(00)02425-9	http://dx.doi.org/10.1016/S0140-6736(00)02425-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892757				2022-12-28	WOS:000087933400007
J	Iglehart, JK				Iglehart, JK			Revisiting the Canadian health care system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EXPENDITURES											*ASS CAN MED COLL, 1999, CAN MED ED STAT; BARER M, PRIVATE HIGHWAY ONE; Barer Morris L., 1991, INTEGRATED MED RESOU; BELTRAME J, 2000, WALL ST J       0410, pB1; *CAN I HLTH INF, 1998, SUPPL DISTR MIGR CAN; *CAN I HLTH INF, 1999, NAT HLTH EXP DAT NAT; *COLL FAM PHYS CAN, 1995, MAN CHANG FAM MED GR; Donelan K, 1999, HEALTH AFFAIR, V18, P206, DOI 10.1377/hlthaff.18.3.206; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; Freund DA, 2000, HEALTH AFFAIR, V19, P259, DOI 10.1377/hlthaff.19.3.259; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GRAHAM W, 1999, ONTARIO MED REV, V66, P21; HARRIMAN D, 1999, 28 FRAS I; *HLTH INS ASS AM, 1999, HLTH INS COV UN 1990; *HLTH SERV RESTR C, 1999, BETT HOSP BETT HLTH; IGLEHART JK, 1990, NEW ENGL J MED, V322, P562, DOI 10.1056/NEJM199002223220827; Iglehart JK, 2000, HEALTH AFFAIR, V19, P132, DOI 10.1377/hlthaff.19.3.132; KENNEDY M, 2000, OTTAWA CITIZEN  0122; MCILROY A, 2000, GLOBE MAIN      0221, P1; Naylor C. David, 1986, PRIVATE PRACTICE PUB; Naylor CD, 1999, HEALTH AFFAIR, V18, P9, DOI 10.1377/hlthaff.18.3.9; *OECD, 2000, OECD HLTH DAT 99; PEAR R, 2000, NY TIMES        1029, pA16; Priest L, 2000, Mod Healthc, V30, P24; PRIEST L, 2000, GLOBE MAIL      0304, P1; ROSENBAUM DE, 1999, NY TIMES        1215, pA21; RYTEN E, 1997, STAT PICTURE PAST PR; TAYLOR MG, 1979, HLTH INSURANCE CANAD; Tuohy C., 1999, ACCIDENTAL LOGICS DY; 1999, ANGUS REID GROU 0206	30	42	42	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					2007	2012		10.1056/NEJM200006293422624	http://dx.doi.org/10.1056/NEJM200006293422624			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874071				2022-12-28	WOS:000087867400033
J	Post, DM; Pace, ML; Hairston, NG				Post, DM; Pace, ML; Hairston, NG			Ecosystem size determines food-chain length in lakes	NATURE			English	Article							TROPHIC STRUCTURE; STABLE ISOTOPES; ARCTIC LAKES; WEBS; PRODUCTIVITY; ENRICHMENT; PATTERNS	Food-chain length is an important characteristic of ecological communities(1) : it influences community structure(2), ecosystem functions(1-4) and contaminant concentrations in top predators(5,6). Since Elton(7) first noted that food-chain length was variable among natural systems, ecologists have considered many explanatory hypotheses(1,4,8,9), but few are supported by empirical evidence(4,10,11). Here we test three hypotheses that predict food-chain length to be determined by productivity alone (productivity hypothesis)(4,10,12,13), ecosystem size alone (ecosystem-size hypothesis)(14,15) or a combination of productivity and ecosystem size (productive-space hypothesis)(7,16-18). The productivity and productive-space hypotheses propose that food-chain length should increase with increasing resource availability; however, the productivity hypothesis does not include ecosystem size as a determinant of resource availability. The ecosystem-size hypothesis is based on the relationship between ecosystem size and species diversity, habitat availability and habitat heterogeneity(14,15). We find that food-chain length increases with ecosystem size, but that the length of the food chain is not related to productivity. Our results support the hypothesis that ecosystem size, and not resource availability, determines food-chain length in these natural ecosystems.	Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; Inst Ecosyst Studies, Millbrook, NY 12545 USA	Cornell University; Cary Institute of Ecosystem Studies	Post, DM (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Corson Hall, Ithaca, NY 14853 USA.	dmp18@cornell.edu	Post, David M/A-6987-2009	Post, David M/0000-0003-1434-7729; Pace, Michael/0000-0001-5945-6131				BRIAND F, 1987, SCIENCE, V238, P956, DOI 10.1126/science.3672136; CABANA G, 1994, NATURE, V372, P255, DOI 10.1038/372255a0; Carpenter S.R., 1993, TROPHIC CASCADE LAKE; COHEN JE, 1991, AM NAT, V138, P1542, DOI 10.1086/285299; DeAngelis D. L., 1992, DYNAMICS NUTR CYCLIN; delGiorgio PA, 1996, LIMNOL OCEANOGR, V41, P359, DOI 10.4319/lo.1996.41.2.0359; Elton C., 1927, ANIMAL ECOLOGY; France RL, 1995, LIMNOL OCEANOGR, V40, P1310, DOI 10.4319/lo.1995.40.7.1310; France RL, 1997, CAN J FISH AQUAT SCI, V54, P1255, DOI 10.1139/f97-044; HAIRSTON NG, 1993, AM NAT, V142, P379, DOI 10.1086/285546; Holt Robert D., 1993, P77; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; JENKINS B, 1992, OIKOS, V65, P249, DOI 10.2307/3545016; Kaunzinger CMK, 1998, NATURE, V395, P495, DOI 10.1038/26741; Kidd KA, 1998, CAN J FISH AQUAT SCI, V55, P869, DOI 10.1139/cjfas-55-4-869; KLING GW, 1992, ECOLOGY, V73, P561, DOI 10.2307/1940762; MINAGAWA M, 1984, GEOCHIM COSMOCHIM AC, V48, P1135, DOI 10.1016/0016-7037(84)90204-7; OKSANEN L, 1981, AM NAT, V118, P240, DOI 10.1086/283817; PAINE RT, 1988, ECOLOGY, V69, P1648, DOI 10.2307/1941141; PERSSON L, 1992, AM NAT, V140, P59, DOI 10.1086/285403; Persson Lennart, 1996, P396; PETERSON BJ, 1987, ANNU REV ECOL SYST, V18, P293, DOI 10.1146/annurev.es.18.110187.001453; PIMM SL, 1978, NATURE, V275, P542, DOI 10.1038/275542a0; SCHINDLER DW, 1978, LIMNOL OCEANOGR, V23, P478, DOI 10.4319/lo.1978.23.3.0478; SCHOENER TW, 1989, ECOLOGY, V70, P1559, DOI 10.2307/1938088; SLOBODKIN LAWRENCE B., 1961; Sterner RW, 1997, ECOLOGY, V78, P2258, DOI 10.1890/0012-9658(1997)078[2258:TEOFCL]2.0.CO;2; Vander Zanden MJ, 1999, AM NAT, V154, P406, DOI 10.1086/303250; VOLLENWEIDER RA, 1979, Z WASSER ABWASS FOR, V12, P46	29	495	529	13	226	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1047	1049		10.1038/35016565	http://dx.doi.org/10.1038/35016565			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890443				2022-12-28	WOS:000087871700043
J	Fiore, MC; Bailey, WC; Cohen, SJ; Dorfman, SF; Fox, BJ; Goldstein, MG; Gritz, E; Hasselblad, V; Heyman, RB; Jaen, CR; Jorenby, D; Kottke, TE; Lando, HA; Mecklenburg, RE; Mullen, PD; Nett, L; Piper, M; Robinson, L; Stitzer, M; Tommasello, A; Welsch, S; Villejo, L; Wewers, ME; Baker, TB				Fiore, MC; Bailey, WC; Cohen, SJ; Dorfman, SF; Fox, BJ; Goldstein, MG; Gritz, E; Hasselblad, V; Heyman, RB; Jaen, CR; Jorenby, D; Kottke, TE; Lando, HA; Mecklenburg, RE; Mullen, PD; Nett, L; Piper, M; Robinson, L; Stitzer, M; Tommasello, A; Welsch, S; Villejo, L; Wewers, ME; Baker, TB		Tobacco Use Dependence Clin Prac	A clinical practice guideline for treating tobacco use and dependence - A US Public Health Service report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; COST-EFFECTIVENESS; NICOTINE GUM; MAINTENANCE ORGANIZATION; QUIT; ADVICE; PROGRAMS; PATTERNS; BENEFITS; SMOKERS	Objective To summarize the recently published US Public Health Service report Treating Tobacco Use and Dependence. A Clinical Practice Guideline, which provides recommendations for brief clinical interventions, intensive clinical interventions, and system changes to promote the treatment of tobacco dependence. Participants An independent panel of 18 scientists, clinicians, consumers, and methodologists selected by the US Agency for Healthcare Research and Quality. A consortium of 7 governmental and nonprofit organizations sponsored the update. Evidence Approximately 6000 English-language, peer-reviewed articles and abstracts, published between 1975 and 1999, were reviewed for data that addressed assessment and treatment of tobacco dependence. This literature served as the basis for more than 50 meta-analyses. Consensus Process One panel meeting and numerous conference calls and staff meetings were held to evaluate meta-analytic and other results, to synthesize the results, and to develop recommendations. The updated guideline was then externally reviewed by more than 70 experts and revised. Conclusions This evidence-based, updated guideline provides specific recommendations regarding brief and intensive tobacco cessation interventions as well as system-level changes designed to promote the assessment and treatment of tobacco use. Brief clinical approaches for patients willing and unwilling to quit are described. Major conclusions and recommendations include: (1) Tobacco dependence is a chronic condition that warrants repeated treatment until long-term or permanent abstinence is achieved. (2) Effective treatments for tobacco dependence exist and all tobacco users should be offered those treatments. (3) Clinicians and health care delivery systems must institutionalize the consistent identification, documentation, and treatment of every tobacco user at every visit. (4) Brief tobacco dependence treatment is effective, and every tobacco user should be offered at least brief treatment. (5) There is a strong dose-response relationship between the intensity of tobacco dependence counseling and its effectiveness. (6) Three types of counseling were found to be especially effective-practical counseling, social support as part of treatment, and social support arranged outside of treatment. (7) Five first-line pharmacotherapies for tobacco dependence-sustained-release bupropion hydrochloride, nicotine gum, nicotine inhaler, nicotine nasal spray, and nicotine patch-are effective, and at least 1 of these medications should be prescribed in the absence of contraindications. (8) Tobacco dependence treatments are cost-effective relative to other medical and disease prevention interventions; as such, all health insurance plans should include as a reimbursed benefit the counseling and pharmacotherapeutic treatments identified as effective in the updated guideline.	Univ Wisconsin, Sch Med, Ctr Tobacco Res & Intervent, Madison, WI 53711 USA; Univ Alabama Birmingham, Birmingham, AL USA; Univ Arizona, Prevent Ctr, Tucson, AZ 85721 USA; Bayer Inst Hlth Care Commun, Portland, OR USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Duke Clin Res Inst, Durham, NC USA; Amer Acad Pediat, Elk Grove Village, IL USA; SUNY Buffalo, Buffalo, NY 14260 USA; Mayo Clin, Rochester, MN USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA; NCI, Bethesda, MD 20892 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Natl Lung Hlth Educ Program, Denver, CO USA; Philadelphia Dept Hlth, Philadelphia, PA USA; Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; Univ Maryland, Sch Pharm, College Pk, MD 20742 USA; Ohio State Univ, Columbus, OH 43210 USA; NHLBI, NIH, Bethesda, MD USA; Agcy Hlth Care Res & Qual, Rockville, MD USA; NIDA, Bethesda, MD USA; Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA; Robert Wood Johnson Fdn, Princeton, NJ 08540 USA	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; University of Arizona; Bayer AG; University of Texas System; UTMD Anderson Cancer Center; Duke University; American Academy of Pediatrics; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland College Park; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Agency for Healthcare Research & Quality; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Robert Wood Johnson Foundation (RWJF)	Fiore, MC (corresponding author), Univ Wisconsin, Sch Med, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA.	mcf@ctri.medicine.wisc.edu			BHP HRSA HHS [AHCPR-98-0015] Funding Source: Medline	BHP HRSA HHS		*AM MED ASS, 1994, AM MED ASS GUID DIAG; BRANDON TH, 1990, ADDICT BEHAV, V15, P105, DOI 10.1016/0306-4603(90)90013-N; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P854; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P613; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1217; Colby SM, 1998, J CONSULT CLIN PSYCH, V66, P574, DOI 10.1037/0022-006X.66.3.574; COX JL, 1990, J FAM PRACTICE, V31, P278; Croghan IT, 1997, MAYO CLIN PROC, V72, P917; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; CUMMINGS KM, 1987, AM J PREV MED, V3, P69; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; Curry SJ, 1998, NEW ENGL J MED, V339, P673, DOI 10.1056/NEJM199809033391006; DAVIS RM, 1997, TOB CONTROL S, V1, pS70; EDDY DM, 1986, J NATL CANCER I, V76, P187; EDDY DM, 1981, CANCER, V47, P1200, DOI 10.1002/1097-0142(19810301)47:5+<1200::AID-CNCR2820471325>3.0.CO;2-6; Ferry LH, 1999, JAMA-J AM MED ASSOC, V282, P825, DOI 10.1001/jama.282.9.825; Fiore M., 2000, AHRQ PUBLICATION; Fiore M. C., 1996, SMOKING CESSATION CL; GLYNN TJ, 1990, PROG CLIN BIOL RES, V339, P11; Glynn TJ, 1990, NIH PUBLICATION, P1990; HATZIANDREU EJ, 1990, J NATL CANCER I, V82, P1402, DOI 10.1093/jnci/82.17.1402; HAYWARD RA, 1989, J PUBLIC HEALTH DENT, V49, P147, DOI 10.1111/j.1752-7325.1989.tb02051.x; Henry R C, 1987, Fam Med, V19, P110; HUGHES JR, 1991, PREV MED, V20, P486, DOI 10.1016/0091-7435(91)90046-7; JOHNSON RE, 1991, DICP ANN PHARMAC, V25, P730, DOI 10.1177/106002809102500705; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; KOTTKE TE, 1992, J FAM PRACTICE, V34, P701; Lightwood JM, 1999, PEDIATRICS, V104, P1312, DOI 10.1542/peds.104.6.1312; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; MARKS JS, 1990, AM J PREV MED, V6, P282, DOI 10.1016/S0749-3797(18)30996-6; Meenan RT, 1998, MED CARE, V36, P670, DOI 10.1097/00005650-199805000-00007; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; Parrott S, 1998, THORAX, V53, pAS1; Plans-Rubio P, 1998, INT J TECHNOL ASSESS, V14, P320, DOI 10.1017/S0266462300012289; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; Rundmo T, 1997, ADDICT BEHAV, V22, P377, DOI 10.1016/S0306-4603(96)00056-1; SCOTT CS, 1985, SOC SCI MED, V21, P299, DOI 10.1016/0277-9536(85)90105-4; SLADE J, 1999, SRNT NEWSLETTER, V5, P1; Tomar SL, 1996, J AM DENT ASSOC, V127, P259, DOI 10.14219/jada.archive.1996.0179; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; Westman EC, 1997, ARCH INTERN MED, V157, P335, DOI 10.1001/archinte.157.3.335; Zhu SH, 1996, J CONSULT CLIN PSYCH, V64, P202, DOI 10.1037/0022-006X.64.1.202	43	586	607	0	108	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3244	3254						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	326TY	10866874				2022-12-28	WOS:000087753900039
J	Horton, R				Horton, R			North and South: bridging the information gap	LANCET			English	Article							GLOBAL BURDEN; DISEASE; DISABILITY; MORTALITY	Information exchange is critical for development of health systems. The information needs of less-developed countries are especially challenging, but many factors inhibit free flow of knowledge. There is much talk about how technical fixes-such as the internet-might fill this information gap. Yet few attempts have been made to ask clinical investigators who work in resource-poor regions for their views on these difficulties and the possible solutions. The messages reported here, from a survey of Lancet editorial advisors, suggest that information, research, and publication capacities are intimately linked. Investigators, publishers, editors, and editorial organisations ail have important parts to play in solving this global information poverty.	The Lancet, London WC1X 8RR, England		Horton, R (corresponding author), The Lancet, London WC1X 8RR, England.							Akhigbe F, 1997, Afr J Med Med Sci, V26, P205; ANNAN K, 2000, WE PEOPLES ROLE UN 2; BERTRAND K, 1998, HLTH LIB REV, V15, P17; BROOTEN D, 1997, J NURS SCHOLARSHIP, V29, P369; CAHILL KM, 1996, PREVENTIVE DIPLOMACY; Cherry M, 1999, NATURE, V402, P225, DOI 10.1038/46140; Cherry M, 2000, NATURE, V403, P692, DOI 10.1038/35001733; Chiejina SN, 1996, VET PARASITOL, V64, P121, DOI 10.1016/0304-4017(96)00965-X; CROSSETTE B, 2000, NY TIMES        0708, pA4; HERBST K, 1994, J PUBLIC HEALTH MED, V21, P305; Kanter AS, 1997, METHOD INFORM MED, V36, P144; McConnell J, 1999, LANCET, V354, P2, DOI 10.1016/S0140-6736(99)00226-3; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Winter C, 1999, WHERES IT GOING	17	143	147	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2231	2236		10.1016/S0140-6736(00)02414-4	http://dx.doi.org/10.1016/S0140-6736(00)02414-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881907				2022-12-28	WOS:000087779000040
J	Buckley, GA; Brochu, CA; Krause, DW; Pol, D				Buckley, GA; Brochu, CA; Krause, DW; Pol, D			A pug-nosed crocodyliform from the Late Cretaceous of Madagascar	NATURE			English	Article							DINOSAUR	Although the image of crocodyliforms as 'unchanged living fossils' is naive, several morphological features of the group are thought to have varied only within narrow limits during the course of evolution(1). These include an elongate snout with an array of conical teeth, a dorsoventrally flattened skull and a posteriorly positioned jaw articulation, which provides a powerful bite force. Here we report an exquisitely preserved specimen of a new taxon from the Late Cretaceous of Madagascar that deviates profoundly from this Bauplan, possessing an extremely blunt snout, a tall, rounded skull, an anteriorly shifted jaw joint and clove-shaped, multicusped teeth reminiscent of those of some ornithischian dinosaurs. This last feature implies that the diet of the new taxon may have been predominantly if not exclusively herbivorous. A close relationship with notosuchid crocodyliforms, particularly Uruguaysuchus (Late Cretaceous, Uruguay)(2) is suggested by several shared derived features; this supports a biogeographical hypothesis that Madagascar and South America were linked during the Late Cretaceous(3).	Roosevelt Univ, Evelyn T Stone Univ Coll, Chicago, IL 60605 USA; Field Museum Nat Hist, Dept Geol, Chicago, IL 60605 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; Amer Museum Nat Hist, Div Paleontol, New York, NY 10024 USA	Field Museum of Natural History (Chicago); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; American Museum of Natural History (AMNH)	Buckley, GA (corresponding author), Roosevelt Univ, Evelyn T Stone Univ Coll, Chicago, IL 60605 USA.		Pol, Diego/A-8007-2008	Pol, Diego/0000-0002-9690-7517				BALOUET JC, 1987, CR ACAD SCI II, V304, P853; Benton M.J., 1988, PHYLOGENY CLASSIFICA, V35A, P295, DOI DOI 10.1017/S0016756800006476; BONAPARTE JF, 1991, PALEONTOLOGIA, V4, P16; Brochu CA, 1996, J VERTEBR PALEONTOL, V16, P49, DOI 10.1080/02724634.1996.10011283; Buckley Gregory A., 1997, Journal of Vertebrate Paleontology, V17, p35A; CARVALHO I D S, 1988, Anais da Academia Brasileira de Ciencias, V60, P437; Carvalho Ismar De Souza, 1994, Anais da Academia Brasileira de Ciencias, V66, P331; CLARK JM, 1989, SCIENCE, V244, P1064, DOI 10.1126/science.244.4908.1064; Coombs W.P. Jr, 1990, P456; GALTON PM, 1990, DINOSAURIA, P456; Gans C., 1974, BIOMECHANICS APPROAC, DOI 10.3998/mpub.7275; Gomani EM, 1997, J VERTEBR PALEONTOL, V17, P280, DOI 10.1080/02724634.1997.10010975; HOTTON NICHOLAS, 1955, AMER MIDLAND NAT, V53, P88; Iordansky N.N., 1973, P201; Krause DW, 1997, NATURE, V390, P504, DOI 10.1038/37343; KRAUSE DW, 1999, GSA TODAY, V9, P1; Langston W. Jr., 1973, P263; MEDEM F., 1963, REV ACAD COLOMBIANA CIENC EXACTAS FIS Y NAT, V12, P5; Pol D., 1999, Journal of Vertebrate Paleontology, V19, p69A; RUSCONI C, 1932, B I GEOLOGIA PERFORA, V19, P3; Sampson SD, 1998, SCIENCE, V280, P1048, DOI 10.1126/science.280.5366.1048; Schumacher GH, 1973, BIOL REPTILIA, V4, P101; Sues HD, 1998, TRENDS ECOL EVOL, V13, P141, DOI 10.1016/S0169-5347(97)01257-3; SWOFFORD DL, 1999, PAUP PHYLOGENETIC AN; Wake Marvalee H., 1993, P197; Willis Paul M. A., 1997, Memoirs of the Queensland Museum, V41, P423; WU XC, 1995, NATURE, V376, P678, DOI 10.1038/376678a0	27	174	184	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					941	944		10.1038/35016061	http://dx.doi.org/10.1038/35016061			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879533				2022-12-28	WOS:000087732700048
J	Jarvis, P; Linder, S				Jarvis, P; Linder, S			Botany - Constraints to growth of boreal forests	NATURE			English	Article							CARBON BALANCE; NORWAY SPRUCE; WATER		Univ Edinburgh, Inst Ecol & Resource Management, Edinburgh EH9 3JU, Midlothian, Scotland; Swedish Univ Agr Sci, Dept Prod Engn, SE-75007 Uppsala, Sweden	University of Edinburgh; Swedish University of Agricultural Sciences	Jarvis, P (corresponding author), Univ Edinburgh, Inst Ecol & Resource Management, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JU, Midlothian, Scotland.							Bergh J, 1998, FOREST ECOL MANAG, V110, P127, DOI 10.1016/S0378-1127(98)00280-1; Bergh J, 1999, FOREST ECOL MANAG, V119, P51, DOI 10.1016/S0378-1127(98)00509-X; Bergh J, 1999, GLOB CHANGE BIOL, V5, P245, DOI 10.1046/j.1365-2486.1999.00205.x; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; Gower ST, 1997, J GEOPHYS RES-ATMOS, V102, P29029, DOI [10.1029/97JD02317, 10.1029/97JD01440]; Jarvis PG, 1997, J GEOPHYS RES-ATMOS, V102, P28953, DOI 10.1029/97JD01176; JARVIS PG, 1996, BOREAS DATA; Linder S, 1995, ECOL B COPENHAGEN, V44, P178, DOI DOI 10.2307/20113161; Malhi Y, 1999, PLANT CELL ENVIRON, V22, P715, DOI 10.1046/j.1365-3040.1999.00453.x; Vaganov EA, 1999, NATURE, V400, P149, DOI 10.1038/22087	10	303	325	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					904	905		10.1038/35016154	http://dx.doi.org/10.1038/35016154			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879523				2022-12-28	WOS:000087732700037
J	de Jong, K; Mulhem, M; Ford, N; van der Kam, S; Kleber, R				de Jong, K; Mulhem, M; Ford, N; van der Kam, S; Kleber, R			The trauma of war in Sierra Leone	LANCET			English	Editorial Material									Univ Utrecht, Inst Psychotrauma, NL-3508 TC Utrecht, Netherlands; Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands	Utrecht University; Doctors Without Borders	de Jong, K (corresponding author), Univ Utrecht, Inst Psychotrauma, NL-3508 TC Utrecht, Netherlands.			van der Kam, Saskia/0000-0002-3608-8054				HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004	1	47	49	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2067	2068		10.1016/S0140-6736(00)02364-3	http://dx.doi.org/10.1016/S0140-6736(00)02364-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885369				2022-12-28	WOS:000087519400040
J	Cain, JM; Howett, MK				Cain, JM; Howett, MK			Cancer - Preventing cervical cancer	SCIENCE			English	Article							HUMAN PAPILLOMAVIRUS		Penn State Univ, Coll Med, Dept Obstet & Gynecol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Cain, JM (corresponding author), Penn State Univ, Coll Med, Dept Obstet & Gynecol, MB103 Hosp, Hershey, PA 17033 USA.							American Cancer Society, 2000, CANC FACTS FIG 2000; Bergstrom R, 1999, BRIT J CANCER, V81, P159, DOI 10.1038/sj.bjc.6690666; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; Carter JJ, 1996, J INFECT DIS, V174, P927, DOI 10.1093/infdis/174.5.927; Eckert L O, 1999, Infect Dis Obstet Gynecol, V7, P158, DOI 10.1155/S1064744999000253; Ford CA, 1999, JAMA-J AM MED ASSOC, V282, P2227, DOI 10.1001/jama.282.23.2227; Howett MK, 1999, ANTIMICROB AGENTS CH, V43, P314, DOI 10.1128/AAC.43.2.314; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; SASLENI P, 1999, BRIT MED J, V318, P1244; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Sherman ME, 1998, DIAGN CYTOPATHOL, V18, P5, DOI 10.1002/(SICI)1097-0339(199801)18:1<5::AID-DC2>3.0.CO;2-G; Syrj?nen KJ., 1996, PAPILLOMAVIRUS REV C, P189; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81	16	44	52	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 9	2000	288	5472					1753	1754		10.1126/science.288.5472.1753	http://dx.doi.org/10.1126/science.288.5472.1753			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	322HH	10877694				2022-12-28	WOS:000087503800030
J	Dobles, M; Liberal, V; Scott, ML; Benezra, R; Sorger, PK				Dobles, M; Liberal, V; Scott, ML; Benezra, R; Sorger, PK			Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2	CELL			English	Article							SPINDLE-ASSEMBLY CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; UNATTACHED KINETOCHORES; CELL-DEATH; GENE; MITOSIS; BUB1; MUTATIONS	The initiation of chromosome segregation at anaphase is linked by the spindle assembly checkpoint to the completion of chromosome-microtubule attachment during metaphase. To determine the function of the mitotic checkpoint protein Mad2 during normal cell division and when mitosis goes awry, we have knocked out Mad2 in mice. We find that E5.5 embryonic cells lacking Mad2, like mad2 yeast, grow normally but are unable to arrest in response to spindle disruption. At E6.5, the cells of the epiblast begin rapid cell division and the absence of a checkpoint results in widespread chromosome missegregation and apoptosis. In contrast, the postmitotic trophoblast giant cells survive without Mad2. Thus, the spindle assembly checkpoint is required for accurate chromosome segregation in mitotic mouse cells, and for embryonic viability, even in the absence of spindle damage.	MIT, Dept Biol, Cambridge, MA 02139 USA; Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA	Massachusetts Institute of Technology (MIT); Memorial Sloan Kettering Cancer Center	Sorger, PK (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sorger, Peter/0000-0002-3364-1838	NCI NIH HHS [R01 CA84179] Funding Source: Medline; NIGMS NIH HHS [R01 GM 54601] Funding Source: Medline; FDA HHS [BD18587/98] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; BACHVAROVA R, 1980, DEV BIOL, V74, P1, DOI 10.1016/0012-1606(80)90048-2; Basu J, 1998, CHROMOSOMA, V107, P376, DOI 10.1007/s004120050321; Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13; Bernard P, 1998, J CELL BIOL, V143, P1775, DOI 10.1083/jcb.143.7.1775; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hardwick KC, 2000, J CELL BIOL, V148, P871, DOI 10.1083/jcb.148.5.871; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hartwell LW, 1982, RECENT ADV YEAST MOL, V1, P28; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Hogan B, 1994, MANIPULATING MOUSE E; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 1996, CANCER RES, V56, P816; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Martinez-Exposito MJ, 1999, P NATL ACAD SCI USA, V96, P8493, DOI 10.1073/pnas.96.15.8493; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; MITELMAN F, 1971, HEREDITAS-GENETISK A, V69, P155; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; ONeill TJ, 1997, J BIOL CHEM, V272, P10035; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; RUGH R, 1990, MOUSE, P44; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor TE, 1998, TROP MED INT HEALTH, V3, P3, DOI 10.1046/j.1365-3156.1998.00166.x; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	61	435	447	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					635	645		10.1016/S0092-8674(00)80875-2	http://dx.doi.org/10.1016/S0092-8674(00)80875-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892650	Bronze			2022-12-28	WOS:000087504500010
J	Critchley, J; Isaacs, AJ; Rosenthall, R; Honeybell, L; Smith, C				Critchley, J; Isaacs, AJ; Rosenthall, R; Honeybell, L; Smith, C			The Newcastle exercise project - Organisational aspects may influence adherence rates	BRITISH MEDICAL JOURNAL			English	Letter									Barnet Hlth Author, Dept Publ Hlth, London NW9 6QQ, England; London Borough Barnet, Barnet Copthall Ctr, London NW4 1PS, England		Critchley, J (corresponding author), Barnet Hlth Author, Dept Publ Hlth, London NW9 6QQ, England.			Critchley, Julia/0000-0002-5248-4188				Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	2000	320	7247					1472	1472						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320RT	10877565				2022-12-28	WOS:000087414700044
J	Berger, A				Berger, A			Minocycline slows progress of Huntington's disease in mice	BRITISH MEDICAL JOURNAL			English	News Item																			0	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					70	70		10.1136/bmj.321.7253.70	http://dx.doi.org/10.1136/bmj.321.7253.70			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884247	Green Published			2022-12-28	WOS:000088196600014
J	Stewart, C				Stewart, C			Tragic choices and the role of administrative law	BRITISH MEDICAL JOURNAL			English	Article									Macquarie Univ, Div Law, N Ryde, NSW 2109, Australia	Macquarie University	Stewart, C (corresponding author), Macquarie Univ, Div Law, N Ryde, NSW 2109, Australia.			Stewart, Cameron/0000-0003-3625-0899				Ham C, 1999, BMJ-BRIT MED J, V319, P1258, DOI 10.1136/bmj.319.7219.1258	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					105	107		10.1136/bmj.321.7253.105	http://dx.doi.org/10.1136/bmj.321.7253.105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884266	Green Published			2022-12-28	WOS:000088196600031
J	Upton, MN; McConnachie, A; McSharry, C; Hart, CL; Smith, GD; Gillis, CR; Watt, GCM				Upton, MN; McConnachie, A; McSharry, C; Hart, CL; Smith, GD; Gillis, CR; Watt, GCM			Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-FUNCTION; YOUNG-ADULTS; POPULATION; CHILDHOOD; MORTALITY; SYMPTOMS; CHILDREN; RENFREW; PAISLEY; MEN	Objective To estimate trends between 1972-6 and 1996 in the prevalences of asthma and hay fever in adults. Design Two epidemiological surveys 20 years apart. Identical questions were asked about asthma, hay fever, and respiratory symptoms at each survey. Setting Renfrew and Paisley, two towns in the west of Scotland. Subjects 1477 married couples aged 45-64 participated in a general population survey in 1972-6; and 2338 offspring aged 30-59 participated in a 1996 survey. Prevalences were compared in 1708 parents and 1124 offspring aged 45-54. Main outcome measures Prevalences of asthma, hay fever, and respiratory symptoms. Results In never smokers, age and sex standardised prevalences of asthma and hay fever were 3.0% and 5.8% respectively in 1972-6, and 8.2% and 19.9% in 1996. In ever smokers, the corresponding values were 1.6% and 5.4% in 1972-6 and 5.3% and 15.5% in 1996. In both generations, the prevalence of asthma was higher in those who reported hay fever (atopic asthma). In never smokers, reports of wheeze not labelled as asthma were about 10 times more common in 1972-6 than in 1996. with a broader definition of asthma (asthma and/or wheeze), to minimise diagnostic bias, the overall prevalence of asthma changed little. However, diagnostic bias mainly affected not-atopic asthma. Atopic asthma increased more than two-fold (prevalence ratio 2.52 (95% confidence interval 1.01 to 6.28)) whereas the prevalence of non-atopic asthma did not change (1.00 (0.53 to 1.90)). Conclusion The prevalence of asthma in adults has increased more than twofold in 20 years, largely in association with trends in atopy, as measured indirectly by the prevalence of hay fever. No evidence was found for an increase in diagnostic awareness being responsible for the trend in atopic asthma, but increased awareness may account for trends in non-atopic asthma.	Univ Glasgow, Dept Gen Practice, Glasgow G12 0RR, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Glasgow; University of Glasgow; University of Glasgow; University of Bristol	Upton, MN (corresponding author), Ctr Hlth, Thornaby & Barwick Med Grp, Thornaby TS17 0BZ, Cleveland, England.	marknupton@aol.com	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Upton, Mark/0000-0003-0839-1141; McSharry, Charles/0000-0003-4758-9038	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; [Anonymous], 1965, LANCET, V1, P775; BRUCE IN, 1993, Q J MED, V86, P425; Burney P, 1996, EUR RESPIR J, V9, P687; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; *CENTR HLTH MON UN, 1995, ASTHM EP OV; COOK DG, 1990, J SMOKING RELATED DI, V1, P45; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; Hole DJ, 1996, BRIT MED J, V313, P711; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721, DOI 10.1164/ajrccm/139.3.721; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; *REG GEN, 1991, STAND OCC CLASS; Russell G, 1997, BRIT MED J, V315, P1014, DOI 10.1136/bmj.315.7114.1014; Smith GD, 1997, BRIT MED J, V315, P1189, DOI 10.1136/bmj.315.7117.1189; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; *STAT CORP, 1997, STAT STAT SOFTW; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Upton MN, 1998, LANCET, V352, P453, DOI 10.1016/S0140-6736(05)79187-X; VERMEIRE PA, 1991, EUR RESPIR J, V4, P490	24	210	217	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2000	321	7253					88	92		10.1136/bmj.321.7253.88	http://dx.doi.org/10.1136/bmj.321.7253.88			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884260	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000088196600027
J	Gershon, D				Gershon, D			Laying a firm foundation for interdisciplinary research endeavours	NATURE			English	Article																			0	5	5	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					107	108		10.1038/35017694	http://dx.doi.org/10.1038/35017694			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894552				2022-12-28	WOS:000087991200055
J	Wilson, K; Code, C; Ricketts, MN				Wilson, K; Code, C; Ricketts, MN			Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the strength of association between history of blood transfusion and development of Creutzfeldt-Jakob disease, Data sources English and non-English language articles published from January 1966 to January 1999 were retrieved using a keyword search of Medline and Embase. These were supplemented by handsearching key journals and searching bibliographies of reviews. Study selection Two independent reviewers selected the relevant abstracts and articles, Articles were chosen that reported the results of case-control studies trying to identify rates of prior blood transfusion in patients with Creutzfeldt-Jakob disease and in controls, Data extraction Odds ratios and information on study quality were extracted from the selected articles by two independent reviewers. Data synthesis Five studies containing data on 2479 patients were included. Three of the five studies used medical or neurological patients as controls, the other two used population controls. Odds ratios for developing Creutzfeldt-Jakob disease from blood transfusion ranged from 0.54 to 0.89. Four of the five studies had confidence intervals that crossed 1.0. The combined odds ratio was 0.70 (95% confidence interval 0.54 to 0.89). Conclusions Case-control studies do not suggest a risk of developing Creutzfeldt-Jakob disease from blood transfusion, Rather, a trend seems to exist towards a lower frequency of previous blood transfusion in patients with Creutzfeldt-Jakob disease than in controls. However, it is important to be aware of these studies' methodological limitations-primarily the choice of control population and reliability of recall of transfusion status.	Univ Ottawa, Div Gen Internal Med, Ottawa, ON, Canada; Ottawa Civic Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada; WHO, Dept Surveillance & Response, CH-1211 Geneva 27, Switzerland	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; World Health Organization	Wilson, K (corresponding author), Civic Parkdale Clin, 737 Parkdale Ave,Suite 414, Ottawa, ON K1Y 1J8, Canada.	kwilson@lri.ca						BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; DAVANIPOUR Z, 1985, NEUROLOGY, V35, P1483, DOI 10.1212/WNL.35.10.1483; Egger M, 1998, BRIT MED J, V316, P140; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; Evatt B, 1998, TRANSFUSION, V38, P817, DOI 10.1046/j.1537-2995.1998.38998409000.x; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P1113, DOI 10.1136/jnnp.51.9.1113; HEYE N, 1994, LANCET, V343, P298, DOI 10.1016/S0140-6736(94)91148-7; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; JULIAN JA, 1993, SUMMARY ODDS RATIOS; KONDO K, 1982, ANN NEUROL, V11, P377, DOI 10.1002/ana.410110410; Krever H., 1997, COMMISSION INQUIRY B; LAU J, 1990, META ANAL PROGRAM 0; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; OPERSKALSKI EA, 1995, LANCET, V346, P1224, DOI 10.1016/S0140-6736(95)92925-8; Ricketts MN, 1997, EMERG INFECT DIS, V3, P155, DOI 10.3201/eid0302.970208; Rothman K. J., 1998, MODERN EPIDEMIOLOGY, P147; van Duijn CM, 1998, LANCET, V351, P1081, DOI 10.1016/S0140-6736(97)09468-3	18	60	62	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					17	19		10.1136/bmj.321.7252.17	http://dx.doi.org/10.1136/bmj.321.7252.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875826	Green Published, Bronze			2022-12-28	WOS:000088030100019
J	Gustafson, DE; Stoecker, DK; Johnson, MD; Van Heukelem, WF; Sneider, K				Gustafson, DE; Stoecker, DK; Johnson, MD; Van Heukelem, WF; Sneider, K			Cryptophyte algae are robbed of their organelles by the marine ciliate Mesodinium rubrum	NATURE			English	Article							PHOTOTROPHIC CILIATE; SOUTHAMPTON WATER; MYRIONECTA-RUBRA; LABOEA-STROBILA; CHLOROPLASTS; CILIOPHORA; ABUNDANCE; ESTUARY; MAINE; GULF	Mesodinium rubrum (Lohmann 1908) Jankowski 1976 (= Myrionecta rubra)(1,2) is a common photosynthetic marine planktonic ciliate which can form coastal red-tides(3). It may represent a 'species complex'(4,5) and since Darwin's voyage on the Beagle, it has been of great cytological, physiological and evolutionary interest(4). It is considered to be functionally a phytoplankter because it was thought to have lost the capacity to feed and possesses a highly modified algal endosymbiont(5,6). Whether M. rubrum is the result of a permanent endosymbiosis or a transient association between a ciliate and an alga is controversial(7). We conducted 'feeding' experiments to determine how exposure to a cryptophyte alga affects M. rubrum. Here we show that although M. rubrum lacks a cytostome (oral cavity)(8), it ingests cryptophytes and steals their organelles, and may not maintain a permanent endosymbiont. M. rubrum does not fall into recognized cellular or functional categories, but may be a chimaera partially supported by organelle robbery.	Univ Maryland, Ctr Environm Sci, Horn Point Environm Lab, Cambridge, MD 21613 USA	University System of Maryland; University of Maryland Center for Environmental Science	Gustafson, DE (corresponding author), Univ Maryland, Ctr Environm Sci, Horn Point Environm Lab, POB 775, Cambridge, MD 21613 USA.		Johnson, Matthew/B-4344-2012; stoecker, diane k/F-9341-2013	Johnson, Matthew/0000-0003-4853-2674; 				BARBER RT, 1969, J PHYCOL, V5, P86, DOI 10.1111/j.1529-8817.1969.tb02583.x; Crawford DW, 1997, ESTUAR COAST SHELF S, V45, P799, DOI 10.1006/ecss.1997.0242; Crawford DW, 1997, AQUAT MICROB ECOL, V13, P267, DOI 10.3354/ame013267; CRAWFORD DW, 1989, MAR ECOL PROG SER, V58, P161, DOI 10.3354/meps058161; Hargraves P., 1991, Maritimes, V35, P6; HIBBERD DJ, 1977, J MAR BIOL ASSOC UK, V57, P45, DOI 10.1017/S0025315400021226; KIFLE D, 1993, J PLANKTON RES, V15, P823, DOI 10.1093/plankt/15.7.823; KRAINER KH, 1990, J PROTOZOOL, V37, P414, DOI 10.1111/j.1550-7408.1990.tb01166.x; Laval-Peuto M., 1986, MAR MICROB FD WEBS, V1, P81; Lindholm T., 1985, Advances in Aquatic Microbiology, V3, P1; LINDHOLM T, 1988, BIOSYSTEMS, V21, P141, DOI 10.1016/0303-2647(88)90007-X; LINDHOLM T, 1989, Memoranda Societatis pro Fauna et Flora Fennica, V65, P17; MONTAGNES DJS, 1989, J PLANKTON RES, V11, P193, DOI 10.1093/plankt/11.2.193; OAKLEY BR, 1978, BIOSYSTEMS, V10, P361, DOI 10.1016/0303-2647(78)90019-9; Packard T.T., 1978, UPWELLING ECOSYSTEMS, P73; Sanders RW, 1995, AQUAT MICROB ECOL, V9, P237, DOI 10.3354/ame009237; Small E.B., 1985, P393; SMITH WO, 1979, J PHYCOL, V15, P27, DOI 10.1111/j.0022-3646.1979.00027.x; Stoecker D.K., 1991, NATO ASI Series Series G Ecological Sciences, V25, P161; STOECKER DK, 1991, MAR ECOL PROG SER, V73, P245, DOI 10.3354/meps073245; STOECKER DK, 1990, MAR BIOL, V107, P491, DOI 10.1007/BF01313434; STOECKER DK, 1988, MAR BIOL, V99, P415, DOI 10.1007/BF02112135; STOECKER DK, 1987, NATURE, V326, P790, DOI 10.1038/326790a0; STOECKER DK, 1989, MAR ECOL PROG SER, V50, P241, DOI 10.3354/meps050241; TAYLOR FJR, 1971, J FISH RES BOARD CAN, V28, P391, DOI 10.1139/f71-052; WHITE AW, 1977, J FISH RES BOARD CAN, V34, P413, DOI 10.1139/f77-066; WILKERSON FP, 1990, J PLANKTON RES, V12, P973, DOI 10.1093/plankt/12.5.973; Yih W, 1997, J MAR BIOTECHNOL, V5, P82	28	167	177	0	40	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1049	1052		10.1038/35016570	http://dx.doi.org/10.1038/35016570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890444				2022-12-28	WOS:000087871700044
J	Stables, RH				Stables, RH			Strategies for coronary stenting	LANCET			English	Editorial Material									Ctr Cardiothorac, Liverpool L7 8XP, Merseyside, England; Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Stables, RH (corresponding author), Ctr Cardiothorac, Liverpool L7 8XP, Merseyside, England.			Stables, Rodney Hilton/0000-0002-9244-7015				Ruygrok PN, 1999, J AM COLL CARDIOL, V34, P1507, DOI 10.1016/S0735-1097(99)00380-0	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2180	2181		10.1016/S0140-6736(00)02396-5	http://dx.doi.org/10.1016/S0140-6736(00)02396-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881886				2022-12-28	WOS:000087779000004
J	Queller, DC; Zacchi, F; Cervo, R; Turillazzi, S; Henshaw, MT; Santorelli, LA; Strassmann, JE				Queller, DC; Zacchi, F; Cervo, R; Turillazzi, S; Henshaw, MT; Santorelli, LA; Strassmann, JE			Unrelated helpers in a social insect	NATURE			English	Article							TRINUCLEOTIDE MICROSATELLITE LOCI; POLISTES-GALLICUS L; REPRODUCTIVE SKEW; GENETIC-MARKERS; RELATEDNESS; WASP; FOUNDRESS; HYMENOPTERA; SOCIETIES; VESPIDAE	High-resolution genetic markers have revolutionized our understanding of vertebrate mating systems(1), but have so far yielded few comparable surprises about kinship in social insects. Here we use microsatellite markers to reveal an unexpected and unique social system in what is probably the best-studied social wasp, Polistes dominulus. Social insect colonies are nearly always composed of close relatives(2,3); therefore, non-reproductive helping behaviour can be favoured by kin selection, because the helpers aid reproductives who share their genes(4). In P. dominulus, however, 35% of foundress nestmates are unrelated and gain no such advantage. The P. dominulus system is unlike all other cases of unrelated social insects, because one individual has nearly complete reproductive dominance over subordinates who could have chosen other reproductive options. The only significant advantage that subordinates obtain is a chance at later reproduction, particularly if the queen dies. Thus, P. dominulus societies are functionally unlike other social insects, but similar to certain vertebrate societies(5,6), in which the unrelated helpers gain through inheritance of a territory or a mate.	Rice Univ, Dept Ecol & Evolut, Houston, TX 77251 USA; Univ Florence, Dipartimento Biol Anim & Genet, I-50125 Florence, Italy	Rice University; University of Florence	Queller, DC (corresponding author), Rice Univ, Dept Ecol & Evolut, POB 1892, Houston, TX 77251 USA.		; CERVO, Rita/B-5441-2018	Strassmann, Joan/0000-0003-0638-8440; CERVO, Rita/0000-0002-0405-6402; Santorelli, Lorenzo/0000-0002-8392-801X				Bernasconi G, 1999, TRENDS ECOL EVOL, V14, P477, DOI 10.1016/S0169-5347(99)01722-X; Bourke A. F., 1995, SOCIAL EVOLUTION ANT; CREEL SR, 1994, BEHAV ECOL, V5, P339, DOI 10.1093/beheco/5.3.339; Crozier R.H., 1996, EVOLUTION SOCIAL INS; GAMBOA GJ, 1986, ANNU REV ENTOMOL, V31, P431, DOI 10.1146/annurev.en.31.010186.002243; Goodnight KF, 1999, MOL ECOL, V8, P1231, DOI 10.1046/j.1365-294x.1999.00664.x; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hughes C, 1998, ECOLOGY, V79, P383, DOI 10.1890/0012-9658(1998)079[0383:IMTWFM]2.0.CO;2; Kokko H, 1999, P ROY SOC B-BIOL SCI, V266, P571, DOI 10.1098/rspb.1999.0674; KUKUK PF, 1994, INSECT SOC, V41, P443, DOI 10.1007/BF01240647; LORENZI MC, 1995, J INSECT BEHAV, V8, P443, DOI 10.1007/BF01995318; PARDI L, 1948, PHYSIOL ZOOL, V21, P1; PARDI L, 1948, ATTI SOC TOSC SCI, V55, P3; PRATTE M, 1982, INSECT SOC, V29, P352, DOI 10.1007/BF02228762; QUELLER DC, 1989, EVOLUTION, V43, P258, DOI [10.2307/2409206, 10.1111/j.1558-5646.1989.tb04226.x]; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; Ragsdale JE, 1999, EVOL ECOL RES, V1, P859; Reeve H.K., 1991, P99; Reeve Hudson K., 1993, P45; REYER HU, 1984, ANIM BEHAV, V32, P1163, DOI 10.1016/S0003-3472(84)80233-X; RISSING SW, 1989, NATURE, V338, P420, DOI 10.1038/338420a0; ROSELER PF, 1985, EXPT BEHAV ECOLOGY S, P259; Strassmann JE, 1996, MOL ECOL, V5, P459, DOI 10.1111/j.1365-294X.1996.tb00338.x; STRASSMANN JE, 1989, NATURE, V342, P268, DOI 10.1038/342268a0; Strassmann JE, 1997, MOL ECOL, V6, P97, DOI 10.1046/j.1365-294X.1997.00158.x; Strassmann JE, 1997, BIOCHEM GENET, V35, P273, DOI 10.1023/A:1021849100346; Strassmann Joan E.., 1996, P163; TURILLAZZI S, 1982, MONIT ZOOL ITAL, V16, P75; VEHRENCAMP SL, 1983, AM ZOOL, V23, P327; ZACCHI F, 1998, THESIS RICE U HOUSTO	30	209	213	0	46	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					784	787		10.1038/35015552	http://dx.doi.org/10.1038/35015552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866197				2022-12-28	WOS:000087620600048
J	Horton, R				Horton, R			Doctors in the NHS: the restless many and the squabbling few	LANCET			English	Editorial Material							PROFESSIONALISM		The Lancet, London WC1X 8RR, England		Horton, R (corresponding author), The Lancet, London WC1X 8RR, England.							ALBERTI G, B R COLL PHYSICI JAN, P1; Horton R, 1998, LANCET, V351, P1900; Irvine D, 1999, LANCET, V353, P1174, DOI 10.1016/S0140-6736(99)91160-1; Jarman B, 2000, J ROY COLL PHYS LOND, V34, P75; JOHNSON J, 2000, HOSP DOCTOR     0525, P61; LAURANCE J, 2000, INDEPENDENT     0511, P1; Morrison I, 2000, ANN INTERN MED, V132, P80, DOI 10.7326/0003-4819-132-1-200001040-00013; Pringle M, 2000, BRIT J GEN PRACT, V50, P355; Sullivan WM, 2000, CAN MED ASSOC J, V162, P673; Wynia MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112; 2000, INDEPENDENT SUN 0604, P26; 2000, SUNDAY TIMES    0604, P18	12	6	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2010	2012		10.1016/S0140-6736(00)02343-6	http://dx.doi.org/10.1016/S0140-6736(00)02343-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885348				2022-12-28	WOS:000087519400004
J	Stockler, M; Beith, J				Stockler, M; Beith, J			Youth and hormone receptors in breast cancer: good or bad news first?	LANCET			English	Editorial Material									Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Dept Med, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Stockler, M (corresponding author), Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Dept Med, Sydney, NSW 2006, Australia.		Stockler, Martin R/N-3859-2016	Stockler, Martin R/0000-0003-3793-8724; Beith, Jane/0000-0002-4946-2789				Abe O, 1998, LANCET, V352, P930; Barley V, 1996, LANCET, V348, P1184, DOI 10.1016/S0140-6736(05)65474-8; BARTLETT K, 1993, LANCET, V341, P1293; Clarke M, 1998, LANCET, V351, P1451; DAVIDSON N, 1999, P AM SOC CLIN ONCOL, V18; EJLERTSEN B, 1999, P AM SOC CLIN ONCOL, V18; JAKESZ R, 1999, P AM SOC CLIN ONCOL, V18; Kroman N, 2000, BRIT MED J, V320, P474, DOI 10.1136/bmj.320.7233.474; Taniguchi S, 1996, LANCET, V348, P1451, DOI 10.1016/S0140-6736(04)70096-3	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1839	1840		10.1016/S0140-6736(00)02281-9	http://dx.doi.org/10.1016/S0140-6736(00)02281-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866433				2022-12-28	WOS:000087306500003
J	White, KL				White, KL			Fundamental research at primary care level	LANCET			English	Editorial Material							DISEASE; CHALLENGE				White, KL (corresponding author), 500 Crestwood Dr, Charlottesville, VA 22903 USA.							ALVAREZ WC, 1954, ANN INTERN MED, V40, P774, DOI 10.7326/0003-4819-40-4-774; Cannon WB, 1942, AM ANTHROPOL, V44, P169, DOI 10.1525/aa.1942.44.2.02a00010; Crabtree BF, 1992, DOING QUALITATIVE RE, V3; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; *FDN NETH I PRIM H, 1997, CONT MORB REG SENT S; GREEN LA, 1984, J FAM PRACTICE, V18, P275; Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037/0003-066X.53.11.1209; Lerner BH, 1996, ANN INTERN MED, V124, P673, DOI 10.7326/0003-4819-124-7-199604010-00008; MACDONALD AJ, 1980, GUT, V21, P323; MAIR A, 1973, J MACKENZIE MD 1853; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; Melmed RN, 1996, ISRAEL J MED SCI, V32, P211; PAULI HG, 1998, HUM RESOURCES HLTH D, V2, P155; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; REVANS RW, 1996, B NY ACAD MED, V3, P418; RYLE J, 1948, PHYSICIAN NATURALIST; Shroder T., 1999, OLD SOULS SCI EVIDEN; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Takeida K, 1997, J Epidemiol, V7, P210; VERNON CR, 1959, JAMA-J AM MED ASSOC, V171, P1947, DOI 10.1001/jama.1959.03010320037009	21	12	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1904	1906		10.1016/S0140-6736(00)02304-7	http://dx.doi.org/10.1016/S0140-6736(00)02304-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866461				2022-12-28	WOS:000087306500044
J	Yancey, KB; Egan, CA				Yancey, KB; Egan, CA			Pemphigoid: Clinical, histologic, immunopathologic, and therapeutic considerations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONIS AUTOANTIBODIES RECOGNIZE; EPIDERMOLYSIS-BULLOSA ACQUISITA; HERPES-GESTATIONIS; EXTRACELLULAR DOMAIN; IGG AUTOANTIBODIES; SUBCLASS DISTRIBUTION; BASEMENT-MEMBRANE; BP180 ECTODOMAIN; PASSIVE TRANSFER; HG-FACTOR	Autoimmune blistering diseases are generally distinct entities characterized by relatively consistent clinical, histologic, and immunopathologic findings. These disorders may cause impaired adhesion of epidermis to epidermal basement membrane (eg, the pemphigoid group of disorders [bullous, gestational, and mucous membrane]) or impaired adhesion of epidermal cells to each other (eg, the pemphigus group of disorders). Recent studies have shown that these disorders are characterized by autoantibodies that often display pathogenic (ie, blister-forming) activity in passive transfer models. Interestingly, the autoantigens targeted by these patients' autoantibodies represent important structural proteins that promote cell matrix (eg, pemphigoid) or cell-to-cell (eg, pemphigus) adhesion in skin. Autoimmune blistering diseases are characterized by substantial morbidity (pruritus, pain, disfigurement), and in some instances, mortality (secondary to loss of epidermal barrier function). Treatment with systemic immunosuppressives has reduced morbidity and mortality in patients with these diseases.	NCI, Dermatol Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yancey, KB (corresponding author), NCI, Dermatol Branch, Div Clin Sci, NIH, Bldg 10,Room 12N238,10 Ctr Dr,MSC 1908, Bethesda, MD 20892 USA.							AHMED AR, 1991, P NATL ACAD SCI USA, V88, P11579, DOI 10.1073/pnas.88.24.11579; Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; Balding SD, 1996, J INVEST DERMATOL, V106, P141, DOI 10.1111/1523-1747.ep12329728; Bedane C, 1997, J INVEST DERMATOL, V108, P901, DOI 10.1111/1523-1747.ep12292701; Bernard P, 1997, BRIT J DERMATOL, V136, P694, DOI 10.1046/j.1365-2133.1997.6581643.x; BERNARD P, 1991, J INVEST DERMATOL, V97, P259, DOI 10.1111/1523-1747.ep12480369; BERNARD P, 1995, ARCH DERMATOL, V131, P48, DOI 10.1001/archderm.131.1.48; BERNARD P, 1992, J INVEST DERMATOL, V99, P174, DOI 10.1111/1523-1747.ep12616797; Beutner E H, 1967, Clin Exp Immunol, V2, P141; BEUTNER EH, 1965, J AMER MED ASSOC, V192, P682, DOI 10.1001/jama.1965.03080210026006; BIRD P, 1986, J INVEST DERMATOL, V86, P21, DOI 10.1111/1523-1747.ep12283737; Budinger L, 1998, J CLIN INVEST, V102, P2082, DOI 10.1172/JCI3335; Delaporte E, 1996, J IMMUNOL, V157, P3642; Delgado JC, 1996, P NATL ACAD SCI USA, V93, P8569, DOI 10.1073/pnas.93.16.8569; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; DOMLOGEHULTSCH N, 1994, ARCH DERMATOL, V130, P1521, DOI 10.1001/archderm.130.12.1521; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; Egan CA, 1999, J INVEST DERMATOL, V112, P148, DOI 10.1046/j.1523-1747.1999.00490.x; Ghohestani RF, 1996, J INVEST DERMATOL, V107, P136, DOI 10.1111/1523-1747.ep12298424; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HALL RP, 1993, J INVEST DERMATOL, V101, P9, DOI 10.1111/1523-1747.ep12358276; Hirako Y, 1996, J BIOL CHEM, V271, P13739, DOI 10.1074/jbc.271.23.13739; HOLMES RC, 1984, BRIT J DERMATOL, V110, P67, DOI 10.1111/j.1365-2133.1984.tb07314.x; JORDON RE, 1967, J AMER MED ASSOC, V200, P751, DOI 10.1001/jama.200.9.751; JORDON RE, 1976, J CLIN INVEST, V57, P1426, DOI 10.1172/JCI108412; KATZ SI, 1976, J CLIN INVEST, V57, P1434, DOI 10.1172/JCI108413; KATZ SI, 1999, DERMATOLOGY GEN MED, P686; KIRTSCHIG G, 1995, J INVEST DERMATOL, V105, P543, DOI 10.1111/1523-1747.ep12323431; LAWLEY TJ, 1978, ARCH DERMATOL, V114, P552, DOI 10.1001/archderm.114.4.552; Lazarova Z, 2000, J INVEST DERMATOL, V114, P178, DOI 10.1046/j.1523-1747.2000.00829.x; Lazarova Z, 1996, J CLIN INVEST, V98, P1509, DOI 10.1172/JCI118942; Lazarova Z, 1998, BRIT J DERMATOL, V139, P791; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; Lin MS, 1999, J IMMUNOL, V162, P4991; Liu Z, 1997, J CLIN INVEST, V100, P1256, DOI 10.1172/JCI119639; LIU Z, 1995, J CLIN INVEST, V95, P1539, DOI 10.1172/JCI117826; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Liu Z, 2000, J CLIN INVEST, V105, P113, DOI 10.1172/JCI3693; Luke MC, 1999, ARCH DERMATOL, V135, P954, DOI 10.1001/archderm.135.8.954; Masunaga T, 1997, J INVEST DERMATOL, V109, P200, DOI 10.1111/1523-1747.ep12319337; MORRISON LH, 1988, J CLIN INVEST, V81, P2023, DOI 10.1172/JCI113554; Perriard J, 1999, J INVEST DERMATOL, V112, P141, DOI 10.1046/j.1523-1747.1999.00497.x; Rico MJ, 1999, BRIT J DERMATOL, V140, P1079; Schmidt E, 2000, ARCH DERMATOL, V136, P174, DOI 10.1001/archderm.136.2.174; SHEVACH EM, 1999, FUNDAMENTAL IMMUNOLO, P1089; SHORNICK JK, 1983, J AM ACAD DERMATOL, V8, P214, DOI 10.1016/S0190-9622(83)70027-7; SHORNICK JK, 1987, J AM ACAD DERMATOL, V17, P539, DOI 10.1016/S0190-9622(87)70237-0; SMITH EP, 1993, J INVEST DERMATOL, V101, P619; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STANLEY JR, 1999, DERMATOLOGY GEN MED, P666; Tanaka M, 1996, CLIN EXP DERMATOL, V21, P23, DOI 10.1111/j.1365-2230.1996.tb00006.x; Tyagi S, 1996, P NATL ACAD SCI USA, V93, P14714, DOI 10.1073/pnas.93.25.14714; YANCEY KB, 1998, HARRISONS PRINCIPLES, P1869; YANCEY KB, 1999, DERMATOLOGY GEN MED, P674; YUNIS JJ, 1994, P NATL ACAD SCI USA, V91, P7747, DOI 10.1073/pnas.91.16.7747; ZILLIKENS D, 1995, ARCH DERMATOL, V131, P957, DOI 10.1001/archderm.131.8.957; Zillikens D, 1997, J INVEST DERMATOL, V109, P573, DOI 10.1111/1523-1747.ep12337492; Zone JJ, 1998, J INVEST DERMATOL, V110, P207, DOI 10.1046/j.1523-1747.1998.00129.x	62	75	79	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					350	356		10.1001/jama.284.3.350	http://dx.doi.org/10.1001/jama.284.3.350			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891967				2022-12-28	WOS:000088123000028
J	Bilder, D; Li, M; Perrimon, N				Bilder, D; Li, M; Perrimon, N			Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors	SCIENCE			English	Article							EPITHELIAL-CELLS; HUMAN HOMOLOG; PLASMA-MEMBRANE; SHAPE CHANGE; DISCS LARGE; PROTEIN; GENE; MELANOGASTER; COMPLEX; EXOCYTOSIS	Loss of cell polarity and tissue architecture are characteristics of malignant cancers derived from epithelial tissues. We provide evidence from Drosophila that a group of membrane-associated proteins act in concert to regulate both epithelial structure and cell proliferation. Scribble (Scrib) is a cell junction-localized protein required for polarization of embryonic and, as demonstrated here, imaginal disc and follicular epithelia. We show that the tumor suppressors lethal giant larvae (lgl) and discs-large (dlg) have identical effects on all three epithelia, and that scrib also acts as a tumor suppressor. Scrib and Dlg colocalize and overlap with Lgl in epithelia; activity of all three genes is required for cortical localization of Lgl and junctional Localization of Scrib and Dlg. scrib, dlg, and lgl show strong genetic interactions. Our data indicate that the three tumor suppressors act together in a common pathway to regulate cell polarity and growth control.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Bilder, D (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	bilder@rascal.med.harvard.edu		Bilder, David/0000-0002-1842-4966; Perrimon, Norbert/0000-0001-7542-472X				Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Chou TB, 1996, GENETICS, V144, P1673; DAVIS I, 1995, DEV BIOL, V170, P726, DOI 10.1006/dbio.1995.1251; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1969, NATL CANCER I MONOGR, P365; *GENBANK, NM004524 GENBANK; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; HARRISON DA, 1993, CURR BIOL, V3, P424, DOI 10.1016/0960-9822(93)90349-S; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; MARTIN PF, 1982, J EXP ZOOL, V222, P97, DOI 10.1002/jez.1402220113; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MUKHERJEE A, 1995, MECH DEVELOP, V51, P227, DOI 10.1016/0925-4773(95)00367-3; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; WATSON KL, 1994, J CELL SCI, P19; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	30	721	731	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	2000	289	5476					113	116		10.1126/science.289.5476.113	http://dx.doi.org/10.1126/science.289.5476.113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884224				2022-12-28	WOS:000088090400044
J	Bristow, CS; Bailey, SD; Lancaster, N				Bristow, CS; Bailey, SD; Lancaster, N			The sedimentary structure of linear sand dunes	NATURE			English	Article							LONGITUDINAL DUNES; INTERNAL STRUCTURE	Linear sand dunes-dunes that extend parallel to each other rather than in star-like or crescentic forms-are the most abundant type of desert sand dune(1). But because their development and their internal structure are poorly understood, they are rarely recognized in the rock record(2). Models of linear dune development(2-6) have not been able to take into account the sub-surface structure of existing dunes, but have relied instead either on the extrapolation of short-term measurements of winds and sediment transport or on observations of near-surface internal sedimentary structures. From such studies, it has not been clear if linear dunes can migrate laterally(2,7,8). Here we present images produced by ground penetrating radar showing the three-dimensional sedimentary structure of a linear dune in the Namib sand sea, where some of the world's largest linear dunes are situated. These profiles show clear evidence for lateral migration in a linear dune. Moreover, the migration of a sinuous crest-line along the dune produces divergent sets of cross-stratification, which can become stacked as the dune height increases, and large linear dunes can support superimposed dunes that produce stacked sets of trough cross-stratification. These clear structural signatures of linear dunes should facilitate their recognition in geological records.	Univ London Birkbeck Coll, Sch Earth Sci, London WC1E 7HX, England; UCCSN, Desert Res Inst, Reno, NV 89512 USA	University of London; Birkbeck University London; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE	Bristow, CS (corresponding author), Univ London Birkbeck Coll, Sch Earth Sci, Malet St, London WC1E 7HX, England.		Bristow, Charlie/F-1979-2011	Lancaster, Nicholas/0000-0003-1585-5282				BAGNOLD RA, 1941, PHYSICS BLOWN SAND D; Bristow C, 1996, SEDIMENTOLOGY, V43, P995, DOI 10.1111/j.1365-3091.1996.tb01515.x; HESP P, 1989, EARTH SURF PROCESSES, V14, P447, DOI 10.1002/esp.3290140510; LANCASTER N, 1982, PROG PHYS GEOG, V6, P475, DOI 10.1177/030913338200600401; Lancaster N., 1995, GEOMORPHOLOGY DESERT; LIVINGSTONE I, 1989, EARTH SURF PROCESSES, V14, P317, DOI 10.1002/esp.3290140407; MCKEE E, 1982, GEOL SOC AM SPEC PAP, V188, P64; Mckee G., 1964, J SEDIMENT PETROL, V34, P5, DOI DOI 10.1306/74D70FBA-2B21-11D7-8648000102C1865D; RUBIN DM, 1990, EARTH SURF PROCESSES, V15, P1, DOI 10.1002/esp.3290150102; RUBIN DM, 1987, SCIENCE, V237, P276, DOI 10.1126/science.237.4812.276; RUBIN DM, 1985, SEDIMENTOLOGY, V32, P147, DOI 10.1111/j.1365-3091.1985.tb00498.x; TSOAR H, 1982, J SEDIMENT PETROL, V52, P823; TSOAR H, 1983, SEDIMENTOLOGY, V30, P567, DOI 10.1111/j.1365-3091.1983.tb00694.x	13	167	180	1	68	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					56	59		10.1038/35017536	http://dx.doi.org/10.1038/35017536			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894538				2022-12-28	WOS:000087991200041
J	Hudson, JJ; Taylor, WD; Schindler, DW				Hudson, JJ; Taylor, WD; Schindler, DW			Phosphate concentrations in lakes	NATURE			English	Article							PHOSPHORUS; PLANKTON; WATERS; REGENERATION; LIMITATION; PACIFIC; RELEASE	Phosphate is an important nutrient that restricts microbial production in many freshwater(1-3) and marine environments(4-6). The actual concentration of phosphate in phosphorus-limited waters is largely unknown because commonly used chemical and radiochemical techniques overestimate the concentration(7,8). Here, using a new steady-state radiobioassay to survey a diverse set of lakes, we report phosphate concentrations in lakes that are orders of magnitude lower than estimates made spectrophotometrically or with the frequently used Rigler radiobioassay. Our results, combined with those from the literature, indicate that microbes can achieve rapid turnover rates at picomolar nutrient concentrations. This occurs even though these concentrations are about two orders of magnitude below the level where phosphate uptake is estimated to be half the saturation level for the picoplankton community. Also, while phosphate concentration increased with the concentration of total phosphorus and soluble reactive phosphorus in the lakes we sampled, the proportion of phosphate in the total phosphorus pool decreased from oligotrophic to eutrophic lakes. Such information, as revealed by the phosphate assay that we use here, should allow us to address hypotheses concerning the concentration of phosphate available to planktonic microorganisms in aquatic systems.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada	University of Alberta; University of Waterloo	Hudson, JJ (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.		hudson, jeff/G-6171-2012; Schindler, David/A-3752-2014	hudson, jeff/0000-0002-0256-3240; Taylor, William/0000-0001-8555-945X				Abakumov V.A, 1983, GUIDANCE METHODS HYD; Atkins W., 1923, J MAR BIOL ASSOC UK, V13, P119; Baldwin DS, 1998, WATER RES, V32, P2265, DOI 10.1016/S0043-1354(97)00474-0; BENTZEN E, 1991, CAN J FISH AQUAT SCI, V48, P73, DOI 10.1139/f91-011; BENTZEN E, 1991, J PLANKTON RES, V13, P1223, DOI 10.1093/plankt/13.6.1223; BRULAND KW, 1991, LIMNOL OCEANOGR, V36, P1555, DOI 10.4319/lo.1991.36.8.1555; *CAN PARK SERV, 1986, PRINCE ALBERT NATL P, V2, P4; Cotner JB, 1997, AQUAT MICROB ECOL, V13, P141, DOI 10.3354/ame013141; DODDS WK, 1993, AQUAT SCI, V55, P132, DOI 10.1007/BF00877441; Edmondson WT., 1991, USES ECOLOGY LAKE WA; FERRANTE JG, 1976, HYDROBIOLOGIA, V50, P11, DOI 10.1007/BF00016836; FISHER TR, 1992, CAN J FISH AQUAT SCI, V49, P252, DOI 10.1139/f92-029; HARRISON WG, 1993, ICES MAR SC, V197, P149; Hudson JJ, 1996, LIMNOL OCEANOGR, V41, P1560, DOI 10.4319/lo.1996.41.7.1560; Hudson JJ, 1999, NATURE, V400, P659, DOI 10.1038/23240; Karl D, 1997, NATURE, V388, P533, DOI 10.1038/41474; Landry MR, 1997, LIMNOL OCEANOGR, V42, P405, DOI 10.4319/lo.1997.42.3.0405; LEAN DRS, 1987, CAN J FISH AQUAT SCI, V44, P2069, DOI 10.1139/f87-256; PETERS R, 1973, LIMNOL OCEANOGR, V18, P270, DOI 10.4319/lo.1973.18.2.0270; PETERS RH, 1973, LIMNOL OCEANOGR, V18, P821, DOI 10.4319/lo.1973.18.6.0821; PREPAS EE, 1983, CAN J FISH AQUAT SCI, V40, P1412, DOI 10.1139/f83-163; RIGLER FH, 1966, VERH INT VER LIMNOL, V16, P465, DOI DOI 10.1080/03680770.1965.11895717; SCHINDLER DW, 1977, SCIENCE, V195, P260, DOI 10.1126/science.195.4275.260; SCHINDLER DW, 1972, P IBP UNESCO S PROD, P303; TARPCHAK SJ, 1988, CAN J FISH AQUAT SCI, V45, P2230; TAYLOR WD, 1991, CAN J FISH AQUAT SCI, V48, P1293, DOI 10.1139/f91-155; TAYLOR WD, 1981, CAN J FISH AQUAT SCI, V38, P1316, DOI 10.1139/f81-177; Thingstad TF, 1998, LIMNOL OCEANOGR, V43, P88, DOI 10.4319/lo.1998.43.1.0088; Wetzel RG, 2001, LIMNOLOGY, Vthird, P331	29	201	216	8	149	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					54	56		10.1038/35017531	http://dx.doi.org/10.1038/35017531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894537				2022-12-28	WOS:000087991200040
J	Jayaraman, KS				Jayaraman, KS			Indian space agency sets its sight on a mission to the Moon	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					5	5		10.1038/35017717	http://dx.doi.org/10.1038/35017717			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894509	Bronze			2022-12-28	WOS:000087991200056
J	Davis, MM; Lantos, JD				Davis, MM; Lantos, JD			Ethical considerations in the public policy laboratory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNIZATION; CHILDREN; PROGRAM; INFANTS; IMPACT; WOMEN		Univ Michigan, Div Pediat, Robert Wood Johnson Clin Scholars Program, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med, Robert Wood Johnson Clin Scholars Program, Ann Arbor, MI 48109 USA; Univ Michigan, McLean Ctr Clin Med Eth, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Davis, MM (corresponding author), Univ Michigan, Div Pediat, Robert Wood Johnson Clin Scholars Program, D3202 MPB,1500 E Med Ctr, Ann Arbor, MI 48109 USA.							BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/jama.274.4.312; BRENNAN N, 1997, NATL SURV AM FAMILIE; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; GEORGE E, 1993, NEEDLING SYSTEM WELF; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Hutchins SS, 1999, J PUBLIC HEALTH POL, V20, P408, DOI 10.2307/3343128; Kerpelman LC, 2000, JAMA-J AM MED ASSOC, V284, P53, DOI 10.1001/jama.284.1.53; Minkovitz C, 1999, ARCH PEDIAT ADOL MED, V153, P1242, DOI 10.1001/archpedi.153.12.1242; Shefer A, 1999, EPIDEMIOL REV, V21, P96, DOI 10.1093/oxfordjournals.epirev.a017992; *US DEP HHS, 1998, GREEN BOOK OV ENT PR; Wood D, 1998, JAMA-J AM MED ASSOC, V280, P1182, DOI 10.1001/jama.280.13.1182	11	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					85	87		10.1001/jama.284.1.85	http://dx.doi.org/10.1001/jama.284.1.85			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872018				2022-12-28	WOS:000087843000030
J	Katzenstein, TL; Dickmeiss, E; Aladdin, H; Hede, A; Nielsen, C; Nielsen, H; Jorgensen, LB; Gerstoft, J				Katzenstein, TL; Dickmeiss, E; Aladdin, H; Hede, A; Nielsen, C; Nielsen, H; Jorgensen, LB; Gerstoft, J			Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	3rd International Workshop on HIV Drug Resistance and Treatment Strategies	JUN 23-26, 1999	SAN DIEGO, CA				HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSFUSION; TRANSMISSION; SEROCONVERSION; INDIVIDUALS; RECIPIENTS; EXPOSURE; TYPE-1; GENE; AIDS		Natl Univ Hosp, Rigshosp, Dept Infect Dis, DK-2100 Copenhagen O, Denmark; State Serum Inst, Copenhagen, Denmark	Rigshospitalet; Statens Serum Institut	Katzenstein, TL (corresponding author), Natl Univ Hosp, Rigshosp, Dept Infect Dis, Biegdamsvej 9, DK-2100 Copenhagen O, Denmark.	terese@rh.dk		Katzenstein, Terese L/0000-0002-2233-500X				Brambilla A, 1998, AIDS, V12, P1928; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; COLEBUNDERS R, 1991, J INFECT DIS, V164, P450, DOI 10.1093/infdis/164.3.450; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *COUNC EUR, 1999, GUID PREP US QUAL AS; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1990, TRANSFUSION, V30, P851, DOI 10.1046/j.1537-2995.1990.30991048798.x; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; NIELSEN C, 1991, J VIROL METHODS, V35, P15, DOI 10.1016/0166-0934(91)90081-A; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schockmel GA, 1998, AIDS, V12, P1726; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SCHUUMAN R, 1997, CURRENT OPINION INFE, P480; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406	19	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					31	34		10.7326/0003-4819-133-1-200007040-00005	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	329TB	10877737				2022-12-28	WOS:000087923100004
J	Roberts, JM				Roberts, JM			Recent advances - Obstetrics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-BIRTH-WEIGHT; CEREBRAL-PALSY; DELIVERY; PREECLAMPSIA; PREVENTION; TRANSMISSION; HYPERTENSION; CHILDBIRTH; INFECTION; WOMEN		Magee Womens Res Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Roberts, JM (corresponding author), Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.	rsislm@mail.magee.edu	Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; ARIAS F, 1993, AM J OBSTET GYNECOL, V168, P585, DOI 10.1016/0002-9378(93)90499-9; BARKER DJP, 1989, LANCET, V2, P577; Barker DJP, 1999, ANN MED, V31, P3, DOI 10.1080/07853890.1999.11904392; CAREY J, IN PRESS N ENGL J ME; CAREY J, 2000, AM J OBSTET GYNECOL, V182; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Cotch MF, 1997, SEX TRANSM DIS, V24, P353, DOI 10.1097/00007435-199707000-00008; Gluckman PD, 1997, ACTA PAEDIATR, V86, P69; Goldenberg RL, 1998, NEW ENGL J MED, V339, P313, DOI 10.1056/NEJM199807303390506; Goldenberg RL, 1996, OBSTET GYNECOL, V87, P643, DOI 10.1016/0029-7844(96)00035-X; Hall MH, 1999, LANCET, V354, P776, DOI 10.1016/S0140-6736(05)76016-5; Hudson CN, 1999, LANCET, V353, P1030, DOI 10.1016/S0140-6736(99)00066-5; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Klebanoff MA, 1999, ARCH INTERN MED, V159, P1607, DOI 10.1001/archinte.159.14.1607; Langley-Evans SC, 1999, BIOCHEM SOC T, V27, P88, DOI 10.1042/bst0270088; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; Nelson KB, 1998, ANN NEUROL, V44, P665, DOI 10.1002/ana.410440413; Paneth N, 1996, J HYPERTENS, V14, pS121; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Paterson-Brown S, 1998, BMJ-BRIT MED J, V317, P462; PHELAN JP, 1998, CURR OPIN OBSTET GYN, V53, P662; Roberts JM, 1998, SEMIN REPROD ENDOCR, V16, P5, DOI 10.1055/s-2007-1016248; Roberts JM, 1999, LANCET, V354, P788, DOI 10.1016/S0140-6736(99)80002-6; Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103; Stringer JSA, 1999, JAMA-J AM MED ASSOC, V281, P1946, DOI 10.1001/jama.281.20.1946; Sultan AH, 1997, CURR OPIN OBSTET GYN, V9, P320; Sultan AH, 1996, BRIT J HOSP MED, V55, P575; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301	29	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					33	35		10.1136/bmj.321.7252.33	http://dx.doi.org/10.1136/bmj.321.7252.33			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875834	Green Published			2022-12-28	WOS:000088030100026
J	Schrag, A; Ben-Shlomo, Y; Quinn, NP				Schrag, A; Ben-Shlomo, Y; Quinn, NP			Cross sectional prevalence survey of idiopathic Parkinson's disease and parkinsonism in London	BRITISH MEDICAL JOURNAL			English	Article							DISTRICT		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England	University of Bristol; University of London; University College London	Ben-Shlomo, Y (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.		Ben-Shlomo, Yoav/ABD-2004-2021; Schrag, Anette E/B-4181-2011; Schrag, Anette/AAA-9344-2020	Ben-Shlomo, Yoav/0000-0001-6648-3007; Schrag, Anette E/0000-0002-9872-6680; Schrag, Anette/0000-0002-9872-6680				MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; Schrag A, 1999, LANCET, V354, P1771, DOI 10.1016/S0140-6736(99)04137-9; Sutcliffe RLG, 1995, ACTA NEUROL SCAND, V92, P443; SUTCLIFFE RLG, 1985, ACTA NEUROL SCAND, V72, P363; [No title captured]	5	185	188	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	2000	321	7252					21	+		10.1136/bmj.321.7252.21	http://dx.doi.org/10.1136/bmj.321.7252.21			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875828	Green Published, Bronze			2022-12-28	WOS:000088030100021
J	Vassallo, R; Ryu, JH; Colby, TV; Hartman, T; Limper, AH				Vassallo, R; Ryu, JH; Colby, TV; Hartman, T; Limper, AH			Medical progress: Pulmonary Langerhans'-cell histiocytosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BRONCHOALVEOLAR LAVAGE FLUID; LOWER RESPIRATORY-TRACT; HIGH-RESOLUTION CT; EOSINOPHILIC GRANULOMA; LUNG TRANSPLANTATION; TRANSFORMING GROWTH-FACTOR-BETA-1; LYMPHOCYTE-PROLIFERATION; GM-CSF; DIAGNOSIS; ADULT		Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Diagnost Radiol, Rochester, MN 55905 USA; Mayo Clin, Div Anat Pathol, Scottsdale, AZ USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic Phoenix	Limper, AH (corresponding author), Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Thorac Dis Res Unit, 601C Guggenheim Bldg, Rochester, MN 55905 USA.		Hug, Balthasar L./G-1568-2010; Vassallo, Robert/R-7752-2019; Arico, Maurizio/S-3039-2019; Nichols, Kim/E-9353-2016	Vassallo, Robert/0000-0003-2328-0255; Arico, Maurizio/0000-0002-1908-6671; Nichols, Kim/0000-0002-5581-6555; Ryu, Jay/0000-0002-9576-2272				AGUAYO SM, 1989, J CLIN INVEST, V84, P1105, DOI 10.1172/JCI114273; Asakura S, 1996, AM J RESP CRIT CARE, V154, P1525, DOI 10.1164/ajrccm.154.5.8912775; AUERSWALD U, 1991, LUNG, V169, P305, DOI 10.1007/BF02714167; BASSET F, 1978, AM REV RESPIR DIS, V118, P811; Benyounes B, 1996, CHEST, V110, P284, DOI 10.1378/chest.110.1.284; BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; Bonelli FS, 1998, AM J ROENTGENOL, V170, P1507, DOI 10.2214/ajr.170.6.9609163; BRAUNER MW, 1989, RADIOLOGY, V172, P255, DOI 10.1148/radiology.172.1.2787036; Brauner MW, 1997, RADIOLOGY, V204, P497, DOI 10.1148/radiology.204.2.9240543; BURNS BF, 1983, AM J SURG PATHOL, V7, P529, DOI 10.1097/00000478-198309000-00003; CASOLARO MA, 1988, AM REV RESPIR DIS, V137, P406, DOI 10.1164/ajrccm/137.2.406; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHOLLET S, 1984, AM J PATHOL, V115, P225; COLASANTE A, 1993, AM REV RESPIR DIS, V148, P752, DOI 10.1164/ajrccm/148.3.752; COLBY TV, 1983, HUM PATHOL, V14, P847, DOI 10.1016/S0046-8177(83)80160-9; Crausman RS, 1996, AM J RESP CRIT CARE, V153, P426, DOI 10.1164/ajrccm.153.1.8542154; deGraaf JH, 1996, J PATHOL, V180, P400, DOI 10.1002/(SICI)1096-9896(199612)180:4<400::AID-PATH701>3.0.CO;2-W; Delobbe K, 1996, EUR RESPIR J, V9, P2002; DELRIO M, 1994, PEPTIDES, V15, P15, DOI 10.1016/0196-9781(94)90164-3; EGAN TM, 1992, SOUTH MED J, V85, P551, DOI 10.1097/00007611-199205000-00019; Egeler RM, 1998, HEMATOL ONCOL CLIN N, V12, P369, DOI 10.1016/S0889-8588(05)70516-5; Etienne B, 1998, AM J RESP CRIT CARE, V157, P288, DOI 10.1164/ajrccm.157.1.96-12107; Favara BE, 1997, MED PEDIATR ONCOL, V29, P157, DOI 10.1002/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-C; FLINT A, 1986, ARCH PATHOL LAB MED, V110, P930; FRANCUS T, 1988, J IMMUNOL, V140, P4413; FRIEDMAN PJ, 1981, MEDICINE, V60, P385, DOI 10.1097/00005792-198111000-00001; GAENSLER EA, 1980, ANN THORAC SURG, V30, P411, DOI 10.1016/S0003-4975(10)61291-X; Giona F, 1997, CANCER, V80, P1786; Habib SB, 1998, THORAX, V53, P323, DOI 10.1136/thx.53.4.323; HIROSE M, 1995, ACTA PAEDIATR, V84, P1204, DOI 10.1111/j.1651-2227.1995.tb13529.x; HIRSCH MS, 1973, AM REV RESPIR DIS, V107, P831; HOUSINI I, 1994, ARCH PATHOL LAB MED, V118, P523; Howarth DM, 1999, CANCER-AM CANCER SOC, V85, P2278, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U; KING TE, 1979, ANN INTERN MED, V91, P397, DOI 10.7326/0003-4819-91-3-397; LACRONIQUE J, 1982, THORAX, V37, P104, DOI 10.1136/thx.37.2.104; LEMAIRE I, 1991, NEUROPEPTIDES, V20, P217, DOI 10.1016/0143-4179(91)90011-7; LEWIS JG, 1964, Q J MED, V33, P337; LOMBARD CM, 1987, ARCH PATHOL LAB MED, V111, P339; Mogulkoc N, 1999, CHEST, V115, P1452, DOI 10.1378/chest.115.5.1452; MOORE ADA, 1989, RADIOLOGY, V172, P249, DOI 10.1148/radiology.172.1.2787035; Morimoto T, 1999, Nihon Kokyuki Gakkai Zasshi, V37, P140; NEUMANN MP, 1986, HUM PATHOL, V17, P1060, DOI 10.1016/S0046-8177(86)80091-0; Nezelof C, 1998, HEMATOL ONCOL CLIN N, V12, P385, DOI 10.1016/S0889-8588(05)70518-9; POMERANZ SJ, 1986, CHEST, V89, P88, DOI 10.1378/chest.89.1.88; Saven A, 1999, BLOOD, V93, P4125, DOI 10.1182/blood.V93.12.4125.412k11_4125_4130; SCHONFELD N, 1993, RESPIRATION, V60, P38; SOLER P, 1985, AM J PATHOL, V118, P439; Tazi A, 1996, THORAX, V51, P611, DOI 10.1136/thx.51.6.611; TAZI A, 1993, AM REV RESPIR DIS, V147, P1531, DOI 10.1164/ajrccm/147.6_Pt_1.1531; TOMASHEFSKI JF, 1991, ARCH PATHOL LAB MED, V115, P499; TRAVIS WD, 1993, AM J SURG PATHOL, V17, P971, DOI 10.1097/00000478-199310000-00002; VONESSEN S, 1990, CHEST, V98, P765, DOI 10.1378/chest.98.3.765; WEBBER D, 1985, AM J CLIN PATHOL, V84, P447, DOI 10.1093/ajcp/84.4.447; WILLMAN CL, 1994, NEW ENGL J MED, V331, P154, DOI 10.1056/NEJM199407213310303; Xing Z, 1997, AM J PATHOL, V150, P59; Yeatman M, 1996, J HEART LUNG TRANSPL, V15, P144; YOUKELES LH, 1995, AM J RESP CRIT CARE, V151, P145, DOI 10.1164/ajrccm.151.1.7812544; Zeid NA, 1995, PATHOLOGY, V27, P247, DOI 10.1080/00313029500169063; Zhang K, 1997, J IMMUNOL, V158, P954	59	284	310	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1969	1978		10.1056/NEJM200006293422607	http://dx.doi.org/10.1056/NEJM200006293422607			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10877650				2022-12-28	WOS:000087867400007
J	Ylitalo, N; Sorensen, P; Josefsson, AM; Magnusson, PKE; Andersen, PK; Ponten, J; Adami, HO; Gyllensten, UB; Melbye, M				Ylitalo, N; Sorensen, P; Josefsson, AM; Magnusson, PKE; Andersen, PK; Ponten, J; Adami, HO; Gyllensten, UB; Melbye, M			Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; TYPE-16 DNA; IN-SITU; CANCER; GRADE; POLYMERASE; INFECTION; SMEARS; PCR; PREDICTOR	Background Persistent infection with certain types of human papillomavirus (HPV) is believed to be a prerequisite for the development of cervical neoplasia. Persistence may depend on certain characteristics, such as viral load, which has so far been given little attention. We investigated the association between HPV 16 viral load and cervical carcinoma in situ. Methods We did a nested case-control study of women participating in cytological screening in Sweden. We used a sensitive quantitative PCR assay to estimate HPV 16 load in multiple smears for each woman, taken during a period of up to 26 years before diagnosis. We calculated C-t values, which decrease as the number of viral DNA copies increases. Findings 2081 smears from 478 cases and 1754 smears from 608 controls were tested. Among cases, we found a consistently increased load of HPV 16 already 13 years or more before diagnosis, and when many smears were still cytologically normal. Women with high HPV 16 viral loads were at least 30 times the relative risk of HPV-16-negative women more than a decade before diagnosis. The increase in relative risk was constant over time. About 25% of women (95% CI 0.12-0.32) infected with a high viral load before age 25 years developed cervical carcinoma in situ within 15 years. Interpretation Cervical carcinoma in situ associated with HPV 16 occurs mainly in HPV-16-positive women who have consistently high viral loads long term. Women at high risk could be identified by use of a quantitative HPV test in addition to cytological screening.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Harvard Ctr Canc Prevent, Boston, MA 02115 USA	Karolinska Institutet; Aarhus University; Statens Serum Institut; Uppsala University; University of Copenhagen; Harvard University; Harvard University	Ylitalo, N (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, SE-17177 Stockholm, Sweden.	nathalie.ylitalo@mep.ki.se	Magnusson, Patrik KE/C-4458-2017	Magnusson, Patrik KE/0000-0002-7315-7899; Sorensen, Per Soelberg/0000-0002-2818-3780; melbye, mads/0000-0001-8264-6785	NINR NIH HHS [NR 1 RO1 CA1197-01A3] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Brisson J, 1996, J INFECT DIS, V173, P794, DOI 10.1093/infdis/173.4.794; CHUA KL, 1995, ANAL QUANT CYTOL, V17, P221; Cuzick J, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P364; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; Cuzick J, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P373; GUSTAFSSON L, 1995, BRIT J CANCER, V72, P498, DOI 10.1038/bjc.1995.362; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ho GYF, 1998, INT J CANCER, V78, P594, DOI 10.1002/(SICI)1097-0215(19981123)78:5&lt;594::AID-IJC11&gt;3.0.CO;2-B; Ho GYF, 1998, INT J CANCER, V78, P281, DOI 10.1002/(SICI)1097-0215(19981029)78:3&lt;281::AID-IJC3&gt;3.0.CO;2-R; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Josefsson A, 1999, J CLIN MICROBIOL, V37, P490, DOI 10.1128/JCM.37.3.490-496.1999; Josefsson AM, 2000, LANCET, V355, P2189, DOI 10.1016/S0140-6736(00)02401-6; Langholz B, 1997, BIOMETRICS, V53, P767, DOI 10.2307/2533977; LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761; Maiman M, 1998, J Natl Cancer Inst Monogr, P43; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; MUNOZ N, 1996, PAPILLOMAVIRUS REV C, P227; PALEFSKY J, 1991, HEMATOL ONCOL CLIN N, V5, P357, DOI 10.1016/S0889-8588(18)30447-7; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Quinn M, 1999, BRIT MED J, V318, P904, DOI 10.1136/bmj.318.7188.904; SASIENI P, 1995, LANCET, V346, P1566, DOI 10.1016/S0140-6736(95)92099-4; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; Swan DC, 1999, J CLIN MICROBIOL, V37, P1030, DOI 10.1128/JCM.37.4.1030-1034.1999; TERRY G, 1993, ARCH VIROL, V128, P123, DOI 10.1007/BF01309793; YLITALO N, 1995, J CLIN MICROBIOL, V33, P1822, DOI 10.1128/JCM.33.7.1822-1828.1995; Ylitalo N, 1999, INT J CANCER, V81, P357, DOI 10.1002/(SICI)1097-0215(19990505)81:3<357::AID-IJC8>3.3.CO;2-T	28	252	266	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2194	2198		10.1016/S0140-6736(00)02402-8	http://dx.doi.org/10.1016/S0140-6736(00)02402-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881892				2022-12-28	WOS:000087779000010
J	Sobol, RW; Prasad, R; Evenski, A; Baker, A; Yang, XP; Horton, JK; Wilson, SH				Sobol, RW; Prasad, R; Evenski, A; Baker, A; Yang, XP; Horton, JK; Wilson, SH			The lyase activity of the DNA repair protein beta-polymerase protects from DNA-damage-induced cytotoxicity	NATURE			English	Article							BASE-EXCISION-REPAIR; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; DEOXYRIBOPHOSPHODIESTERASE DRPASE ACTIVITY; ESCHERICHIA-COLI; SITE; CELLS; IDENTIFICATION; RESIDUES; CONTAINS; RELEASE	Small DNA lesions such as oxidized or alkylated bases are repaired by the base excision repair (BER) pathway(1). BER includes removal of the damaged base by a lesion-specific DNA glycosylase, strand scission by apurinic/apyrimidinic endonuclease, DNA resynthesis and ligation(2). BER may be further subdivided into DNA beta-polymerase (beta-pol)-dependent single-nucleotide repair and beta-pol-dependent or -independent long patch repair subpathways(3-6). Two important enzymatic steps in mammalian single-nucleotide BER are contributed by beta-pol: DNA resynthesis of the repair patch and lyase removal of 5'-deoxyribose phosphate (dRP)(2). Fibroblasts from beta-pol null mice are hypersensitive to monofunctional DNA-methylating agents, resulting in increases in chromosomal damage, apoptosis and necrotic cell death(3,7). Here we show that only the dRP lyase activity of beta-pol is required to reverse methylating agent hypersensitivity in beta-pol null cells. These results indicate that removal of the dRP group is a pivotal step in BER in vivo. Persistence of the dRP moiety in DNA results in the hypersensitivity phenotype of beta-pol null cells and may signal downstream events such as apoptosis and necrotic cell death.	NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Sobol, Robert W./E-4125-2013; Wilson, Samuel H/E-6644-2019	Sobol, Robert W./0000-0001-7385-3563; Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050159, Z01ES050159] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; Ochs K, 1999, CANCER RES, V59, P1544; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; Sandigursky M, 1997, J BIOL CHEM, V272, P17480, DOI 10.1074/jbc.272.28.17480; SANDIGURSKY M, 1994, NUCLEIC ACIDS RES, V22, P247, DOI 10.1093/nar/22.2.247; Sandigursky M, 1997, NUCLEIC ACIDS RES, V25, P4557, DOI 10.1093/nar/25.22.4557; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	27	281	290	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					807	810		10.1038/35015598	http://dx.doi.org/10.1038/35015598			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866204				2022-12-28	WOS:000087620600055
J	Tombler, TW; Zhou, CW; Alexseyev, L; Kong, J; Dai, HJ; Lei, L; Jayanthi, CS; Tang, MJ; Wu, SY				Tombler, TW; Zhou, CW; Alexseyev, L; Kong, J; Dai, HJ; Lei, L; Jayanthi, CS; Tang, MJ; Wu, SY			Reversible electromechanical characteristics of carbon nanotubes under local-probe manipulation	NATURE			English	Article							ELECTRONIC-STRUCTURE; ROPES	The effects of mechanical deformation on the electrical properties of carbon nanotubes are of interest given the practical potential of nanotubes in electromechanical devices, and they have been studied using both theoretical(1-4) and experimental(5,6) approaches. One recent experiment 6 used the tip of an atomic force microscope (AFM) to manipulate multi-walled nanotubes, revealing that changes in the sample resistance were small unless the nanotubes fractured or the metal-tube contacts were perturbed. But it remains unclear how mechanical deformation affects the intrinsic electrical properties of nanotubes. Here we report an experimental and theoretical elucidation of the electromechanical characteristics of individual single-walled carbon nanotubes (SWNTs) under local-probe manipulation. We use AFM tips to deflect suspended SWNTs reversibly, without changing the contact resistance; in situ electrical measurements reveal that the conductance of an SWNT sample can be reduced by two orders of magnitude when deformed by an AFM tip. Our tight-binding simulations indicate that this effect is owing to the formation of local sp(3) bonds caused by the mechanical pushing action of the tip.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Univ Louisville, Dept Phys, Louisville, KY 40292 USA; Lawrence Livermore Natl Lab, Phys Directorate, Livermore, CA 94551 USA	Stanford University; University of Louisville; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Dai, HJ (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	hdai@chem.stanford.edu	Dai, Hongjie/ABC-4574-2021; Zhou, Chongwu/F-7483-2010					Alfonso DR, 1999, PHYS REV B, V59, P7745, DOI 10.1103/PhysRevB.59.7745; Bezryadin A, 1998, PHYS REV LETT, V80, P4036, DOI 10.1103/PhysRevLett.80.4036; Crespi VH, 1997, PHYS REV LETT, V79, P2093, DOI 10.1103/PhysRevLett.79.2093; Datta S., 1997, ELECT TRANSPORT MESO; Hertel T, 1998, J PHYS CHEM B, V102, P910, DOI 10.1021/jp9734686; Jayanthi CS, 1998, PHYS REV B, V57, P3799, DOI 10.1103/PhysRevB.57.3799; Kane CL, 1997, PHYS REV LETT, V78, P1932, DOI 10.1103/PhysRevLett.78.1932; Kim P, 1999, SCIENCE, V286, P2148, DOI 10.1126/science.286.5447.2148; Kong J, 1999, APPL PHYS A-MATER, V69, P305, DOI 10.1007/s003390051005; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Nardelli MB, 1999, PHYS REV B, V60, pR16338, DOI 10.1103/PhysRevB.60.R16338; Paulson S, 1999, APPL PHYS LETT, V75, P2936, DOI 10.1063/1.125193; Rochefort A, 1998, CHEM PHYS LETT, V297, P45, DOI 10.1016/S0009-2614(98)01105-1; Rochefort A, 1999, PHYS REV B, V60, P13824, DOI 10.1103/PhysRevB.60.13824; Salvetat JP, 1999, PHYS REV LETT, V82, P944, DOI 10.1103/PhysRevLett.82.944; Soh HT, 1999, APPL PHYS LETT, V75, P627, DOI 10.1063/1.124462; Timoshenko S, 1930, STRENGTH MAT 1; Walters DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185; WU SY, 1995, INT J MOD PHYS B, V9, P1869, DOI 10.1142/S0217979295000768	19	1038	1080	8	283	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					769	772		10.1038/35015519	http://dx.doi.org/10.1038/35015519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866192				2022-12-28	WOS:000087620600043
J	Emery, VC; Sabin, CA; Cope, AV; Gor, D; Hassan-Walker, AF; Griffiths, PD				Emery, VC; Sabin, CA; Cope, AV; Gor, D; Hassan-Walker, AF; Griffiths, PD			Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; LIVER-TRANSPLANTATION; CMV DISEASE; VIRUS INFECTIONS; RISK-FACTORS; RECIPIENTS; SEROSTATUS; QUANTITY; THERAPY	Background Cytomegalovirus (CMV) continues to be a major problem post-transplantation; early markers for predicting patients at risk of CMV disease are needed. Peak CMV load in the blood correlates with CMV disease but frequently occurs too late to provide prognostic information. Methods 359 transplant recipients (162 liver, 87 renal, and 110 bone marrow) were prospectively monitored for CMV DNA in the blood with qualitative and quantitative PCR. 3873 samples were analysed. The CMV load in the first PCR-positive sample and the rate of increase in CMV load in blood during the initial phase of replication were assessed as risk factors for CMV disease using logistic regression. Findings 127 of the 359 patients had CMV DNA in the blood and 49 developed CMV disease. initial viral load correlated significantly with peak CMV load (R-2=0.47, p=<0.001) and with CMV disease (odds ratio 1.82 [95% CI 1.11-2.98; p=0.02; 1.34 [1.07-1.68] p=0.01, and 1.52 [1.13-2.05], p=0.006, per 0.25 log(10) increase in viral load for liver, renal, and bone-marrow patients, respectively). The rate of increase in CMV load between the last PCR-negative and first PCR-positive sample was significantly faster in patients with CMV disease (0.33 log(10) versus 0.19 log(10) genomes/mL daily, p<0.001). In multivariate-regression analyses, both initial CMV load and rate of viral load increase were independent risk factors for CMV disease (1.28 [1.06-1.52], p=0.01, per 0.25 log(10) increase in CMV load and 1.52 [1.06-2.17], p=0.02, per 0.1 log(10) increase in CMV load/mL daily, respectively). Interpretation CMV load in the initial phase of active infection and the rate of increase in viral load both correlate with CMV disease in transplant recipients; in combination, they have the potential to identify patients at imminent risk of CMV disease.	UCL Royal Free & Univ Coll, Sch Med, Dept Virol, London NW3 2PF, England; UCL Royal Free & Univ Coll, Sch Med, Dept Primary Care & Populat Sci, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Emery, VC (corresponding author), UCL Royal Free & Univ Coll, Sch Med, Dept Virol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	v.emery@rfc.ucl.ac.uk	Sabin, Caroline/C-2464-2008; Emery, Vincent/G-8928-2013	Sabin, Caroline/0000-0001-5173-2760; Emery, Vincent/0000-0001-5893-9756				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BETTS RF, 1977, AM J DIS CHILD, V131, P759, DOI 10.1001/archpedi.1977.02120200041010; BOPPANA SB, 1995, J INFECT DIS, V171, P182, DOI 10.1093/infdis/171.1.182; Chang FY, 1998, CLIN INFECT DIS, V26, P59, DOI 10.1086/516265; CHOU SW, 1989, J INFECT DIS, V160, P11, DOI 10.1093/infdis/160.1.11; Cope AV, 1997, J INFECT DIS, V176, P1484, DOI 10.1086/514145; Cope AV, 1997, J MED VIROL, V52, P200, DOI 10.1002/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.0.CO;2-O; EINSELE H, 1995, BLOOD, V86, P2815; Emery VC, 1999, J EXP MED, V190, P177, DOI 10.1084/jem.190.2.177; Falagas ME, 1997, ANN INTERN MED, V126, P275, DOI 10.7326/0003-4819-126-4-199702150-00003; FOX JC, 1992, J GEN VIROL, V73, P2405, DOI 10.1099/0022-1317-73-9-2405; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; Gor D, 1998, BONE MARROW TRANSPL, V21, P597, DOI 10.1038/sj.bmt.1701139; GROB JP, 1987, LANCET, V1, P774; GRUNDY JE, 1988, LANCET, V2, P132; Hassan-Walker AF, 1999, J MED VIROL, V58, P182, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt;182::AID-JMV14&gt;3.0.CO;2-Q; LJUNGMAN P, 1995, SCAND J INFECT DIS S, V99, P87; Manez R, 1996, J INFECT DIS, V173, P1072, DOI 10.1093/infdis/173.5.1072; PATEL R, 1995, J INFECT DIS, V171, P1010, DOI 10.1093/infdis/171.4.1010; PAYA CV, 1993, J HEPATOL, V18, P185, DOI 10.1016/S0168-8278(05)80245-4; PRENTICE HG, 1994, LANCET, V343, P749, DOI 10.1016/S0140-6736(94)91835-X; Riddell SR, 1997, REV MED VIROL, V7, P181, DOI 10.1002/(SICI)1099-1654(199709)7:3<181::AID-RMV200>3.0.CO;2-W; RUBIN RH, 1989, JAMA-J AM MED ASSOC, V261, P3607; TorokStorb B, 1997, BLOOD, V90, P2097, DOI 10.1182/blood.V90.5.2097; Wang FZ, 1996, BLOOD, V88, P3615, DOI 10.1182/blood.V88.9.3615.bloodjournal8893615; WINSTON DJ, 1985, ANN INTERN MED, V102, P16, DOI 10.7326/0003-4819-102-1-16	26	415	431	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2000	355	9220					2032	2036		10.1016/S0140-6736(00)02350-3	http://dx.doi.org/10.1016/S0140-6736(00)02350-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885354				2022-12-28	WOS:000087519400011
J	Carroll, SB				Carroll, SB			Endless forms: the evolution of gene regulation and morphological diversity	CELL			English	Review							DROSOPHILA-MELANOGASTER; BRISTLE NUMBER; HOX GENES; ULTRABITHORAX; EXPRESSION; SELECTION; IDENTITY		Univ Wisconsin, Howard Hughes Med Inst, RM Bock Labs, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, RM Bock Labs, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu						Akam M, 1998, INT J DEV BIOL, V42, P445; ANH DG, 1999, EVOL DEV, V1, P100; Arnone MI, 1997, DEVELOPMENT, V124, P1851; Arthur W, 1999, EVOL DEV, V1, P62; Belting HG, 1998, P NATL ACAD SCI USA, V95, P2355, DOI 10.1073/pnas.95.5.2355; CARROLL SB, 2000, IN PRESS DNA DIVERSI; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; Gibson G, 1999, GENETICS, V151, P1081; Gibson G, 1996, SCIENCE, V271, P200, DOI 10.1126/science.271.5246.200; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; Long AD, 1998, GENETICS, V149, P999; Mackay TFC, 1996, BIOESSAYS, V18, P113, DOI 10.1002/bies.950180207; Nuzhdin SV, 1999, GENETICS, V153, P1317; Polaczyk PJ, 1998, DEV GENES EVOL, V207, P462, DOI 10.1007/s004270050137; SHUBIN N, 1995, EVOLUTION, V49, P874, DOI 10.1111/j.1558-5646.1995.tb02323.x; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Weatherbee SD, 1999, CELL, V97, P283, DOI 10.1016/S0092-8674(00)80737-0	20	328	339	3	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2000	101	6					577	580		10.1016/S0092-8674(00)80868-5	http://dx.doi.org/10.1016/S0092-8674(00)80868-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892643	Bronze			2022-12-28	WOS:000087504500003
J	Wassarman, KM; Storz, G				Wassarman, KM; Storz, G			6S RNA regulates E-coli RNA polymerase activity	CELL			English	Article							ANTI-SIGMA FACTORS; ESCHERICHIA-COLI; OXIDATIVE STRESS; STATIONARY-PHASE; GENE; GROWTH; PROMOTER; PROTEIN; 6S-RNA	The E. coli 6S RNA was discovered more than three decades ago, yet its function has remained elusive. Here, we demonstrate that 6S RNA associates with RNA polymerase in a highly specific and efficient manner. UV crosslinking experiments revealed that 6S RNA directly contacts the sigma(70) and beta/beta' subunits of RNA polymerase. 6S RNA accumulates as cells reach the stationary phase of growth and mediates growth phase-specific changes in RNA polymerase. Stable association between sigma(70) and core RNA polymerase in extracts is only observed in the presence of 6S RNA. We show 6S RNA represses expression from a sigma(70)-dependent promoter during stationary phase. Our results suggest that the interaction of 6S RNA with RNA polymerase modulates sigma(70)-holoenzyme activity.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wassarman, KM (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.			Storz, Gisela/0000-0001-6698-1241	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001608] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001608] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Altuvia S, 1997, CELL, V90, P43, DOI 10.1016/S0092-8674(00)80312-8; Brosius J, 1996, SCIENCE, V271, P1302; BROWNLEE GG, 1971, NATURE-NEW BIOL, V229, P147, DOI 10.1038/newbio229147a0; BURGESS RR, 1971, ANNU REV BIOCHEM, V40, P711, DOI 10.1146/annurev.bi.40.070171.003431; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; Helmann JD, 1999, CURR OPIN MICROBIOL, V2, P135, DOI 10.1016/S1369-5274(99)80024-1; HELMANN JD, 1994, TRANSCRIPTION MECH R, P1; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; HINDLEY J, 1967, J MOL BIOL, V30, P125, DOI 10.1016/0022-2836(67)90248-3; HSU LM, 1985, J BACTERIOL, V161, P1162, DOI 10.1128/JB.161.3.1162-1170.1985; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; ISHIHAMA A, 1991, CONTROL CELL GROWTH, P121; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; Jishage M, 1999, J BACTERIOL, V181, P3768, DOI 10.1128/JB.181.12.3768-3776.1999; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KRAKOW JS, 1970, COLD SPRING HARB SYM, V35, P73, DOI 10.1101/SQB.1970.035.01.013; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; LEE CA, 1985, J BACTERIOL, V161, P1156, DOI 10.1128/JB.161.3.1156-1161.1985; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; LERNER MR, 1981, SCIENCE, V211, P400, DOI 10.1126/science.6164096; NGUYEN LH, 1993, BIOCHEMISTRY-US, V32, P11112, DOI 10.1021/bi00092a021; Siegele DA, 1996, J BACTERIOL, V178, P6352, DOI 10.1128/jb.178.21.6352-6356.1996; Silhavy T. J., 1984, EXPT GENE FUSIONS; SPASSKY A, 1979, EUR J BIOCHEM, V99, P187, DOI 10.1111/j.1432-1033.1979.tb13245.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; VOGEL DW, 1987, NUCLEIC ACIDS RES, V15, P4583, DOI 10.1093/nar/15.11.4583; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; Wassarman KM, 1999, TRENDS MICROBIOL, V7, P37	33	342	353	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					613	623		10.1016/S0092-8674(00)80873-9	http://dx.doi.org/10.1016/S0092-8674(00)80873-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892648	Bronze			2022-12-28	WOS:000087504500008
J	Bucher, HC; Hengstler, P; Schindler, C; Guyatt, GH				Bucher, HC; Hengstler, P; Schindler, C; Guyatt, GH			Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; ARTERY DISEASE; UNITED-STATES; BALLOON ANGIOPLASTY; BYPASS-SURGERY; STABLE ANGINA; THERAPY; CANADA; VESSEL	Objective To determine whether percutaneous transluminal coronary angioplasty (angioplasty) is superior to medical treatment in non-acute coronary artery disease. Design Meta-analysis of randomised controlled trials. Setting Randomised controlled trials conducted worldwide and published between 1979 and 1998. Participants 953 patients treated wit angioplasty and 951 with medical treatment from six randomised controlled trials, three of which included patients with multivessel disease and pre-existing myocardial infarction. Main outcome measures Angina, fatal and non-fatal myocardial infarction, death, repeated angioplasty, and coronary artery bypass grafting. Results In patients treated with angioplasty compared wit medical treatment the risk ratios were 0.70 (95% confidence interval 0.50 to 0.98; heterogenicity P>0.001) for angina; 1.42 (0.90 to 2.25) for fatal and non-fatal myocardial infarction, 1.32 (0.65 to 2.70) for death, 1.59 (1.09 to 2.32) for coronary artery bypass graft, and 1.29 (0.71 to 3.36; heterogeneity P < 0.001) for repeated angioplasty. Differences in the methodological quality of the trials, in follow up, or in single versus multivessel disease did not explain the variability in study results in any analysis. Conclusions Percutaneous transluminal coronary angioplasty may lead to a greater reduction in angina in patients with coronary heart disease than medical treatment but at the cost of more coronary artery bypass grafting. Trials have not included enough patients for informative estimates of the effect of angioplasty on myocardial infarction, death, or subsequent revascularisation, though trends so far do not favour angioplasty.	Univ Basel, Kantonsspital, Med Poliklin, CH-4031 Basel, Switzerland; Univ Basel, Inst Sozial & Pravent Med, CH-4003 Basel, Switzerland; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	Kantonsspital Aarau AG (KSA); University of Basel; University of Basel; McMaster University	Bucher, HC (corresponding author), Univ Basel, Kantonsspital, Med Poliklin, CH-4031 Basel, Switzerland.	hbucher@uhbs.ch	Schindler, Christian/D-3472-2015					Anderson WD, 1996, CURR OPIN CARDIOL, V11, P583, DOI 10.1097/00001573-199611000-00005; Bates DW, 1997, ANN INTERN MED, V126, P539, DOI 10.7326/0003-4819-126-7-199704010-00007; Chamberlain DA, 1997, LANCET, V350, P461; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Folland ED, 1997, J AM COLL CARDIOL, V29, P1505, DOI 10.1016/S0735-1097(97)00097-1; GILLUM BS, 1996, DHHS PUBLICATION 13, V124; HIGGINSON LAJ, 1994, CAN J CARDIOL, V10, P728; HUEB WA, 1995, J AM COLL CARDIOL, V26, P1600, DOI 10.1016/0735-1097(95)00384-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Macaya C, 1996, J AM COLL CARDIOL, V27, P255, DOI 10.1016/0735-1097(95)00473-4; Madsen JK, 1997, CIRCULATION, V96, P748; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; PEDERSEN TR, 1994, LANCET, V344, P1383; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; ROGERS WJ, 1995, J AM COLL CARDIOL, V26, P594, DOI 10.1016/0735-1097(95)00228-V; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Shook TL, 1996, AM J CARDIOL, V77, P331, DOI 10.1016/S0002-9149(97)89359-9; SIEVERS B, 1993, CIRCULATION, V88, P297; Solomon AJ, 1998, ANN INTERN MED, V128, P216, DOI 10.7326/0003-4819-128-3-199802010-00008; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093	26	179	186	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2000	321	7253					73	77		10.1136/bmj.321.7253.73	http://dx.doi.org/10.1136/bmj.321.7253.73			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884254	Green Published, Bronze			2022-12-28	WOS:000088196600021
J	McCabe, H				McCabe, H			Galileo set for suicide flight	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					8	8		10.1038/35017732	http://dx.doi.org/10.1038/35017732			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894514	Bronze			2022-12-28	WOS:000087991200012
J	Philpotts, AR; Dickson, LD				Philpotts, AR; Dickson, LD			The formation of plagioclase chains during convective transfer in basaltic magma	NATURE			English	Article							MODEL; FLOW	The basaltic rock in the lower part of the thick Holyoke lava flow in Connecticut and Massachusetts has been shown to have a remarkable texture, with crystals of feldspar linked together in a continuous three-dimensional network of chains(1). Heating experiments have revealed that this network persists to temperatures where the rock is 75% liquid(2), and therefore the network was interpreted to have formed at an early stage of crystallization and to have played an important role in the compaction of crystal mush in the lower part of the flow(3,4). Despite the texture's importance to our understanding of how such basalt flows form, the origin of the texture has remained uncertain(1-3). Here we show that, although the network is present in the lower third of the flow, it was actually formed in the upper solidification front and was transported down in plumes of dense crystal mush. Convection of this type has been postulated for intrusive magma chambers, but corroborative field evidence has been equivocal, especially in lava lakes and flows. Preservation of the roof-generated texture in the lower part of a thick flood-basalt flow therefore constitutes important evidence for the role of convection in the solidification and differentiation of a simple magma sheet.	Univ Connecticut, Dept Geol & Geophys, Storrs, CT 06269 USA	University of Connecticut	Philpotts, AR (corresponding author), Univ Connecticut, Dept Geol & Geophys, Storrs, CT 06269 USA.							DEGRAFF JM, 1987, GEOL SOC AM BULL, V99, P605, DOI 10.1130/0016-7606(1987)99<605:SMOCJA>2.0.CO;2; DOWTY E, 1974, J PETROL, V15, P419, DOI 10.1093/petrology/15.3.419; GHIORSO MS, 1995, CONTRIB MINERAL PETR, V119, P197, DOI 10.1007/BF00307281; LINDSLEY DH, 1983, AM MINERAL, V68, P477; LONG PE, 1986, GEOL SOC AM BULL, V97, P1144, DOI 10.1130/0016-7606(1986)97<1144:STACHO>2.0.CO;2; MARSH BD, 1988, GEOL SOC AM BULL, V100, P1720, DOI 10.1130/0016-7606(1988)100<1720:CCSARI>2.3.CO;2; Philpotts AR, 1998, NATURE, V395, P343, DOI 10.1038/26404; Philpotts AR, 1999, AM MINERAL, V84, P1819; Philpotts AR, 1996, GEOLOGY, V24, P1029, DOI 10.1130/0091-7613(1996)024<1029:PPOPMT>2.3.CO;2; Philpotts AR, 1996, J PETROL, V37, P811, DOI 10.1093/petrology/37.4.811; Self S, 1996, GEOPHYS RES LETT, V23, P2689, DOI 10.1029/96GL02450	11	52	52	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					59	61		10.1038/35017542	http://dx.doi.org/10.1038/35017542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894539				2022-12-28	WOS:000087991200042
J	Meade, TW; Brennan, PJ				Meade, TW; Brennan, PJ		MRC Gen Res Practice Res Framework	Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; LOW-DOSE ASPIRIN; HYPERTENSION; SEVERITY; RISK	Objective To determine which groups of patients may derive particular benefit or experience harm from the use of low dose aspirin for the primary prevention of coronary heart disease. Design Randomised controlled trial. Setting 108 group practices in the Medical Research Council's general practice research framework who were taking part in the thrombosis prevention trial. Participants 5499 men aged between 45 and 69 years at entry who were at increased risk of coronary heart disease. Main outcome measures Myocardial infarction, coronary death, and stroke. Results Aspirin reduced coronary events by 20%. This benefit, mainly for non-fatal events, was significantly greater the lower the systolic blood pressure at entry (interaction P = 0.0015), the relative risk at pressures 130 mm Hg being 0.55 compared with 0.94 at pressures > 145 mm Hg. Aspirin also reduced strokes at low but not high pressures, the relative risks being 0.41 and 1.42 (P = 0.006) respectively. The relative risk of all major cardiovascular events-that is, the sum of coronary heart disease and stroke-was 0.59 at pressures < 130 mm Hg compared with 1.08 at pressures > 145 mm Hg (P = 0.0001). Conclusion Even with the limitations of subgroup analyses the evidence suggests that the benefit of low dose aspirin in primary prevention may occur mainly in those with lower systolic blood pressures, although it is not clear even in these men that the benefit outweighs the potential hazards. Men with higher pressures may be exposed to the risks of bleeding while deriving no benefit through reductions in coronary heart disease and stroke.	Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London EC1M 6BQ, England	University of London; Queen Mary University London	Meade, TW (corresponding author), Wolfson Inst Prevent Med, MRC, Epidemiol & Med Care Unit, London EC1M 6BQ, England.	t.w.meade@mds.qmw.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander JH, 1999, AM J CARDIOL, V83, P1147, DOI 10.1016/S0002-9149(99)00049-1; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Boissel JP, 1998, JAMA-J AM MED ASSOC, V280, P1949, DOI 10.1001/jama.280.22.1949; Cairns JA, 1998, CHEST, V114, p611S, DOI 10.1378/chest.114.5_Supplement.611S; COL NF, 1995, ARCH INTERN MED, V155, P1386, DOI 10.1001/archinte.155.13.1386; GARCIADORADO D, 1995, CIRCULATION, V92, P1743, DOI 10.1161/01.CIR.92.7.1743; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LOWEL H, 1993, CIRCULATION, V88, P2524, DOI 10.1161/01.CIR.88.6.2524; MEADE TW, 1988, EUR HEART J, V9, P836, DOI 10.1093/oxfordjournals.eurheartj.a062576; Meade TW, 1998, LANCET, V351, P233; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; *WHO, 1976, PUBLIC HLTH EUROPE, V5	16	88	92	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					13	17		10.1136/bmj.321.7252.13	http://dx.doi.org/10.1136/bmj.321.7252.13			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875825	Bronze, Green Published			2022-12-28	WOS:000088030100018
J	Jackson, A				Jackson, A			Critical time for fluid dynamos	NATURE			English	Article									Univ Leeds, Dept Earth Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Jackson, A (corresponding author), Univ Leeds, Dept Earth Sci, Leeds LS2 9JT, W Yorkshire, England.							Bullard EC, 1955, P CAMBRIDGE PHIL SOC, V51, P744; Busse FH, 2000, ANNU REV FLUID MECH, V32, P383, DOI 10.1146/annurev.fluid.32.1.383; Cowling TG, 1933, MON NOT R ASTRON SOC, V94, P0039, DOI 10.1093/mnras/94.1.39; Gailitis A, 2000, PHYS REV LETT, V84, P4365, DOI 10.1103/PhysRevLett.84.4365; Larmor J, 1919, BRIT ASS ADV SCI REP, P159; LOWES FJ, 1968, NATURE, V219, P717, DOI 10.1038/219717a0; LOWES FJ, 1963, NATURE, V198, P1158, DOI 10.1038/1981158a0; MULLER U, 2000, WORKSH HOM DYN FORSC; Tilgner A, 2000, PHYS EARTH PLANET IN, V117, P171, DOI 10.1016/S0031-9201(99)00095-3	9	2	2	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1003	1004		10.1038/35016667	http://dx.doi.org/10.1038/35016667			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890425				2022-12-28	WOS:000087871700025
J	Schulteis, G; Ahmed, SH; Morse, AC; Koob, GF; Everitt, BJ				Schulteis, G; Ahmed, SH; Morse, AC; Koob, GF; Everitt, BJ			Conditioning and opiate withdrawal	NATURE			English	Article							NUCLEUS-ACCUMBENS; REINFORCEMENT; ADDICTION		Univ Calif San Diego, Sch Med, VAMC 125, Dept Anesthesiol, San Diego, CA 92161 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Scripps Research Institute; University of Cambridge	Schulteis, G (corresponding author), Univ Calif San Diego, Sch Med, VAMC 125, Dept Anesthesiol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.		AHMED, Serge H/D-5236-2014	Everitt, Barry/0000-0003-4431-6536; Ahmed, Serge/0000-0002-1225-9234	Medical Research Council [G9537855] Funding Source: Medline; MRC [G9537855] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aston-Jones G, 1999, ANN NY ACAD SCI, V877, P486, DOI 10.1111/j.1749-6632.1999.tb09284.x; BALDWIN HA, 1993, NEUROPSYCHOPHARMACOL, V8, P15, DOI 10.1038/npp.1993.3; Everitt BJ, 1999, ANN NY ACAD SCI, V877, P412, DOI 10.1111/j.1749-6632.1999.tb09280.x; EVERITT BJ, IN PRESS AMYGDALA FU; Groenewegen HJ, 1996, PROG BRAIN RES, V107, P485; KOOB GF, 1989, PSYCHOPHARMACOLOGY, V98, P530, DOI 10.1007/BF00441954; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; OBRIEN CP, 1977, SCIENCE, V195, P1000, DOI 10.1126/science.841320; Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611	12	51	55	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1013	1014		10.1038/35016630	http://dx.doi.org/10.1038/35016630			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890431				2022-12-28	WOS:000087871700031
J	Wang, PS; Solomon, DH; Mogun, H; Avorn, J				Wang, PS; Solomon, DH; Mogun, H; Avorn, J			HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELIMINATION HALF-LIFE; OLDER WOMEN; BENZODIAZEPINES; OSTEOPOROSIS	Context Recent animal studies have found that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) lipid-lowering drugs (statins) substantially increase bone formation, but whether statin use in humans results in clinically meaningful bone formation or a reduction in the risk of osteoporotic fractures is not known. Objective To determine whether the use of statins is associated with reduced hip fracture risk. Design Case-control study. Setting and Patients A total of 6110 New Jersey residents aged 65 years or older and enrolled in Medicare and either Medicaid or the Pharmacy Assistance for the Aged and Disabled program. Case patients (n =1222) underwent surgical repair of a hip fracture in 1994. Control patients (n = 4888) were identified at a ratio of 4:1 and frequency-matched to case patients for age and sex. Main Outcome Measure Adjusted odds ratio (OR) of hip fracture by statin use in the 180 days and 3 years prior to the index date (the earliest date of admission for surgery), adjusted for demographic and clinical characteristics and health care utilization. Results Use of statins in either the prior 180 days (adjusted OR, 0.50; 95% confidence interval [CI], 0.33-0.76) or prior 3 years (adjusted OR, 0.57; 95% CI, 0.40-0.82) was associated with a significant reduction in the risk of hip fracture, even after controlling for variables such as race, insurance status, psychoactive medications, estrogen and thiazide use, ischemic heart disease, cancer, and diabetes mellitus. No significant relationship was observed between use of nonstatin lipid-lowering agents and hip fracture risk. Clear relationships were observed between the degree of reduction in hip fracture risk and the extent of statin use; there was no evidence of such relationships with nonstatin lipid-lowering agents. After adjusting for extent of statin use in the prior 3 years, current use ton the index date) was associated with a 71% reduction in risk (adjusted OR, 0.29; 95% CI, 0.10-0.81). The relationship between statin use and hip fracture risk persisted after controlling for variables such as the n umber of medications, the Charlson comorbidity index score, and hospitalization or nursing home stay in the last 180 days, as well as after excluding patients who were in a nursing home prior to their index date or who died in the year after their index date. Use of nonstatin lipid-lowering agents was not observed to be associated with reduction in hip fracture risk in any of these alternative models or analyses. Conclusions These findings support an association between statin use by elderly patients and reduction in the risk of hip fracture. Controlled trials are needed to exclude the possibility of unmeasured confounders.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Program Anal Clin Studies, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Wang, PS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Program Anal Clin Studies, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 221 Longwood Ave, Boston, MA 02115 USA.	pwang@rics.bwh.harvard.edu						[Anonymous], 1989, PHYS CURR PROC TERM; BARON JA, 1994, EPIDEMIOLOGY, V5, P541; Bauer DC, 1999, J BONE MINER RES, V14, pS179; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; CUMMING RG, 1993, MED J AUSTRALIA, V158, P414, DOI 10.5694/j.1326-5377.1993.tb121839.x; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Gregg EW, 1998, ANN INTERN MED, V129, P81, DOI 10.7326/0003-4819-129-2-199807150-00002; HERINGS RMC, 1995, ARCH INTERN MED, V155, P1801, DOI 10.1001/archinte.155.16.1801; Hofer TP, 1996, AM J PUBLIC HEALTH, V86, P1755, DOI 10.2105/AJPH.86.12.1755; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LOOKER AC, 1995, J BONE MINER RES, V10, P796; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; PEDERSEN TR, 1994, LANCET, V344, P1383; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SILVERMAN SL, 1988, AM J PUBLIC HEALTH, V78, P1482, DOI 10.2105/AJPH.78.11.1482; *ST ANTH DIAGN REL, 1993, ST ANTH DIAGN REL GR; Thapa PB, 1998, NEW ENGL J MED, V339, P875, DOI 10.1056/NEJM199809243391303; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS	25	337	373	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3211	3216		10.1001/jama.283.24.3211	http://dx.doi.org/10.1001/jama.283.24.3211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866868				2022-12-28	WOS:000087753900033
J	Bellman, M; Pathan, AH; Sinclair, L				Bellman, M; Pathan, AH; Sinclair, L			A girl who laughed and fell down	LANCET			English	Article							GELASTIC EPILEPSY		Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Sinclair, L (corresponding author), Royal Natl Throat Nose & Ear Hosp, Grays Inn Rd, London WC1X 8DA, England.							ARROYO S, 1993, BRAIN, V116, P757, DOI 10.1093/brain/116.4.757; CURATOLO P, 1984, DEV MED CHILD NEUROL, V26, P509; DALY DD, 1957, NEUROLOGY, V7, P189, DOI 10.1212/WNL.7.3.189; GASCON GG, 1971, EPILEPSIA, V12, P63, DOI 10.1111/j.1528-1157.1971.tb03916.x; Striano S, 1999, EPILEPSIA, V40, P294, DOI 10.1111/j.1528-1157.1999.tb00707.x	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2216	2216		10.1016/S0140-6736(00)02406-5	http://dx.doi.org/10.1016/S0140-6736(00)02406-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881896				2022-12-28	WOS:000087779000014
J	Bashaw, GJ; Kidd, T; Murray, D; Pawson, T; Goodman, CS				Bashaw, GJ; Kidd, T; Murray, D; Pawson, T; Goodman, CS			Repulsive axon guidance: Abelson and enabled play opposing roles downstream of the roundabout receptor	CELL			English	Article							ABL TYROSINE KINASE; ACTIN-BASED MOTILITY; PHOSPHATASE DLAR; CNS MIDLINE; C-ABL; DROSOPHILA; MUTATIONS; PROTEIN; SLIT; BINDING	Drosophila Roundabout (Robo) is the founding member of a conserved family of repulsive axon guidance receptors that respond to secreted Slit proteins. Little is known about the signaling mechanisms which function downstream of Robe to mediate repulsion. Here, we present genetic and biochemical evidence that the Abelson (Abl) tyrosine kinase and its substrate Enabled (Ena) play direct and opposing roles in Robe signal transduction. Genetic interactions support a model in which Abl functions to antagonize Robe signaling, while Ena is required in part for Robe's repulsive output. Both Abl and Ena can directly bind to Robo's cytoplasmic domain. A mutant form of Robe that interferes with Ena binding is partially impaired in Robe function, while a mutation in a conserved cytoplasmic tyrosine that can be phosphorylated by Abl generates a hyperactive Robe receptor.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Goodman, CS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, 229 Stanley Hall, Berkeley, CA 94720 USA.		Kidd, Thomas/AAT-9993-2020; Pawson, Tony J/E-4578-2013	Kidd, Thomas/0000-0001-7190-4208	NINDS NIH HHS [NS18366] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Sink H., 1994, Society for Neuroscience Abstracts, V20, P1283; Sun Q, 2000, DEVELOPMENT, V127, P801; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2	31	367	384	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					703	715		10.1016/S0092-8674(00)80883-1	http://dx.doi.org/10.1016/S0092-8674(00)80883-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892742	Bronze			2022-12-28	WOS:000087821400005
J	Herschbach, D				Herschbach, D			Kent R. Wilson (1937-2000) - Obituary	NATURE			English	Biographical-Item									Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Herschbach, D (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.							WILSON KG, PUBLICATION LIST	1	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					902	902		10.1038/35016200	http://dx.doi.org/10.1038/35016200			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879520				2022-12-28	WOS:000087732700034
J	Eisenberg, D; Marcotte, EM; Xenarios, I; Yeates, TO				Eisenberg, D; Marcotte, EM; Xenarios, I; Yeates, TO			Protein function in the post-genomic era	NATURE			English	Article							YEAST; MICROARRAYS; GENES	Faced with the avalanche of genomic sequences and data on messenger RNA expression, biological scientists are confronting a frightening prospect: piles of information but only flakes of knowledge. How can the thousands of sequences being determined and deposited, and the thousands of expression profiles being generated by the new array methods, be synthesized into useful knowledge? What form will this knowledge take? These are questions being addressed by scientists in the field known as 'functional genomics'.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, UCLA DOA Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Box 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu	Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; Marcotte, Edward/0000-0001-8808-180X; Yeates, Todd/0000-0001-5709-9839				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrade MA, 1998, BIOINFORMATICS, V14, P600, DOI 10.1093/bioinformatics/14.7.600; Bork P, 1998, J MOL BIOL, V283, P707, DOI 10.1006/jmbi.1998.2144; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Gaasterland T, 1998, Microb Comp Genomics, V3, P177, DOI 10.1089/omi.1.1998.3.177; Huynen M, 1998, FEBS LETT, V426, P1, DOI 10.1016/S0014-5793(98)00276-2; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; KIM SH, IN PRESS CURR OPIN S; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Ouzounis C, 1996, FEBS LETT, V390, P119, DOI 10.1016/0014-5793(96)00631-X; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Xenarios I, 2000, NUCLEIC ACIDS RES, V28, P289, DOI 10.1093/nar/28.1.289	26	519	567	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					823	826		10.1038/35015694	http://dx.doi.org/10.1038/35015694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866208				2022-12-28	WOS:000087620600060
J	Risch, NJ				Risch, NJ			Searching for genetic determinants in the new millennium	NATURE			English	Review							COMPLEX HUMAN-DISEASES; SINGLE-NUCLEOTIDE POLYMORPHISMS; DEPENDENT DIABETES-MELLITUS; CASE-CONTROL DESIGNS; LINKAGE DISEQUILIBRIUM; ALLELIC ASSOCIATION; RELATIVE POWER; MAPPING GENES; LOCI; MARKERS	Human genetics is now at a critical juncture. The molecular methods used successfully to identify the genes underlying rare mendelian syndromes are failing to find the numerous genes causing more common, familial, non-mendelian diseases. With the human genome sequence nearing completion, new opportunities are being presented for unravelling the complex genetic basis of non-mendelian disorders based on large-scale genome-wide studies. Considerable debate has arisen regarding the best approach to take. In this review I discuss these issues, together with suggestions for optimal post-genome strategies.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University	Risch, NJ (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.							ARNHEIM N, 1985, P NATL ACAD SCI USA, V82, P6970, DOI 10.1073/pnas.82.20.6970; Barcellos LF, 1997, AM J HUM GENET, V61, P734, DOI 10.1086/515512; Boehnke M, 1998, AM J HUM GENET, V62, P950, DOI 10.1086/301787; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CLARKE CA, 1956, BRIT MED J, V2, P725, DOI 10.1136/bmj.2.4995.725; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Concannon P, 1998, NAT GENET, V19, P292, DOI 10.1038/985; Curtis D, 1997, ANN HUM GENET, V61, P319, DOI 10.1017/S000348009700626X; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; EAVES L, 1994, BEHAV GENET, V24, P443, DOI 10.1007/BF01076180; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Kempthorne O., 1969, INTRO GENETIC STAT; Khoury M, 1993, FUNDAMENTALS GENETIC; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Laan M, 1997, NAT GENET, V17, P435, DOI 10.1038/ng1297-435; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LITT M, 1989, AM J HUM GENET, V44, P397; Lonjou C, 1999, P NATL ACAD SCI USA, V96, P1621, DOI 10.1073/pnas.96.4.1621; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389; MORTON NE, 1955, AM J HUM GENET, V7, P277; MullerMyhsok B, 1997, SCIENCE, V275, P1328; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Ott J., 1991, ANAL HUMAN GENETIC L; PENROSE L. S., 1939, OHIO JOUR SCI, V39, P291; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; RAO DC, 1978, AM J HUM GENET, V30, P516; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; RISCH N, 1990, AM J HUM GENET, V46, P222; RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schaid DJ, 1998, AM J HUM GENET, V63, P1492, DOI 10.1086/302094; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; Teng J, 1999, GENOME RES, V9, P234; Terwilliger JD, 1998, HUM HERED, V48, P138, DOI 10.1159/000022794; TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096; THOMSON G, 1995, AM J HUM GENET, V57, P487; Tu IP, 1999, AM J HUM GENET, V64, P641, DOI 10.1086/302253; Vogel F, 1982, HUMAN GENETICS PROBL, V2nd; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	47	1362	1428	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					847	856		10.1038/35015718	http://dx.doi.org/10.1038/35015718			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866211				2022-12-28	WOS:000087620600063
J	Koonin, EV; Aravind, L; Kondrashov, AS				Koonin, EV; Aravind, L; Kondrashov, AS			The impact of comparative genomics on our understanding of evolution	CELL			English	Review							GENE; SEQUENCE; PROTEINS; HEDGEHOG		Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Koonin, EV (corresponding author), Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.			Aravind, L/0000-0003-0771-253X				Aravind L, 1998, TRENDS GENET, V14, P442, DOI 10.1016/S0168-9525(98)01553-4; Aspock G, 1999, GENOME RES, V9, P909, DOI 10.1101/gr.9.10.909; Brown JR, 1998, CURR BIOL, V8, pR365, DOI 10.1016/S0960-9822(98)70238-6; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Fitz-Gibbon ST, 1999, NUCLEIC ACIDS RES, V27, P4218, DOI 10.1093/nar/27.21.4218; Galperin MY, 1998, GENOME RES, V8, P779, DOI 10.1101/gr.8.8.779; Gellner K, 1999, GENOME RES, V9, P251; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; Himmelreich R, 1997, NUCLEIC ACIDS RES, V25, P701, DOI 10.1093/nar/25.4.701; Hutter H, 2000, SCIENCE, V287, P989, DOI 10.1126/science.287.5455.989; Ponting CP, 2000, ADV PROTEIN CHEM, V54, P185, DOI 10.1016/S0065-3233(00)54007-8; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Teichmann SA, 1999, J MOL EVOL, V49, P98, DOI 10.1007/PL00006538; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000	20	193	204	5	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					573	576		10.1016/S0092-8674(00)80867-3	http://dx.doi.org/10.1016/S0092-8674(00)80867-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892642	Bronze			2022-12-28	WOS:000087504500002
J	Melek, M; Gellert, M				Melek, M; Gellert, M			RAG1/2-mediated resolution of transposition intermediates: Two pathways and possible consequences	CELL			English	Article							DNA STRAND TRANSFER; V(D)J RECOMBINATION; RAG2 PROTEINS; IMMUNE-SYSTEM; 2 STEPS; C-MYC; GENES; MECHANISM; INTEGRATION; CLEAVAGE	During B and T cell development, the RAG1/RAG2 protein complex cleaves DNA at conserved recombination signal sequences (RSS) to initiate V(D)J recombination. RAG1/2 has also been shown to catalyze transpositional strand transfer of RSS-containing substrates into target DNA to form branched DNA intermediates. We show that RAG1/2 can resolve these intermediates by two pathways. RAG1/2 catalyzes hairpin formation on target DNA adjacent to transposed RSS ends in a manner consistent with a model leading to chromosome translocations. Alternatively, disintegration removes transposed donor DNA from the intermediate. At high magnesium concentrations, such as are present in mammalian cells, disintegration is the favored pathway of resolution. This may explain in part why RAG1/2-mediated transposition does not occur at high frequency in cells.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK033001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Alberts B., 1989, MOL BIOL CELL; BERNARD O, 1988, ONCOGENE, V2, P195; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Gerton JL, 1999, J BIOL CHEM, V274, P33480, DOI 10.1074/jbc.274.47.33480; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; KABOTYANSKI EB, 1995, NUCLEIC ACIDS RES, V23, P3872, DOI 10.1093/nar/23.19.3872; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Santagata S, 1999, MOL CELL, V4, P935, DOI 10.1016/S1097-2765(00)80223-3; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1997, EMBO J, V16, P2265	36	56	58	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					625	633		10.1016/S0092-8674(00)80874-0	http://dx.doi.org/10.1016/S0092-8674(00)80874-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892649	Bronze			2022-12-28	WOS:000087504500009
J	McCarthy, M				McCarthy, M			Voice of reason in nuclear-weapon talks	LANCET			English	Editorial Material									Lancet, Seattle, WA 98103 USA		McCarthy, M (corresponding author), Lancet, Seattle, WA 98103 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1844	1844		10.1016/S0140-6736(00)02285-6	http://dx.doi.org/10.1016/S0140-6736(00)02285-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866437				2022-12-28	WOS:000087306500007
J	Hildebrand, P; Meyer-Wyss, BM; Mossi, S; Beglinger, C				Hildebrand, P; Meyer-Wyss, BM; Mossi, S; Beglinger, C			Risk among gastroenterologists of acquiring Helicobacter pylori infection: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Gastroenterol, CH-4031 Basel, Switzerland; St Clara Hosp, Dept Internal Med, CH-4058 Basel, Switzerland	University of Basel; University of Basel	Hildebrand, P (corresponding author), Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland.		Beglinger, Christoph/D-2247-2010					Braden B, 1997, GASTROINTEST ENDOSC, V46, P305, DOI 10.1016/S0016-5107(97)70115-9; DILL S, 1990, GUT, V31, P1237, DOI 10.1136/gut.31.11.1237; MEGRAUD F, 1993, GASTROENTEROL CLIN N, V22, P73; MEYERWYSS BM, 1997, STABLE ISOTOPES PHAR; MITCHELL HM, 1989, SCAND J GASTROENTERO, V24, P396, DOI 10.3109/00365528909093065	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					149	149		10.1136/bmj.321.7254.149	http://dx.doi.org/10.1136/bmj.321.7254.149			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894693	Green Published, Bronze			2022-12-28	WOS:000088305700022
J	Glynn, SA; Kleinman, SH; Schreiber, GB; Busch, MP; Wright, DJ; Smith, JW; Nass, CC; Williams, AE				Glynn, SA; Kleinman, SH; Schreiber, GB; Busch, MP; Wright, DJ; Smith, JW; Nass, CC; Williams, AE		Retrovirus Epidemiology Donor Stud	Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; RISK; HEPATITIS	Context Evaluating trends in blood donor infectious disease rates is essential for monitoring blood supply safety and donor screening effectiveness. Objective To determine changes overtime in blood donor population infection rates of human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis C virus (HCV), and hepatitis B virus (HBV), Design Cross-sectional survey data from the National Heart, Lung, and Blood Institute-sponsored Retrovirus Epidemiology Donor Study. Setting Five blood centers in different regions of the United States. Participants A total of 1.9 million volunteer blood donors with 1 or more nonautologous donations from January 1991 to December 1996. Main Outcome Measures Changes in rates of HIV, HTLV, HCV, and HBV infections were evaluated by comparing yearly prevalence estimates (per 100 000 donations) for first-ti me allogeneic donors and period-specific incidence rates (IRs) (per 100 000 person-years) for repeat allogeneic donors between 1991 and 1996 (for HCV, from about March 1992 to June 1996). Results Prevalence of HIV decreased in first-time donors from 0.030% to 0.015% (P=.006) and HCV prevalence decreased from 0.63% to 0.40% (P<.001). Trends were not statistically significant for the proportion of first-time donors with hepatitis B surface antigen (HBsAg) or HTLV, For repeat donors, IRs did not change significantly, indicating a stable but low level of seroconversion. The overall IRs (95% confidence intervals) per 100 000 person-years were 2.92 (2.26-3.70) for HIV, 1.59 (1.12-2.19) for HTLV, 3.25 (2.36-4.36) for HCV, and an estimated 10.43 (7.99-13.37) for HBV (based on an HBsAg rate of 2.66 [2.04-3.41] with presumed false-positive results considered negative). The HBV IR estimate with presumed false-positive results considered positive (for comparability to previous analyses) was 17.83 (14.60-21.56). Conclusion The decrease in HIV and HCV prevalence rates, combined with the previously documented lower rates of infection in first-time donors compared with the general population, suggests the continued benefit of behavioral risk factor screening.	WESTAT Corp, Rockville, MD 20850 USA; Blood Ctr Pacific, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Blood Syst Inc, Scottsdale, AZ USA; Oklahoma Blood Inst, Oklahoma City, OK USA; Amer Red Cross, Blood Serv Greater Chesapeake & Potomac Reg, Baltimore, MD USA; Amer Red Cross, Holland Lab, Biomed Serv, Rockville, MD USA	Westat; University of California System; University of California San Francisco; Vitalant; American Red Cross; American Red Cross	Glynn, SA (corresponding author), WESTAT Corp, WB 280,1441 W Montgomery Ave, Rockville, MD 20850 USA.	GlynnS1@westat.com			DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB097077, N01HB097078, N01HB047114] Funding Source: NIH RePORTER	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BASTIAANS MJS, 1982, VOX SANG, V42, P203, DOI 10.1111/j.1423-0410.1982.tb01096.x; BUSCH MP, 1994, BLOOD, V83, P1143; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; BUSCH MP, 1992, BLOOD SAFETY CURRENT, P1; BUSCH MP, 1997, APPL MOL BIOL BLOOD, P123; Coleman PJ, 1998, J INFECT DIS, V178, P954, DOI 10.1086/515696; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD R, 1982, VIRAL HEPATITIS, P145; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; KAPLAN JE, 1989, AM FAM PHYSICIAN, V40, P189; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; Kleinman S, 1998, TRANSFUSION, V38, p92S; Kleinman S, 1998, TRANSFUS MED REV, V12, P288, DOI 10.1016/S0887-7963(98)80004-7; Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; Kleinman S, 1996, CLIN PRACTICE TRANSF, P245; KLEINMAN SH, 1994, J CLIN MICROBIOL, V32, P603, DOI 10.1128/JCM.32.3.603-607.1994; Korelitz JJ, 1997, TRANSFUSION, V37, P634, DOI 10.1046/j.1537-2995.1997.37697335159.x; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; *SAS I INC, 1989, SAS STAT US GUID VER, P405; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SNEDECOR GW, 1980, STAT METHODS, P75; Ward J W, 1997, AIDS Clin Rev, P1; Williams AE, 1997, JAMA-J AM MED ASSOC, V277, P967, DOI 10.1001/jama.277.12.967; Wright DJ, 1999, TRANSFUSION, V39, p106S; ZUCK TF, 1988, NEW ENGL J MED, V318, P511, DOI 10.1056/NEJM198802253180809; 1990, MMWR MORB MORTAL WKL, V39, P915	33	194	207	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					229	235		10.1001/jama.284.2.229	http://dx.doi.org/10.1001/jama.284.2.229			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889598	Bronze			2022-12-28	WOS:000087933100029
J	Anglin, J				Anglin, J			Theoretical physics - Why trapped atoms are attractive	NATURE			English	Editorial Material							VORTICES		Harvard Smithsonian Ctr Astrophys, Inst Theoret Atom & Mol Phys, Cambridge, MA 02138 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Anglin, J (corresponding author), Harvard Smithsonian Ctr Astrophys, Inst Theoret Atom & Mol Phys, 60 Garden St,MS 14, Cambridge, MA 02138 USA.							Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Anglin JR, 1999, PHYS REV LETT, V83, P1707, DOI 10.1103/PhysRevLett.83.1707; Deng L, 1999, NATURE, V398, P218, DOI 10.1038/18395; Giovanazzi S, 2000, PHYS REV LETT, V84, P4521, DOI 10.1103/PhysRevLett.84.4521; Hagley EW, 1999, SCIENCE, V283, P1706, DOI 10.1126/science.283.5408.1706; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; O'Dell D, 2000, PHYS REV LETT, V84, P5687, DOI 10.1103/PhysRevLett.84.5687; Stenger J, 1998, NATURE, V396, P345, DOI 10.1038/24567	11	12	12	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					29	30		10.1038/35017678	http://dx.doi.org/10.1038/35017678			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894525				2022-12-28	WOS:000087991200027
J	Nixon, J; Stoykova, B; Christie, J; Glanville, J; Kleijnen, J; Drummond, M				Nixon, J; Stoykova, B; Christie, J; Glanville, J; Kleijnen, J; Drummond, M			NHS Economic Evaluation Database for healthcare decision makers	BRITISH MEDICAL JOURNAL			English	Article									Univ York, NHS Ctr Rev & Disseminat, York YO10 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK; University of York - UK	Nixon, J (corresponding author), Univ York, NHS Ctr Rev & Disseminat, York YO10 5DD, N Yorkshire, England.		Glanville, Julie May/C-2358-2008	Glanville, Julie May/0000-0002-1253-8524				BACKHOUSE ME, 1992, HLTH EC S, V1, P1; Morrell CJ, 1998, BMJ-BRIT MED J, V316, P1487, DOI 10.1136/bmj.316.7143.1487; *NHS EX, 1999, FAST ACC MOD TREATM	3	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	2000	321	7252					32	32		10.1136/bmj.321.7252.32	http://dx.doi.org/10.1136/bmj.321.7252.32			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875833	Bronze, Green Published			2022-12-28	WOS:000088030100025
J	Wallentin, L; Lagerqvist, B; Husted, S; Kontny, F; Stahle, E; Swahn, E				Wallentin, L; Lagerqvist, B; Husted, S; Kontny, F; Stahle, E; Swahn, E		FRISC II Investigators	Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial	LANCET			English	Article							WAVE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; UNFRACTIONATED HEPARIN; ANGINA; THROMBOLYSIS; MANAGEMENT; SURVIVAL; PLACEBO; SURGERY; DEATH	Background The Fragmin and Fast Revascularisation during instability in Coronary artery disease II trial (FRISC II) compared an early invasive with an early non-invasive strategy in unstable coronary-artery disease. We report outcome at 1 year. Methods 2457 patients were randomly assigned invasive or non-invasive treatment and 3 months of dalteparin or placebo. Complete information at 1 year was available for 1222 in the invasive group and 1234 in the non-invasive group. Analyses were by intention to treat. Findings Revascularisation was done within the first 10 days in 71% of the invasive group and 9% of the non-invasive group and within the first year in 78% and 43%. During the first year, 27 (2.2%) patients in the invasive group and 48 (3.9%) in the non-invasive group died (risk ratio 0.57 [95% CI 0.36-0.90], p=0.016). 105 (8.6%) versus 143 (11.6%) had myocardial infarction (0.74 [0.59-0.94], p=0.015). The composite of death or myocardial infarction occurred in 127 (10.4%) versus 174 (14.1%) patients (0.74 [0.60-0.92], p=0.005). There were also reductions in readmission (451 [37%] vs 704 [57%]; 0.67 [0.62-0.72]), and revascularisation after the initial admission (92 [7.5%] vs 383 [31%]; 0.24 [0.20-0.30]). The results did not interact with the dalteparin/placebo allocation. Interpretation After 1 year in 100 patients, an invasive strategy saves 1.7 lives, prevents 2.0 non-fatal myocardial infarctions and 20 readmissions, and provides earlier and better symptom relief at the cost of 15 more patients with coronary-artery bypass grafting and 21 more with percutaneous transluminal angioplasty. Therefore, an invasive approach should be the preferred strategy in patients with unstable coronary-artery disease and signs of ischaemia on electrocardiography or raised levels of biochemical markers of myocardial damage.	Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Thorac Surg, S-75185 Uppsala, Sweden; Aarhus Univ Hosp, Dept Cardiol, DK-8000 Aarhus, Denmark; Aker Univ Hosp, Dept Cardiol, Oslo, Norway; Linkoping Univ Hosp, Dept Cardiol, S-58185 Linkoping, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Aarhus University; University of Oslo; Linkoping University	Wallentin, L (corresponding author), Univ Uppsala Hosp, Ctr Cardiothorac, Dept Cardiol, S-75185 Uppsala, Sweden.	Lars.Wallentin@card.uas.lul.se						Abdelmeguid AE, 1996, CIRCULATION, V94, P3369, DOI 10.1161/01.CIR.94.12.3369; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Chamberlain DA, 1997, LANCET, V350, P461; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; *FIBR THER TRIAL F, 1994, LANCET, V343, P11; Guerrero RAA, 1999, EUR HEART J, V20, P1553; Klein W, 1997, CIRCULATION, V96, P61; KOLLI AK, 1999, J AM COLL CARDIOL  S, V33, P397; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Simoons ML, 1997, LANCET, V349, P1429; Simoons ML, 1999, EUR HEART J, V20, P1112, DOI 10.1053/euhj.1999.1521; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; TURPIE AGG, 1999, AM J CARDIOL, V1, pR18; URETSKY BF, 1999, CARDIOL CLIN, V17, P247; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1999, LANCET, V354, P701; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Yusuf S, 1999, LANCET, V353, P429	28	498	531	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					9	16		10.1016/S0140-6736(00)02427-2	http://dx.doi.org/10.1016/S0140-6736(00)02427-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892758				2022-12-28	WOS:000087933400009
J	Bresnahan, WA; Shenk, T				Bresnahan, WA; Shenk, T			A subset of viral transcripts packaged within human cytomegalovirus particles	SCIENCE			English	Article							RNA-BINDING PROTEIN; STRAIN AD169; DENSE BODIES; SEQUENCE; REPEAT	A human cytomegalovirus gene array was used to identify a previously unidentified class of viral transcripts, These transcripts, termed virion RNAs, were packaged within infectious virions and were delivered to the host cell on infection, This mechanism of herpesvirus gene expression allows for viral genes to be expressed within an infected cell immediately after virus entry and in the absence of transcription from the viral genome.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Shenk, T (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	tshenk@princeton.edu			NCI NIH HHS [CA85786] Funding Source: Medline; NIAID NIH HHS [F32 AI010448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldick CJ, 1996, J VIROL, V70, P6097, DOI 10.1128/JVI.70.9.6097-6105.1996; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirsch AJ, 1999, J VIROL, V73, P404, DOI 10.1128/JVI.73.1.404-410.1999; HUTCHINSON NI, 1986, VIROLOGY, V155, P160, DOI 10.1016/0042-6822(86)90176-5; IRMIERE A, 1983, VIROLOGY, V130, P118, DOI 10.1016/0042-6822(83)90122-8; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MCDONOUGH SH, 1985, J VIROL, V53, P711, DOI 10.1128/JVI.53.3.711-718.1985; Mullberg J, 1999, J GEN VIROL, V80, P437, DOI 10.1099/0022-1317-80-2-437; PLATCHER B, 1988, J GEN VIROL, V69, P2251; RAWLINSON WD, 1993, J VIROL, V67, P5502, DOI 10.1128/JVI.67.9.5502-5513.1993; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROLLER RJ, 1992, J VIROL, V66, P3624, DOI 10.1128/JVI.66.6.3624-3632.1992; SAROV I, 1975, VIROLOGY, V66, P464, DOI 10.1016/0042-6822(75)90218-4; STINSKI MF, 1976, J VIROL, V19, P594, DOI 10.1128/JVI.19.2.594-609.1976; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982; Zhu H., UNPUB	18	129	132	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2373	2376		10.1126/science.288.5475.2373	http://dx.doi.org/10.1126/science.288.5475.2373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875924				2022-12-28	WOS:000087913400042
J	Takaoka, A; Mitani, Y; Suemori, H; Sato, M; Yokochi, T; Noguchi, S; Tanaka, N; Taniguchi, T				Takaoka, A; Mitani, Y; Suemori, H; Sato, M; Yokochi, T; Noguchi, S; Tanaka, N; Taniguchi, T			Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains	SCIENCE			English	Article							IFN-GAMMA; ACTIVATION; RECEPTOR; RESPONSES; PROTEIN; GENES; CELLS	Definition of cellular responses to cytokines often involves cross-communication through their respective receptors. Here, signaling by interferon-gamma (IFN-gamma) is shown to depend on the IFN-alpha/beta receptor components. Although these IFNs transmit signals through distinct receptor complexes, the IFN-alpha/beta receptor component, IFNAR1, facilitates efficient assembly of IFN-gamma-activated transcription factors. This cross talk is contingent on a constitutive subthreshold IFN-alpha/beta signaling and the association between the two nonligand-binding receptor components, IFNAR1 and IFNGR2, in the caveolar membrane domains. This aspect of signaling cross talk by IFNs may apply to other cytokines.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Meiji Inst Hlth Sci, Odawara, Kanagawa 2500862, Japan	University of Tokyo	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.			Tanaka, Nobuyuki/0000-0002-6373-2220				Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; Erlandsson L, 1998, CURR BIOL, V8, P223, DOI 10.1016/S0960-9822(98)70086-7; FLEISCHMANN WR, 1979, INFECT IMMUN, V26, P248, DOI 10.1128/IAI.26.1.248-253.1979; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; SATO M, UNPUB; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; TAKAOKA A, UNPUB; VILCEK J, 1996, FIELDS VIROLOGY, P375; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x	31	266	272	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2357	2360		10.1126/science.288.5475.2357	http://dx.doi.org/10.1126/science.288.5475.2357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875919				2022-12-28	WOS:000087913400037
J	Arens, R; Kramer, SS				Arens, R; Kramer, SS			Pulmonary Langerhans'-cell granulomatosis (Histiocytosis X)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Arens, R (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.								0	1	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1959	1959		10.1056/NEJM200006293422605	http://dx.doi.org/10.1056/NEJM200006293422605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874064				2022-12-28	WOS:000087867400005
J	Cooper, ME; Johnston, CI				Cooper, ME; Johnston, CI			Optimizing treatment of hypertension in patients with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; CARDIOVASCULAR MORTALITY; SYSTOLIC HYPERTENSION; MORBIDITY; INTERVENTION; PREVENTION; DISEASE; RISK		Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Heidelberg, Vic, Australia; Baker Med Res Inst, Melbourne, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Baker Heart and Diabetes Institute	Johnston, CI (corresponding author), Alfred Hosp, Baker Med Res Inst, Commercial Rd, Prahran, Vic 3181, Australia.		Cooper, Mark/AAC-5326-2020; Cooper, Mark E/E-8680-2010	Cooper, Mark E/0000-0002-5953-642X				Black HR, 1997, ARCH INTERN MED, V157, P2413; Chalmers J, 1999, J HYPERTENS, V17, P151; Cooper ME, 1998, LANCET, V352, P213, DOI 10.1016/S0140-6736(98)01346-4; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gaede P, 1999, LANCET, V353, P617, DOI 10.1016/S0140-6736(98)07368-1; Gerstein HC, 2000, LANCET, V355, P253; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Gustafsson I, 1999, J AM COLL CARDIOL, V34, P83, DOI 10.1016/S0735-1097(99)00146-1; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Zuanetti G, 1997, CIRCULATION, V96, P4239	22	57	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3177	3179		10.1001/jama.283.24.3177	http://dx.doi.org/10.1001/jama.283.24.3177			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866846				2022-12-28	WOS:000087753900002
J	Bidmead, J; Cardozo, L				Bidmead, J; Cardozo, L			Short cut to continence?	LANCET			English	Editorial Material							GENUINE STRESS-INCONTINENCE; 2-YEAR FOLLOW-UP; URINARY-INCONTINENCE; COLLAGEN; SURGERY; WOMEN		Kings Coll Hosp London, Dept Urogynaecol, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Bidmead, J (corresponding author), Kings Coll Hosp London, Dept Urogynaecol, Denmark Hill, London SE5 9RS, England.							Anders K, 1999, NEUROUROL URODYNAM, V18, P297; Black NA, 1996, BRIT J UROL, V78, P497, DOI 10.1046/j.1464-410X.1996.01422.x; Burton G., 1997, Neurourology and Urodynamics, V16, P353; ECKFORD SD, 1991, BRIT J UROL, V68, P586, DOI 10.1111/j.1464-410X.1991.tb15420.x; Gorton E, 1999, BJU INT, V84, P966; Hutchings A, 1998, BRIT J UROL, V82, P634; JARVIS GJ, 1994, BRIT J OBSTET GYNAEC, V101, P371, DOI 10.1111/j.1471-0528.1994.tb11907.x; Khullar V, 1997, BRIT J OBSTET GYNAEC, V104, P96, DOI 10.1111/j.1471-0528.1997.tb10657.x; KLIGMAN AM, 1986, J DERMATOL SURG ONC, V12, P351, DOI 10.1111/j.1524-4725.1986.tb01920.x; LAYCOCK J, 1995, INVESTIGATION MANAGE; Leach GE, 1997, J UROLOGY, V158, P875, DOI 10.1016/S0022-5347(01)64346-5; MONGA AK, 1995, BRIT J UROL, V76, P156, DOI 10.1111/j.1464-410X.1995.tb07664.x; PETROS P, 1995, SCAND J UROL NEPHROL, V29, P75; Schultheiss D., 1998, Neurourology and Urodynamics, V17, P457; Ulmsten U, 1999, BRIT J OBSTET GYNAEC, V106, P345, DOI 10.1111/j.1471-0528.1999.tb08272.x	15	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2183	2184		10.1016/S0140-6736(00)02398-9	http://dx.doi.org/10.1016/S0140-6736(00)02398-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881888				2022-12-28	WOS:000087779000006
J	Gonzalez, S; Kitchener, AC; Lister, AM				Gonzalez, S; Kitchener, AC; Lister, AM			Survival of the Irish elk into the Holocene	NATURE			English	Article							MEGALOCEROS-GIGANTEUS		Liverpool John Moores Univ, Sch Biol & Earth Sci, Liverpool L3 3AF, Merseyside, England; UCL, Dept Biol, London WC1E 6BT, England; Natl Museums Scotland, Dept Geol & Zool, Edinburgh EH1 1JF, Midlothian, Scotland	Liverpool John Moores University; University of London; University College London	Gonzalez, S (corresponding author), Liverpool John Moores Univ, Sch Biol & Earth Sci, Byrom St, Liverpool L3 3AF, Merseyside, England.	A.Lister@ucl.ac.uk		Kitchener, Andrew/0000-0003-2594-0827; Lister, Adrian/0000-0002-7985-138X				DICKSON CA, 1970, PHILOS T ROY SOC B, V258, P31, DOI 10.1098/rstb.1970.0031; GOULD SJ, 1974, EVOLUTION, V28, P191, DOI 10.1111/j.1558-5646.1974.tb00740.x; Guthrie R.D., 1984, P259; Hibbert S., 1825, EDINB J SCI, V3, P15; KERMODE PMC, 1898, GEOL MAG, V5, P116; LAMBECK K, 1995, J GEOL SOC LONDON, V152, P437, DOI 10.1144/gsjgs.152.3.0437; Lister Adrian M., 1995, Geological Society Special Publication, V96, P151, DOI 10.1144/GSL.SP.1995.096.01.12; LISTER AM, 1994, ZOOL J LINN SOC-LOND, V112, P65, DOI 10.1111/j.1096-3642.1994.tb00312.x; MITCHELL G. F., 1949, PROC ROY IRISH ACAD SECT B, V52, P291; Moen RA, 1999, EVOL ECOL RES, V1, P235; OSWALD HR, 1825, EDINB J SCI, V3, P28; REEVES GM, 1982, P IOM NAT HIST ANT S, P416; STUART AJ, 1991, BIOL REV, V66, P453, DOI 10.1111/j.1469-185X.1991.tb01149.x; VARTANYAN SL, 1993, NATURE, V362, P337, DOI 10.1038/362337a0; WOODMAN PC, 1978, 58 BR ARCH	15	23	26	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					753	754		10.1038/35015668	http://dx.doi.org/10.1038/35015668			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866185				2022-12-28	WOS:000087620600035
J	Oelgeschlager, M; Larrain, J; Geissert, D; De Robertis, EM				Oelgeschlager, M; Larrain, J; Geissert, D; De Robertis, EM			The evolutionarily conserved BMP-binding protein Twisted gastrulation promotes BMP signalling	NATURE			English	Article							DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; ACTIVITY GRADIENT; ZEBRAFISH EMBRYO; FAMILY MEMBER; GROWTH-FACTOR; XENOPUS; DPP; ORGANIZER; RECEPTOR	Dorsal-ventral patterning in vertebrate and Drosophila embryos requires a conserved system of extracellular proteins to generate a positional information gradient. The components involved include bone morphogenetic proteins (BMP/Dpp), a BMP antagonist (Chordin/Short gastrulation; Chd/Sog) and a secreted metalloproteinase (Xolloid/Tolloid) that cleaves Chd/Sog. Here we describe Xenopus Twisted gastrulation (xTsg), another member of this signalling pathway. xTsg is expressed ventrally as part of the BMP-4 synexpression group and encodes a secreted BMP-binding protein that is a BMP signalling agonist. The data suggest a molecular mechanism by which xTsg dislodges latent BMPs bound to Chordin BMP-binding fragments generated by Xolloid cleavage, providing a permissive signal that allows high BMP signalling in the embryo. Drosophila Tsg also binds BMPs and is expressed dorsally, supporting the proposal that the dorsal-ventral axis was inverted in the course of animal evolution.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	derobert@hhmi.ucla.edu		De Robertis, Edward/0000-0002-7843-1869	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502-14, R37 HD021502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Bier E, 1999, NATURE, V398, P375, DOI 10.1038/18778; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Connors SA, 1999, DEVELOPMENT, V126, P3119; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; De Robertis E.M., 1994, P11; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Dick A, 2000, DEVELOPMENT, V127, P343; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Geoffroy Saint-Hilaire E., 1822, MEMOIRES DU MUSEUM D, V9, P89; Goodman SA, 1998, DEV BIOL, V195, P144, DOI 10.1006/dbio.1997.8840; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hild M, 1999, DEVELOPMENT, V126, P2149; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; JONES CM, 1992, DEVELOPMENT, V115, P639; Kishimoto Y, 1997, DEVELOPMENT, V124, P4457; KNOLL AH, 1999, SCIENCE, V284, P2129, DOI DOI 10.1126/SCIENCE.284.5423.2129; Larrain J, 2000, DEVELOPMENT, V127, P821; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Mason ED, 1997, MECH DEVELOP, V64, P61, DOI 10.1016/S0925-4773(97)00049-X; Neul JL, 1998, CELL, V95, P483, DOI 10.1016/S0092-8674(00)81616-5; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schmid B, 2000, DEVELOPMENT, V127, P957; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Weinmaster G, 1998, SCIENCE, V279, P336, DOI 10.1126/science.279.5349.336; Yu K, 2000, DEVELOPMENT, V127, P2143; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	50	228	266	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					757	763		10.1038/35015500	http://dx.doi.org/10.1038/35015500			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866189	Green Accepted			2022-12-28	WOS:000087620600040
J	Pauly, N; Knight, MR; Thuleau, P; van der Luit, AH; Moreau, M; Trewavas, AJ; Ranjeva, R; Mazars, C				Pauly, N; Knight, MR; Thuleau, P; van der Luit, AH; Moreau, M; Trewavas, AJ; Ranjeva, R; Mazars, C			Cell signalling - Control of free calcium in plant cell nuclei	NATURE			English	Article							CYTOPLASMIC CALCIUM; GENE-EXPRESSION; TOBACCO		UPS, CNRS, UMR 5546, F-31326 Castanet Tolosan, France; Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; Univ Toulouse 3, Ctr Dev Biol, CNRS, UMR 5547, F-31062 Toulouse, France; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Oxford; Netherlands Cancer Institute; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Edinburgh	Pauly, N (corresponding author), UPS, CNRS, UMR 5546, Pole Biotechnol Vegetale,24 Chemin de Borde Rouge, F-31326 Castanet Tolosan, France.		Pauly, Nicolas/L-1484-2015	Pauly, Nicolas/0000-0003-2990-3150; Mazars, Christian/0000-0002-0670-6042; Knight, Marc/0000-0002-4830-8608				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Malviya AN, 1998, CELL, V92, P17, DOI 10.1016/S0092-8674(00)80895-8; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; STOPPIN V, 1994, PLANT CELL, V6, P1099, DOI 10.1105/tpc.6.8.1099; Takahashi K, 1998, BBA-MOL CELL RES, V1401, P339, DOI 10.1016/S0167-4889(97)00134-1; van der Luit AH, 1999, PLANT PHYSIOL, V121, P705, DOI 10.1104/pp.121.3.705	9	98	106	1	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					754	755		10.1038/35015671	http://dx.doi.org/10.1038/35015671			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866186				2022-12-28	WOS:000087620600036
J	Umeta, M; West, CE; Haidar, J; Deurenberg, P; Hautvast, JGAJ				Umeta, M; West, CE; Haidar, J; Deurenberg, P; Hautvast, JGAJ			Zinc supplementation and stunted infants in Ethiopia: a randomised controlled trial	LANCET			English	Article							BODY-COMPOSITION; RESPIRATORY-INFECTIONS; GUATEMALAN CHILDREN; SEVERE MALNUTRITION; INTERVENTION TRIAL; PRESCHOOL-CHILDREN; TISSUE DEPOSITION; WEIGHT-GAIN; ENERGY-COST; GROWTH	Background Stunting is highly prevalent in Ethiopia and many other developing countries but the reason for it is poorly understood. Zinc is essential for growth but diets in such countries often do not contain zinc in sufficient quantity or of sufficient bioavailability. Thus zinc deficiency may play a major role in stunting. The aim of the study was to investigate whether the low rate of linear growth of apparently healthy breastfed infants in a rural village in Ethiopia could be improved by zinc supplementation. Methods A randomised, double-blind, placebo-controlled trial was done on apparently healthy breastfed infants aged 6-12 months. 100 non-stunted (length-for-age, Z score <-2) were matched for age and sex with 100 randomly selected stunted (>-2) infants. Infants, both stunted and non stunted, were matched by sex, age (within 2 months) and recumbent length (within 3 cm) for random assignment, to receive a zinc supplement (10 mg zinc per day, as zinc sulphate) or placebo, 6 days a week for 6 months. Anthropometric measurements were taken monthly, data on illness and appetite were collected daily, and samples of serum and hair were taken at the end of the intervention for the analysis of zinc. Findings The length of stunted infants increased significantly more (p<0.001) when supplemented with zinc (7.0 cm [SE 1.1]) than with placebo (2.8 cm [0.9]); and the effect was greater (p<0.01) than in non-stunted infants (6.6 [0.9] vs 5.0 [0.8] cm for the zinc and placebo groups respectively, p<0.01). Zinc supplementation also increased the weight of stunted children (1.73 [0.39] vs 0.95 [0.39] kg for the corresponding placebo group, p<0.001) and of non-stunted children (1.19 [0.39] vs 1.02 [0.32] kg for the corresponding placebo group, p<0.05). Zinc supplementation resulted in a markedly lower incidence of anorexia and morbidity from cough, diarrhoea, fever, and vomiting in the stunted children. The total number of these conditions per child was 1.56 and 1.11 in the stunted and non-stunted zinc supplemented children Versus 3.38 and 1.64 in the stunted and non-stunted placebo-treated children, respectively. At the end of the intervention period, the concentrations of zinc in serum and hair of stunted infants, who had not been supplemented with zinc, were lower than the respective concentrations of zinc in serum and hair of their non-stunted counterparts. Interpretation Combating zinc deficiency can increase the growth rate of stunted children to that of non-stunted infants in rural Ethiopia. This would appear to be due, at least in part, to reduction in morbidity from infection and increased appetite.				clive.west@staff.nutepi.wau.nl						[Anonymous], ZINC HUMAN BIOL; BATES CJ, 1993, BRIT J NUTR, V69, P243, DOI 10.1079/BJN19930026; Beaton G., 1993, EFFECTIVENESS VITAMI; Brown KH, 1998, BIBL NUTR DIET, P76; BUTRIMOVITZ GP, 1977, ANAL CHIM ACTA, V94, P63, DOI 10.1016/S0003-2670(01)83632-1; BUZINA R, 1980, AM J CLIN NUTR, V33, P2262, DOI 10.1093/ajcn/33.11.2262; CARTER JP, 1969, AM J CLIN NUTR, V22, P59; CASTILLODURAN C, 1987, AM J CLIN NUTR, V45, P602, DOI 10.1093/ajcn/45.3.602; CAVAN KR, 1993, AM J CLIN NUTR, V57, P344, DOI 10.1093/ajcn/57.3.344; Christian P, 1998, AM J CLIN NUTR, V68, p435S, DOI 10.1093/ajcn/68.2.435S; DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703; Friis H, 1997, EUR J CLIN NUTR, V51, P38, DOI 10.1038/sj.ejcn.1600358; Gibson Rosalind S., 1994, Nutrition Research Reviews, V7, P151, DOI 10.1079/NRR19940010; GLEGG MS, 1989, ZINC HUMAN BIOL, P129; GOLDEN BE, 1981, AM J CLIN NUTR, V34, P892, DOI 10.1093/ajcn/34.5.892; GOLDEN BE, 1992, EUR J CLIN NUTR, V46, P697; Golden M. H. N., 1989, ZINC HUMAN BIOL, P323; GOLDEN MHN, 1981, AM J CLIN NUTR, V34, P900, DOI 10.1093/ajcn/34.5.900; HARRISON WW, 1969, CLIN CHIM ACTA, V23, P83, DOI 10.1016/0009-8981(69)90014-X; Kikafunda JK, 1998, AM J CLIN NUTR, V68, P1261, DOI 10.1093/ajcn/68.6.1261; MAHLOUDJI M, 1975, AM J CLIN NUTR, V28, P721, DOI 10.1093/ajcn/28.7.721; *NAT CTR HLTH STAT, 1978, DHEW PUBL; Ninh NX, 1996, AM J CLIN NUTR, V63, P514, DOI 10.1093/ajcn/63.4.514; PRASAD AS, 1982, CLIN BIOCH NUTRITION, P3; Roy SK, 1998, ACTA PAEDIATR, V87, P1235, DOI 10.1080/080352598750030898; Ruel MT, 1997, PEDIATRICS, V99, P808, DOI 10.1542/peds.99.6.808; Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; SIMMER K, 1988, AM J CLIN NUTR, V47, P1036, DOI 10.1093/ajcn/47.6.1036; SIMONDON KB, 1994, HUMANBIOL, V25, P311; 1992, NATL RURAL NUTR SURV	31	188	195	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2000	355	9220					2021	2026		10.1016/S0140-6736(00)02348-5	http://dx.doi.org/10.1016/S0140-6736(00)02348-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885352				2022-12-28	WOS:000087519400009
J	Allwright, S; Bradley, F; Long, J; Barry, J; Thornton, L; Parry, JV				Allwright, S; Bradley, F; Long, J; Barry, J; Thornton, L; Parry, JV			Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							BLOODBORNE VIRUSES; FACTOR ELICITATION; SURVEILLANCE; BEHAVIORS; SCOTLAND; SALIVA; MEN	Objectives To determine the prevalence of antibodies to hepatitis B core antigen, hepatitis C virus, and HIV in the prison population of the Republic of Ireland and to examine risk factors for infection. Design Cross sectional, anonymous, unlinked survey, with self completed risk factor questionnaire and provision of oral fluid specimen for antibody testing. Setting Nine of the 15 prisons in the Republic of Ireland. Participants 1366 prisoners, of whom 1205 (57 women) participated. In the smaller prisons all prisoners were surveyed, while in the three largest prisons one half of the population was randomly sampled. Three small prisons believed not to have a problem with injecting drug use were excluded. Main outcome measures Prevalence of antibodies to hepatitis B core antigen, antibodies to hepatis C virus, and antibodies to HIV. Self reported risk factor status. Results Prevalence of antibodies to hepatis B core antigen was 104/1193 (8.7%; 95% confidence interval 7.2% to 10.5%), to hepatitis C virus, 442/1193 (37%; 34.3% to 39.9%), and to HIV, 24/1193 (2%; 1.3% to 3%). The most important predictor of being positive for hepatitis B and hepatitis C was a history of injecting drug use. Thirty four women (60%) and 474 men (42%) reported ever injecting drugs. A fifth (104) of 501 injecting drug users reported first injecting in prison, and 347 (71%) users reported sharing needles in prison. Conclusions Infection with hepatitis C secondary to use of injected drugs is endemic in Irish prisons. Better access to harm reduction strategies is needed in this environment.	Univ Dublin Trinity Coll, Dept Community Hlth & Gen Practice, Dublin 2, Ireland; Dr Steevens Hosp, Eastern Reg Hlth Author, Dept Publ Hlth, Dublin 8, Ireland; Cent Publ Hlth Lab, PHLS, Hepatitis & Retrovirus Lab, London NW9 5HT, England	Trinity College Dublin; Public Health England	Allwright, S (corresponding author), Univ Dublin Trinity Coll, Dept Community Hlth & Gen Practice, Dublin 2, Ireland.		Allwright, Shane/A-1537-2012	Allwright, Shane/0000-0003-1841-4781				Bellis MA, 1997, BRIT MED J, V315, P30, DOI 10.1136/bmj.315.7099.30; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; Butler TG, 1997, MED J AUSTRALIA, V166, P127, DOI 10.5694/j.1326-5377.1997.tb140041.x; Connell J A, 1994, Clin Diagn Virol, V1, P299, DOI 10.1016/0928-0197(94)90060-4; CONNELL JA, 1993, J MED VIROL, V41, P159, DOI 10.1002/jmv.1890410212; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; DOLAN K, 1998, METHADONE MAINTENANC, P379; FARRELL M, 1999, REV CURRENT PRACTICE; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; Gore SM, 1997, INT J STD AIDS, V8, P166, DOI 10.1258/0956462971919831; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; Gore SM, 1999, QJM-MON J ASSOC PHYS, V92, P25, DOI 10.1093/qjmed/92.1.25; LAMGANI TL, 1999, COMMUN DIS PUBLIC HL, V2, P174; Malliori M, 1998, ADDICTION, V93, P243, DOI 10.1046/j.1360-0443.1998.9322438.x; *MIN TASK FORC MEA, 1997, 2 REP; OMahony Paul, 1997, MOUNTJOY PRISONERS S; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; *PRINC PROD, 1997, REM OFF OMR VERS 4; ROTILY M., 1995, AIDS CARE, V7, P89; SALL J, 1996, JMP START STAT VERS; Smyth BP, 1999, J EPIDEMIOL COMMUN H, V53, P434, DOI 10.1136/jech.53.7.434	24	171	179	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					78	82		10.1136/bmj.321.7253.78	http://dx.doi.org/10.1136/bmj.321.7253.78			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884256	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000088196600022
J	Bonabeau, E; Dorigo, M; Theraulaz, G				Bonabeau, E; Dorigo, M; Theraulaz, G			Inspiration for optimization from social insect behaviour	NATURE			English	Article							QUADRATIC ASSIGNMENT PROBLEM; TRAVELING SALESMAN PROBLEM; ANT COLONIES; ROBOTICS	Research in social insect behaviour has provided computer scientists with powerful methods for designing distributed control and optimization algorithms. These techniques are being applied successfully to a variety of scientific and engineering problems. In addition to achieving good performance on a wide spectrum of 'static' problems, such techniques tend to exhibit a high degree of flexibility and robustness in a dynamic environment.	Santa Fe Inst, Santa Fe, NM 87501 USA; Eurobios Tour Ernst & Young, F-92037 La Defense, France; Free Univ Brussels, IRIDIA, B-1050 Brussels, Belgium; Univ Toulouse 3, Lab Ethol & Cognit Anim, CNRS FRE 2041, F-31062 Toulouse, France	The Santa Fe Institute; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bonabeau, E (corresponding author), Santa Fe Inst, 1399 Hyde Pk Rd, Santa Fe, NM 87501 USA.	eric.bonabeau@eurobios.com; mdorigo@ulb.ac.be	Theraulaz, Guy/H-8464-2016; Dorigo, Marco/B-5664-2013	Theraulaz, Guy/0000-0002-3062-4215; Dorigo, Marco/0000-0002-3971-0507				BALUJA S, 1995, P 12 INT C MACH LEAR, P38; Bauer A., 1999, Proceedings of the 1999 Congress on Evolutionary Computation-CEC99 (Cat. No. 99TH8406), P1445, DOI 10.1109/CEC.1999.782653; Bertsekas D. P., 1992, DATA NETWORKS, V2; Bonabeau E DdRDF, 1999, SWARM INTELLIGENCE N; Bullnheimer B., 1999, METAHEURISTICS ADV T, P109; Cao YU, 1997, AUTON ROBOT, V4, P7, DOI 10.1023/A:1008855018923; Chen K, 1997, PHYS REV E, V55, P7809, DOI 10.1103/PhysRevE.55.7809; Costa D, 1997, J OPER RES SOC, V48, P295, DOI 10.1057/palgrave.jors.2600357; DENEUBOURG JL, 1989, ETHOL ECOL EVOL, V1, P295, DOI 10.1080/08927014.1989.9525500; DENEUBOURG JL, 1991, P 1 INT C SIM AD BEH, P356; Di Caro G, 1998, J ARTIF INTELL RES, V9, P317, DOI 10.1613/jair.530; Dorigo M, 1997, BIOSYSTEMS, V43, P73, DOI 10.1016/S0303-2647(97)01708-5; Dorigo M, 1996, IEEE T SYST MAN CY B, V26, P29, DOI 10.1109/3477.484436; FRANKS NR, 1986, BEHAV ECOL SOCIOBIOL, V18, P425, DOI 10.1007/BF00300517; FRANKS NR, 1992, BEHAV ECOL SOCIOBIOL, V30, P109; GAMBARDELLA IM, 1999, NEW IDEAS OPTIMIZATI, P63; Gambardella LM, 1999, J OPER RES SOC, V50, P167, DOI 10.2307/3010565; GAMBARDELLA LM, IN PRESS INFORMS J C; GOSS S, 1989, NATURWISSENSCHAFTEN, V76, P579, DOI 10.1007/BF00462870; HEUSSE M, 1998, ADV COMPLEX SYST, V1, P237, DOI DOI 10.1142/S0219525998000168; Kelly K., 1998, NEW RULES NEW EC; Kube C. Ronald, 1993, Adaptive Behavior, V2, P189, DOI 10.1177/105971239300200204; Kube CR, 1997, AUTON ROBOT, V4, P53, DOI 10.1023/A:1008859119831; Kuntz P, 1999, J HEURISTICS, V5, P327, DOI 10.1023/A:1009665701840; Leguizamon G, 1999, P 1999 C EV COMP, V2, P1459, DOI DOI 10.1109/CEC.1999.782655; LUMER ED, 1994, COM ADAP SY, P501; Maniezzo V, 2000, FUTURE GENER COMP SY, V16, P927, DOI 10.1016/S0167-739X(00)00046-7; Maniezzo V, 1999, IEEE T KNOWL DATA EN, V11, P769, DOI 10.1109/69.806935; MARTINOLI A, 1997, P 4 EUR C ART LIF; MATARIC MJ, 1995, IROS '95 - 1995 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS: HUMAN ROBOT INTERACTION AND COOPERATIVE ROBOTS, PROCEEDINGS, VOL 3, P556, DOI 10.1109/IROS.1995.525940; Michel R, 1998, LECT NOTES COMPUT SC, V1498, P692, DOI 10.1007/BFb0056911; MOFFETT MW, 1988, NATL GEOGR RES, V4, P386; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; Schoonderwoerd R, 1996, ADAPT BEHAV, V5, P169, DOI 10.1177/105971239700500203; SOBKOWSKI A, 1997, BIOCOMPUTATION EMERG, P36; Stutzle T, 1997, PROCEEDINGS OF 1997 IEEE INTERNATIONAL CONFERENCE ON EVOLUTIONARY COMPUTATION (ICEC '97), P309, DOI 10.1109/ICEC.1997.592327; Stutzle T., 1999, METAHEURISTICS ADV T, P313, DOI [10.1007/978-1-4615-5775-3_22, DOI 10.1007/978-1-4615-5775-3_22]; SUDD JH, 1965, BEHAVIOUR, V25, P234, DOI 10.1163/156853965X00156; VANDERPUT R, IN PRESS SIMULATION; Walters T, 1998, LECT NOTES COMPUT SC, V1498, P813, DOI 10.1007/BFb0056923; Ward M, 1998, NEW SCI, V157, P32	41	612	735	7	162	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					39	42		10.1038/35017500	http://dx.doi.org/10.1038/35017500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	330ZE	10894532				2022-12-28	WOS:000087991200035
J	Ihde, D				Ihde, D			Epistemology engines	NATURE			English	Editorial Material									SUNY Stony Brook, Dept Philosophy, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ihde, D (corresponding author), SUNY Stony Brook, Dept Philosophy, Stony Brook, NY 11794 USA.								0	15	15	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					21	21		10.1038/35017666	http://dx.doi.org/10.1038/35017666			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894521	Bronze			2022-12-28	WOS:000087991200023
J	Ries, G; Heller, W; Puchta, H; Sandermann, H; Seidlitz, HK; Hohn, B				Ries, G; Heller, W; Puchta, H; Sandermann, H; Seidlitz, HK; Hohn, B			Elevated UV-B radiation reduces genome stability in plants	NATURE			English	Article							INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; DNA-REPAIR; OZONE DEPLETION; DAMAGE; RAD51; PROTEIN; STRESS; MAIZE; LIFE	Long-term depletion of the stratospheric ozone layer contributes to an increase in terrestrial solar ultraviolet-B radiation(1-3). This has deleterious effects on living organisms, such as DNA damage(4,5). When exposed to elevated ultraviolet-B radiation (UV-B; 280-315 nm), plants display a wide variety of physiological and morphological responses characterized as acclimation and adaptation(6). Here we show, using special sun simulators, that elevated solar UV-B doses increase the frequency of somatic homologous DNA rearrangements in Arabidopsis and tobacco plants. Increases in recombination are accompanied by a strong induction of photolyase and Rad51 gene expression. These genes are putatively involved in major DNA repair pathways, photoreactivation and recombination repair(7,8). In mutant Arabidopsis plants that are deficient in photoreactivating ultraviolet-induced cyclobutane pyrimidine dimers, recombination under elevated UV-B regimes greatly exceeds wild-type levels. Our results show that homologous recombination repair pathways might be involved in eliminating UV-B-induced DNA lesions in plants. Thus, increases in terrestrial solar UV-B radiation as forecasted for the early 21st century may affect genome stability in plants.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; GSF Forschungszentrum Umwelt & Gesundheit, D-85764 Neuherberg, Germany	Friedrich Miescher Institute for Biomedical Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Ries, G (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		Puchta, Holger/ABE-6271-2020	Puchta, Holger/0000-0003-1073-8546				Britt AB, 1999, TRENDS PLANT SCI, V4, P20, DOI 10.1016/S1360-1385(98)01355-7; CALDWELL MM, 1994, PLANT CELL ENVIRON, V17, P267, DOI 10.1111/j.1365-3040.1994.tb00292.x; Caldwell MM., 1971, PHOTOPHYSIOLOGY, V6, P131, DOI [10.1016/b978-0-12-282606-1.50010-6, DOI 10.1016/B978-0-12-282606-1.50010-6, 10.1016/B978-0-12-282606-1.50010-6]; Dohring T, 1996, J PLANT PHYSIOL, V148, P115, DOI 10.1016/S0176-1617(96)80302-6; Doutriaux MP, 1998, MOL GEN GENET, V257, P283, DOI 10.1007/s004380050649; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; JACKSON JF, 1987, MUTAT RES, V181, P17; Jansen MAK, 1998, TRENDS PLANT SCI, V3, P131, DOI 10.1016/S1360-1385(98)01215-1; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Landry LG, 1997, P NATL ACAD SCI USA, V94, P328, DOI 10.1073/pnas.94.1.328; Madronich S, 1998, J PHOTOCH PHOTOBIO B, V46, P5, DOI 10.1016/S1011-1344(98)00182-1; McKenzie R, 1999, SCIENCE, V285, P1709, DOI 10.1126/science.285.5434.1709; Mount DW, 1996, NATURE, V383, P763, DOI 10.1038/383763a0; Puchta H, 1996, TRENDS PLANT SCI, V1, P340; PUCHTA H, 1995, PLANT MOL BIOL, V28, P281, DOI 10.1007/BF00020247; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; Rousseaux MC, 1999, P NATL ACAD SCI USA, V96, P15310, DOI 10.1073/pnas.96.26.15310; Rozema J, 1997, TRENDS ECOL EVOL, V12, P22, DOI 10.1016/S0169-5347(96)10062-8; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Stapleton A. E., 1993, Plant Molecular Biology Reporter, V11, P230, DOI 10.1007/BF02669850; STAPLETON AE, 1994, PLANT PHYSIOL, V105, P881, DOI 10.1104/pp.105.3.881; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x; Tevini Manfred, 1993, P125; TOVAR J, 1992, PLANT CELL, V4, P319, DOI 10.1105/tpc.4.3.319; Turunen M, 1999, ENVIRON POLLUT, V106, P219, DOI 10.1016/S0269-7491(99)00070-6; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; Walbot V, 1999, NATURE, V397, P398, DOI 10.1038/17043	30	296	320	2	54	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					98	101		10.1038/35017595	http://dx.doi.org/10.1038/35017595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894550	Green Accepted			2022-12-28	WOS:000087991200053
J	Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Meibohm, A; Condra, JH; Valentine, FT; McMahon, D; Gonzalez, C; Jonas, L; Emini, EA; Chodakewitz, JA; Isaacs, R; Richman, DD				Gulick, RM; Mellors, JW; Havlir, D; Eron, JJ; Meibohm, A; Condra, JH; Valentine, FT; McMahon, D; Gonzalez, C; Jonas, L; Emini, EA; Chodakewitz, JA; Isaacs, R; Richman, DD			3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE-INHIBITOR; LIPODYSTROPHY; RITONAVIR; RESERVOIR; ADULTS	Background: Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known. Objective: To describe the 3-year follow-up of patients randomly assigned to receive indinavir, zidovudine, and lamivudine in an ongoing clinical trial. Design: Open-label extension of a randomized, double-blind study. Setting: Four clinical research units. Patients: 33 HIV-infected, zidovudine-experienced patients with serum HIV RNA levels of at least 20 000 copies/mL and CD4 counts ranging from 50 to 400 cells/mm(3). Intervention: Indinavir, zidovudine, and lamivudine. Measurements: Safety assessments, HIV RNA levels, CD4 cell counts, and genotypic analyses. Results: After 3 years of follow-up, 21 of 31 contributing patients (68% [95% CI, 49% to 83%]) had serum viral load levels less than 500 copies/mL. Twenty of 31 (65% [CI, 45% to 80%]) had levels less than 50 copies/mL. The median increase in CD4 count from baseline was 230 cells/mm(3) (interquartile range, 150 to 316 cells/mm3). Nephrolithiasis occurred in 12 of 33 patients (36%). Conclusion: A three-drug regimen of indinavir, zidovudine, and lamivudine suppressed viremia in two thirds of patients for at least 3 years.	Cornell Univ, Weill Med Coll, New York, NY USA; NYU, Sch Med, New York, NY USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Pittsburgh Vet Affairs Med Ctr, Pittsburgh, PA USA; Univ Calif San Diego, San Diego, CA 92103 USA; San Diego Vet Affairs Med Ctr, San Diego, CA USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Merck Res Labs, West Point, PA USA	Cornell University; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Merck & Company	Gulick, RM (corresponding author), Cornell Clin Trials Unit, 525 E 68th St,Box 566, New York, NY 10021 USA.	rgulick@med.cornell.edu		Valentine, Fred/0000-0002-6046-5913	NIAID NIH HHS [AI 36214] Funding Source: Medline; NICHD NIH HHS [P30-HD37260] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591; *MERCK CO INC, 1999, IND SULF PACK INS; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Murphy RL, 1999, J INFECT DIS, V179, P808, DOI 10.1086/314668; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN CLINPRACT TRE, 2000, GUID US ANT AG HIV I; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	17	156	161	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					35	39		10.7326/0003-4819-133-1-200007040-00007	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877738				2022-12-28	WOS:000087923100005
J	Ronco, C; Bellomo, R; Homel, P; Brendolan, A; Dan, M; Piccinni, P; La Greca, G				Ronco, C; Bellomo, R; Homel, P; Brendolan, A; Dan, M; Piccinni, P; La Greca, G			Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial	LANCET			English	Article							INTENSIVE-CARE UNIT; CONTINUOUS HEMOFILTRATION; CRITICALLY ILL; THERAPY; DIALYSIS; REPLACEMENT	Background Continuous veno-venous haemofiltration is increasingly used to treat acute renal failure in critically ill patients, but a clear definition of an adequate treatment dose has not been established. We undertook a prospective randomised study of the impact different ultrafiltration doses in continuous renal replacement therapy on survival. Methods We enrolled 425 patients, with a mean age of 61 years, in intensive care who had acute renal failure. Patients were randomly assigned ultrafiltration at 20 mL h(-1) kg(-1) (group 1, n=146), 35 mL h(-1) kg(-1) (group 2, n=139), or 45 mL h(-1) kg(-1) (group 3, n=140). The primary endpoint was survival at 15 days after stopping haemofiltration. We also assessed recovery of renal function and frequency of complications during treatment. Analysis was by intention to treat. Results Survival in group 1 was;significantly lower than in groups 2 (p=0.0007) and 3 (p=0.0013). Survival in groups 2 and 3 did not differ significantly (p=0.87). Adjustment for possible confounding factors did not change the pattern of differences among the groups. Survivors in all groups had lower concentrations of blood urea nitrogen before continuous haemofiltration was started than non-survivors. 95%, 92%, and 90% of survivors in groups 1, 2, and 3, respectively, had full recovery of renal function. The frequency of complications was similarly low in all groups. Interpretation Mortality among these critically ill patients was high, but increase in the rate of ultrafiltration improved survival significantly. We recommend that ultrafiltration should be prescribed according to patient's bodyweight and should reach at least 35 mL h(-1) kg(-1).	St Bortolo Hosp, Dept Nephrol, I-36100 Vicenza, Italy; St Bortolo Hosp, Dept Intens Care, I-36100 Vicenza, Italy; Austin & Repatriat Med Ctr, Dept Intens Care, Heidelberg, Vic, Australia; Beth Israel Deaconess Med Ctr, Off Res Support, New York, NY 10003 USA	ULSS 8 Berica; Ospedale San Bortolo di Vicenza; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Harvard University; Beth Israel Deaconess Medical Center	Ronco, C (corresponding author), Renal Res Inst, 207 E 94th St,Suite 303, New York, NY 10128 USA.	cronco@rriny.com	Ronco, Cyril/ABA-9149-2021	Ronco, Cyril/0000-0002-9023-5940; Bellomo, Rinaldo/0000-0002-1650-8939; Ronco, Claudio/0000-0002-6697-4065				AMOROSO P, 1992, BR J INT CARE, V2, P92; BELLOMO R, 1993, RENAL FAILURE, V15, P595, DOI 10.3109/08860229309069409; Bellomo R, 1999, INTENS CARE MED, V25, P781, DOI 10.1007/s001340050953; Bellomo R, 1998, KIDNEY INT, V53, pS106; BOSCH JP, 1989, REPLACEMENT RENAL FU, P347; Briglia A, 1999, CLIN CHEST MED, V20, P347, DOI 10.1016/S0272-5231(05)70146-5; Clark W R, 1992, ASAIO J, V38, pM664, DOI 10.1097/00002480-199207000-00120; Clark WR, 1997, J AM SOC NEPHROL, V8, P804; Douma CE, 1997, J AM SOC NEPHROL, V8, P111; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Halstenberg WK, 1997, CLIN NEPHROL, V47, P81; Jones CH, 1998, AM J KIDNEY DIS, V31, P227, DOI 10.1053/ajkd.1998.v31.pm9469492; Nissenson AR, 1998, KIDNEY INT, V53, pS7; Paganini EP, 1996, AM J KIDNEY DIS, V28, pS81, DOI 10.1016/S0272-6386(96)90084-0; Pagnini EP, 1996, CLIN NEPHROL, V46, P206; PARKER RA, 1994, J AM SOC NEPHROL, V5, P402; Ronco C, 1998, CRITICAL CARE NEPHRO, pPP 1269; Schetz MRC, 1998, KIDNEY INT, V53, pS129; Silvester W, 1998, KIDNEY INT, V53, pS138; STEVENS PE, 1992, BR J INTENSIVE CARE, V2, P361; STORCK M, 1991, LANCET, V337, P452, DOI 10.1016/0140-6736(91)93393-N; Swartz RD, 1999, AM J KIDNEY DIS, V34, P424, DOI 10.1016/S0272-6386(99)70068-5; TATTERSALL J, 1998, OXFORD TXB CLIN NEPH, P2075; vanBommel EFH, 1995, RENAL FAILURE, V17, P731, DOI 10.3109/08860229509037641	24	1045	1180	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					26	30		10.1016/S0140-6736(00)02430-2	http://dx.doi.org/10.1016/S0140-6736(00)02430-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892761				2022-12-28	WOS:000087933400012
J	Paredes, JM; Marti, J; Ribo, M; Massi, M				Paredes, JM; Marti, J; Ribo, M; Massi, M			Discovery of a high-energy gamma-ray-emitting persistent microquasar	SCIENCE			English	Article							X-RAY; GALACTIC PLANE; SKY SURVEY; RADIO; CATALOG; BINARY; GALAXY	Microquasars are stellar x-ray binaries that behave as a scaled-down version of extragalactic quasars. The star LS 5039 is a new microquasar system with apparent persistent ejection of relativistic plasma at a 3-kiloparsec distance from the sun. It may also be associated with a gamma-ray source discovered by the Energetic Gamma Ray Experiment Telescope (EGRET) on board the COMPTON-Gamma Ray Observatory satellite. Before the discovery of LS 5039, merely a handful of microquasars had been identified in the Galaxy, and none of them was detected in high-energy gamma-rays.	Univ Barcelona, Dept Astron & Meteorol, E-08028 Barcelona, Spain; Univ Jaen, Escuela Politecn Super, Dept Fis, E-23071 Jaen, Spain; Max Planck Inst Radioastron, D-53121 Bonn, Germany	University of Barcelona; Universidad de Jaen; Max Planck Society	Paredes, JM (corresponding author), Univ Barcelona, Dept Astron & Meteorol, Av Diagonal 647, E-08028 Barcelona, Spain.		Martí, Josep/Y-6538-2019; Ribó, Marc/B-3579-2015	Ribó, Marc/0000-0002-9931-4557; Paredes, Josep M./0000-0002-1566-9044; Marti, Josep/0000-0001-5302-0660				Condon JJ, 1998, ASTRON J, V115, P1693, DOI 10.1086/300337; FENDER RP, IN PRESS MON NOT R A; GREINER J, 1999, IN PRESS COSMIC EXPL; Hartman RC, 1999, ASTROPHYS J SUPPL S, V123, P79, DOI 10.1086/313231; HELFAND DJ, 1992, ASTROPHYS J SUPPL S, V80, P211, DOI 10.1086/191664; HJELLMING RM, 1998, 9872 INT ASTR UN; HJELLMING RM, 1999, 7265 INT ASTR UN; LAHULLA JF, 1992, ASTRON ASTROPHYS SUP, V94, P265; LASKER BM, 1990, ASTRON J, V99, P2019, DOI 10.1086/115483; Marti J, 1998, ASTRON ASTROPHYS, V338, pL71; MERK M, 1996, ASTRON ASTROPHYS SUP, V120, P465; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; MIRABEL IF, 1994, NATURE, V371, P46, DOI 10.1038/371046a0; MIRABEL IF, 1992, NATURE, V358, P215, DOI 10.1038/358215a0; Motch C, 1997, ASTRON ASTROPHYS, V323, P853; Pacholczyk A. G., 1970, RADIO ASTROPHYSICS; Pearson T. J, 1987, SUPERLUMINAL RADIO S, P1; REED BC, 1993, PUBL ASTRON SOC PAC, V105, P1465, DOI 10.1086/133329; Ribo M, 1999, ASTRON ASTROPHYS, V347, P518; Stephenson C.B., 1971, PUBLICATION WARNER S, V1, P1; Voges W, 1999, ASTRON ASTROPHYS, V349, P389	21	262	263	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2340	2342		10.1126/science.288.5475.2340	http://dx.doi.org/10.1126/science.288.5475.2340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875913	Green Submitted, Green Accepted			2022-12-28	WOS:000087913400031
J	Allen, PB				Allen, PB			Condensed-matter physics - Misbehaviour in metals	NATURE			English	Editorial Material									SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Allen, PB (corresponding author), SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA.		Allen, Philip/O-2163-2019					EMERY VJ, 1995, PHYS REV LETT, V74, P3253, DOI 10.1103/PhysRevLett.74.3253; Gunnarsson O, 2000, NATURE, V405, P1027, DOI 10.1038/35016512; KIVELSON SA, 1990, PHYS REV B, V41, P11693, DOI 10.1103/PhysRevB.41.11693; PEIERLS RE, 1977, SURPRISES THEORETICA; SHANKAR R, 1994, REV MOD PHYS, V66, P129, DOI 10.1103/RevModPhys.66.129; VAREKA WA, 1994, PHYS REV LETT, V72, P4121, DOI 10.1103/PhysRevLett.72.4121	6	10	10	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1007	1008		10.1038/35016675	http://dx.doi.org/10.1038/35016675			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890427				2022-12-28	WOS:000087871700027
J	Buxton, AE; Lee, KL; DiCarlo, L; Gold, MR; Greer, GS; Prystowsky, EN; O'Toole, MF; Tang, A; Fisher, JD; Coromilas, J; Talajic, M; Hafley, G				Buxton, AE; Lee, KL; DiCarlo, L; Gold, MR; Greer, GS; Prystowsky, EN; O'Toole, MF; Tang, A; Fisher, JD; Coromilas, J; Talajic, M; Hafley, G		Multicenter Unsustained Tachycardi	Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; NONSUSTAINED VENTRICULAR-TACHYCARDIA; PROGRAMMED ELECTRICAL-STIMULATION; IDIOPATHIC DILATED CARDIOMYOPATHY; ARRHYTHMIAS; SURVIVORS; PROGNOSIS; REPRODUCIBILITY; STRATIFICATION; PREDICTION	Background: The mortality rate among patients with coronary artery disease, abnormal ventricular function, and unsustained ventricular tachycardia is high. The usefulness of electrophysiologic testing for risk stratification in these patients is unclear. Methods: We performed electrophysiologic testing in patients who had coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and asymptomatic, unsustained ventricular tachycardia. Patients in whom sustained ventricular tachyarrhythmias could be induced were randomly assigned to receive either antiarrhythmic therapy guided by electrophysiologic testing or no antiarrhythmic therapy. The primary end point was cardiac arrest or death from arrhythmia. Patients without inducible tachyarrhythmias were followed in a registry. We compared the outcomes of 1397 patients in the registry with those of 353 patients with inducible tachyarrhythmias who were randomly assigned to receive no antiarrhythmic therapy in order to assess the prognostic value of electrophysiologic testing. Results: Patients were followed for a median of 39 months. In a Kaplan-Meier analysis, two-year and five-year rates of cardiac arrest or death due to arrhythmia were 12 and 24 percent, respectively, among the patients in the registry, as compared with 18 and 32 percent among the patients with inducible tachyarrhythmias who were assigned to no antiarrhythmic therapy (adjusted P < 0.001). Overall mortality after five years was 48 percent among the patients with inducible tachyarrhythmias, as compared with 44 percent among the patients in the registry (adjusted P = 0.005). Deaths among patients without inducible tachyarrhythmias were less likely to be classified as due to arrhythmia than those among patients with inducible tachyarrhythmias (45 and 54 percent, respectively; P = 0.06). Conclusions: Patients with coronary artery disease, left ventricular dysfunction, and asymptomatic, unsustained ventricular tachycardia in whom sustained ventricular tachyarrhythmias cannot be induced have a significantly lower risk of sudden death or cardiac arrest and lower overall mortality than similar patients with inducible sustained tachyarrhythmias. (N Engl J Med 2000;342:1937-45.) (C)2000, Massachusetts Medical Society.	Rhode Isl Hosp, Div Cardiol, Providence, RI 02905 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Duke Univ, Clin Res Inst, Durham, NC USA; Michigan Heart, Ann Arbor, MI USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Arkansas Cardiol Clin, Little Rock, AR USA; Northside Cardiol, Indianapolis, IN USA; Midw Heart Res Fdn, Lombard, IL USA; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Montefiore Med Ctr, Bronx, NY 10467 USA; Albert Einstein Sch Med, Bronx, NY USA; Columbia Univ, Sch Med, New York, NY USA; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Duke University; University System of Maryland; University of Maryland Baltimore; University of Ottawa; University of Ottawa Heart Institute; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Columbia University; Universite de Montreal	Buxton, AE (corresponding author), Rhode Isl Hosp, Div Cardiol, 2 Dudley St,Suite 360, Providence, RI 02905 USA.		Tang, Anthony S/E-6203-2014	Fisher, John/0000-0003-2748-8715; Talajic, Mario/0000-0001-8469-4748	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL045726, U01HL045700] Funding Source: NIH RePORTER; NHLBI NIH HHS [UO1 HL45726, UO1 HL45700] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHANDARI AK, 1990, J AM COLL CARDIOL, V15, P1075, DOI 10.1016/0735-1097(90)90243-I; BHANDARI AK, 1987, AM J CARDIOL, V59, P284, DOI 10.1016/0002-9149(87)90800-9; BHANDARI AK, 1985, AM J CARDIOL, V56, P737, DOI 10.1016/0002-9149(85)91125-7; BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Buxton AE, 1999, CIRCULATION, V99, P1843, DOI 10.1161/01.CIR.99.14.1843; BUXTON AE, 1993, PROG CARDIOVASC DIS, V36, P215, DOI 10.1016/0033-0620(93)90015-6; BUXTON AE, 1987, CIRCULATION, V75, P1178, DOI 10.1161/01.CIR.75.6.1178; COX DR, 1972, J R STAT SOC B, V34, P187; DAS SK, 1986, AM J CARDIOL, V58, P998, DOI 10.1016/S0002-9149(86)80026-1; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; GOMES JAC, 1984, CIRCULATION, V70, P43, DOI 10.1161/01.CIR.70.1.43; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; IESAKA Y, 1990, AM J CARDIOL, V65, P1057, DOI 10.1016/0002-9149(90)90314-Q; KADISH A, 1993, PACE, V16, P1037, DOI 10.1111/j.1540-8159.1993.tb04578.x; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN RC, 1989, J AM COLL CARDIOL, V14, P155, DOI 10.1016/0735-1097(89)90066-1; KUCK KH, 1986, J AM COLL CARDIOL, V8, P1279, DOI 10.1016/S0735-1097(86)80298-4; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; MEINERTZ T, 1985, AM J CARDIOL, V56, P337, DOI 10.1016/0002-9149(85)90860-4; NOGAMI A, 1991, AM J CARDIOL, V68, P13, DOI 10.1016/0002-9149(91)90702-M; POLL DS, 1986, AM J CARDIOL, V58, P992, DOI 10.1016/S0002-9149(86)80025-X; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; Rouleau JL, 1996, J AM COLL CARDIOL, V27, P1119, DOI 10.1016/0735-1097(95)00599-4; ROY D, 1985, CIRCULATION, V72, P487, DOI 10.1161/01.CIR.72.3.487; ROY D, 1986, J AM COLL CARDIOL, V8, P32, DOI 10.1016/S0735-1097(86)80088-2; STAMATO NJ, 1986, AM HEART J, V112, P505, DOI 10.1016/0002-8703(86)90514-4; Tavazzi L, 1997, CIRCULATION, V95, P1341; TURITTO G, 1994, J AM COLL CARDIOL, V24, P1523, DOI 10.1016/0735-1097(94)90149-X; WILBER DJ, 1990, CIRCULATION, V82, P350, DOI 10.1161/01.CIR.82.2.350	33	380	399	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1937	1945		10.1056/NEJM200006293422602	http://dx.doi.org/10.1056/NEJM200006293422602			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874061	Bronze			2022-12-28	WOS:000087867400002
J	Grzybowski, BA; Stone, HA; Whitesides, GM				Grzybowski, BA; Stone, HA; Whitesides, GM			Dynamic self-assembly of magnetized, millimetre-sized objects rotating at a liquid-air interface	NATURE			English	Article							COLLOIDAL CRYSTALS; VORTICES; PATTERNS; SYSTEMS; FLOW	Spontaneous pattern formation by self-assembly is of long-standing(1-3) and continuing interest(4,5) not only for its aesthetic appeal(6,7), but also for its fundamental(8-18) and technological relevance(19). So far, the study of self-organization processes has mainly focused on static structures, but dynamic systems(20-22) - those that develop order only when dissipating energy - are of particular interest for studying complex behaviour(23,24). Here we describe the formation of dynamic patterns of millimetre-sized magnetic disks at a liquid-air interface, subject to a magnetic field produced by a rotating permanent magnet. The disks spin around their axes with angular frequency equal to that of the magnet, and are attracted towards its axis of rotation while repelling each other. This repulsive hydrodynamic interaction is due to fluid motion associated with spinning; the interplay between attractive and repulsive interactions leads to the formation of patterns exhibiting various types of ordering, some of which are entirely new. This versatile system should lead to a better understanding of dynamic self-assembly, while providing a test-bed for stability theories of interacting point vortices(25-28) and vortex patches(29).	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Stone, Howard A/B-6435-2008; Grzybowski, Bartosz A/H-5741-2017	Grzybowski, Bartosz/0000-0001-6613-4261				Aref H, 1998, NATURE, V392, P769, DOI 10.1038/33827; Ball P., 1999, SELF MADE TAPESTRY P; BAYER AM, 1878, NATURE, V18, P258; Bowden N, 1999, J AM CHEM SOC, V121, P5373, DOI 10.1021/ja983882z; Bowden N, 1998, NATURE, V393, P146, DOI 10.1038/30193; Bubeck R, 1999, PHYS REV LETT, V82, P3364, DOI 10.1103/PhysRevLett.82.3364; BUDRENE EO, 1995, NATURE, V376, P49, DOI 10.1038/376049a0; BURNS MM, 1990, SCIENCE, V249, P749, DOI 10.1126/science.249.4970.749; Derr L, 1909, P AM ACAD ARTS SCI, V44, P525, DOI 10.2307/20022464; DRITSCHEL DG, 1985, J FLUID MECH, V157, P95, DOI 10.1017/S0022112085002324; ENGELBORGHS Y, 1994, BIOSENS BIOELECTRON, V9, P685, DOI 10.1016/0956-5663(94)80066-9; Ghyka Matila, 1977, GEOMETRY ART LIFE; GomezLopez M, 1996, NANOTECHNOLOGY, V7, P183, DOI 10.1088/0957-4484/7/3/004; Havelock TH, 1931, PHILOS MAG, V11, P617; JAKUBITH S, 1990, PHYS REV LETT, V65, P3013, DOI 10.1103/PhysRevLett.65.3013; KOSCHMIEDER A, 1993, BENARD CELLS TAYLOR; Lindgren K, 1998, J STAT PHYS, V91, P909, DOI 10.1023/A:1023027932419; Lounasmaa OV, 1999, P NATL ACAD SCI USA, V96, P7760, DOI 10.1073/pnas.96.14.7760; MONCKMAN J, 1888, P CAMB PHILOS SOC, V6, P179; Morton W.B., 1935, P R IR ACAD, V42, P21; MURRAY CA, 1995, AM SCI, V83, P238; Philp D, 1996, ANGEW CHEM INT EDIT, V35, P1154, DOI 10.1002/anie.199611541; Schecter DA, 1999, PHYS FLUIDS, V11, P905, DOI 10.1063/1.869961; SCHONBERG JA, 1989, J FLUID MECH, V203, P517, DOI 10.1017/S0022112089001564; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Shinbrot T, 1997, NATURE, V389, P574, DOI 10.1038/39264; Singh R, 1998, J NONLINEAR SCI, V8, P235, DOI 10.1007/s003329900051; Thompson DW, 1992, GROWTH FORM, V2nd, DOI DOI 10.1017/CBO978110732585210.1017/CBO9781107325852; Thomson GM, 1883, WORLD COPEPODS; Whitesell J.K., 1999, ORG MOL ASSEMBLIES S	30	404	407	6	219	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1033	1036		10.1038/35016528	http://dx.doi.org/10.1038/35016528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890439				2022-12-28	WOS:000087871700039
J	van Beek, JD; Beaulieu, L; Schafer, H; Demura, M; Asakura, T; Meier, BH				van Beek, JD; Beaulieu, L; Schafer, H; Demura, M; Asakura, T; Meier, BH			Solid-state NMR determination of the secondary structure of Samia cynthia ricini silk	NATURE			English	Article							C-13 CHEMICAL-SHIFT; SPIDER DRAGLINE SILK; NUCLEAR-MAGNETIC-RESONANCE; POWDER PATTERNS; TENSORS; N-15; SPECTROSCOPY; CONFORMATION; PEPTIDES; FIBERS	Silks are fibrous proteins that form heterogeneous, semi-crystalline solids. Silk proteins have a variety of physical properties reflecting their range of functions. Spider dragline silk, for example, has high tensile strength and elasticity(1), whereas other silks(2) are better suited to making housing, egg sacs or the capture spiral of spiders' webs. The differing physical properties arise from variation in the protein's primary and secondary structure, and their packing in the solid phase. The high mechanical performance of spider dragline silk, for example, is probably due to a beta-sheet conformation of poly-alanine domains(3), embedded as small crystallites within the fibre. Only limited structural information can be obtained from diffraction of silks(3-6), so further characterization requires spectroscopic studies such as NMR7-11. However, the classical approach to NMR structure determination(12) fails because the high molecular weight(13), repetitive primary structure(13) and structural heterogeneity of solid silk means that signals from individual amino-acid residues cannot be resolved. Here we adapt a recently developed solid-state NMR technique(14,15) to determine torsion angle pairs (phi, Psi) in the protein backbone, and we study the distribution of conformations in silk from the Eri silkworm, Samia cynthia ricini. Although the most probable conformation in native fibres is an anti-parallel beta-sheet, film produced from liquid directly extracted from the silk glands appears to be primarily alpha-helical.	Swiss Fed Inst Technol, Phys Chem Lab, CH-8092 Zurich, Switzerland; Catholic Univ Nijmegen, Phys Chem Lab, NL-6525 ED Nijmegen, Netherlands; Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Tokyo Univ Agr & Technol, Dept Biotechnol, Tokyo 1848588, Japan	Swiss Federal Institutes of Technology Domain; ETH Zurich; Radboud University Nijmegen; Hokkaido University; Tokyo University of Agriculture & Technology	Meier, BH (corresponding author), Swiss Fed Inst Technol, Phys Chem Lab, CH-8092 Zurich, Switzerland.	beme@nmr.phys.chem.ethz.ch	Meier, Beat H/K-4066-2016; Asakura, Tetsuo/B-9970-2013; Demura, Makoto/F-5272-2011	Meier, Beat H/0000-0002-9107-4464; Asakura, Tetsuo/0000-0003-4472-6105; Demura, Makoto/0000-0003-0912-9284				Antzutkin ON, 1999, J CHEM PHYS, V110, P2749, DOI 10.1063/1.477876; ARNOTT S, 1967, J MOL BIOL, V30, P201, DOI 10.1016/0022-2836(67)90252-5; Asakura T, 1999, MACROMOLECULES, V32, P4940, DOI 10.1021/ma990442z; BECKER MA, 1994, ACS SYM SER, V544, P185; Bram A, 1997, J APPL CRYSTALLOGR, V30, P390, DOI 10.1107/S0021889896012344; Denny M.W., 1980, Symposia of the Society for Experimental Biology, P247; Ernst M, 1998, STUD PHYS THEO CHEM, V84, P83, DOI 10.1016/S0167-6881(98)80007-4; HARTZELL CJ, 1987, J AM CHEM SOC, V109, P5966, DOI 10.1021/ja00254a012; Heller J, 1997, J AM CHEM SOC, V119, P7827, DOI 10.1021/ja970124k; Honerkamp J, 1990, CONTINUUM MECHANICS, V2, P17, DOI [10.1007/BF01170953, DOI 10.1007/BF01170953]; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; KAPLAN D, 1994, ACS SYM SER, V544, P2; Kummerlen J, 1996, MACROMOLECULES, V29, P2920, DOI 10.1021/ma951098i; OAS TG, 1987, J AM CHEM SOC, V109, P5956, DOI 10.1021/ja00254a010; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; SAITO H, 1984, MACROMOLECULES, V17, P1405, DOI 10.1021/ma00137a018; SCHAFER H, 1994, CHEM PHYS, V182, P53, DOI 10.1016/0301-0104(94)00011-5; Schmidt-Rohr K, 1998, SCIENCE, V280, P714, DOI 10.1126/science.280.5364.714; Schmidt-Rohr K, 1996, MACROMOLECULES, V29, P3975, DOI 10.1021/ma9517106; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; STARK RE, 1983, J MAGN RESON, V55, P266, DOI 10.1016/0022-2364(83)90238-X; TENG Q, 1992, J AM CHEM SOC, V114, P5312, DOI 10.1021/ja00039a048; Tikhonov A., 1977, SOLUTION ILL POSED P; VOLLRATH F, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0392-70; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; WEESE J, 1992, COMPUT PHYS COMMUN, V69, P99, DOI 10.1016/0010-4655(92)90132-I; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang Z, 1997, MACROMOLECULES, V30, P8254, DOI 10.1021/ma970548z	29	156	157	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1077	1079		10.1038/35016625	http://dx.doi.org/10.1038/35016625			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890452				2022-12-28	WOS:000087871700052
J	Johnston, C				Johnston, C			Quantitative tests for human papillomavirus	LANCET			English	Editorial Material							CERVICAL NEOPLASIA; WOMEN; DNA; INFECTION; GRADE; RISK		Univ Michigan Hosp, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Johnston, C (corresponding author), Univ Michigan Hosp, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA.							CAMPION MJ, 1986, LANCET, V2, P237; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; Hillemanns P, 1999, LANCET, V354, P1970, DOI 10.1016/S0140-6736(99)04110-0; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; Swan DC, 1999, J CLIN MICROBIOL, V37, P1030, DOI 10.1128/JCM.37.4.1030-1034.1999; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	11	12	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2179	2180		10.1016/S0140-6736(00)02395-3	http://dx.doi.org/10.1016/S0140-6736(00)02395-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881885				2022-12-28	WOS:000087779000003
J	Chowdhury, TA; Tanchel, BM; Jaganathan, RS; Dodson, PM				Chowdhury, TA; Tanchel, BM; Jaganathan, RS; Dodson, PM			A toxic testicle	LANCET			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HYPERTHYROIDISM; MEN		Birmingham Heartlands Hosp, Dept Med, Birmingham B9 5ST, W Midlands, England; Birmingham Heartlands Hosp, Dept Pathol, Birmingham B9 5ST, W Midlands, England; Birmingham Heartlands Hosp, Dept Urol, Birmingham B9 5ST, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham	Chowdhury, TA (corresponding author), Cent Middlesex Hosp, Ctr Diabet, Acton Lane, London NW10 7NS, England.							CASSELS JW, 1989, CANCER, V64, P2313, DOI 10.1002/1097-0142(19891201)64:11<2313::AID-CNCR2820641122>3.0.CO;2-L; GIRALT SA, 1992, CANCER-AM CANCER SOC, V69, P1286; GLEASON PE, 1994, J UROLOGY, V151, P1063, DOI 10.1016/S0022-5347(17)35183-2; SOWERS JR, 1978, J CLIN ENDOCR METAB, V47, P898, DOI 10.1210/jcem-47-4-898; STEIGBIEGEL N, 1964, NEW ENGL J MED, V271, P345, DOI 10.1056/NEJM196408132710704	5	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2046	2046		10.1016/S0140-6736(00)02353-9	http://dx.doi.org/10.1016/S0140-6736(00)02353-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885357				2022-12-28	WOS:000087519400014
J	Hillis, DM				Hillis, DM			Aids - Origins of HIV	SCIENCE			English	Editorial Material									Univ Texas, Sch Biol Sci, Sect Integrat Biol, Austin, TX 78712 USA; Univ Texas, Sch Biol Sci, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Hillis, DM (corresponding author), Univ Texas, Sch Biol Sci, Sect Integrat Biol, Austin, TX 78712 USA.		Hillis, David/L-5421-2019; Hillis, David M/B-4278-2008					Chitnis A, 2000, AIDS RES HUM RETROV, V16, P5, DOI 10.1089/088922200309548; Hillis David M., 1996, P515; Hooper E, 1999, RIVER; Huelsenbeck JP, 2000, GENETICS, V154, P1879; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; McCutchan FE, 1999, EVOLUTION OF HIV, P41; Thorne JL, 1998, MOL BIOL EVOL, V15, P1647, DOI 10.1093/oxfordjournals.molbev.a025892	7	18	20	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 9	2000	288	5472					1757	+		10.1126/science.288.5472.1757	http://dx.doi.org/10.1126/science.288.5472.1757			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	322HH	10877695				2022-12-28	WOS:000087503800033
J	John, RM; Surani, MA				John, RM; Surani, MA			Genomic imprinting, mammalian evolution, and the mystery of egg-laying mammals	CELL			English	Review							MONOTREMES; GROWTH; BRAIN; IGF2; H19		Univ Cambridge, CRC, Wellcome Inst Canc & Dev Biol, Cambridge CB2 1QR, England	University of Cambridge	Surani, MA (corresponding author), Univ Cambridge, CRC, Wellcome Inst Canc & Dev Biol, Cambridge CB2 1QR, England.		John, Ros/AFI-8619-2022; John, Rosalind/AAQ-8221-2021; John, Rosalind M/A-4491-2010; John, Ros/AAF-4229-2022	John, Ros/0000-0002-3827-7617; John, Rosalind M/0000-0002-3827-7617; John, Ros/0000-0002-3827-7617; Surani, Azim/0000-0002-8640-4318				Bielinska B, 2000, NAT GENET, V25, P74, DOI 10.1038/75629; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; HAIG D, 1991, CELL, V64, P1045; Janke A, 1996, J MOL EVOL, V42, P153, DOI 10.1007/BF02198841; Keverne EB, 1997, CURR OPIN NEUROBIOL, V7, P463, DOI 10.1016/S0959-4388(97)80023-2; Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X; Krubitzer L, 1998, PHILOS T ROY SOC B, V353, P1127, DOI 10.1098/rstb.1998.0271; Kullander K, 1997, J MOL EVOL, V45, P311, DOI 10.1007/PL00006235; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; O'Neill MJ, 2000, DEV GENES EVOL, V210, P18, DOI 10.1007/PL00008182; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Toder R, 1996, CHROMOSOME RES, V4, P295, DOI 10.1007/BF02263680; Wakefield MJ, 1997, P NATL ACAD SCI USA, V94, P9665, DOI 10.1073/pnas.94.18.9665; [No title captured]	17	46	47	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					585	588		10.1016/S0092-8674(00)80870-3	http://dx.doi.org/10.1016/S0092-8674(00)80870-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892645	Bronze			2022-12-28	WOS:000087504500005
J	Ali, HM; Shah, IH				Ali, HM; Shah, IH			Sanctions and childhood mortality in Iraq	LANCET			English	Article								Background In 1999 UNICEF, in cooperation government of Iraq and the local authorities In "autonomous" (northern Kurdish) region, conducted similar surveys to provide regionally representative and reliable estimates of child mortality (the subject of this paper) and maternal mortality. Methods In a cross-sectional household survey in the south/centre of Iraq in February and March, 1999, 23 105 ever-married women aged 15-49 years living in sampled households were interviewed by trained interviewers with a structured questionnaire that was developed using the Demographic and Health Surveys questionnaire and following a pre-test. In a similar survey in the autonomous region in April and May 14 035 ever-married women age 15-49 were interviewed. Findings In the south/centre, infant and under-5 mortality increased during the 10 years before the survey, which roughly corresponds to the period following the Gulf conflict and the start of the United Nations sanctions. Infant mortality rose from 47 per 1000 live births during 1984-89 to 108 per 1000 in 1994-99, and under-5 mortality rose from 56 to 131 per 1000 live births. In the autonomous region during the same period, infant mortality declined from 64 to 59 per 1000 and under-5 mortality fell from 80 to 72 per 1000. Childhood mortality was higher among children born in rural areas, children born to women with no education, and in boys, and these differentials were broadly similar in the two regions. Interpretation Childhood mortality clearly increased after the Gulf conflict and under UN sanctions in the south/centre of Iraq, but in the autonomous region since the start of the Oil-for-Food Programme childhood mortality has begun to decline. Better food and resource allocation to the autonomous region contributed to the continued gains in lower mortality, whereas the situation in the south/centre deteriorated despite the high level of literacy in that region.	Univ London, London Sch Hyg & Trop Med, Ctr Populat Studies, Dept Epidemiol & Populat Hlth, London WC1B 3DP, England; WHO, Special Programme Res Dev & Res Training Human Re, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland	University of London; London School of Hygiene & Tropical Medicine; World Health Organization	Ali, HM (corresponding author), Univ London, London Sch Hyg & Trop Med, Ctr Populat Studies, Dept Epidemiol & Populat Hlth, 49-51 Bedford Sq, London WC1B 3DP, England.	Mohamed.Ali@lshtm.ac.uk						ARMIJOHUSSEIN NA, 1991, NEW ENGL J MED, V325, P977; ASCHERIO A, 1992, NEW ENGL J MED, V327, P931, DOI 10.1056/NEJM199209243271306; BICEGO G, 1996, INFANT CHILD MORTALI; *CENTR STAT ORG, 1997, IRQ97288 UNICEF CENT; *EC INT UN, 1998, EC IR COUNTR PROF; GREENWOOD M, 1926, REPORT PUBLIC HLTH M; HOSKINS E, 1997, WAR PUBLIC HLTH; *I RES DEV, 1987, 7 I RES DEV; Ministry of Health, 1990, NAT CHILD HLTH SURV; Ronsmans C, 1996, LANCET, V347, P198, DOI 10.1016/S0140-6736(96)90384-0; SCF, 1998, SIT CHILD RWANDA; *UNICEF, 1990, IR IMM DIARRH DIS MA, V9; United Nations Children's Fund (UNICEF), 1997, STAT WORLDS CHILDR 1; ZAIDI S, 1997, LANCET, V350, P1150	14	96	96	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 27	2000	355	9218					1851	1857		10.1016/S0140-6736(00)02289-3	http://dx.doi.org/10.1016/S0140-6736(00)02289-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866440				2022-12-28	WOS:000087306500011
J	Bifani, PJ; Shopsin, B; Alcabes, P; Mathema, B; Kreiswirth, BN; Liu, ZY; Driscoll, J; Frothingham, R; Musser, JM				Bifani, PJ; Shopsin, B; Alcabes, P; Mathema, B; Kreiswirth, BN; Liu, ZY; Driscoll, J; Frothingham, R; Musser, JM			Molecular epidemiology and tuberculosis control - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRANSMISSION		NYU, Sch Med, New York, NY 10003 USA; Publ Hlth Res Inst, TB Ctr, New York, NY USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA; New York State Dept Hlth, Albany, NY USA; Durham Vet Affairs Med Ctr, Durham, NC USA	New York University; New Jersey Department of Health & Senior Services; State University of New York (SUNY) System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center	Bifani, PJ (corresponding author), NYU, Sch Med, New York, NY 10003 USA.			Mathema, Barun/0000-0003-2772-479X; Bifani, Pablo/0000-0001-9651-6439				Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Bishai WR, 1998, JAMA-J AM MED ASSOC, V280, P1679, DOI 10.1001/jama.280.19.1679; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991; 2000, MMWR MORB MORTAL WKL, V49, P317	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					306	307						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891955				2022-12-28	WOS:000088123000016
J	Kogan, MD; Alexander, GR; Kotelchuck, M; MacDorman, MF; Buekens, P; Martin, JA; Papiernik, E				Kogan, MD; Alexander, GR; Kotelchuck, M; MacDorman, MF; Buekens, P; Martin, JA; Papiernik, E			Trends in twin birth outcomes and prenatal care utilization in the United States, 1981-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONAL-AGE; MULTIPLE BIRTHS; PRETERM BIRTH; ASSISTED REPRODUCTION; INFANT-MORTALITY; WEIGHT; PREGNANCIES; SINGLETONS; ADEQUACY; HEALTH	Context Multiple births account for an increasing percentage of all low-birth-weight infants, preterm births, and infant mortality in the United States. Since 1981, the percentage of women with multiple births who received intensive prenatal care (defined as a high number of visits, exceeding the recommendation of the American College of Obstetricians and Gynecologists by approximately 1 SD beyond the mean number of visits for women initiating care within each trimester) has increased significantly. Objectives To explore the hypothesis that more aggressive management of twin-birth pregnancies may be associated with changes in birth outcomes in this population. Design, Setting, and Subjects Cross-sectional and trend analysis of data from the National Center for Health Statistics' birth and infant death records for all twin births occurring in the United States between 1981 and 1997, excluding those with missing or inconsistent data. Main Outcome Measures Trends in preterm birth, low birth weight, preterm and term small-for-gestational-age (SGA) births, and infant mortality, by level of prenatal care utilization. Results The preterm birth rate for twins increased from 40.9% in 1981 to 55.0% in 1997, The percentage of low-birth-weight infants increased from 51.0% to 54.0%, The preterm SGA rate also increased from 11.9% to 14.1%, while the term SGA rate decreased from 30.7% to 20.5%. For women with intensive prenatal care utilization, the preterm birth rate increased from 35.1% to 55.8%, compared with an increase from 50.6% to 592% among women with only adequate use. Twin preterm deliveries involving either induction or first cesarean delivery also increased from 21.9% to 27.3% between 1989-1991 and 1995-1997. The twin infant mortality rate for women with intensive prenatal care use declined between 1983 and 1996 and remained lower than the overall twin infant mortality rate. Conclusions An apparent increase in medical interventions in the management of twins may result in the seeming incongruity of more prenatal care and more preterm births; however, these data suggest that women with intensive prenatal care utilization also have a lower infant mortality rate.	US Hlth Resources & Serv Adm, Maternal & Chil Hlth Bur, Rockville, MD 20857 USA; Univ Alabama Birmingham, Dept Maternal & Child Hlth, Birmingham, AL USA; Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Univ Paris 05, Dept Obstet & Gynecol, Paris, France	United States Health Resources & Service Administration (HRSA); University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); UDICE-French Research Universities; Universite Paris Cite	Kogan, MD (corresponding author), US Hlth Resources & Serv Adm, Maternal & Chil Hlth Bur, 5600 Fishers Ln,Room 18A-55, Rockville, MD 20857 USA.	mkogan@hrsa.gov			PHS HHS [MCJ-107, MCJ-9040] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alexander G R, 1996, J Perinatol, V16, P53; Alexander GR, 1998, CLIN OBSTET GYNECOL, V41, P115, DOI 10.1097/00003081-199803000-00017; Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; ALEXANDER GR, 1987, AM J PREV MED, V3, P243; Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; *AM COLL OBST GYN, 1974, STAND OBST GYN SERV; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; BUEKENS P, 1993, AM J OBSTET GYNECOL, V168, P937, DOI 10.1016/S0002-9378(12)90849-2; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P185; Cooperstock M, 1998, PAEDIATR PERINAT EP, V12, P347, DOI 10.1046/j.1365-3016.1998.00114.x; Daltveit AK, 1999, AM J EPIDEMIOL, V149, P1128; DEROM C, 1993, FERTIL STERIL, V60, P493; Dhont M, 1997, J ASSIST REPROD GEN, V14, P575, DOI 10.1023/A:1022576500894; Emery ES, 1997, PAEDIATR PERINAT EP, V11, P313; FISCELLA K, 1995, OBSTET GYNECOL, V85, P468, DOI 10.1016/0029-7844(94)00408-6; Fitzsimmons BP, 1998, AM J OBSTET GYNECOL, V179, P1162, DOI 10.1016/S0002-9378(98)70125-5; Friedman SA, 1997, AM J OBSTET GYNECOL, V176, P1193, DOI 10.1016/S0002-9378(97)70334-X; Gardner MO, 1996, CURR OPIN OBSTET GYN, V8, P106; GARDNER MO, 1995, OBSTET GYNECOL, V85, P553, DOI 10.1016/0029-7844(94)00455-M; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; Joseph KS, 1998, NEW ENGL J MED, V339, P1434, DOI 10.1056/NEJM199811123392004; KEITH LG, 1995, MULTIPLE PREGNANCY E, V163, P174; Khan-Neelofur D, 1998, PAEDIATR PERINAT EP, V12, P7, DOI 10.1046/j.1365-3016.12.s2.6.x; KIELY JL, 1990, B NEW YORK ACAD MED, V66, P618; KLEINMAN JC, 1991, AM J EPIDEMIOL, V133, P133, DOI 10.1093/oxfordjournals.aje.a115852; Kogan MD, 1998, PEDIATRICS, V102, P25, DOI 10.1542/peds.102.1.25; Kogan MD, 1998, JAMA-J AM MED ASSOC, V279, P1623, DOI 10.1001/jama.279.20.1623; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Kramer MS, 1999, JAMA-J AM MED ASSOC, V281, P705; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Kramer MS, 1998, JAMA-J AM MED ASSOC, V280, P1849, DOI 10.1001/jama.280.21.1849; Luke B., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P333; LUKE B, 1993, AM J OBSTET GYNECOL, V169, P588, DOI 10.1016/0002-9378(93)90628-V; MacDorman M F, 1999, Natl Vital Stat Rep, V47, P1; MARTIN JA, 1999, NATL VITAL STAT REP, P47; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; Misra DP, 1998, JAMA-J AM MED ASSOC, V279, P1661, DOI 10.1001/jama.279.20.1661; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; MUSTARD CA, 1994, AM J PUBLIC HEALTH, V84, P1450, DOI 10.2105/AJPH.84.9.1450; *NAT CTR HLTH STAT, 1992, VIT STAT US 1992 NAT, V1; PANETH N, 1990, AM J PUBLIC HEALTH, V80, P791, DOI 10.2105/AJPH.80.7.791; PANETH NS, 1995, FUTURE CHILD, V5, P19, DOI 10.2307/1602505; ROBERTSON CMT, 1992, PEDIATRICS, V90, P750; ROBERTSON PA, 1992, AM J OBSTET GYNECOL, V166, P1629, DOI 10.1016/0002-9378(92)91551-K; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SCHWARTZ RM, IN PRESS MAT CHILD H; TAFFEL S, 1982, VITAL HLTH STAT, V2; Ventura S J, 1999, Natl Vital Stat Rep, V47, P1; Wilcox LS, 1996, FERTIL STERIL, V65, P361, DOI 10.1016/S0015-0282(16)58100-X	51	117	119	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					335	341		10.1001/jama.284.3.335	http://dx.doi.org/10.1001/jama.284.3.335			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333GR	10891965	Bronze			2022-12-28	WOS:000088123000026
J	Slonczewski, J				Slonczewski, J			Tuberculosis bacteria join UN - WHO proposes to include disinfectant under the Geneva Convention.	NATURE			English	Article									Kenyon Coll, Gambier, OH 43022 USA	Kenyon College	Slonczewski, J (corresponding author), Kenyon Coll, Gambier, OH 43022 USA.								0	2	2	1	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1001	1001		10.1038/35016664	http://dx.doi.org/10.1038/35016664			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890424	Bronze			2022-12-28	WOS:000087871700024
J	Wongsrichanalai, C; Thimasarn, K; Sirichaisinthop, J				Wongsrichanalai, C; Thimasarn, K; Sirichaisinthop, J			Antimalarial drug combination policy: a caveat	LANCET			English	Editorial Material							RESISTANT FALCIPARUM-MALARIA; IN-VITRO ACTIVITY; PLASMODIUM-FALCIPARUM; ARTEMISININ DERIVATIVES; THAILAND		Armed Forces Res Inst Med Sci, Dept Immunol, Bangkok 10400, Thailand; Minist Publ Hlth, Dept Communicable Dis Control, Nonthaburi, Thailand; Minist Publ Hlth, Dept Communicable Dis Control, Off Vector Borne Dis Control 1, Malaria Div, Saraburi, Thailand	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Ministry of Public Health - Thailand; Ministry of Public Health - Thailand	Wongsrichanalai, C (corresponding author), Armed Forces Res Inst Med Sci, Dept Immunol, Bangkok 10400, Thailand.							BASCO LK, 1993, AM J TROP MED HYG, V49, P301, DOI 10.4269/ajtmh.1993.49.301; Brundtland G. H., 1998, 51 WORLD HLTH ASS GE; BUSTOS MDG, 1994, B WORLD HEALTH ORGAN, V72, P729; *DEP COMM DIS CONT, 1992, ANN REP MAL DIV; *DEP COMM DIS CONT, 1993, ANN REP MAL DIV; FONTANET AL, 1993, AM J TROP MED HYG, V49, P465, DOI 10.4269/ajtmh.1993.49.465; KETRANGSEE S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P55; Kyle D E, 1998, Med Trop (Mars), V58, P38; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; Pradines B, 1998, AM J TROP MED HYG, V58, P354, DOI 10.4269/ajtmh.1998.58.354; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Thimasarn K, 1995, Southeast Asian J Trop Med Public Health, V26, P204; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; Wernsdorfer W. H., 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P11; WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4; White NJ, 1998, BRIT MED BULL, V54, P703, DOI 10.1093/oxfordjournals.bmb.a011721; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; WONGSRICHANALAI C, 1992, AM J TROP MED HYG, V47, P112, DOI 10.4269/ajtmh.1992.47.112; Wongsrichanalai C, 1999, B WORLD HEALTH ORGAN, V77, P392	20	23	24	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2245	2247		10.1016/S0140-6736(00)02416-8	http://dx.doi.org/10.1016/S0140-6736(00)02416-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881909				2022-12-28	WOS:000087779000042
J	Lee, HK; Barbarosie, M; Kameyama, K; Bear, MF; Huganir, RL				Lee, HK; Barbarosie, M; Kameyama, K; Bear, MF; Huganir, RL			Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity	NATURE			English	Article							LONG-TERM POTENTIATION; DEPENDENT KINASE-II; GLUTAMATE RECEPTORS; GLUR1 SUBUNIT; DEPRESSION; HIPPOCAMPUS; MEMORY; CONDUCTANCE; INVOLVEMENT; EXPRESSION	Bidirectional changes in the efficacy of neuronal synaptic transmission, such as hippocampal long-term potentiation (LTP) and long-term depression (LTD), are thought to be mechanisms for information storage in the brain(1-4). LTP and LTD may be mediated by the modulation of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazloe proprionic acid) receptor phosphorylation(5-7). Here we show that LTP and LTD reversibly modify the phosphorylation of the AMPA receptor GluR1 subunit. However, contrary to the hypothesis that LTP and LTD are the functional inverse of each other, we rnd that they are associated with phosphorylation and dephosphorylation, respectively, of distinct GluR1 phosphorylation sites. Moreover, the site modulated depends on the stimulation history of the synapse. LTD induction in naive synapses dephosphorylates the major cyclic-AMP-dependent protein kinase (PKA) site, whereas in potentiated synapses the major calcium/calmodulin-dependent protein kinase II (CaMKII) site is dephosphorylated. Conversely, LTP induction in naive synapses and depressed synapses increases phosphorylation of the CaMKII site and the PKA site, respectively. LTP is differentially sensitive to CaMKII and PKA inhibitors depending on the history of the synapse. These results indicate that AMPA receptor phosphorylation is critical for synaptic plasticity, and that identical stimulation conditions recruit different signal-transduction pathways depending on synaptic history.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Brown Univ, Dept Neurosci, Howard Hughes Med Inst, Providence, RI 02912 USA; Natl Inst Biosci & Human Technol, Mol Neurobiol Lab, Tsukuba, Ibaraki 3058566, Japan	Howard Hughes Medical Institute; Johns Hopkins University; Brown University; Howard Hughes Medical Institute; National Institute of Advanced Industrial Science & Technology (AIST)	Huganir, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA.		Kameyama, Kimihiko/M-6672-2018	Kameyama, Kimihiko/0000-0003-2550-3651; Bear, Mark/0000-0002-9903-2541				ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	27	819	847	1	68	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					955	959		10.1038/35016089	http://dx.doi.org/10.1038/35016089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879537				2022-12-28	WOS:000087732700052
J	Poulin, C				Poulin, C			Prevention of paracetamol poisoning	LANCET			English	Editorial Material									Dalhousie Univ, Fac Med, Halifax, NS BEH 4H7, Canada	Dalhousie University	Poulin, C (corresponding author), Dalhousie Univ, Fac Med, Halifax, NS BEH 4H7, Canada.							Bond GR, 1999, ACAD EMERG MED, V6, P1115, DOI 10.1111/j.1553-2712.1999.tb00113.x; Gunnell D, 1997, J EPIDEMIOL COMMUN H, V51, P175, DOI 10.1136/jech.51.2.175; Hawton K, 1996, BRIT J PSYCHIAT, V168, P43, DOI 10.1192/bjp.168.1.43; McLoone P, 1996, BRIT J PSYCHIAT, V169, P81, DOI 10.1192/bjp.169.1.81	4	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2009	2010		10.1016/S0140-6736(00)02342-4	http://dx.doi.org/10.1016/S0140-6736(00)02342-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885347				2022-12-28	WOS:000087519400003
J	Storek, J; Storb, R				Storek, J; Storb, R			T-cell reconstitution after stem-cell transplantation - by which organ?	LANCET			English	Editorial Material							AGE		Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Storek, J (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98109 USA.							DEJBAKHSHJONES S, 1995, J IMMUNOL, V155, P3338; JENDRO MC, 1995, ARTHRITIS RHEUM, V38, P1242, DOI 10.1002/art.1780380912; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1998, EUR J IMMUNOL, V28, P1886, DOI 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M; ROCHA B, 1990, EUR J IMMUNOL, V20, P919, DOI 10.1002/eji.1830200430; STOREK J, 1995, BONE MARROW TRANSPL, V16, P413; STOREK J, 2000, CLIN BONE MARROW BLO, P111; Weinberg K, 1995, Biol Blood Marrow Transplant, V1, P18	8	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1843	1844		10.1016/S0140-6736(00)02284-4	http://dx.doi.org/10.1016/S0140-6736(00)02284-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866436				2022-12-28	WOS:000087306500006
J	Scully, C; Porter, S				Scully, C; Porter, S			ABC of oral health - Oral cancer	BRITISH MEDICAL JOURNAL			English	Review							CARCINOMA		Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England	University of London; University College London	Scully, C (corresponding author), Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England.			Porter, Stephen/0000-0002-3328-2759				Allison PJ, 1999, ORAL ONCOL, V35, P138, DOI 10.1016/S1368-8375(98)00108-0; *CANC RES CAMP, 1993, FACTSH 14 1; Prince S, 1999, BRIT J ORAL MAX SURG, V37, P164, DOI 10.1054/bjom.1999.0031; Rodrigues VC, 1998, ORAL ONCOL, V34, P454, DOI 10.1016/S1368-8375(98)00052-9; Rogers SN, 1999, J CRANIO MAXILL SURG, V27, P187, DOI 10.1016/S1010-5182(99)80049-3; Schepman KP, 1999, ORAL DIS, V5, P206; Sciubba JJ, 1999, J AM DENT ASSOC, V130, P1445, DOI 10.14219/jada.archive.1999.0055; Scully C, 1995, CRIT REV ONCOL HEMAT, V21, P63, DOI 10.1016/1040-8428(94)00165-0	8	48	54	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					97	100		10.1136/bmj.321.7253.97	http://dx.doi.org/10.1136/bmj.321.7253.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884263	Green Published			2022-12-28	WOS:000088196600029
J	Friedman, JR; Patel, V; Chen, W; Tolpygo, SK; Lukens, JE				Friedman, JR; Patel, V; Chen, W; Tolpygo, SK; Lukens, JE			Quantum superposition of distinct macroscopic states	NATURE			English	Article							MAGNETIZATION; TEMPERATURE; MOLECULES	In 1935, Schrodinger(1) attempted to demonstrate the limitations of quantum mechanics using a thought experiment in which a cat is put in a quantum superposition of alive and dead states. The idea remained an academic curiosity until the 1980s when it was proposed(2-4) that, under suitable conditions, a macroscopic object with many microscopic degrees of freedom could behave quantum mechanically, provided that it was sufficiently decoupled from its environment. Although much progress has been made in demonstrating the macroscopic quantum behaviour of various systems such as superconductors(5-9), nanoscale magnets(10-12), laser-cooled trapped ions(13), photons in a microwave cavity(14) and C-60 molecules(15), there has been no experimental demonstration of a quantum superposition of truly macroscopically distinct states. Here we present experimental evidence that a superconducting quantum interference device (SQUID) can be put into a superposition of two magnetic-flux states: one corresponding to a few microamperes of current flowing clockwise, the other corresponding to the same amount of current flowing anticlockwise.	SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Friedman, JR (corresponding author), SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA.		Friedman, Jonathan/A-6323-2008	Friedman, Jonathan/0000-0003-3614-4623				Arndt M, 1999, NATURE, V401, P680, DOI 10.1038/44348; AVERIN D, 2000, CONDMAT0005081; Brune M, 1996, PHYS REV LETT, V77, P4887, DOI 10.1103/PhysRevLett.77.4887; CALDEIRA AO, 1981, PHYS REV LETT, V46, P211, DOI 10.1103/PhysRevLett.46.211; CLARKE J, 1988, SCIENCE, V239, P992, DOI 10.1126/science.239.4843.992; del Barco E, 1999, EUROPHYS LETT, V47, P722, DOI 10.1209/epl/i1999-00450-8; Friedman JR, 1996, PHYS REV LETT, V76, P3830, DOI 10.1103/PhysRevLett.76.3830; LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/RevModPhys.59.1; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; ROUSE R, 1995, PHYS REV LETT, V75, P1614, DOI 10.1103/PhysRevLett.75.1614; Rouse R, 1998, PROCEEDINGS OF THE SECOND INTERNATIONAL CONFERENCE ON PHENOMENOLOGY OF UNIFICATION FROM PRESENT TO FUTURE, P207; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]; Silvestrini P, 1997, PHYS REV LETT, V79, P3046, DOI 10.1103/PhysRevLett.79.3046; WEISS U, 1987, J LOW TEMP PHYS, V68, P213, DOI 10.1007/BF00683900; Wernsdorfer W, 1997, PHYS REV LETT, V79, P4014, DOI 10.1103/PhysRevLett.79.4014	18	915	989	7	143	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					43	46		10.1038/35017505	http://dx.doi.org/10.1038/35017505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894533				2022-12-28	WOS:000087991200036
J	Hoeflich, KP; Luo, J; Rubie, EA; Tsao, MS; Jin, O; Woodgett, JR				Hoeflich, KP; Luo, J; Rubie, EA; Tsao, MS; Jin, O; Woodgett, JR			Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappa B activation	NATURE			English	Article							INDUCED APOPTOSIS; XENOPUS EMBRYOS; KINASE; LITHIUM; DEATH; MICE; AKT; INHIBITION; LETHALITY; 3-KINASE	Glycogen synthase kinase-3 (GSK-3)-alpha and -beta are closely related protein-serine kinases, which act as inhibitory components of Wnt signalling during embryonic development and cell proliferation in adult tissues(1,2). Insight into the physiological function of GSK-3 has emerged from genetic analysis in Drosophila(3,4), Dictyostelium(5) and yeast(6,7). Here we show that disruption of the murine GSK-3 beta gene results in embryonic lethality caused by severe liver degeneration during mid-gestation, a phenotype consistent with excessive tumour necrosis factor (TNF) toxicity, as observed in mice lacking genes involved in the activation of the transcription factor activation NF-kappa B. GSK-3 beta-dercient embryos were rescued by inhibition of TNF using an anti-TNF-alpha antibody. Fibroblasts from GSK-3b-dercient embryos were hypersensitive to TNF-alpha and showed reduced NF-kappa B function. Lithium treatment (which inhibits GSK-3; refs 8, 9) sensitized wild-type fibroblasts to TNF and inhibited transactivation of NF-kappa B. The early steps leading to NF-kappa B activation (degradation of I-kappa B and translocation of NF-kappa B to the nucleus) were unaffected by the loss of GSK-3b, indicating that NF-kappa B is regulated by GSK-3b at the level of the transcriptional complex. Thus, GSK-3b facilitates NF-kappa B function.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Woodgett, JR (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jwoodgett@uhnres.utoronto.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Woodgett, Jim/F-1087-2010	Tsao, Ming Sound/0000-0002-9160-5405; Woodgett, Jim/0000-0003-3731-5797				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BEYAERT R, 1989, P NATL ACAD SCI USA, V86, P9494, DOI 10.1073/pnas.86.23.9494; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DALE TC, 1998, BIOCHEM J, V239, P209; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Nasevicius A, 1998, DEVELOPMENT, V125, P4283; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Ozes ON, 1999, NATURE, V401, P82; Plyte SE, 1996, MOL CELL BIOL, V16, P179; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	30	1171	1240	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					86	90		10.1038/35017574	http://dx.doi.org/10.1038/35017574			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894547				2022-12-28	WOS:000087991200050
J	Reid, SD; Herbelin, CJ; Bumbaugh, AC; Selander, RK; Whittam, TS				Reid, SD; Herbelin, CJ; Bumbaugh, AC; Selander, RK; Whittam, TS			Parallel evolution of virulence in pathogenic Escherichia coli	NATURE			English	Article							ENTEROCYTE EFFACEMENT; STRAINS; RECOMBINATION; MUTATION; DIARRHEA; INTIMIN; LOCUS	The mechanisms underlying the evolution and emergence of new bacterial pathogens are not well understood. To elucidate the evolution of pathogenic Escherichia coli strains, here we sequenced seven housekeeping genes to build a phylogenetic tree and trace the history of the acquisition of virulence genes. Compatibility analysis indicates that more than 70% of the informative sites agree with a single phylogeny, suggesting that recombination has not completely obscured the remnants of ancestral chromosomes(1-3). On the basis of the rate of synonymous substitution for E. coli and Salmonella enterica (4.7 x 10(-9) per site per year(3)), the radiation of clones began about 9 million years ago and the highly virulent pathogen responsible for epidemics of food poisoning, E. coli O157:H7, separated from a common ancestor of E. coli K-12 as long as 4.5 million years ago. Phylogenetic analysis reveals that old lineages of E. coli have acquired the same virulence factors in parallel, including a pathogenicity island involved in intestinal adhesion, a plasmid-borne haemolysin, and phage-encoded Shiga toxins. Such parallel evolution indicates that natural selection has favoured an ordered acquisition of genes and the progressive build-up of molecular mechanisms that increase virulence.	Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Whittam, TS (corresponding author), Penn State Univ, Inst Mol Evolutionary Genet, University Pk, PA 16802 USA.	tswl@psu.edu						Bandelt HJ, 1992, MOL PHYLOGENET EVOL, V1, P242, DOI 10.1016/1055-7903(92)90021-8; Boyd EF, 1998, J BACTERIOL, V180, P1159, DOI 10.1128/JB.180.5.1159-1165.1998; DOPAZO J, 1993, P NATL ACAD SCI USA, V90, P10320, DOI 10.1073/pnas.90.21.10320; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Feng P, 1998, J INFECT DIS, V177, P1750, DOI 10.1086/517438; GUTTMAN DS, 1994, SCIENCE, V266, P1380, DOI 10.1126/science.7973728; Holmes EC, 1999, MOL BIOL EVOL, V16, P741, DOI 10.1093/oxfordjournals.molbev.a026159; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jakobsen IB, 1996, COMPUT APPL BIOSCI, V12, P291; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Kumar S., 1993, MEGA MOL EVOLUTIONAR; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Li W. H, 1997, MOL EVOLUTION; McGraw EA, 1999, MOL BIOL EVOL, V16, P12, DOI 10.1093/oxfordjournals.molbev.a026032; MILKMAN R, 1996, ESCHERICHIA COLI SAL, P2663; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; OBrien AD., 1998, ESCHERICHIA COLI O15, P183; Reid SD, 1999, J CLIN MICROBIOL, V37, P2719, DOI 10.1128/JCM.37.8.2719-2722.1999; Schmidt H, 1996, J CLIN MICROBIOL, V34, P2364, DOI 10.1128/JCM.34.10.2364-2367.1996; SCHMIDT H, 1995, INFECT IMMUN, V63, P1055, DOI 10.1128/IAI.63.3.1055-1061.1995; Sperandio V, 1998, FEMS MICROBIOL LETT, V164, P133, DOI 10.1016/S0378-1097(98)00205-5; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang FS, 1997, J BACTERIOL, V179, P6551, DOI 10.1128/jb.179.21.6551-6559.1997; Whittam T. S., 1998, ESCHERICHIA COLI O15, P195; WHITTAM TS, 1993, INFECT IMMUN, V61, P1619, DOI 10.1128/IAI.61.5.1619-1629.1993; Wieler LH, 1997, FEMS MICROBIOL LETT, V156, P49, DOI 10.1016/S0378-1097(97)00403-5	29	384	394	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					64	67		10.1038/35017546	http://dx.doi.org/10.1038/35017546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894541				2022-12-28	WOS:000087991200044
J	Ainsworth, M; Teokul, W				Ainsworth, M; Teokul, W			Breaking the silence: setting realistic priorities for AIDS control in less-developed countries	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; SUB-SAHARAN AFRICA; HIV-INFECTION; ANTIRETROVIRAL THERAPY; UGANDA; SEROPREVALENCE; PREVENTION; PROGRAM; COHORT; TRIAL	The AIDS pandemic is a human tragedy that is threatening development in the poorest countries. There is no cure or vaccine, but the tools to control the epidemic already exist. Nevertheless, there are few examples of national AIDS control programmes that have had an impact on the epidemic. We (an economist and a planner) attribute this to the reluctance of governments to confront AIDS and a failure to prioritise activities in the face of severe financial and administrative constraints. When implementation capacity is weak, expanding the number of activities may not improve programme effectiveness. Rather, by implementing a smaller, core set of the most cost-effective activities on a national scale, policymakers could have a huge effect on the overall epidemic in a sustained way and provide a foundation for expansion. We propose three core priorities for AIDS control in poor countries for prevention, treatment, and mitigation of the impact.	World Bank, Dev Res Grp, Washington, DC 20433 USA; Off Prime Minister, Natl Econ & Social Dev Board, Bangkok, Thailand	The World Bank	Teokul, W (corresponding author), 962 Krungkasem Rd, Bangkok 10100, Thailand.							AINSWORTH M, 1999, 5 INT C AIDS AS PAC; Ainsworth M., 1998, CONFRONTING AIDS EVI; Ainsworth M, 2000, 2266 WORLD BANK DEV; Aral SO, 1998, LANCET, V351, P33; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; Bernstein RS, 1998, INTERFACES, V28, P101, DOI 10.1287/inte.28.3.101; Caldwell JC, 2000, POPUL DEV REV, V26, P117, DOI 10.1111/j.1728-4457.2000.00117.x; Celentano DD, 1998, AIDS, V12, pF29, DOI 10.1097/00002030-199805000-00004; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hogg RS, 1997, LANCET, V350, P1406, DOI 10.1016/S0140-6736(05)65188-4; *KINGD CAMB, 1999, CAMB POV ASS; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; MERSON MH, IN PRESS AIDS, V2; *MIN PUBL HLTH DIV, 1999, MONTHL EP SURV REP, V30; MOSES S, 1991, AIDS, V5, P407, DOI 10.1097/00002030-199104000-00008; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; Muller O, 1998, LANCET, V351, P68, DOI 10.1016/S0140-6736(05)78051-X; OVER M, 1993, DIS CONTROL PRIORITI; Over M., 1998, CONFRONTING AIDS EVI; PHOOLCHAROEN W, 1998, THAILAND LESSONS STR; Reich MR, 2000, SCIENCE, V287, P1979, DOI 10.1126/science.287.5460.1979; Rojanapithayakorn W, 1996, AIDS, V10, P1, DOI 10.1097/00002030-199601000-00001; SERWADDA D, 1995, 9 INT C AIDS STDS AF; TEOKUL W, 2000, SUBR SEM HIV AIDS EC; Thomas JC, 1996, J INFECT DIS, V174, pS134, DOI 10.1093/infdis/174.Supplement_2.S134; *UNAIDS, 1999, AIDS EP UPD DEC 1999; *UNAIDS, 1999, M UNAIDS COSP AG SEC; *UNAIDS, 1999, AIDS MOV 4TH PLAC WO; UNAIDS, 1998, EXP GLOB RESP HIV AI; *UNAIDS WELLC TRUS, 1999, TRENDS HIV INC PREV; VANVLIET C, 1998, CONFRONTING AIDS EVI; Wawer MJ, 1997, AIDS, V11, P1023, DOI 10.1097/00002030-199708000-00011; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; WHITE J, 2000, POLICY SERIES NATURA, V6; World Bank, 1999, CONFR AIDS PUBL PRIO; *WORLD BANK, 2000, WORLD DEV IND 2000; *WORLD BANK, 1999, WORLD DEV IND 1999; *WORLD BANK AIDS V, 2000, ACC AIDS VACC DEV CO	40	73	75	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					55	60		10.1016/S0140-6736(00)02440-5	http://dx.doi.org/10.1016/S0140-6736(00)02440-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892777				2022-12-28	WOS:000087933400040
J	Atkinson, MA				Atkinson, MA			The $64000 question in diabetes continues...	LANCET			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; STIFF-MAN SYNDROME; AUTOANTIBODIES		Univ Florida, Dept Pathol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Atkinson, MA (corresponding author), Univ Florida, Dept Pathol, Gainesville, FL 32610 USA.							BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Dinkel K, 1998, ANN NEUROL, V44, P194, DOI 10.1002/ana.410440209; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; JONES DB, 1990, LANCET, V336, P583, DOI 10.1016/0140-6736(90)93390-B; Leslie RDG, 1999, DIABETOLOGIA, V42, P3, DOI 10.1007/s001250051105; Levy Lucien M., 1999, Annals of Internal Medicine, V131, P522; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; 1990, LANCET, V336, P597	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					4	6		10.1016/S0140-6736(00)02421-1	http://dx.doi.org/10.1016/S0140-6736(00)02421-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892753				2022-12-28	WOS:000087933400003
J	He, ZH; Wang, ZY; Li, JM; Zhu, Q; Lamb, C; Ronald, P; Chory, J				He, ZH; Wang, ZY; Li, JM; Zhu, Q; Lamb, C; Ronald, P; Chory, J			Perception of brassinosteroids by the extracellular domain of the receptor kinase BRI1	SCIENCE			English	Article							GENE ENCODES; ARABIDOPSIS; CLONING; SHOOT	An assay was developed to study plant receptor kinase activation and signaling mechanisms. The extracellular leucine-rich repeat (LRR) and transmembrane domains of the Arabidopsis receptor kinase BRI1, which is implicated in brassinosteroid signaling, were fused to the serine/threonine kinase domain of XA21, the rice disease resistance receptor. The chimeric receptor initiates plant defense responses in rice cells upon treatment with brassinosteroids. These results, which indicate that the extracellular domain of BRI1 perceives brassinosteroids, suggest a general signaling mechanism for the LRR receptor kinases of plants. This system should allow the discovery of ligands for the LRR kinases, the largest group of plant receptor kinases.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; Zhejiang Univ, Inst Biotechnol, Hangzhou 310029, Peoples R China	Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California Davis; Zhejiang University	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	chory@salk.edu	Wang, Zhi-Yong/E-3810-2012; Ronald, Pamela/AAK-7664-2020; Li, Jianming/O-1772-2014	Wang, Zhi-Yong/0000-0003-4602-3390; Li, Jianming/0000-0003-3231-0778; He, Zuhua/0000-0002-6098-7893				Becraft PW, 1998, TRENDS PLANT SCI, V3, P384, DOI 10.1016/S1360-1385(98)01301-6; Chen L, 1998, PLANT CELL REP, V18, P25, DOI 10.1007/s002990050526; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; FRIEDRICHSEN D, IN PRESS PLANT PHYSL; HE ZT, UNPUB; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Lease K, 1998, CURR OPIN PLANT BIOL, V1, P388, DOI 10.1016/S1369-5266(98)80261-6; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LIN TL, 2000, GENE DEV, V14, P108; Martin GB, 1999, CURR OPIN PLANT BIOL, V2, P273, DOI 10.1016/S1369-5266(99)80049-1; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; SONG W, UNPUB; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Yi SY, 1999, MOL CELLS, V9, P320; YOSHIKAWA M, UNPUB; Zhu Q, 1995, PLANT MOL BIOL, V29, P535, DOI 10.1007/BF00020983; ZHU Q, 1991, MOL GEN GENET, V226, P289, DOI 10.1007/BF00273615	23	324	372	4	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2360	2363		10.1126/science.288.5475.2360	http://dx.doi.org/10.1126/science.288.5475.2360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875920	Green Published			2022-12-28	WOS:000087913400038
J	Robertson, BA				Robertson, BA			The patient's heart	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3173	3174		10.1001/jama.283.24.3173	http://dx.doi.org/10.1001/jama.283.24.3173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866844				2022-12-28	WOS:000087753900001
J	Bear, JE; Loureiro, JJ; Libova, I; Fassler, R; Wehland, J; Gertler, FB				Bear, JE; Loureiro, JJ; Libova, I; Fassler, R; Wehland, J; Gertler, FB			Negative regulation of fibroblast motility by Ena/VASP proteins	CELL			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIN-BASED MOTILITY; LISTERIA-MONOCYTOGENES; SPATIAL CONTROL; HUMAN PLATELETS; FOCAL ADHESION; EVH1 DOMAIN; VASP; BINDING; DROSOPHILA	Ena/VASP proteins have been implicated in cell motility through regulation of the actin cytoskeleton and are found at focal adhesions and the leading edge. Using overexpression, loss-of-function, and inhibitory approaches, we find that Ena/VASP proteins negatively regulate fibroblast motility. A close-dependent decrease in movement is observed when Ena/VASP proteins are overexpressed in fibroblasts. Neutralization or deletion of all Ena/VASP proteins results in increased cell movement. Selective depletion of Ena/VASP proteins from focal adhesions, but not the leading edge, has no effect on motility. Constitutive membrane targeting of Ena/VASP proteins inhibits motility. These results are in marked contrast to current models for Ena/VASP function derived mainly from their role in the actin-driven movement of Listeria monocytogenes.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Lund Hosp, S-22185 Lund, Sweden; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany	Massachusetts Institute of Technology (MIT); Lund University; Skane University Hospital; Gesellschaft fur Biotechnologische Forschung mbH	Gertler, FB (corresponding author), MIT, Dept Biol, Cambridge, MA 02139 USA.	fgertler@mit.edu			NIGMS NIH HHS [GM58801] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058801] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; HALBRUGGE M, 1990, J CHROMATOGR, V521, P335, DOI 10.1016/0021-9673(90)85057-3; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Wills Z, 1999, NEURON, V22, P301, DOI 10.1016/S0896-6273(00)81091-0	37	370	382	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					717	728		10.1016/S0092-8674(00)80884-3	http://dx.doi.org/10.1016/S0092-8674(00)80884-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892743	Green Published, Bronze			2022-12-28	WOS:000087821400006
J	Bergeron, V; Bonn, D; Martin, JY; Vovelle, L				Bergeron, V; Bonn, D; Martin, JY; Vovelle, L			Controlling droplet deposition with polymer additives	NATURE			English	Article							SOLID-SURFACE; LIQUID-FILMS; IMPACT; THIN	Controlling the impact of drops onto solid surfaces is important for a wide variety of coating and deposition processes-for example, the treatment of plants with herbicides and pesticides requires precise targeting in order to meet stringent toxicological regulations. However, the outer wax-like layer of the leaves is a non-wetting substrate that causes sprayed droplets to rebound; often less than 50% of the initial spray is retained by the plant(1). Although the impact and subsequent retraction of non-wetting aqueous drops on a hydrophobic surface have been the subjects of extensive experimental and theoretical work(2-7), non-newtonian rheological effects have not been considered in any detail. Here we report that, by adding very small amounts of a flexible polymer to the aqueous phase, we can inhibit droplet rebound on a hydrophobic surface and markedly improve deposition without significantly altering the shear viscosity of the solutions. Our results can be understood by taking into account the non-newtonian elongational viscosity, which provides a large resistance to drop retraction after impact, thereby suppressing droplet rebound.	Rhodia Rech, Ctr Rech Lyon, F-69192 St Fons, France; Ecole Normale Super, Lab Phys Stat, F-75231 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite	Bergeron, V (corresponding author), Rhodia Rech, Ctr Rech Lyon, 85 Av Des Freres Perret BP62, F-69192 St Fons, France.	vance.bergeron@rhone-poulenc.com	Bonn, Daniel/F-9928-2011					BENNETT T, 1993, J MATER SCI, V28, P963, DOI 10.1007/BF00400880; Bergeron V, 1998, French Patent Application, Patent No. 9810471; BERGERON V, 1999, Patent No. 02002; BIRD RB, 1987, DYNAMICS POLYM LIQUI, V2, P495; BIRD RB, 1987, DYNAMICS POLYM LIQUI, V1, P495; CHANDRA S, 1991, P R SOC-MATH PHYS SC, V432, P13, DOI 10.1098/rspa.1991.0002; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; Dontula P, 1997, RHEOL ACTA, V36, P429, DOI 10.1007/BF00396329; FUKAI J, 1995, PHYS FLUIDS, V7, P236, DOI 10.1063/1.868622; HAYES RA, 1993, J COLLOID INTERF SCI, V159, P429, DOI 10.1006/jcis.1993.1343; HUDSON NE, 1993, J NON-NEWTON FLUID, V46, P69, DOI 10.1016/0377-0257(93)80004-U; Mao T, 1997, AICHE J, V43, P2169, DOI 10.1002/aic.690430903; REIN M, 1993, FLUID DYN RES, V12, P61, DOI 10.1016/0169-5983(93)90106-K; SCHELLER BL, 1995, AICHE J, V41, P1357, DOI 10.1002/aic.690410602; TANNER RI, 1992, ENG RHEOLOGY, P168; WIRTH W, 1991, PESTIC SCI, V33, P411, DOI 10.1002/ps.2780330403; YERUSHALMIROZEN R, 1995, LANGMUIR, V11, P2806, DOI 10.1021/la00007a074; YERUSHALMIROZEN R, 1994, SCIENCE, V263, P793, DOI 10.1126/science.263.5148.793	18	448	482	18	264	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					772	775		10.1038/35015525	http://dx.doi.org/10.1038/35015525			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866193				2022-12-28	WOS:000087620600044
J	Gottlieb, S				Gottlieb, S			In vitro fertilisation is preferable to fertility drugs	BRITISH MEDICAL JOURNAL			English	News Item																		Gleicher N, 2000, NEW ENGL J MED, V343, P2, DOI 10.1056/NEJM200007063430101	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					134	134						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894685				2022-12-28	WOS:000088305700013
J	Popeijus, H; Overmars, H; Jones, J; Blok, V; Goverse, A; Helder, J; Schots, A; Bakker, J; Smant, G				Popeijus, H; Overmars, H; Jones, J; Blok, V; Goverse, A; Helder, J; Schots, A; Bakker, J; Smant, G			Enzymology - Degradation of plant cell walls by a nematode	NATURE			English	Article							CELLULASE		Agr Univ Wageningen, Dept Plant Sci, Grad Sch Expt Plant Sci, Nematol Lab, NL-6708 PD Wageningen, Netherlands; Agr Univ Wageningen, Dept Plant Sci, Grad Sch Expt Plant Sci, Lab Monoclonal Antibodies, NL-6708 PD Wageningen, Netherlands; Scottish Crop Res Inst, Dept Nematol, Dundee DD2 5DA, Scotland	Wageningen University & Research; Wageningen University & Research; James Hutton Institute	Popeijus, H (corresponding author), Agr Univ Wageningen, Dept Plant Sci, Grad Sch Expt Plant Sci, Nematol Lab, Binnenhaven 10, NL-6708 PD Wageningen, Netherlands.		Schots, Arjen/ABF-8014-2020; Schots, Arjen/U-1839-2017	Schots, Arjen/0000-0002-6036-7088; Schots, Arjen/0000-0002-6036-7088; Jones, John/0000-0003-2074-0551				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Byrne KA, 1999, GENE, V239, P317, DOI 10.1016/S0378-1119(99)00396-0; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; deBoer JM, 1996, MOL PLANT MICROBE IN, V9, P39, DOI 10.1094/MPMI-9-0039; Shevchik VE, 1997, J BACTERIOL, V179, P7321, DOI 10.1128/jb.179.23.7321-7330.1997; Smant G, 1998, P NATL ACAD SCI USA, V95, P4906, DOI 10.1073/pnas.95.9.4906; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Watanabe H, 1998, NATURE, V394, P330, DOI 10.1038/28527	8	134	150	3	47	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					36	37		10.1038/35017641	http://dx.doi.org/10.1038/35017641			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894530				2022-12-28	WOS:000087991200033
J	Coventry, J; Griffiths, G; Scully, C; Tonetti, M				Coventry, J; Griffiths, G; Scully, C; Tonetti, M			ABC of oral health - Periodontal disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London, England	University of London; University College London	Coventry, J (corresponding author), Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London, England.		Tonetti, Maurizio/ABE-2947-2020					Beck JD, 1999, AM HEART J, V138, pS528, DOI 10.1016/S0002-8703(99)70293-0; Birkenfeld L, 1999, MENOPAUSE, V6, P129; Moore PA, 1999, J PERIODONTOL, V70, P409, DOI 10.1902/jop.1999.70.4.409; Morrison HI, 1999, J CARDIOVASC RISK, V6, P7; Offenbacher S, 1998, J Dent Educ, V62, P852; SCHENKEIN H, 1999, J PERIODONTOL, V70, P457; SCULLY C, 1998, PERIODONTOL 2000, V18, P7; SCULLY C, 1996, ORAL DIS	8	39	45	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					36	39		10.1136/bmj.321.7252.36	http://dx.doi.org/10.1136/bmj.321.7252.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875835	Green Published			2022-12-28	WOS:000088030100027
J	Hall, W; Zador, D				Hall, W; Zador, D			Challenge of reducing drug-related deaths	LANCET			English	Editorial Material							OVERDOSE; TRENDS		Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; Mental Hlth Serv Salford, Drugs North West, Manchester, Lancs, England	University of New South Wales Sydney	Hall, W (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				Advisory Council on the Misuse of Drugs, 2000, RED DRUG REL DEATHS; Darke S, 1996, ADDICTION, V91, P1765, DOI 10.1111/j.1360-0443.1996.tb03800.x; DONOGHOE M, 1998, OPIOID OVERDOSE TREN; Hall W, 2000, DRUG ALCOHOL DEPEN, V57, P247, DOI 10.1016/S0376-8716(99)00057-5; Hall WD, 1999, MED J AUSTRALIA, V171, P34, DOI 10.5694/j.1326-5377.1999.tb123495.x; Neeleman J, 1997, J EPIDEMIOL COMMUN H, V51, P435, DOI 10.1136/jech.51.4.435; *UK DEP HLTH, 1999, DRUG MIS DEP GUID CL; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2	8	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					7	8		10.1016/S0140-6736(00)02423-5	http://dx.doi.org/10.1016/S0140-6736(00)02423-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892755				2022-12-28	WOS:000087933400005
J	Lohmann, T; Hawa, M; Leslie, RDG; Lane, R; Picard, J; Londei, M				Lohmann, T; Hawa, M; Leslie, RDG; Lane, R; Picard, J; Londei, M			Immune reactivity to glutamic acid decarboxylase 65 in stiff-man syndrome and type 1 diabetes mellitus	LANCET			English	Article							HUMAN MONOCLONAL-ANTIBODIES; BETA-CELLS; AUTOANTIBODIES; EPITOPES; PATIENT; DISEASE; IDENTIFICATION; AUTOANTIGEN; IDDM; MICE	Background The immune response to an isoform of glutamic acid decarboxylase (GAD), GAD65, is associated with two clinically distinct diseases, stiff-man syndrome (SMS) and type 1 (insulin-dependent) diabetes mellitus. We sought to identify differences in the cellular and humoral immune responses to GAD in these two diseases. Methods We compared T-cell responses in 14 SMS patients with axial disease and 17 patients with type 1 diabetes. Findings Peripheral blood T cells of eight SMS patients recognised different immunodominant epitopes of GAD65 compared with T cells from 17 patients with type 1 diabetes. GAD regions 81-171 and 313-403 induced a dominant T-cell response in six of eight patients with SMS but in only one of 17 patients with type 1 diabetes (p=0.001). No SMS patients responded dominantly to GAD fragments 161-243 and 473-555 compared with ten patients with type 1 diabetes (p=0.008). GAD antibodies were detected in 11 of 14 SMS patients (seven with diabetes) and 11 of 17 patients with type 1 diabetes; IgG1 was dominant in both groups. SMS patients, however, were more likely than patients with diabetes to have isotypes other than IgG1 (p=0.03), in particular, IgG4 or IgE isotypes, which were not detected in patients with type 1 diabetes (p=0.012). Interpretation Our findings indicate differences between patients with SMS and type 1 diabetes in cellular (epitope recognition) and humoral (isotype pattern) responses to GAD65. Thus the same autoantigen can elicit distinct immune responses in patients with SMS, even when associated with diabetes, compared with patients with type 1 diabetes.	St Bartholomews Hosp, Dept Diabet & Metab, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Kennedy Inst Rheumatol, London, England; Charing Cross Hosp, Dept Neurosci, London, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London, England; Univ Leipzig, Dept Internal Med 3, D-7010 Leipzig, Germany	University of London; Queen Mary University London; Imperial College London; University of Oxford; Imperial College London; Imperial College London; Leipzig University	Leslie, RDG (corresponding author), St Bartholomews Hosp, Dept Diabet & Metab, London EC1A 7BE, England.		Leslie, Richard/AAF-6977-2020	Leslie, Richard/0000-0002-1786-1531				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Barker RA, 1998, J NEUROL NEUROSUR PS, V65, P633, DOI 10.1136/jnnp.65.5.633; BJORK E, 1994, DIABETES, V43, P161, DOI 10.2337/diabetes.43.1.161; Bonifacio E, 1999, J IMMUNOL, V163, P525; BUTLER MH, 1993, J EXP MED, V178, P2097, DOI 10.1084/jem.178.6.2097; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; Dinkel K, 1998, ANN NEUROL, V44, P194, DOI 10.1002/ana.410440209; Dosch HM, 1999, J IMMUNOL, V163, P6933; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; HARRIS M, 1979, DIABETES, V28, P1039; Hawa M, 1997, DIABETES, V46, P1270, DOI 10.2337/diabetes.46.8.1270; Hummel M, 1998, J NEUROL NEUROSUR PS, V65, P204, DOI 10.1136/jnnp.65.2.204; Kallmann BA, 1997, DIABETES, V46, P237, DOI 10.2337/diabetes.46.2.237; KIM J, 1994, J EXP MED, V180, P595, DOI 10.1084/jem.180.2.595; LI LS, 1994, J IMMUNOL, V152, P930; LOHMANN T, 1994, LANCET, V343, P1607, DOI 10.1016/S0140-6736(94)93061-9; Madec AM, 1996, J IMMUNOL, V156, P3541; MILLWARD A, 1988, CLIN EXP IMMUNOL, V71, P353; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PICARD JK, 1993, HUM IMMUNOL, V38, P115, DOI 10.1016/0198-8859(93)90527-8; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PUGLIESE A, 1993, J CLIN ENDOCR METAB, V77, P1550, DOI 10.1210/jc.77.6.1550; PUGLIESE A, 1994, LANCET, V344, P1027, DOI 10.1016/S0140-6736(94)91691-8; REECE JC, 1993, J IMMUNOL, V151, P6175; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; Schloot NC, 1999, J AUTOIMMUN, V12, P289, DOI 10.1006/jaut.1999.0280; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TUOMILEHTO J, 1994, LANCET, V343, P1383, DOI 10.1016/S0140-6736(94)92521-6; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	33	63	65	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					31	35		10.1016/S0140-6736(00)02431-4	http://dx.doi.org/10.1016/S0140-6736(00)02431-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892762				2022-12-28	WOS:000087933400013
J	Ruiz-Echevarria, MJ; Peltz, SW				Ruiz-Echevarria, MJ; Peltz, SW			The RNA binding protein Pub1 modulates the stability of transcripts containing upstream open reading frames	CELL			English	Article							TRANSLATIONAL TERMINATION CODON; SACCHAROMYCES-CEREVISIAE GENE; ABERRANT MESSENGER-RNAS; SURVEILLANCE COMPLEX; LEADER PEPTIDE; YEAST; NONSENSE; IDENTIFICATION; INITIATION; TURNOVER	The nonsense-mediated mRNA decay (NMD) pathway functions to degrade transcripts containing nonsense codons. Transcripts containing mutations that insert an upstream open reading frame (uORF) in the 5'-UTR are degraded through NMD. However, several naturally occurring uORF-containing transcripts are resistant to NMD. Here we demonstrate that the GCN4 and YAP1 mRNAs, which contain uORFs, harbor a stabilizer element (STE) that prevents rapid NMD by interacting with the RNA binding protein Pub1. conversely, a uORF-containing mRNA that lacks an STE, such as CPA1, is degraded by the NMD pathway. These results indicate that uORFs can play a pivotal role regulating both translation and turnover and that the Pub1p is a critical factor that modulates the stability of uORF-containing transcripts.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Ruiz-Echevarria, MJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Lane, Piscataway, NJ 08854 USA.			Ruiz Echevarria, Maria Jesus/0000-0001-7133-9982	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048631] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48631] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JT, 1993, MOL CELL BIOL, V13, P6102, DOI 10.1128/MCB.13.10.6102; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; Czaplinski K, 1999, BIOESSAYS, V21, P685, DOI 10.1002/(SICI)1521-1878(199908)21:8<685::AID-BIES8>3.0.CO;2-4; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; Dever TE, 1997, METHODS, V11, P403, DOI 10.1006/meth.1996.0437; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; Gonzalez CI, 2000, MOL CELL, V5, P489, DOI 10.1016/S1097-2765(00)80443-8; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P281; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LEE BS, 1995, P NATL ACAD SCI USA, V92, P10354, DOI 10.1073/pnas.92.22.10354; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MATUNIS MJ, 1993, MOL CELL BIOL, V13, P6114, DOI 10.1128/MCB.13.10.6114; Muhlrad D, 1999, RNA, V5, P1299, DOI 10.1017/S1355838299990829; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; PINTO I, 1992, GENETICS, V132, P97; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; Ruiz-Echevarria MJ, 1998, EMBO J, V17, P575, DOI 10.1093/emboj/17.2.575; RuizEchevarria MJ, 1996, TRENDS BIOCHEM SCI, V21, P433, DOI 10.1016/S0968-0004(96)10055-4; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Vilela C, 1998, NUCLEIC ACIDS RES, V26, P1150, DOI 10.1093/nar/26.5.1150; Wang Z, 1999, J BIOL CHEM, V274, P37565, DOI 10.1074/jbc.274.53.37565; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Welch EM, 1999, EMBO J, V18, P6134, DOI 10.1093/emboj/18.21.6134; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; Wright MB, 1996, J BACTERIOL, V178, P7197, DOI 10.1128/jb.178.24.7197-7205.1996; YUN DF, 1995, MOL CELL BIOL, V15, P1021; ZHANG SA, 1995, MOL CELL BIOL, V15, P2231	50	141	144	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					741	751		10.1016/S0092-8674(00)80886-7	http://dx.doi.org/10.1016/S0092-8674(00)80886-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892745	Bronze			2022-12-28	WOS:000087821400008
J	Hewitt, G				Hewitt, G			The genetic legacy of the Quaternary ice ages	NATURE			English	Review							GRASSHOPPER CHORTHIPPUS-PARALLELUS; MITOCHONDRIAL-DNA PHYLOGEOGRAPHY; LONG POLLEN RECORD; INDO-WEST PACIFIC; FRESH-WATER; INTRASPECIFIC PHYLOGEOGRAPHY; RANGE EXPANSION; CLIMATE-CHANGE; MODERN HUMANS; URSUS-ARCTOS	Global climate has fluctuated greatly during the past three million years, leading to the recent major ice ages. An inescapable consequence for most living organisms is great changes in their distribution, which are expressed differently in boreal, temperate and tropical zones. Such range changes can be expected to have genetic consequences, and the advent of DNA technology provides most suitable markers to examine these. Several good data sets are now available, which provide tests of expectations, insights into species colonization and unexpected genetic subdivision and mixture of species. The genetic structure of human populations may be viewed in the same context. The present genetic structure of populations, species and communities has been mainly formed by Quaternary ice ages, and genetic, fossil and physical data combined can greatly help our understanding of how organisms were so affected.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Hewitt, G (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	g.hewitt@uea.ac.uk						Ambrose SH, 1998, J HUM EVOL, V34, P623, DOI 10.1006/jhev.1998.0219; Arctander P, 1999, MOL BIOL EVOL, V16, P1724, DOI 10.1093/oxfordjournals.molbev.a026085; Armbruster P, 1998, EVOLUTION, V52, P1697, DOI 10.1111/j.1558-5646.1998.tb02249.x; Ashworth AC, 1997, NATO ASI SER SER I, V47, P119; Avise JC, 1998, MOL ECOL, V7, P371, DOI 10.1046/j.1365-294x.1998.00391.x; AVISE JC, 1987, ANNU REV ECOL SYST, V18, P489, DOI 10.1146/annurev.es.18.110187.002421; Avise JC, 1998, P ROY SOC B-BIOL SCI, V265, P1707, DOI 10.1098/rspb.1998.0492; Avise John C., 1996, P431; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; Bennett, 1997, EVOLUTION ECOLOGY PA; Bermingham E, 1998, MOL ECOL, V7, P499, DOI 10.1046/j.1365-294x.1998.00358.x; Bernatchez L, 1998, MOL ECOL, V7, P431, DOI 10.1046/j.1365-294x.1998.00319.x; Bowen BW, 1997, EVOLUTION, V51, P1601, DOI 10.1111/j.1558-5646.1997.tb01483.x; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Chenoweth SF, 1998, P ROY SOC B-BIOL SCI, V265, P415, DOI 10.1098/rspb.1998.0310; Colbourne JK, 1998, BIOL J LINN SOC, V65, P347, DOI 10.1006/bijl.1998.0251; Colinvaux PA, 1996, SCIENCE, V274, P85, DOI 10.1126/science.274.5284.85; Colinvaux PA, 1997, TRENDS ECOL EVOL, V12, P318, DOI 10.1016/S0169-5347(97)89916-8; Conroy CJ, 2000, MOL ECOL, V9, P165, DOI 10.1046/j.1365-294x.2000.00846.x; COOPE GR, 1994, PHILOS T ROY SOC B, V344, P19, DOI 10.1098/rstb.1994.0046; COOPER SJB, 1995, MOL ECOL, V4, P49, DOI 10.1111/j.1365-294X.1995.tb00191.x; Da Silva MNF, 1998, MOL ECOL, V7, P475, DOI 10.1046/j.1365-294x.1998.00276.x; DODSON JJ, 1995, MOL ECOL, V4, P331, DOI 10.1111/j.1365-294X.1995.tb00226.x; Duke NC, 1998, EVOLUTION, V52, P1612, DOI [10.1111/j.1558-5646.1998.tb02242.x, 10.2307/2411335]; Ferris C, 1998, HEREDITY, V80, P584, DOI 10.1046/j.1365-2540.1998.00342.x; Fjeldsa J, 1997, BIODIVERS CONSERV, V6, P325, DOI 10.1023/A:1018356506390; FJELDSA J, 1994, BIODIVERS CONSERV, V3, P207, DOI 10.1007/BF00055939; Flanagan NS, 1999, J EVOLUTION BIOL, V12, P577, DOI 10.1046/j.1420-9101.1999.00049.x; Garcia-Moreno J, 1999, MOL PHYLOGENET EVOL, V12, P273, DOI 10.1006/mpev.1999.0617; Gravlund P, 1998, MOL PHYLOGENET EVOL, V10, P151, DOI 10.1006/mpev.1998.0525; Gray AJ, 1997, NATO ASI SER SER I, V47, P371; Harpending HC, 1998, P NATL ACAD SCI USA, V95, P1961, DOI 10.1073/pnas.95.4.1961; Hauser L, 1998, NATO ADV SCI I A-LIF, V306, P191; Hewitt G.M., 1989, P85; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; HEWITT GM, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P140; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; Hisheh S, 1998, BIOL J LINN SOC, V65, P329; Hublin JJ, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P295; Ibrahim KM, 1996, HEREDITY, V77, P282, DOI 10.1038/hdy.1996.142; Jaarola M, 1999, BIOL J LINN SOC, V68, P113, DOI 10.1111/j.1095-8312.1999.tb01161.x; Jorde LB, 1998, BIOESSAYS, V20, P126, DOI 10.1002/(SICI)1521-1878(199802)20:2<126::AID-BIES5>3.0.CO;2-R; Kidd MG, 1998, EVOLUTION, V52, P1158, DOI 10.1111/j.1558-5646.1998.tb01842.x; KING RA, 1998, MOL ECOL, V4, P95; Klicka J, 1999, P ROY SOC B-BIOL SCI, V266, P695, DOI 10.1098/rspb.1999.0691; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; LI WH, 1997, MOL EVOLUTON; MELLARS P, 1998, NEANDERTHALS MODERN; Orange DI, 1999, COPEIA, P267; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; Palumbi SR, 1997, CORAL REEFS, V16, pS47, DOI 10.1007/s003380050241; Parsons TJ, 1998, NAT GENET, V18, P110; Patton JL, 1998, ENDLESS FORMS, P202; Reille M, 1998, QUATERNARY SCI REV, V17, P1107, DOI 10.1016/S0277-3791(97)00093-0; REMINGTON C L, 1968, Evolutionary Biology (New York), P321; Richards M, 1996, AM J HUM GENET, V59, P185; Richards MB, 1998, ANN HUM GENET, V62, P241, DOI 10.1046/j.1469-1809.1998.6230241.x; Rohling EJ, 1998, NATURE, V394, P162, DOI 10.1038/28134; Roy MS, 1997, P ROY SOC B-BIOL SCI, V264, P1337, DOI 10.1098/rspb.1997.0185; Ruedi M, 1996, J ZOOL SYST EVOL RES, V34, P153; Santucci F, 1998, MOL ECOL, V7, P1163, DOI 10.1046/j.1365-294x.1998.00436.x; Schluter D, 1998, ENDLESS FORMS, P114; Schneider CJ, 1998, MOL ECOL, V7, P487, DOI 10.1046/j.1365-294x.1998.00334.x; Schug MD, 1997, NAT GENET, V15, P99, DOI 10.1038/ng0197-99; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; Showers W.B., 1981, P97; Soltis DE, 1997, PLANT SYST EVOL, V206, P353, DOI 10.1007/BF00987957; Stauffer B, 1999, NATURE, V399, P412, DOI 10.1038/20807; Stringer C., 1996, AFRICAN EXODUS ORIGI; Surridge AK, 1999, NATURE, V400, P726, DOI 10.1038/23393; Taberlet P, 1998, MOL ECOL, V7, P453, DOI 10.1046/j.1365-294x.1998.00289.x; TABERLET P, 1994, P ROY SOC B-BIOL SCI, V255, P195, DOI 10.1098/rspb.1994.0028; Talbot SL, 1996, MOL PHYLOGENET EVOL, V5, P477, DOI 10.1006/mpev.1996.0044; TCHERNOV E, 1998, NEANDERTALS MODERN H; Templeton AR, 1998, MOL ECOL, V7, P381, DOI 10.1046/j.1365-294x.1998.00308.x; Templeton AR, 1997, CURR OPIN GENET DEV, V7, P841, DOI 10.1016/S0959-437X(97)80049-4; VanAndel TH, 1996, QUATERNARY SCI REV, V15, P481, DOI 10.1016/0277-3791(96)00028-5; Wade MJ, 1998, EVOLUTION, V52, P1537, DOI 10.1111/j.1558-5646.1998.tb02235.x; Walker D, 1998, ANNU REV ECOL SYST, V29, P23, DOI 10.1146/annurev.ecolsys.29.1.23; Webb RS, 1997, NATURE, V385, P695, DOI 10.1038/385695a0; Weisrock DW, 2000, MOL PHYLOGENET EVOL, V14, P152, DOI 10.1006/mpev.1999.0689; Wenink PW, 1996, EVOLUTION, V50, P318, DOI 10.1111/j.1558-5646.1996.tb04495.x; WILLIAMS D, 1978, QUATERNARY ENV; Williams ST, 1998, EVOLUTION, V52, P87, DOI 10.1111/j.1558-5646.1998.tb05141.x; Zink RM, 1996, EVOLUTION, V50, P308, DOI 10.1111/j.1558-5646.1996.tb04494.x	86	5092	5318	35	1174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					907	913		10.1038/35016000	http://dx.doi.org/10.1038/35016000			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879524				2022-12-28	WOS:000087732700039
J	Rikken, GLJA; Raupach, E				Rikken, GLJA; Raupach, E			Enantioselective magnetochiral photochemistry	NATURE			English	Article							ABSOLUTE ASYMMETRIC-SYNTHESIS; MAGNETIC-FIELD; CHIRALITY; BIREFRINGENCE; ABSORPTION; DICHROISM; LIQUIDS	Many chemical and physical systems can occur in two forms distinguished solely by being mirror images of each other. This phenomenon, known as chirality, is important in biochemistry, where reactions involving chiral molecules often require the participation of one specific enantiomer (mirror image) of the two possible ones. In fact, terrestrial life utilizes only the L enantiomers of amino acids, a pattern that is known as the 'homochirality of life' and which has stimulated long-standing efforts to understand its origin(1). Reactions can proceed enantioselectively if chiral reactants or catalysts are involved, or if some external chiral influence is present(2). But because chiral reactants and catalysts themselves require an enantioselective production process, efforts to understand the homochirality of life have focused on external chiral influences. One such external influence is circularly polarized light, which can influence the chirality of photochemical reaction products(2,13,14). Because natural optical activity, which occurs exclusively in media lacking mirror symmetry, and magnetic optical activity, which can occur in all media and is induced by longitudinal magnetic fields, both cause polarization rotation of light, the potential for magnetically induced enantioselectivity in chemical reactions has been investigated, but no convincing demonstrations of such an effect have been found(2-4). Here we show experimentally that magnetochiral anisotropy-an effect linking chirality and magnetism(5-7)-can give rise to an enantiomeric excess in a photochemical reaction driven by unpolarized light in a parallel magnetic field, which suggests that this effect may have played a role in the origin of the homochirality of life.	Max Planck Inst Festkorperforsch, CNRS, Grenoble High Magnet Field Lab, F-38042 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Max Planck Society	Rikken, GLJA (corresponding author), Max Planck Inst Festkorperforsch, CNRS, Grenoble High Magnet Field Lab, BP 166, F-38042 Grenoble, France.							Avalos M, 1998, CHEM REV, V98, P2391, DOI 10.1021/cr970096o; Bailey J, 1998, SCIENCE, V281, P672, DOI 10.1126/science.281.5377.672; BARANOVA NB, 1979, MOL PHYS, V38, P1085, DOI 10.1080/00268977900102261; BARRON LD, 1986, J AM CHEM SOC, V108, P5539, DOI 10.1021/ja00278a029; BARRON LD, 1984, MOL PHYS, V51, P715, DOI 10.1080/00268978400100481; BARRON LD, 1994, SCIENCE, V266, P1491, DOI 10.1126/science.266.5190.1491; BERNSTEIN WJ, 1972, THESIS L BERKELEY LA; BONNER WA, 1995, ORIGINS LIFE EVOL B, V25, P175, DOI 10.1007/BF01581581; CLINE DB, 1996, PHYSICAL ORIGIN HOMO; Engel MH, 1997, NATURE, V389, P265, DOI 10.1038/38460; INOUE Y, 1992, CHEM REV, V92, P741, DOI 10.1021/cr00013a001; Kleindienst P, 1998, CHEM PHYS LETT, V288, P89, DOI 10.1016/S0009-2614(98)00218-8; LYNE AG, 1984, NATURE, V308, P605, DOI 10.1038/308605b0; Mason S. F., 1994, CIRCULAR DICHROISM; MCCAFFERY AJ, 1965, J CHEM SOC, P2883, DOI 10.1039/jr9650002883; MCCAFFERY AJ, 1967, INORG CHEM, V6, P1614, DOI 10.1021/ic50055a002; PORTIGAL DL, 1971, J PHYS CHEM SOLIDS, V32, P603, DOI 10.1016/0022-3697(71)90009-6; PRACEJUS H, 1967, FORTSCHR CHEM FORSCH, V8, P493; RAU H, 1983, CHEM REV, V83, P535, DOI 10.1021/cr00057a003; Rikken GLJA, 1997, NATURE, V390, P493, DOI 10.1038/37323; Rikken GLJA, 1998, PHYS REV E, V58, P5081, DOI 10.1103/PhysRevE.58.5081; Stevenson K. L., 1969, MOL PHOTOCHEM, V1, P271; Teutsch H., 1988, THESIS U BREMEN; WAGNIERE G, 1983, EXPERIENTIA, V39, P1090, DOI 10.1007/BF01943122	25	449	456	3	175	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					932	935		10.1038/35016043	http://dx.doi.org/10.1038/35016043			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879530				2022-12-28	WOS:000087732700045
J	Walker, ML; Burgess, SA; Sellers, JR; Wang, F; Hammer, JA; Trinick, J; Knight, PJ				Walker, ML; Burgess, SA; Sellers, JR; Wang, F; Hammer, JA; Trinick, J; Knight, PJ			Two-headed binding of a processive myosin to F-actin	NATURE			English	Article							MOTOR PROTEIN; RESOLUTION; FILAMENTS; MOLECULES; MOVEMENT; ATP	Myosins are motor proteins in cells. They move along actin by changing shape after making stereospecific interactions with the actin subunits(1). As these are arranged helically, a succession of steps will follow a helical path. However, if the myosin heads are long enough to span the actin helical repeat (similar to 36 nm), linear motion is possible. Muscle myosin (myosin II) heads are about 16 nm long(2), which is insufficient to span the repeat(3). Myosin V, however, has heads of about 31 nm that could span 36 nm (refs 4, 5) and thus allow single two-headed molecules to transport cargo by walking straight 5. Here we use electron microscopy to show that while working, myosin V spans the helical repeat. The heads are mostly 13 actin subunits apart, with values of 11 or 15 also found. Typically the structure is polar and one head is curved, the other straighter. Single particle processing reveals the polarity of the underlying actin filament, showing that the curved head is the leading one. The shape of the leading head may correspond to the beginning of the working stroke of the motor. We also observe molecules attached by one head in this conformation.	Univ Leeds, Sch Biomed Sci, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	University of Leeds; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Knight, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004229, Z01HL004229] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burgess SA, 1997, J CELL BIOL, V139, P675, DOI 10.1083/jcb.139.3.675; Burgess SA, 2000, BIOPHYS J, V78, p8A; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CRAIG R, 1980, J MOL BIOL, V140, P35, DOI 10.1016/0022-2836(80)90355-1; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; EGELMAN EH, 1992, BIOPHYS J, V63, P1299, DOI 10.1016/S0006-3495(92)81716-2; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Moore JR, 2000, BIOPHYS J, V78, p272A; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sellers J. R., 1999, MYOSINS; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUGIMOTO Y, 1995, BIOPHYS J, V68, pS29; TRINICK J, 1979, J MOL BIOL, V133, P549, DOI 10.1016/0022-2836(79)90407-8; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Veigel C, 2000, BIOPHYS J, V78, p242A; WALKER M, 1995, BIOPHYS J, V68, pS87; WALKER M, 1985, J MOL BIOL, V184, P535, DOI 10.1016/0022-2836(85)90300-6; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	27	257	260	0	33	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					804	+		10.1038/35015592	http://dx.doi.org/10.1038/35015592			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866203				2022-12-28	WOS:000087620600054
J	Croft, A				Croft, A			Extracts from "Clinical evidence" - Malaria: prevention in travellers	BMJ-BRITISH MEDICAL JOURNAL			English	Review							THAI-CAMBODIAN BORDER; FALCIPARUM-MALARIA; MEFLOQUINE PROPHYLAXIS; INSECT REPELLENT; EXISTING METHODS; DOUBLE-BLIND; TRAVELERS; CHEMOPROPHYLAXIS; CHLOROQUINE; AMODIAQUINE		Minist Def, London SW1A 2HB, England		Croft, A (corresponding author), Minist Def, London SW1A 2HB, England.	AshleyCroft@compuserve.com						ALEXANDER B, 1995, AM J TROP MED HYG, V52, P169, DOI 10.4269/ajtmh.1995.52.169; [Anonymous], 1993, MOSQUITO ECOLOGY FIE; Ashby D, 1998, STAT MED, V17, P1839; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; Baudon D, 1997, Med Trop (Mars), V57, P497; BEIER JC, 1994, AM J TROP MED HYG, V50, P529, DOI 10.4269/ajtmh.1994.50.529; BEM JL, 1992, J TROP MED HYG, V95, P167; BERNUAU J, 1988, J HEPATOL, V6, P109, DOI 10.1016/S0168-8278(88)80469-0; BLOMQUIST L, 1977, ACTA PHARMACOL TOX, V41, P235; Bouchaud O, 1998, Rev Prat, V48, P279; Bradley D J, 1997, Commun Dis Rep CDR Rev, V7, pR137; Carnevale P, 1997, Med Trop (Mars), V57, P505; CHARMOT G, 1987, B SOC PATHOL EXOT, V80, P266; COT M, 1992, AM J TROP MED HYG, V46, P21, DOI 10.4269/ajtmh.1992.46.21; Croft A, 1997, BRIT MED J, V315, P1412, DOI 10.1136/bmj.315.7120.1412; CROFT AMJ, 1999, COCHRANE LIB; Curtis CF, 1998, BRIT MED BULL, V54, P311, DOI 10.1093/oxfordjournals.bmb.a011690; DEGARBINO JP, 1983, VET HUM TOXICOL, V25, P422; DOLAN G, 1993, T ROY SOC TROP MED H, V87, P620, DOI 10.1016/0035-9203(93)90262-O; DOLMANS WMV, 1996, NED TIJDSCHR GENEES, V140, P892; DRYSDALE SF, 1990, LANCET, V335, P164, DOI 10.1016/0140-6736(90)90033-2; FOGH S, 1988, BMJ-BRIT MED J, V296, P820, DOI 10.1136/bmj.296.6625.820; Fradin MS, 1998, ANN INTERN MED, V128, P931, DOI 10.7326/0003-4819-128-11-199806010-00013; GARNER P, 1999, COCHRANE LIB; Gherardin T, 1999, Aust Fam Physician, V28, P310; GRAVES P, 1999, COCHRANE LIB; Handschin, 1997, J Travel Med, V4, P121, DOI 10.1111/j.1708-8305.1997.tb00798.x; HATTON CSR, 1986, LANCET, V1, P411; Hewitt SE, 1996, ANN TROP MED PARASIT, V90, P337, DOI 10.1080/00034983.1996.11813059; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; Juckett G, 1999, AM FAM PHYSICIAN, V59, P2523; Kain KC, 1998, INFECT DIS CLIN N AM, V12, P267, DOI 10.1016/S0891-5520(05)70005-2; Krogstad DJ, 1996, EPIDEMIOL REV, V18, P77, DOI 10.1093/oxfordjournals.epirev.a017918; LAMBERG SI, 1969, ARCH DERMATOL, V100, P582, DOI 10.1001/archderm.100.5.582; LARREY D, 1986, ANN INTERN MED, V104, P801, DOI 10.7326/0003-4819-104-6-801; LENGELER C, 1999, COCHRANE LIB; Leutscher P D, 1997, Ugeskr Laeger, V159, P4866; LEWIS DJ, 1982, CAN ENTOMOL, V114, P699, DOI 10.4039/Ent114699-8; LILLIE TH, 1988, J MED ENTOMOL, V25, P475, DOI 10.1093/jmedent/25.6.475; Lobel HO, 1997, JAMA-J AM MED ASSOC, V278, P1767, DOI 10.1001/jama.278.21.1767; Luxemburger C, 1996, ANN TROP PAEDIATR, V16, P281, DOI 10.1080/02724936.1996.11747839; MCCONNELL R, 1986, HETA830851757 NIOSH; MILLER KD, 1986, AM J TROP MED HYG, V35, P451, DOI 10.4269/ajtmh.1986.35.451; Miller S A, 1999, J R Army Med Corps, V145, P20; MITTELHOLZER ML, 1996, J TRAVEL MED, V4, P219; Murphy GS, 1996, INFECT DIS CLIN N AM, V10, P747, DOI 10.1016/S0891-5520(05)70325-1; NASCI RS, 1983, MOSQ NEWS, V43, P180; NEFTEL KA, 1986, BRIT MED J, V292, P721, DOI 10.1136/bmj.292.6522.721; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Olsen V V, 1998, Ugeskr Laeger, V160, P2410; OSIMITZ TG, 1995, J AM MOSQUITO CONTR, V11, P274; Osimitz TG, 1997, J TOXICOL-CLIN TOXIC, V35, P435, DOI 10.3109/15563659709001224; Petersen E, 1997, Ugeskr Laeger, V159, P2723; Phillips, 1996, J Travel Med, V3, P40, DOI 10.1111/j.1708-8305.1996.tb00695.x; PHILLIPSHOWARD PA, 1990, B WORLD HEALTH ORGAN, V68, P493; RAYMOND JM, 1989, J CLIN GASTROENTEROL, V11, P602, DOI 10.1097/00004836-198910000-00034; Samuel BU, 1998, INFECT DIS CLIN N AM, V12, P325, DOI 10.1016/S0891-5520(05)70008-8; SCHAEFER C, 1992, REPROD TOXICOL, V6, P175, DOI 10.1016/0890-6238(92)90120-I; Schlagenhauf P, 1996, TROP MED INT HEALTH, V1, P485, DOI 10.1046/j.1365-3156.1996.d01-85.x; Schlagenhauf P, 1997, AM J TROP MED HYG, V56, P235, DOI 10.4269/ajtmh.1997.56.235; Schlagenhauf P, 1999, J TRAVEL MED, V6, P122, DOI 10.1111/j.1708-8305.1999.tb00843.x; SCHOEPKE A, 1998, J TRAVEL MED, V128, P931; Shamiss A, 1996, AVIAT SPACE ENVIR MD, V67, P872; SHANKS GD, 1992, AM J TROP MED HYG, V46, P643, DOI 10.4269/ajtmh.1992.46.643; Smith HR, 1999, CLIN EXP DERMATOL, V24, P249, DOI 10.1046/j.1365-2230.1999.00471.x; SMITHUIS FM, 1993, ANTIMICROB AGENTS CH, V37, P1977, DOI 10.1128/AAC.37.9.1977; STEMBERGER H, 1984, ACTA TROP, V41, P391; Suh KN, 1996, INFECT DIS CLIN PRAC, V5, P541, DOI 10.1097/00019048-199612000-00007; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M; *US DEP HHS PHS CD, 1997, US DEP HHS PHS CDCP; vanRiemsdijk MM, 1997, EUR J CLIN PHARMACOL, V52, P1, DOI 10.1007/s002280050240; Vernede Raoul, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P771; WETSTEYN JCFM, 1993, BMJ-BRIT MED J, V307, P1041, DOI 10.1136/bmj.307.6911.1041; White N. J., 1996, Manson's tropical diseases., P1087; Winstanley P, 1998, J ROY COLL PHYS LOND, V32, P203; WOODTLI W, 1986, SCHWEIZ MED WSCHR, V116, P966; World Health Organization, 1997, WORLD HLTH REP 1997; YAP H H, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P558; 1989, MED LETT DRUGS THER, V31, P45; 1988, LANCET, V2, P616; 1998, DRUG THER B, V36, P20	83	21	23	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2000	321	7254					154	160		10.1136/bmj.321.7254.154	http://dx.doi.org/10.1136/bmj.321.7254.154			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894695	Green Published			2022-12-28	WOS:000088305700024
J	Sheik, M; Gutierrez, MI; Bolton, P; Spiegel, P; Thieren, M; Burnham, G				Sheik, M; Gutierrez, MI; Bolton, P; Spiegel, P; Thieren, M; Burnham, G			Deaths among humanitarian workers	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCIES		Johns Hopkins Sch Hyg & Publ Hlth, Ctr Refugee & Disaster Studies, Baltimore, MD 21205 USA; WHO, Dept Emergency & Humanitarian Act, CH-1211 Geneva 27, Switzerland	Johns Hopkins University; World Health Organization	Burnham, G (corresponding author), Johns Hopkins Sch Hyg & Publ Hlth, Ctr Refugee & Disaster Studies, Baltimore, MD 21205 USA.		Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; BAKER TD, 1992, PUBLIC HEALTH REP, V107, P155; Burkle FM, 1999, BRIT MED J, V319, P422, DOI 10.1136/bmj.319.7207.422; FRAME JD, 1992, AM J TROP MED HYG, V46, P686, DOI 10.4269/ajtmh.1992.46.686; HARGARTEN SW, 1985, JAMA-J AM MED ASSOC, V254, P1326, DOI 10.1001/jama.254.10.1326; MARTIN R, 1999, FORCED MIGRATION REV, P4; NICKERSON C, 1997, BOSTON GLOBE    0727; SCHOUTEN EJ, 1995, BRIT MED J, V311, P1342; SHCERAN L, 1993, GUARDIAN        0310; Slim H, 1997, DISASTERS, V21, P244, DOI 10.1111/1467-7717.00059; SOMMARUGA C, 1998, HARD CHOICES; *US COMM REF, 1998, WORLD REF SURV 1998; VANBRABANT K, 1997, RELIEF REHAB NET FEB; VANBRABANT K, 1999, FORCED MIGRATION REV, P7; WOODHOUSE T, 1999, BRIT MED J, V319, P397; 1999, LANCET, V354, P609	16	60	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					166	168		10.1136/bmj.321.7254.166	http://dx.doi.org/10.1136/bmj.321.7254.166			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336MG	10894699	Green Published			2022-12-28	WOS:000088305700027
J	Charatan, F				Charatan, F			US doctors win round in battle for right to negotiate with HMOs	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					71	71		10.1136/bmj.321.7253.71	http://dx.doi.org/10.1136/bmj.321.7253.71			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884250	Green Published			2022-12-28	WOS:000088196600017
J	Geller, DS; Farhi, A; Pinkerton, N; Fradley, M; Moritz, M; Spitzer, A; Meinke, G; Tsai, FTF; Sigler, PB; Lifton, RP				Geller, DS; Farhi, A; Pinkerton, N; Fradley, M; Moritz, M; Spitzer, A; Meinke, G; Tsai, FTF; Sigler, PB; Lifton, RP			Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy	SCIENCE			English	Article							GLUCOCORTICOID RECEPTOR; ANTAGONISM; BINDING	Hypertension and pregnancy-related hypertension are major public health problems of largely unknown causes. We describe a mutation in the mineralocorticoid receptor (MR), S810L, that causes early-onset hypertension that is markedly exacerbated in pregnancy. This mutation results in constitutive MR activity and alters receptor specificity, with progesterone and other steroids lacking 21-hydroxyl groups, normally MR antagonists, becoming potent agonists. Structural and biochemical studies indicate that the mutation results in the gain of a van der Waals interaction between helix 5 and helix 3 that substitutes for interaction of the steroid 21-hydroxyl group with helix 3 in the wild-type receptor. This helix 5-helix 3 interaction is highly conserved among diverse nuclear hormone receptors, suggesting its general role in receptor activation.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Internal Med Nephrol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; Yeshiva University; Albert Einstein College of Medicine	Lifton, RP (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, Room 154,295 Congress Ave, New Haven, CT 06510 USA.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; August Phyllis, 1995, P2407; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; DUAX WL, 1972, J AM CHEM SOC, V94, P5467, DOI 10.1021/ja00770a050; DUNN JF, 1981, J CLIN ENDOCR METAB, V53, P58, DOI 10.1210/jcem-53-1-58; Fagart J, 1998, EMBO J, V17, P3317, DOI 10.1093/emboj/17.12.3317; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; IGARASHI P, 1996, J BIOL CHEM, V19, P271; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775	16	405	424	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					119	123		10.1126/science.289.5476.119	http://dx.doi.org/10.1126/science.289.5476.119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884226				2022-12-28	WOS:000088090400046
J	Ishimoto, H; Matsumoto, A; Tanimura, T				Ishimoto, H; Matsumoto, A; Tanimura, T			Molecular identification of a taste receptor gene for trehalose in Drosophila	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; ODORANT RECEPTORS; TISSUE; MELANOGASTER; PROTEINS; FAMILY	The molecular nature of sweet taste receptors has not been fully explored. Employing a differential screening strategy, we identified a taste receptor gene, Tre1, that controls the taste sensitivity to trehalose in Drosophila melanogaster. The Tre1 gene encodes a novel protein with similarity to G protein-coupled seven-transmembrane receptors. Disruption of the Tre1 gene lowered the taste sensitivity to trehalose, whereas sensitivities to other sugars were unaltered. Overexpression of the Tre1 gene restored the taste sensitivity to trehalose in the Tre1 deletion mutant. The Tre1 gene is expressed in taste sensory cells. These results provide direct evidence that Tre1 encodes a putative taste receptor for trehalose in Drosophila.	Kyushu Univ, Dept Biol, Fukuoka 8108560, Japan	Kyushu University	Tanimura, T (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8108560, Japan.							ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; Awasaki T, 1997, J NEUROBIOL, V32, P707, DOI 10.1002/(SICI)1097-4695(19970620)32:7<707::AID-NEU6>3.0.CO;2-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, UNPUB; Bhatt TR, 1997, BIOTECHNIQUES, V23, P1000, DOI 10.2144/97236bm06; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KIMURA K, 1986, J EXP ZOOL, V239, P393, DOI 10.1002/jez.1402390310; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MATSUOKA I, 1993, BIOCHEM BIOPH RES CO, V194, P504, DOI 10.1006/bbrc.1993.1848; NOTTEBOHM E, 1994, NEURON, V12, P25, DOI 10.1016/0896-6273(94)90149-X; ROBERTSON HM, 1988, GENETICS, V118, P461; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Singh RN, 1997, MICROSC RES TECHNIQ, V39, P547, DOI 10.1002/(SICI)1097-0029(19971215)39:6<547::AID-JEMT7>3.0.CO;2-A; STOKER RF, 1994, CELL TISSUE RES, V275, P3; TANIMURA T, 1988, GENETICS, V119, P399; TANIMURA T, 1982, J COMP PHYSIOL, V147, P433, DOI 10.1007/BF00612007; TANIMURA T, 1981, J COMP PHYSIOL, V141, P265, DOI 10.1007/BF01342672; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WRONG GT, 1996, NATURE, V381, P796; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	25	41	44	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					116	119		10.1126/science.289.5476.116	http://dx.doi.org/10.1126/science.289.5476.116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884225				2022-12-28	WOS:000088090400045
J	Warren, SJP; Lin, MS; Giudice, GJ; Hoffmann, RG; Hans, G; Aoki, V; Rivitti, EA; dos Santos, V; Diaz, LA				Warren, SJP; Lin, MS; Giudice, GJ; Hoffmann, RG; Hans, G; Aoki, V; Rivitti, EA; dos Santos, V; Diaz, LA		Cooperative Grp on Fogo Selvagem R	The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED-IMMUNOSORBENT-ASSAY; FOGO-SELVAGEM; VULGARIS AUTOANTIBODIES; AMERINDIAN RESERVATION; DISTINCT; DISEASE; FOCUS	Background: Pemphigus foliaceus is an autoimmune skin disease mediated by autoantibodies against desmoglein 1. The endemic form is thought to have an environmental cause. The Terena reservation of Limao Verde in Mato Grosso do Sul, Brazil, is a recently identified focus of the disease, with a prevalence of 3.4 percent in the population. We tested the hypothesis that normal subjects living in an endemic area have antibodies against desmoglein 1. Methods: We used an enzyme-linked immunosorbent assay to detect antibodies against desmoglein 1 in serum samples from 60 patients with endemic pemphigus foliaceus (fogo selvagem) who lived in Limao Verde or elsewhere in Brazil, 372 normal subjects (without pemphigus foliaceus) from Limao Verde and surrounding locations, and 126 normal subjects from the United States and Japan. Results: Antibodies against desmoglein 1 were detected in 59 of the 60 patients with fogo selvagem (98 percent) but in only 3 of the 126 normal subjects from the United States and Japan (2 percent). Antibodies were also detected in 51 of the 93 normal subjects from Limao Verde (55 percent) and in 54 of the 279 normal subjects from surrounding areas (19 percent). Serum samples obtained one to four years before the onset of disease were available for five patients; all five had antibodies in the initial serum samples, and the onset of disease was associated with a marked increase in antibody values. Conclusions: The prevalence of antibodies against desmoglein 1 is high among normal subjects living in an area where fogo selvagem is endemic, and the onset of the disease is preceded by a sustained antibody response. These findings support the concept that the production of antibodies against desmoglein 1 is initiated by exposure to an unknown environmental agent. (N Engl J Med 2000;343:23-30.) (C) 2000, Massachusetts Medical Society.	Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Clin Epidemiol & Biostat, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI USA; Univ Fed Mato Grosso do Sul, Dept Dermatol, Campo Grande, Brazil; Univ Sao Paulo, Dept Dermatol, Sao Paulo, Brazil; Secretaria Estado Saude do Mato Grosso do Sul, Aquidauana, Brazil	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); Universidade Federal de Mato Grosso do Sul; Universidade de Sao Paulo	Diaz, LA (corresponding author), Univ N Carolina, Sch Med, Dept Dermatol, Suite 3100,Thurston Bldg,CB 7287, Chapel Hill, NC 27599 USA.		Aoki, Valeria/ABD-2863-2020; HANS-FILHO, GUNTER/R-9779-2017; Aoki, Valeria/H-1415-2012	Aoki, Valeria/0000-0003-4256-4413; HANS-FILHO, GUNTER/0000-0001-9324-3703; Aoki, Valeria/0000-0003-4256-4413	NIAMS NIH HHS [R37-AR30281, R01-AR32599, R01-AR40410, R01 AR032599] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040410, R01AR032599] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1995, J INVEST DERMATOL, V104, P895, DOI 10.1111/1523-1747.ep12606168; Amagai M, 1999, BRIT J DERMATOL, V140, P351; Cazenave PLA, 1844, ANN MAL PEU, V1, P208; DIAZ LA, 1989, J AM ACAD DERMATOL, V20, P657, DOI 10.1016/S0190-9622(89)70079-7; DIAZ LA, 1989, J INVEST DERMATOL, V92, P4, DOI 10.1111/1523-1747.ep13070394; Ding X, 1999, J INVEST DERMATOL, V112, P739, DOI 10.1046/j.1523-1747.1999.00585.x; Ding X, 1997, J INVEST DERMATOL, V109, P592, DOI 10.1111/1523-1747.ep12337524; Eaton DP, 1998, J MED ENTOMOL, V35, P120, DOI 10.1093/jmedent/35.2.120; EMERY DJ, 1995, J INVEST DERMATOL, V104, P323, DOI 10.1111/1523-1747.ep12665364; FRIEDMAN H, 1995, J AM ACAD DERMATOL, V32, P949, DOI 10.1016/0190-9622(95)91330-0; Hans G, 1996, J INVEST DERMATOL, V107, P68, DOI 10.1111/1523-1747.ep12298213; Ishii K, 1997, J IMMUNOL, V159, P2010; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; Liebman JM, 1999, BIOTECHNIQUES, V26, P36, DOI 10.2144/99261bm05; MATIS WL, 1987, J INVEST DERMATOL, V89, P302, DOI 10.1111/1523-1747.ep12471587; Moraes ME, 1997, TISSUE ANTIGENS, V49, P35, DOI 10.1111/j.1399-0039.1997.tb02707.x; MORINI JP, 1993, ARCH DERMATOL, V129, P69, DOI 10.1001/archderm.129.1.69; Oldstone MB, 1987, CELL, V51, P878; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PAESLEME C, 1903, THESIS FM RIO DE JAN; ROBLEDO MA, 1988, BRIT J DERMATOL, V118, P737, DOI 10.1111/j.1365-2133.1988.tb02590.x; STANLEY JR, 1986, J INVEST DERMATOL, V87, P197, DOI 10.1111/1523-1747.ep12695334; Vieira J, 1937, CONTRIBUICAO AO ESTU; WALLER RA, 1969, J AM STAT ASSOC, V64, P1484, DOI 10.2307/2286085; Zillikens D, 1997, J INVEST DERMATOL, V109, P679, DOI 10.1111/1523-1747.ep12338088	25	109	115	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					23	30		10.1056/NEJM200007063430104	http://dx.doi.org/10.1056/NEJM200007063430104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882765				2022-12-28	WOS:000087987600004
J	Brody, H; Rip, MR; Vinten-Johansen, P; Paneth, N; Rachman, S				Brody, H; Rip, MR; Vinten-Johansen, P; Paneth, N; Rachman, S			Map-making and myth-making in Broad Street: the London cholera epidemic, 1854	LANCET			English	Review									Michigan State Univ, Dept Family Practice, Clin Ctr B100, E Lansing, MI 48824 USA; Michigan State Univ, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA; Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Hist, E Lansing, MI 48824 USA; Michigan State Univ, Dept English, E Lansing, MI 48824 USA; Michigan State Univ, Inst Publ Policy & Social Res, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; Michigan State University; Michigan State University	Brody, H (corresponding author), Michigan State Univ, Dept Family Practice, Clin Ctr B100, E Lansing, MI 48824 USA.		Brody, Howard/GQA-6310-2022					Brody H, 1999, Pharos Alpha Omega Alpha Honor Med Soc, V62, P2; *CHOL INQ COMM ST, 1855, REP CHOL OUTBR PAR S; COOPER E, 1854, MCS478128 METR COMM; DESAVIGNY D, 1995, P INT WORKSH COL SRI; General Board of Health, 1855, REP COMM SCI INQ REL; Marantz Henig R, 1997, PEOPLES HLTH MEMOIR; McLeod KS, 2000, SOC SCI MED, V50, P923, DOI 10.1016/S0277-9536(99)00345-7; Okabe A., 1999, SPATIAL TESSELLATION; Paneth N, 1998, AM J PUBLIC HEALTH, V88, P1545, DOI 10.2105/AJPH.88.10.1545; PARKES EA, 1855, BRIT FOREIGN MED CHI, V15, P458; PEREZPENA R, 1999, NY TIMES B      0118; RICHARDS TB, IN PRESS GEOGRAPHIC; SACHS S, 1998, DALLAS MORNING 0927, P10; Seaman V., 1798, MED REPOSITORY, V1, P315; Sedgwick WT, 1902, PRINCIPLES SANITARY; Shapter T, 1849, HIST CHOLERA EXETER; Snow J., 1854, MED TIMES GAZ, V9, P321; Snow J., 1849, MODE COMMUNICATION C; Snow J., 1855, MODE COMMUNICATION C; STEVENSON LG, 1965, J HIST MED, V20, P227; 1854, LANCET, V2, P531; 1854, TIMES LONDON    0927, P12	22	90	97	0	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					64	68		10.1016/S0140-6736(00)02442-9	http://dx.doi.org/10.1016/S0140-6736(00)02442-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892779				2022-12-28	WOS:000087933400042
J	Horton, R				Horton, R			The refiguration of medical thought	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; STATEMENT; QUALITY		The Lancet, London WC1X 8RR, England		Horton, R (corresponding author), The Lancet, London WC1X 8RR, England.							Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Arranz MJ, 2000, LANCET, V355, P1615, DOI 10.1016/S0140-6736(00)02221-2; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; de Silva S, 2000, LANCET, V355, P786, DOI 10.1016/S0140-6736(99)08246-X; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Geertz Clifford, 1983, LOCAL KNOWLEDGE; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; HORTON R, IN PRESS STAT MED; Jungblut PR, 1999, ELECTROPHORESIS, V20, P2100; Keavney B, 2000, LANCET, V355, P434; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; OSLER W, 1802, PRINCIPLES PRACTICE; Pierce CS., 1885, MEMOIRS NATL ACAD SC, V3, P73; Relman AS, 1999, NEW ENGL J MED, V340, P1828, DOI 10.1056/NEJM199906103402309; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; World Health Organization, 2000, WORLD HLTH REP 2000	20	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					2	4		10.1016/S0140-6736(00)02420-X	http://dx.doi.org/10.1016/S0140-6736(00)02420-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892752				2022-12-28	WOS:000087933400002
J	Wilson, S; Delaney, BC; Roalfe, A; Roberts, L; Redman, V; Wearn, AM; Hobbs, FDR				Wilson, S; Delaney, BC; Roalfe, A; Roberts, L; Redman, V; Wearn, AM; Hobbs, FDR			Randomised controlled trials in primary care: case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI; GENERAL-PRACTICE; CLINICAL-TRIALS; DYSPEPTIC PATIENTS; ENDOSCOPY; RANDOMIZATION; PRACTITIONERS; SEROLOGY; DISEASE		Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Div Primary Care Publ & Occupat Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Wilson, S (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Div Primary Care Publ & Occupat Hlth, Birmingham B15 2TT, W Midlands, England.	s.wilson@bham.ac.uk	Delaney, Brendan C/C-5578-2008	Delaney, Brendan/0000-0002-3518-0131; hobbs, richard/0000-0001-7976-7172				Asante M, 1999, EUR J GASTROEN HEPAT, V11, P851, DOI 10.1097/00042737-199908000-00007; AXON ATR, 1995, BMJ-BRIT MED J, V310, P853, DOI 10.1136/bmj.310.6983.853; BARNETT HJM, 1987, NEW ENGL J MED, V316, P817, DOI 10.1056/NEJM198703263161320; Bradley F, 1999, BMJ-BRIT MED J, V318, P711; Briggs AH, 1996, BRIT MED J, V312, P1321, DOI 10.1136/bmj.312.7042.1321; Department of Health, 1996, PRIM CAR DEL FUT; *EUR HEL PYL STUD, 1997, CURR EUR CONC MAN HE, V41, P8; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; Fendrick AM, 1996, AM J GASTROENTEROL, V91, P1544; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; Lilford R, 1998, J Health Serv Res Policy, V3, P159; Lilford RJ, 1995, J ROY SOC MED, V88, P552; MACINTYRE IMC, 1991, BRIT MED J, V302, P1099, DOI 10.1136/bmj.302.6785.1099; MCCORMICK A, 1995, MORBIDITY STAT GEN P; *MED RES COUNC, 1997, MRC TOP REV PRIM HLT; MENDALL MA, 1995, GUT, V36, P330, DOI 10.1136/gut.36.3.330; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V217, P408; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Ward E, 1999, BRIT J GEN PRACT, V49, P919; Wilson S, 1999, BRIT MED J, V318, P1484, DOI 10.1136/bmj.318.7196.1484a	25	84	84	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					24	27		10.1136/bmj.321.7252.24	http://dx.doi.org/10.1136/bmj.321.7252.24			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875830	Green Published, Bronze			2022-12-28	WOS:000088030100023
J	Lubowich, DA; Pasachoff, JM; Balonek, TJ; Millar, TJ; Tremonti, C; Roberts, H; Galloway, RP				Lubowich, DA; Pasachoff, JM; Balonek, TJ; Millar, TJ; Tremonti, C; Roberts, H; Galloway, RP			Deuterium in the Galactic Centre as a result of recent infall of low-metallicity gas	NATURE			English	Article							HOT MOLECULAR CORES; GAMMA-RAY EMISSION; ABUNDANCE; GALAXY; CLOUD; NUCLEOSYNTHESIS; ELEMENTS; REGIONS; LIGHT	The Galactic Centre is the most active and heavily processed region of the Milky Way, so it can be used as a stringent test for the abundance of deuterium (a sensitive indicator of conditions in the first 1,000 seconds in the life of the Universe). As deuterium is destroyed in stellar interiors, chemical evolution models 1 predict that its Galactic Centre abundance relative to hydrogen is D/H = 5 x 10(-12), unless there is a continuous source of deuterium from relatively primordial (low-metallicity) gas. Here we report the detection of deuterium (in the molecule DCN) in a molecular cloud only 10 parsecs from the Galactic Centre. Our data, when combined with a model of molecular abundances, indicate that D/H = (1.7 +/- 0.3) x 10(-6), five orders of magnitude larger than the predictions of evolutionary models with no continuous source of deuterium. The most probable explanation is recent infall of relatively unprocessed metal-poor gas into the Galactic Centre (at the rate inferred by Wakker(2)). Our measured D/H is nine times less than the local interstellar value, and the lowest D/H observed in the Galaxy. We conclude that the observed Galactic Centre deuterium is cosmological, with an abundance reduced by stellar processing and mixing, and that there is no significant Galactic source of deuterium.	Hofstra Univ, Dept Phys & Astron, Hempstead, NY 11550 USA; Amer Inst Phys, Melville, NY 11747 USA; Williams Coll, Hopkins Observ, Williamstown, MA 01267 USA; Colgate Univ, Dept Phys & Astron, Hamilton, NY 13346 USA; Univ Manchester, Inst Sci & Technol, Dept Phys, Manchester M60 1QD, Lancs, England	Hofstra University; Johns Hopkins University; Williams College; Colgate University; University of Manchester	Lubowich, DA (corresponding author), Hofstra Univ, Dept Phys & Astron, Hempstead, NY 11550 USA.	dlubowic@aip.org		Millar, Tom/0000-0001-5178-3656; Balonek, Thomas/0000-0002-9844-1730				AUDOUZE J, 1976, ASTROPHYS J, V208, pL51, DOI 10.1086/182231; BOYD RN, 1989, ASTROPHYS J, V336, pL1, DOI 10.1086/185347; Chengalur JN, 1997, ASTRON ASTROPHYS, V318, pL35; COPI CJ, 1995, PHYS REV LETT, V75, P3981, DOI 10.1103/PhysRevLett.75.3981; FUKUI Y, 1977, PUBL ASTRON SOC JPN, V29, P643; GENZEL R, 1990, ASTROPHYS J, V356, P160, DOI 10.1086/168827; GUSTEN R, 1985, ASTRON ASTROPHYS, V145, P241; Hatchell J, 1998, ASTRON ASTROPHYS, V332, P695; Jacq T, 1999, ASTRON ASTROPHYS, V347, P957; Linsky JL, 1998, SPACE SCI REV, V84, P285, DOI 10.1023/A:1005048124341; LOVAS FJ, 1992, J PHYS CHEM REF DATA, V21, P181, DOI 10.1063/1.555920; Lubowich DA, 1998, ASTROPHYS J, V508, P729, DOI 10.1086/306411; LUBOWICH DA, 1989, ASTROPHYS J, V345, P770, DOI 10.1086/167948; MASTICHIADIS A, 1994, ASTROPHYS J, V426, P599, DOI 10.1086/174096; Matteucci F, 1999, ASTRON ASTROPHYS, V341, P458; MILLAR TJ, IN PRESS PHIL T R A; MINH YC, 1992, ASTRON ASTROPHYS, V258, P489; MORRIS M, 1993, ASTROPHYS J, V408, P496, DOI 10.1086/172607; Ozernoi L. M., 1976, Soviet Astronomy, V19, P693; Pasachoff J. M., 1989, Comments on Astrophysics. Comments on Modern Physics: Part C, V14, P61; PENZIAS AA, 1979, ASTROPHYS J, V228, P430, DOI 10.1086/156862; POGLITSCH A, 1991, ASTROPHYS J, V374, pL33, DOI 10.1086/186065; Prantzos N, 1996, ASTRON ASTROPHYS, V310, P106; Rodgers SD, 1996, MON NOT R ASTRON SOC, V280, P1046, DOI 10.1093/mnras/280.4.1046; Schramm DN, 1998, REV MOD PHYS, V70, P303, DOI 10.1103/RevModPhys.70.303; SERABYN E, 1992, ASTROPHYS J, V395, P166, DOI 10.1086/171640; SIMPSON JP, 1995, ASTROPHYS J, V444, P721, DOI 10.1086/175645; Wakker BP, 1999, NATURE, V402, P388, DOI 10.1038/46498; Yusef-Zadeh F, 2000, SCIENCE, V287, P85, DOI 10.1126/science.287.5450.85	30	57	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 29	2000	405	6790					1025	1027		10.1038/35016506	http://dx.doi.org/10.1038/35016506			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890436				2022-12-28	WOS:000087871700036
J	Spiegel, PB; Salama, P				Spiegel, PB; Salama, P			War and mortality in Kosovo, 1998-99: an epidemiological testimony	LANCET			English	Article							POPULATIONS; SOMALIA; FAMINE; BOSNIA; SUDAN	Background The total number, rates, and causes of mortality in Kosovo during the last war remain unclear despite intense international attention. Understanding mortality that results from modern warfare, in which 90% of casualties are civilian, and identifying vulnerable civilian groups, are of critical public-health importance. Methods In September 1999 we conducted a two-stage cluster survey among the Kosovar Albanian population in Kosovo. We collected retrospective mortality data, including cause of death, for the period of the conflict. Findings The survey included 1197 households comprising 8605 people. From February, 1998, through June, 1999, 67 (64%) of 105 deaths in the sample population were attributed to war-related trauma, corresponding to 12 000 (95% CI 5500-18 300) deaths in the total population. The crude mortality rate increased 2.3 times from the pre-conflict level to 0.72 per 1000 a month. Mortality rates peaked in April 1999 at 3.25 per 1000 a month, coinciding with an intensification of the Serbian campaign of "ethnic cleansing". Men of military age (15-49 years) and men 50 years and older had the highest age-specific mortality rates from war-related trauma. However, the latter group were more than three times as likely to die of war-related trauma than were men of military age (relative risk 3.2). Interpretation Raising awareness among the international humanitarian community of the increased risk of mortality from war-related trauma among men of 50 years and older in some settings is an urgent priority. Establishing evacuation programmes to assist older people to find refuge may prevent loss of life. Such mortality data could be used as evidence that governments and military groups have violated international standards of conduct during warfare.	Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; CDC, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Spiegel, PB (corresponding author), Ctr Dis Control & Prevent, Int Emergency & Refugee Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.	pspiegel@cdc.gov	Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				[Anonymous], 1995, Lancet, V345, P339; [Anonymous], 1997, PUBLIC HLTH CONSEQUE; ASCHERIO A, 1992, NEW ENGL J MED, V327, P931, DOI 10.1056/NEJM199209243271306; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P973; Creusvaux H, 1999, LANCET, V354, P832, DOI 10.1016/S0140-6736(99)80016-6; DELMUNDO F, 1999, REFUGEES, V11, P23; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; *I PUBL HLTH, 1998, HLTH STAT KOS 1989 1; Ignatieff M., 1999, NY TIMES 1121; KIFNER J, 1999, NY TIMES        0718; Levy Barry S, 1997, WAR PUBLIC HLTH; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; *ORG SEC COOP, 1999, SEEN TOLD 1; *ORG SEC CORP, 1999, SEEN TOLD 2; PEREA W, 1999, UNPUB REPORT RAPID A; *PHYS HUM RIGHTS, 1999, WAR CRIM KOS POP BAS; Robinson WC, 1999, LANCET, V354, P291, DOI 10.1016/S0140-6736(99)02266-7; SHENON P, 1999, NY TIMES        1210; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; VanRooyen MJ, 1999, JAMA-J AM MED ASSOC, V282, P428, DOI 10.1001/jama.282.5.428-a; WATSON F, 1995, DISASTERS, V19, P216, DOI 10.1111/j.1467-7717.1995.tb00341.x; WINES M, 1999, NY TIMES        1212; WOODRUFF BA, 1999, REPORT NUTR HLTH SUR; [No title captured]; 1997, HLTH STAT YB 1996; 1999, UNPUB ACT HUNG REP A	28	120	121	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2204	2209		10.1016/S0140-6736(00)02404-1	http://dx.doi.org/10.1016/S0140-6736(00)02404-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881894				2022-12-28	WOS:000087779000012
J	Park, YC; Ye, H; Hsia, C; Segal, D; Rich, RL; Liou, HC; Myszka, DG; Wu, H				Park, YC; Ye, H; Hsia, C; Segal, D; Rich, RL; Liou, HC; Myszka, DG; Wu, H			A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction	CELL			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INDUCED CELL-DEATH; FACTOR RECEPTOR; ANOMALOUS DIFFRACTION; KINASE RIP; TNF; ACTIVATION; PROTEIN; INDUCTION	TRAP proteins are major mediators for the cell activation, cell survival, and antiapoptotic functions of the TNF receptor superfamily. They can be recruited to activated TNF receptors either by direct interactions with the receptors or indirectly via the adaptor protein TRADD. We now report the structure of the TRADD-TRAF2 complex, which is highly distinct from receptor-TRAF2 interactions. This interaction is significantly stronger and we show by an in vivo signaling assay that TRAF2 signaling is more readily initiated by TRADD than by direct receptor-TRAF2 interactions. TRADD is specific for TRAF1 and TRAF2, which ensures the recruitment of cIAPs for the direct inhibition of caspase activation in the signaling complex. The stronger affinity and unique specificity of the TRADD-TRAF2 interaction are crucial for the suppression of apoptosis and provide a mechanistic basis for the perturbation of TRAP recruitment in sensitizing cell death induction.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84132 USA	Cornell University; Cornell University; Cornell University; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA.	haowu@med.cornell.edu			NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047831] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIAID NIH HHS [AI47831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Haridas V, 1998, J IMMUNOL, V160, P3152; HELLER RA, 1992, CELL, V70, P47; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hodgkin P D, 1997, Int Rev Immunol, V15, P101, DOI 10.3109/08830189709068173; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Loenen WAM, 1998, SEMIN IMMUNOL, V10, P417, DOI 10.1006/smim.1998.0159; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszka DG, 1999, MOL RECOGNIT, V12, P1; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton RC, 1999, J MED CHEM, V42, P2295, DOI 10.1021/jm980541n; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; Otwinowski Z., 1990, DENZO DATA PROCESSIN; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SARIN A, 1995, J IMMUNOL, V155, P3716; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Wajant H, 1998, J MOL EVOL, V47, P656, DOI 10.1007/PL00006423; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weiss T, 1998, J IMMUNOL, V161, P3136; Weiss T, 1997, J IMMUNOL, V158, P2398; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; YE H, 2000, IN PRESS P NATL ACAD; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	64	140	178	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					777	787		10.1016/S0092-8674(00)80889-2	http://dx.doi.org/10.1016/S0092-8674(00)80889-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892748	Bronze			2022-12-28	WOS:000087821400011
J	Hahnloser, RHR; Sarpeshkar, R; Mahowald, MA; Douglas, RJ; Seung, HS				Hahnloser, RHR; Sarpeshkar, R; Mahowald, MA; Douglas, RJ; Seung, HS			Digital selection and analogue amplification coexist in a cortex-inspired silicon circuit	NATURE			English	Article							VISUAL-CORTEX; NETWORKS; ORIENTATION; ATTENTION; DYNAMICS; NEURONS; FIELDS; MODEL	Digital circuits such as the flip-flop use feedback to achieve multistability and nonlinearity to restore signals to logical levels, for example 0 and 1. Analogue feedback circuits are generally designed to operate linearly, so that signals are over a range, and the response is unique. By contrast, the response of cortical circuits to sensory stimulation can be both multistable and graded(1-4). We propose that the neocortex combines digital selection of an active set of neurons with analogue response by dynamically varying the positive feedback inherent in its recurrent connections. Strong positive feedback causes differential instabilities that drive the selection of a set of active neurons under the constraints embedded in the synaptic weights. Once selected, the active neurons generate weaker, stable feedback that provides analogue amplification of the input. Here we present our model of cortical processing as an electronic circuit that emulates this hybrid operation, and so is able to perform computations that are similar to stimulus selection, gain modulation and spatiotemporal pattern generation in the neocortex.	Univ Zurich, ETHZ, Inst Neuroinformat, CH-8057 Zurich, Switzerland; Bell Labs, Murray Hill, NJ 07974 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; AT&T; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hahnloser, RHR (corresponding author), Univ Zurich, ETHZ, Inst Neuroinformat, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Hahnloser, Richard/0000-0002-4039-7773				ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Amari S, 1977, SYSTEMS NEUROSCIENCE, V119, P165, DOI [DOI 10.1016/B978-0-12-491850-4.50009-X, 10.1007/978-3-642-46466-9]; AMARI SI, 1977, BIOL CYBERN, V27, P77, DOI 10.1007/BF00337259; AMIT DJ, 1995, BEHAV BRAIN SCI, V18, P617, DOI 10.1017/S0140525X00040164; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDREOU AG, 1989, NEURAL COMPUTAT, V1; BENYISHAI R, 1995, P NATL ACAD SCI USA, V92, P3844, DOI 10.1073/pnas.92.9.3844; Camperi M, 1998, J COMPUT NEUROSCI, V5, P383, DOI 10.1023/A:1008837311948; DEWEERTH SP, 1995, ELECTRON LETT, V31, P1051, DOI 10.1049/el:19950729; GEORGOPOULOS AP, 1993, SCIENCE, V260, P47, DOI 10.1126/science.8465199; Hahnloser RLT, 1998, NEURAL NETWORKS, V11, P691, DOI 10.1016/S0893-6080(98)00012-4; Hansel D., 1998, METHODS NEURONAL MOD, P499; HOPFIELD JJ, 1985, BIOL CYBERN, V52, P141; Horn RA., 1985, MATRIX ANAL; Indiveri G, 1997, ANALOG INTEGR CIRC S, V13, P185, DOI 10.1023/A:1008200515504; KOPECZ K, 1995, BIOL CYBERN, V73, P49, DOI 10.1007/BF00199055; Lazzaro J., 1988, ADV NEURAL INF PROCE, V1, P703; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; Mead C. A., 1991, Analog Integrated Circuits and Signal Processing, V1, P93, DOI 10.1007/BF00161303; Reynolds JH, 1999, J NEUROSCI, V19, P1736; Salinas E, 1996, P NATL ACAD SCI USA, V93, P11956, DOI 10.1073/pnas.93.21.11956; Sarpeshkar R, 1998, ANALOG INTEGR CIRC S, V16, P245, DOI 10.1023/A:1008218308069; SEUNG HS, 1993, P NATL ACAD SCI USA, V90, P10749, DOI 10.1073/pnas.90.22.10749; Treue S, 1999, NATURE, V399, P575, DOI 10.1038/21176; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; Zhang K, 1996, J NEUROSCI, V16, P2112	27	684	702	5	57	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					947	951		10.1038/35016072	http://dx.doi.org/10.1038/35016072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879535				2022-12-28	WOS:000087732700050
J	Chen, KS; Hirst, J; Camba, R; Bonagura, CA; Stout, CD; Burgess, BK; Armstrong, FA				Chen, KS; Hirst, J; Camba, R; Bonagura, CA; Stout, CD; Burgess, BK; Armstrong, FA			Atomically defined mechanism for proton transfer to a buried redox centre in a protein	NATURE			English	Article							AZOTOBACTER-VINELANDII FERREDOXIN; CYTOCHROME-C-OXIDASE; RHODOBACTER-SPHAEROIDES; STRUCTURAL-CHANGES; FILM VOLTAMMETRY; BACTERIORHODOPSIN; RESOLUTION; DYNAMICS; PATHWAYS; ATOMS	The basis of the chemiosmotic theory is that energy from light or respiration is used to generate a trans-membrane proton gradient(1). This is largely achieved by membrane-spanning enzymes known as 'proton pumps'(2-5). There is intense interest in experiments which reveal, at the molecular level, how protons are drawn through proteins(6-13). Here we report the mechanism, at atomic resolution, for a single long-range electron-coupled proton transfer. In Azotobacter vinelandii ferredoxin I, reduction of a buried iron-sulphur cluster draws in a solvent proton, whereas re-oxidation is 'gated' by proton release to the solvent. Studies of this 'proton-transferring module' by fast-scan protein film voltammetry, high-resolution crystallography, site-directed mutagenesis and molecular dynamics, reveal that proton transfer is exquisitely sensitive to the position and pK of a single amino acid. The proton is delivered through the protein matrix by rapid penetrative excursions of the side-chain carboxylate of a surface residue (Asp 15), whose pK shifts in response to the electrostatic charge on the iron-sulphur cluster. Our analysis defines the structural, dynamic and energetic requirements for proton courier groups in redox-driven proton-pumping enzymes.	Univ Oxford, Dept Chem, Oxford OX1 3QR, England; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92612 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Oxford; University of California System; University of California Irvine; Scripps Research Institute	Armstrong, FA (corresponding author), Univ Oxford, Dept Chem, S Parks Rd, Oxford OX1 3QR, England.	fraser.armstrong@chem.ox.ac.uk	Hirst, Judy/F-4803-2011	Hirst, Judy/0000-0001-8667-6797				Aono S, 1998, BIOCHEMISTRY-US, V37, P9812, DOI 10.1021/bi972818b; Armstrong FA, 1997, CHEM SOC REV, V26, P169, DOI 10.1039/cs9972600169; BANCI L, 1992, J AM CHEM SOC, V114, P10683, DOI 10.1021/ja00053a001; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P33692, DOI 10.1074/jbc.273.50.33692; Gennis RB, 1998, P NATL ACAD SCI USA, V95, P12747, DOI 10.1073/pnas.95.22.12747; Guthrie JP, 1996, J AM CHEM SOC, V118, P12886, DOI 10.1021/ja9618614; GUTMAN M, 1995, BBA-BIOENERGETICS, V1231, P123, DOI 10.1016/0005-2728(95)00074-S; Hirst J, 1998, J AM CHEM SOC, V120, P7085, DOI 10.1021/ja980380c; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; Junemann S, 1999, BIOCHEMISTRY-US, V38, P5248, DOI 10.1021/bi9830112; KLINMAN JP, 1989, TRENDS BIOCHEM SCI, V14, P368, DOI 10.1016/0968-0004(89)90010-8; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; Lubben M, 1999, BIOCHEMISTRY-US, V38, P2048, DOI 10.1021/bi981859k; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Malmstrom BG, 1998, J BIOL INORG CHEM, V3, P339, DOI 10.1007/s007750050242; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Nabedryk E, 1998, BIOCHEMISTRY-US, V37, P14457, DOI 10.1021/bi981139d; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; NOODLEMAN L, 1985, J AM CHEM SOC, V107, P3418, DOI 10.1021/ja00298a004; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Schipke CG, 1999, BIOCHEMISTRY-US, V38, P8228, DOI 10.1021/bi983008i; SHEN BH, 1993, J BIOL CHEM, V268, P25928; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STOUT CD, 1993, J BIOL CHEM, V268, P25920; Stout CD, 1998, J MOL BIOL, V278, P629, DOI 10.1006/jmbi.1998.1732; Wikstrom M, 1998, CURR OPIN STRUC BIOL, V8, P480, DOI 10.1016/S0959-440X(98)80127-9; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	30	138	139	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					814	817		10.1038/35015610	http://dx.doi.org/10.1038/35015610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866206				2022-12-28	WOS:000087620600057
J	Meijers-Heijboer, EJ; Verhoog, LC; Brekelmans, CTM; Seynaeve, C; Tilanus-Linthorst, MMA; Wagner, A; Dukel, L; Devilee, P; van den Ouweland, AMW; van Geel, AN; Klijn, JGM				Meijers-Heijboer, EJ; Verhoog, LC; Brekelmans, CTM; Seynaeve, C; Tilanus-Linthorst, MMA; Wagner, A; Dukel, L; Devilee, P; van den Ouweland, AMW; van Geel, AN; Klijn, JGM			Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation	LANCET			English	Article							HEREDITARY BREAST-CANCER; OVARIAN-CANCER; GERMLINE MUTATIONS; DECISION-MAKING; WOMEN; RISK; MASTECTOMY; TAMOXIFEN; SURVIVAL; HISTORY	Background Germline mutations in the BRCA1. and BRCA2 genes highly predispose to breast and ovarian cancer. In families with BRCA1 or BRCA2 mutations, identification of mutation carriers is clinically relevant in view of the options for surveillance and prevention. Methods We assessed presymptomatic DNA testing and prophylactic surgery in 53 consecutive families presenting to the Rotterdam Family Cancer Clinic with a known BRCA1 or BRCA2 mutation. We identified predictors for DNA testing and prophylactic surgery with univariate and multivariate analysis. Findings 682 unaffected individuals with a 50% risk (275 women and 271 men) or with a 25% risk (136 women) for carrying a mutation were identified and offered a DNA test. Presymptomatic DNA testing was requested by 48% (198 of 411) of women and 22% (59 of 271) of men (odds ratio for difference between sexes 3.21 [95% CI 2.27-4.51]; p<0.001). In women, DNA testing was significantly more frequent at young age, in the presence of children, and at high pre-test genetic risk for a mutation. Of the unaffected women with an identified mutation who were eligible for prophylactic surgery, 51% (35 of 68) opted for bilateral mastectomy and 64% (29 of 45) for oophorectomy. Parenthood was a predictor for prophylactic mastectomy but not for prophylactic oophorectomy. Age was significantly associated with prophylactic oophorectomy, but not with prophylactic mastectomy, although there was a tendency towards mastectomy at younger ages. Interpretation In a clinical setting, we show a high demand for BRCA1 and BRCA2 testing by unaffected women at risk, and of prophylactic surgery by unaffected women with the mutation. Young women with children especially opt for DNA testing and prophylactic mastectomy.	Erasmus Univ, Med Ctr Rotterdam, Dr Daniel dan Hoed Klin,Rotterdam Canc Inst, Dept Med Oncol,Family Canc Clin, NL-3075 EA Rotterdam, Netherlands; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Acad Hosp Rotterdam Dijkzigt, Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Klijn, JGM (corresponding author), Erasmus Univ, Med Ctr Rotterdam, Dr Daniel dan Hoed Klin,Rotterdam Canc Inst, Dept Med Oncol,Family Canc Clin, Groene Hilledyk 301, NL-3075 EA Rotterdam, Netherlands.		DEVILEE, PETER/ABR-2140-2022					Borgen PI, 1998, ANN SURG ONCOL, V5, P603, DOI 10.1007/BF02303829; Easton DF, 1997, AM J HUM GENET, V61, P120, DOI 10.1086/513891; EASTON DF, 1995, AM J HUM GENET, V56, P265; Eisen A, 1999, NEW ENGL J MED, V340, P137, DOI 10.1056/NEJM199901143400209; Eisinger F, 1999, LANCET, V353, P919, DOI 10.1016/S0140-6736(98)07516-3; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FORD D, 1994, LANCET, V343, P992; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Jacobsen PB, 1997, PSYCHOSOM MED, V59, P459, DOI 10.1097/00006842-199709000-00001; Klijn JGM, 1997, EUR J CANCER, V33, P2149, DOI 10.1016/S0959-8049(97)00360-2; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1998, J CLIN ONCOL, V16, P1650, DOI 10.1200/JCO.1998.16.5.1650; LERMAN C, 1995, AM J MED GENET, V57, P385, DOI 10.1002/ajmg.1320570304; Lynch HT, 1997, CANCER, V79, P2219, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2219::AID-CNCR21>3.0.CO;2-Y; Lynch HT, 1999, CANCER GENET CYTOGEN, V109, P91, DOI 10.1016/S0165-4608(98)00165-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; Powles T, 1998, LANCET, V352, P98; Rosenthal A, 1998, SEMIN ONCOL, V25, P315; SHRAG D, 1997, NEW ENGL J MED, V336, P1465; STEFANEK ME, 1995, PREV MED, V24, P412, DOI 10.1006/pmed.1995.1066; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; Verhoog LC, 1999, J CLIN ONCOL, V17, P3396, DOI 10.1200/JCO.1999.17.11.3396; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; 1999, BREAST CANC INFORMAT; 1999, J NATL CANC I, V91, P1310	29	224	225	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2015	2020		10.1016/S0140-6736(00)02347-3	http://dx.doi.org/10.1016/S0140-6736(00)02347-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885351				2022-12-28	WOS:000087519400008
J	Biggar, RJ; Frisch, M; Goedert, JJ				Biggar, RJ; Frisch, M; Goedert, JJ		AIDS-Canc Match Registry Study Grp	Risk of cancer in children with AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							KAPOSIS-SARCOMA; HIV-INFECTION; LYMPHOMA; EPIDEMIOLOGY; PEOPLE	Context Population-based data on cancers associated with acquired immunodeficiency syndrome (AIDS) in children are lacking. Objective To determine risk of pediatric AIDS-associated cancers. Design, Setting, and Participants Using records from 11 locations in the United States for varying periods between 1978 and 1996, we linked data for children aged 14 years and younger at AIDS diagnosis to local cancer registry data. Main Outcome Measures Cancer frequency and, in the 2-year post-AIDS onset period, cancer incidence and relative risk (RR; measured as standardized incidence ratio), by cancer type. Results Among 4954 children with AIDS, 124 (2.5%) were identified as having cancer before, at, or after AIDS onset, including 100 cases of non-Hodgkin lymphoma (NHL), 8 of Kaposi sarcoma (KS), 4 of leiomyosarcoma, and 2 of Hodgkin disease; there were 10 other or unspecified cancers. Expected numbers for all cancers identified in the study sample, based on population rates (using area-specific registry data), were less than 1. In the first 2 years after AIDS diagnosis (5485 person-years), NHL incidence was 510 per 100 000 person-years (RR, 651; 95% confidence interval [CI], 432-941). Median time for developing NHL after AIDS diagnosis was 14 months (range, 3-107 months). The most common type of NHL was Burkitt lymphoma. However, the risk of primary brain lymphoma (91 per 100 000 person-years) was especially high (RR, 7143; 95% CI, 2321-16692), and 4 cases were diagnosed more than 2 years (range, 37-98 months) after AIDS onset. Leiomyosarcomas also tended to occur several years after AIDS onset, with 3 of the 4 cases occurring 33 to 76 months after AIDS diagnosis, whereas KS was reported only at or within 2 years of AIDS diagnosis. Hodgkin disease risk was also significantly increased (RR, 62; 95% CI, 2-342). Conclusions The spectrum of AIDS-associated pediatric cancers resembled that seen in adults, with the addition of leiomyosarcoma. Both primary brain lymphomas and leiomyosarcomas tended to occur in children surviving several years after AIDS onset. Because the expected numbers of these cancers in this population were less than 1 and because of the small numbers of some types of observed cancers, the RR estimates are imprecise and caution is warranted in their interpretation.	NCI, VEB, Rockville, MD 20852 USA; Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Aarhus University; Statens Serum Institut	Biggar, RJ (corresponding author), NCI, VEB, 6120 Execut Blvd,Room 8014, Rockville, MD 20852 USA.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP005781] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; Biggar RJ, 1996, HEMATOL ONCOL CLIN N, V10, P997, DOI 10.1016/S0889-8588(05)70380-4; Breslow NE., 1987, STAT METHODS CANC RE, P81; *CDCP, 1995, HIV AIDS SURV REP, V7, P13; Cote TR, 1996, J NATL CANCER I, V88, P675, DOI 10.1093/jnci/88.10.675; Cote TR, 1997, INT J CANCER, V73, P645, DOI 10.1002/(SICI)1097-0215(19971127)73:5&lt;645::AID-IJC6&gt;3.0.CO;2-X; Evans JA, 1997, ARCH DIS CHILD, V76, P330, DOI 10.1136/adc.76.4.330; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Granovsky MO, 1998, J CLIN ONCOL, V16, P1729, DOI 10.1200/JCO.1998.16.5.1729; KROGHJENSEN M, 1994, ANN ONCOL, V5, P349, DOI 10.1093/oxfordjournals.annonc.a058839; McClain KL, 1996, HEMATOL ONCOL CLIN N, V10, P1189, DOI 10.1016/S0889-8588(05)70393-2; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; Percy C., 1990, INT CLASSIFICATION D; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; Serraino D, 1996, AIDS, V10, P643, DOI 10.1097/00002030-199606000-00010	16	100	106	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					205	209		10.1001/jama.284.2.205	http://dx.doi.org/10.1001/jama.284.2.205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889594	Bronze			2022-12-28	WOS:000087933100025
J	Paterson, DL; Swindells, S; Mohr, J; Brester, M; Vergis, EN; Squier, C; Wagener, MM; Singh, N				Paterson, DL; Swindells, S; Mohr, J; Brester, M; Vergis, EN; Squier, C; Wagener, MM; Singh, N			Adherence to protease inhibitor therapy and outcomes in patients with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; MORBIDITY; DISEASE; AIDS	Background: Combination antiretroviral therapy with protease inhibitors has transformed HIV infection from a terminal condition into one that is manageable. However, the complexity of regimens makes adherence to therapy difficult. Objective: To assess the effects of different levels of adherence to therapy on virologic, immunologic, and clinical outcome; to determine modifiable conditions associated with suboptimal adherence; and to determine how well clinicians predict patient adherence. Design: Prospective, observational study. Setting: HIV clinics in a Veterans Affairs medical center and a university medical center. Patients: 99 HIV-infected patients who were prescribed a protease inhibitor and who neither used a medication organizer nor received their medications in an observed setting (such as a jail or nursing home). Measurements: Adherence was measured by using a microelectronic monitoring system. The adherence rate was calculated as the number of doses taken divided by the number prescribed. Patients were followed for a median of 6 months (range, 3 to 15 months). Results: During the study period, 45 397 doses of protease inhibitor were monitored in 81 evaluable patients. Adherence was significantly associated with successful virologic: outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006). Virologic failure was documented in 22% of patients with adherence of 95% or greater, 61% of those with 80% to 94.9% adherence, and 80% of those with less than 80% adherence. Patients with adherence of 95% or greater had fewer days in the hospital (26 days per 1000 days of follow-up) than those with less than 95% adherence (12.9 days per 1000 days of follow-up; P = 0.001). No opportunistic infections or deaths occurred in patients with 95% or greater adherence. Active psychiatric illness was an independent risk factor for adherence less than 95% (P = 0.04), Physicians predicted adherence incorrectly for 41% of patients, and clinic nurses predicted it incorrectly for 30% of patients. Conclusions: Adherence to protease inhibitor therapy of 95% or greater optimized virologic outcome for patients with HIV infection. Diagnosis and treatment of psychiatric illness should be further investigated as a means to improve adherence to therapy.	Univ Pittsburgh, Med Ctr, European Med Div, Pittsburgh, PA 15213 USA; Vet Affairs Med Ctr, Pittsburgh, PA USA; Univ Nebraska, Med Ctr, Omaha, NE USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center	Singh, N (corresponding author), Univ Pittsburgh, Med Ctr, European Med Div, 10th Floor,Forbes Tower,200Lothrop St, Pittsburgh, PA 15213 USA.		Paterson, David L/A-9258-2010	Paterson, David/0000-0003-2079-4437				ANDERSON RJ, 1982, ARCH INTERN MED, V142, P1673, DOI 10.1001/archinte.142.9.1673; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BANGSBERG DR, 1999, 6 C RETR OPP INF CHI, P84; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BESCH CL, 1997, 4 NAT C RETR OPP INF, P111; BUCHSBAUM DG, 1992, J AM GERIATR SOC, V40, P662, DOI 10.1111/j.1532-5415.1992.tb01956.x; CARNEY RM, 1995, HEALTH PSYCHOL, V14, P88, DOI 10.1037/0278-6133.14.1.88; COONS SJ, 1994, CLIN THER, V16, P110; Deeks S., 1997, 37 INT C ANT AG CHEM; DRAINE J, 1994, J NERV MENT DIS, V182, P50, DOI 10.1097/00005053-199401000-00009; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; FERNANDEZ F, 1989, SOUTHERN MED J, V82, P999, DOI 10.1097/00007611-198908000-00018; Gallant J E, 1998, J Int Assoc Physicians AIDS Care, V4, P32; Gatley M S, 1968, J R Coll Gen Pract, V16, P39; Hecht F M, 1998, AIDS Clin Care, V10, P57; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Kastrissios H, 1998, AIDS, V12, P2295, DOI 10.1097/00002030-199817000-00011; Lopez-Suarez A, 1998, AIDS, V12, P685; Lyketsos CG, 1996, AIDS, V10, P1033, DOI 10.1097/00002030-199610090-00015; Malahy B, 1966, Am J Hosp Pharm, V23, P283; Mehta S, 1997, AIDS, V11, P1665, DOI 10.1097/00002030-199714000-00002; Montaner JSG, 1998, LANCET, V352, P1919, DOI 10.1016/S0140-6736(98)07532-1; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PORTER AMW, 1969, BMJ-BRIT MED J, V1, P218, DOI 10.1136/bmj.1.5638.218; PUGH R, 1983, BRIT J MED PSYCHOL, V56, P205, DOI 10.1111/j.2044-8341.1983.tb01548.x; Rodriguez-Rosado R, 1998, AIDS, V12, P1112; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WATERHOUSE DM, 1993, J CLIN ONCOL, V11, P1189, DOI 10.1200/JCO.1993.11.6.1189; Young J L, 1986, Bull Am Acad Psychiatry Law, V14, P105; ZICH J, 1987, J APPL SOC PSYCHOL, V17, P193, DOI 10.1111/j.1559-1816.1987.tb00310.x	32	2387	2448	5	119	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					21	30		10.7326/0003-4819-133-1-200007040-00004	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329TB	10877736				2022-12-28	WOS:000087923100003
J	Tattersall, R; Turner, B				Tattersall, R; Turner, B			Brown-Sequard and his syndrome	LANCET			English	Article									Univ Nottingham Hosp, Nottingham NG7 2UH, England	University of Nottingham	Tattersall, R (corresponding author), Curzon House, Gotham NG11 0HQ, Notts, England.							AMINOFF MJ, 1993, BROWNSEQUARD VISIONA; Brown-S?quard C-E., 1856, CR HEBD ACAD SCI, V43, P422; Brown-Sequard C E, 1893, Br Med J, V1, P1145; Brown-Sequard CE, 1869, LANCET, V1, P1; KOEHLER PJ, 1986, ARCH NEUROL-CHICAGO, V43, P921, DOI 10.1001/archneur.1986.00520090051015; OLMSTED JMD, 1946, CE BROWNSEQUARD 19TH; 1889, BMJ, V1, P1416	7	28	28	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					61	63		10.1016/S0140-6736(00)02441-7	http://dx.doi.org/10.1016/S0140-6736(00)02441-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892778				2022-12-28	WOS:000087933400041
J	Gray, RD; Jordan, FM				Gray, RD; Jordan, FM			Language trees support the express-train sequence of Austronesian expansion	NATURE			English	Article							POLYNESIA; HISTORY; PACIFIC; MTDNA; ANTHROPOLOGY; PREHISTORY; PHYLOGENY; SPEAKING; PATTERNS; ORIGIN	Languages, like molecules, document evolutionary history. Darwin(1) observed that evolutionary change in languages greatly resembled the processes of biological evolution: inheritance from a common ancestor and convergent evolution operate in both. Despite many suggestions(2-4), few attempts have been made to apply the phylogenetic methods used in biology to linguistic data. Here we report a parsimony analysis of a large language data set. We use this analysis to test competing hypotheses - the "express-train''(5) and the "entangled-bank''(6,7) models - for the colonization of the Pacific by Austronesian-speaking peoples. The parsimony analysis of a matrix of 77 Austronesian languages with 5,185 lexical items produced a single most-parsimonious tree. The express-train model was converted into an ordered geographical character and mapped onto the language tree. We found that the topology of the language tree was highly compatible with the express-train model.	Univ Auckland, Dept Psychol, Auckland 92019, New Zealand	University of Auckland	Gray, RD (corresponding author), Univ Auckland, Dept Psychol, Auckland 92019, New Zealand.		Gray, Russell/H-2078-2015	Gray, Russell/0000-0002-9858-0191				[Anonymous], 1997, GUNS GERMS STEEL; BATEMAN R, 1990, CURR ANTHROPOL, V31, P1, DOI 10.1086/203800; BELLWOOD P, 1991, SCI AM, V265, P88, DOI 10.1038/scientificamerican0791-88; Bellwood Peter, 1997, PREHISTORY INDOMALAY; BLUST R, 1995, J WORLD PREHIST, V9, P453, DOI 10.1007/BF02221119; BLUST R, 1991, CURRENTS PACIFIC LIN, P27; Crowley T., 1997, INTRO HIST LINGUISTI, V3; Cunningham CW, 1998, TRENDS ECOL EVOL, V13, P361, DOI 10.1016/S0169-5347(98)01382-2; Darwin C., 1871, P475; DIAMOND JM, 1988, NATURE, V336, P307, DOI 10.1038/336307a0; Green RC., 1999, B INDOPACIFIC PREHIS, V18, P3; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; KIRCH PV, 1987, CURR ANTHROPOL, V28, P431, DOI 10.1086/203547; KIRCH PV, 1997, LAPITA PEOPLES; Lum JK, 1998, AM J PHYS ANTHROPOL, V105, P109, DOI 10.1002/(SICI)1096-8644(199802)105:2<109::AID-AJPA1>3.0.CO;2-Q; MACE R, 1994, CURR ANTHROPOL, V35, P549, DOI 10.1086/204317; MADDISON WP, 1992, MACCLADE ANAL PHYLOG; MARTIN A, 1993, NATURE, V364, P494, DOI 10.1038/364494a0; Matisoo-Smith E, 1998, P NATL ACAD SCI USA, V95, P15145, DOI 10.1073/pnas.95.25.15145; MELTON T, 1995, AM J HUM GENET, V57, P403; MOORE JH, 1994, AM ANTHROPOL, V96, P925, DOI 10.1525/aa.1994.96.4.02a00110; Rossabi Morris, 1994, CENTRAL ASIA HIST PE, P27; Ruvolo M., 1987, P193; SANDERSON MJ, 1989, EVOLUTION, V43, P1781, DOI 10.1111/j.1558-5646.1989.tb02626.x; Swofford D.L., 1999, PHYLOGENETIC ANAL US; TERRELL J, 1988, ANTIQUITY, V62, P642, DOI 10.1017/S0003598X00075049; Terrell J., 1986, PREHISTORY PACIFIC I; Terrell JE, 1997, CURR ANTHROPOL, V38, P155, DOI 10.1086/204604; Warnow T, 1997, P NATL ACAD SCI USA, V94, P6585, DOI 10.1073/pnas.94.13.6585; Weisler MI, 1998, CURR ANTHROPOL, V39, P521, DOI 10.1086/204768	30	242	247	1	39	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1052	1055		10.1038/35016575	http://dx.doi.org/10.1038/35016575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	328VN	10890445	Green Published			2022-12-28	WOS:000087871700045
J	Tevosian, SG; Deconinck, AE; Tanaka, M; Schinke, M; Litovsky, SH; Izumo, S; Fujiwara, Y; Orkin, SH				Tevosian, SG; Deconinck, AE; Tanaka, M; Schinke, M; Litovsky, SH; Izumo, S; Fujiwara, Y; Orkin, SH			FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium	CELL			English	Article							ZINC-FINGER PROTEIN; CARDIAC DEVELOPMENT; SMOOTH-MUSCLE; RXR-ALPHA; VENTRAL MORPHOGENESIS; TRANSGENIC MICE; TUBE FORMATION; MOUSE EMBRYO; AVIAN HEART; DIFFERENTIATION	We disrupted the FOG-2 gene in mice to define its requirement in vivo. FOG-2(-/-) embryos die at midgestation with a cardiac defect characterized by a thin ventricular myocardium, common atrioventricular canal, and the tetralogy of Fallot malformation. Remarkably, coronary vasculature is absent in FOG-2(-/-) hearts. Despite formation of an intact epicardial layer and expression of epicardium-specific genes, markers of cardiac vessel development (ICAM-2 and FLK-1) are not detected, indicative of failure to activate their expression and/or to initiate the epithelial to mesenchymal transformation of epicardial cells. Transgenic reexpression of FOG-2 in cardiomyocytes rescues the FOG-2(-/-) vascular phenotype, demonstrating that FOG-2 function in myocardium is required and sufficient for coronary vessel development. Our findings provide the molecular inroad into the induction of coronary vasculature by myocardium in the developing heart.	Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Cardiol, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute	Orkin, SH (corresponding author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.	orkin@rascal.med.harvard.edu						BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen J, 1998, DEVELOPMENT, V125, P1943; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; GELB BD, 1991, AM J MED GENET, V40, P471, DOI 10.1002/ajmg.1320400420; Gittenberger-de Groot AC, 1998, CIRC RES, V82, P1043, DOI 10.1161/01.RES.82.10.1043; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; HARVEY RP, 1999, HEART DEV, P111; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HONG X, 1992, J IMMUNOL, V149, P2650; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KOMIYAMA M, 1987, ANAT EMBRYOL, V176, P183, DOI 10.1007/BF00310051; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; KWEE L, 1995, DEVELOPMENT, V121, P489; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Lee RY, 1997, CIRC RES, V80, P757; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Markwald R, 1996, ACTA ANAT, V156, P173; MIKAWA T, 1992, P NATL ACAD SCI USA, V89, P9504, DOI 10.1073/pnas.89.20.9504; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Moore AW, 1999, DEVELOPMENT, V126, P1845; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; ORKIN SH, 1998, MOL BIOL B CELL T CE; PARMACEK MS, 1999, HEART DEV, P291; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; Pehlivan T, 1999, AM J MED GENET, V83, P201, DOI 10.1002/(SICI)1096-8628(19990319)83:3<201::AID-AJMG11>3.0.CO;2-V; Perez-Pomares JM, 1998, DEV BIOL, V200, P57, DOI 10.1006/dbio.1998.8949; POELMANN RE, 1993, CIRC RES, V73, P559, DOI 10.1161/01.RES.73.3.559; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SRIVASTAVA D, 1999, HEART DEV, P143; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tomanek RJ, 1996, CARDIOVASC RES, V31, pE46; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Van Praagh R, 1989, Eur J Cardiothorac Surg, V3, P381, DOI 10.1016/1010-7940(89)90044-4; VIRAGH S, 1981, ANAT REC, V201, P157, DOI 10.1002/ar.1092010117; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Wu H, 1999, DEVELOPMENT, V126, P3597; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YANG JT, 1995, DEVELOPMENT, V121, P549; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zou YM, 1997, DEVELOPMENT, V124, P793	64	317	325	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 23	2000	101	7					729	739		10.1016/S0092-8674(00)80885-5	http://dx.doi.org/10.1016/S0092-8674(00)80885-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892744	Bronze			2022-12-28	WOS:000087821400007
J	Hoffman, JR; Mower, WR; Wolfson, AB; Todd, KH; Zucker, MI				Hoffman, JR; Mower, WR; Wolfson, AB; Todd, KH; Zucker, MI		Natl Emergency X-Radiography Utilil Study Grp	Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	National Scientific Assembly of the Society-for-Academic-Emergency-Medicine	MAY   21, 1999	BOSTON, MASSACHUSETTS				RADIOGRAPHIC EVALUATION; EMERGENCY-MEDICINE; FRACTURE; METHODOLOGY; RELIABILITY; STANDARDS	Background: Because clinicians fear missing occult cervical-spine injuries, they obtain cervical radiographs for nearly all patients who present with blunt trauma. Previous research suggests that a set of clinical criteria (decision instrument) can identify patients who have an extremely low probability of injury and who consequently have no need for imaging studies. Methods: We conducted a prospective, observational study of such a decision instrument at 21 centers across the United States. The decision instrument required patients to meet five criteria in order to be classified as having a low probability of injury: no midline cervical tenderness, no focal neurologic deficit, normal alertness, no intoxication, and no painful, distracting injury. We examined the performance of the decision instrument in 34,069 patients who underwent radiography of the cervical spine after blunt trauma. Results: The decision instrument identified all but 8 of the 818 patients who had cervical-spine injury (sensitivity, 99.0 percent [95 percent confidence interval, 98.0 to 99.6 percent]). The negative predictive value was 99.8 percent (95 percent confidence interval, 99.6 to 100 percent), the specificity was 12.9 percent, and the positive predictive value was 2.7 percent. Only two of the patients classified as unlikely to have an injury according to the decision instrument met the preset definition of a clinically significant injury (sensitivity, 99.6 percent [95 percent confidence interval, 98.6 to 100 percent]; negative predictive value, 99.9 percent [95 percent confidence interval, 99.8 to 100 percent]; specificity, 12.9 percent; positive predictive value, 1.9 percent), and only one of these two patients received surgical treatment. According to the results of assessment with the decision instrument, radiographic imaging could have been avoided in the cases of 4309 (12.6 percent) of the 34,069 evaluated patients. Conclusions: A simple decision instrument based on clinical criteria can help physicians to identify reliably the patients who need radiography of the cervical spine after blunt trauma. Application of this instrument could reduce the use of imaging in such patients. (N Engl J Med 2000;343:94-9.) (C) 2000, Massachusetts Medical Society.	Univ Calif Los Angeles, Ctr Emergency Med, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Radiol, Los Angeles, CA 90024 USA; Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; Emory Univ, Sch Med, Dept Surg, Div Emergency Med, Atlanta, GA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University	Mower, WR (corresponding author), Univ Calif Los Angeles, Ctr Emergency Med, Sch Med, 924 Westwood Blvd,Suite 300, Los Angeles, CA 90024 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008239] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS08239] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BRESLER MJ, 1982, ANN EMERG MED, V11, P440, DOI 10.1016/S0196-0644(82)80043-7; CADOUX CG, 1987, ANN EMERG MED, V16, P738, DOI 10.1016/S0196-0644(87)80565-6; *COMM BIOL EFF ION, 1990, BEIR, V4, P281; COX G R, 1991, Journal of Emergency Medicine, V9, P123, DOI 10.1016/0736-4679(91)90316-8; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; FLANCBAUM L, 1987, EMERG MED SERV, V16, P89; FLANCBAUM L, 1987, EMERG MED SERV, V16, P36; FLANCBAUM L, 1987, EMERG MED SERV, V16, P38; GATRELL CB, 1985, AM J EMERG MED, V3, P263, DOI 10.1016/0735-6757(85)90108-1; HAINES JD, 1986, POSTGRAD MED, V80, P73, DOI 10.1080/00325481.1986.11699483; HAINES JD, 1986, POSTGRAD MED, V80, P77; Hoffman JR, 1998, ANN EMERG MED, V32, P461, DOI 10.1016/S0196-0644(98)70176-3; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; HUDA W, 1990, MED PHYS, V17, P998, DOI 10.1118/1.596445; JACOBS LM, 1986, ANN EMERG MED, V15, P44, DOI 10.1016/S0196-0644(86)80485-1; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KNOPP RK, 1987, ANN EMERG MED, V16, P819, DOI 10.1016/S0196-0644(87)80587-5; KREIPKE DL, 1989, J TRAUMA, V29, P1438, DOI 10.1097/00005373-198910000-00024; Lieberman J F, 1988, J Tenn Med Assoc, V81, P243; LINDSEY RW, 1993, SOUTHERN MED J, V86, P1253, DOI 10.1097/00007611-199311000-00013; MACE SE, 1991, ANN EMERG MED, V20, P1373, DOI 10.1016/S0196-0644(05)81083-2; Mahadevan S, 1998, ANN EMERG MED, V31, P197, DOI 10.1016/S0196-0644(98)70306-3; MAULL KI, 1977, SOUTHERN MED J, V70, P477, DOI 10.1097/00007611-197704000-00033; MCKEE TR, 1990, J TRAUMA, V30, P623, DOI 10.1097/00005373-199005000-00018; MCNAMARA RM, 1988, ANN EMERG MED, V17, P906, DOI 10.1016/S0196-0644(88)80669-3; Moorhead JC, 1998, ANN EMERG MED, V31, P595, DOI 10.1016/S0196-0644(98)70207-0; Mower WR, 1990, ANN EMERG MED, V19, P1220; NEIFELD G L, 1988, Journal of Emergency Medicine, V6, P203, DOI 10.1016/0736-4679(88)90327-7; PLUNKETT PK, 1987, J ROY SOC MED, V80, P46, DOI 10.1177/014107688708000117; RIFKINSONMANN S, 1986, SURG NEUROL, V26, P413, DOI 10.1016/0090-3019(86)90148-5; RINGENBERG BJ, 1988, ANN EMERG MED, V17, P792, DOI 10.1016/S0196-0644(88)80555-9; ROBERGE R J, 1992, Journal of Emergency Medicine, V10, P539, DOI 10.1016/0736-4679(92)90133-E; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSA L, 1989, MIL MED, V154, P39, DOI 10.1093/milmed/154.1.39; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; SUMCHAI AP, 1987, ANN EMERG MED, V16, P726; SWEENEY JF, 1992, ANN EMERG MED, V21, P1288, DOI 10.1016/S0196-0644(05)81768-8; THAMBYRAJAH K, 1972, MED J MALAYSIA, V26, P244; WALTER J, 1984, ANN EMERG MED, V13, P512, DOI 10.1016/S0196-0644(84)80515-6; WALTER JJ, 1985, AM J EMERG MED, V3, P264, DOI 10.1016/0735-6757(85)90109-3; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEBB JK, 1976, J BONE JOINT SURG BR, V58, P322, DOI 10.1302/0301-620X.58B3.956249	43	759	770	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					94	99		10.1056/NEJM200007133430203	http://dx.doi.org/10.1056/NEJM200007133430203			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891516				2022-12-28	WOS:000088116500003
J	Dorozynski, A				Dorozynski, A			France bans morning after pill from schools	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					70	70						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884249				2022-12-28	WOS:000088196600015
J	Reed, CA; Kim, KC; Bolskar, RD; Mueller, LJ				Reed, CA; Kim, KC; Bolskar, RD; Mueller, LJ			Taming superacids: Stabilization of the fullerene cations HC60+ and C-60(.+)	SCIENCE			English	Article							SPECTROSCOPIC OBSERVATION; CHEMISTRY; ANIONS; C60; C-13; C-70; C70; NMR; ION	A new superacid, H(CB11H6X6) (where X = chlorine or bromine), whose conjugate base is the exceptionally inert CB11H6X6- carborane anion, separates Bronsted acidity from oxidizing capacity and anion nucleophilicity in a manner not previously achieved. Reaction of this superacid with C-60 gives HC60+ as a stable ion in solution and in the solid state. In a separate experiment, an oxidant was developed such that the long-sought C-60(.+) ion can be synthesized in solution. The preparation of these two fullerene carbocations is a notable departure from the prevalent chemistry of C-60, which is dominated by the formation of anions or the addition of nucleophiles. The H(CB11H6X6) superacid overcomes the major limitations of presently known superacids and has potentially wide application.	Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Reed, CA (corresponding author), Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA.			Mueller, Leonard/0000-0002-2607-9875	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023851] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23851] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARD AJ, 1976, ADV PHYSICAL ORGANIC, V13, P155; BAUSCH JW, 1991, J AM CHEM SOC, V113, P3205, DOI 10.1021/ja00008a077; Bolskar RD, 1996, J AM CHEM SOC, V118, P13093, DOI 10.1021/ja962294n; CATALDO F, 1995, SPECTROCHIM ACTA A, V51, P405, DOI 10.1016/0584-8539(94)E0111-M; Connelly NG, 1996, CHEM REV, V96, P877, DOI 10.1021/cr940053x; deRege PJF, 1997, SCIENCE, V276, P776, DOI 10.1126/science.276.5313.776; Drews T, 1997, ANGEW CHEM INT EDIT, V36, P273, DOI 10.1002/anie.199702731; Gillespie R.J., 1975, ADV INORG CHEM RAD, V17, P49; HADDON RC, 1992, ACCOUNTS CHEM RES, V25, P127, DOI 10.1021/ar00015a005; Haw JF, 1996, ACCOUNTS CHEM RES, V29, P259, DOI 10.1021/ar950105k; HENDERSON CC, 1993, SCIENCE, V259, P1885, DOI 10.1126/science.259.5103.1885; KATO T, 1991, CHEM PHYS LETT, V180, P446, DOI 10.1016/0009-2614(91)85147-O; Kitagawa T, 1999, J AM CHEM SOC, V121, P4298, DOI 10.1021/ja9900048; MILLER GP, 1992, MATER RES SOC SYMP P, V247, P293, DOI 10.1557/PROC-247-293; O'Donnell T. A., 1993, SUPERACIDS ACIDIC ME; OLAH GA, 1978, J AM CHEM SOC, V100, P6299, DOI 10.1021/ja00488a001; OLAH GA, 1985, SUPERACIDS; Reed CA, 2000, CHEM REV, V100, P1075, DOI 10.1021/cr980017o; Reed CA, 1998, ACCOUNTS CHEM RES, V31, P133, DOI 10.1021/ar970230r; Reed CA, 1999, J AM CHEM SOC, V121, P6314, DOI 10.1021/ja981861z; Reed CA, 1998, ACCOUNTS CHEM RES, V31, P325, DOI 10.1021/ar960132q; Taylor R., 1999, LECT NOTES FULLERENE; Wang GW, 1997, NATURE, V387, P583, DOI 10.1038/42439; WILLNER H, 1997, ANGEW CHEM INT EDIT, V36, P2402; WUDL F, 1992, ACCOUNTS CHEM RES, V25, P157, DOI 10.1021/ar00015a009; XIE QS, 1993, J AM CHEM SOC, V115, P9818, DOI 10.1021/ja00074a066	26	224	226	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					101	104		10.1126/science.289.5476.101	http://dx.doi.org/10.1126/science.289.5476.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884220	Green Published			2022-12-28	WOS:000088090400040
J	Morton-Bours, EC; Jacobs, MB; Albers, GW				Morton-Bours, EC; Jacobs, MB; Albers, GW			Eyes wide open.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ISCHEMIC STROKE; YOUNG-ADULTS; HEART		Stanford Med Grp, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Stanford, CA 94305 USA; Stanford Stroke Ctr, Dept Neurol & Neurol Sci, Palo Alto, CA USA	Stanford University; Stanford University; Stanford University	Jacobs, MB (corresponding author), Stanford Med Grp, Dept Med, 900 Blake Wilbur Dr,Rm 2071, Palo Alto, CA 94304 USA.	mbjacobs@leland.stanford.edu		Albers, Gregory/0000-0003-0263-4632				ADAMS HP, 1994, CIRCULATION, V90, P1588, DOI 10.1161/01.CIR.90.3.1588; [Anonymous], 1989, ARCH NEUROL-CHICAGO, V46, P1079; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BEVAN H, 1990, STROKE, V21, P382, DOI 10.1161/01.STR.21.3.382; BOGOUSSLAVSKY J, 1992, NEUROL CLIN, V10, P113, DOI 10.1016/S0733-8619(18)30236-6; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Kittner SJ, 1998, NEUROLOGY, V50, P890, DOI 10.1212/WNL.50.4.890; REYNEN K, 1995, NEW ENGL J MED, V333, P1610, DOI 10.1056/NEJM199512143332407; Roberts WC, 1997, AM J CARDIOL, V80, P671, DOI 10.1016/S0002-9149(97)00587-0; SCHMID C, 1988, KLIN WOCHENSCHR, V66, P713, DOI 10.1007/BF01726413; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445	12	8	8	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					50	55		10.1056/NEJM200007063430108	http://dx.doi.org/10.1056/NEJM200007063430108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882769				2022-12-28	WOS:000087987600008
J	Janne, PA; Mayer, RJ				Janne, PA; Mayer, RJ			Primary care: Chemoprevention of colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; EPITHELIAL-CELL PROLIFERATION; FATAL COLON-CANCER; METHIONINE SYNTHASE GENE; METHYLENETETRAHYDROFOLATE REDUCTASE; CYCLOOXYGENASE-2 LEVELS; BETA-CAROTENE		Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Janne, PA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.							Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; Baron JA, 1998, J NATL CANCER I, V90, P57, DOI 10.1093/jnci/90.1.57; BARON JA, 1995, JNCI-J NATL CANCER I, V87, P1303, DOI 10.1093/jnci/87.17.1303; BENITO E, 1991, INT J CANCER, V49, P161, DOI 10.1002/ijc.2910490202; Boolbol SK, 1996, CANCER RES, V56, P2556; BOSTICK RM, 1995, JNCI-J NATL CANCER I, V87, P1307, DOI 10.1093/jnci/87.17.1307; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CAMPAGNOLI C, 1993, GYNECOL ENDOCRINOL, V7, P251, DOI 10.3109/09513599309152509; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen J, 1998, CARCINOGENESIS, V19, P2129, DOI 10.1093/carcin/19.12.2129; Collet JP, 1999, BRIT J CANCER, V81, P62, DOI 10.1038/sj.bjc.6690651; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; EARNEST DL, 1994, CANCER RES, V54, P5071; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fernandez E, 1998, CANCER EPIDEM BIOMAR, V7, P329; FERRARONI M, 1994, BRIT J CANCER, V70, P1150, DOI 10.1038/bjc.1994.463; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Fujita T, 1998, CANCER RES, V58, P4823; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grodstein F, 1998, ANN INTERN MED, V128, P705, DOI 10.7326/0003-4819-128-9-199805010-00001; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hebert-Croteau N, 1998, CANCER EPIDEM BIOMAR, V7, P653; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Holt PR, 1998, JAMA-J AM MED ASSOC, V280, P1074, DOI 10.1001/jama.280.12.1074; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Hyman J, 1998, CANCER EPIDEM BIOMAR, V7, P291; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; Kawamori T, 1998, CANCER RES, V58, P409; Keller JJ, 1999, GUT, V45, P822, DOI 10.1136/gut.45.6.822; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LAPRE JA, 1993, CANCER RES, V53, P248; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; Ma J, 1999, CANCER EPIDEM BIOMAR, V8, P825; Ma J, 1997, CANCER RES, V57, P1098; Ma J, 1999, J NATL CANCER I, V91, P620, DOI 10.1093/jnci/91.7.620; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; Malila N, 1999, CANCER EPIDEM BIOMAR, V8, P489; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MARTINEZ ME, 1995, CANCER EPIDEM BIOMAR, V4, P703; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCKEOWNEYSSEN GE, 1995, J CLIN EPIDEMIOL, V48, pR1; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; Meyskens FL, 1999, CLIN CANCER RES, V5, P945; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; PENCE BC, 1993, MUTAT RES, V290, P87, DOI 10.1016/0027-5107(93)90036-F; Piazza GA, 1997, CANCER RES, V57, P2909; Potter JD, 1996, CANCER EPIDEM BIOMAR, V5, P779; RAO CV, 1993, CANCER RES, V53, P2502; RAO CV, 1995, CANCER RES, V55, P1464; Reeves MJ, 1996, CANCER EPIDEM BIOMAR, V5, P955; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; RUSTGI AK, 1994, NEW ENGL J MED, V331, P1694, DOI 10.1056/NEJM199412223312507; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Sheng HM, 1998, CANCER RES, V58, P362; Slattery ML, 1999, CANCER EPIDEM BIOMAR, V8, P513; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; SPAGNESI MT, 1994, GASTROENTEROLOGY, V106, P362, DOI 10.1016/0016-5085(94)90593-2; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tsujii M, 1998, CELL, V94; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yang VW, 1998, CANCER RES, V58, P1750	101	388	405	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1960	1968		10.1056/NEJM200006293422606	http://dx.doi.org/10.1056/NEJM200006293422606			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874065				2022-12-28	WOS:000087867400006
J	Rutberg, RL; Hemming, SR; Goldstein, SL				Rutberg, RL; Hemming, SR; Goldstein, SL			Reduced North Atlantic Deep Water flux to the glacial Southern Ocean inferred from neodymium isotope ratios	NATURE			English	Article							CIRCULATION; SEA; DELTA-C-13; SEAWATER; ND; SEDIMENT; STAGE-2; CLIMATE; VOSTOK; CARBON	The global circulation of the oceans and the atmosphere transports heat around the Earth. Broecker and Denton(1) suggested that changes in the global ocean circulation might have triggered or enhanced the glacial-interglacial cycles. But proxy data for past circulation taken from sediment cores in the South Atlantic Ocean have yielded conflicting interpretations of ocean circulation in glacial times-delta(13)C variations in benthic foraminifera(2-6) support the idea of a glacial weakening or shutdown of North Atlantic Deep Water production, whereas other proxies, such as Cd/Ca, Ba/Ca and Pa-231/Th-230 ratios, show little change from the Last Glacial Maximum to the Holocene epoch(7-9). Here we report neodymium isotope ratios from the dispersed Fe-Mn oxide component of two southeast Atlantic sediment cores. Both cores show variations that tend towards North Atlantic signatures during the warm marine isotope stages 1 and 3, whereas for the full glacial stages 2 and 4 they are closer to Pacific Ocean signatures. We conclude that the export of North Atlantic Deep Water to the Southern Ocean has resembled present-day conditions during the warm climate intervals, but was reduced during the cold stages. An increase in biological productivity may explain the various proxy data during the times of reduced North Atlantic Deep Water export.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Columbia University; Columbia University	Goldstein, SL (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Hemming, Sidney/0000-0001-8117-2303				Abouchami W, 1997, GEOCHIM COSMOCHIM AC, V61, P3957, DOI 10.1016/S0016-7037(97)00218-4; ALBAREDE F, 1992, GEOLOGY, V20, P761, DOI 10.1130/0091-7613(1992)020<0761:WMONII>2.3.CO;2; Albarede F, 1997, GEOCHIM COSMOCHIM AC, V61, P1277, DOI 10.1016/S0016-7037(96)00404-8; Asmus T, 1999, MAR GEOL, V159, P63, DOI 10.1016/S0025-3227(98)00199-6; Basile I, 1997, EARTH PLANET SC LETT, V146, P573, DOI 10.1016/S0012-821X(96)00255-5; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; Broecker W.S., 1982, TRACERS SEA; BROECKER WS, 1989, GEOCHIM COSMOCHIM AC, V53, P2465, DOI 10.1016/0016-7037(89)90123-3; CHARLES CD, 1992, NATURE, V355, P416, DOI 10.1038/355416a0; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; CURRY WB, 1983, NATURE, V308, P317; FOWLER SW, 1987, NATURE, V329, P56, DOI 10.1038/329056a0; JEANDEL C, 1995, GEOCHIM COSMOCHIM AC, V59, P535, DOI 10.1016/0016-7037(94)00367-U; JEANDEL C, 1993, EARTH PLANET SC LETT, V117, P581, DOI 10.1016/0012-821X(93)90104-H; JONES CE, 1994, EARTH PLANET SC LETT, V127, P55, DOI 10.1016/0012-821X(94)90197-X; KUMAR N, 1995, NATURE, V378, P675, DOI 10.1038/378675a0; Labeyrie L, 1996, PALEOCEANOGRAPHY, V11, P57, DOI 10.1029/95PA02255; Lea DW, 1990, PALEOCEANOGRAPHY, V5, P719, DOI 10.1029/PA005i005p00719; LEA DW, 1995, PALEOCEANOGRAPHY, V10, P733, DOI 10.1029/95PA01546; Levitus S, 1994, WORLD OCEAN ATLAS 19; MACKENSEN A, 1993, PALEOCEANOGRAPHY, V8, P587, DOI 10.1029/93PA01291; Matsumoto K, 1999, PALEOCEANOGRAPHY, V14, P149, DOI 10.1029/1998PA900028; MCCORKLE DC, 1995, PALEOCEANOGRAPHY, V10, P699, DOI 10.1029/95PA01427; OPPO DW, 1987, EARTH PLANET SC LETT, V86, P1, DOI 10.1016/0012-821X(87)90183-X; PETIT JR, 1990, NATURE, V343, P56, DOI 10.1038/343056a0; PIEPGRAS DJ, 1982, SCIENCE, V217, P207, DOI 10.1126/science.217.4556.207; PIEPGRAS DJ, 1987, GEOCHIM COSMOCHIM AC, V51, P1257, DOI 10.1016/0016-7037(87)90217-1; PIEPGRAS DJ, 1988, GEOCHIM COSMOCHIM AC, V52, P1373, DOI 10.1016/0016-7037(88)90208-6; Pudsey CJ, 1998, MAR GEOL, V148, P83, DOI 10.1016/S0025-3227(98)00014-0; SCHMITZ WJ, 1996, 9608 WHOI; STORDAL MC, 1986, EARTH PLANET SC LETT, V77, P259, DOI 10.1016/0012-821X(86)90138-X; TUCHOLKE BE, 1984, INTERREGIONAL UNCONF, P145; Yu EF, 1996, NATURE, V379, P689, DOI 10.1038/379689a0	34	231	238	5	58	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					935	938		10.1038/35016049	http://dx.doi.org/10.1038/35016049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879531				2022-12-28	WOS:000087732700046
J	Willenheimer, R; Swedberg, K				Willenheimer, R; Swedberg, K			Dressing heart-failure patients on Savile row - tailored treatment?	LANCET			English	Editorial Material									Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden; Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden	Lund University; Skane University Hospital; Sahlgrenska University Hospital	Willenheimer, R (corresponding author), Malmo Univ Hosp, Dept Cardiol, SE-20502 Malmo, Sweden.		Swedberg, Karl/B-2475-2008					BENEDICT CR, 1995, AM J CARDIOL, V75, P1151, DOI 10.1016/S0002-9149(99)80748-6; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; CLELAND JGF, 1994, EUR HEART J, V15, P125, DOI 10.1093/oxfordjournals.eurheartj.a060364; Hjalmarson A, 1999, LANCET, V353, P2001; Lechat P, 1999, LANCET, V353, P9; Lim PO, 2000, HEART, V83, P257, DOI 10.1136/heart.83.3.257; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Roig E, 2000, EUR HEART J, V21, P53, DOI 10.1053/euhj.1999.1740; Troughton RW, 2000, LANCET, V355, P1126, DOI 10.1016/S0140-6736(00)02060-2; Yusuf S, 2000, NEW ENGL J MED, V342, P145	11	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2012	2013		10.1016/S0140-6736(00)02344-8	http://dx.doi.org/10.1016/S0140-6736(00)02344-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885349				2022-12-28	WOS:000087519400005
J	Metzgar, D; Wills, C				Metzgar, D; Wills, C			Evidence for the adaptive evolution of mutation rates	CELL			English	Review							ESCHERICHIA-COLI; MUTATORS; POPULATIONS; BACTERIA		Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Metzgar, D (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	dmetzgar@biomail.ucsd.edu						de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Dickinson WJ, 1999, NATURE, V399, P30, DOI 10.1038/19894; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; GOULD SJ, 1979, P ROY SOC LOND B BIO, V205, P581, DOI DOI 10.1098/RSPB.1979.0086; Haraguchi Y, 1996, J THEOR BIOL, V183, P121, DOI 10.1006/jtbi.1996.9999; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Miller JH, 1999, J BACTERIOL, V181, P1576, DOI 10.1128/JB.181.5.1576-1584.1999; Moxon ER, 1999, SCI AM, V280, P94, DOI 10.1038/scientificamerican0199-94; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Najdenski H, 1995, CONTRIB TO MICROBIOL, V13, P281; Radman M, 1999, NATURE, V401, P866, DOI 10.1038/44738; Rosenberg SM, 1998, GENETICS, V148, P1559; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Tenaillon O, 1999, GENETICS, V152, P485; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Weber M, 1996, BIOL PHILOS, V11, P67, DOI 10.1007/BF00127472	18	96	96	5	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2000	101	6					581	584		10.1016/S0092-8674(00)80869-7	http://dx.doi.org/10.1016/S0092-8674(00)80869-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892644	Bronze			2022-12-28	WOS:000087504500004
J	Naryshkin, N; Revyakin, A; Kim, YG; Mekler, V; Ebright, RH				Naryshkin, N; Revyakin, A; Kim, YG; Mekler, V; Ebright, RH			Structural organization of the RNA polymerase-promoter open complex	CELL			English	Article							TRANSCRIPTION ELONGATION COMPLEX; ACID RESTRICTION FRAGMENTS; PHOTO-CROSS-LINKING; CAP-DNA COMPLEX; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; SIGMA(70) SUBUNIT; BETA-SUBUNIT; BINDING	We have used systematic site-specific protein-DNA photocrosslinking to define interactions between bacterial RNA polymerase (RNAP) and promoter DNA in the catalytically competent RNAP-promoter open complex (RPo). We have mapped more than 100 distinct crosslinks between individual segments of RNAP subunits and individual phosphates of promoter DNA. The results provide a comprehensive description of protein-DNA interactions in RPo, permit construction of a detailed model for the structure of RPo, and permit analysis of effects of a transcriptional activator on the structure of RPo.	Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Dept Chem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick	Ebright, RH (corresponding author), Rutgers State Univ, Waksman Inst, Howard Hughes Med Inst, Dept Chem, POB 759, Piscataway, NJ 08854 USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN G, 1989, SEQUENCING PROTEINS; ARTHUR T, 2000, IN PRESS J BIOL CHEM; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Bown JA, 1999, J BIOL CHEM, V274, P2263, DOI 10.1074/jbc.274.4.2263; Brodolin K, 2000, J BIOL CHEM, V275, P3661, DOI 10.1074/jbc.275.5.3661; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; Burr T, 2000, NUCLEIC ACIDS RES, V28, P1864, DOI 10.1093/nar/28.9.1864; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Darst SA, 1998, COLD SPRING HARB SYM, V63, P269, DOI 10.1101/sqb.1998.63.269; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Ebright RH, 1998, COLD SPRING HARB SYM, V63, P11, DOI 10.1101/sqb.1998.63.11; Estrem ST, 1999, GENE DEV, V13, P2134, DOI 10.1101/gad.13.16.2134; GRACHEV M, 1987, EUR J BIOCHEM, V180, P577; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; MELANCON P, 1983, BIOCHEMISTRY-US, V22, P5169, DOI 10.1021/bi00291a017; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; NARYSHKIN N, 2000, IN PRESS METHODS MOL; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; NIU W, 1998, THESIS RUTGERS U NEW; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Opalka N, 2000, P NATL ACAD SCI USA, V97, P617, DOI 10.1073/pnas.97.2.617; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; REZNIKOFF WS, 1984, S SOC GEN MICROBIOL, V36, P195; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; Smith Bryan John, 1996, P389, DOI 10.1007/978-1-60327-259-9_67; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929	58	156	163	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					601	611		10.1016/S0092-8674(00)80872-7	http://dx.doi.org/10.1016/S0092-8674(00)80872-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892647	Bronze			2022-12-28	WOS:000087504500007
J	Schmucker, D; Clemens, JC; Shu, H; Worby, CA; Xiao, J; Muda, M; Dixon, JE; Zipursky, SL				Schmucker, D; Clemens, JC; Shu, H; Worby, CA; Xiao, J; Muda, M; Dixon, JE; Zipursky, SL			Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity	CELL			English	Article							GROWTH CONE GUIDANCE; ADAPTER PROTEIN; GENETIC-ANALYSIS; NERVOUS-SYSTEM; MECHANISMS; CADHERINS; REGION; KINASE; DOCK; CELL	A Drosophila homolog of human Down syndrome cell adhesion molecule (DSCAM), an immunoglobulin superfamily member, was isolated by its affinity to Dock, an SH3/SH2 adaptor protein required for axon guidance. Dscam binds directly to both Dock's SH2 and SH3 domains. Genetic studies revealed that Dscam, Dock and Pak, a serine/threonine kinase, act together to direct pathfinding of Bolwig's nerve, containing a subclass of sensory axons, to an intermediate target in the embryo. Dscam also is required for the formation of axon pathways in the embryonic central nervous system. cDNA and genomic analyses reveal the existence of multiple forms of Dscam with a conserved architecture containing variable Ig and transmembrane domains. Alternative splicing can potentially generate more than 38,000 Dscam isoforms. This molecular diversity may contribute to the specificity of neuronal connectivity.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90024 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, 1301 E Catherine, Ann Arbor, MI 48109 USA.			Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM08042] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright TD, 2000, CELL, V100, pS1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; CLEMENS JC, 2000, IN PRESS P NATL ACAD; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; Desai CJ, 1999, DEVELOPMENT, V126, P1527; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Guthrie S, 1999, CURR BIOL, V9, pR432, DOI 10.1016/S0960-9822(99)80274-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEITZLER P, 1993, GENETICS, V135, P105; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; HOCH M, 1994, DEVELOPMENT, V120, P3439; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LIN CH, 1993, J CELL BIOL, V121, P1369, DOI 10.1083/jcb.121.6.1369; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1995, DNA CLONING PRACTICA, P1; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKANE CJ, 1998, DROSOPHILA PRACTICAL, P139; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARDUE ML, 1994, DROSOPHILA MELANOGAS, P334; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schmucker D, 1997, DEVELOPMENT, V124, P937; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Serafini T, 1999, CELL, V98, P133, DOI 10.1016/S0092-8674(00)81008-9; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; Takeichi M, 1997, COLD SPRING HARB SYM, V62, P505; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TANG J, 2000, IN PRESS J BIOL CHEM; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THOMAS JB, 1984, NATURE, V310, P203, DOI 10.1038/310203a0; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yamakawa K, 1998, HUM MOL GENET, V7, P227, DOI 10.1093/hmg/7.2.227	55	788	813	4	88	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					671	684		10.1016/S0092-8674(00)80878-8	http://dx.doi.org/10.1016/S0092-8674(00)80878-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892653	Bronze			2022-12-28	WOS:000087504500013
J	Guzman, MG; Kouri, G; Halstead, SB				Guzman, MG; Kouri, G; Halstead, SB			Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics?	LANCET			English	Article							ANTIBODY-DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; POLIOVIRUS; VIRUS; EVOLUTION	During the Cuban dengue epidemics of 1981 and 1997, significant monthly increases were observed in the proportion of total cases that presented as dengue haemorrhagic fever or dengue shock syndrome (DHF/DSS), and in case-fatality rates for both dengue fever and DHF/DSS. We believe that theses increases can be explained by the hypothesis that some of the population of antibodies against dengue 1 virus raised after natural primary infections react with "neutralisation" determinants found on dengue 2 viruses. These heterotypic antibodies do not prevent secondary dengue 2 infections, but serve to down-regulate the disease to mild illness or symptomless infections. A population of dengue 2 viruses that replicates in dengue-1-immune hosts escape heterotypic neutralisation. When inoculated into a new dengue-1-immune host, these viruses are free to interact with the more abundant infection-enhancing antibodies to produce severe disease.	Inst Trop Med Pedro Kouri, Havana, Cuba; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA	Johns Hopkins University	Guzman, MG (corresponding author), Autopista Novia del Meliodia, Inst Trop Med, Dept Virol, Km 6 POB 601, Havana 13, Cuba.							Bottiger B, 1997, CLIN DIAGN VIROL, V8, P105, DOI 10.1016/S0928-0197(97)00018-4; Ferguson N, 1999, P NATL ACAD SCI USA, V96, P790, DOI 10.1073/pnas.96.2.790; GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179; GUZMAN MG, 1997, IN PRESS AM J EPIDEM; HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1; HUOVILAINEN A, 1987, J GEN VIROL, V68, P1373, DOI 10.1099/0022-1317-68-5-1373; KETTERLINUS R, 1993, VIROLOGY, V192, P525, DOI 10.1006/viro.1993.1068; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; KOURI GP, 1987, T ROY SOC TROP MED H, V81, P821, DOI 10.1016/0035-9203(87)90042-3; LAMBKIN R, 1994, J GEN VIROL, V75, P3493, DOI 10.1099/0022-1317-75-12-3493; MINOR PD, 1993, DEV BIOL STAND, V78, P17; OGRA PL, 1991, J INFECT DIS, V164, P191, DOI 10.1093/infdis/164.1.191; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30; Valdes L, 1999, Rev Panam Salud Publica, V6, P16, DOI 10.1590/S1020-49891999000600003	16	59	69	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1902	1903		10.1016/S0140-6736(00)02303-5	http://dx.doi.org/10.1016/S0140-6736(00)02303-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866460				2022-12-28	WOS:000087306500043
J	Frost, MH; Schaid, DJ; Sellers, TA; Slezak, JM; Arnold, PG; Woods, JE; Petty, PM; Johnson, JL; Sitta, DL; McDonnell, SK; Rummans, TA; Jenkins, RB; Sloan, JA; Hartmann, LC				Frost, MH; Schaid, DJ; Sellers, TA; Slezak, JM; Arnold, PG; Woods, JE; Petty, PM; Johnson, JL; Sitta, DL; McDonnell, SK; Rummans, TA; Jenkins, RB; Sloan, JA; Hartmann, LC			Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; OUTCOMES; QUALITY; HEALTH; LIFE	Context Prophylactic mastectomy is a preventive option for women who wish to reduce their risk of breast cancer. There has been concern about possible negative psychological sequelae following this procedure. However, few data are available regarding long-term satisfaction and psychological and social function following this procedure. Objective To evaluate patients' long-term satisfaction and psychological and social function following prophylactic mastectomy. Design, Setting, and Participants Descriptive study of all women known to be alive (n=609) who had a family history of breast cancer and elected to undergo bilateral prophylactic mastectomy at a large, tertiary US health care clinic between 1960 and 1993, 94% (n = 572) of whom completed a study questionnaire. Main Outcome Measures Satisfaction with procedure and effects on psychological and social function, based on responses to the study-specific questionnaire. Results Mean time from prophylactic mastectomy to last follow-up was 14.5 years. Most women (70%) were satisfied with the procedure; 11% were neutral; and 19% were dissatisfied. Among the psychological and social variables, the most striking finding was that 74% reported a diminished level of emotional concern about developing breast cancer. The majority of women reported no change/favorable effects in levels of emotional stability (68%/23%), level of stress (58%/28%), self-esteem (69%/ 13%), sexual relationships (73%/4%), and feelings of femininity (67%/8%). Forty-eight percent reported no change in their level of satisfaction with body appearance; 16% reported favorable effects. However, 9%, 14%, 18%, 23%, 25%, and 36% reported negative effects in these 6 variables, respectively. Conclusions This study suggests that positive outcomes following prophylactic mastectomy include decreased emotional concern about developing breast cancer and generally favorable psychological and social outcomes. These must be weighed against the irreversibility of the decision, potential problems with implants and reconstructive surgery, and occurrence of adverse psychological and social outcomes in some women.	Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Res Serv, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Plast & Reconstruct Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Clin Epidemiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Frost, MH (corresponding author), Mayo Clin & Mayo Fdn, Div Med Oncol, 200 1st St SW, Rochester, MN 55905 USA.			McDonnell, Shannon/0000-0001-6201-369X	PHS HHS [R01-80181] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Borgen PI, 1998, ANN SURG ONCOL, V5, P603, DOI 10.1007/BF02303829; Eisen A, 1999, NEW ENGL J MED, V340, P137, DOI 10.1056/NEJM199901143400209; Eisinger F, 1997, J NATL CANCER I, V89, P731, DOI 10.1093/jnci/89.10.731; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Grana G., 1994, Breast Cancer Research and Treatment, V32, P72; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; KRAUSE NM, 1994, MED CARE, V32, P930, DOI 10.1097/00005650-199409000-00004; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LOVE SM, 1995, S LOVES BREAST BOOK, P247; MARGOLIS GJ, 1989, PSYCHOSOMATICS, V30, P192, DOI 10.1016/S0033-3182(89)72300-8; SPITZER WO, 1987, J CHRON DIS, V40, P465, DOI 10.1016/0021-9681(87)90002-6; Stefanek M E, 1995, J Natl Cancer Inst Monogr, P37; STEFANEK ME, 1995, PREV MED, V24, P412, DOI 10.1006/pmed.1995.1066; WARE JE, 1991, CANCER, V67, P774, DOI 10.1002/1097-0142(19910201)67:3+<774::AID-CNCR2820671404>3.0.CO;2-I; Wolberg W H, 1990, Oncology (Williston Park), V4, P101	15	226	228	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					319	324		10.1001/jama.284.3.319	http://dx.doi.org/10.1001/jama.284.3.319			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891963	Bronze			2022-12-28	WOS:000088123000024
J	Neil, HAW; Hammond, T; Huxley, R; Matthews, DR; Humphries, SE				Neil, HAW; Hammond, T; Huxley, R; Matthews, DR; Humphries, SE			Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study	BRITISH MEDICAL JOURNAL			English	Article									Radcliffe Infirm, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX2 6HE, England; Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England; Royal Free & UCL, Rayne Inst, Ctr Cardiovasc Genet, London WC1E 6JJ, England	Radcliffe Infirmary; University of Oxford; University of Oxford; University of London; King's College London; University College London	Neil, HAW (corresponding author), Radcliffe Infirm, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX2 6HE, England.	andrew.neil@dphpc.ox.ac.uk	Huxley, Rachel R/C-7032-2013; Humphries, Stephen E/C-5075-2008; Huxley, Rachel R/J-4638-2013	Huxley, Rachel R/0000-0002-2705-6616; Huxley, Rachel R/0000-0002-2705-6616; Humphries, Stephen E/0000-0002-8221-6547				Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; MARKS D, IN PRESS HLTH TECHNO; Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105; SLACK J, 1969, LANCET, V2, P1380; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476	5	140	143	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					148	148		10.1136/bmj.321.7254.148	http://dx.doi.org/10.1136/bmj.321.7254.148			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894692	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000088305700021
J	Lederman, MM; Valdez, H				Lederman, MM; Valdez, H			Immune restoration with antiretroviral therapies - Implications for clinical management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ADVANCED HIV-1 DISEASE; T-CELL FUNCTION; PNEUMOCYSTIS-CARINII PNEUMONIA; PROTEASE-INHIBITOR THERAPY; CYTOMEGALOVIRUS RETINITIS; CONTROLLED TRIAL; MAINTENANCE THERAPY; LOAD REDUCTION; AIDS	Recent dramatic decreases in acquired immunodeficiency syndrome-related mortality are largely due to the introduction of highly active antiretroviral therapy (HAART). Although immune restoration due to suppression of human immunodeficiency virus (HIV) replication is a critical determinant of these trends, the magnitude of immune restoration seen after treatment with HAART varies substantially among treated persons and is generally incomplete. Nonetheless, even partial immune restoration is sufficient to provide protection from most major opportunistic infections; these risks can be largely predicted by the number of circulating CD4 cells. Limited data suggest that treatment earlier during the course of HIV infection may result in greater preservation of immune function, though this has not been studied in great detail. Preliminary studies performed among persons with multidrug-resistant virus whose treatment regimens are failing suggest that there is likely a benefit to continuation of therapy that may be related to diminished pathogenicity of drug-resistant virus, As deaths related to opportunistic infections diminish, the spectrum of causes of mortality in HIV infection is changing. Except for Kaposi sarcoma, there is insufficient information to conclude that the risks of non-Hodgkin lymphoma and other malignancies are diminishing among persons with HIV infection. How much immune restoration will be enough,to ensure long-term survival in persons with HIV infection remains an open question.	Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr AIDS Res, Cleveland, OH USA	University Hospitals of Cleveland; Case Western Reserve University	Lederman, MM (corresponding author), Univ Hosp Cleveland, Div Infect Dis, 2061 Cornell Rd, Cleveland, OH 44106 USA.	MXL6@po.cwru.edu			NIAID NIH HHS [AI25879, AI36219, AI85388] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219, U01AI025879, R21AI085388] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERG J, 2000, 7 C RETR OPP INF JAN; Aberg JA, 1998, J INFECT DIS, V178, P1446, DOI 10.1086/314469; Al-Harthi L, 1998, J CLIN IMMUNOL, V18, P124, DOI 10.1023/A:1023246800353; Al-Harthi L, 2000, AIDS, V14, P761, DOI 10.1097/00002030-200005050-00001; Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Arno A, 1999, J INFECT DIS, V180, P56, DOI 10.1086/314831; Arno A, 1998, AIDS, V12, P697, DOI 10.1097/00002030-199807000-00005; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Badley AD, 1998, J CLIN INVEST, V102, P79, DOI 10.1172/JCI2691; Bisset LR, 1998, AIDS, V12, P2115, DOI 10.1097/00002030-199816000-00006; BRITES EA, 1998, 12 INT C AIDS JUN 28; Bucy RP, 1999, J CLIN INVEST, V103, P1391, DOI 10.1172/JCI5863; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; Canzano JC, 1998, RETINA-J RET VIT DIS, V18, P443; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; Chehimi J, 1997, J IMMUNOL, V158, P5978; CHOWDRY TVH, 2000, 7 C RETR OPP INF JAN; Connick E, 2000, J INFECT DIS, V181, P358, DOI 10.1086/315171; Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971; DEEKS S, 2000, 7 C RETR OPP INF JAN; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Deresinski SC, 1999, AIDS, V13, P633, DOI 10.1097/00002030-199904160-00003; El-Sadr WM, 2000, NEW ENGL J MED, V342, P1085, DOI 10.1056/NEJM200004133421503; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; Garcia F, 2000, CLIN INFECT DIS, V30, P392, DOI 10.1086/313660; Giorgi JV, 1998, AIDS, V12, P1833, DOI 10.1097/00002030-199814000-00015; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gray CM, 1998, AIDS RES HUM RETROV, V14, P561, DOI 10.1089/aid.1998.14.561; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HILL A, 1999, 3 INT WORKSH DRUG RE; Jacobson LP, 1999, J ACQ IMMUN DEF SYND, V21, pS34; JOHNSON S, 2000, 7 C RETR OPP INF JAN; Jones JL, 1999, J ACQ IMMUN DEF SYND, V21, pS11; Kanai T, 1996, J IMMUNOL, V157, P3681; Karavellas MP, 1999, J INFECT DIS, V179, P697, DOI 10.1086/314639; KATLAMA C, 2000, 7 C RETR OPP INF JAN; Kees UR, 1999, IMMUNOLOGY, V96, P202; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kostense S, 1998, AIDS, V12, pF235, DOI 10.1097/00002030-199818000-00001; Kovacs JA, 2000, NEW ENGL J MED, V342, P1416, DOI 10.1056/NEJM200005113421907; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; LEDERGERBER B, 2000, 7 C RETR OPP INF JAN; Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202; MCGOVERN B, 1999, 37 ANN M INF DIS SOC; Mezzaroma I, 1999, AIDS, V13, P1187, DOI 10.1097/00002030-199907090-00006; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; MILLER V, 1999, 39 INT  ANT AG CHEM; MIRO J, 2000, 7 C RETR OPP INF JAN; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V21, P401; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; Notermans DW, 1999, J INFECT DIS, V180, P1050, DOI 10.1086/315013; OKAMOTO Y, 2000, 7 C RETR OPP INF JAN; Pakker NG, 1997, J ACQ IMMUN DEF SYND, V16, P318, DOI 10.1097/00042560-199712150-00002; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Patki AH, 1999, AIDS, V13, P1177, DOI 10.1097/00002030-199907090-00005; Patki AH, 1996, J CLIN INVEST, V98, P616, DOI 10.1172/JCI118831; Pezzotti P, 1999, INT J EPIDEMIOL, V28, P975, DOI 10.1093/ije/28.5.975; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; Rabkin CS, 1999, J ACQ IMMUN DEF SYND, V21, pS31; Race EM, 1998, LANCET, V351, P252, DOI 10.1016/S0140-6736(97)04352-3; Renaud M, 1999, AIDS, V13, P669, DOI 10.1097/00002030-199904160-00007; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSENBERG ES, 1999, 37 ANN M INF DIS SOC; TEIXEIRA L, 2000, 7 C RETR OPP INF JAN; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; Valdez H, 2000, AIDS, V14, P11, DOI 10.1097/00002030-200001070-00002; Valdez H, 1999, ARCH INTERN MED, V159, P1771, DOI 10.1001/archinte.159.15.1771; VALENTINE F, 1999, 6 C RETR OPP INF JAN; VALENTINE F, 2000, 7 C RETR OPP INF JAN; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; Weiss L, 1999, J INFECT DIS, V180, P1057, DOI 10.1086/315025; Wendland T, 1999, AIDS, V13, P1857, DOI 10.1097/00002030-199910010-00007; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Whitcup SM, 2000, JAMA-J AM MED ASSOC, V283, P653, DOI 10.1001/jama.283.5.653; Whitcup SM, 1999, JAMA-J AM MED ASSOC, V282, P1633, DOI 10.1001/jama.282.17.1633; WU H, 2000, 7 C RETR OPP INF JAN; Wu HL, 1999, J INFECT DIS, V179, P799, DOI 10.1086/314670; Yangco BG, 2000, ANN INTERN MED, V132, P201, DOI 10.7326/0003-4819-132-3-200002010-00005	84	97	100	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					223	228		10.1001/jama.284.2.223	http://dx.doi.org/10.1001/jama.284.2.223			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889597				2022-12-28	WOS:000087933100028
J	Persson, M; Vitols, S; Yue, QY				Persson, M; Vitols, S; Yue, QY			Drug points - Orlistat associated with hypertension	BRITISH MEDICAL JOURNAL			English	Letter									Karolinska Univ Hosp, Reg Ctr Pharmacovigilance, SE-17176 Stockholm, Sweden; Med Prod Agcy, Pharmacovigilance Unit, Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Medical Products Agency	Persson, M (corresponding author), Karolinska Univ Hosp, Reg Ctr Pharmacovigilance, SE-17176 Stockholm, Sweden.							TONSTAD S, 1994, EUR J CLIN PHARMACOL, V46, P405, DOI 10.1007/BF00191901	1	16	16	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 8	2000	321	7253					87	87		10.1136/bmj.321.7253.87	http://dx.doi.org/10.1136/bmj.321.7253.87			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884258	Bronze			2022-12-28	WOS:000088196600026
J	Schink, B; Friedrich, M				Schink, B; Friedrich, M			Bacterial metabolism - Phosphite oxidation by sulphate reduction	NATURE			English	Article							ACIDS		Univ Constance, Fac Biol, D-78457 Constance, Germany; Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	University of Konstanz; Max Planck Society	Schink, B (corresponding author), Univ Constance, Fac Biol, POB 5560, D-78457 Constance, Germany.		Friedrich, Michael W./B-3151-2013	Friedrich, Michael W./0000-0002-8055-3232				COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; DEVAI I, 1988, NATURE, V333, P343, DOI 10.1038/333343a0; FOSTER TL, 1978, APPL ENVIRON MICROB, V35, P937, DOI 10.1128/AEM.35.5.937-944.1978; GASSMANN G, 1993, ANGEW CHEM INT EDIT, V32, P761, DOI 10.1002/anie.199307611; GASSMANN G, 1993, NATURWISSENSCHAFTEN, V80, P78, DOI 10.1007/BF01140420; MALACINSKI G, 1966, J BACTERIOL, V91, P578, DOI 10.1128/JB.91.2.578-582.1966; Metcalf WW, 1998, J BACTERIOL, V180, P5547, DOI 10.1128/JB.180.21.5547-5558.1998; Schwartz AW, 1997, J THEOR BIOL, V187, P523, DOI 10.1006/jtbi.1996.0386; Ternan NG, 1998, WORLD J MICROB BIOT, V14, P635, DOI 10.1023/A:1008848401799; TSUBOTA G., 1959, Soil and Plant Food, V5, P10; WEAST RC, 1988, CRC HDB CHEM PHYSICS; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470	12	100	112	3	60	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					37	37		10.1038/35017644	http://dx.doi.org/10.1038/35017644			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894531	Green Submitted, Bronze			2022-12-28	WOS:000087991200034
J	Bignami, GF				Bignami, GF			The microscope's coat of arms ... or, the sting of the bee and the moons of Jupiter.	NATURE			English	Editorial Material									Italian Space Agcy, I-00198 Rome, Italy	Agenzia Spaziale Italiana (ASI)	Bignami, GF (corresponding author), Italian Space Agcy, Viale Liegi 26, I-00198 Rome, Italy.			Bignami, Giovanni/0000-0001-9582-2450					0	6	6	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					999	999		10.1038/35016689	http://dx.doi.org/10.1038/35016689			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890423				2022-12-28	WOS:000087871700023
J	Baxter, AG				Baxter, AG			Symptomless infection with Ebola virus	LANCET			English	Editorial Material									Centenary Inst Canc Med & Cell Biol, Newtown, NSW 2042, Australia	University of Sydney; Centenary Institute	Baxter, AG (corresponding author), Centenary Inst Canc Med & Cell Biol, Locked Bag 6, Newtown, NSW 2042, Australia.		Baxter, Alan G/A-1412-2010	Baxter, Alan G/0000-0002-6960-9821				Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; BENNETT D, 1995, BRIT MED J, V310, P1344, DOI 10.1136/bmj.310.6991.1344; Calain P, 1999, VIROLOGY, V262, P114, DOI 10.1006/viro.1999.9915; Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284; Georges AJ, 1999, J INFECT DIS, V179, pS65, DOI 10.1086/514290; Morvan JM, 1999, MICROBES INFECT, V1, P1193, DOI 10.1016/S1286-4579(99)00242-7; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034	8	8	10	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2178	2179		10.1016/S0140-6736(00)02394-1	http://dx.doi.org/10.1016/S0140-6736(00)02394-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881884				2022-12-28	WOS:000087779000002
J	Graham, HK				Graham, HK			Pendulum test in cerebral palsy	LANCET			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; BOTULINUM TOXIN; RHIZOTOMY; LIMB		Royal Childrens Hosp, Dept Orthopaed Surg, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Graham, HK (corresponding author), Royal Childrens Hosp, Dept Orthopaed Surg, Parkville, Vic 3052, Australia.		Graham, Kerr/AAK-4383-2020					Corry IS, 1997, DEV MED CHILD NEUROL, V39, P185; COSGROVE AP, 1994, DEV MED CHILD NEUROL, V36, P386; Fowler EG, 2000, DEV MED CHILD NEUROL, V42, P182; KIRSCHNER B, 1985, J CHRON DIS, V40, P171; McLaughlin JF, 1998, DEV MED CHILD NEUROL, V40, P220; ROSENBAUM PL, 1991, DIPLEGIC CHILD; RUSSELL D, 1989, DEV MED CHILD NEUROL, V18, P341; Stanley FJ, 2000, CEREBRAL PALSIES EPI; Steinbok P, 1997, DEV MED CHILD NEUROL, V39, P178; WARTENBERG R, 1951, NEUROLOGY, V1, P18, DOI 10.1212/WNL.1.1.18	10	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 24	2000	355	9222					2184	2184		10.1016/S0140-6736(00)02399-0	http://dx.doi.org/10.1016/S0140-6736(00)02399-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881889				2022-12-28	WOS:000087779000007
J	Leroy, EM; Baize, S; Volchkov, VE; Fisher-Hoch, SP; Georges-Courbot, MC; Lansoud-Soukate, J; Capron, M; Debre, P; McCormick, JB; Georges, AJ				Leroy, EM; Baize, S; Volchkov, VE; Fisher-Hoch, SP; Georges-Courbot, MC; Lansoud-Soukate, J; Capron, M; Debre, P; McCormick, JB; Georges, AJ			Human asymptomatic Ebola infection and strong inflammatory response	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; VIRUS-INFECTION; INTERLEUKIN-1; LYMPHOCYTES; DISEASE; CELLS	Background Ebola virus is one of the most virulent pathogens, killing a very high proportion of patients within 5-7 days. Two outbreaks of fulminating haemorrhagic fever occurred in northern Gabon in 1996, with a 70% case-fatality rate. During both outbreaks we identified some individuals in direct contact with sick patients who never developed symptoms. We aimed to determine whether these individuals were indeed infected with Ebola virus, and how they maintained asymptomatic status. Methods Blood was collected from 24 close contacts of symptomatic patients. These asymptomatic individuals were sampled 2, 3, or 4 times during a 1-month period after the first exposure to symptomatic patients. Serum samples were analysed for the presence of Ebola antigens, virus-specific IgM and IgG (by ELISA and western blot), and different cytokines and chemokines. RNA was extracted from peripheral blood mononuclear cells, and reverse-transcriptase-PCR assays were done to amplify RNA of Ebola virus. PCR products were then sequenced. Findings 11 of 24 asymptomatic individuals developed both IgM and IgG responses to Ebola antigens, indicating viral infection. Western-blot analysis showed that IgG responses were directed to nucleoprotein and viral protein of 40 kDa. The glycoprotein and viral protein of 24 kDa genes showed no nucleotide differences between symptomatic and asymptomatic individuals. Asymptomatic individuals had a strong inflammatory response characterised by high circulating concentrations of cytokines and chemokines. Interpretation This study showed that asymptomatic, replicative Ebola infection can and does occur in human beings. The lack of genetic differences between symptomatic and asymptomatic individuals suggest that asymptomatic Ebola infection did not result from viral mutations. Elucidation of the factors related to the genesis of the strong inflammatory response occurring early during the infectious process in these asymptomatic individuals could increase our understanding of the disease.	Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Fdn Marcel Merieux, F-69002 Lyon, France; Inst Pasteur, Ctr Immunol & Biol Parasitaire, INSERM, U167, F-59019 Lille, France; Hop La Pitie Salpetriere, CNRS, Lab Cent Immunol Cellulaire & Tissulaire, Paris, France; Hop La Pitie Salpetriere, Unite U625, Paris, France	Philipps University Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Leroy, EM (corresponding author), Ctr Int Rech Med Franceville, BP 769, Franceville, Gabon.	leroy@cirmf.sci.ga	LEROY, Eric M/I-4347-2016; Volchkov, Viktor/M-7846-2014	LEROY, Eric M/0000-0003-0022-0890; Volchkov, Viktor/0000-0001-7896-8706; McCormick, Joseph/0000-0002-5844-8102; Baize, Sylvain/0000-0002-3234-7477				Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BOWEN ETW, 1977, LANCET, V1, P571; Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; Feldmann H, 1996, J VIROL, V70, P2208, DOI 10.1128/JVI.70.4.2208-2214.1996; Feldmann H, 1996, ADV VIRUS RES, V47, P1, DOI 10.1016/S0065-3527(08)60733-2; FELDMANN H, 1993, ARCH VIROL, V7, pS81; GEISBERT TW, 1992, J COMP PATHOL, V106, P137, DOI 10.1016/0021-9975(92)90043-T; Georges AJ, 1999, J INFECT DIS, V179, pS65, DOI 10.1086/514290; Gunn MD, 1997, J IMMUNOL, V158, P376; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; LE JM, 1987, J IMMUNOL, V139, P3330; Leroy EM, 2000, J MED VIROL, V60, P463, DOI 10.1002/(SICI)1096-9071(200004)60:4&lt;463::AID-JMV15&gt;3.0.CO;2-M; Martini G.A., 1971, MARBURG VIRUS DIS; Orange JS, 1996, J IMMUNOL, V156, P4746; Peters CJ, 1999, CURR TOP MICROBIOL, V235, P85; Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291; Rowe AK, 1999, J INFECT DIS, V179, pS28, DOI 10.1086/514318; Ruby J, 1997, J EXP MED, V186, P1591, DOI 10.1084/jem.186.9.1591; Ryabchikova E, 1996, ARCH VIROL, V141, P909, DOI 10.1007/BF01718165; Sanchez A, 1999, J INFECT DIS, V179, pS164, DOI 10.1086/514282; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SMITH DIH, 1978, B WORLD HEALTH ORGAN, V56, P2447; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yang ZY, 1998, SCIENCE, V279, P1034, DOI 10.1126/science.279.5353.1034; Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319	33	301	313	2	71	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	2000	355	9222					2210	2215		10.1016/S0140-6736(00)02405-3	http://dx.doi.org/10.1016/S0140-6736(00)02405-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327DX	10881895	Bronze			2022-12-28	WOS:000087779000013
J	Gammon, D				Gammon, D			Semiconductor physics - Electrons in artificial atoms	NATURE			English	Editorial Material							QUANTUM-DOT; SPECTROSCOPY; STATES		USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Gammon, D (corresponding author), USN, Res Lab, Code 6876,Bldg 208,Room 348,4555 Overlook Ave SW, Washington, DC 20375 USA.							[Anonymous], 1998, MRS B, V23; Banin U, 1999, NATURE, V400, P542, DOI 10.1038/22979; Bayer M, 2000, NATURE, V405, P923, DOI 10.1038/35016020; Berman G P, 1998, INTRO QUANTUM COMPUT; Bonadeo NH, 1998, SCIENCE, V282, P1473, DOI 10.1126/science.282.5393.1473; Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991; Findeis F, 2000, SOLID STATE COMMUN, V114, P227, DOI 10.1016/S0038-1098(00)00019-3; Landin L, 1998, SCIENCE, V280, P262, DOI 10.1126/science.280.5361.262; Miller BT, 1997, PHYS REV B, V56, P6764, DOI 10.1103/PhysRevB.56.6764; Warburton RJ, 2000, NATURE, V405, P926, DOI 10.1038/35016030	11	56	56	1	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					899	900		10.1038/35016189	http://dx.doi.org/10.1038/35016189			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879518				2022-12-28	WOS:000087732700031
J	Nadis, S				Nadis, S			Brookhaven collider opens its quest for Big Bang conditions	NATURE			English	News Item																		Abbott A, 2000, NATURE, V403, P581, DOI 10.1038/35001196	1	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					874	874		10.1038/35016225	http://dx.doi.org/10.1038/35016225			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879502	Bronze			2022-12-28	WOS:000087732700009
J	Warburton, RJ; Schaflein, C; Haft, D; Bickel, F; Lorke, A; Karrai, K; Garcia, JM; Schoenfeld, W; Petroff, PM				Warburton, RJ; Schaflein, C; Haft, D; Bickel, F; Lorke, A; Karrai, K; Garcia, JM; Schoenfeld, W; Petroff, PM			Optical emission from a charge-tunable quantum ring	NATURE			English	Article							ELECTRON GROUND-STATES; EXCHANGE INTERACTION; CARRIER RELAXATION; MAGNETIC-FIELD; FINE-STRUCTURE; DOTS; SPECTROSCOPY; EXCITONS; SPECTRUM; STORAGE	Quantum dots or rings are artificial nanometre-sized clusters that confine electrons in all three directions. They can be fabricated in a semiconductor system by embedding an island of low-bandgap material in a sea of material with a higher bandgap. Quantum dots are often referred to as artificial atoms because, when filled sequentially with electrons, the charging energies are pronounced for particular electron numbers(1-3); this is analogous to Hund's rules in atomic physics. But semiconductors also have a valence band with strong optical transitions to the conduction band. These transitions are the basis for the application of quantum dots as laser emitters(4), storage devices(5-7) and fluorescence markers(8). Here we report how the optical emission (photoluminescence) of a single quantum ring changes as electrons are added one-by-one. We find that the emission energy changes abruptly whenever an electron is added to the artificial atom, and that the sizes of the jumps reveal a shell structure.	Univ Munich, Sekt Phys, D-80539 Munich, Germany; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, QUEST, Santa Barbara, CA 93106 USA; Univ Munich, Ctr Nanosci, D-80539 Munich, Germany	University of Munich; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Munich	Warburton, RJ (corresponding author), Heriot Watt Univ, Dept Phys, Edinburgh EH14 4AS, Midlothian, Scotland.		Lorke, Axel/A-1170-2013; Lorke, Axel/AAI-9116-2021; Petroff, Pierre/M-9840-2019; Garcia, Jorge M./B-5221-2008; Warburton, Richard/ABC-3609-2021	Lorke, Axel/0000-0002-0405-7720; Lorke, Axel/0000-0002-0405-7720; Garcia, Jorge M./0000-0001-6906-6268; Schoenfeld, Winston/0000-0003-4008-0458				ASHOORI RC, 1993, PHYS REV LETT, V71, P613, DOI 10.1103/PhysRevLett.71.613; Banin U, 1999, NATURE, V400, P542, DOI 10.1038/22979; Bayer M, 1999, PHYS REV LETT, V82, P1748, DOI 10.1103/PhysRevLett.82.1748; BIMBERG D, 1998, QUANTUM DOT HETEROST; BLACKWOOD E, 1994, PHYS REV B, V50, P14246, DOI 10.1103/PhysRevB.50.14246; Bockelmann U, 1996, PHYS REV LETT, V76, P3622, DOI 10.1103/PhysRevLett.76.3622; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Dekel E, 1998, PHYS REV LETT, V80, P4991, DOI 10.1103/PhysRevLett.80.4991; DREXLER H, 1994, PHYS REV LETT, V73, P2252, DOI 10.1103/PhysRevLett.73.2252; Empedocles SA, 1997, SCIENCE, V278, P2114, DOI 10.1126/science.278.5346.2114; Finley JJ, 1998, APPL PHYS LETT, V73, P2618, DOI 10.1063/1.122524; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Garcia JM, 1997, APPL PHYS LETT, V71, P2014, DOI 10.1063/1.119772; Lorke A, 2000, PHYS REV LETT, V84, P2223, DOI 10.1103/PhysRevLett.84.2223; Lundstrom T, 1999, SCIENCE, V286, P2312, DOI 10.1126/science.286.5448.2312; MedeirosRibeiro G, 1997, PHYS REV B, V55, P1568, DOI 10.1103/PhysRevB.55.1568; Miller BT, 1997, PHYS REV B, V56, P6764, DOI 10.1103/PhysRevB.56.6764; Miller BT, 1998, PHYSICA B, V249, P257, DOI 10.1016/S0921-4526(98)00110-0; Ridley B.K., 1982, QUANTUM PROCESSES SE; Sosnowski TS, 1998, PHYS REV B, V57, pR9423, DOI 10.1103/PhysRevB.57.R9423; Toda Y, 1999, PHYS REV LETT, V82, P4114, DOI 10.1103/PhysRevLett.82.4114; Wojs A, 1997, PHYS REV B, V55, P13066, DOI 10.1103/PhysRevB.55.13066; Yusa G, 1997, APPL PHYS LETT, V70, P345, DOI 10.1063/1.119068	24	813	817	2	116	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					926	929		10.1038/35016030	http://dx.doi.org/10.1038/35016030			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879528	Green Submitted			2022-12-28	WOS:000087732700043
J	[Anonymous]				[Anonymous]			A significant time for Europe	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 22	2000	405	6789					869	869						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879496				2022-12-28	WOS:000087732700001
J	Lockhart, DJ; Winzeler, EA				Lockhart, DJ; Winzeler, EA			Genomics, gene expression and DNA arrays	NATURE			English	Review							LASER-CAPTURE MICRODISSECTION; DENSITY OLIGONUCLEOTIDE ARRAYS; POLYMERASE CHAIN-REACTION; LARGE-SCALE ANALYSIS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELL-CYCLE; SPECIES IDENTIFICATION; QUANTITATIVE-ANALYSIS; PROTEIN INTERACTIONS	Experimental genomics in combination with the growing body of sequence information promise to revolutionize the way cells and cellular processes are studied. Information on genomic sequence can be used experimentally with high-density DNA arrays that allow complex mixtures of RNA and DNA to be interrogated in a parallel and quantitative fashion. DNA arrays can be used for many different purposes, most prominently to measure levels of gene expression (messenger RNA abundance) for tens of thousands of genes simultaneously. Measurements of gene expression and other applications of arrays embody much of what is implied by the term 'genomics'; they are broad in scope, large in scale, and take advantage of all available sequence information for experimental design and data interpretation in pursuit of biological understanding.	Novartis Res Fdn, Genome Inst, San Diego, CA 92121 USA	Novartis	Lockhart, DJ (corresponding author), Novartis Res Fdn, Genome Inst, 3115 Merryfield Row, San Diego, CA 92121 USA.		Winzeler, Elizabeth/AAP-6752-2020	Winzeler, Elizabeth/0000-0002-4049-2113				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Arkin A, 1998, GENETICS, V149, P1633; Bachem CWB, 1996, PLANT J, V9, P745, DOI 10.1046/j.1365-313X.1996.9050745.x; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BOUCHERIE H, 1995, YEAST, V11, P601, DOI 10.1002/yea.320110702; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Bulyk ML, 1999, NAT BIOTECHNOL, V17, P573, DOI 10.1038/9878; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Chambers J, 1999, J VIROL, V73, P5757, DOI 10.1128/JVI.73.7.5757-5766.1999; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 1998, P NATL ACAD SCI USA, V95, P3752, DOI 10.1073/pnas.95.7.3752; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diehn M, 2000, NAT GENET, V25, P58, DOI 10.1038/75603; Dulac C, 1998, CURR TOP DEV BIOL, V36, P245; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FAN JB, IN PRESS GENOME RES; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GILLESPIE D, 1965, J MOL BIOL, V12, P829, DOI 10.1016/S0022-2836(65)80331-X; Gingeras TR, 1998, GENOME RES, V8, P435, DOI 10.1101/gr.8.5.435; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray DE, 1997, LANGMUIR, V13, P2833, DOI 10.1021/la962139m; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P7797, DOI 10.1073/pnas.87.19.7797-a; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IVANOVA NB, 1995, NUCLEIC ACIDS RES, V23, P2954, DOI 10.1093/nar/23.15.2954; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; Jena PK, 1996, J IMMUNOL METHODS, V190, P199, DOI 10.1016/0022-1759(95)00277-4; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karp PD, 1999, NUCLEIC ACIDS RES, V27, P55, DOI 10.1093/nar/27.1.55; KATO K, 1995, NUCLEIC ACIDS RES, V23, P3685, DOI 10.1093/nar/23.18.3685; KWOH DY, 1989, P NATL ACAD SCI USA, V86, P1173, DOI 10.1073/pnas.86.4.1173; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LENNON GG, 1991, TRENDS GENET, V7, P314, DOI 10.1016/0168-9525(91)90420-U; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MACK DH, 1998, DECIPHERING MOL CIRC, P85; Mann M, 1999, NAT BIOTECHNOL, V17, P954, DOI 10.1038/13646; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; MEI R, IN PESS GENOME RES; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Rosania GR, 2000, NAT BIOTECHNOL, V18, P304, DOI 10.1038/73753; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Troesch A, 1999, J CLIN MICROBIOL, V37, P49, DOI 10.1128/JCM.37.1.49-55.1999; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Walsh S, 1998, METHOD BIOCHEM ANAL, V39, P299; Walt DR, 2000, SCIENCE, V287, P451, DOI 10.1126/science.287.5452.451; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Weinstein JN, 1998, SCIENCE, V282, P628; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Winzeler EA, 1999, PARASITOLOGY, V118, pS73, DOI 10.1017/S0031182099004047; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wolfsberg TG, 1999, GENOME RES, V9, P775; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; ZHAO ND, 1995, GENE, V156, P207, DOI 10.1016/0378-1119(95)00023-Y; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632; 1999, NATURE GENET S, V21, P1	108	1531	1700	9	270	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					827	836		10.1038/35015701	http://dx.doi.org/10.1038/35015701			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866209				2022-12-28	WOS:000087620600061
J	Pandey, A; Mann, M				Pandey, A; Mann, M			Proteomics to study genes and genomes	NATURE			English	Review							ELECTROSPRAY MASS-SPECTROMETRY; POLYACRYLAMIDE-GEL ELECTROPHORESIS; SIGNAL-TRANSDUCTION PATHWAYS; LASER-DESORPTION IONIZATION; PEPTIDE SEQUENCE TAGS; 2-DIMENSIONAL ELECTROPHORESIS; PHOSPHORYLATION SITES; MICROFABRICATED DEVICES; MOLECULAR SCANNER; INTACT PROTEINS	Proteomics, the large-scale analysis of proteins, will contribute greatly to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale identification of proteins and their post-translational modifications; (2) 'differential display' proteomics for comparison of protein levels with potential application in a wide range of diseases; and (3) studies of protein-protein interactions using techniques such as mass spectrometry or the yeast two-hybrid system. Because it is often difficult to predict the function of a protein based on homology to other proteins or even their three-dimensional structure, determination of components of a protein complex or of a cellular structure is central in functional analysis. This aspect of proteomic studies is perhaps the area of greatest promise. After the revolution in molecular biology exemplified by the ease of cloning by DNA methods, proteomics will add to our understanding of the biochemistry of proteins, processes and pathways for years to come.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ So Denmark, Prot Interact Lab, DK-5230 Odense M, Denmark; Protana AS, DK-5230 Odense M, Denmark	Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Southern Denmark	Pandey, A (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	mann@cebi.sdu.dk	Mann, Matthias/A-3454-2013; Pandey, Akhilesh/B-4127-2009	Mann, Matthias/0000-0003-1292-4799; Pandey, Akhilesh/0000-0001-9943-6127				Aicher L, 1998, ELECTROPHORESIS, V19, P1998, DOI 10.1002/elps.1150191118; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anderson NG, 1996, ELECTROPHORESIS, V17, P443, DOI 10.1002/elps.1150170303; Berndt P, 1999, ELECTROPHORESIS, V20, P3521, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3521::AID-ELPS3521>3.0.CO;2-8; Betts JC, 1997, J BIOL CHEM, V272, P12922, DOI 10.1074/jbc.272.20.12922; Bienvenut WV, 1999, ANAL CHEM, V71, P4800, DOI 10.1021/ac990448m; Binz PA, 1999, ANAL CHEM, V71, P4981, DOI 10.1021/ac990449e; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Breitenbach M, 1996, ADV EXP MED BIOL, V409, P117; Brenner SE, 1999, TRENDS GENET, V15, P132, DOI 10.1016/S0168-9525(99)01706-0; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Celis JE, 1999, ELECTROPHORESIS, V20, P300; Celis JE, 1996, FEBS LETT, V398, P129, DOI 10.1016/S0014-5793(96)01247-1; Claverie JM, 1997, HUM MOL GENET, V6, P1735, DOI 10.1093/hmg/6.10.1735; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Davies H, 1999, BIOTECHNIQUES, V27, P1258; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; ECKERSKORN C, 1992, ELECTROPHORESIS, V13, P664, DOI 10.1002/elps.11501301140; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Figeys D, 1998, ANAL CHEM, V70, P3728, DOI 10.1021/ac980320p; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gauss C, 1999, ELECTROPHORESIS, V20, P575, DOI 10.1002/(SICI)1522-2683(19990301)20:3<575::AID-ELPS575>3.0.CO;2-3; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hufton SE, 1999, J IMMUNOL METHODS, V231, P39, DOI 10.1016/S0022-1759(99)00139-8; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Jensen ON, 1997, ANAL CHEM, V69, P1706, DOI 10.1021/ac961189t; Jensen PK, 1999, ANAL CHEM, V71, P2076, DOI 10.1021/ac990196p; Krogh Anders, 1998, P261, DOI 10.1016/B978-012102051-4/50012-X; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; Li JJ, 1999, ANAL CHEM, V71, P3036, DOI 10.1021/ac981420y; Li WQ, 1999, ANAL CHEM, V71, P4397, DOI 10.1021/ac990011e; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Nelson RW, 1997, MASS SPECTROM REV, V16, P353, DOI 10.1002/(SICI)1098-2787(1997)16:6<353::AID-MAS3>3.0.CO;2-G; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NUWAYSIR LM, 1993, J AM SOC MASS SPECTR, V4, P662, DOI 10.1016/1044-0305(93)85031-R; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ostergaard M, 1999, ELECTROPHORESIS, V20, P349; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Pandey A, 1999, TRENDS BIOCHEM SCI, V24, P276, DOI 10.1016/S0968-0004(99)01400-0; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; PANDEY A, IN PRESS SCI STKE; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Rappsilber J, 2000, ANAL CHEM, V72, P267, DOI 10.1021/ac991081o; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rowley A, 2000, METHODS, V20, P383, DOI 10.1006/meth.2000.0951; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256, DOI 10.1016/S0091-6749(98)70109-5; Shevchenko A, 2000, ANAL CHEM, V72, P2132, DOI 10.1021/ac9913659; Shevchenko A, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P237; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 1999, TRENDS BIOTECHNOL, V17, P374, DOI 10.1016/S0167-7799(99)01338-4; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; Wilkins MR, 1997, PROTEOME RES NEW FRO, P1; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Yates JR, 2000, TRENDS GENET, V16, P5, DOI 10.1016/S0168-9525(99)01879-X; Yates JR, 1998, ELECTROPHORESIS, V19, P893, DOI 10.1002/elps.1150190604; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhang B, 1999, ANAL CHEM, V71, P3258, DOI 10.1021/ac990090u; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zozulya S, 1999, NAT BIOTECHNOL, V17, P1193, DOI 10.1038/70736	88	1693	1942	10	678	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					837	846		10.1038/35015709	http://dx.doi.org/10.1038/35015709			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866210				2022-12-28	WOS:000087620600062
J	Schiellerup, H; Lambert, RD; Prestvik, T; Robins, B; McBride, JS; Larsenk, RB				Schiellerup, H; Lambert, RD; Prestvik, T; Robins, B; McBride, JS; Larsenk, RB			Re-Os isotopic evidence for a lower crustal origin of massif-type anorthosites	NATURE			English	Article							SW NORWAY; PROTEROZOIC ANORTHOSITES; ROGALAND; CONSTRAINTS; EVOLUTION; COMPLEX; MAGMA; PB; ND; PETROGENESIS	Massif-type anorthosites are large igneous complexes of Proterozoic age. They are almost monomineralic, representing vast accumulations of plagioclase with subordinate pyroxene or olivine and Fe-Ti oxides-the 930-Myr-old Rogaland anorthosite province in southwest Norway(1) represents one of the youngest known expressions of such magmatism. The source of the magma and geodynamic setting of massif-type anorthosites remain longstanding controversies in Precambrian geology, with no consensus existing as to the nature of the parental magmas or whether these magmas primarily originate in the Earth's mantle or crust. At present, massif-type anorthosites are believed to have crystallized from either crustally contaminated mantle-derived melts that have fractionated olivine and pyroxenes at depth(2) or primary aluminous gabbroic to jotunitic melts derived from the lower continental crust(3). Here we report rhenium and osmium isotopic data from the Rogaland anorthosite province that strongly support a lower crustal source for the parental magmas. There is no evidence of significantly older crust in southwest Scandinavia and models invoking crustal contamination of mantle-derived magmas fail to account for the isotopic data from the Rogaland province. Initial osmium and neodymium isotopic values testify to the melting of marc source rocks in the lower crust with an age of 1,400-1,550 Myr.	Norwegian Univ Sci & Technol, Dept Geol & Mineral Resources Engn, N-7491 Trondheim, Norway; Monash Univ, Dept Earth Sci, Melbourne, Vic 3800, Australia; Univ Bergen, Dept Geol, N-5007 Bergen, Norway; Geol Survey Norway, N-7491 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Monash University; University of Bergen; Geological Survey of Norway	Schiellerup, H (corresponding author), Norwegian Univ Sci & Technol, Dept Geol & Mineral Resources Engn, N-7491 Trondheim, Norway.							Andersson M, 1996, TERRA NOVA, V8, P558, DOI 10.1111/j.1365-3121.1996.tb00785.x; ASHWAL LD, 1980, GEOL SOC AM BULL, V91, P105, DOI 10.1130/0016-7606(1980)91<105:RGOAAR>2.0.CO;2; Asmerom Y, 1998, GEOLOGY, V26, P359, DOI 10.1130/0091-7613(1998)026<0359:PAOICO>2.3.CO;2; DEMAIFFE D, 1986, CHEM GEOL, V57, P167, DOI 10.1016/0009-2541(86)90101-4; DEMAIFFE D, 1981, GEOCHIM COSMOCHIM AC, V45, P1545, DOI 10.1016/0016-7037(81)90284-2; DUCHESNE JC, 1988, CR ACAD SCI II, V306, P45; Duchesne JC, 1999, TERRA NOVA, V11, P100, DOI 10.1046/j.1365-3121.1999.00232.x; Emslie R.F., 1985, PROTEROZOIC ANORTHOS, V158, P39; EMSLIE RF, 1994, J GEOL, V102, P539, DOI 10.1086/629697; Esperanca S, 1997, GEOLOGY, V25, P651, DOI 10.1130/0091-7613(1997)025<0651:DCMSRO>2.3.CO;2; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; FRICK LR, 1996, J C ABS, V1, P85; Johnson CM, 1996, T ROY SOC EDIN-EARTH, V87, P339, DOI 10.1017/S0263593300006738; Lambert DD, 1998, ECON GEOL BULL SOC, V93, P121, DOI 10.2113/gsecongeo.93.2.121; LONGHI J, 1993, AM MINERAL, V78, P1016; Longhi J, 1999, J PETROL, V40, P339, DOI 10.1093/petrology/40.2.339; MENUGE JF, 1988, CONTRIB MINERAL PETR, V98, P363, DOI 10.1007/BF00375186; MICHARD A, 1985, GEOCHIM COSMOCHIM AC, V49, P601, DOI 10.1016/0016-7037(85)90051-1; MITCHELL JN, 1995, CONTRIB MINERAL PETR, V119, P166, DOI 10.1007/BF00307279; MORSE SA, 1982, AM MINERAL, V67, P1087; Robins B, 1997, LITHOS, V39, P121, DOI 10.1016/S0024-4937(96)00021-7; Saal AE, 1998, NATURE, V393, P58, DOI 10.1038/29966; Scharer U, 1996, EARTH PLANET SC LETT, V139, P335, DOI 10.1016/0012-821X(96)00033-7; Scoates JS, 1996, GEOCHIM COSMOCHIM AC, V60, P95, DOI 10.1016/0016-7037(95)00368-1; SIMMONS EC, 1978, CONTRIB MINERAL PETR, V66, P119, DOI 10.1007/BF00372151; Stein H.J., 1998, GEOPHYS J+, V4, P111; TAYLOR SR, 1984, NATURE, V311, P372, DOI 10.1038/311372a0; Versteeve A. J., 1975, NOR GEOL UNDERS, V318, P1; WALKER RJ, 1989, GEOCHIM COSMOCHIM AC, V53, P1583, DOI 10.1016/0016-7037(89)90240-8	29	57	59	1	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					781	784		10.1038/35015546	http://dx.doi.org/10.1038/35015546			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866196				2022-12-28	WOS:000087620600047
J	Roberts, CL; Tracy, S; Peat, B				Roberts, CL; Tracy, S; Peat, B			Rates for obstetric intervention among private and public patients in Australia: population based descriptive study	BRITISH MEDICAL JOURNAL			English	Article							NULLIPAROUS WOMEN; CESAREAN-SECTION; VAGINAL DELIVERY; HEALTH; LABOR; SATISFACTION; CHILDBIRTH; DECISION; FORCEPS; BIRTH	Objective To compare the risk profile of women receiving public and private obstetric care and to compare the rates of obstetric intervention among women at low risk in these groups. Design Population based descriptive study. Setting New South Wales, Australia. Subjects All 171 157 women having a live baby during 1996 and 1997. Interventions Epidural, augmentation or induction of labour episiotomy, and births by forceps, vacuum, or caesarean section. Main outcome measures Risk profile: of public and private patients, intervention rates, and the accumulation of interventions by both patient and hospital classification (public or private). Results Overall, the frequency of women classified as low risk was similar (48%) among those choosing private obstetric care and those receiving standard care in a public hospital. Among low risk women, rates of obstetric intervention were highest in private patients in private hospitals, lowest in public patients, and generally intermediate for private patients in public hospitals. Among primiparas at low risk, 34% of private patients in private hospitals had a forceps or vacuum delivery compared with 17% of public patients. For multiparas the rates were 8% and 3% respectively. Private patients were significantly more likely to have interventions before birth (epidural, induction or augmentation) but this alone did not account for the increased interventions at birth, particularly the high rates of instrumental births. Conclusions Public patients have a lower chance of an instrumental delivery. Women should have equal access to quality maternity services, but information on the outcomes associated with the various models of care may influence their choices.	Univ Sydney, NSW Ctr Perinatal Hlth Serv Res, Sch Populat Hlth & Hlth Serv Res, Sydney, NSW 2006, Australia; Univ Technol Sydney, Fac Nursing Midwifery & Hlth, Sydney, NSW 2007, Australia; King George V Mem Hosp Mothers & Babies, Camperdown, NSW 2050, Australia	University of Sydney; University of Technology Sydney	Roberts, CL (corresponding author), Univ Sydney, NSW Ctr Perinatal Hlth Serv Res, Sch Populat Hlth & Hlth Serv Res, Sydney, NSW 2006, Australia.			Tracy, Sally Katherine/0000-0002-3753-5362				AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; Brown S, 1998, BRIT J OBSTET GYNAEC, V105, P156, DOI 10.1111/j.1471-0528.1998.tb10045.x; BROWN S, 1994, BIRTH-ISS PERINAT C, V21, P4, DOI 10.1111/j.1523-536X.1994.tb00909.x; Brown S, 1998, BRIT J OBSTET GYNAEC, V105, P143, DOI 10.1111/j.1471-0528.1998.tb10044.x; CARROLI G, 1999, COCHRANE LIB; CARY AJ, 1990, AUST NZ J OBSTET GYN, V30, P46, DOI 10.1111/j.1479-828X.1990.tb03195.x; DAY P, 1999, AUSTR MOTHERS BABIES; FISHER J, 1995, J PSYCHOSOM OBST GYN, V16, P1, DOI 10.3109/01674829509025651; Fraser W, 1998, BRIT J OBSTET GYNAEC, V105, P189, DOI 10.1111/j.1471-0528.1998.tb10051.x; Graham WJ, 1999, BRIT J OBSTET GYNAEC, V106, P213, DOI 10.1111/j.1471-0528.1999.tb08233.x; HODNETT ED, 1999, COCHRANE LIB; HOWELL CJ, 1999, COCHRANE LIB; Johanson RB, 1999, BRIT J OBSTET GYNAEC, V106, P544, DOI 10.1111/j.1471-0528.1999.tb08322.x; JOHANSON RB, 1999, COCHRANE LIB; KING JF, 1993, BRIT J OBSTET GYNAEC, V100, P303, DOI 10.1111/j.1471-0528.1993.tb12967.x; *NSW HLTH DEP, 1998, NSW PUBL HLTH B, V9, P9; Pym M, 1993, NSW PUBLIC HLTH B, V4, P1; Roberts CL, 1999, MED J AUSTRALIA, V170, P114, DOI 10.5694/j.1326-5377.1999.tb127678.x; SEIDMAN DS, 1991, LANCET, V337, P1583, DOI 10.1016/0140-6736(91)93273-C; SIMKIN P, 1993, EFFECTIVE CARE PREGN, P1182; Stephenson P A, 1993, Paediatr Perinat Epidemiol, V7, P45, DOI 10.1111/j.1365-3016.1993.tb00600.x; SULLIVAN DA, 1982, MED CARE, V20, P321, DOI 10.1097/00005650-198203000-00009; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; Turnbull DA, 1999, MED J AUSTRALIA, V170, P580, DOI 10.5694/j.1326-5377.1999.tb127903.x	24	142	143	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					137	141		10.1136/bmj.321.7254.137	http://dx.doi.org/10.1136/bmj.321.7254.137			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894690	Bronze, Green Published			2022-12-28	WOS:000088305700018
J	Mackay, IR				Mackay, IR			Science, medicine, and the future - Tolerance and autoimmunity	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MOLECULAR MIMICRY; DISEASE; LYMPHOCYTES; ERYTHEMATOSUS; CHEMOKINES; THERAPY; HUMANS		Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Monash University	Mackay, IR (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.	ian.mackay@med.monash.edu.au	Mackay, Ian R/A-7228-2010					Darnell RB, 1999, NEW ENGL J MED, V340, P1831, DOI 10.1056/NEJM199906103402311; Feldmann M, 1998, SPRINGER SEMIN IMMUN, V20, P211, DOI 10.1007/BF00832008; Giannoukakis N, 1999, DIABETES, V48, P2107, DOI 10.2337/diabetes.48.11.2107; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Granville DJ, 1998, LAB INVEST, V78, P893; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; Griffiths MM, 1999, CURR OPIN IMMUNOL, V11, P689, DOI 10.1016/S0952-7915(99)00038-2; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701; Korb LC, 1997, J IMMUNOL, V158, P4525; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; Marelli-Berg FM, 1999, IMMUNOL REV, V172, P297; Nepom GT, 1998, ADV IMMUNOL, V68, P315, DOI 10.1016/S0065-2776(08)60563-5; NEUMANN DA, 1994, J IMMUNOL, V152, P343; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; PORTER M, 1999, BMJ-BRIT MED J, V318, P750; Quill H, 1996, J IMMUNOL, V156, P1325; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sayegh MH, 1999, J CLIN INVEST, V103, P1223, DOI 10.1172/JCI6952; Seddon B, 2000, IMMUNOL TODAY, V21, P95, DOI 10.1016/S0167-5699(99)01559-5; STOCKINGER B, 1998, ADV IMMUNOL, V71, P229; Tarlinton D, 1997, CURR BIOL, V7, pR155, DOI 10.1016/S0960-9822(97)70077-0; Tian J, 1999, IMMUNOL TODAY, V20, P190, DOI 10.1016/S0167-5699(99)01445-0; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; Tyndall A, 1999, BONE MARROW TRANSPL, V24, P729, DOI 10.1038/sj.bmt.1701987; Vaishnaw AK, 1999, ARTHRITIS RHEUM, V42, P1833, DOI 10.1002/1529-0131(199909)42:9<1833::AID-ANR7>3.0.CO;2-Q; Van Parijs L, 1998, SCIENCE, V280, P243	30	53	56	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 8	2000	321	7253					93	96		10.1136/bmj.321.7253.93	http://dx.doi.org/10.1136/bmj.321.7253.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334QF	10884262	Green Published			2022-12-28	WOS:000088196600028
J	Lee, K; Loros, JJ; Dunlap, JC				Lee, K; Loros, JJ; Dunlap, JC			Interconnected feedback loops in the Neurospora circadian system	SCIENCE			English	Article							LIGHT SIGNAL-TRANSDUCTION; CLOCK GENE-FREQUENCY; PROTEIN; PAS; PHOSPHORYLATION; TRANSCRIPTION; DOMAINS; COMPLEX; FORMS; TIME	In Neurospora crassa, white collar 1 (WC-1), a transcriptional activator and positive clock element, is rhythmically expressed from a nonrhythmic steady-state pool of wc-1 transcript, consistent with posttranscriptional regulation of rhythmicity. Mutations in frq influence both the level and periodicity of WC-1 expression, and driven FRQ expression not only depresses its own endogenous levels, but positively regulates WC-1 synthesis with a lag of about 8 hours, a delay similar to that seen in the wild-type clock. FRQ thus plays dual roles in the Neurospora clock and thereby, with WC-1, forms a second feedback loop that would promote robustness and stability in this circadian system. The existence also of interlocked loops in Drosophila melanogaster and mouse clocks suggests that such interlocked loops may be a conserved aspect of circadian timing systems.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Loros, JJ (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	jennifer.loros@dartmouth.edu; jay.c.dunlap@dartmouth.edu	Lee, Kwangwon/AAC-8060-2021; Weydahl, Andi/C-6391-2008; Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Dunlap, Jay/0000-0003-1577-0457; Lee, Kwangwon/0000-0001-8225-4220	NIGMS NIH HHS [R37-GM 34985] Funding Source: Medline; NIMH NIH HHS [MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DENAULT D, UNPUB; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Iwasaki H, 2000, CURR OPIN MICROBIOL, V3, P189, DOI 10.1016/S1369-5274(00)00074-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Linden H, 1999, ADV GENET, V41, P35, DOI 10.1016/S0065-2660(08)60150-9; Liu Y, 2000, P NATL ACAD SCI USA, V97, P234, DOI 10.1073/pnas.97.1.234; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; Loros JJ, 1998, CURR OPIN MICROBIOL, V1, P698, DOI 10.1016/S1369-5274(98)80118-5; LUO C, 1998, THESIS DARTMOUTH U H; Luo CH, 1998, EMBO J, V17, P1228, DOI 10.1093/emboj/17.5.1228; Merrow M, 1999, NATURE, V399, P584, DOI 10.1038/21190; Schibler U, 2000, NATURE, V404, P25, DOI 10.1038/35003674; Scully AL, 2000, CELL, V100, P297, DOI 10.1016/S0092-8674(00)80665-0; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999	31	274	282	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 7	2000	289	5476					107	110		10.1126/science.289.5476.107	http://dx.doi.org/10.1126/science.289.5476.107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884222				2022-12-28	WOS:000088090400042
J	Rueckes, T; Kim, K; Joselevich, E; Tseng, GY; Cheung, CL; Lieber, CM				Rueckes, T; Kim, K; Joselevich, E; Tseng, GY; Cheung, CL; Lieber, CM			Carbon nanotube-based nonvolatile random access memory for molecular computing	SCIENCE			English	Article							QUANTUM WIRES; ROPES; PHYSICS; DEVICE	A concept for molecular electronics exploiting carbon nanotubes as both molecular device elements and molecular wires for reading and writing information was developed. Each device element is based on a suspended, crossed nanotube geometry that Leads to bistable, electrostatically switchable ON/OFF states. The device elements are naturally addressable in large arrays by the carbon nanotube molecular wires making up the devices. These reversible, bistable device elements could be used to construct nonvolatile random access memory and logic function tables at an integration level approaching 10(12) elements per square centimeter and an element operation frequency in excess of 100 gigahertz. The viability of this concept is demonstrated by detailed calculations and by the experimental realization of a reversible, bistable nanotube-based bit.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.		Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833; Joselevich, Ernesto/0000-0002-9919-0734				Bachtold A, 1998, APPL PHYS LETT, V73, P274, DOI 10.1063/1.121778; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Brebbia C., 1978, BOUNDARY ELEMENT MET; Burns AR, 1999, LANGMUIR, V15, P2922, DOI 10.1021/la981521r; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui Y, 2000, J PHYS CHEM B, V104, P5213, DOI 10.1021/jp0009305; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Hertel T, 1998, PHYS REV B, V58, P13870, DOI 10.1103/PhysRevB.58.13870; Hu JT, 1999, ACCOUNTS CHEM RES, V32, P435, DOI 10.1021/ar9700365; Jackson J. D., 1974, CLASSICAL ELECTRODYN; Joachim C, 1997, CHEM PHYS LETT, V265, P353, DOI 10.1016/S0009-2614(97)00014-6; KIM KK, UNPUB; Kim P, 1999, SCIENCE, V286, P2148, DOI 10.1126/science.286.5447.2148; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Lee YH, 1997, CHEM PHYS LETT, V265, P667, DOI 10.1016/S0009-2614(96)01486-8; Liu J, 1999, CHEM PHYS LETT, V303, P125, DOI 10.1016/S0009-2614(99)00209-2; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; Nardelli MB, 1998, PHYS REV LETT, V81, P4656, DOI 10.1103/PhysRevLett.81.4656; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Petty M. C., 1995, INTRO MOL ELECT; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; *SEMATECH, 1997, 1997 NAT TECHN ROADM; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Walters DA, 1999, APPL PHYS LETT, V74, P3803, DOI 10.1063/1.124185; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	30	1458	1657	5	385	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					94	97		10.1126/science.289.5476.94	http://dx.doi.org/10.1126/science.289.5476.94			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884232	Green Published			2022-12-28	WOS:000088090400038
J	Gleicher, N; Oleske, DM; Tur-Kaspa, I; Vidali, A; Karande, V				Gleicher, N; Oleske, DM; Tur-Kaspa, I; Vidali, A; Karande, V			Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Joint Annual Meeting of the American-Society-for-Reproductive-Medicine/Canadian-Fertility-and-Andrology-Society	SEP 25-30, 1999	TORONTO, CANADA	Amer Soc Reprod Med, Canadian Fertil & Androl Soc			IN-VITRO FERTILIZATION; PROSPECTIVE RANDOMIZED TRIAL; INTRAUTERINE INSEMINATION; HUMAN BLASTOCYSTS; INFERTILITY; CULTURE; BIRTHS; GESTATION; PATTERNS; COUPLES	Background: The incidence of multiple gestation after therapy for infertility is especially high among women in whom ovulation is induced with gonadotropins. Whether the number of high-order multiple pregnancies (those with three or more fetuses) can be reduced is not known. Methods: We analyzed data on 3347 consecutive treatment cycles in 1494 infertile women, 441 of which resulted in pregnancy. The data collected included the peak serum estradiol concentration, the number of follicles 16 mm or larger in diameter, and the total number of follicles on the day of induction of ovulation with human chorionic gonadotropin. Receiver-operating-characteristic curves and ordinal logistic-regression analyses were used to identify values that predicted multiple conceptions. Results: Among the 441 pregnancies, 314 resulted from the conception of singletons, 88 of twins, 22 of triplets, 10 of quadruplets, 5 of quintuplets, and 2 of sextuplets. Neither the number of follicles 16 mm or larger nor peak serum estradiol concentrations greater than 2000 or 2500 pg per milliliter (7342 or 9178 pmol per liter) (the cutoff values currently in wide use) were significantly associated with the incidence of high-order multiple pregnancy. However, increasing total numbers of follicles and increasing peak serum estradiol concentrations correlated significantly with an increasing risk of high-order multiple pregnancy (P<0.001), as did younger age (P=0.008). The risk of high-order multiple pregnancy was significantly increased in women with a peak serum estradiol concentration of 1385 pg per milliliter (5084 pmol per liter) or higher (multivariate odds ratio, 1.9; 95 percent confidence interval, 1.3 to 2.8) or with seven or more follicles (multivariate odds ratio, 2.1; 95 percent confidence interval, 1.2 to 3.9) on the day of induction of ovulation. Conclusions: Gonadotropin stimulation that is less intensive than is currently customary may reduce the incidence of high-order multiple pregnancy in infertile women, though only to a limited extent and at the expense of overall pregnancy rates. (N Engl J Med 2000;343:2-7.) (C) 2000, Massachusetts Medical Society.	Ctr Human Reprod New New, New York, NY 10022 USA; Ctr Human Reprod Illinois, Chicago, IL USA; Fdn Reprod Med, Chicago, IL USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Hlth Syst Management, Chicago, IL 60612 USA; Ben Gurion Univ Negev, Barzilai Med Ctr, Dept Obstet & Gynecol, In Vitro Fertilizat Unit, Ashqelon, Israel	Rush University; Rush University; Ben Gurion University; Barzilai Medical Center	Gleicher, N (corresponding author), Ctr Human Reprod New New, 635 Madison Ave, New York, NY 10022 USA.	chrjournal@aol.com						American Society for Reproductive Medicine. Practice Committee Opinion, 1998, GUID NUMB EMBR TRANS; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; COLLINS JA, 1994, NEW ENGL J MED, V331, P270, DOI 10.1056/NEJM199407283310412; Crosignani PG, 1996, EXCERPTS HUMAN REPRO, V4, P5; EVANS MI, 1995, AM J OBSTET GYNECOL, V172, P1750, DOI 10.1016/0002-9378(95)91407-2; Faber K, 1997, HUM REPROD, V12, P1614; Gardner DK, 1998, FERTIL STERIL, V69, P84, DOI 10.1016/S0015-0282(97)00438-X; Gardner DK, 1998, HUM REPROD, V13, P148, DOI 10.1093/humrep/13.suppl_3.148; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; GLEICHER N, 1995, HUM REPROD, V10, P1079, DOI 10.1093/oxfordjournals.humrep.a136098; GLEICHER N, IN PRESS J ASSIST RE; Guzick DS, 1999, NEW ENGL J MED, V340, P177, DOI 10.1056/NEJM199901213400302; JEWELL SE, 1995, OBSTET GYNECOL, V85, P229, DOI 10.1016/0029-7844(94)00354-G; Karande VC, 1999, FERTIL STERIL, V71, P468, DOI 10.1016/S0015-0282(98)00490-7; KARANDE VC, 1995, FERTIL STERIL, V64, P638, DOI 10.1016/S0015-0282(16)57805-4; *SAS I INC, 1995, LOG REGR EX US SAS S, P163; SPSS, 1999, SPSS WIND REL 10 0; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; VENTURA SJ, 1998, MON VITAL STAT REP S, V46	19	182	186	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					2	7		10.1056/NEJM200007063430101	http://dx.doi.org/10.1056/NEJM200007063430101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	330XW	10882762				2022-12-28	WOS:000087987600001
J	[Anonymous]				[Anonymous]			Los Alamos deserves better	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					1	1						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894503				2022-12-28	WOS:000087991200001
J	[Anonymous]				[Anonymous]			The Durban Declaration	NATURE			English	Editorial Material							HIV-1; AIDS; TRANSMISSION; POPULATION; ZIDOVUDINE; MORTALITY; INFECTION; TRIAL											*CDCP, 1999, HIV AIDS SURVEILLANC, V11, P1; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; *JOINT UN PROGR HI, 2000, REP GLOB HIV AIDS EP; Liska V, 1999, AIDS RES HUM RETROV, V15, P445, DOI 10.1089/088922299311196; Nunn AJ, 1997, BRIT MED J, V315, P767, DOI 10.1136/bmj.315.7111.767; OBrien SJ, 1996, CURR OPIN IMMUNOL, V8, P613, DOI 10.1016/S0952-7915(96)80075-6; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Sitas F, 1999, NEW ENGL J MED, V340, P1863, DOI 10.1056/NEJM199906173402403; SPERLING RS, 1996, NEW ENGL J MED, V335, P1678; WEISS RA, 1990, NATURE, V345, P659, DOI 10.1038/345659a0	12	30	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 6	2000	406	6791					15	16		10.1038/35017662	http://dx.doi.org/10.1038/35017662			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894520				2022-12-28	WOS:000087991200018
J	Leape, LL				Leape, LL			Institute of medicine medical error figures are not exaggerated	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADVERSE DRUG EVENTS; DEATHS; CARE		Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Leape, LL (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.							ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; Hall M, 1998, AMBULATORY SURG US 1; Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; KOZAK L, 1999, NATL HOSP DISCHARGE; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; *NAT NOS INF SURV, 1996, SEM REP; Rao RB, 1999, NEW ENGL J MED, V340, P1471, DOI 10.1056/NEJM199905133401904; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; Weingart SN, 2000, BRIT MED J, V320, P774, DOI 10.1136/bmj.320.7237.774	18	185	188	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					95	97		10.1001/jama.284.1.95	http://dx.doi.org/10.1001/jama.284.1.95			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872022				2022-12-28	WOS:000087843000034
J	Emery, J; Walton, R; Murphy, M; Austoker, J; Yudkin, P; Chapman, C; Coulson, A; Glasspool, D; Fox, J				Emery, J; Walton, R; Murphy, M; Austoker, J; Yudkin, P; Chapman, C; Coulson, A; Glasspool, D; Fox, J			Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-PRACTICE; GENETICS; SERVICES; SYSTEMS	Objectives To evaluate the potential effect of computer support on general practitioners' management of familial breast and ovarian cancer, and to compare the effectiveness of two different types of computer program. Design Crossover experiment with balanced block design. Participants Of a random sample of 100 general practitioners from Buckinghamshire who were invited, 41 agreed to participate. From these, 36 were selected for a fully balanced study. Interventions Doctors managed 18 simulated cases: 6 with computerised decision support system Risk Assessment in Genetics (RAGs), 6 with Cyrillic (an established pedigree drawing program designed for clinical geneticists), and 6 with pen and paper. Main outcome measures Number of appropriate management decisions made (maximum 6), mean time taken to reach a decision, number of pedigrees accurately drawn (maximum 6). Secondary measures were method of support preferred for particular aspects of managing family histories of cancer; importance of specific information on cancer genetics that might be provided by an "ideal computer program." Results RAGs resulted in significantly more appropriate management decisions (median 6) than either Cyrillic (median 3) or pen and paper (median 3); median difference between RAGs and Cyrillic 2.5 (95% confidence interval 2.0 to 3.0; P < 0.0001). RAGs also resulted in significantly more accurate pedigrees (median 5) than both Cyrillic (median 3.5) and pen and paper (median 2); median difference between RAGs and Cyrillic 1.5 (1.0 to 2.0; P < 0.0001). The time taken to use RAGs (median 178 seconds) was 51 seconds longer per case (95% confidence interval 36 to 65; P < 0.0001) than pen and paper (median 124 seconds) but was less than Cyrillic (median 203 seconds; difference 23. (5 to 43; P = 0.02)). 33 doctors (92% (78% to 98%)) preferred using RAGs overall. The most important elements of an "ideal computer program" for genetic advice in primary care were referral advice, the capacity to create pedigrees, and provision of evidence and explanations to support advice. Conclusions RAGs could enable general practitioners to be more effective gatekeepers to genetics services, empowering them to reassure the majority of patients with a family history of breast and ovarian cancer who are not at increased genetic risk.	Univ Oxford, Div Publ Hlth & Primary Hlth Care, Inst Hlth Sci, ICRF,Gen Practice Res Grp, Oxford OX3 7LF, England; Univ Oxford, Div Publ Hlth & Primary Hlth Care, Canc Res Campaign, Primary Care Educ Res Grp, Oxford OX3 7LF, England; Univ Oxford, Dept Primary Hlth Care, Oxford OX1 2JD, England; Churchill Hosp, Oxford Radcliffe NHS Trust, Dept Clin Genet, Oxford OX3 7JL, England; Imperial Canc Res Fund, Adv Computat Lab, London WC2A 3PX, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; Cancer Research UK	Emery, J (corresponding author), Univ Oxford, Div Publ Hlth & Primary Hlth Care, Inst Hlth Sci, ICRF,Gen Practice Res Grp, Oxford OX3 7LF, England.	jon.emery@dphpc.ox.ac.uk						Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; Collins FS, 1997, JAMA-J AM MED ASSOC, V278, P1285, DOI 10.1001/jama.278.15.1285; Emery J, 1999, FAM PRACT, V16, P426, DOI 10.1093/fampra/16.4.426; Emery J, 1999, BRIT MED J, V319, P32, DOI 10.1136/bmj.319.7201.32; Emery J, 1999, BRIT J GEN PRACT, V49, P572; Fox J, 1998, IEEE Trans Inf Technol Biomed, V2, P217, DOI 10.1109/4233.737577; Foy R, 1998, BRIT MED J, V317, P1168, DOI 10.1136/bmj.317.7167.1168; FRIEMAN CP, 1997, EVALUATION METHODS M; Fry A, 1999, FAM PRACT, V16, P468, DOI 10.1093/fampra/16.5.468; Gill M, 1998, BMJ-BRIT MED J, V316, P570, DOI 10.1136/bmj.316.7131.570; Hayflick S J, 1998, Community Genet, V1, P18, DOI 10.1159/000016131; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; KAY C, 1998, 77 ROYAL COLL GEN PR; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Watkins C, 1999, BRIT J GEN PRACT, V49, P381; *WELLC TRUST, 1998, REP CONS M MAN WOM F; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; Wyatt JC, 1998, LANCET, V352, P1375, DOI 10.1016/S0140-6736(97)08306-2; 1989, CONFIDENCE INTERVAL; 1997, CYRILLIC VERSION 2 1	23	87	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					28	32		10.1136/bmj.321.7252.28	http://dx.doi.org/10.1136/bmj.321.7252.28			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875832	Green Published, Bronze			2022-12-28	WOS:000088030100024
J	Kamat, S; Su, X; Ballarini, R; Heuer, AH				Kamat, S; Su, X; Ballarini, R; Heuer, AH			Structural basis for the fracture toughness of the shell of the conch Strombus gigas	NATURE			English	Article							BRITTLE	Natural composite materials are renowned for their mechanical strength and toughness: despite being highly mineralized, with the organic component constituting not more than a few per cent of the composite material, the fracture toughness exceeds that of single crystals of the pure mineral by two to three orders of magnitude(1). The judicious placement of the organic matrix, relative to the mineral phase, and the hierarchical structural architecture extending over several distinct length scales both play crucial roles in the mechanical response of natural composites to external loads(.)(2-4) Here we use transmission electron microscopy studies and beam bending experiments to show that the resistance of the shell of the conch Strombus gigas to catastrophic fracture can be understood quantitatively by invoking two energy-dissipating mechanisms: multiple microcracking in the outer layers at low mechanical loads, and crack bridging in the shell's tougher middle layers at higher loads. Both mechanisms are intimately associated with the so-called crossed lamellar microarchitecture of the shell, which provides for 'channel' cracking in the outer layers and uncracked structural features that bridge crack surfaces, thereby significantly increasing the work of fracture, and hence the toughness, of the material. Despite a high mineral content of about 99% (by volume) of aragonite, the shell of Strombus gigas can thus be considered a 'ceramic plywood', and can guide the biomimetic design of tough, lightweight structures.	Case Western Reserve Univ, Dept Mat Sci & Engn, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Civil Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Heuer, AH (corresponding author), Case Western Reserve Univ, Dept Mat Sci & Engn, Cleveland, OH 44106 USA.							Boggild O. B., 1930, KGL DAN VIDENSK SELS, V9, P232; Carter JG, 1980, SKELETAL GROWTH AQUA, P69; COX BN, 1994, ACTA METALL MATER, V42, P341, DOI 10.1016/0956-7151(94)90492-8; CURREY JD, 1976, J MATER SCI, V11, P1615, DOI 10.1007/BF00737517; CURREY JD, 1974, J ZOOL, V173, P395; CURREY JD, 1980, MECH PROPERTIES BIOL, P75; JACKSON AP, 1988, PROC R SOC SER B-BIO, V234, P415, DOI 10.1098/rspb.1988.0056; JACKSON AP, 1990, J MATER SCI, V25, P3173, DOI 10.1007/BF00587670; Kessler H, 1996, COMP MATER SCI, V5, P157, DOI 10.1016/0927-0256(95)00067-4; KuhnSpearing LT, 1996, J MATER SCI, V31, P6583, DOI 10.1007/BF00356266; TAYLOR J D, 1972, Palaeontology (Oxford), V15, P73; WEGST UGK, 1997, CUEDCEDCTR55	12	553	575	13	304	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1036	1040		10.1038/35016535	http://dx.doi.org/10.1038/35016535			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890440				2022-12-28	WOS:000087871700040
J	Sonderegger-Iseli, K; Burger, S; Muntwyler, J; Salomon, F				Sonderegger-Iseli, K; Burger, S; Muntwyler, J; Salomon, F			Diagnostic errors in three medical eras: a necropsy study	LANCET			English	Article							AUTOPSY; CARE	Background Studies comparing the accuracy of clinical diagnosis in unselected patients who died in hospital in different medical ems have shown no decline of errors in the main diagnosis. We assessed changes in diagnostic accuracy over 20 years. Methods We analysed retrospectively diagnostic errors, with use of necropsy as the gold standard for diagnosis. We randomly selected 300 patients who died at a tertiary-care teaching hospital in Switzerland-100 in each of 1972, 1982, and 1992. We classified discrepancies between clinical diagnosis and necropsy findings as major and minor errors. Findings The overall necropsy rate at the hostpial stayed at around 90% for the whole period. During the study, the frequency of major discrepancies declined significantly (1972, 30%; 1982, 18%; 1992, 14%; p=0.007). The rate of minor diagnostic errors increased significantly from 23% in 1972 to 46% in 1992 (p<0.001). The increase in overall diagnostic accuracy occurred mainly because of a significant improvement in specificity for cardiovascular diseases (1972, 85%; 1982, 82%; 1992, 97%; p=0.034) and nonsignificantly improved sensitivity (1972, 69%; 1982, 82%; 1992, 86%; p=0.061). Sensitivity also improved for infectious diseases (1972, 25%; 1982, 67%; 1992, 86%; p=0.036). Sensitivity and specificity for neoplastic diseases were high originally and did not change. The total number of diagnostic procedures per year increased from 191 in 1972 to 259 in 1992, mainly because of non-invasive techniques, such as ultrasonography, and endoscopies. Interpretation The frequency of major diagnostic errors in unselected patients who died in hospital was halved over 20 years, probably because of improved clinical skills and new diagnostic procedures.	Univ Zurich, Univ Hosp, Dept Internal Med, Med Clin B, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Salomon, F (corresponding author), Univ Zurich, Univ Hosp, Dept Internal Med, Med Clin B, CH-8091 Zurich, Switzerland.							ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; BELLWALD M, 1982, SCHWEIZ MED WSCHR, V112, P75; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1507, DOI 10.1056/NEJM199506013322210; Kirch W, 1996, MEDICINE, V75, P29, DOI 10.1097/00005792-199601000-00004; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; PELLETIER LL, 1989, J GEN INTERN MED, V4, P300, DOI 10.1007/BF02597401; SARACCI R, 1991, BRIT MED J, V303, P898, DOI 10.1136/bmj.303.6807.898; Schwartz DA, 1996, CLIN INFECT DIS, V23, P248, DOI 10.1093/clinids/23.2.248; STEIN PD, 1995, CHEST, V108, P978, DOI 10.1378/chest.108.4.978; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VOYTOVICH AE, 1985, J MED EDUC, V60, P302; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; ZARLING EJ, 1983, JAMA-J AM MED ASSOC, V250, P1177; ZIMMERMANNHOSLI.MB, 1988, KLIN WOCHENSCHR, V66, P1110; 1980, WISSENSCHAFTLICHE TA, V8	19	145	152	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2027	2031		10.1016/S0140-6736(00)02349-7	http://dx.doi.org/10.1016/S0140-6736(00)02349-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885353				2022-12-28	WOS:000087519400010
J	Holtzman, NA; Marteau, TM				Holtzman, NA; Marteau, TM			Will genetics revolutionize medicine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; ALZHEIMER-DISEASE; BREAST-CANCER; RISK; MUTATIONS; BRCA1; POPULATIONS; PREVALENCE		Johns Hopkins Med Inst, Baltimore, MD 21205 USA; Guys Kings & St Thomas Med Sch, London SE1 9RT, England	Johns Hopkins University; Johns Hopkins Medicine; University of London; King's College London	Holtzman, NA (corresponding author), Johns Hopkins Med Inst, Baltimore, MD 21205 USA.			Marteau, Theresa/0000-0003-3025-1129				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Balaban E, 1998, SCI CONTEXT, V11, P331, DOI 10.1017/S0269889700003069; BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; Eisinger F, 1999, LANCET, V353, P919, DOI 10.1016/S0140-6736(98)07516-3; Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fodor FH, 1998, AM J HUM GENET, V63, P45, DOI 10.1086/301903; Friddle C, 2000, AM J HUM GENET, V66, P205, DOI 10.1086/302697; HOLTZMAN NA, 1996, J AM HUM GENET S A, V59, pA56; INGRAM VM, 1959, BIOCHIM BIOPHYS ACTA, V36, P402, DOI 10.1016/0006-3002(59)90183-0; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KHOURY MJ, 1985, AM J PUBLIC HEALTH, V75, P1204, DOI 10.2105/AJPH.75.10.1204; KIDD KK, 1993, AM J MED GENET, V48, P71, DOI 10.1002/ajmg.1320480202; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Lerman C, 1999, JAMA-J AM MED ASSOC, V281, P1618, DOI 10.1001/jama.281.17.1618; Lilienfeld AM, 1980, FDN EPIDEMIOLOGY; Mandrup-Poulsen T, 1998, BMJ-BRIT MED J, V316, P1221, DOI 10.1136/bmj.316.7139.1221; Marteau TM, 1998, BMJ-BRIT MED J, V316, P693, DOI 10.1136/bmj.316.7132.693; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; McKinlay JB, 1999, AM J PUBLIC HEALTH, V89, P295, DOI 10.2105/AJPH.89.3.295; *NAT CTR HLTH STAT, 1999, VIT HLTH STAT SER, V10; Owen MJ, 1999, LANCET, V354, pSI11; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Quoted in Lawrence M.Fisher, 1999, NY TIMES        0829, pC; Ries L. A. G., 1999, SEER CANC STAT REV 1; Risch N, 1996, NAT GENET, V12, P351, DOI 10.1038/ng0496-351; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SCHWAB SG, 1995, NAT GENET, V11, P325, DOI 10.1038/ng1195-325; Senior V, 1999, PSYCHOL HEALTH, V14, P1077, DOI 10.1080/08870440008407368; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAMBOR ES, 1994, AM J HUM GENET, V55, P626; TODD JA, 1999, LANCET S1, V354, pS115; TREACY E, 1995, AM J HUM GENET, V56, P359; Wald NJ, 1999, BMJ-BRIT MED J, V319, P1562, DOI 10.1136/bmj.319.7224.1562; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7	43	276	278	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					141	144		10.1056/NEJM200007133430213	http://dx.doi.org/10.1056/NEJM200007133430213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333EP	10891526				2022-12-28	WOS:000088116500013
J	Davies, DR; Goryshin, IY; Reznikoff, WS; Rayment, I				Davies, DR; Goryshin, IY; Reznikoff, WS; Rayment, I			Three-dimensional structure of the Tn5 synaptic complex transposition intermediate	SCIENCE			English	Article							SARCOMA VIRUS INTEGRASE; DNA-BINDING DOMAIN; HIV-1 INTEGRASE; MU-TRANSPOSASE; ACTIVE-SITE; RETROVIRAL INTEGRATION; V(D)J RECOMBINATION; MAXIMUM-LIKELIHOOD; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN	Genomic evolution has been profoundly influenced by DNA transposition, a process whereby defined DNA segments move freely about the genome. Transposition is mediated by transposases, and similar events are catalyzed by retroviral integrases such as human immunodeficiency virus-1 (HIV-1) integrase, Understanding how these proteins interact with DNA is central to understanding the molecular basis of transposition. We report the three-dimensional structure of prokaryotic Tn5 transposase complexed with Tn5 transposon end DNA determined to 2.3 angstrom resolution. The molecular assembly is dimeric, where each double-stranded DNA molecule is bound by both protein subunits, orienting the transposon ends into the active sites. This structure provides a molecular framework for understanding many aspects of transposition, including the binding of transposon end DNA by one subunit and cleavage by a second, cleavage of two strands of DNA by a single active site via a hairpin intermediate, and strand transfer into target DNA.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Davies, Douglas/0000-0002-3729-3463	NIAMS NIH HHS [AR35186] Funding Source: Medline; NIGMS NIH HHS [GM50692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Allingham JS, 1999, J MOL BIOL, V289, P1195, DOI 10.1006/jmbi.1999.2837; ANDERSON WF, 1979, J MOL BIOL, V130, P507, DOI 10.1016/0022-2836(79)90437-6; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; BHASIN A, IN PRESS J MOL BIOL; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Braam LAM, 1999, J BIOL CHEM, V274, P86, DOI 10.1074/jbc.274.1.86; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; Davies DR, 1999, J BIOL CHEM, V274, P11904, DOI 10.1074/jbc.274.17.11904; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Eijkelenboom APAM, 1999, PROTEINS, V36, P556, DOI 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; GORYSHIN IY, UNPUB; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; ISBERG RR, 1985, J BIOL CHEM, V260, P3645; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jilk RA, 1996, J BACTERIOL, V178, P1671, DOI 10.1128/jb.178.6.1671-1679.1996; JORDAN SR, 1985, SCIENCE, V230, P1383; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAUMANN T, UNPUB; NAUMANN TA, IN PRESS P NATL ACAD; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Roussel A., 1991, SILICON GRAPHICS GEO, V86; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Schumacher S, 1997, EMBO J, V16, P7532, DOI 10.1093/emboj/16.24.7532; STEINIGERWHITE M, IN PRESS J BIOL CHEM; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STOFER E, 1994, BIOPOLYMERS, V34, P337, DOI 10.1002/bip.360340305; Tateno M, 1997, BIOPOLYMERS, V44, P335, DOI 10.1002/(SICI)1097-0282(1997)44:4<335::AID-BIP3>3.3.CO;2-I; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; York D, 1997, NUCLEIC ACIDS RES, V25, P2153, DOI 10.1093/nar/25.11.2153; York D, 1996, NUCLEIC ACIDS RES, V24, P3790, DOI 10.1093/nar/24.19.3790; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188	64	304	316	9	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 7	2000	289	5476					77	85		10.1126/science.289.5476.77	http://dx.doi.org/10.1126/science.289.5476.77			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	332TW	10884228				2022-12-28	WOS:000088090400034
J	Gan, SC; Beaver, SK; Houck, PM; MacLehose, RF; Lawson, HW; Chan, L				Gan, SC; Beaver, SK; Houck, PM; MacLehose, RF; Lawson, HW; Chan, L			Treatment of acute myocardial infarction and 30-day mortality among women and men.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY HEART-DISEASE; SEX-DIFFERENCES; THROMBOLYTIC THERAPY; GENDER DIFFERENCES; ELDERLY PATIENTS; INTERVENTION REGISTRY; CARDIAC PROCEDURES; NATIONAL REGISTRY; BETA-BLOCKERS	Background: Previous studies have suggested that women with acute myocardial infarction receive less aggressive therapy than men. We used data from the Cooperative Cardiovascular Project to determine whether women and men who were ideal candidates for therapy after acute myocardial infarction were treated differently. Methods: Information was abstracted from the charts of 138,956 Medicare beneficiaries (49 percent of them women) who had an acute myocardial infarction in 1994 or 1995. Multivariate analysis was used to assess differences between women and men in the medications administered, the procedures used, the assignment of do-not-resuscitate status, and 30-day mortality. Results: Among ideal candidates for therapy, women in all age groups were less likely to undergo diagnostic catheterization than men. The difference was especially pronounced among older women; for a woman 85 years of age or older, the adjusted relative risk was 0.75 (95 percent confidence interval, 0.68 to 0.83). Women were somewhat less likely than men to receive thrombolytic therapy within 60 minutes (adjusted relative risk, 0.93; 95 percent confidence interval, 0.90 to 0.96) or to receive aspirin within 24 hours after arrival at the hospital (adjusted relative risk, 0.96; 95 percent confidence interval, 0.95 to 0.97), but they were equally likely to receive beta-blockers (adjusted relative risk, 0.99; 95 percent confidence interval, 0.95 to 1.03) and somewhat more likely to receive angiotensin-converting-enzyme inhibitors (adjusted relative risk, 1.05; 95 percent confidence interval, 1.02 to 1.08). Women were more likely than men to have a do-not-resuscitate order in their records (adjusted relative risk, 1.26; 95 percent confidence interval, 1.22 to 1.29). After adjustment, women and men had similar 30-day mortality rates (hazard ratio, 1.02; 95 percent confidence interval, 0.99 to 1.04). Conclusions: As compared with men, women receive somewhat less aggressive treatment during the early management of acute myocardial infarction. However, many of these differences are small, and there is no apparent effect on early mortality. (N Engl J Med 2000;343:8-15.) (C) 2000, Massachusetts Medical Society.	Swedish Med Ctr, Dept Cardiol, Seattle, WA 98104 USA; US Hlth Care Financing Adm, Div Clin Stand & Qual, Seattle, WA USA; Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Swedish Medical Center; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle	Gan, SC (corresponding author), Swedish Med Ctr, Dept Cardiol, 515 Minor Ave,Suite 300, Seattle, WA 98104 USA.							*AM HEART ASS, 1996, 1997 HEART STROK STA; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; Cannon CP, 1999, CLIN CARDIOL, V22, P17, DOI 10.1002/clc.4960220108; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; Chu PH, 1998, INT J CARDIOL, V65, P75, DOI 10.1016/S0167-5273(98)00094-1; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; GOTTLIEB S, 1994, AM J CARDIOL, V74, P727, DOI 10.1016/0002-9149(94)90319-0; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; Harpaz D, 1996, AM J CARDIOL, V78, P1215, DOI 10.1016/S0002-9149(96)00598-X; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; JENKINS JS, 1994, AM J CARDIOL, V73, P319, DOI 10.1016/0002-9149(94)90001-9; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Krumholz HM, 1999, JAMA-J AM MED ASSOC, V281, P37; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; Krumholz HM, 1996, ANN INTERN MED, V124, P292, DOI 10.7326/0003-4819-124-3-199602010-00002; Krumholz HM, 1999, CIRCULATION, V99, P2986, DOI 10.1161/01.CIR.99.23.2986; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Krumholz HM, 1998, AM HEART J, V135, P523, DOI 10.1016/S0002-8703(98)70331-X; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; LUDWIGS U, 1995, CRIT CARE MED, V23, P854, DOI 10.1097/00003246-199505000-00013; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; Marrugat J, 1998, JAMA-J AM MED ASSOC, V280, P1405, DOI 10.1001/jama.280.16.1405; MAYNARD C, 1991, AM J CARDIOL, V68, P529, DOI 10.1016/0002-9149(91)90791-I; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; Maynard C, 1996, CIRCULATION, V94, P93; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; MCLAUGHLIN TJ, 1996, ARCH INTERN MED, V156, P1920; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; *PRACT MAN INF, 1999, INT CLASS DIS; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; *STAT, 1999, VERS 6 0; TSUYUKI RT, 1994, CHEST, V105, P1687, DOI 10.1378/chest.105.6.1687; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; VISCOLI CM, 1993, ANN INTERN MED, V118, P99, DOI 10.7326/0003-4819-118-2-199301150-00004; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; WENGER NS, 1995, ARCH INTERN MED, V155, P2063, DOI 10.1001/archinte.155.19.2063; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4; Yarzebski J, 1996, AM HEART J, V131, P43, DOI 10.1016/S0002-8703(96)90049-6; 1971, MMWR MORB MORTAL WKL, V41, P526	53	265	273	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					8	15		10.1056/NEJM200007063430102	http://dx.doi.org/10.1056/NEJM200007063430102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882763	Bronze			2022-12-28	WOS:000087987600002
J	Godoy, R; Wilkie, D; Overman, H; Cubas, A; Cubas, G; Demmer, J; McSweeney, K; Brokaw, N				Godoy, R; Wilkie, D; Overman, H; Cubas, A; Cubas, G; Demmer, J; McSweeney, K; Brokaw, N			Valuation of consumption and sale of forest goods from a Central American rain forest	NATURE			English	Article								Researchers recognize that society needs accurate and comprehensive estimates of the economic value of rain forests to assess conservation and management options(1-7). Valuation of forests can help us to decide whether to implement policies that reconcile the value different groups attach to forests. Here we have measured the value of the rain forest to local populations by monitoring the foods, construction and craft materials, and medicines consumed or sold from the forest by 32 Indian households in two villages in Honduras over 2.5 years. We have directly measured the detailed, comprehensive consumption patterns of rain forest products by an indigenous population and the value of that consumption in local markets(8,9). The combined value of consumption and sale of forest goods ranged from US$17.79 to US$23.72 per hectare per year, at the lower end of previous estimates (between US$49 and US$1,089 (mean US$347) per hectare per year)(4). Although outsiders value the rain forest for its high-use and non-use values(10), local people receive a small share of the total value. Unless rural people are paid for the non-local values of rain forests, they may be easily persuaded to deforest.	Brandeis Univ, Dept Anthropol, Waltham, MA 02254 USA; Associates Forest Res & Dev, Waltham, MA 02154 USA; Honduras Coral Reef Fund, La Ceiba, Atlantida, Honduras; Univ Pedag Nacl, Tegucigalpa, MDC, Honduras; Univ Amsterdam, Amsterdam Res Inst Global Issues & Dev Studies, NL-1018 VZ Amsterdam, Netherlands; McGill Univ, Dept Geog, Montreal, PQ H3A 2K6, Canada; Manomet Ctr Conservat Sci, Manomet, MA 02345 USA	Brandeis University; University of Amsterdam; McGill University	Godoy, R (corresponding author), Brandeis Univ, Dept Anthropol, Waltham, MA 02254 USA.							Chomitz KM, 1998, WORLD BANK RES OBSER, V13, P13, DOI 10.1093/wbro/13.1.13; Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; GODOY R, 1993, ECON BOT, V47, P220, DOI 10.1007/BF02862288; Godoy R, 1997, WORLD DEV, V25, P977, DOI 10.1016/S0305-750X(97)00007-7; GODOY R, UNPUB J DEV EC; GODOY R, INDIANS RAIN FORESTS; KUMARI K, 1995, ENV EC SERIES PAPER, V26; LAMPIETTI JA, 1995, 013 WORLD BANK ENV D; MCSWEENEY K, 1999, EQUINOX, V103, P78; PANAYOTOU T, 1993, NOT BY TIMBER ALONE; Perez MR, 1997, P WORKSH RES NTFP HO; PETERS CM, 1989, NATURE, V339, P655, DOI 10.1038/339655a0; ROSTONEN MAF, 1999, NTFP RES TROPENBOS P	14	114	118	1	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					62	63		10.1038/35017647	http://dx.doi.org/10.1038/35017647			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894540				2022-12-28	WOS:000087991200043
J	Van Rie, A; Warren, R; Richardson, M; Gie, RP; Enarson, DA; Beyers, N; Van Helden, PD				Van Rie, A; Warren, R; Richardson, M; Gie, RP; Enarson, DA; Beyers, N; Van Helden, PD			Classification of drug-resistant tuberculosis in an epidemic area	LANCET			English	Article							MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; POPULATION; OUTBREAK	Background Traditionally, patients with drug-resistant tuberculosis are classified as having acquired drug-resistant or primary drug-resistant disease on the basis of a history of previous tuberculosis treatment. Only cases of primary drug resistance are assumed to be due to transmission of drug-resistant strains. Methods This descriptive study of 63 patients with drug-resistant tuberculosis assessed the relative contribution of transmission of drug-resistant strains in a high-incidence community of Cape Town, South Africa, by restriction-fragment length polymorphism (RFLP). The RFLP results were compared with the results obtained by traditional classification methods. Findings According to RFLP definitions, 52% (33 cases) of drug-resistant tuberculosis was caused by transmission of a drug-resistant strain. The proportion of cases due to transmission was higher for multidrug-resistant (64%; 29 cases) than for single-drug-resistant (no cases) tuberculosis. By the clinical classification, only 18 (29%) patients were classified as having primary drug-resistant tuberculosis (implying transmission). The clinical classification was thus misleading in 25 patients. Interpretation The term acquired drug resistance includes patients infected with strains that truly acquired drug resistance during treatment and patients who were initially infected with or reinfected with a drug-resistant strain. This definition could lead to misinterpretation of surveillance studies, incorrect evaluation of tuberculosis programmes, and delayed diagnosis and treatment of patients with multidrug-resistant disease. The clinical term acquired drug resistance should be replaced with the term "drug resistance in previously treated cases", which includes cases with drug resistance due to true acquisition as well as that due to transmitted drug-resistant strains.	Univ Stellenbosch, Dept Paediat & Child Hlth, ZA-7600 Stellenbosch, South Africa; Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7600 Stellenbosch, South Africa; Univ Stellenbosch, Dept Med Biochem, ZA-7600 Stellenbosch, South Africa; Katholieke Univ Leuven, Dept Paediat, Louvain, Belgium; Int Union TB & Lung Dis, Paris, France	Stellenbosch University; Stellenbosch University; Stellenbosch University; KU Leuven	Beyers, N (corresponding author), Univ Stellenbosch, Dept Paediat & Child Hlth, POB 19063, ZA-7505 Tygerberg, South Africa.		Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Warren, Robin/0000-0001-5741-7358				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; Carpels G, 1995, TUBERCLE LUNG DIS, V76, P480, DOI 10.1016/0962-8479(95)90522-7; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CROFTON J, WHOTB9621, P8; Fang Z, 1999, J CLIN MICROBIOL, V37, P998, DOI 10.1128/JCM.37.4.998-1003.1999; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; MENDOZ AP, 1994, WHOTB97229; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Warren R, 1996, J CLIN MICROBIOL, V34, P2219, DOI 10.1128/JCM.34.9.2219-2224.1996; Warren R, 1999, ELECTROPHORESIS, V20, P1807, DOI 10.1002/(SICI)1522-2683(19990101)20:8<1807::AID-ELPS1807>3.3.CO;2-0; WEYER K, 1995, S AFR MED J, V85, P499; WHO, 1998, INT J TUBERC LUNG D, V2, P71; *WHO, 1997, WHO REP TUB EP	19	73	75	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 1	2000	356	9223					22	25		10.1016/S0140-6736(00)02429-6	http://dx.doi.org/10.1016/S0140-6736(00)02429-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892760				2022-12-28	WOS:000087933400011
J	Sun, ZM; Unutmaz, D; Zou, YR; Sunshine, MJ; Pierani, A; Brenner-Morton, S; Mebius, RE; Littman, DR				Sun, ZM; Unutmaz, D; Zou, YR; Sunshine, MJ; Pierani, A; Brenner-Morton, S; Mebius, RE; Littman, DR			Requirement for ROR gamma in thymocyte survival and lymphoid organ development	SCIENCE			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; TUMOR-NECROSIS-FACTOR; ORPHAN RECEPTOR; CELL-DEATH; T-CELL; ABNORMAL-DEVELOPMENT; NEGATIVE SELECTION; DEFICIENT MICE; FAS LIGAND; ORGANOGENESIS	Most developing thymocytes undergo apoptosis because they cannot interact productively with molecules encoded by the major histocompatibility complex. Here, we show that mice lacking the orphan nuclear hormone receptor ROR gamma lose thymic expression of the anti-apoptotic factor Bcl-xL. ROR gamma thus regulates the survival of CD4(+)8(+) thymocytes and may control the temporal window during which thymocytes can undergo positive selection. ROR gamma was also required for development of lymph nodes and Peyer's patches, but not splenic follicles, In its absence, there was loss of a population of CD3(-)CD4(+)CD45(+) cells that normally express ROR gamma and that are Likely early progenitors of lymphoid organs. Hence, ROR gamma has critical functions in T cell repertoire selection and Lymphoid organogenesis.	NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Free Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands	New York University; Howard Hughes Medical Institute; New York University; Columbia University; Columbia University; Howard Hughes Medical Institute; Vrije Universiteit Amsterdam	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA.	littman@saturn.med.nyu.edu	Pierani, Alessandra/O-6136-2017	Pierani, Alessandra/0000-0002-4872-4791; Sunshine, Mary Jean/0000-0002-2188-7881; Mebius, Reina/0000-0003-0451-7464				Alimzhanov MB, 1997, P NATL ACAD SCI USA, V94, P9302, DOI 10.1073/pnas.94.17.9302; CALNAN BJ, 1995, IMMUNITY, V3, P273; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Endres R, 1999, J EXP MED, V189, P159, DOI 10.1084/jem.189.1.159; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; Littman DR, 1999, COLD SPRING HARB SYM, V64, P373, DOI 10.1101/sqb.1999.64.373; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Neumann B, 1996, J EXP MED, V184, P259, DOI 10.1084/jem.184.1.259; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; Sun Z., UNPUB; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	23	579	630	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 30	2000	288	5475					2369	2373		10.1126/science.288.5475.2369	http://dx.doi.org/10.1126/science.288.5475.2369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875923				2022-12-28	WOS:000087913400041
J	McCreath, KJ; Howcroft, J; Campbell, KHS; Colman, A; Schnieke, AE; Kind, AJ				McCreath, KJ; Howcroft, J; Campbell, KHS; Colman, A; Schnieke, AE; Kind, AJ			Production of gene-targeted sheep by nuclear transfer from cultured somatic cells	NATURE			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; CLONED TRANSGENIC CALVES; HOMOLOGOUS RECOMBINATION; 3'-UNTRANSLATED REGION; FETAL FIBROBLASTS; EXPRESSION; THERAPY; SEQUENCES	It is over a decade since the first demonstration that mouse embryonic stem cells could be used to transfer a predetermined genetic modification to a whole animal(1). The extension of this technique to other mammalian species, particularly livestock, might bring numerous biomedical benefits, for example, ablation of xenoreactive transplantation antigens, inactivation of genes responsible for neuropathogenic disease and precise placement of transgenes designed to produce proteins for human therapy. Gene targeting has not yet been achieved in mammals other than mice, however, because functional embryonic stem cells have not been derived. Nuclear transfer from cultured somatic cells provides an alternative means of cell-mediated transgenesis(2,3). Here we describe efficient and reproducible gene targeting in fetal fibroblasts to place a therapeutic transgene at the ovine alpha 1(I) procollagen (COL1A1) locus and the production of live sheep by nuclear transfer.	PPL Therapeut Ltd, Roslin EH25 9PP, Midlothian, Scotland		Kind, AJ (corresponding author), PPL Therapeut Ltd, Roslin EH25 9PP, Midlothian, Scotland.			Schnieke, Angelika/0000-0002-5761-9635				Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; CHU ML, 1985, J BIOL CHEM, V260, P2315; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; EBERT KM, 1994, BIO-TECHNOL, V12, P699, DOI 10.1038/nbt0794-699; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kay MA, 1999, P NATL ACAD SCI USA, V96, P9973, DOI 10.1073/pnas.96.18.9973; Kono T, 1998, REPROD FERT DEVELOP, V10, P593, DOI 10.1071/RD98056; Lai LW, 1999, EXP NEPHROL, V7, P11; LIN FL, 1985, P NATL ACAD SCI USA, V82, P1391, DOI 10.1073/pnas.82.5.1391; MAATTA A, 1995, BBA-GENE STRUCT EXPR, V1260, P294, DOI 10.1016/0167-4781(94)00207-J; MCCLENAGHAN M, 1991, Animal Biotechnology, V2, P161, DOI 10.1080/10495399109525756; McWhir J, 1996, NAT GENET, V14, P223, DOI 10.1038/ng1096-223; MOOSLEHNER K, 1988, NUCLEIC ACIDS RES, V16, P773, DOI 10.1093/nar/16.2.773; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Sedivy JM, 1999, TRENDS GENET, V15, P88, DOI 10.1016/S0168-9525(98)01689-8; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WARBURTON MJ, 1986, J CELL PHYSIOL, V128, P76, DOI 10.1002/jcp.1041280113; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601	25	449	586	1	43	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1066	1069		10.1038/35016604	http://dx.doi.org/10.1038/35016604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890449				2022-12-28	WOS:000087871700049
J	Triplett, B				Triplett, B			Astronomers fume over night light	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					987	988		10.1038/35016714	http://dx.doi.org/10.1038/35016714			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890413	Bronze			2022-12-28	WOS:000087871700009
J	Canto, JG; Shlipak, MG; Rogers, WJ; Malmgren, JA; Frederick, PD; Lambrew, CT; Ornato, JP; Barron, HV; Kiefe, CI				Canto, JG; Shlipak, MG; Rogers, WJ; Malmgren, JA; Frederick, PD; Lambrew, CT; Ornato, JP; Barron, HV; Kiefe, CI			Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL REGISTRY; UNITED-STATES; THROMBOLYTIC THERAPY; REPERFUSION THERAPY; EMERGENCY; WOMEN	Context Although chest pain is widely considered a key symptom in the diagnosis of myocardial infarction (MI), not all patients with MI present with chest pain. The extent to which this phenomenon occurs is largely unknown. Objectives To determine the frequency with which patients with MI present without chest pain and to examine their subsequent management and outcome. Design Prospective observational study. Setting and Patients A total of 434 877 patients with confirmed MI enrolled June 1994 to March 1998 in the National Registry of Myocardial Infarction 2, which includes 1674 hospitals in the United States. Main Outcome Measures Prevalence of presentation without chest pain; clinical characteristics, treatment, and mortality among MI patients without chest pain vs those with chest pain, Results Of all patients diagnosed as having MI, 142 445 (33%) did not have chest pain on presentation to the hospital. This group of MI patients was, on average, 7 years older than those with chest pain (74.2 vs 66.9 years), with a higher proportion of women (49.0% vs 38.0%) and patients with diabetes mellitus (32.6% vs 25.4%) or prior heart failure (26.4% vs 12.3%). Also, MI patients without chest pain had a longer delay before hospital presentation (mean, 7.9 vs 5.3 hours), were less likely to be diagnosed as having confirmed MI at the time of admission (22.2% vs 50.3%), and were less likely to receive thrombolysis or primary angioplasty (25.3% vs 74.0%), aspirin (60.4% vs 84.5%), beta-blockers (28.0% vs 48.0%), or heparin (53.4% vs 83.2%). Myocardial infarction patients without chest pain had a 23.3% in-hospital mortality rate compared with 9.3% among patients with chest pain (adjusted odds ratio for mortality, 2.21 [95% confidence interval, 2.17-2.26]). Conclusions Our results suggest that patients without chest pain on presentation represent a large segment of the MI population and are at increased risk for delays in seeking medical attention, less aggressive treatments, and in-hospital mortality.	Univ Alabama, Birmingham, AL 35294 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, S San Francisco, CA 94080 USA; Univ Washington, Cardiol Outcomes Res Ctr, Seattle, WA 98195 USA; Univ Vermont, Portland, ME USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; Roche Holding; Genentech; University of Washington; University of Washington Seattle; University of Vermont; Virginia Commonwealth University	Canto, JG (corresponding author), Univ Alabama, 363 BDB,1808 7th Ave S, Birmingham, AL 35294 USA.			Frederick, Paul/0000-0002-7936-5488	AHRQ HHS [HS08843] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008843] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACHARYA DU, 1991, AM J CARDIOL, V68, P793, DOI 10.1016/0002-9149(91)90657-7; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BEAN WB, 1977, LANCET, V1, P1044; BELLER GA, 1995, CLIN NUCL CARDIOLOGY, P98; Braunwald E., 1992, HEART DIS, P1214; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; Canto JG, 1997, J AM COLL CARDIOL, V29, P498, DOI 10.1016/S0735-1097(96)00532-3; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; COX DA, 1994, AM J CARDIOL, V73, P729, DOI 10.1016/0002-9149(94)90872-9; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; ROUAN GW, 1987, ANN EMERG MED, V16, P1145, DOI 10.1016/S0196-0644(87)80474-2; Taylor HA, 1998, AM J CARDIOL, V82, P1019, DOI 10.1016/S0002-9149(98)00547-5; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	20	476	489	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3223	3229		10.1001/jama.283.24.3223	http://dx.doi.org/10.1001/jama.283.24.3223			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866870	Green Published, Bronze			2022-12-28	WOS:000087753900035
J	Rinberg, D; Davidowitz, H				Rinberg, D; Davidowitz, H			Insect perception - Do cockroaches 'know' about fluid dynamics?	NATURE			English	Article									NEC Res Inst, Princeton, NJ 08540 USA	NEC Corporation	Rinberg, D (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.							Camhi JM, 1984, NEUROETHOLOGY; GNATZY W, 1990, J COMP PHYSIOL A, V167, P551, DOI 10.1007/BF00190826; KONDOH Y, 1991, J COMP PHYSIOL A, V169, P653; PLUMMER MR, 1981, J COMP PHYSIOL, V142, P347, DOI 10.1007/BF00605447; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; TRITTON DJ, 1998, PHYSICAL FLUID DYNAM; Vedenina VY, 1998, J COMP PHYSIOL A, V183, P553, DOI 10.1007/s003590050281	7	11	11	4	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					756	756		10.1038/35015677	http://dx.doi.org/10.1038/35015677			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866188				2022-12-28	WOS:000087620600038
J	Clapp, R; Ozonoff, D				Clapp, R; Ozonoff, D			Where the boys aren't: dioxin and the sex ratio	LANCET			English	Editorial Material							EXPOSURE		Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA	Boston University	Clapp, R (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA.		Groenewoud, Hans JMM/R-3588-2017; Roeleveld, Nel/B-4242-2008	Groenewoud, Hans JMM/0000-0002-4974-150X; Roeleveld, Nel/0000-0002-3390-4466; Ozonoff, David/0000-0002-4281-4171; Clapp, Richard/0000-0001-8174-0825				Ashraf H, 1999, LANCET, V353, P2049, DOI 10.1016/S0140-6736(05)77877-6; Davis DL, 1998, JAMA-J AM MED ASSOC, V279, P1018, DOI 10.1001/jama.279.13.1018; Devito Michael J., 1994, P139; Gustafson ML, 1995, REPROD MED SURG, P39; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; *I MED, 1996, VET AG OR 1996 UPD; *I MED, 1993, VET AG OR; International Agency for Research on Cancer (IARC), 1997, IARC MON EV CARC RIS, V69; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; OZONOFF D, 1987, SCI TECHNOL HUM VAL, V12, P70; Patandin S, 1999, ENVIRON HEALTH PERSP, V107, P45, DOI 10.2307/3434288	11	14	14	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1838	1839		10.1016/S0140-6736(00)02280-7	http://dx.doi.org/10.1016/S0140-6736(00)02280-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866432				2022-12-28	WOS:000087306500002
J	Giacomini, MK; Cook, DJ				Giacomini, MK; Cook, DJ		Evidence Based Med Working Grp	Users' guides to the medical literature XXIII. Qualitative research in health care A. Are the results of the study valid?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Quantitative research is designed to test well-specified hypotheses, determine whether an intervention did more harm than good, and find out how much a risk factor predisposes persons to disease. Equally important, qualitative research offers insight into emotional and experiential phenomena in health care to determine what, how, and why. There are 4 essential aspects of qualitative analysis. First, the participant selection must be well reasoned and their inclusion must be relevant to the research question. Second, the data collection methods must be appropriate for the research objectives and setting. Third, the data collection process, which includes field observation, interviews, and document analysis, must be comprehensive enough to support rich and robust descriptions of the observed events. Fourth, the data must be appropriately analyzed and the findings adequately corroborated by using multiple sources of information, more than 1 investigator to collect and analyze the raw data, member checking to establish whether the participants' viewpoints were adequately interpreted, or by comparison with existing social science theories. Qualitative studies offer an alternative when insight into the research is not well established or when conventional theories seem inadequate.	McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Ctr Hlth Econ & Policy Anal, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Div Gen Med,Evidence Based Med Working Grp, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Dept Med, Div Crit Care,Evidence Based Med Working Grp, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Giacomini, MK (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Clin Epidemiol & Biostat, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							BATTISTA RN, 1995, J CLIN EPIDEMIOL, V48, P875, DOI 10.1016/0895-4356(94)00199-Z; Clandinin DJ., 1994, HDB QUALITATIVE RES, P413; CORBIN J, 1990, Z SOZIOL, V19, P418, DOI 10.1007/BF00988593; Denzin NK., 1978, SOCIOLOGICAL METHODS; Glaser B., 1967, CONSTANT COMP METHOD, P101; Goering PN, 1996, CAN J PSYCHIAT, V41, P491, DOI 10.1177/070674379604100804; Guba E.G., 1994, HDB QUALITATIVE RES, V2, P105; Hodder I., 1994, HDB QUALITATIVE RES, P393; HOLLOWAY I, 1995, NURS ETHICS, V2, P223, DOI 10.1177/096973309500200305; Hughes J A, 1990, PHILOS SOCIAL RES, P89; Kirk J., 1986, RELIABILITY VALIDITY; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Lincoln Y, 1985, NATURALISTIC ENQUIRY; Morse JM, 1996, QUAL HEALTH RES, V6, P3, DOI 10.1177/104973239600600101; NEUMANN WL, 1991, SOCIAL RES METHODS, P43; Patton M. Q., 1990, QUALITATIVE EVALUATI; Patton MQ, 1999, HEALTH SERV RES, V34, P1189; Poses RM, 1998, J GEN INTERN MED, V13, P32, DOI 10.1046/j.1525-1497.1998.00005.x; Robling MR, 1998, J GEN INTERN MED, V13, P64, DOI 10.1046/j.1525-1497.1998.00017.x; ROSENFIELD PL, 1992, SOC SCI MED, V35, P1343, DOI 10.1016/0277-9536(92)90038-R; Smith J. K., 1983, EDUC RES, V12, P6, DOI [DOI 10.2307/1175144, DOI 10.3102/0013189X012003006]; Sofaer S, 1999, HEALTH SERV RES, V34, P1101; STAKE RE, 1995, ART CASE STUDY RES, P107; Stange K C, 1989, Fam Med, V21, P448; STEWARD DW, 1950, GROUP DYNAMICS FOCUS, P33; TILDEN VP, 1995, ARCH INTERN MED, V155, P633, DOI 10.1001/archinte.155.6.633; VENTRES W, 1993, J CLIN ETHIC, V4, P134; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; [No title captured]	29	648	659	0	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					357	362		10.1001/jama.284.3.357	http://dx.doi.org/10.1001/jama.284.3.357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333GR	10891968				2022-12-28	WOS:000088123000029
J	Scully, C; Shotts, R				Scully, C; Shotts, R			ABC of oral health - Mouth ulcers and other causes of orofacial soreness and pain	BRITISH MEDICAL JOURNAL			English	Review							RECURRENT APHTHOUS STOMATITIS; BEHCETS-DISEASE		Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England	University of London; University College London	Scully, C (corresponding author), Univ London, Univ Coll London, Eastman Dent Inst Oral Hlth Care Sci, London WC1E 7HU, England.							Krause I, 1999, J ORAL PATHOL MED, V28, P193; Marbach JJ, 1999, MED CLIN N AM, V83, P691, DOI 10.1016/S0025-7125(05)70130-9; Porter SR, 1998, CRIT REV ORAL BIOL M, V9, P306, DOI 10.1177/10454411980090030401; Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; SCULLY C, 1996, ORAL DIS; Scully Crispian, 1999, Annals Academy of Medicine Singapore, V28, P704; Tammiala-Salonen T, 1999, J OROFAC PAIN, V13, P83; Van der Waal I, 1990, BURNING MOUTH SYNDRO	8	40	44	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					162	165		10.1136/bmj.321.7254.162	http://dx.doi.org/10.1136/bmj.321.7254.162			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894697	Green Published			2022-12-28	WOS:000088305700026
J	Helfand, WH; Ittmann, J				Helfand, WH; Ittmann, J			The Ars Medica Collection at the Philadelphia Museum of Art	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Philadelphia Museum Art, Philadelphia, PA 19101 USA		Helfand, WH (corresponding author), 2 Sutton Pl S, New York, NY 10022 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					76	79		10.7326/0003-4819-133-1-200007040-00020	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	329TB	10877749				2022-12-28	WOS:000087923100017
J	Fontaine, H; Chaix, ML; Lagneau, JL; Brechot, C; Pol, S				Fontaine, H; Chaix, ML; Lagneau, JL; Brechot, C; Pol, S			Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa	LANCET			English	Article							COMBINATION; THERAPY; VIRUS; RNA	In 45 sustained responders to interferon alfa and ribavirin, we found long-lasting elimination of hepatitis C virus RNA from serum and liver, together with histopathological improvement, suggesting complete recovery from chronic hepatitis C.	Hop Necker Enfants Malad, Unite Hepatol, F-75015 Paris, France; Hop Necker Enfants Malad, INSERM, U370, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Pol, S (corresponding author), Hop Necker Enfants Malad, Unite Hepatol, F-75015 Paris, France.							Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; ROMEO R, 1994, ANN INTERN MED, V121, P276, DOI 10.7326/0003-4819-121-4-199408150-00008	5	42	56	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					41	41		10.1016/S0140-6736(00)02434-X	http://dx.doi.org/10.1016/S0140-6736(00)02434-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10892765				2022-12-28	WOS:000087933400016
J	Gunnarsson, O; Han, JE				Gunnarsson, O; Han, JE			The mean free path for electron conduction in metallic fullerenes	NATURE			English	Article							RESISTIVITY SATURATION; FERMION SYSTEMS; FIELD THEORY; DOPED C-60; STATE; K3C60; TEMPERATURE; RB3C60; TRANSITION	The electrical resistivity, rho, of a metal is usually interpreted in terms of the mean free path (the average distance, l, an electron travels before it is scattered). As the temperature is raised, the resistivity increases and the apparent mean free path is correspondingly reduced. In this semi-classical picture, the mean free path cannot be much shorter than the distance, d, between two atoms. This has been confirmed for many systems and was considered to be a universal behaviour(1,2). Recently, some apparent exceptions were found, including alkali-doped fullerenes(3-7) and high-temperature superconductors. However, there remains the possibility that these systems are in exotic states, with only a small fraction of the conduction electrons contributing to the conductivity; the mean free path would then have to be correspondingly larger to explain the observed resistivity. Here we report a model calculation of electron conduction in alkali-doped fullerenes, in which the electrons are scattered by intramolecular vibrations. The resistivity at large temperatures implies l << d, demonstrating that there is no fundamental principle requiring l greater than or similar to d. At high temperatures, the semi-classical picture breaks down, and the electrons cannot be described as quasiparticles.	Max Planck Inst Festkorperforsch, D-70506 Stuttgart, Germany	Max Planck Society	Gunnarsson, O (corresponding author), Max Planck Inst Festkorperforsch, D-70506 Stuttgart, Germany.		Han, Jong/E-7311-2011; Gunnarsson, Olle/B-4011-2012	Han, Jong/0000-0002-5518-2986; 				Allen P. B., 1980, Superconductivity in d- and f-Band Metals. Proceedings of the Conference on Superconductivity in d- and f-Band Metals, P291; ALLEN PB, 1974, PHYS REV B, V9, P4733, DOI 10.1103/PhysRevB.9.4733; BLANKENBECLER R, 1981, PHYS REV D, V24, P2278, DOI 10.1103/PhysRevD.24.2278; DEGIORGI L, 1992, PHYS REV LETT, V69, P2987, DOI 10.1103/PhysRevLett.69.2987; FISK Z, 1976, PHYS REV LETT, V36, P1084, DOI 10.1103/PhysRevLett.36.1084; GELFAND MP, 1992, PHYS REV B, V46, P4367, DOI 10.1103/PhysRevB.46.4367; Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13; GRIMVALL G, 1981, ELECT PHONON INTERAC, P212; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HEBARD AF, 1993, PHYS REV B, V48, P9945, DOI 10.1103/PhysRevB.48.9945; HOLSTEIN T, 1964, ANN PHYS-NEW YORK, V29, P410, DOI 10.1016/0003-4916(64)90008-9; HOU JG, 1993, SOLID STATE COMMUN, V86, P643, DOI 10.1016/0038-1098(93)90831-7; HOU JG, 1995, SOLID STATE COMMUN, V93, P973, DOI 10.1016/0038-1098(94)00915-5; Jarrell M, 1996, PHYS REP, V269, P133, DOI 10.1016/0370-1573(95)00074-7; MAZIN II, 1993, PHYS REV LETT, V70, P4142, DOI 10.1103/PhysRevLett.70.4142; Millis AJ, 1999, PHYS REV LETT, V82, P2354, DOI 10.1103/PhysRevLett.82.2354; Palsson G, 1998, PHYS REV LETT, V80, P4775, DOI 10.1103/PhysRevLett.80.4775; SATPATHY S, 1992, PHYS REV B, V46, P1773, DOI 10.1103/PhysRevB.46.1773; STEPHENS PW, 1991, NATURE, V351, P632, DOI 10.1038/351632a0; VAREKA WA, 1994, PHYS REV LETT, V72, P4121, DOI 10.1103/PhysRevLett.72.4121	20	39	41	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1027	1030		10.1038/35016512	http://dx.doi.org/10.1038/35016512			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890437	Green Submitted			2022-12-28	WOS:000087871700037
J	Machesky, LM				Machesky, LM			Putting on the brakes: A negative regulatory function for Ena/VASP proteins in cell migration	CELL			English	Review							ACTIN-BASED MOTILITY; LISTERIA-MONOCYTOGENES; C-ABL; FAMILY; DYNAMICS; LAMELLIPODIA; MENA; VASP		Univ Birmingham, Sch Biosci, Div Cell & Mol Biol, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Machesky, LM (corresponding author), Univ Birmingham, Sch Biosci, Div Cell & Mol Biol, Birmingham B15 2TT, W Midlands, England.		Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856				Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7	18	48	49	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 23	2000	101	7					685	688		10.1016/S0092-8674(00)80879-X	http://dx.doi.org/10.1016/S0092-8674(00)80879-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	327YE	10892738	Bronze			2022-12-28	WOS:000087821400001
J	Tallon, D; Chard, J; Dieppe, P				Tallon, D; Chard, J; Dieppe, P			Relation between agendas of the research community and the research consumer	LANCET			English	Article							HEALTH	Background Previous studies have suggested that research agendas can be biased. To determine whether there is a mismatch between available research evidence and the research preferences of consumers we examined research on interventions for the treatment of osteoarthritis of the knee joint. Methods We searched published and unpublished studies on interventions in this condition to assess the structure of the evidence base. Focus groups and a postal survey of research consumers were then undertaken to examine their views and research priorities. Findings Review of published and unpublished reports showed that the evidence base was dominated by studies of pharmaceutical (550, 59%) and surgical (238, 26%) interventions. 24 (36%) of 67 survey respondents ranked knee replacement as the highest priority for research, whereas 14 (21%) chose education and advice as their first choice. Interpretation There is a mismatch between the amount of published work on different interventions, and the degree of interest of consumers. We suggest that broadening of the research agenda would be more in line with current treatment patterns and consumer views. If this mismatch is not addressed, then evidence-based medicine will not be representative of consumer needs.	Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England	University of Bristol	Tallon, D (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.							CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; CHALMERS I, 1991, BIRTH-ISS PERINAT C, V18, P137, DOI 10.1111/j.1523-536X.1991.tb00083.x; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Glaser B.G., 1965, AWARENESS DYING; Goodman NW, 1999, J ROY COLL PHYS LOND, V33, P249; GRANTPEARCE C, 1999, INVOLVEMENT WORKS; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; OXMAN AD, 1996, COCHRANE COLLABORATI; PAYER L, 1988, MED CULTURE VARIATIO; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157	12	270	272	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	2000	355	9220					2037	2040		10.1016/S0140-6736(00)02351-5	http://dx.doi.org/10.1016/S0140-6736(00)02351-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885355				2022-12-28	WOS:000087519400012
J	Bonnie, R; Schwartzman, S; Oppenheimer, M; Bloomfield, J				Bonnie, R; Schwartzman, S; Oppenheimer, M; Bloomfield, J			Environmental policy - Counting the cost of deforestation	SCIENCE			English	Editorial Material									Environm Def, Washington, DC 20009 USA		Bonnie, R (corresponding author), Environm Def, 1875 Connecticut Ave NW, Washington, DC 20009 USA.	Robert_Bonnie@environmentaldefense.org		Oppenheimer, Michael/0000-0002-9708-5914				Costanza R, 1997, NATURE, V387, P253, DOI 10.1038/387253a0; *FAO, 1997, STATE WORLDS FOR; Kremen C, 2000, SCIENCE, V288, P1828, DOI 10.1126/science.288.5472.1828; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066	4	19	20	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	2000	288	5472					1763	1764		10.1126/science.288.5472.1763	http://dx.doi.org/10.1126/science.288.5472.1763			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	322HH	10877697				2022-12-28	WOS:000087503800037
J	Sarov-Blat, L; So, WV; Liu, L; Rosbash, M				Sarov-Blat, L; So, WV; Liu, L; Rosbash, M			The Drosophila takeout gene is a novel molecular link between circadian rhythms and feeding behavior	CELL			English	Article							HORMONE-BINDING-PROTEIN; CLOCK GENE; SUPRACHIASMATIC NUCLEUS; LIGAND-BINDING; MESSENGER-RNA; PERIOD GENE; DOUBLE-TIME; EXPRESSION; MELANOGASTER; MUTANT	We report the characterization of a novel Drosophila circadian clock-regulated output gene, takeout (to). The to amino acid sequence shows similarity to two ligand binding proteins, including juvenile hormone binding protein, to mRNA is expressed in the head and the cardia, crop, and antennae-structures related to feeding. to expression is induced by starvation, which is blocked in all arrhythmic central clock mutants, suggesting a direct molecular link between the circadian clock and the feeding/starvation response. A to mutant has aberrant locomotor activity and dies rapidly in response to starvation, indicating a link between locomotor activity, survival, and food status. We propose that to participates in a novel circadian output pathway that conveys temporal and food status information to feeding-relevant metabolisms and activities.	Brandeis Univ, Howard Hughes Med Inst, Natl Sci Fdn, Ctr Biol Timing,Dept Biol, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute; National Science Foundation (NSF); NSF - Center for Biological Timing	Rosbash, M (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Natl Sci Fdn, Ctr Biol Timing,Dept Biol, Waltham, MA 02454 USA.	rosbash@brandeis.edu						Ahima RS, 1998, J CLIN INVEST, V101, P1020, DOI 10.1172/JCI1176; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BARGIELLO TA, 1984, P NATL ACAD SCI-BIOL, V81, P2142, DOI 10.1073/pnas.81.7.2142; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; Cassone VM, 1998, CHRONOBIOL INT, V15, P457, DOI 10.3109/07420529808998702; COWAN SW, 1999, PROTEIN-STRUCT FUNCT, V8, P44; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; DU GH, 1994, BIOCHEMISTRY-US, V33, P4812, DOI 10.1021/bi00182a009; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FLOWER D, 1999, BIOCHEMISTRY-US, V318, P1; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Green CB, 1996, P NATL ACAD SCI USA, V93, P14884, DOI 10.1073/pnas.93.25.14884; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HASAN G, 1992, DEVELOPMENT, V116, P967; HekmatScafe DS, 1997, J NEUROSCI, V17, P1616; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Krishnan B, 1999, NATURE, V400, P375, DOI 10.1038/22566; Lavery DJ, 1999, MOL CELL BIOL, V19, P6488; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LORENZ LJ, 1989, DEVELOPMENT, V107, P869; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; Miller A., 1950, BIOL DROSOPHILA, P420; NEWBY LM, 1993, GENETICS, V135, P1077; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; North MA, 1999, CURR OPIN GENET DEV, V9, P283, DOI 10.1016/S0959-437X(99)80042-2; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REDDY P, 1984, CELL, V38, P701, DOI 10.1016/0092-8674(84)90265-4; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; REPPERT SM, 1987, TRENDS NEUROSCI, V10, P76, DOI 10.1016/0166-2236(87)90029-4; Ripperger JA, 2000, GENE DEV, V14, P679; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; RUTILA JE, 1996, NEURON, V5, P621; RUTILA JE, 1989, MOL CLONING LAB MANU; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; TOUHARA K, 1992, BIOCHEM BIOPH RES CO, V182, P466, DOI 10.1016/0006-291X(92)91755-F; TOUHARA K, 1993, BIOCHEMISTRY-US, V32, P2068, DOI 10.1021/bi00059a026; van Naters WMV, 1998, CHEM SENSES, V23, P351, DOI 10.1093/chemse/23.3.351; VanGelder RN, 1996, EMBO J, V15, P1625, DOI 10.1002/j.1460-2075.1996.tb00507.x; Wisor JP, 1997, J COMP NEUROL, V378, P229; WOJTASEK H, 1995, BIOCHEMISTRY-US, V34, P5234, DOI 10.1021/bi00015a037; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	59	194	204	0	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 9	2000	101	6					647	656		10.1016/S0092-8674(00)80876-4	http://dx.doi.org/10.1016/S0092-8674(00)80876-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892651	Bronze			2022-12-28	WOS:000087504500011
J	Eggimann, P; Harbarth, S; Constantin, MN; Touveneau, S; Chevrolet, JC; Pittet, D				Eggimann, P; Harbarth, S; Constantin, MN; Touveneau, S; Chevrolet, JC; Pittet, D			Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care	LANCET			English	Article							CENTRAL VENOUS CATHETERS; BLOOD-STREAM INFECTION; CRITICALLY ILL; NOSOCOMIAL INFECTIONS; SEPSIS; METAANALYSIS; MORTALITY; RATES	Background Intravascular devices are a leading cause of nosocomial infection. Specific prevention strategies and improved guidelines for the use of intravascular devices can decrease the rate of infection; however, the impact of a combination of these strategies on rates of vascular-access infection in intensive-care units (ICUs) is not known. We implemented a multiple-approach prevention programme to decrease the occurrence of vascular-access infection in an 18-bed medical ICU at a tertiary centre. Methods 3154 critically ill patients, admitted between October, 1995, and November, 1997, were included in a cohort study with longitudinal assessment of an overall catheter-care policy targeted at the reduction of vascular-access infections and based on an educational campaign for vascular-access insertion and on device use and care. Incidence of ICU-acquired infections was measured by means of on-site surveillance. Findings 613 infections occurred in 353 patients (19.4 infections per 100 admissions). The incidence density of exit-site catheter infection was 9.2 episodes per 1000 patient-days before the intervention, and 3.3 episodes per 1000 patient-days afterwards (relative risk 0.36 [95% CI 0.20-0.63]), Corresponding rates for bloodstream infection were 11.3 and 3.8 episodes per 1000 patient-days, respectively (0.33 [0.20-0.56]) due to decreased rates of both microbiologically documented infections and clinical sepsis, Rates of respiratory and urinary-tract infections remained unchanged, whereas those of skin or mucous-membrane infections decreased from 11.4 to 7.0 episodes per 1000 patient-days (0.62 [0.41-0.93]). Overall, the incidence of nosocomial infections decreased from 52.4 to 34.0 episodes per 1000 patient-days (0.65 [0.54-0.78]). Interpretation A multiple-approach prevention strategy, targeted at the insertion and maintenance of vascular access, can decrease rates of vascular-access infections and can have a substantial impact on the overall incidence of ICU-acquired infections.	Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Dept Internal Med, Med Intens Care Unit, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland.			Pittet, Didier/0000-0002-3667-7131				ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; Badley AD, 1996, MAYO CLIN PROC, V71, P838, DOI 10.4065/71.9.838; Bijma R, 1999, INFECT CONT HOSP EP, V20, P618, DOI 10.1086/501682; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gerberding J, 1999, AM J INFECT CONTROL, V27, P520; HEISELMAN D, 1994, JAMA-J AM MED ASSOC, V272, P1819, DOI 10.1001/jama.272.23.1819; Hernandez C A, 1996, Can J Nurs Adm, V9, P32; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; Legras A, 1998, INTENS CARE MED, V24, P1040, DOI 10.1007/s001340050713; Maas A, 1998, J HOSP INFECT, V40, P211, DOI 10.1016/S0195-6701(98)90139-6; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1998, HOSP INFECT, P689; Pearson ML, 1996, INFECT CONT HOSP EP, V17, P438; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Pittet D, 1998, HOSP INFECT, P381; PITTET D, 1999, SCHWEIZ MED WOC S105, V129, pA300; PUNTIS JWL, 1991, ARCH DIS CHILD, V66, P335, DOI 10.1136/adc.66.3.335; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; RAAD II, 1996, INFECT MED, V13, P807; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554	26	315	319	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1864	1868		10.1016/S0140-6736(00)02291-1	http://dx.doi.org/10.1016/S0140-6736(00)02291-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866442				2022-12-28	WOS:000087306500013
J	Gill, TM; DiPietro, L; Krumholz, HM				Gill, TM; DiPietro, L; Krumholz, HM			Role of exercise stress testing and safety monitoring for older persons starting an exercise program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; ACTIVE LIFE EXPECTANCY; CARDIOVASCULAR HEALTH; PHYSICAL-ACTIVITY; RISK-FACTORS; COMMUNITY POPULATION; ELDERLY PEOPLE; ADULTS; EXERTION	While the benefits of physical activity and exercise among older persons are becoming increasingly clear, the role of exercise stress testing and safety monitoring for older persons who want to start an exercise program is unclear. Current guidelines regarding exercise stress testing likely are not applicable to the majority of persons aged 75 years or older who are interested in restoring or enhancing their physical function through a program of physical activity and exercise. In addition to being expensive and of unproven benefit, the current policy of routine exercise stress testing potentially could deter many older persons from participating in an exercise program. Research is needed to investigate current physician practices, evaluate the risk of adverse cardiac events, determine the role of pharmacological stress testing, and measure and compare absolute and relative exercise intensifies. To assist clinicians, we offer a set of recommendations regarding precautions that can be taken to minimize the risk of adverse cardiac events among previously sedentary older persons who do not have symptomatic cardiovascular disease and are interested in starting an exercise program.	Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06504 USA; Yale Univ, Sch Med, John B Pierce Lab, New Haven, CT 06504 USA	Yale University; Yale University; Yale University; The John B Pierce Laboratory, Inc	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Med, 20 York St, New Haven, CT 06504 USA.	gill@ynhh.com	, Harlan/AAI-2875-2020; Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [K32AG00759, R01AG17163, P60AG10469] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469, R01AG017163] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ades PA, 1999, J AM GERIATR SOC, V47, P98, DOI 10.1111/j.1532-5415.1999.tb01909.x; *AM COLL SPORTS ME, 1952, MED SCI SPORTS EXERC, V30, P992; Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; [Anonymous], 1995, GUID EX TEST PRESCR; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; Bijnen FCH, 1999, AM J EPIDEMIOL, V150, P1289, DOI 10.1093/oxfordjournals.aje.a009960; BORG G, 1970, ACTA MED SCAND, V187, P17; Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; Ferrucci L, 1999, AM J EPIDEMIOL, V149, P645, DOI 10.1093/oxfordjournals.aje.a009865; Fiatarone M A, 1990, TOP GERIATR REHABIL, V5, P63, DOI DOI 10.1097/00013614-199001000-00009; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; Giri S, 1999, JAMA-J AM MED ASSOC, V282, P1731, DOI 10.1001/jama.282.18.1731; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; HAKIM AA, 1999, AM J EPIDEMIOL, V149, P645; Hollenberg M, 1998, J GERONTOL A-BIOL, V53, pB259, DOI 10.1093/gerona/53A.4.B259; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; JUDGE JO, 1994, J AM GERIATR SOC, V42, P937, DOI 10.1111/j.1532-5415.1994.tb06584.x; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; Kohrt WM, 1998, J AM GERIATR SOC, V46, P129, DOI 10.1111/j.1532-5415.1998.tb02528.x; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LAKATTA EG, 1993, PHYSIOL REV, V73, P413, DOI 10.1152/physrev.1993.73.2.413; Leveille SG, 1999, AM J EPIDEMIOL, V149, P654; MITTELMARK MB, 1993, AM J EPIDEMIOL, V137, P311, DOI 10.1093/oxfordjournals.aje.a116678; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MOLDLICHER VF, 2000, OUUJCISE HEART; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; National Center for Chronic Disease Prevention and Health Promotion, 1996, PHYS ACT HLTH REP SU; National Center for Chronic Disease Prevention and Health Promotion, 1997, UNR PREV OPP RED HLT; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Panton LB, 1996, J GERONTOL A-BIOL, V51, pM165, DOI 10.1093/gerona/51A.4.M165; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; POSNER JD, 1986, AM J CARDIOL, V57, pC52, DOI 10.1016/0002-9149(86)91027-1; Psaty BM, 1999, ARCH INTERN MED, V159, P1339, DOI 10.1001/archinte.159.12.1339; RAUTAHARJU PM, 1995, INT J CARDIOL, V51, P165, DOI 10.1016/0167-5273(95)02414-R; Rooks DS, 1997, J GERONTOL A-BIOL, V52, pM161, DOI 10.1093/gerona/52A.3.M161; SALIVE ME, 1992, OPHTHALMOLOGY, V99, P1840; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; SKELTON DA, 1995, J AM GERIATR SOC, V43, P1081, DOI 10.1111/j.1532-5415.1995.tb07004.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; WENGER NK, 1995, AHCPR PUBL; Wennberg DE, 1996, JAMA-J AM MED ASSOC, V275, P1161, DOI 10.1001/jama.275.15.1161; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; [No title captured]	58	88	90	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					342	349		10.1001/jama.284.3.342	http://dx.doi.org/10.1001/jama.284.3.342			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333GR	10891966				2022-12-28	WOS:000088123000027
J	Satchithananda, DK; Stone, DL; Chauhan, A; Ritchie, AJ				Satchithananda, DK; Stone, DL; Chauhan, A; Ritchie, AJ			Lesson of the week - Unrecognised accidental overdose with diltiazem	BRITISH MEDICAL JOURNAL			English	Review							CALCIUM-ANTAGONISTS; EXPERIENCE		Papworth Hosp, Cambridge CB3 8RE, England	Papworth Hospital	Satchithananda, DK (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.							BAYLISS J, 1983, BRIT MED J, V287, P187, DOI 10.1136/bmj.287.6386.187; ERICKSON F C, 1991, Journal of Emergency Medicine, V9, P357, DOI 10.1016/0736-4679(91)90380-X; KENNY J, 1994, BRIT MED J, V308, P992, DOI 10.1136/bmj.308.6935.992; LIP GYH, 1995, J HUM HYPERTENS, V9, P155; Melanson P, 1993, VET HUM TOXICOL, V35, P345; PEARIGEN PD, 1991, DRUG SAFETY, V6, P408, DOI 10.2165/00002018-199106060-00003; PROANO L, 1995, AM J EMERG MED, V13, P444, DOI 10.1016/0735-6757(95)90137-X; ROBERTS D, 1991, J TOXICOL-CLIN TOXIC, V29, P45, DOI 10.3109/15563659109038596; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; Williamson KM, 1996, ANN PHARMACOTHER, V30, P608, DOI 10.1177/106002809603000608	10	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					160	161		10.1136/bmj.321.7254.160	http://dx.doi.org/10.1136/bmj.321.7254.160			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894696	Green Published			2022-12-28	WOS:000088305700025
J	Delves, PJ; Roitt, IM				Delves, PJ; Roitt, IM			Advances in immunology: The immune system - Second of two parts.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTRANASAL IMMUNIZATION; CYTOKINE PRODUCTION; DENDRITIC CELLS; T-LYMPHOCYTES; B-CELLS; RESPONSES; RECEPTOR; MUCOSAL; SELF; TRANSPLANTATION		UCL, Dept Immunol, London, England; UCL, Windeyer Inst Med Sci, London, England	University of London; University College London; University of London; University College London	Delves, PJ (corresponding author), UCL, Dept Immunol, Mortimer St, London, England.							Akkaraju S, 1997, J EXP MED, V186, P2005, DOI 10.1084/jem.186.12.2005; Barrett T A, 1995, Semin Immunol, V7, P299, DOI 10.1016/1044-5323(95)90011-X; Beagley KW, 1998, CRIT REV IMMUNOL, V18, P237, DOI 10.1615/CritRevImmunol.v18.i3.40; Biancone L, 1999, INT J MOL MED, V3, P343; Bluestone JA, 1997, J IMMUNOL, V158, P1989; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P267, DOI 10.1016/S0167-5699(99)01468-1; Burdin N, 1999, CURR OPIN IMMUNOL, V11, P326, DOI 10.1016/S0952-7915(99)80052-1; BURTON DR, 1998, ENCY IMMUNOLOGY, V3, P1315; CAO DR, 1993, J CELL PHYSIOL, V156, P428, DOI 10.1002/jcp.1041560227; Cox NJ, 1998, INFECT DIS CLIN N AM, V12, P27, DOI 10.1016/S0891-5520(05)70406-2; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Fairchild PJ, 1996, INT IMMUNOL, V8, P1035, DOI 10.1093/intimm/8.7.1035; Falcone M, 1999, CLIN IMMUNOL, V90, P2, DOI 10.1006/clim.1998.4619; FRIEDMAN H, 1996, MICROORGANISMS AUTOI; Gapin L, 1998, J IMMUNOL, V160, P1555; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Goding J.W., 1996, MONOCLONAL ANTIBODIE; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; Holter W, 1996, IMMUNOL REV, V153, P107, DOI 10.1111/j.1600-065X.1996.tb00922.x; Joseph SB, 1998, EUR J IMMUNOL, V28, P277, DOI 10.1002/(SICI)1521-4141(199801)28:01<277::AID-IMMU277>3.0.CO;2-8; Justement LB, 1997, ADV IMMUNOL, V66, P1, DOI 10.1016/S0065-2776(08)60595-7; Karlsen AE, 1998, SEMIN IMMUNOL, V10, P25, DOI 10.1006/smim.1997.0102; Kelsoe G, 1999, CURR OPIN IMMUNOL, V11, P70, DOI 10.1016/S0952-7915(99)80013-2; Klavinskis LS, 1999, J IMMUNOL, V162, P254; KRAJCI P, 1995, ADV EXP MED BIOL, V371, P617; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; MCCAFFERTY J, 1996, ANTIBODY ENG PRACTIC; McGhee JR, 1998, ENCY IMMUNOLOGY, V3, P1774; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Mosmann T R, 1997, Semin Immunol, V9, P87, DOI 10.1006/smim.1997.0065; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Opelz G, 1995, TRANSPLANTATION, V60, P1220; PABST R, 1998, ENCY IMMUNOLOGY, V3, P1616; Parham P, 1999, IMMUNOL REV, V167, P5, DOI 10.1111/j.1600-065X.1999.tb01378.x; PARHAM P, 1997, IMMUNOL REV, V156, P5; Pisetsky DS, 1996, J IMMUNOL, V156, P421; PODACK ER, 1995, J LEUKOCYTE BIOL, V57, P548, DOI 10.1002/jlb.57.4.548; POWERS DB, 1999, ANTIBODY FUSION PROT, P151; Pringault E, 1999, SEMIN IMMUNOL, V11, P155, DOI 10.1006/smim.1999.0170; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Reiter Y, 1996, CLIN CANCER RES, V2, P245; Rossiter H, 1997, MOL MED TODAY, V3, P214, DOI 10.1016/S1357-4310(97)01040-X; Sayegh MH, 1998, NEW ENGL J MED, V338, P1813, DOI 10.1056/NEJM199806183382506; SHERIFF S, 1998, ENCY IMMUNOLOGY, V1, P159; Tarlinton D, 1998, CURR OPIN IMMUNOL, V10, P245, DOI 10.1016/S0952-7915(98)80161-1; TUNNACLIFFE A, 1998, ENCY IMMUNOLOGY, V1, P465; van de Winkel JG, 1996, HUMAN IGG FC RECEPTO; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; vandeWinkel JGJ, 1997, IMMUNOL TODAY, V18, P562, DOI 10.1016/S0167-5699(97)01167-5; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wang BP, 1997, IMMUNOL REV, V157, P53, DOI 10.1111/j.1600-065X.1997.tb00973.x; Wang HW, 1997, J IMMUNOL, V159, P1125; Williams NS, 1997, J IMMUNOL, V159, P2091; Wu HY, 1998, VACCINE, V16, P286, DOI 10.1016/S0264-410X(97)00168-0; Young AJ, 1999, SEMIN IMMUNOL, V11, P73, DOI 10.1006/smim.1999.0163; ZUBLER RH, 1998, ENCY IMMUNOLOGY, V1, P214	63	280	299	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					108	117		10.1056/NEJM200007133430207	http://dx.doi.org/10.1056/NEJM200007133430207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891520				2022-12-28	WOS:000088116500007
J	Fassil, Y				Fassil, Y			Looking after the health of refugees	BRITISH MEDICAL JOURNAL			English	Editorial Material									Westminster Hlth Author, London, England		Fassil, Y (corresponding author), Westminster Hlth Author, London, England.								0	12	12	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 1	2000	321	7252					59	59		10.1136/bmj.321.7252.59	http://dx.doi.org/10.1136/bmj.321.7252.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875842	Green Published			2022-12-28	WOS:000088030100066
J	Cayol, V; Dieterich, JH; Okamura, AT; Miklius, A				Cayol, V; Dieterich, JH; Okamura, AT; Miklius, A			High magma storage rates before the 1983 eruption of Kilauea, Hawaii	SCIENCE			English	Article							SOUTH-FLANK; RIFT ZONES; VOLCANO; DEFORMATION; BENEATH; EARTHQUAKE; ISLAND	After a magnitude 7.2 earthquake in 1975 and before the start of the ongoing eruption in 1983, deformation of Kilauea volcano was the most rapid ever recorded. Three-dimensional numerical modeling shows that this deformation is consistent with the dilation of a dike within Kilauea's rift zones coupled with creep over a narrow area of a Low-angle fault beneath the south flank. Magma supply is estimated to be 0.18 cubic kilometers per year, twice that of previous estimates. The 1983 eruption may be a direct consequence of the high rates of magma storage within the rift zone that followed the 1975 earthquake.	US Geol Survey, Menlo Park, CA 94025 USA; US Geol Survey, Hawaiian Volcano Observ, Hawaii Natl Pk, HI 96718 USA	United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Cayol, V (corresponding author), Lab Magmas & Volcans, UMR 6524, 5 Rue Kessler, F-63000 Clermont Ferrand, France.		Cayol, Valerie/AGV-1316-2022; Cayol, Valerie/AAK-6394-2020	Cayol, Valerie/0000-0001-9225-7441				ANDO M, 1979, J GEOPHYS RES, V84, P7616, DOI 10.1029/JB084iB13p07616; Cayol V, 1998, J GEOPHYS RES-SOL EA, V103, P18025, DOI 10.1029/98JB00201; CHEN WP, 1990, EOS T AGU, V71, P562; CHENG CH, 1981, GEOPHYS RES LETT, V8, P39, DOI 10.1029/GL008i001p00039; CLAGUE DA, 1994, B VOLCANOL, V56, P425, DOI 10.1007/s004450050052; CROSSON RS, 1982, TECTONICS, V1, P495, DOI 10.1029/TC001i006p00495; DELANEY PT, 1990, SCIENCE, V247, P1311, DOI 10.1126/science.247.4948.1311; Delaney PT, 1998, J GEOPHYS RES-SOL EA, V103, P18003, DOI 10.1029/98JB01665; DELANEY PT, 1993, J GEOPHYS RES-SOL EA, V98, P17801, DOI 10.1029/93JB01819; DELANEY PT, 1994, 94567 US GEOL SURV; DIETERICH JH, 1988, J GEOPHYS RES-SOLID, V93, P4258, DOI 10.1029/JB093iB05p04258; DZURISIN D, 1984, J VOLCANOL GEOTH RES, V21, P177, DOI 10.1016/0377-0273(84)90022-2; FISKE RS, 1969, SCIENCE, V165, P341, DOI 10.1126/science.165.3891.341; Gillard D, 1996, NATURE, V384, P343, DOI 10.1038/384343a0; GOT JL, 1994, J GEOPHYS RES-SOL EA, V99, P15375, DOI 10.1029/94JB00577; HILL DP, 1987, US GEOL SURV PROF PA, V1350, P903; Klein F.W., 1987, VOLCANISM HAWAII, P1019; LIPMAN PW, 1985, US GEOL SURV PROF PA, V1276, P1; Okubo PG, 1997, GEOLOGY, V25, P867, DOI 10.1130/0091-7613(1997)025<0867:ITCMSB>2.3.CO;2; OWEN S, 1995, SCIENCE, V267, P1328, DOI 10.1126/science.267.5202.1328; POLLARD DD, 1983, TECTONOPHYSICS, V94, P541, DOI 10.1016/0040-1951(83)90034-3; Rubin AM, 1998, J GEOPHYS RES-SOL EA, V103, P10003, DOI 10.1029/97JB03513; SEGALL P, 1988, J GEOPHYS RES-SOLID, V93, P14954, DOI 10.1029/JB093iB12p14954; SWANSON DA, 1972, SCIENCE, V175, P169, DOI 10.1126/science.175.4018.169; SWANSON DA, 1976, US GEOL SURV PROF PA, V963, P963; THURBER CH, 1988, J GEOPHYS RES-SOLID, V93, P4271, DOI 10.1029/JB093iB05p04271; WOLFE EW, 1987, US GEOL SURV PROF PA, V1350, P471; WRIGHT TL, 1971, J PETROL, V12, P1	28	93	93	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2343	2346		10.1126/science.288.5475.2343	http://dx.doi.org/10.1126/science.288.5475.2343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875914	Green Published			2022-12-28	WOS:000087913400032
J	Malin, MC; Edgett, KS				Malin, MC; Edgett, KS			Evidence for recent groundwater seepage and surface runoff on Mars	SCIENCE			English	Article							MARTIAN VALLEYS; LANDING SITE; CHANNELS; MISSION; EARTH; AGE	Relatively young Landforms on Mars, seen in high-resolution images acquired by the Mars Global Surveyor Mars Orbiter Camera since March 1999, suggest the presence of sources of liquid water at shallow depths beneath the martian surface. Found at middle and high martian latitudes (particularly in the southern hemisphere), gullies within the walls of a very small number of impact craters, south polar pits, and two of the Larger martian valleys display geomorphic features that can be explained by processes associated with groundwater seepage and surface runoff. The relative youth of the landforms is indicated by the superposition of the gullies on otherwise geologically young surfaces and by the absence of superimposed Landforms or cross-cutting features, including impact craters, small polygons, and eolian dunes. The limited size and geographic distribution of the features argue for constrained source reservoirs.	Malin Space Sci Syst, San Diego, CA 92191 USA		Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.			Edgett, Kenneth/0000-0001-7197-5751				ALBEE A, 1996, EOS T AGU, V77, P441; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; Baker V.R., 1982, THE CHANNELS OF MARS, DOI [10.1029/EO063i045p00862, DOI 10.1029/EO063I045P00862]; BAKER VR, 1979, J GEOPHYS RES, V84, P7961, DOI 10.1029/JB084iB14p07961; BAKER VR, 1974, ICARUS, V23, P27, DOI 10.1016/0019-1035(74)90101-8; BAKER VR, 1983, GEOL SOC AM BULL, V94, P1035; BLACK RF, 1976, QUATERNARY RES, V6, P3, DOI 10.1016/0033-5894(76)90037-5; Bryan RB, 1997, GEOMORPHOLOGY, V20, P209, DOI 10.1016/S0169-555X(97)00024-X; Carr M.H, 1996, WATER MARS; Carr M. J., UNPUB; Edgett KS, 2000, J GEOPHYS RES-PLANET, V105, P1623, DOI 10.1029/1999JE001152; FINK JH, 1981, GEOPHYS RES LETT, V8, P43, DOI 10.1029/GL008i001p00043; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Higgins C. G., 1990, Special Paper - Geological Society of America, P139; Higgins C.G., 1984, GROUNDWATER GEOMORPH, P18; HIGGINS CG, 1982, GEOLOGY, V10, P147, DOI 10.1130/0091-7613(1982)10<147:DSDBSO>2.0.CO;2; HOWARD AD, 1988, NASA SPEC PUBL NASA; KAFURA CJ, 1988, THESIS ARIZONA STATE; LACHENBRUCH AH, 1962, GEOL SOC AM SPEC PAP, V70; LAITY JE, 1985, GEOL SOC AM BULL, V96, P203, DOI 10.1130/0016-7606(1985)96<203:SPATDO>2.0.CO;2; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; MALIN MC, 1976, J GEOPHYS RES, V81, P4825, DOI 10.1029/JB081i026p04825; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; MALIN MC, 2000, LUNAR PLANET SCI, V31; Masursky H., 1977, Journal of Geophysical Research, V82, P4016, DOI 10.1029/JS082i028p04016; MILTON DJ, 1973, J GEOPHYS RES, V78, P4037, DOI 10.1029/JB078i020p04037; Parker G. G. Sr., 1990, Special Paper - Geological Society of America, P77; PIERI D, 1976, ICARUS, V27, P25, DOI 10.1016/0019-1035(76)90182-2; PIERI DC, 1980, SCIENCE, V210, P895, DOI 10.1126/science.210.4472.895; SAGAN C, 1973, SCIENCE, V181, P1045, DOI 10.1126/science.181.4104.1045; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; SHARPE CFS, 1939, LANDSLIDES RELATED P; SIDORENKO AV, 1980, SURFACE MARS; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; Varnes D.J., 1978, LANDSLIDES ANAL CONT, V176, P11; VARNES DJ, 1958, LANDSLIDES ENG PRACT, P20; Ward AW, 1999, J GEOPHYS RES-PLANET, V104, P8555, DOI 10.1029/1998JE900021; WASHBURN AL, 1956, GEOL SOC AM BULL, V67, P823, DOI 10.1130/0016-7606(1956)67[823:COPGAR]2.0.CO;2; Zimbelman JR, 2000, GEOPHYS RES LETT, V27, P1069, DOI 10.1029/1999GL008399; [No title captured]	40	778	794	1	203	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2330	2335		10.1126/science.288.5475.2330	http://dx.doi.org/10.1126/science.288.5475.2330			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875910				2022-12-28	WOS:000087913400028
J	Schulman, S; Lindmarker, P				Schulman, S; Lindmarker, P		Duration Anticoagulation Trial	Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ANTICOAGULANT-THERAPY; THROMBOSIS; LUNG	Background: The length of time after an episode of venous thromboembolism during which the risk of newly diagnosed cancer is increased is not known, and whether vitamin K antagonists have an antineoplastic effect is controversial. Methods: In a prospective, randomized study of the duration of oral anticoagulation (six weeks or six months) after a first episode of venous thromboembolism, patients were questioned annually about any newly diagnosed cancer. After a mean follow-up of 8.1 years, we used the Swedish Cancer Registry to identify all diagnoses of cancer and causes of death in the study population. The observed numbers of cases of cancer were compared with expected numbers based on national incidence rates, and the standardized incidence ratios were calculated. Results: A first cancer was diagnosed in 111 of 854 patients (13.0 percent) during follow-up. The standardized incidence ratio for newly diagnosed cancer was 3.4 (95 percent confidence interval, 2.2 to 4.6) during the first year after the thromboembolic event and remained between 1.3 and 2.2 for the following five years. Cancer was diagnosed in 66 of 419 patients (15.8 percent) who were treated for six weeks with oral anticoagulants, as compared with 45 of 435 patients (10.3 percent) who were treated for six months (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The difference was mainly due to the occurrence of new urogenital cancers, of which there were 28 cases in the six-week group (6.7 percent) and 12 cases in the six-month group (2.8 percent) (odds ratio, 2.5; 95 percent confidence interval, 1.3 to 5.0). The difference in the incidence of cancer between the treatment groups became evident only after two years of follow-up, and it remained significant after adjustment for sex, age, and whether the thromboembolism was idiopathic or nonidiopathic. Older age at the time of the venous thrombosis and an idiopathic thromboembolism were also independent risk factors for a diagnosis of cancer. No difference in the incidence of cancer-related deaths was detected. Conclusions: The risk of newly diagnosed cancer after a first episode of venous thromboembolism is elevated during at least the following two years. Subsequently, the risk seems to be lower among patients treated with oral anticoagulants for six months than among those treated for six weeks. (N Engl J Med 2000;342:1953-8.) (C)2000, Massachusetts Medical Society.	Karolinska Hosp, Dept Hematol, Coagulat Unit, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Schulman, S (corresponding author), Karolinska Hosp, Dept Hematol, Coagulat Unit, SE-17176 Stockholm, Sweden.		Schulman, Sam/I-7559-2019; Miranda, Fausto/N-9780-2018	Schulman, Sam/0000-0002-8512-9043; Miranda, Fausto/0000-0003-2954-8638				ANNEGERS JF, 1980, THROMB RES, V18, P399, DOI 10.1016/0049-3848(80)90335-7; Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; CARPI A, 1995, AM J CLIN ONCOL-CANC, V18, P15, DOI 10.1097/00000421-199502000-00003; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1353; Maurer LH, 1997, J CLIN ONCOL, V15, P3378, DOI 10.1200/JCO.1997.15.11.3378; MICHAELS L, 1964, LANCET, V2, P832; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Taniguchi T, 1998, CANCER RES, V58, P4461; ZACHARSKI LR, 1981, JAMA-J AM MED ASSOC, V245, P831, DOI 10.1001/jama.245.8.831	11	274	287	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1953	1958		10.1056/NEJM200006293422604	http://dx.doi.org/10.1056/NEJM200006293422604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874063				2022-12-28	WOS:000087867400004
J	Sigrist, SJ; Thiel, PR; Reiff, DF; Lachance, PED; Lasko, P; Schuster, CM				Sigrist, SJ; Thiel, PR; Reiff, DF; Lachance, PED; Lasko, P; Schuster, CM			Postsynaptic translation affects the efficacy and morphology of neuromuscular junctions	NATURE			English	Article							PRESYNAPTIC TRANSMITTER RELEASE; TERM SYNAPTIC PLASTICITY; LOCAL PROTEIN-SYNTHESIS; MESSENGER-RNA; FUNCTIONAL COMPONENTS; GENETIC DISSECTION; RETROGRADE SIGNAL; AMPA RECEPTORS; DROSOPHILA; SYNAPSES	Long-term synaptic plasticity may be associated with structural rearrangements within the neuronal circuitry(1,2). Although the molecular mechanisms governing such activity-controlled morphological alterations are mostly elusive, polysomal accumulations at the base of developing dendritic spines(3) and the activity-induced synthesis of synaptic components suggest that localized translation is involved during synaptic plasticity(4,5). Here we show that large aggregates of translational components as well as messenger RNA of the postsynaptic glutamate receptor subunit DGluR-IIA(6) are localized within subsynaptic compartments of larval neuromuscular junctions of Drosophila melanogaster. Genetic models of junctional plasticity(7) and genetic manipulations using the translation initiation factors eIF4E(8) and poly(A)binding protein(9) showed an increased occurrence of subsynaptic translation aggregates. This was associated with a significant increase in the postsynaptic DGluR-IIA protein levels and a reduction in the junctional expression of the cell-adhesion molecule Fasciclin II. In addition, the efficacy of junctional neurotransmission and the size of larval neuromuscular junctions were significantly increased. Our results therefore provide evidence for a postsynaptic translational control of long-term junctional plasticity.	Max Planck Gesell, Friedrich Miescher Lab, D-72076 Tubingen, Germany; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	Eberhard Karls University of Tubingen; Max Planck Society; McGill University	Schuster, CM (corresponding author), Max Planck Gesell, Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.		Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Davis GW, 1998, NEURON, V20, P305, DOI 10.1016/S0896-6273(00)80458-4; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Lavoie CA, 1996, J BIOL CHEM, V271, P16393, DOI 10.1074/jbc.271.27.16393; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Petersen SA, 1997, NEURON, V19, P1237, DOI 10.1016/S0896-6273(00)80415-8; Schuman EM, 1999, NEURON, V23, P645, DOI 10.1016/S0896-6273(01)80023-4; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; SCHUSTER CM, 1991, SCIENCE, V254, P112, DOI 10.1126/science.1681587; Sherff CM, 1999, SCIENCE, V285, P1911, DOI 10.1126/science.285.5435.1911; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Steinbach OC, 1999, METH MOL B, V127, P41, DOI 10.1385/1-59259-678-9:41; STEWARD O, 1986, J NEUROSCI, V6, P412; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3	29	133	134	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 29	2000	405	6790					1062	1065		10.1038/35016598	http://dx.doi.org/10.1038/35016598			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	328VN	10890448				2022-12-28	WOS:000087871700048
J	Brauner, DJ; Muir, JC; Sachs, GA				Brauner, DJ; Muir, JC; Sachs, GA			Treating nondementia illnesses in patients with dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; CONSENSUS STATEMENT; INFORMED CONSENT; CARE; ALENDRONATE; ASSOCIATION; OUTPATIENTS; CAREGIVERS; GUIDELINES; MANAGEMENT	Physicians increasingly are called on to provide primary care for the growing population of people with Alzheimer-type dementia, However, little attention has been paid to the care of nondementia illnesses in this group of patients. To illustrate how presence of dementia can alter the risk-benefit ratio of treatment of a common medical problem, we present a case study in which a patient with dementia developed disastrous adverse effects to a drug commonly used to treat osteoporosis. This case and 2 composite vignettes illuminate how presence of dementia should influence the decision-making process for treatment of nondementia illnesses. We address issues such as decreased decision-making capacity, problems with reporting adverse effects, decreased cognition leading to problems with treatment adherence, and the role of screening and basic questions about acceptable burdens of treatments in patients with limited prognosis. We Suggest ways to improve communication with patients with dementia in an effort to minimize complications and improve care, as well as policy changes to include patients with dementia in clinical trials.	Univ Chicago, Pritzker Sch Med, Dept Med, Sect Geriatr, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA; Northwestern Univ, Sch Med, Dept Hematol Oncol Palliat Care, Chicago, IL USA	University of Chicago; University of Chicago; Northwestern University	Brauner, DJ (corresponding author), Univ Chicago Hosp, Dept Med, 5841 S Maryland,MC 6098, Chicago, IL 60637 USA.							APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Barrett JJ, 1996, SOUTH MED J, V89, P1, DOI 10.1097/00007611-199601000-00001; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CLARK HH, 1989, COGNITIVE SCI, V13, P259, DOI 10.1207/s15516709cog1302_7; deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; DRANE JF, 1984, JAMA-J AM MED ASSOC, V252, P925, DOI 10.1001/jama.252.7.925; Eccles M, 1998, BMJ-BRIT MED J, V317, P802, DOI 10.1136/bmj.317.7161.802; Etchells E, 1999, J GEN INTERN MED, V14, P27, DOI 10.1046/j.1525-1497.1999.00277.x; Gambert Steven R., 1997, Comprehensive Therapy, V23, P174; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; Gorelick PB, 1999, JAMA-J AM MED ASSOC, V281, P1112, DOI 10.1001/jama.281.12.1112; Grisso T, 1998, ASSESSING COMPETENCE; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Guttman R, 1999, DIAGNOSIS MANAGEMENT; Hamilton H., 1994, CONVERSATION ALZHEIM; Irvine P, 1988, Clin Geriatr Med, V4, P703; ISSAC LM, 1993, GERONTOLOGIST, V33, P772; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; LARSON EB, 1986, WESTERN J MED, V145, P488; Larson EB, 1998, AM J GERIAT PSYCHIAT, V6, pS34, DOI 10.1097/00019442-199821001-00005; Lee V K, 1991, J Gerontol Nurs, V17, P16; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; MARSON DC, 1995, ARCH NEUROL-CHICAGO, V52, P955, DOI 10.1001/archneur.1995.00540340035011; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; MURDOCH BE, 1987, BRAIN LANG, V31, P122, DOI 10.1016/0093-934X(87)90064-2; *NIH, 2000, POL GUID INCL CHILDR; *NIH, 2000, NIH GUID INCL WOM MI; Post SG, 1998, J AM GERIATR SOC, V46, P784, DOI 10.1111/j.1532-5415.1998.tb03819.x; RANGO N, 1985, ANN INTERN MED, V102, P835, DOI 10.7326/0003-4819-102-6-835; Rhymes JA, 2000, JAMA-J AM MED ASSOC, V283, P1061, DOI 10.1001/jama.283.8.1061; RIPICH DN, 1995, GERIATR NURS, V16, P15, DOI 10.1016/S0197-4572(05)80073-4; Sachs GA, 1998, J AM GERIATR SOC, V46, P782, DOI 10.1111/j.1532-5415.1998.tb03818.x; SACHS GA, 1994, CLIN RES, V42, P403; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; THORPE J, 1994, AGING-CLIN EXP RES, V6, P159, DOI 10.1007/BF03324233; *US PEV SERV TASK, 1996, GUID CLIN PREV SERV; WALSH JS, 1990, ANN INTERN MED, V113, P429, DOI 10.7326/0003-4819-113-6-429; Wolf-Klein G P, 1994, Int Psychogeriatr, V6, P135, DOI 10.1017/S1041610294001705	41	115	116	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3230	3235		10.1001/jama.283.24.3230	http://dx.doi.org/10.1001/jama.283.24.3230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	326TY	10866871				2022-12-28	WOS:000087753900036
J	Fowler, FJ; Collins, MM; Albertsen, PC; Zietman, A; Elliott, DB; Barry, MJ				Fowler, FJ; Collins, MM; Albertsen, PC; Zietman, A; Elliott, DB; Barry, MJ			Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; THERAPY; PHYSICIANS; SEQUELAE; MEN	Context Multiple treatment options are available for men with prostate cancer, but therapeutic recommendations may differ depending on the type of specialist they consult. Objective To define and contrast the distribution of management recommendations by urologists and radiation oncologists for a spectrum of men with prostate cancer. Design, Setting, and Participants Mail survey sent in 1998 to a random sample of physicians in the United States, who were listed as urologists (response rate 64%, n = 504) and radiation oncologists (response rate 76%, n=559) in the American Medical Association Registry of Physicians and practicing at least 20 hours per week. Main Outcome Measure Questionnaire addressing beliefs and practices regarding prostate cancer management. Results Forty-three percent of radiation oncologists vs 16% of urologists would recommend routine prostate-specific antigen testing for men aged 80 years and older. For men with moderately differentiated, clinically localized cancers, and a more than 10-year life expectancy, 93% of urologists chose radical prostatectomy as the preferred treatment option, while 72% of radiation oncologists believed surgery and external beam radiotherapy were equivalent treatments. For most tu mor grades and prostate-specific antigen levels, both specialty groups were significantly more likely to recommend the treatment in their specialty than the other treatment, Both groups reported giving patients similar estimates of the risks of complications due to surgery and radiation. Neither group favored watchful waiting In their treatment management except for a subset of men with life expectancies of less than 10 years and cancers with very favorable prognoses (Gleason score of 3 or 4 and prostate-specific antigen level less than or equal to 5 ng/mL), Conclusions Based on this study, while urologists and radiation oncologists do agree on a variety of issues regarding detection and treatment of prostate cancer, specialists overwhelmingly recommend the therapy that they themselves deliver.	Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA; Univ Connecticut, Ctr Hlth, Div Urol, Farmington, CT USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Massachusetts System; University of Massachusetts Boston; University of Connecticut	Barry, MJ (corresponding author), Massachusetts Gen Hosp, Med Practices Evaluat Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA.	mbarry@partners.org			AHRQ HHS [HS 08397] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Coley CM, 1997, ANN INTERN MED, V126, P480; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Fowler FJ, 1998, AM J MED, V104, P526, DOI 10.1016/S0002-9343(98)00124-7; Fowler FJ, 1996, J CLIN ONCOL, V14, P2258, DOI 10.1200/JCO.1996.14.8.2258; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; JONLER M, 1994, UROLOGY, V44, P876, DOI 10.1016/S0090-4295(94)80174-6; JONLER M, 1994, BRIT J UROL, V74, P352, DOI 10.1111/j.1464-410X.1994.tb16626.x; LuYao GL, 1997, LANCET, V349, P906, DOI 10.1016/S0140-6736(96)09380-4; MOORE MJ, 1988, J CLIN ONCOL, V6, P1736, DOI 10.1200/JCO.1988.6.11.1736; ONTEL E, 1998, UROLOGY, V51, P63; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; SOX HC, 1994, AM J PREV MED, V10, P187, DOI 10.1016/S0749-3797(18)30589-0; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Wilt T J, 1997, Oncology (Williston Park), V11, P1133	17	309	312	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3217	3222		10.1001/jama.283.24.3217	http://dx.doi.org/10.1001/jama.283.24.3217			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866869	Bronze			2022-12-28	WOS:000087753900034
J	Stover, CK; Warrener, P; VanDevanter, DR; Sherman, DR; Arain, TM; Langhorne, MH; Anderson, SW; Towell, JA; Yuan, Y; McMurray, DN; Kreiswirth, BN; Barry, CE; Baker, WR				Stover, CK; Warrener, P; VanDevanter, DR; Sherman, DR; Arain, TM; Langhorne, MH; Anderson, SW; Towell, JA; Yuan, Y; McMurray, DN; Kreiswirth, BN; Barry, CE; Baker, WR			A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; F-420-DEPENDENT GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; MYCOLIC ACIDS; METRONIDAZOLE; BIOSYNTHESIS; MECHANISM; SMEGMATIS; BACILLI	Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly two million people annually(1). Estimates indicate that one-third of the world population is infected with latent M. tuberculosis(2). The synergy between tuberculosis and the AIDS epidemic(3-5), and the surge of multidrug-resistant clinical isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat. However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years. Here we report a series of compounds containing a nitroimidazopyran nucleus that possess antitubercular activity. After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid. In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis. Lead compound PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis.	PathoGenesis Corp, Seattle, WA 98119 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Pathobiol, Seattle, WA 98195 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Microbiol & Immunol, College Stn, TX 77843 USA; Publ Hlth Res Inst City New York Inc, TB Ctr, New York, NY 10016 USA; NIAID, TB Res Sect, Host Def Lab, NIH, Rockville, MD 20852 USA	University of Washington; University of Washington Seattle; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Stover, CK (corresponding author), PathoGenesis Corp, 201 Elliott Ave W, Seattle, WA 98119 USA.		Barry, III, Clifton/H-3839-2012; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Barry, Clifton E/0000-0002-2927-270X; Stover, Charles/0000-0002-7406-1696; VanDevanter, Donald/0000-0002-5727-8164	Intramural NIH HHS [Z01 AI000693-15] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000693, Z01AI000734] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGRAWAL KC, 1979, J MED CHEM, V22, P593; Arain TM, 1996, ANTIMICROB AGENTS CH, V40, P1536, DOI 10.1128/AAC.40.6.1536; ASHTEKAR DR, 1993, ANTIMICROB AGENTS CH, V37, P183, DOI 10.1128/AAC.37.2.183; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; EDWARDS DI, 1979, J ANTIMICROB CHEMOTH, V5, P499, DOI 10.1093/jac/5.5.499; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; Hickey MJ, 1996, ANTIMICROB AGENTS CH, V40, P400, DOI 10.1128/AAC.40.2.400; HOLT J. G., 1994, BERGEYS MANUAL DETER, P597; Kaufmann S H, 1993, Trends Microbiol, V1, P2, DOI 10.1016/0966-842X(93)90015-J; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; NAGARAJAN K, 1989, EUR J MED CHEM, V24, P631, DOI 10.1016/0223-5234(89)90034-2; Purwantini E, 1996, J BACTERIOL, V178, P2861, DOI 10.1128/jb.178.10.2861-2866.1996; Purwantini E, 1998, J BACTERIOL, V180, P2212, DOI 10.1128/JB.180.8.2212-2219.1998; Samuelson J, 1999, ANTIMICROB AGENTS CH, V43, P1533, DOI 10.1128/AAC.43.7.1533; SMITH DW, 1991, TUBERCLE, V72, P223, DOI 10.1016/0041-3879(91)90013-I; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WALSH JS, 1987, J MED CHEM, V30, P150, DOI 10.1021/jm00384a025; WAYNE LG, 1994, ANTIMICROB AGENTS CH, V38, P2054, DOI 10.1128/AAC.38.9.2054; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828	24	807	857	3	66	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					962	966		10.1038/35016103	http://dx.doi.org/10.1038/35016103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879539				2022-12-28	WOS:000087732700054
J	Douek, DC; Vescio, RA; Betts, MR; Brenchley, JM; Hill, BJ; Zhang, L; Berenson, JR; Collins, RH; Koup, RA				Douek, DC; Vescio, RA; Betts, MR; Brenchley, JM; Hill, BJ; Zhang, L; Berenson, JR; Collins, RH; Koup, RA			Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; INTENSIVE CHEMOTHERAPY; IMMUNE RECONSTITUTION; AGE; EXPANSION; MEMORY; THYMOPOIESIS; REGENERATION; PROGENITORS; GENERATION	Background The potential benefits of haematopoietic stem-cell transplantation are tempered by the depletion of T-cells accompanying this procedure. We used a new technique which quantifies the excisional DNA products of T-cell-receptor (TCR) gene rearrangement to measure thymic output directly in patients with multiple myeloma, and thus assessed the contribution of the thymus to immune recovery after transplantation. Methods We studied 40 patients, 34-66 years of age, who had been randomly assigned myeloablative chemotherapy and autologous peripheral-blood haematopoietic stem-cell transplantation with unmanipulated grafts or grafts enriched for CD34 stem cells. CD4 and CD8 T-cell counts were measured, thymic output was estimated serially until 2 years after transplantation, and percentages of naive T-cells were measured. Findings The production of substantial numbers of new naive T cells by the thymus could be detected by 100 days post-transplant; there was a significant inverse relation between age and recovery of new T cells. In the CD34-unselected group, numbers of TCR-rearrangement excision circles returned to baseline after 2 years, whereas in the CD34-selected group, numbers at 2 years were significantly higher than both baseline numbers (p=0.004), and 2-year numbers in the unselected group (p=0.046). Increased thymic output correlated with, and was predictive of, increased naive T-cell numbers and broader T-cell-receptor repertoires. Interpretation Our results provide evidence that the adult thymus contributes more substantially to immune reconstitution after haematopoietic stem-cell transplantation than was previously thought, and therefore could be a target for therapeutic intervention.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Hematol Oncol, Los Angeles, CA USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Douek, DC (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.		Brenchley, Jason/AAC-5085-2019	Brenchley, Jason/0000-0001-8357-2984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI144758] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44758] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Bolotin E, 1996, BLOOD, V88, P1887; Bomberger C, 1998, BLOOD, V91, P2588, DOI 10.1182/blood.V91.7.2588.2588_2588_2600; DEGAST GC, 1985, BLOOD, V66, P428; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DREGER P, 1995, EXP HEMATOL, V23, P147; Garcia-Ojeda ME, 1998, J EXP MED, V187, P1813, DOI 10.1084/jem.187.11.1813; GOROCHOV G, 1994, BLOOD, V83, P587; Hakim FT, 1997, BLOOD, V90, P3789, DOI 10.1182/blood.V90.9.3789; Heitger A, 1997, BLOOD, V90, P850, DOI 10.1182/blood.V90.2.850.850_850_857; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; KEEVER CA, 1989, BLOOD, V73, P1340; Livak F, 1996, MOL CELL BIOL, V16, P609; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Mackall CL, 1998, EUR J IMMUNOL, V28, P1886, DOI 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M; Mackall CL, 1996, J IMMUNOL, V156, P4609; Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; McCune JM, 1998, J CLIN INVEST, V101, P2301, DOI 10.1172/JCI2834; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P3707, DOI 10.1073/pnas.92.9.3707; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Roux E, 1996, BLOOD, V87, P3984, DOI 10.1182/blood.V87.9.3984.bloodjournal8793984; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275; SATO K, 1995, J EXP MED, V182, P759, DOI 10.1084/jem.182.3.759; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; Soares MVD, 1998, J IMMUNOL, V161, P5909; STOREK J, 1995, BONE MAR TRANSPL, V16, P416; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Vescio R, 1999, BLOOD, V93, P1858; Weinberg K, 1995, Biol Blood Marrow Transplant, V1, P18; Young JL, 1997, EUR J IMMUNOL, V27, P2383, DOI 10.1002/eji.1830270937	31	439	454	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 27	2000	355	9218					1875	1881		10.1016/S0140-6736(00)02293-5	http://dx.doi.org/10.1016/S0140-6736(00)02293-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318VZ	10866444				2022-12-28	WOS:000087306500015
J	Cook, AJC; Gilbert, RE; Buffolano, W; Zufferey, J; Petersen, E; Jenum, PA; Foulon, W; Semprini, AE; Dunn, DT				Cook, AJC; Gilbert, RE; Buffolano, W; Zufferey, J; Petersen, E; Jenum, PA; Foulon, W; Semprini, AE; Dunn, DT		European Res Network Congenital	Sources of toxoplasma infection in pregnant women: European multicentre case-control study	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL TOXOPLASMOSIS; GONDII INFECTION; TISSUE CYSTS; RISK-FACTORS; SEROPREVALENCE; PREVALENCE; TRANSMISSION; PERSISTENCE; POPULATION; ANTIBODIES	Objective To determine the odds ratio and population attributable fraction associated with food and environmental risk factors for acute toxoplasmosis in pregnancy. Design Case-control study. Setting Six large European cities. Participants Pregnant women with acute infection (cases) detected by seroconversion or positive for anti-Toxoplasma gondii IgM were compared with pregnant women seronegative for toxoplasma (controls). Main outcome measures Odds ratios for acute infection adjusted for confounding variables; the population attributable fraction for risk factors. Results Risk factors most strongly predictive of acute infection in pregnant women were eating undercooked lamb, beef, or game, contact with soil, and travel outside Europe and the United States and Canada. Contact with cats was not a risk factor. Between 30% and 63% of infections in different centres were attributed to consumption of undercooked or cured meat products and 6% to 17% to soil contact. Conclusions Inadequately cooked or cured meat is Naples, Italy the main risk factor for infection with toxoplasma in consultant all centres. Preventive strategies should aim to reduce Paediatrician prevalence of infection in meat, improve labelling of Institute of meat according to farming and processing methods, and improve the quality and consistency of health information given to pregnant women.	Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England; Univ London, Royal Vet Coll, Dept Farm Anim & Equine Med, N Mimms AL9 7TA, Herts, England; Univ Naples Federico II, Dept Paediat, I-80131 Naples, Italy; CHUV, Inst Microbiol, Lausanne, Switzerland; Statens Serum Inst, DK-2300 Copenhagen S, Denmark; Natl Publ Hlth Inst, Dept Bacteriol, N-0403 Oslo, Norway; Free Univ Brussels, Akad Ziekenhuis, Dept Obstet & Gynaecol, B-1090 Brussels, Belgium; Osped San Paolo, Dept Obstet & Gynaecol, Milan, Italy	University of London; University College London; University of London; University of London Royal Veterinary College; University of Naples Federico II; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Statens Serum Institut; Universite Libre de Bruxelles; Vrije Universiteit Brussel; San Paolo-Polo Universitaria Hospital	Gilbert, RE (corresponding author), Inst Child Hlth, Dept Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Cook, A/AAL-2872-2021; Cook, Alex/E-3030-2010; SEMPRINI, AUGUSTO ENRICO/S-6415-2017	Cook, A/0000-0002-3444-9493; Gilbert, Ruth/0000-0001-9347-2709; SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012; Dunn, David/0000-0003-1836-4446	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; Allain JP, 1998, J INFECTION, V36, P189, DOI 10.1016/S0163-4453(98)80012-1; Ancelle T., 1996, Bulletin Epidemiologique Hebdomadaire, P227; Asbury C, 1994, Midwives Chron, V107, P388; Baril L., 1995, B EPIDEMIOLOGIQUE HE, V16, P73; Buffolano W, 1996, EPIDEMIOL INFECT, V116, P347, DOI 10.1017/S0950268800052675; Carme B, 1996, MED MALADIES INFECT, V26, P431, DOI 10.1016/S0399-077X(96)80188-0; CONYNVANSPAEDON.MA, 1991, PREVENTION CONGENITA; COUGHLIN SS, 1991, AM J EPIDEMIOL, V133, P305, DOI 10.1093/oxfordjournals.aje.a115875; CUBITT WD, 1992, J CLIN PATHOL, V45, P435, DOI 10.1136/jcp.45.5.435; DECAVALAS G, 1990, EUR J EPIDEMIOL, V6, P223, DOI 10.1007/BF00145798; Department of Health, 1991, PAT CHART; DESMONTS G, 1965, REV FR ETUD CLIN BIO, V10, P952; DUBEY JP, 1993, AM J VET RES, V54, P270; Dubey JP, 1996, VET PARASITOL, V64, P65, DOI 10.1016/0304-4017(96)00961-2; DUBEY JP, 1988, AM J VET RES, V49, P910; DUBEY JP, 1988, TOXOPLASMOSIS ANIMAL, P61; DUFFY KMT, 1989, J CLIN PATHOL, V42, P1291, DOI 10.1136/jcp.42.12.1291; DUPOUYCAMET J, 1993, MED MALADIES INFECT, V23, P139, DOI 10.1016/S0399-077X(05)80614-6; *EUR, 1996, EUR AGR YB; FAULL WB, 1986, VET REC, V119, P491, DOI 10.1136/vr.119.20.491; GILBERT RE, 1993, BRIT MED J, V306, P185, DOI 10.1136/bmj.306.6871.185; Gilbert RE, 1999, EPIDEMIOL INFECT, V123, P283, DOI 10.1017/S0950268899002800; GILBERT RE, 1999, CONGENITAL TOXOPLASM; Greenland, 1998, MODERN EPIDEMIOLOGY, P47; GRILLI R, 2000, COCHRANE LIB; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HORION M, 1990, Revue Medicale de Liege, V45, P492; HOYEN DO, 1995, HLTH ED J, V54, P415; HOYEN DO, 1992, HUMAN TOXOPLASMOSIS, P184; Jenum PA, 1998, EPIDEMIOL INFECT, V120, P87, DOI 10.1017/S0950268897008480; Kapperud G, 1996, AM J EPIDEMIOL, V144, P405, DOI 10.1093/oxfordjournals.aje.a008942; KOPPE JG, 1986, LANCET, V1, P254; LAPPALAINEN M, 1995, PEDIATR INFECT DIS J, V14, P354, DOI 10.1097/00006454-199505000-00004; Lebech M, 1999, LANCET, V353, P1834, DOI 10.1016/S0140-6736(98)11281-3; LUNDEN A, 1992, INT J FOOD MICROBIOL, V15, P357, DOI 10.1016/0168-1605(92)90069-F; Newton L H, 1994, Commun Dis Rep CDR Rev, V4, pR121; Newton L H, 1995, Commun Dis Rep CDR Rev, V5, pR21; NOKES DJ, 1993, PARASITOLOGY, V107, P33, DOI 10.1017/S0031182000079373; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; SILAGY C, 2000, COCHRANE LIB; SMITH JL, 1991, J FOOD SAFETY, V12, P17, DOI 10.1111/j.1745-4565.1991.tb00063.x; STEAD LF, 2000, COCHRANE LIB; WALLON M, 1994, PRESSE MED, V23, P1467; Warnekulasuriya MR, 1998, INT J FOOD MICROBIOL, V45, P211, DOI 10.1016/S0168-1605(98)00158-5; Wills, 1994, HLTH PROMOTION FDN P	47	666	721	1	92	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	2000	321	7254					142	147		10.1136/bmj.321.7254.142	http://dx.doi.org/10.1136/bmj.321.7254.142			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MG	10894691	Bronze, Green Published			2022-12-28	WOS:000088305700019
J	Ito, S				Ito, S			Drug therapy: Drug therapy for breast-feeding women.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN-MILK; FED INFANTS; COTININE CONCENTRATIONS; N-DESMETHYLSERTRALINE; LACTATION PERIOD; PASSIVE SMOKING; NURSING MOTHER; TOPICAL IODINE; IN-VIVO; EXCRETION		Hosp Sick Children, Res Inst, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Ito, S (corresponding author), Hosp Sick Children, Res Inst, Div Clin Pharmacol & Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ito@sickkids.on.ca						ALTSHULER LL, 1995, J CLIN PSYCHIAT, V56, P243; ANDERSON PO, 1991, CLIN PHARMACY, V10, P594; ANDERSON PO, 1989, DICP ANN PHARMAC, V23, P614, DOI 10.1177/1060028089023007-822; ARNADA JV, 1992, PEDIAT PHARM, P193; ASTLEY SJ, 1990, NEUROTOXICOL TERATOL, V12, P161, DOI 10.1016/0892-0362(90)90129-Z; BAUER JH, 1979, AM J CARDIOL, V43, P860, DOI 10.1016/0002-9149(79)90090-0; BEGG EJ, 1992, BRIT J CLIN PHARMACO, V33, P501, DOI 10.1111/j.1365-2125.1992.tb04077.x; BENNETT PN, 1990, BRIT J CLIN PHARMACO, V29, P777, DOI 10.1111/j.1365-2125.1990.tb03703.x; BERLIN CM, 1980, PEDIATR PHARMACOL, V1, P135; BINKIEWICZ A, 1978, J PEDIATR-US, V93, P965, DOI 10.1016/S0022-3476(78)81220-7; BISDOM CJW, 1937, JAMA-J AM MED ASSOC, V109, P178; BLINICK G, 1975, AM J OBSTET GYNECOL, V121, P617, DOI 10.1016/0002-9378(75)90461-5; BONA G, 1992, EUR J RADIOL, V14, P22, DOI 10.1016/0720-048X(92)90056-F; BONATI M, 1992, INT J GYNECOL OBSTET, V39, P185; BOUTROY MJ, 1986, EUR J CLIN PHARMACOL, V30, P737, DOI 10.1007/BF00608227; Brent NB, 1998, CLIN PEDIATR, V37, P41, DOI 10.1177/000992289803700107; BRIGGS GG, 1998, DRUGS PREGNANCY LACT; BUCHANAN RA, 1968, CURR THER RES CLIN E, V10, P592; BURCH KJ, 1992, PEDIATRICS, V89, P676; CAZENEUVE C, 1994, BRIT J CLIN PHARMACO, V37, P405, DOI 10.1111/j.1365-2125.1994.tb05706.x; Chambers CD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e61; CHASNOFF IJ, 1987, PEDIATRICS, V80, P836; CLARK JH, 1981, CLIN PEDIATR, V20, P53, DOI 10.1177/000992288102000107; COBO E, 1973, AM J OBSTET GYNECOL, V115, P817, DOI 10.1016/0002-9378(73)90526-7; COULAM CB, 1982, TRANSPLANT P, V14, P605; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Cushing AH, 1998, AM J EPIDEMIOL, V147, P863, DOI 10.1093/oxfordjournals.aje.a009540; DAHLSTROM A, 1990, ACTA PAEDIATR SCAND, V79, P142, DOI 10.1111/j.1651-2227.1990.tb11430.x; DANZIGER Y, 1987, ARCH DIS CHILD, V62, P295, DOI 10.1136/adc.62.3.295; DELANGE F, 1988, ARCH DIS CHILD, V63, P106, DOI 10.1136/adc.63.1.106-a; DELGADOESCUETA AV, 1992, NEUROLOGY, V42, P149; DESWIET M, 1977, NEW ENGL J MED, V297, P1471; Epperson CN, 1997, NEW ENGL J MED, V336, P1189, DOI 10.1056/NEJM199704173361615; FAZIO G, 1990, NUCL PHYS A, V506, P158; FINCH E, 1954, J OBSTET GYN BRIT EM, V61, P833; FITZJOHN TP, 1982, BRIT J RADIOL, V55, P603, DOI 10.1259/0007-1285-55-656-603; FLECHNER SM, 1985, AM J KIDNEY DIS, V5, P60, DOI 10.1016/S0272-6386(85)80138-4; FREY B, 1990, EUR J PEDIATR, V150, P136, DOI 10.1007/BF02072057; Gale CR, 1996, LANCET, V347, P1072, DOI 10.1016/S0140-6736(96)90278-0; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; GREENBERGER PA, 1993, CLIN PHARMACOL THER, V53, P324, DOI 10.1038/clpt.1993.28; GREKAS DM, 1984, NEPHRON, V37, P68, DOI 10.1159/000183213; HACKETT LP, 1990, BRIT J CLIN PHARMACO, V29, P277, DOI 10.1111/j.1365-2125.1990.tb03635.x; HILBERT J, 1988, J CLIN PHARMACOL, V28, P234, DOI 10.1002/j.1552-4604.1988.tb03138.x; HILL R M, 1977, Clinical Obstetrics and Gynecology, V20, P381, DOI 10.1097/00003081-197706000-00018; HOLMDAHL KH, 1956, ACTA RADIOL, V45, P303; Howard CR, 1998, OBSTET GYN CLIN N AM, V25, P195, DOI 10.1016/S0889-8545(05)70365-X; ILETT KF, 1981, BRIT J RADIOL, V54, P537, DOI 10.1259/0007-1285-54-642-537; ISENBERG KE, 1990, J CLIN PSYCHIAT, V51, P169; ITO S, 1993, AM J OBSTET GYNECOL, V168, P1393, DOI 10.1016/S0002-9378(11)90771-6; ITO S, 1994, BRIT J CLIN PHARMACO, V38, P99, DOI 10.1111/j.1365-2125.1994.tb04331.x; ITO S, 1999, AMBULATORY PEDIAT CA, P1036; Jensen A.A., 1996, DRUGS HUMAN LACTATIO; KACEW S, 1993, J CLIN PHARMACOL, V33, P213, DOI 10.1002/j.1552-4604.1993.tb03946.x; KANEKO S, 1979, BRIT J CLIN PHARMACO, V7, P624, DOI 10.1111/j.1365-2125.1979.tb04654.x; KAUFFMAN RE, 1994, PEDIATRICS, V93, P137; KEMP J, 1985, BRIT J CLIN PHARMACO, V20, P497, DOI 10.1111/j.1365-2125.1985.tb05106.x; KOLETZKO S, 1989, BRIT MED J, V298, P1617, DOI 10.1136/bmj.298.6688.1617; Kristensen JH, 1998, BRIT J CLIN PHARMACO, V45, P453, DOI 10.1046/j.1365-2125.1998.00705.x; KUHNZ W, 1988, DEV PHARMACOL THERAP, V11, P147, DOI 10.1159/000457682; LESTER BM, 1993, J AM ACAD CHILD PSY, V32, P1253, DOI 10.1097/00004583-199311000-00020; LEWIS GJ, 1983, BRIT MED J, V286, P603, DOI 10.1136/bmj.286.6365.603; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCK W, 1987, EUR J PEDIATR, V146, P21, DOI 10.1007/BF00647276; LUNELL NO, 1985, EUR J CLIN PHARMACOL, V28, P597, DOI 10.1007/BF00544073; Mammen OK, 1997, J CLIN PSYCHIAT, V58, P100, DOI 10.4088/JCP.v58n0302; Marquet P, 1997, CLIN PHARMACOL THER, V62, P569, DOI 10.1016/S0009-9236(97)90053-9; MATHESON I, 1985, LANCET, V2, P1124; MATHESON I, 1985, PEDIATRICS, V76, P651; MATHESON I, 1985, BRIT MED J, V290, P1588, DOI 10.1136/bmj.290.6481.1588-a; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MCKENNA R, 1983, J PEDIATR-US, V103, P325, DOI 10.1016/S0022-3476(83)80378-3; MCKENNA WJ, 1983, AM J CARDIOL, V51, P1231, DOI 10.1016/0002-9149(83)90377-6; Mennella JA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.5.e2; MENNELLA JA, 1993, JAMA-J AM MED ASSOC, V269, P1637, DOI 10.1001/jama.269.13.1637; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MOMOTANI N, 1989, CLIN ENDOCRINOL, V31, P591, DOI 10.1111/j.1365-2265.1989.tb01283.x; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; NAU H, 1982, CLIN PHARMACOKINET, V7, P508, DOI 10.2165/00003088-198207060-00003; NIELSEN ST, 1987, ACTA RADIOL, V28, P523; Nulman I, 1997, NEW ENGL J MED, V336, P258, DOI 10.1056/NEJM199701233360404; Nyberg G, 1998, TRANSPLANTATION, V65, P253; OHARE MF, 1980, BRIT J OBSTET GYNAEC, V87, P814, DOI 10.1111/j.1471-0528.1980.tb04618.x; OHMAN I, 1998, EPILEPSIA S2, V39; OO CY, 1995, CLIN PHARMACOL THER, V58, P548, DOI 10.1016/0009-9236(95)90175-2; ORME ML, 1977, BRIT MED J, V1, P1564, DOI 10.1136/bmj.1.6076.1564; OST L, 1985, J PEDIATR-US, V106, P1008, DOI 10.1016/S0022-3476(85)80259-6; PATRICK MJ, 1972, LANCET, V1, P542; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; PLOMP TA, 1992, EUR J OBSTET GYN R B, V43, P201, DOI 10.1016/0028-2243(92)90174-W; POLLOCK JI, 1994, DEV MED CHILD NEUROL, V36, P429, DOI 10.1111/j.1469-8749.1994.tb11869.x; PONS G, 1994, CLIN PHARMACOKINET, V27, P270, DOI 10.2165/00003088-199427040-00003; POSTELLON DC, 1982, JAMA-J AM MED ASSOC, V247, P463, DOI 10.1001/jama.1982.03320290013017; Rambeck B, 1997, EUR J CLIN PHARMACOL, V51, P481, DOI 10.1007/s002280050234; RAMBECK B, 1993, CLIN PHARMACOKINET, V25, P433, DOI 10.2165/00003088-199325060-00003; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; Ryan AS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.4.e12; RYU JE, 1985, DEV PHARMACOL THERAP, V8, P329, DOI 10.1159/000457057; RYU JE, 1985, DEV PHARMACOL THERAP, V8, P355, DOI 10.1159/000457060; SCHMIMMEL MS, 1989, J PEDIATR-US, V114, P476, DOI 10.1016/S0022-3476(89)80578-5; SCHOU M, 1973, BRIT MED J, V2, P138, DOI 10.1136/bmj.2.5859.138; SCHULTEHOBEIN B, 1992, ACTA PAEDIATR, V81, P550, DOI 10.1111/j.1651-2227.1992.tb12293.x; SCHWARTZBICKENBACH D, 1987, TOXICOL LETT, V35, P73, DOI 10.1016/0378-4274(87)90088-9; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516; SMITH IJ, 1989, J CLIN PHARMACOL, V29, P174, DOI 10.1002/j.1552-4604.1989.tb03309.x; Sprouse J, 1996, NEUROPSYCHOPHARMACOL, V14, P225, DOI 10.1016/0893-133X(95)00112-Q; Stahl MMS, 1997, J PEDIATR-US, V130, P1001, DOI 10.1016/S0022-3476(97)70292-0; Stowe ZN, 1997, AM J PSYCHIAT, V154, P1255; STRUNGE P, 1988, EUR HEART J, V9, P106; SYKES PA, 1976, BRIT MED J, V2, P1299, DOI 10.1136/bmj.2.6047.1299; Taddio A, 1996, J CLIN PHARMACOL, V36, P42, DOI 10.1002/j.1552-4604.1996.tb04150.x; TANAKA PA, 1987, CAN MED ASSOC J, V136, P940; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005; Thiru Y, 1997, BRIT MED J, V315, P463, DOI 10.1136/bmj.315.7106.463; Tomson T, 1997, EPILEPSIA, V38, P1039, DOI 10.1111/j.1528-1157.1997.tb01489.x; TOWNSEND RJ, 1984, AM J OBSTET GYNECOL, V149, P184, DOI 10.1016/0002-9378(84)90195-9; Tran A, 1998, BRIT J CLIN PHARMACO, V45, P409, DOI 10.1046/j.1365-2125.1998.t01-1-00693.x; TUNNESSEN WW, 1972, J PEDIATR-US, V81, P804, DOI 10.1016/S0022-3476(72)80111-2; VIO F, 1991, AM J CLIN NUTR, V54, P1011, DOI 10.1093/ajcn/54.6.1011; WEINSTEIN MR, 1969, DIS NERV SYST, V30, P828; Weyrauch U, 1977, Rofo, V127, P275; WILSON JT, 1980, CLIN PHARMACOKINET, V5, P1, DOI 10.2165/00003088-198005010-00001; WISCHNIK A, 1989, EUR J CLIN PHARMACOL, V36, P521, DOI 10.1007/BF00558080; Wisner KL, 1998, AM J PSYCHIAT, V155, P690, DOI 10.1176/ajp.155.5.690; WITTELS B, 1990, ANESTHESIOLOGY, V73, P864, DOI 10.1097/00000542-199011000-00012; Wojnar-Horton RE, 1997, BRIT J CLIN PHARMACO, V44, P543, DOI 10.1046/j.1365-2125.1997.t01-1-00624.x; WojnarHorton RE, 1996, BRIT J CLIN PHARMACO, V41, P217, DOI 10.1111/j.1365-2125.1996.tb00185.x; Yoshida K, 1998, BRIT J PSYCHIAT, V172, P175, DOI 10.1192/bjp.172.2.175	129	176	184	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	2000	343	2					118	126		10.1056/NEJM200007133430208	http://dx.doi.org/10.1056/NEJM200007133430208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333EP	10891521				2022-12-28	WOS:000088116500008
J	Aulisio, MP; Arnold, RM; Youngner, SJ				Aulisio, MP; Arnold, RM; Youngner, SJ		Soc Hlth Human Values Soc Bioethic	Health care ethics consultation: Nature, goals, and competencies - A position paper from the Society for Health and Human Values - Society for Bioethics Consultation Task Force on Standards for Bioethics Consultation	ANNALS OF INTERNAL MEDICINE			English	Article							COMMITTEES; TIME	Patients, families, and health care providers have a right to expect that ethics consultants can deal competently with the complex issues that they are asked to address. The Society for Health and Human Values-Society for Bioethics Consultation Task Force on Standards for Bioethics Consultation explored core competencies and related issues in ethics consultation. This position paper summarizes the content of the resulting Task Force Report, which included nine general conclusions: 1) U.S. societal context makes "ethics facilitation" an appropriate approach to ethics consultation; 2) ethics facilitation requires certain core competencies; 3) core competencies can be acquired in various ways; 4) individual consultants, teams, or committees should have the core competencies for ethics consultation; 5) consult services should have policies that address access, patient notification, documentation, and case review; 6) abuse of power and conflicts of interest must be avoided; 7) ethics consultation must have institutional support; 8) evaluation of process, outcomes, and competencies is needed; and 9) certification of individuals and accreditation of programs are rejected.	Univ Pittsburgh, Ctr Med Eth, Consortium Eth Program, Pittsburgh, PA 15213 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University	Aulisio, MP (corresponding author), Univ Pittsburgh, Ctr Med Eth, Consortium Eth Program, Med Arts Bldg,3708 5th Ave,Suite 300, Pittsburgh, PA 15213 USA.	maa13@pitt.edu		Aulisio, Mark/0000-0002-6423-8523				*AM SOC BIOETH CON, 1998, SOC HLTH HUM VAL SOC; Aulisio M. P., 1998, HLTH CARE ETHICS CRI, P484; CAPRON AM, 1995, HASTINGS CENT REP, V25, P24, DOI 10.2307/3562158; *CHIC JOINT COMM A, 1995, COMPR ACC MAN HOSP, P66; CRANFORD RE, 1984, I ETHICS COMMITTEES, P5; CRIGGER BJ, 1995, KENNEDY INST ETHIC J, V5, P89; Fink A, 1993, EVALUATION FUNDAMENT; FLETCHER JC, 1994, ANN INTERN MED, V120, P335, DOI 10.7326/0003-4819-120-4-199402150-00012; FLETCHER JC, 1997, INTRO CLIN EHTICS, P270; Fox E, 1996, J CLIN ETHIC, V7, P146; Fox E, 1996, J CLIN ETHIC, V7, P116; Fox E, 1996, J CLIN ETHIC, V7, P127; Fry-Revere S, 1994, Pediatr Nurs, V20, P95; Fry-Revere S, 1993, Camb Q Healthc Ethics, V2, P449; FRYREVERE S, 1992, ACCOUNTABILITY BIOET, P141; Lapuma J, 1991, ANN INTERN MED, V114, P155, DOI 10.7326/0003-4819-114-2-155; LAPUMA J, 1994, ETHICS CONSULTATION, P234; Lipkin MJ, 1995, MED INTERVIEW CLIN C; Patton M.Q., 1987, USE QUALITATIVE METH; Pellegrino E D, 1991, J Clin Ethics, V2, P5; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE, P153; Ross Judith Wilson, 1993, Camb Q Healthc Ethics, V2, P445; Ross Judith Wilson, 1996, HEC Forum, V8, P22; Scofield G R, 1993, Camb Q Healthc Ethics, V2, P417; Scofield G R, 1993, Trends Health Care Law Ethics, V8, P19; SCOFIELD GR, 1995, CAMB Q HEALTHC ETHIC, V4, P225, DOI 10.1017/S0963180100005922; Singer P A, 1990, J Clin Ethics, V1, P263; Tulsky JA, 1996, J CLIN ETHIC, V7, P139; Tulsky JA, 1996, J CLIN ETHIC, V7, P109; WOLF SM, 1994, AM J LAW MED, V20, P105; YOUNGNER SJ, 1983, CRIT CARE MED, V11, P902, DOI 10.1097/00003246-198311000-00013; ZANER RM, 1993, J MED PHILOS, V18, P9, DOI 10.1093/jmp/18.1.9	32	145	147	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 4	2000	133	1					59	69		10.7326/0003-4819-133-1-200007040-00012	http://dx.doi.org/10.7326/0003-4819-133-1-200007040-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	329TB	10877742				2022-12-28	WOS:000087923100009
J	Loftus, TM; Jaworsky, DE; Frehywot, GL; Townsend, CA; Ronnett, GV; Lane, MD; Kuhajda, FP				Loftus, TM; Jaworsky, DE; Frehywot, GL; Townsend, CA; Ronnett, GV; Lane, MD; Kuhajda, FP			Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors	SCIENCE			English	Article							MALONYL-COA; OXIDATION; GLUCOSE; GENE; KETOGENESIS; EXPRESSION	With the escalation of obesity-related disease, there is great interest in defining the mechanisms that control appetite and body weight. We have identified a link between anabolic energy metabolism and appetite control. Both systemic and intracerebroventricular treatment of mice with fatty acid synthase (FAS) inhibitors (cerulenin and a synthetic compound C75) Led to inhibition of feeding and dramatic weight Loss. C75 inhibited expression of the prophagic signal neuropeptide Y in the hypothalamus and acted in a leptin-independent manner that appears to be mediated by malonyl-coenzyme A. Thus, FAS may represent an important Link in feeding regulation and may be a potential therapeutic target.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002979] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC02979] Funding Source: Medline; NIDDK NIH HHS [DK09623] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORISYRUDIN F, UNPUB; Grossman BM, 1997, PHYSIOL BEHAV, V61, P169, DOI 10.1016/S0031-9384(96)00368-X; HALVORSON DL, 1984, LIPIDS, V19, P851, DOI 10.1007/BF02534514; KUHAJDA F, UNPUB; Kusakabe T, 2000, J HISTOCHEM CYTOCHEM, V48, P613, DOI 10.1177/002215540004800505; Loftus TM, 1999, SEMIN CELL DEV BIOL, V10, P11, DOI 10.1006/scdb.1998.0274; MARAGOUDAKIS ME, 1972, J BIOL CHEM, V247, P342; MCGARRY JD, 1979, J BIOL CHEM, V254, P8163; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; OShea D, 1997, ENDOCRINOLOGY, V138, P196, DOI 10.1210/en.138.1.196; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Scharrer E, 1999, NUTRITION, V15, P704, DOI 10.1016/S0899-9007(99)00125-2; Schwartz MW, 1998, ENDOCRINOLOGY, V139, P2629, DOI 10.1210/en.139.5.2629; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	19	762	838	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 30	2000	288	5475					2379	2381		10.1126/science.288.5475.2379	http://dx.doi.org/10.1126/science.288.5475.2379			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	329NP	10875926				2022-12-28	WOS:000087913400044
J	Wong, CS; Jelacic, S; Habeeb, RL; Watkins, SL; Tarr, PI				Wong, CS; Jelacic, S; Habeeb, RL; Watkins, SL; Tarr, PI			The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157 : H7 infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th United States -Japan Cholera and related diarrheal Disease Conference	DEC 03-05, 1999	BALTIMORE, MARYLAND				HEMORRHAGIC COLITIS; SUBINHIBITORY CONCENTRATIONS; NURSING-HOME; TOXIN; OUTBREAK; GASTROENTERITIS; ENTERITIS; DIARRHEA; THERAPY; DISEASE	Background: Children with gastrointestinal infections caused by Escherichia coli O157:H7 are at risk for the hemolytic-uremic syndrome. Whether antibiotics alter this risk is unknown. Methods: We conducted a prospective cohort study of 71 children younger than 10 years of age who had diarrhea caused by E. coli O157:H7 to assess whether antibiotic treatment in these children affects the risk of the hemolytic-uremic syndrome and to assess the influence of confounding factors on this outcome. Estimates of relative risks were adjusted for possible confounding effects with the use of logistic-regression analysis. Results: Among the 71 children, 9 (13 percent) received antibiotics and the hemolytic-uremic syndrome developed in 10 (14 percent). Five of these 10 children had received antibiotics. Factors significantly associated with the hemolytic-uremic syndrome were a higher initial white-cell count (relative risk, 1.3; 95 percent confidence interval, 1.1 to 1.5), evaluation with stool culture soon after the onset of illness (relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.8), and treatment with antibiotics (relative risk, 14.3; 95 percent confidence interval, 2.9 to 70.7). The clinical and laboratory characteristics of the 9 children who received antibiotics and the 62 who did not receive antibiotics were similar. In a multivariate analysis that was adjusted for the initial white-cell count and the day of illness on which stool was obtained for culture, antibiotic administration remained a risk factor for the development of the hemolytic-uremic syndrome (relative risk, 17.3; 95 percent confidence interval, 2.2 to 137). Conclusions: Antibiotic treatment of children with E. coli O157:H7 infection increases the risk of the hemolytic-uremic syndrome. (N Engl J Med 2000;342:1930-6.) (C)2000, Massachusetts Medical Society.	Childrens Hosp & Reg Med Ctr, Div Gastroenterol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Seattle, WA USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle	Tarr, PI (corresponding author), Childrens Hosp & Reg Med Ctr, Div Gastroenterol, CH-24,4800 Sand Point Way NE, Seattle, WA 98105 USA.			Jelacic, Srdjan/0000-0002-6617-9870	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052081] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK052081, 1RO1DK52081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2000, M2A7 NCCLS; BELL BP, 1997, PEDIATRICS, V100, P127; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; Chisaki Takafumi, 1997, Japanese Journal of Antibiotics, V50, P821; CIMOLAI N, 1992, PEDIATRICS, V90, P616; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; CIMOLAI N, 1994, CLIN NEPHROL, V42, P85; Cimolai N, 1990, J PEDIATR, V116, P1008; Colton T, 1974, STAT MED; Dryden MS, 1996, CLIN INFECT DIS, V22, P1019, DOI 10.1093/clinids/22.6.1019; Fukushima H, 1999, PEDIATR INT, V41, P213, DOI 10.1046/j.1442-200X.1999.4121041.x; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; Grif K, 1998, EUR J CLIN MICROBIOL, V17, P761, DOI 10.1007/s100960050181; Higami S, 1998, Kansenshogaku Zasshi, V72, P266; Igarashi T, 1999, J PEDIATR-US, V135, P768, DOI 10.1016/S0022-3476(99)70100-9; Ikeda K, 1999, CLIN NEPHROL, V52, P357; KARCH H, 1986, FEMS MICROBIOL LETT, V35, P141, DOI 10.1016/0378-1097(86)90080-7; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Kawamura N, 1999, PEDIATR INT, V41, P218, DOI 10.1046/j.1442-200X.1999.4121040.x; Kimmitt PT, 1999, LANCET, V353, P1588, DOI 10.1016/S0140-6736(99)00621-2; Kohsaka T, 1997, Nihon Rinsho, V55, P706; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; Moriguchi Naohiko, 1997, Japanese Journal of Antibiotics, V50, P591; Neil M.A., 1998, ESCHERICHIA COLI O15, P357; Oshima Toshio, 1997, Japanese Journal of Antibiotics, V50, P855; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; Rowe PC, 1998, J PEDIATR-US, V132, P777, DOI 10.1016/S0022-3476(98)70303-8; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; Shiomi M, 1999, PEDIATR INT, V41, P228, DOI 10.1046/j.1442-200X.1999.4121038.x; Slutsker L, 1998, J INFECT DIS, V177, P962, DOI 10.1086/515258; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WALTERSPIEL JN, 1992, INFECTION, V20, P25, DOI 10.1007/BF01704889; WISTROM J, 1992, ANN INTERN MED, V117, P202, DOI 10.7326/0003-4819-117-3-202; Yoh M, 1997, Kansenshogaku Zasshi, V71, P1144	37	705	753	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	2000	342	26					1930	1936		10.1056/NEJM200006293422601	http://dx.doi.org/10.1056/NEJM200006293422601			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328TZ	10874060	Green Accepted, Bronze			2022-12-28	WOS:000087867400001
J	Raman, V; Martensen, SA; Reisman, D; Evron, E; Odenwald, WF; Jaffee, E; Marks, J; Sukumar, S				Raman, V; Martensen, SA; Reisman, D; Evron, E; Odenwald, WF; Jaffee, E; Marks, J; Sukumar, S			Compromised HOXA5 function can limit p53 expression in human breast tumours	NATURE			English	Article							REGULATORY REGIONS; GENE-EXPRESSION; CANCER; MUTATIONS; APOPTOSIS; ASSAY	Expression of the p53 gene protects cells against malignant transformation(1,2). Whereas control of p53 degradation has been a subject of intense scrutiny, little is known about the factors that regulate p53 synthesis(1,2). Here we show that p53 messenger RNA levels are low in a large proportion of breast tumours. Seeking potential regulators of p53 transcription, we found consensus HOX binding sites(3,4) in the p53 promoter(5). Transient transfection of Hox/HOXA5 activated the p53 promoter. Expression of HOXA5 in epithelial cancer cells expressing wild-type p53, but not in isogenic variants lacking the p53 gene(6), led to apoptotic cell death. Moreover, breast cancer cell lines and patient tumours display a coordinate loss of p53 and HOXA5 mRNA and protein expression. The HOXA5 promoter region was methylated in 16 out of 20 p53-negative breast tumour specimens. We conclude that loss of expression of p53 in human breast cancer may be primarily due to lack of expression of HOXA5.	Johns Hopkins Oncol Ctr, Breast Canc Program, Baltimore, MD 21231 USA; Univ S Carolina, Columbia, SC 29208 USA; NIH, Bethesda, MD 20892 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA	Johns Hopkins University; Johns Hopkins Medicine; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; National Institutes of Health (NIH) - USA; Duke University	Sukumar, S (corresponding author), Johns Hopkins Oncol Ctr, Breast Canc Program, Baltimore, MD 21231 USA.			Evron, Ella/0000-0002-1003-5042; Jaffee, Elizabeth/0000-0003-3841-6549				Aubin J, 1998, DEV DYNAM, V212, P141, DOI 10.1002/(SICI)1097-0177(199805)212:1<141::AID-AJA13>3.0.CO;2-A; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Care A, 1996, MOL CELL BIOL, V16, P4842; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; GLEBOV OK, 1994, CANCER RES, V54, P3703; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Larochelle C, 1999, DEV DYNAM, V214, P127, DOI 10.1002/(SICI)1097-0177(199902)214:2<127::AID-AJA3>3.0.CO;2-F; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Prives C, 1999, J PATHOL, V187, P112; RAMAN V, 1993, INT J DEV BIOL, V37, P499; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Scott MP, 1997, NAT GENET, V15, P117, DOI 10.1038/ng0297-117; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Snedecor GW, 1982, STAT METHODS, V8th; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Zhao JJG, 1996, EMBO J, V15, P1313, DOI 10.1002/j.1460-2075.1996.tb00473.x	28	387	422	1	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					974	978		10.1038/35016125	http://dx.doi.org/10.1038/35016125			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879542				2022-12-28	WOS:000087732700057
J	Egbert, GD; Ray, RD				Egbert, GD; Ray, RD			Significant dissipation of tidal energy in the deep ocean inferred from satellite altimeter data	NATURE			English	Article							INTERNAL TIDES; ENERGETICS; CIRCULATION; FRICTION	How and where the ocean tides dissipate their energy are longstanding questions(1) that have consequences ranging from the history of the Moon(2) to the mixing of the oceans(3). Historically, the principal sink of tidal energy has been thought to be bottom friction in shallow seas(4,5). There has long been suggestive evidence(6,7), however, that tidal dissipation also occurs in the open ocean through the scattering by ocean-bottom topography of surface tides into internal waves, but estimates of the magnitude of this possible sink have varied widely(3,8-11). Here we use satellite altimeter data from Topex/Poseidon to map empirically the tidal energy dissipation. We show that approximately 10(12) watts-that is, 1 TW, representing 25-30% of the total dissipation-occurs in the deep ocean, generally near areas of rough topography. Of the estimated 2 TW of mixing energy required to maintain the large-scale thermohaline circulation of the ocean(12), one-half could therefore be provided by the tides, with the other half coming from action(13) on the surface of the ocean.	Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Oregon State University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Egbert, GD (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA.	egbert@oce.orst.edu	Ray, Richard/D-1034-2012	Egbert, Gary/0000-0003-1276-8538				ARMI L, 1978, J GEOPHYS RES-OCEANS, V83, P1971, DOI 10.1029/JC083iC04p01971; BAINES PG, 1982, DEEP-SEA RES, V29, P307, DOI 10.1016/0198-0149(82)90098-X; BELL TH, 1975, J GEOPHYS RES, V80, P320, DOI 10.1029/JC080i003p00320; CARTWRIGHT DE, 1991, J GEOPHYS RES-OCEANS, V96, P16897, DOI 10.1029/91JC01059; Dushaw BD, 1997, PROG OCEANOGR, V40, P337, DOI 10.1016/S0079-6611(98)00008-1; Egbert GD, 1997, PROG OCEANOGR, V40, P53, DOI 10.1016/S0079-6611(97)00023-2; EGBERT GD, 1994, J GEOPHYS RES-OCEANS, V99, P24821, DOI 10.1029/94JC01894; GREGG MC, 1989, J GEOPHYS RES-OCEANS, V94, P9686, DOI 10.1029/JC094iC07p09686; HANSEN KS, 1982, REV GEOPHYS, V20, P457, DOI 10.1029/RG020i003p00457; Hendershott M. C., 1977, The sea. Ideas and observations on progress in the study of the seas. Vol.6. Marine modeling, P47; Jeffreys H., 1921, PHILOS T R SOC LONDO, V221, P239; Le Provost C, 1997, PROG OCEANOGR, V40, P37; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; MOROZOV EG, 1995, DEEP-SEA RES PT I, V42, P135, DOI 10.1016/0967-0637(95)92886-C; Munk W, 1997, PROG OCEANOGR, V40, P7, DOI 10.1016/S0079-6611(97)00021-9; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; MUNK W., 1966, DEEP SEA RES OCEANOG, V13, P707, DOI [10.1016/0011-7471(66)90602-4, DOI 10.1016/0011-7471(66)90602-4]; Munk W. H., 1960, ROTATION EARTH GEOPH; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; Ray R. D., 1998, MAR GEOD, V21, P181, DOI [DOI 10.1080/01490419809388134, 10.1080/01490419809388134]; Ray R. D., 1999, GLOBAL OCEAN TIDE MO; Ray RD, 1996, NATURE, V381, P595, DOI 10.1038/381595a0; Ray RD, 1997, PROG OCEANOGR, V40, P135, DOI 10.1016/S0079-6611(97)00025-6; RAY RD, UNPUB J MAR SYS; Samelson RM, 1998, J PHYS OCEANOGR, V28, P712, DOI 10.1175/1520-0485(1998)028<0712:LSCWLE>2.0.CO;2; Shum CK, 1997, J GEOPHYS RES-OCEANS, V102, P25173, DOI 10.1029/97JC00445; SJOBERG B, 1992, DEEP-SEA RES, V39, P269, DOI 10.1016/0198-0149(92)90109-7; Taylor GI, 1919, PHILOS T R SOC LON A, V220, P1, DOI DOI 10.1098/RSTA.1920.0001; WUNSCH C, 1975, REV GEOPHYS, V13, P167, DOI 10.1029/RG013i001p00167; Wunsch C, 1998, J PHYS OCEANOGR, V28, P2332, DOI 10.1175/1520-0485(1998)028<2332:TWDBTW>2.0.CO;2	30	529	557	5	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 15	2000	405	6788					775	778		10.1038/35015531	http://dx.doi.org/10.1038/35015531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866194				2022-12-28	WOS:000087620600045
J	Nolting, F; Scholl, A; Stohr, J; Seo, JW; Fompeyrine, J; Siegwart, H; Locquet, JP; Anders, S; Luning, J; Fullerton, EE; Toney, MF; Scheinfein, MR; Padmore, HA				Nolting, F; Scholl, A; Stohr, J; Seo, JW; Fompeyrine, J; Siegwart, H; Locquet, JP; Anders, S; Luning, J; Fullerton, EE; Toney, MF; Scheinfein, MR; Padmore, HA			Direct observation of the alignment of ferromagnetic spins by antiferromagnetic spins	NATURE			English	Article							ANISOTROPY	The arrangement of spins at interfaces in a layered magnetic material often has an important effect on the properties of the material. One example of this is the directional coupling between the spins in an antiferromagnet and those in an adjacent ferromagnet, an effect first discovered(1) in 1956 and referred to as exchange bias. Because of its technological importance for the development of advanced devices such as magnetic read heads(2) and magnetic memory cells(3), this phenomenon has received much attention(4,5). Despite extensive studies, however, exchange bias is still poorly understood, largely due to the lack of techniques capable of providing detailed information about the arrangement of magnetic moments near interfaces. Here we present polarization-dependent X-ray magnetic dichroism spectro-microscopy that reveals the micromagnetic structure on both sides of a ferromagnetic-antiferromagnetic interface. Images of thin ferromagnetic Co films grown on antiferromagnetic LaFeO3 show a direct link between the arrangement of spins in each material. Remanent hysteresis loops, recorded for individual ferromagnetic domains, show a local exchange bias. Our results imply that the alignment of the ferromagnetic spins is determined, domain by domain, by the spin directions in the underlying antiferromagnetic layer.	Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA; Univ Neuchatel, Inst Phys, CH-2000 Neuchatel, Switzerland; IBM Corp, Div Res, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; International Business Machines (IBM); University of Neuchatel; International Business Machines (IBM); Arizona State University; Arizona State University-Tempe	Nolting, F (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, 1 Cyclotron Rd, Berkeley, CA 94720 USA.		Raoux, Simone/G-3920-2016; Fullerton, Eric E/H-8445-2013; Nolting, Frithjof/ABD-7373-2021; Seo, Maria/L-9960-2018; Seo, Jin Won/J-3980-2013; Scholl, Andreas/K-4876-2012; Nolting, Frithjof/J-4820-2017; Toney, Michael/ABD-5429-2021	Fullerton, Eric E/0000-0002-4725-9509; Nolting, Frithjof/0000-0002-5679-5370; Seo, Maria/0000-0003-4937-0769; Seo, Jin Won/0000-0003-4937-0769; Scholl, Andreas/0000-0002-1990-4769; Nolting, Frithjof/0000-0002-5679-5370; Toney, Michael/0000-0002-7513-1166; padmore, howard/0000-0003-0172-4871; Locquet, Jean-Pierre/0000-0002-4214-7081				Anders S, 1999, REV SCI INSTRUM, V70, P3973, DOI 10.1063/1.1150023; Berkowitz AE, 1999, J MAGN MAGN MATER, V200, P552, DOI 10.1016/S0304-8853(99)00453-9; EIBSCHUTZ M, 1967, PHYS REV, V156, P562, DOI 10.1103/PhysRev.156.562; LOCQUET JP, 1994, APPL PHYS LETT, V64, P372, DOI 10.1063/1.111151; Locquet JP, 1998, NATURE, V394, P453, DOI 10.1038/28810; MEIKLEJOHN WH, 1956, PHYS REV, V102, P1413, DOI 10.1103/PhysRev.102.1413; Nogues J, 1999, J MAGN MAGN MATER, V192, P203, DOI 10.1016/S0304-8853(98)00266-2; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; Scholl A, 2000, SCIENCE, V287, P1014, DOI 10.1126/science.287.5455.1014; STOHR J, 1993, SCIENCE, V259, P658, DOI 10.1126/science.259.5095.658; Stohr J, 1998, SURF REV LETT, V5, P1297, DOI 10.1142/S0218625X98001638; Takano K, 1997, PHYS REV LETT, V79, P1130, DOI 10.1103/PhysRevLett.79.1130; TSANG C, 1994, IEEE T MAGN, V30, P3801, DOI 10.1109/20.333909	13	388	394	4	194	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					767	769		10.1038/35015515	http://dx.doi.org/10.1038/35015515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866191				2022-12-28	WOS:000087620600042
J	Ling, AE; Robbins, KE; Brown, TM; Dunmire, V; Thoe, SYS; Wong, SY; Leo, YS; Teo, D; Gallarda, J; Phelps, B; Chamberland, ME; Busch, MP; Folks, TM; Kalish, ML				Ling, AE; Robbins, KE; Brown, TM; Dunmire, V; Thoe, SYS; Wong, SY; Leo, YS; Teo, D; Gallarda, J; Phelps, B; Chamberland, ME; Busch, MP; Folks, TM; Kalish, ML			Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; TYPE-1 RNA; PLASMA; RISK	Context Current screening practices for blood donations have been successful in reducing human immunodeficiency virus (HIV) transmission through receipt of contaminated blood products. However, HIV-infected blood donations made prior to seroconversion and before high levels of viral replication occur could test negative using both serologic antigen and antibody tests, Testing based on nucleic acid amplification (NAT) is being implemented to screen for HIV-infected blood donated during this period, yet the issue of single vs minipool donation screening remains unresolved. Objectives To determine HIV-1 genetic linkage between virus in 2 HIV-1-infected recipients of blood components and virus in the donor, who was HIV antigen and antibody negative at the time of donation; to screen the blood donor's plasma with HIV NAT assays, including those currently proposed for use in US blood donation screening. Design and Setting Case study conducted in October 1997 involving the Communicable Disease Centre, Singapore General Hospital, and the Singapore Blood Transfusion Service, Singapore. Subjects The blood donor and the 2 recipients of donor platelets and red blood cells. Main Outcome Measures Genetic analysis of the HIV-1 p17 coding region of gag and the C2V5 region of env to determine the genetic relatedness of virus from the donor and recipients; reactivity in quantitative and qualitative assays, and reactivity in donor screening HIV NAT assays in single donation and minipool screening contexts. Results Direct DNA sequencing demonstrated identical HIV-1 subtype E viral sequences in the donor and recipients. Based on comparisons of a qualitative and quantitative assay for HIV-1 RNA levels, a low level of viremia (range, 5-39 copies/mL in plasma) was estimated to be in the donor's undiluted blood at the time of donation. Additional testing using donor-screening NAT assays showed consistent detection of HIV RNA in the undiluted donor plasma whereas detection was inconsistent at the 1:16 and 1:24 dilution levels currently used in minipool screening of blood donations in the United States. Conclusions Transmission of HIV from a blood donor to a platelet recipient and a red blood cell recipient occurred in the preseroconversion infectious window period. The viral load in the implicated donation was estimated to be less than 40 copies/mL of plasma. Current US minipool HIV NAT screening protocols may not be sufficiently sensitive to detect all infectious window-period donations.	Singapore Gen Hosp, Singapore 0316, Singapore; Ctr Dis Control & Prevent, Div AIDS STD & TB Res, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Communicable Dis Ctr, Singapore, Singapore; Singapore Blood Transfus Serv, Singapore, Singapore; Roche Mol Syst, Pleasanton, CA USA; Chiron Corp, Blood Testing Div, Emeryville, CA 94608 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Blood Ctr Pacific, San Francisco, CA USA; Blood Syst Inc, Scottsdale, AZ USA	Singapore General Hospital; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Roche Holding; Novartis; University of California System; University of California San Francisco; Vitalant	Robbins, KE (corresponding author), 1600 Clifton Rd NE,Mailstop G-19, Atlanta, GA 30333 USA.							[Anonymous], 1990, MMWR MORB MORTAL WKL, V39, P380; Brown AE, 1997, TRANSFUSION, V37, P926, DOI 10.1046/j.1537-2995.1997.37997454019.x; Busch M. P., 1996, Transfusion (Bethesda), V36, p41S; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; BUSCH MP, 1997, APPL MOL BIOL BLOOD, P123; Cardoso MS, 1998, TRANSFUSION, V38, P905, DOI 10.1046/j.1537-2995.1998.381098440853.x; *CHIR PROCL, 1998, HIV 1 HCV TMA ASS 50; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; *CTR BIOL EV RES, 1995, REC DON SCREEN LIC T; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Diaz RS, 1997, AIDS, V11, P415, DOI 10.1097/00002030-199704000-00003; Ginocchio CC, 1999, J CLIN MICROBIOL, V37, P1210, DOI 10.1128/JCM.37.4.1210-1212.1999; *INT TASK FORC NUC, 2000, KLEISFUSION, V40, P143; Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080; KLEINMAN SH, BEST PRACTICE RES CL; Lackritz EM, 1995, NEW ENGL J MED, V333, P1721, DOI 10.1056/NEJM199512283332601; Laperche S, 1998, AIDS, V12, P1397, DOI 10.1097/00002030-199811000-00027; Le Corfec E, 1999, TRANSFUSION, V39, P1141, DOI 10.1046/j.1537-2995.1999.39101141.x; MCNEARNEY T, 1990, P NATL ACAD SCI USA, V87, P1917, DOI 10.1073/pnas.87.5.1917; Murthy KK, 1999, TRANSFUSION, V39, P688, DOI 10.1046/j.1537-2995.1999.39070688.x; *ROCH MOL SYST INC, 1999, COBAS AMPL HIV 1 TES; Schochetman Gerald, 1996, P25; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; *US PUBL HLTH SERV, 1996, MMWR-MORBID MORTAL W, V45, P1; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; Yerly S, 1998, TRANSFUSION, V38, P908, DOI 10.1046/j.1537-2995.1998.381098440854.x; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 1999, AABB WKLY REP, V5, P3; 1998, AM BLOOD CTR NE 0925, P9	31	79	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					210	214		10.1001/jama.284.2.210	http://dx.doi.org/10.1001/jama.284.2.210			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889595	Bronze			2022-12-28	WOS:000087933100026
J	Blatter, G				Blatter, G			Schrodinger's cat is now fat	NATURE			English	Editorial Material							SYSTEM		ETH Honggerberg, Inst Theoret Phys, CH-8093 Zurich, Switzerland	ETH Zurich	Blatter, G (corresponding author), ETH Honggerberg, Inst Theoret Phys, CH-8093 Zurich, Switzerland.							CALDEIRA AO, 1983, ANN PHYS-NEW YORK, V149, P374, DOI 10.1016/0003-4916(83)90202-6; CHAKRAVARTY S, 1984, PHYS REV LETT, V52, P5, DOI 10.1103/PhysRevLett.52.5; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; SCHMID A, 1983, PHYS REV LETT, V51, P1506, DOI 10.1103/PhysRevLett.51.1506; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P807, DOI 10.1007/BF01491891; Schroedinger E., 1935, NATURWISSENSCHAFTEN, V23, P823, DOI [DOI 10.1007/BF01491914, 10.1007/BF01491914]	8	20	22	0	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					25	26		10.1038/35017670	http://dx.doi.org/10.1038/35017670			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894523				2022-12-28	WOS:000087991200025
J	Dalton, R				Dalton, R			Astronomers fight to save telescope	NATURE			English	News Item																		LUDOWICH DA, 2000, NATURE, V405, P1025; 2000, NATURE, V404, P7	2	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					8	8		10.1038/35017735	http://dx.doi.org/10.1038/35017735			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894515	Bronze			2022-12-28	WOS:000087991200013
J	Delves, PJ; Roitt, IM				Delves, PJ; Roitt, IM			The immune system - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							T-CELL DEVELOPMENT; POSITIVE SELECTION; INNATE IMMUNITY; NATURAL-KILLER; SELF-TOLERANCE; RECEPTORS; RECOGNITION; LYMPHOCYTES; MECHANISMS; EXPRESSION		UCL, Windeyer Inst Med Sci, Dept Immunol, London, England	University of London; University College London	Delves, PJ (corresponding author), UCL, Windeyer Inst Med Sci, Dept Immunol, London, England.		Anforova, Mariia/AAG-1497-2021	Anforova, Mariia/0000-0002-2182-8865				Abraham SN, 1998, SEMIN IMMUNOL, V10, P373, DOI 10.1006/smim.1998.0140; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; Arnaout M. Amin, 1993, P191; Bell D, 1999, ADV IMMUNOL, V72, P255, DOI 10.1016/S0065-2776(08)60023-1; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Born W, 1999, Adv Immunol, V71, P77; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; EDELMAN GM, 1973, SCIENCE, V180, P830, DOI 10.1126/science.180.4088.830; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065-2776(08)60891-3; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; Fraser IP, 1998, SEMIN IMMUNOL, V10, P363, DOI 10.1006/smim.1998.0141; Gabay C, 1999, NEW ENGL J MED, V340, P1376; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; Heaney ML, 1998, J LEUKOCYTE BIOL, V64, P135, DOI 10.1002/jlb.64.2.135; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Keilholz U, 1998, J CLIN ONCOL, V16, P2921, DOI 10.1200/JCO.1998.16.9.2921; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kruisbeek AM, 1996, CURR OPIN IMMUNOL, V8, P233, DOI 10.1016/S0952-7915(96)80062-8; Kruisbeek AM, 1999, SEMIN IMMUNOL, V11, P1, DOI 10.1006/smim.1998.0161; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Law S.K.A., 1995, COMPLEMENT; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; METCALF D, 1995, COLONY STIMULATING F; Miller JFAP, 1996, CURR OPIN IMMUNOL, V8, P815, DOI 10.1016/S0952-7915(96)80010-0; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; Mire-Sluis A.R., 1998, CYTOKINES; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; NOVOTNY J, 1983, J BIOL CHEM, V258, P4433; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Savill J, 1997, BRIT MED BULL, V53, P491; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SIRAGANIAN RP, 1998, ENCY IMMUNOLOGY, P332; Slifka MK, 1998, CURR OPIN IMMUNOL, V10, P252, DOI 10.1016/S0952-7915(98)80162-3; STEWARTTULL D, 1995, THEORY PRACTICAL APP; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Townsend SE, 1999, IMMUNOL TODAY, V20, P217, DOI 10.1016/S0167-5699(98)01440-6; Van Parijs L, 1998, SCIENCE, V280, P243; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; Youinou P, 1999, IMMUNOL TODAY, V20, P312, DOI 10.1016/S0167-5699(99)01476-0	56	541	566	1	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					37	49		10.1056/NEJM200007063430107	http://dx.doi.org/10.1056/NEJM200007063430107			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882768				2022-12-28	WOS:000087987600007
J	Higuchi, M; Stefan, M; Single, FN; Hartner, J; Rozov, A; Burnashev, N; Feldmeyer, D; Sprengel, R; Seeburg, PH				Higuchi, M; Stefan, M; Single, FN; Hartner, J; Rozov, A; Burnashev, N; Feldmeyer, D; Sprengel, R; Seeburg, PH			Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2	NATURE			English	Article							SUBUNIT GLUR-B; PRE-MESSENGER-RNAS; ADENOSINE-DEAMINASE; GENOMIC ORGANIZATION; CHANNELS; LOCATION	RNA editing by site-selective deamination of adenosine to inosine(1,2) alters codons(3,4) and splicing(5) in nuclear transcripts(6), and therefore protein function. ADAR2 (refs 7, 8) is a candidate mammalian editing enzyme that is widely expressed in brain and other tissues(7), but its RNA substrates are unknown. Here we have studied ADAR2-mediated RNA editing by generating mice that are homozygous for a targeted functional null allele. Editing in ADAR2(-/-) mice was substantially reduced at most of 25 positions in diverse transcripts(3-6); the mutant mice became prone to seizures and died young. The impaired phenotype appeared to result entirely from a single underedited position, as it reverted to normal when both alleles for the underedited transcript were substituted with alleles encoding the edited version exonically(9). The critical position specifies an ion channel determinant(10), the Q/R site(3,6), in AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate) receptor(10) GluR-B pre-messenger RNA. We conclude that this transcript is the physiologically most important substrate of ADAR2.	Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany	Max Planck Society; Max Planck Society	Seeburg, PH (corresponding author), Max Planck Inst Med Res, Dept Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.		Feldmeyer, Dirk/H-5940-2013; Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013	Feldmeyer, Dirk/0000-0002-1716-8972; 				BASS BL, 1995, CURR BIOL, V5, P598, DOI 10.1016/S0960-9822(95)00119-9; Bass BL, 1997, RNA, V3, P947; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Jia ZP, 1996, NEURON, V17, P945, DOI 10.1016/S0896-6273(00)80225-1; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; KOHLER M, 1994, J BIOL CHEM, V269, P17367; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; WANG Y, 1995, J MOL BIOL, V254, P184, DOI 10.1006/jmbi.1995.0610; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805	27	698	720	0	30	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					78	81		10.1038/35017558	http://dx.doi.org/10.1038/35017558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894545				2022-12-28	WOS:000087991200048
J	Morita, T; Tokue, A				Morita, T; Tokue, A			Patent urachus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Jichi Med Sch, Mibu, Tochigi, Japan	Jichi Medical University	Morita, T (corresponding author), Jichi Med Sch, Mibu, Tochigi, Japan.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2000	343	1					36	36		10.1056/NEJM200007063430106	http://dx.doi.org/10.1056/NEJM200007063430106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330XW	10882767				2022-12-28	WOS:000087987600006
J	Tsoi, M; Jansen, AGM; Bass, J; Chiang, WC; Tsoi, V; Wyder, P				Tsoi, M; Jansen, AGM; Bass, J; Chiang, WC; Tsoi, V; Wyder, P			Generation and detection of phase-coherent current-driven magnons in magnetic multilayers	NATURE			English	Article							WAVE EMITTING DIODES; GIANT MAGNETORESISTANCE; ELECTRIC-CURRENT; SPIN-WAVES; EXCITATION; METALS	The magnetic state of a ferromagnet can affect the electrical transport properties of the material; for example, the relative orientation of the magnetic moments in magnetic multilayers(1) underlies the phenomenon of giant magnetoresistance. The inverse effect-in which a large electrical current density can perturb the magnetic state of a multilayer-has been predicted(2-7) and observed experimentally with point contacts(8,9) and lithographically patterned samples(10,11). Some of these observations were taken as indirect evidence for current-induced excitation of spin waves, or 'magnons'. Here we probe directly the high-frequency behaviour and partial phase coherence of such current-induced excitations, by externally irradiating a point contact with microwaves. We determine the magnon spectrum and investigate how the magnon frequency and amplitude vary with the exciting current. Our observations support the feasibility of a spin-wave maser(2) or 'SWASER' (spin-wave amplification by stimulated emission of radiation).	Max Planck Inst Festkorperforsch, Grenoble High Magnet Field Lab, F-38042 Grenoble 9, France; CNRS, F-38042 Grenoble, France; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Russian Acad Sci, Inst Solid State Phys, Chernogolovka 142432, Moscow Region, Russia	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Michigan State University; Russian Academy of Sciences; Osipyan Institute of Solid State Physics RAS	Tsoi, M (corresponding author), Max Planck Inst Festkorperforsch, Grenoble High Magnet Field Lab, BP 166, F-38042 Grenoble 9, France.							BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; Berger L, 1997, J APPL PHYS, V81, P4880, DOI 10.1063/1.364902; Berger L, 1998, IEEE T MAGN, V34, P3837, DOI 10.1109/20.728292; Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; HERRING C, 1951, PHYS REV, V81, P869, DOI 10.1103/PhysRev.81.869; JANSEN AGM, 1980, J PHYS C SOLID STATE, V13, P6073, DOI 10.1088/0022-3719/13/33/009; Javan A., 1973, FUNDAMENTAL APPL LAS, P295; KATINE JA, 1999, CONDMAT9908231; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; SEAVEY MH, 1958, PHYS REV LETT, V1, P168, DOI 10.1103/PhysRevLett.1.168; Seck M, 1998, REV SCI INSTRUM, V69, P1817, DOI 10.1063/1.1148847; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Slonczewski JC, 1999, J MAGN MAGN MATER, V195, pL261, DOI 10.1016/S0304-8853(99)00043-8; Sun JZ, 1999, J MAGN MAGN MATER, V202, P157, DOI 10.1016/S0304-8853(99)00289-9; Tsoi M, 1998, PHYS REV LETT, V80, P4281, DOI 10.1103/PhysRevLett.80.4281; Tsoi MV, 1997, J APPL PHYS, V81, P5530, DOI 10.1063/1.364944; VANDERHEIJDEN RW, 1980, APPL PHYS LETT, V37, P245, DOI 10.1063/1.91841; [No title captured]	19	384	396	2	77	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					46	48		10.1038/35017512	http://dx.doi.org/10.1038/35017512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894534				2022-12-28	WOS:000087991200037
J	Zhu, GF; Spellman, PT; Volpe, T; Brown, PO; Botstein, D; Davis, TN; Futcher, B				Zhu, GF; Spellman, PT; Volpe, T; Brown, PO; Botstein, D; Davis, TN; Futcher, B			Two yeast forkhead genes regulate the cell cycle and pseudohyphal growth	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; TRANSCRIPTION; SWI5; HEAD; EXPRESSION; PROTEIN; KINASE; MCM1; CHITINASE	There are about 800 genes in Saccharomyces cerevisiae whose transcription is cell-cycle regulated(1,2). Some of these form clusters of co-regulated genes(1). The 'CLB2' cluster contains 33 genes whose transcription peaks early in mitosis, including CLB1, CLB2, SWI5, ACE2, CDC5, CDC20 and other genes important for mitosis(1). Here we rnd that the genes in this cluster lose their cell cycle regulation in a mutant that lacks two forkhead transcription factors, Fkh1 and Fkh2. Fkh2 protein is associated with the promoters of CLB2, SWI5 and other genes of the cluster. These results indicate that Fkh proteins are transcription factors for the CLB2 cluster. The fkh1 fkh2 mutant also displays aberrant regulation of the 'SIC1' cluster(1), whose member genes are expressed in the M-G1 interval and are involved in mitotic exit. This aberrant regulation may be due to aberrant expression of the transcription factors Swi5 and Ace2, which are members of the CLB2 cluster and controllers of the SIC1 cluster. Thus, a cascade of transcription factors operates late in the cell cycle. Finally, the fkh1 fkh2 mutant displays a constitutive pseudohyphal morphology, indicating that Fkh1 and Fkh2 may help control the switch to this mode of growth.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94306 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94306 USA	Cold Spring Harbor Laboratory; University of Washington; University of Washington Seattle; Stanford University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stanford University	Futcher, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Davis, Trisha/F-8584-2010	Davis, Trisha/0000-0003-4797-3152				ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; Edgington NP, 1999, MOL CELL BIOL, V19, P1369; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Grallert A, 1998, J BACTERIOL, V180, P892, DOI 10.1128/JB.180.4.892-900.1998; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; King L, 1998, CURR GENET, V34, P183, DOI 10.1007/s002940050384; Knapp D, 1996, MOL CELL BIOL, V16, P5701; Kovacech B, 1996, MOL CELL BIOL, V16, P3264; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Zhu GF, 1998, BBA-MOL CELL RES, V1448, P236, DOI 10.1016/S0167-4889(98)00135-9	26	287	295	0	17	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 6	2000	406	6791					90	94		10.1038/35017581	http://dx.doi.org/10.1038/35017581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	330ZE	10894548				2022-12-28	WOS:000087991200051
J	Carley, SD; Libetta, C; Flavin, B; Butler, J; Tong, N; Sammy, I				Carley, SD; Libetta, C; Flavin, B; Butler, J; Tong, N; Sammy, I			An open prospective randomised trial to reduce the pain of blood glucose testing: ear versus thumb	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Hope Hosp, Salford M6 8HD, Lancs, England		Carley, SD (corresponding author), Manchester Royal Infirm, Dept Emergency Med, Oxford Rd, Manchester M13 9WL, Lancs, England.	s.carley@btinternet.com	carley, simon/W-7944-2019	carley, simon/0000-0003-1561-5553; Sammy, Ian/0000-0003-4265-5569				*COMM TRAUM, 1993, ADV TRAUM LIF SUPP P; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Loveland ME, 1999, LANCET, V354, P921, DOI 10.1016/S0140-6736(99)02902-5	3	14	14	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	2000	321	7252					20	20		10.1136/bmj.321.7252.20	http://dx.doi.org/10.1136/bmj.321.7252.20			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	331QQ	10875827	Bronze, Green Published			2022-12-28	WOS:000088030100020
J	Meier, CR; Schlienger, RG; Kraenzlin, ME; Schlegel, B; Jick, H				Meier, CR; Schlienger, RG; Kraenzlin, ME; Schlegel, B; Jick, H			HMG-CoA reductase inhibitors and the risk of fractures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE RESEARCH DATABASE; CONTROLLED TRIALS; PREVENTION; METAANALYSIS; OSTEOPOROSIS; PRAVASTATIN; EXERCISE; THERAPY; STATINS; DISEASE	Context Recent animal studies have suggested that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) increase bone formation, volume, and density. It is unknown whether use of statins is associated with a decreased risk of fractures in humans. Objective To determine whether exposure to statins, fibrates, or other lipid-lowering drugs is associated with reduced bone fracture risk. Design Population-based, nested case-control analysis. Setting The UK-based General Practice Research Database (GPRD), comprising some 300 practices, with data collection from the late 1980s until September 1998. Subjects Within a base population of 91 611 individuals aged at least 50 years (28340 individuals taking lipid-lowering drugs, 13 271 untreated individuals with a diagnosis of hyperlipidemia, and 50 000 randomly selected individuals without diagnosis of hyperlipidemia), we identified 3940 case patients who had a bone fracture and 23 379 control patients matched for age (+/-5 years), sex, general practice attended, calendar year, and years since enrollment in the GPRD, Main Outcome Measures Use of statins, fibrates, or other lipid-lowering drugs in case patients vs control patients. Results After controlling for body mass index, smoking, number of physician visits, and corticosteroid and estrogen use, current use of statins was associated with a significantly reduced fracture risk (adjusted odds ratio [OR], 0.55; 95% confidence interval [CI], 0.44-0.69) compared with nonuse of lipid-lowering drugs. Current use of fibrates or other lipid-lowering drugs was not related to a significantly decreased bone fracture risk (adjusted OR, 0.87; 95% CI, 0.70-1.08 and adjusted OR, 0.76; 95% CI, 0.41-1.39, respectively). Conclusions This study suggests that current exposure to statins is associated with a decreased risk of bone fractures in individuals age 50 years and older. This finding has a potentially important public health impact and should be confirmed further in controlled prospective trials.	Univ Basel Hosp, Div Clin Pharmacol, Basel Pharmacoepidemiol Unit, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Endocrinol Diabet Clin Nutr, CH-4031 Basel, Switzerland; Univ Basel, Inst Pharmacotherapy, Dept Pharm, Basel, Switzerland; Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA USA	University of Basel; University of Basel; University of Basel; Boston University	Meier, CR (corresponding author), Univ Basel Hosp, Div Clin Pharmacol, Basel Pharmacoepidemiol Unit, Petersgraben 4, CH-4031 Basel, Switzerland.	Christoph.Meier@unibas.ch	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Jick, Hershel/0000-0003-4270-5992				Bauer DC, 1999, J BONE MINER RES, V14, pS179; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; Chung YS, 2000, J CLIN ENDOCR METAB, V85, P1137, DOI 10.1210/jcem.85.3.6476; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUI Q, 1997, CLIN ORTHOP RELAT R, V344, P8; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; GAMERO P, 1994, J CLIN ENDOCR METAB, V79, P1693; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDRAZZONI M, 1995, CALCIFIED TISSUE INT, V57, P25, DOI 10.1007/BF00298992; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; WANG GJ, 1995, J FORMOS MED ASSOC, V94, P589; Wolff I, 1999, OSTEOPOROSIS INT, V9, P1, DOI 10.1007/s001980050109	21	391	427	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3205	3210		10.1001/jama.283.24.3205	http://dx.doi.org/10.1001/jama.283.24.3205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866867	Bronze			2022-12-28	WOS:000087753900032
J	Loder, N				Loder, N			UK panel calls for more cuts to carbon dioxide emission	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 22	2000	405	6789					873	874		10.1038/35016222	http://dx.doi.org/10.1038/35016222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	326JT	10879501	Bronze			2022-12-28	WOS:000087732700008
J	Sasaki, S; De Franceschi, S; Elzerman, JM; van der Wiel, WG; Eto, M; Tarucha, S; Kouwenhoven, LP				Sasaki, S; De Franceschi, S; Elzerman, JM; van der Wiel, WG; Eto, M; Tarucha, S; Kouwenhoven, LP			Kondo effect in an integer-spin quantum dot	NATURE			English	Article							ELECTRON-TRANSPORT; IMPURITY	The Kondo effect-a many-body phenomenon in condensed-matter physics involving the interaction between a localized spin and free electrons-was discovered in metals containing small amounts of magnetic impurities, although it is now recognized to be of fundamental importance in a wide class of correlated electron systems(1,2). In fabricated structures, the control of single, localized spins is of technological relevance for nanoscale electronics(3,4). Experiments have already demonstrated artificial realizations of isolated magnetic impurities at metallic surfaces(5,6), nanoscale magnets(7), controlled transitions between two-electron singlet and triplet states(8), and a tunable Kondo effect in semiconductor quantum dots(9-12). Here we report an unexpected Kondo effect in a few-electron quantum dot containing singlet and triplet spin states, whose energy difference can be tuned with a magnetic field. We observe the effect for an even number of electrons, when the singlet and triplet states are degenerate. The characteristic energy scale is much larger than in the ordinary spin-1/2 case.	Delft Univ Technol, DIMES, Dept Appl Phys, NL-2600 GA Delft, Netherlands; Delft Univ Technol, ERATO Mesoscop Correlat Project, NL-2600 GA Delft, Netherlands; NTT, Basic Res Labs, Atsugi, Kanagawa 2430129, Japan; Keio Univ, Fac Sci & Technol, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Univ Tokyo, ERATO Mesoscop Correlat Project, Bunkyo Ku, Tokyo 1130033, Japan	Delft University of Technology; Delft University of Technology; Nippon Telegraph & Telephone Corporation; Keio University; University of Tokyo	De Franceschi, S (corresponding author), Delft Univ Technol, DIMES, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.		Eto, Mikio/D-6021-2014; van der Wiel, Wilfred/F-8812-2014; TARUCHA, SEIGO/I-7030-2012; Elzerman, Jeroen M/J-3551-2012	van der Wiel, Wilfred/0000-0002-3479-8853; Elzerman, Jeroen M/0000-0002-4596-8483				Austing DG, 1999, PHYS REV B, V60, P11514, DOI 10.1103/PhysRevB.60.11514; AVERIN DV, 1991, P NATO ASI B, V294, P217; AWSCHALOM DD, 1995, PHYS TODAY, V48, P43, DOI 10.1063/1.881448; COX DL, 1995, PHYS TODAY, V48, P32, DOI 10.1063/1.881443; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; ETO M, 2000, CONDMAT0002010; Funabashi Y, 1999, JPN J APPL PHYS 1, V38, P388, DOI 10.1143/JJAP.38.388; Giuliano D, 2000, PHYS REV LETT, V84, P4677, DOI 10.1103/PhysRevLett.84.4677; GLAZMAN LI, 1988, JETP LETT+, V47, P452; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Hewson A C, 1993, KONDO PROBLEM HEAVY; INOSHITA T, 1993, PHYS REV B, V48, P14725, DOI 10.1103/PhysRevB.48.14725; Izumida W, 1998, J PHYS SOC JPN, V67, P2444, DOI 10.1143/JPSJ.67.2444; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; MATTIS DC, 1967, PHYS REV LETT, V19, P1478, DOI 10.1103/PhysRevLett.19.1478; Maurer SM, 1999, PHYS REV LETT, V83, P1403, DOI 10.1103/PhysRevLett.83.1403; NG TK, 1988, PHYS REV LETT, V61, P1768, DOI 10.1103/PhysRevLett.61.1768; NOZIERES P, 1980, J PHYS-PARIS, V41, P193, DOI 10.1051/jphys:01980004103019300; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Pustilnik M, 2000, PHYS REV LETT, V84, P1756, DOI 10.1103/PhysRevLett.84.1756; Schmid J, 1998, PHYSICA B, V256, P182, DOI 10.1016/S0921-4526(98)00533-X; SCHMID J, UNPUB PHYS REV LETT; Simmel F, 1999, PHYS REV LETT, V83, P804, DOI 10.1103/PhysRevLett.83.804; SIVAN U, 1994, EUROPHYS LETT, V25, P605, DOI 10.1209/0295-5075/25/8/008; Tarucha S, 2000, PHYS REV LETT, V84, P2485, DOI 10.1103/PhysRevLett.84.2485; WAN Y, 1995, PHYS REV B, V51, P14782, DOI 10.1103/PhysRevB.51.14782; WINGREEN NS, 1994, PHYS REV B, V49, P11040, DOI 10.1103/PhysRevB.49.11040	30	437	440	3	64	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 15	2000	405	6788					764	767		10.1038/35015509	http://dx.doi.org/10.1038/35015509			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	324KJ	10866190	Green Submitted			2022-12-28	WOS:000087620600041
J	Lell, B; Faucher, JF; Missinou, MA; Borrmann, S; Dangelmaier, O; Horton, J; Kremsner, PG				Lell, B; Faucher, JF; Missinou, MA; Borrmann, S; Dangelmaier, O; Horton, J; Kremsner, PG			Malaria chemoprophylaxis with tafenoquine: a randomised study	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; PLUS PROGUANIL; VIVAX MALARIA; PROPHYLAXIS; PREVENTION; FALCIPARUM; WR-238605; KENYA; ANTIMALARIAL; PRIMAQUINE	Background Tafenoquine is an analogue of primaquine with an improved therapeutic and safety profile. It has a long half-life and activity against liver-stage malaria parasites, so may be useful for chemoprophylaxis. In this randomised, double-blind study we assessed the efficacy and safety of tafenoquine in different doses. Methods 2144 individuals aged 12-20 years living in Lambarene, Gabon, an endemic area for Plasmodium falciparum malaria, were invited to take part. 535 attended, and 426 eligible participants were randomly assigned tafenoquine (250 mg, 125 mg, 62.5 mg, or 31.25 mg) or placebo daily for 3 days. 417 received initial curative treatment with halofantrine, and 410 completed the assigned prophylaxis regimen. During follow-up of 70 days, adverse events were recorded and thick blood smears were examined weekly. The primary and secondary endpoints were the number of individuals with positive blood smears by day 56 and day 77, respectively. Analyses were per-protocol. Findings Eight positive blood smears were recorded by day 56 (four/82 participants in the placebo group; four/79 tafenoquine 31.25 mg group). By day 77, 34 positive blood smears had been recorded (14/82 placebo; 16/79 tafenoquine 31.25 mg; three/86 tafenoquine 62.5 mg; one/79 tafenoquine 125 mg; none/84 tafenoquine 250 mg). Numbers of adverse events did not differ significantly between the treatment groups. Interpretation Tafenoquine is effective and well tolerated. It has the potential to replace currently used drugs for malaria chemoprophylaxis.	Univ Tubingen, Inst Trop Med, Dept Parasitol, Sekt Humanparasitol, D-72074 Tubingen, Germany; Albert Schweltzer Hosp, Res Unit, Lambarene, Gabon; SmithKline Beecham Pharmaceut, Brentford, England	Eberhard Karls University of Tubingen; GlaxoSmithKline	Kremsner, PG (corresponding author), Univ Tubingen, Inst Trop Med, Dept Parasitol, Sekt Humanparasitol, Wilhelmstr 27, D-72074 Tubingen, Germany.		Borrmann, Steffen/G-1838-2013	Borrmann, Steffen/0000-0001-9189-4393				Brown V, 1998, LANCET, V352, P1356, DOI 10.1016/S0140-6736(05)60747-7; Brueckner RP, 1998, ANTIMICROB AGENTS CH, V42, P1293, DOI 10.1128/AAC.42.5.1293; Brueckner RP, 1998, AM J TROP MED HYG, V58, P645, DOI 10.4269/ajtmh.1998.58.645; CLYDE DF, 1981, B WORLD HEALTH ORGAN, V59, P391; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; FLEMING AF, 1989, BLOOD REV, V3, P18; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; Garfield R, 1999, LANCET, V354, P414, DOI 10.1016/S0140-6736(99)02226-6; GREENWOOD AM, 1994, T ROY SOC TROP MED H, V88, P311, DOI 10.1016/0035-9203(94)90094-9; Lell B, 1999, CLIN INFECT DIS, V28, P794, DOI 10.1086/515193; Lell B, 1998, LANCET, V351, P709, DOI 10.1016/S0140-6736(97)09222-2; Lobel HO, 1997, JAMA-J AM MED ASSOC, V278, P1767, DOI 10.1001/jama.278.21.1767; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; PETERS W, 1993, ANN TROP MED HYG, V55, P243; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P144; SOME ES, 1994, E AFR MED J, V71, P2; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Walsh DS, 1999, J INFECT DIS, V180, P1282, DOI 10.1086/315034; WEISS WR, 1995, J INFECT DIS, V171, P1569, DOI 10.1093/infdis/171.6.1569; WILDLING E, 1995, TROP MED PARASITOL, V46, P77	20	98	98	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 10	2000	355	9220					2041	2045		10.1016/S0140-6736(00)02352-7	http://dx.doi.org/10.1016/S0140-6736(00)02352-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	322QC	10885356				2022-12-28	WOS:000087519400013
J	Knight, RD; Landweber, LF				Knight, RD; Landweber, LF			The early evolution of the genetic code	CELL			English	Review							TRANSFER-RNA SYNTHETASE; AMINO-ACID SPECIFICITY		Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA	Princeton University	Knight, RD (corresponding author), Princeton Univ, Dept Ecol & Evolut Biol, Princeton, NJ 08544 USA.			Knight, Rob/0000-0002-0975-9019				Agou F, 1998, BIOCHEMISTRY-US, V37, P11309, DOI 10.1021/bi9805590; Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Chihade JW, 1999, P NATL ACAD SCI USA, V96, P12316, DOI 10.1073/pnas.96.22.12316; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; Ellington AD, 2000, RNA, V6, P485, DOI 10.1017/S1355838200000224; Freeland SJ, 2000, MOL BIOL EVOL, V17, P511, DOI 10.1093/oxfordjournals.molbev.a026331; Hong KW, 1998, FEBS LETT, V434, P149, DOI 10.1016/S0014-5793(98)00968-5; Illangasekare M, 1999, RNA, V5, P1482, DOI 10.1017/S1355838299991264; Karamyshev AL, 1999, FEBS LETT, V457, P483, DOI 10.1016/S0014-5793(99)01089-3; Knight RD, 1998, CHEM BIOL, V5, pR215, DOI 10.1016/S1074-5521(98)90001-1; Knight RD, 2000, RNA, V6, P499, DOI 10.1017/S1355838200000145; Lee N, 2000, NAT STRUCT BIOL, V7, P28; Li T, 1999, BIOCHEMISTRY-US, V38, P9084, DOI 10.1021/bi9901984; Mannironi C, 2000, RNA, V6, P520, DOI 10.1017/S1355838200991763; Nelson KE, 2000, P NATL ACAD SCI USA, V97, P3868, DOI 10.1073/pnas.97.8.3868; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; Tomita K, 1999, NUCLEIC ACIDS RES, V27, P4291, DOI 10.1093/nar/27.21.4291; WONG JT, 1981, TRENDS BIOCHEM SCI, V6, P33; Yarus M, 2000, RNA, V6, P475, DOI 10.1017/S1355838200002569	19	57	62	2	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 9	2000	101	6					569	572		10.1016/S0092-8674(00)80866-1	http://dx.doi.org/10.1016/S0092-8674(00)80866-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	322HQ	10892641	Bronze			2022-12-28	WOS:000087504500001
J	Marik, P; Zaloga, G				Marik, P; Zaloga, G			Prognostic value of cortisol response in septic shock	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADRENOCORTICOTROPIN		Washington Hosp Ctr, Washington, DC 20010 USA	MedStar Washington Hospital Center	Marik, P (corresponding author), Washington Hosp Ctr, Washington, DC 20010 USA.							Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; HART BB, 1989, CRIT CARE MED, V17, P1203, DOI 10.1097/00003246-198911000-00021; Henzen C, 2000, LANCET, V355, P542, DOI 10.1016/S0140-6736(99)06290-X; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; Marik PE, 1999, CRIT CARE MED, V27, pA141, DOI 10.1097/00003246-199912001-00399; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285	6	39	41	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 19	2000	284	3					308	309		10.1001/jama.284.3.308	http://dx.doi.org/10.1001/jama.284.3.308			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	333GR	10891959				2022-12-28	WOS:000088123000020
J	Barnett, HM; Eliasziw, M; Meldrum, H				Barnett, HM; Eliasziw, M; Meldrum, H			Plaque morphology as a risk factor for stroke - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Western Ontario, John P Robarts Res Inst, London, ON, Canada	Western University (University of Western Ontario)	Barnett, HM (corresponding author), Univ Western Ontario, John P Robarts Res Inst, London, ON, Canada.		Bluth, Edward I./A-8613-2011					Fahrig R, 1997, AM J NEURORADIOL, V18, P1507; Inzitari D, 2000, NEUROLOGY, V54, P660, DOI 10.1212/WNL.54.3.660; NICOLAIDES AN, 1995, INT ANGIOL, V14, P21; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035	4	12	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					177	177		10.1001/jama.284.2.177	http://dx.doi.org/10.1001/jama.284.2.177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889586				2022-12-28	WOS:000087933100017
J	Bluth, EI				Bluth, EI			Plaque morphology as a risk factor for stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CAROTID PLAQUE; ARTERY		Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA	Ochsner Health System	Bluth, EI (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, 1516 Jefferson Highway, New Orleans, LA 70121 USA.		Bluth, Edward I./A-8613-2011					Barnett HJM, 2000, JAMA-J AM MED ASSOC, V283, P1429, DOI 10.1001/jama.283.11.1429; Bluth EI, 1997, SEMIN ULTRASOUND CT, V18, P57, DOI 10.1016/S0887-2171(97)90038-X; BLUTH EI, 1986, AM J ROENTGENOL, V146, P1061, DOI 10.2214/ajr.146.5.1061; GEROULAKOS G, 1994, J VASC SURG, V20, P263, DOI 10.1016/0741-5214(94)90014-0; Polak JF, 1998, RADIOLOGY, V208, P649, DOI 10.1148/radiology.208.3.9722841; STERPETTI AV, 1988, SURGERY, V104, P652	6	12	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					177	177		10.1001/jama.284.2.177	http://dx.doi.org/10.1001/jama.284.2.177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889586				2022-12-28	WOS:000087933100016
J	Wright, TC; Kuhn, L; Denny, L				Wright, TC; Kuhn, L; Denny, L			Human papillomavirus detection to screen for cervical cancer - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Univ Cape Town, ZA-7925 Cape Town, South Africa	Columbia University; University of Cape Town	Wright, TC (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							Miller A. B., 1992, Cervical cancer screening programmes: managerial guidelines.; NEL JT, 1994, S AFR MED J, V84, P18; Poljak M, 1999, J CLIN MICROBIOL, V37, P796, DOI 10.1128/JCM.37.3.796-797.1999; SCHATZKIN A, 1987, AM J EPIDEMIOL, V125, P672, DOI 10.1093/oxfordjournals.aje.a114580; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					39	40		10.1001/jama.284.1.39	http://dx.doi.org/10.1001/jama.284.1.39			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872004				2022-12-28	WOS:000087843000015
J	Culver, G; Fallon, K; Londner, RB; Montalvo, N; Vila, B; Ramsey, BJ; Ramsey, CS; Trebaol, G; Houle, L; Williams, A; Williams, H; Wolding, T				Culver, G; Fallon, K; Londner, RB; Montalvo, N; Vila, B; Ramsey, BJ; Ramsey, CS; Trebaol, G; Houle, L; Williams, A; Williams, H; Wolding, T			Informed decisions for extremely low-birth-weight infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter													Rosenbaum, Peter/AAW-7913-2021; Furlong, William J/A-1077-2008	Rosenbaum, Peter/0000-0001-6751-5613; 				ABRAMS FR, 1989, COLORADO SPEAKS OUT; ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; *AM OBST GYN COMM, 1995, PEDIATRICS, V96, P974; Hefferman P, 1999, CAMB Q HEALTHC ETHIC, V8, P173, DOI 10.1017/S0963180199802060; Saigal S, 1999, JAMA-J AM MED ASSOC, V281, P1991, DOI 10.1001/jama.281.21.1991; TAYLOR H, 1990, NEW ENGL J MED, V322, P1891	6	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3201	3201		10.1001/jama.283.24.3201	http://dx.doi.org/10.1001/jama.283.24.3201			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866862				2022-12-28	WOS:000087753900026
J	Mandelblatt, J; Yabroff, KR; Lawrence, W; Yi, B; Orosz, G; Bloom, HG; Schecther, CB; Extermann, M; Balducci, L; Satadano, W; Fox, S; Silliman, RA; Fahs, MC				Mandelblatt, J; Yabroff, KR; Lawrence, W; Yi, B; Orosz, G; Bloom, HG; Schecther, CB; Extermann, M; Balducci, L; Satadano, W; Fox, S; Silliman, RA; Fahs, MC			Screening mammography in elderly women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CANCER		Lombardi Canc Ctr, Washington, DC 20007 USA; Mt Sinai Sch Med, New York, NY USA; Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; RAND Corp, Santa Monica, CA 90406 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Boston Univ, Med Ctr, Boston, MA USA; New Sch Social Res, Res Breast Canc Older Women Consortium, New York, NY 10011 USA	Icahn School of Medicine at Mount Sinai; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of California System; University of California Berkeley; RAND Corporation; University of California System; University of California Los Angeles; Boston University; The New School	Mandelblatt, J (corresponding author), Lombardi Canc Ctr, Washington, DC 20007 USA.			Silliman, Rebecca/0000-0001-9958-8403; Yabroff, K. Robin/0000-0003-0644-5572; Cauley, Jane A/0000-0003-0752-4408				Extermann M, 2000, J CLIN ONCOL, V18, P1709, DOI 10.1200/JCO.2000.18.8.1709; HELZLSOUER K, 1995, CANC PREVENTION CONT, P512; Kerlikowske K, 1999, JAMA-J AM MED ASSOC, V282, P2156, DOI 10.1001/jama.282.22.2156; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; Ravdin PM, 1998, J CLIN ONCOL, V16, P515, DOI 10.1200/JCO.1998.16.2.515	5	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3202	3203		10.1001/jama.283.24.3202	http://dx.doi.org/10.1001/jama.283.24.3202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866866				2022-12-28	WOS:000087753900028
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	15	19	2	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 1	2000	356	9223					81	81		10.1016/S0140-6736(05)73417-6	http://dx.doi.org/10.1016/S0140-6736(05)73417-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XH	10859071				2022-12-28	WOS:000087933400062
J	Bhasin, S; Storer, TW				Bhasin, S; Storer, TW			Exercise regimens for men with HIV - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HUMAN-IMMUNODEFICIENCY-VIRUS; STRENGTH		Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA; El Camino Coll, Torrance, CA USA	Charles R. Drew University of Medicine & Science	Bhasin, S (corresponding author), Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA.							Bhasin S, 1996, NEW ENGL J MED, V335, P1, DOI 10.1056/NEJM199607043350101; Fleck SJ, 1999, J STRENGTH COND RES, V13, P82, DOI 10.1519/00124278-199902000-00015; FLECK SJ, 1987, DESIGNING RESISTANCE; Roubenoff R, 1999, AIDS, V13, P231, DOI 10.1097/00002030-199902040-00011; Sattler FR, 1999, J CLIN ENDOCR METAB, V84, P1268, DOI 10.1210/jc.84.4.1268; Strawford A, 1999, JAMA-J AM MED ASSOC, V281, P1282, DOI 10.1001/jama.281.14.1282	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					175	176		10.1001/jama.284.2.175	http://dx.doi.org/10.1001/jama.284.2.175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889580				2022-12-28	WOS:000087933100012
J	Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L				Saigal, S; Stoskopf, BL; Feeny, D; Furlong, W; Burrows, E; Rosenbaum, PL; Hoult, L			Informed decisions for extremely low-birth-weight infants - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									McMaster Univ, Hamilton, ON, Canada	McMaster University	Saigal, S (corresponding author), McMaster Univ, Hamilton, ON, Canada.		Rosenbaum, Peter/AAW-7913-2021; Furlong, William J/A-1077-2008	Rosenbaum, Peter/0000-0001-6751-5613; 				*FET NEWB COMM CAN, 1994, CMAJ, V51, P547; OH W, 1995, PEDIATRICS, V96, P974; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; Saigal S, 1996, PEDIATR RES, V39, P1650	4	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	2000	283	24					3201	3202		10.1001/jama.283.24.3201	http://dx.doi.org/10.1001/jama.283.24.3201			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326TY	10866862				2022-12-28	WOS:000087753900027
J	Winett, RA; Carpinelli, RN				Winett, RA; Carpinelli, RN			Exercise regimens for men with HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							STRENGTH		Virginia Tech, Blacksburg, VA 24061 USA; Adelphi Univ, Garden City, NY 11530 USA	Virginia Polytechnic Institute & State University; Adelphi University	Winett, RA (corresponding author), Virginia Tech, Blacksburg, VA 24061 USA.							Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763; Carpinelli RN, 1998, SPORTS MED, V26, P73, DOI 10.2165/00007256-199826020-00002; Feigenbaum MS, 1997, PHYSICIAN SPORTSMED, V25, P44, DOI 10.3810/psm.1997.02.1137; Gannon G., 1995, EXERC IMMUNOL REV, V1, P26; Hass CJ, 2000, MED SCI SPORT EXER, V32, P235; Schiotz MK, 1998, J STRENGTH COND RES, V12, P173	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	2000	284	2					175	175		10.1001/jama.284.2.175	http://dx.doi.org/10.1001/jama.284.2.175			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329XE	10889580				2022-12-28	WOS:000087933100011
J	Moselhi, M				Moselhi, M			Human papillomavirus detection to screen for cervical cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							WOMEN		Llandough Hosp, Penarth, S Glam, Wales		Moselhi, M (corresponding author), Llandough Hosp, Penarth, S Glam, Wales.							Carter JJ, 1996, J INFECT DIS, V174, P927, DOI 10.1093/infdis/174.5.927; Chock C, 1997, J CLIN EPIDEMIOL, V50, P1211, DOI 10.1016/S0895-4356(97)00122-4; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Womack SD, 2000, BRIT J OBSTET GYNAEC, V107, P33, DOI 10.1111/j.1471-0528.2000.tb11576.x; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	2000	284	1					39	39		10.1001/jama.284.1.39	http://dx.doi.org/10.1001/jama.284.1.39			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	328GX	10872004				2022-12-28	WOS:000087843000014
